GenericName	TradeName	DateDesignated	OrphanDesignation	OrphanDesignationStatus	FDAOrphanApprovalStatus	SponsorCompany
"a nonreplicating adeno-associated virus, serotype SAN011, that expresses an artificial microRNA which reduces and degrades the DMPK mRNA trapping the RBPs (RNA Binding Proteins)"		7/10/2024	treatment of myotonic dystrophy type 1	Designated	Not FDA Approved for Orphan Indication	Sanofi US Services Inc.
fixed dose combination of decitabine and cedazuridine		7/10/2024	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Taiho Oncology Inc.
"autologous T cells genetically engineered to express an HLA-C*08:02-restricted TCR specific to KRAS G12D and a modified dihydrofolate reductase gene (mDHFR) sequence, and to knock out endogenous human TCR alpha and beta chains and the gene encoding the transforming growth factor-beta receptor 2 (TGFBR2)"		7/9/2024	treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Neogene Therapeutics, Inc., a member of the AstraZeneca Group"
Ambrisentan/tadalafil fixed dose combination		7/9/2024	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	"Midas Pharmaceuticals, Inc."
padnarsertib		7/9/2024	treatment of Ewing sarcoma	Designated	Not FDA Approved for Orphan Indication	Karyopharm Therapeutics Inc.
Humanized immunoglobulin G1 monoclonal antibody directed against WNT1-inducible signaling pathway protein-1		7/8/2024	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"Mediar Therapeutics, Inc."
Granaticin B		7/8/2024	treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Lin BioScience, Inc."
padnarsertib		7/8/2024	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	Karyopharm Therapeutics Inc.
insulin like growth factor 2 receptor ligand		7/3/2024	treatment of Angelman syndrome.	Designated	Not FDA Approved for Orphan Indication	Ritrova Therapeutics Inc.
elraglusib		7/3/2024	treatment of soft tissue sarcomas	Designated	Not FDA Approved for Orphan Indication	"Actuate Therapeutics, Inc."
salicylsalicylic acid		7/3/2024	treatment of Hutchinson Gilford progeria syndrome (HGPS) and Progeroid Laminopathies (PL)	Designated	Not FDA Approved for Orphan Indication	J & D Pharmaceuticals LLC
bevacizumab		7/2/2024	treatment of recurrent respiratory papillomatosis	Designated	Not FDA Approved for Orphan Indication	ODDIFACT SAS
proglumide		7/1/2024	treatment of chronic pancreatitis	Designated	Not FDA Approved for Orphan Indication	CCKr Therapeutics. Inc.
humanized immunoglobulin G4 monoclonal antibody against activated factor IX [FIXa] and factor X [FX]		7/1/2024	Treatment of hemophilia A	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
"Acetyl-D-tyrosylglycyl-D-arginyl-D-lysyl-D-lysyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-D arginyl-D-arginylglycyl-D-lysyl-D-threonyl-D-leucyl-D-arginyl-D-valyl-D-alanyl-D-lysyl-D-alanyl-D-isoleucyl-D-tyrosyl-D-lysyl-D-arginyl-D-tyrosyl-D-isoleucyl-D-isoglutamine, acetate salt"		7/1/2024	treatment of adrenocortical carcinoma	Designated	Not FDA Approved for Orphan Indication	Cytovation AS
"N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2- oxopiperazin-1-yl)methyl)-3,4-dihydro-2,4-methano-1,8-naphthyridine-1(2H)- carboxamide 2-hydroxypropane-1,2,3-tricarboxylate"		7/1/2024	treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"BroadenBio Co., Ltd."
peginterferon alfa-2a		6/27/2024	Treatment of essential thrombocythemia (ET)	Designated	Not FDA Approved for Orphan Indication	Pharma& U.S. Inc.
bemiltenase alfa		6/26/2024	Treatment of hemophilia A and hemophilia B	Designated	Not FDA Approved for Orphan Indication	"Staidson (Beijing) Biopharmaceuticals Co., LTD."
DNAI1 mRNA encapsulated in a selective organ targeting lipid nanoparticle		6/25/2024	treatment of primary ciliary dyskinesia	Designated	Not FDA Approved for Orphan Indication	"ReCode Therapeutics, Inc."
"1-(3-Cyano-5-methylthiophen-2-yl)-N-(6-methoxy-1H-benzo[d]imidazol-2-yl)-2,5- dimethyl-1H-pyrrole-3-carboxamide"		6/24/2024	treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"Shenzhen KeYe Life Technologies, Co., Ltd"
folate-TRPV6-peptide exatecan drug conjugate		6/24/2024	treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Coherent Biophanna (Hefei) Co., Ltd."
an orally bioavailable TEAD inhibitor (multiple-substituted indazole compound)		6/24/2024	treatment of mesothelioma	Designated	Not FDA Approved for Orphan Indication	Insilico Medicine Hong Kong Limited
"a therapeutic transgene cassette with an adeno-associated viral (AAV)-9 vector expressing a functional human codon optimized complimentary deoxyribonucleic acid (cDNA) encoding hEPM2A, under control of a CAG promoter"		6/24/2024	treatment of Lafora disease (LD)	Designated	Not FDA Approved for Orphan Indication	Genixcure Inc.
recombinant humanized IgG1 anti-TROP2 monoclonal antibody conjugated to a topoisomerase I inhibitor		6/18/2024	treatment of gastric cancer including cancer of the gastroesophageal junction	Designated	Not FDA Approved for Orphan Indication	"Merck, Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (MSD)"
solution stable glucagon analog		6/17/2024	Treatment of congenital hyperinsulinism	Designated	Not FDA Approved for Orphan Indication	"AmideBio, Inc."
Small molecule allosteric mitofusin activator		6/12/2024	Treatment of Charcot-Marie-Tooth Disease	Designated	Not FDA Approved for Orphan Indication	"Mitochondria in Motion, Inc."
Dual targeting chimeric antigen receptor (CAR) T cell therapy directed against B-cell maturation antigen (BCMA) and G-protein coupled receptor family C group 5 member D (GPRC5D)		6/12/2024	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company"
"(R)-3-(((6-(methyl(phenyl)amino)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)amino)isonicotinic acid"		6/11/2024	treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"Tachyon Therapeutics, Inc."
calpurbatug		6/10/2024	treatment of infective endocarditis	Designated	Not FDA Approved for Orphan Indication	Trellis Bioscience Inc.
bispecific Fc fusion protein containing a CD80 ectodomain and an IL-2v3 moiety		6/10/2024	treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"GI Innovation, Inc."
SIRPalpha-Fc-CD40L		6/7/2024	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Shattuck Labs, Inc."
"(R,E)-1-(3-(4-(trifluoromethyl)styryl)pyrrolidin-1-yl)prop-2-en-1-one"		6/7/2024	treatment of malignant mesothelioma	Designated	Not FDA Approved for Orphan Indication	BridGene Biosciences Inc.
empasiprubart		6/5/2024	treatment of multifocal motor neuropathy	Designated	Not FDA Approved for Orphan Indication	argenx BV
Tafenoquine		6/5/2024	treatment of babesiosis	Designated	Not FDA Approved for Orphan Indication	"60 Degrees Pharmaceuticals, Inc."
cabozantinib		6/5/2024	treatment of pancreatic neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	"Exelixis, Inc."
Nicotinamide riboside chloride		6/3/2024	Treatment of ataxia telangiectasia	Designated	Not FDA Approved for Orphan Indication	"ChromaDex, Inc."
bispecific antibody against CLDN18.2 and T cell receptor complex CD3		6/3/2024	treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Astellas Pharma Global Development, Inc."
"Zinc (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate and (3S,9aS)-3-(1H-imidazol-5-ylmethyl)-octahydro-1H-pyrido[1,2-a]piperazine-1,4-dione"		5/30/2024	treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"NovMetaPharma Co., Ltd."
Humanized monoclonal antibody targeting tissue factor conjugated to monomethyl auristatin E payload		5/29/2024	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Nanolattix Biotechnology Co., Ltd."
anti-Siglec-15 monoclonal antibody on a human IgG1-Fc-silenced backbone		5/29/2024	treatment of osteogenesis imperfecta	Designated	Not FDA Approved for Orphan Indication	"NextCure, Inc."
Allogeneic Teazeled receptor-activated human white blood cells		5/28/2024	treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Second Life Therapeutics, Inc"
(-)-Huperzine A		5/28/2024	treatment of neonatal hypoxic-ischemic encephalopathy	Designated	Not FDA Approved for Orphan Indication	"Wanbangde Pharmaceutical Group Co, Ltd."
recombinant human alpha-galactosidase A fused in-frame to the aglycosylated human IgG4 Fc mutein		5/24/2024	treatment of Fabry disease	Designated	Not FDA Approved for Orphan Indication	"Hanmi Pharmaceutical. Co., Ltd."
lixudebart		5/24/2024	treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	Alentis Therapeutics AG
vorinostat		5/24/2024	treatment of Rett syndrome	Designated	Not FDA Approved for Orphan Indication	"Unravel Biosciences, Inc."
peptide-oligonucleotide conjugate that targets OPA1 mRNA		5/22/2024	treatment of OPA1 mutation-associated autosomal dominant optic atrophy	Designated	Not FDA Approved for Orphan Indication	"PYC Therapeutics, LLC"
"replication-competent oncolytic herpes simplex virus (oHSV), engineered by removing the two endogenous copies of infected cell protein 34.5 (ICP34.5) and re-inserting one copy of the ICP34.5 gene under transcriptional control mediated by the promoter-enhancer elements of nestin"		5/21/2024	treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Brigham and Women's Hospital
zanubrutinib		5/20/2024	treatment of membranous nephropathy	Designated	Not FDA Approved for Orphan Indication	"BeiGene USA, Inc."
azeliragon		5/16/2024	treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Cantex Pharmaceuticals
monepantel		5/16/2024	treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	PharmAust Limited
2-(Piperazin-1-yl)ethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamido)benzoate		5/15/2024	treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"AgomAb Spain, S.L."
Autologous B cell-derived ex vivo gene edited cell therapy comprised of expanded/differentiated B lymphocyte lineage genetically engineered to express and secrete factor IX		5/15/2024	Treatment of hemophilia B	Designated	Not FDA Approved for Orphan Indication	"Be BioPharma, Inc."
(R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide		5/14/2024	treatment of fragile X syndrome	Designated	Not FDA Approved for Orphan Indication	"Spinogenix, Inc."
human anti-CD94 IgG1 monoclonal antibody (non-fucosylated)		5/9/2024	treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Dren Bio, Inc"
l-arginine		5/8/2024	treatment of sickle cell disease and its complications including pain; acute chest syndrome; vasculopathy; pulmonary hypertension; mitochondrial dysfunction; oxidative stress; leg ulcers; priapism; consequences of arginine deficiency	Designated	Not FDA Approved for Orphan Indication	Emory University
fixed-dosed combination of L-citrulline + allopurinol		4/30/2024	treatment of Duchenne muscular dystrophy (DMD)	Designated	Not FDA Approved for Orphan Indication	"Dr. Noah Biotech, Inc."
Anti-nectin-4 IgG1 monoclonal antibody conjugated to monomethyl auristatin E		4/30/2024	treatment of esophageal cancer	Designated	Not FDA Approved for Orphan Indication	"Mabwell (Shanghai) Bioscience Co., Ltd."
"human recombinant, monoclonal antibody (mAb) of the IgG1 isotype against alpha-synuclein"		4/30/2024	treatment of multiple system atrophy (MSA)	Designated	Not FDA Approved for Orphan Indication	Lundbeck Pharmaceuticals LLC
osilodrostat		4/29/2024	Treatment of endogenous Cushing's syndrome excluding Cushing's disease	Designated	Not FDA Approved for Orphan Indication	Recordati Rare Diseases Inc.
"Targeted antigen-loaded liposomes (TALL) comprised of a neutral stealth liposome, encapsulated synthetic immunogenic HLA class I restricted peptide (H250) derived from measles virus and a tumor-targeting peptide"		4/29/2024	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	SRI International
14-species commensal bacterial flora with prebiotics and postbiotic complex composed of gut microbiome modulating formulation		4/29/2024	treatment of Angelman syndrome	Designated	Not FDA Approved for Orphan Indication	Biom Pharmaceutical Corporation
(-)-Epigallocatechin 3-gallate		4/29/2024	treatment of pouchitis	Designated	Not FDA Approved for Orphan Indication	PharmassetX LLC
(R)-3-(1-cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)ureido)piperidine-1-carboxamide		4/24/2024	treatment of phenylketonuria	Designated	Not FDA Approved for Orphan Indication	Jnana Therapeutics
autologous anti-CD19 CAR T cell immunotherapy		4/24/2024	treatment of myasthenia gravis	Designated	Not FDA Approved for Orphan Indication	"Kyverna Therapeutics, Inc."
recombinant adeno-associated virus serotype 2 vector encoding human cytochrome P450 family 4 subfamily V member 2 (CYP4V2)		4/24/2024	treatment of Bietti crystalline corneoretinal dystrophy	Designated	Not FDA Approved for Orphan Indication	"NGGT (Suzhou) Biotechnology Co., Ltd."
selective small molecule messenger RNA (mRNA) degrader of MYB		4/24/2024	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	Remix Therapeutics
A small molecule messenger RNA (mRNA) degrader of MYB		4/24/2024	Treatment of adenoid cystic carcinoma	Designated	Not FDA Approved for Orphan Indication	Remix Therapeutics
"small molecule inhibitor of AAK1, a protein kinase member of the Notch pathway"		4/23/2024	treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	Satellos Bioscience Inc.
"autologous human CD34+ hematopoietic stem and progenitor cells (HSPCs), derived from G-CSF/plerixafor mobilized peripheral blood stem cells (PBSCs) of patients with Danon disease (DD)"		4/23/2024	treatment of Danon disease (DD)	Designated	Not FDA Approved for Orphan Indication	Papillon Therapeutics
Allogenic donor peripheral blood mononuclear cell-derived natural killer cells		4/22/2024	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Ingenium Therapeutics, Inc."
recombinant humanized anti-CD3/CD19 bispecific antibody		4/22/2024	treatment of follicular lymphoma (FL)	Designated	Not FDA Approved for Orphan Indication	"Curon Biopharmaceutical (Shanghai) Co., Limited"
selective small molecular inhibitor of fibroblast growth factor receptor 4		4/22/2024	treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"Abbisko Therapeutics Co., Ltd."
"N-[(2S)-1-[(3aS,6R,6aR)-6-Ethynyl-3-oxohexahydro-2H-furo[3,2-b]pyrrol-4-yl]-4-methyl-1-oxopentan-2-yl]-4-[5-fluoro-2-(4-methylpiperazin-1-yl)-1,3-thiazol-4-yl]benzamide hydrochloride"		4/15/2024	treatment of Legg-Calve-Perthes Disease (LCPD)	Designated	Not FDA Approved for Orphan Indication	Medivir AB
bispecific antibody drug conjugate (ADC) comprised of a humanized anti-CD33 and a humanized anti-CD7 Fab chemically linked to form a bi-Fab and conjugated to maleimidocaproyl monomethylauristatin F (mcMMAF)		4/15/2024	treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	BiVictriX Therapeutics plc.
calpurbatug		4/12/2024	treatment of prosthetic joint infection	Designated	Not FDA Approved for Orphan Indication	Trellis Bioscience Inc.
N-(4-((2-aminopyrimidin-5-yl)ethynyl)-3-fluoropyridin-2-yl)-5-chloro-2-methoxypyridine-3-sulfonamide		4/11/2024	treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Apollo Therapeutics Inc.
celastrol		4/10/2024	treatment of Prader-Willi syndrome	Designated	Not FDA Approved for Orphan Indication	"ERX Pharmaceuticals, Inc."
"6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-alpha-Ltalofuranosyl)-paromamine sulfate"		4/10/2024	Treatment of Alport Syndrome	Designated	Not FDA Approved for Orphan Indication	Eloxx Pharmaceuticals Inc.
small molecule inhibitor of hyaluronan synthesis		4/9/2024	Treatment of Primary Sclerosing Cholangitis	Designated	Not FDA Approved for Orphan Indication	"Halo Biosciences, Inc."
aglatimagene besadenovec		4/8/2024	treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Candel Therapeutics, Inc."
"Two AAV vectors, the first expressing the N- and the second expressing the C-region of the ATP-binding cassette subfamily A member 4 (ABCA4) protein fused to N- or C-terminal split-intein sequences"		4/8/2024	treatment of patients with confirmed ABCA4 gene mutation-associated inherited retinal dystrophy (IRD)	Designated	Not FDA Approved for Orphan Indication	SpliceBio S.L.
Glecirasib		4/8/2024	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Jacobio Pharmaceuticals Co., Ltd."
Folate-TRPV6-peptide exatecan drug conjugate		4/8/2024	treatment of esophageal cancer	Designated	Not FDA Approved for Orphan Indication	"Coherent Biophanna (Hefei) Co., Ltd."
"Subunit protein vaccine of recombinantly expressed Marburg Marburgvirus glycoprotein (MARV GP, MarVax)"		4/8/2024	prevention (which includes post-exposure prophylaxis) against Marburg marburgvirus infection	Designated	Not FDA Approved for Orphan Indication	"Soligenix, Inc."
"(S)-N-(1-(3-fluoro-2'-methoxy-[1,1'-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-5-(pyridin-2-yl) thiophene-2-sulfonamide"		4/8/2024	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"Amira Therapeutics, S.L."
Self-complementary adeno-associated virus serotype 9 vector harboring a miniaturized codon-optimized human IDUA gene		4/8/2024	Treatment of mucopolysaccharidosis type I	Designated	Not FDA Approved for Orphan Indication	"NeuroGT, Inc."
Humanized anti-GD2 monoclonal antibody		4/8/2024	Treatment of Neuroblastoma	Designated	Not FDA Approved for Orphan Indication	"Renaissance Pharma, Ltd."
tecarfarin		4/8/2024	"Prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device (left ventricular assist device, right ventricular assist device, biventricular assist device, total artificial heart)"	Designated	Not FDA Approved for Orphan Indication	Cadrenal Therapeutics
subunit protein vaccine of recombinantly expressed Sudan Ebola virus glycoprotein		4/8/2024	prevention (which includes post-exposure prophylaxis) against Sudan Ebola Virus (SUDV) infection	Designated	Not FDA Approved for Orphan Indication	"Soligenix, Inc."
"Hematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1r, 4r)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate"		4/2/2024	Treatment to enhance cell engraftment and immune reconstitution in patients receiving hematopoietic stem cell transplant	Designated	Not FDA Approved for Orphan Indication	Cordex Biologics Inc.
certepetide		3/28/2024	Treatment of Osteosarcoma	Designated	Not FDA Approved for Orphan Indication	"Lisata Therapeutics, Inc"
allantoin (5-ureidohydantoin or glyoxyldiureide)		3/28/2024	Treatment of Epidermolysis Bullosa	Designated	Not FDA Approved for Orphan Indication	Paradigm Therapeutics
neratinib		3/25/2024	Treatment of gastric cancer (including gastroesophageal Junction cancer)	Designated	Not FDA Approved for Orphan Indication	"Convalife (Shanghai) CO., Ltd."
"small synthetic peptide based on a sequence found in the human endogenous protein, central coordination network protein 3"		3/21/2024	Treatment of Systemic Sclerosis	Designated	Not FDA Approved for Orphan Indication	BLR Bio LLC
topotecan liposome injection		3/21/2024	Treatment of Merkel Cell Carcinoma	Designated	Not FDA Approved for Orphan Indication	"Fujifilm Pharmaceuticals U.S.A., Inc."
Potassium citrate and potassium bicarbonate		3/21/2024	Treatment of cystinuria	Designated	Not FDA Approved for Orphan Indication	Advicenne S.A.
utidelone		3/21/2024	treatment of breast cancer brain metastases	Designated	Not FDA Approved for Orphan Indication	"Biostar Pharma, Inc."
pyridine derivative containing pyridazine that inhibits lysophospholipase		3/21/2024	Treatment of Systemic Sclerosis	Designated	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
mecasermin rinfabate		3/21/2024	Prevention of intraventricular hemorrhage in preterm infants less than 32 weeks gestational age	Designated	Not FDA Approved for Orphan Indication	OHB Neonatology Ltd.
(-)-epi-gallocatechin-3-gallate		3/21/2024	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	Merdury Biopharmaceutical Corporation
prednisone		3/20/2024	Treatment of Chronic Inflammatory Demyelinating Polyneuropathy	Designated	Not FDA Approved for Orphan Indication	Sarcomed AB
Cevidoplenib		3/20/2024	Treatment of primary immune thrombocytopenia (ITP)	Designated	Not FDA Approved for Orphan Indication	Oscotec Inc.
Human induced pluripotent stem cells (iPSC)-derived Photoreceptor Progenitor Cells		3/20/2024	Treatment of Retinitis Pigmentosa	Designated	Not FDA Approved for Orphan Indication	"iRegene Therapeutics Co., Ltd"
autologous cluster of differentiation 34 positive (CD34+) hematopoietic stem/progenitor cells transduced with the LVMWAS lentiviral vector encoding the human Wiskott-Aldrich Syndrome protein		3/20/2024	Treatment of Wiskott-Aldrich Syndrome	Designated	Not FDA Approved for Orphan Indication	CSL Behring
autologous T cells transduced with lentivirus to express a fully human anti-CD19 single chain variable fragment		3/19/2024	Treatment of Systemic Sclerosis	Designated	Not FDA Approved for Orphan Indication	"Cabaletta Bio, Inc."
humanized IgG1 monoclonal antibody against BCMA conjugated to synthetic amatoxin via a cathepsin B cleavable linker		3/19/2024	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Heidelberg Pharma AG
Andecaliximab		3/19/2024	Treatment of fibrodysplasia ossificans progressiva	Designated	Not FDA Approved for Orphan Indication	ashibio Inc
D-beta-hydroxybutyrate		3/18/2024	Treatment of Fatty Acid Oxidation Disorders	Designated	Not FDA Approved for Orphan Indication	Aimmune Nestle US R&D LLC
lentiviral-transduced CD33-directed CAR-T cell therapy		3/18/2024	treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Vor Biopharma
Safusidenib erbumine		3/14/2024	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	AnHeart Therapeutics Inc.
recombinant humanized anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody		3/14/2024	Treatment of hemophilia A	Designated	Not FDA Approved for Orphan Indication	"Suzhou Alphamab Co., Ltd."
Proglumide		3/13/2024	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"CCKr Therapeutics, Inc."
Utidelone		3/12/2024	treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	"Biostar Pharma, Inc."
prednisone		3/12/2024	Treatment of Myasthenia Gravis	Designated	Not FDA Approved for Orphan Indication	Sarcomed AB
felzartamab		3/12/2024	Treatment of antibody mediated rejection in kidney transplant recipients	Designated	Not FDA Approved for Orphan Indication	"Human Immunology Biosciences, Inc."
repotrectinib	Augtyro	3/12/2024	Treatment of NTRK fusion-positive solid tumors	Designated/Approved		Bristol-Myers Squibb Company
genetically modified allogeneic chimeric antigen receptor (CAR)-T cell therapy designed to target cell surface B-Cell Maturation Antigen		3/12/2024	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Poseida Therapeutics, Inc."
antibody-drug conjugate of a humanized monoclonal antibody specific for CD6 conjugated to monomethyl auristatin E		3/11/2024	Treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Abcon Therapeutics, Inc."
eflornithine HCl		3/11/2024	Treatment of Bachmann-Bupp Syndrome	Designated	Not FDA Approved for Orphan Indication	"Orbus Therapeutics, Inc."
self-complementary adeno-associated virus 9 containing human methyl-CpG binding protein 2		3/11/2024	Treatment of Rett syndrome	Designated	Not FDA Approved for Orphan Indication	Genecombio Ltd.
"Derivative of 6-[2-(pyridin-2-yl)phenoxy]methyl}-1,2,3,4-tetrahydroisoquinoline"		3/9/2024	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
Enhanced delivery peptide-oligonucleotide conjugate for Duchenne Muscular Dystrophy Exon 51		3/7/2024	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	PepGen Inc.
Small molecule inhibitor of the bcr-abl tyrosine kinase		3/7/2024	Treatment of chronic myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	"Terns, Inc."
autologous ex vivo expanded polyclonal CD4plusCD25plusCD127 lo/- FOXP3plus regulatory T cells (CELZ-101)		3/5/2024	Prevention of allograft rejection in patients undergoing pancreatic islet cell transplantation	Designated	Not FDA Approved for Orphan Indication	"Creative Medical Technology Holdings, Inc"
Avutometinib		3/5/2024	Treatment of low grade serous ovarian cancer (LGSOC)	Designated	Not FDA Approved for Orphan Indication	"Verastem, Inc"
Prednisone		3/5/2024	Treatment of Limb-Girdle Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	Sarcomed AB
Avutometinib; defactinib		3/5/2024	Treatment of low grade serous ovarian cancer (LGSOC)	Designated	Not FDA Approved for Orphan Indication	"Verastem, Inc."
humanized IgG1k monoclonal antibody against LAIR-1		3/5/2024	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	"NextCure, Inc."
Recombinant human IgG4 monoclonal antibody against FGF19		2/29/2024	treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Huahui Health Ltd.
CRISPR/Cas13X RNA base-editing gene therapy drug targeting human OTOF Q829X mutation		2/29/2024	Treatment of OTOF Q829X mutation-induced hearing loss	Designated	Not FDA Approved for Orphan Indication	"Cholgene Therapeutics, Inc."
(S)-1-((((1-Cyclohexylethyl)carbamoyl)oxy)methyl)-3-((2- nitrooxy)ethyl)carbamoyl)pyridin-1-ium iodide		2/29/2024	Prevention of delayed graft function in patients undergoing solid organ transplantation.	Designated	Not FDA Approved for Orphan Indication	"Unicycive Therapeutics, Inc."
Cambritaxestat		2/28/2024	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	iOnctura BV
topiramate		2/28/2024	Treatment of neonatal seizures	Designated	Not FDA Approved for Orphan Indication	PrevEP Inc.
methyldopa		2/27/2024	Prevention of retinopathy of prematurity	Designated	Not FDA Approved for Orphan Indication	FELIQS Corporation
Fully human anti-galectin-9 IgG4 monoclonal antibody		2/27/2024	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	PureTech Health LLC
combination Resveratrol and Curcumin		2/27/2024	Treatment of patients with Dercum's disease (adiposis dolorosa)	Designated	Not FDA Approved for Orphan Indication	"Caliway Biopharmaceuticals Co., Ltd."
Dilanubicel		2/26/2024	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Deverra Therapeutics
combination of 7-ethtyl-10-hydroxycamptothecin and irinotecan hydrochloride trihydrate		2/26/2024	Treatment of Pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	SN BioScience Inc.
bispecific anti-GD2/anti-B7-H3 monoclonal antibody		2/26/2024	Treatment of Neuroblastoma	Designated	Not FDA Approved for Orphan Indication	Invenra Inc.
a humanized anti-CD3/CD19 bispecific antibody		2/26/2024	Treatment of Acute Lymphocytic Leukemia (ALL)	Designated	Not FDA Approved for Orphan Indication	"Curon Biopharmaceutical (Shanghai) Co., Limited"
immunomodulatory inhibitor of high mobility group box 1		2/22/2024	Treatment of Idiopathic Pulmonary Fibrosis (IPF)	Designated	Not FDA Approved for Orphan Indication	"Spark Biopharma, Inc."
autologous logic-gated Tmod chimeric antigen receptor (CAR) T cells expressing a carcinoembryonic antigen targeted CAR activator and a human leukocyte antigen serotype A*02 (HLA-A*02) targeted blocker		2/22/2024	Treatment of germline heterozygous HLA-A*02(+) patients with colorectal cancer that expresses CEA and has lost HLA A*02 expression	Designated	Not FDA Approved for Orphan Indication	"A2 Biotherapeutics, Inc."
"DNA, (Cm-Gm-Gm-Gm-G-T-G-T-G-G-G-T-T-C-G-T-C-G-T-T-A-G-C-T-T-G-A-T-T-T-G-G-C-A-G-C-Um-Gm-Cm-Cm-(5'->3')-idT), 5'-ester with (29S)-29-carboxy-8,17,26,31-tetraoxo-10,13,19,22-tetraoxa-7,16,25,30-tetraazaoctatetracontan-48-oic acid"		2/21/2024	Treatment of X-Linked Hypophosphatemia	Designated	Not FDA Approved for Orphan Indication	Aptacure Therapeutics Limited
sirpiglenastat		2/20/2024	Treatment of Hepatocellular Carcinoma	Designated	Not FDA Approved for Orphan Indication	"Dracen Pharmaceuticals, Inc"
co-packaged combination of pocapavir and imocitrelvir		2/20/2024	Treatment of poliovirus infection	Designated	Not FDA Approved for Orphan Indication	ViroDefense Inc.
Spesolimab-sbzo		2/20/2024	Treatment of Netherton Syndrome	Designated	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc"
CAR-T cell engager protein that links the CD19-directed CAR-T cell to a B cell antigen CD20		2/20/2024	Treatment of mantle cell lymphoma	Designated	Not FDA Approved for Orphan Indication	Aleta Biotherapeutics
Small molecule inhibitor of non-muscle myosin II (NMII) A and B		2/20/2024	Treatment of Malignant Glioma	Designated	Not FDA Approved for Orphan Indication	Myosin Therapeutics Inc.
N-sulfoglucosamine sulfohydrolase		2/20/2024	Treatment of Mucopolysaccharidosis type IIIA (MPS IIIA; Sanfilippo syndrome type A)	Designated	Not FDA Approved for Orphan Indication	Denali Therapeutics Inc.
Gleolan		2/15/2024	"diagnostic for the management of ovarian, fallopian tube, and primary peritoneal cancer"	Designated	Not FDA Approved for Orphan Indication	NX Development Corp.
Recombinant adeno-associated virus vector serotype 5 (AAV5) harboring a codon-optimized human GLA transgene		2/15/2024	Treatment of Fabry Disease	Designated	Not FDA Approved for Orphan Indication	"Sichuan Real&Best Biotech Co., Ltd."
Cannabidiol		2/14/2024	Treatment of pericarditis.	Designated	Not FDA Approved for Orphan Indication	Cardiol Therapeutics Inc.
olezarsen		2/14/2024	Treatment of Familial Chylomicronemia Syndrome	Designated	Not FDA Approved for Orphan Indication	Ionis Pharmaceuticals
Camoteskimab		2/14/2024	Treatment of Still’s Disease including Adult-Onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis	Designated	Not FDA Approved for Orphan Indication	Apollo Therapeutics Inc.
rexlemestrocel-L		2/14/2024	Treatment of Hypoplastic Left Heart Syndrome	Designated	Not FDA Approved for Orphan Indication	"Mesoblast, Inc."
pitolisant		2/12/2024	Treatment of Prader-Willi syndrome (PWS)	Designated	Not FDA Approved for Orphan Indication	"Harmony Biosciences, LLC"
"(S)-2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy-1,1-d2)benzo[b]thiophen-7-yl)propanoic acid"		2/12/2024	Treatment of autosomal dominant polycystic kidney disease	Designated	Not FDA Approved for Orphan Indication	Shanghai Alebund Pharmaceuticals Ltd.
Recombinant Oncolytic Herpes Simplex Virus Type II (OH2) Therapeutic Injection (Vero Cell) for Human Use (rHSV2hGM-CSF)		2/12/2024	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Binhui Biopharmaceutical Co., Ltd."
recombinant humanized monoclonal antibody targeting transmembrane serine protease matripase-6		2/8/2024	Treatment of Polycythemia Vera	Designated	Not FDA Approved for Orphan Indication	"Disc Medicine, Inc."
"recombinant, humanized immunoglobulin G1 monoclonal antibody that targets the leukocyte immunoglobulin-like receptor subfamily B4"		2/8/2024	Treatment of Chronic Myelomonocytic Leukemia	Designated	Not FDA Approved for Orphan Indication	Immune-Onc Therapeutics
small molecule inhibitor of the B-Raf protein		2/8/2024	Treatment of epidermal growth factor receptor inhibitor (EGFRi) and mitogen-activated extracellular signal-regulated kinase inhibitor (MEKi) induced acneiform rash	Designated	Not FDA Approved for Orphan Indication	Lutris Pharma Ltd.
DAsn-Ile-Pro-Nva-Leu-Tyr-DSer-Phe-Ala-DSer		2/8/2024	Treatment of Duchenne Muscular Dystrophy (DMD)	Designated	Not FDA Approved for Orphan Indication	"Allysta Pharmaceuticals, Inc."
"Modified Recombinant adeno-associated virus (rAAV) serotype 2 vector, AAV.IVT18, expressing human retinoschisis gene RS1 driven by RS1 and CMV chimeric promoter"		2/8/2024	Treatment of X-linked Retinoschisis	Designated	Not FDA Approved for Orphan Indication	InnoVec Biotherapeutics Inc.
"[4,4'-(((dodecylazanediyl)bis(ethane-2,1-diyl))bis(azanediyl))bis(7-chloroquinoline 1-oxide)]"		2/8/2024	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	Theranostec Inc.
Tigilanol Tiglate		2/8/2024	Treatment of Soft Tissue Sarcoma	Designated	Not FDA Approved for Orphan Indication	QBiotics Group Limited
Soquelitinib		2/7/2024	Treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Corvus Pharmaceuticals, Inc."
adeno-associated virus gene therapy comprised of a transgene cassette encoding codon-optimzed human CFTR delta R		2/5/2024	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"4D Molecular Therapeutics, Inc."
Cinnamtannin B-1		2/5/2024	Treatment of Osteosarcoma	Designated	Not FDA Approved for Orphan Indication	"GTS Biotech, LLC"
furmonertinib		2/5/2024	Treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations or human epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations.	Designated	Not FDA Approved for Orphan Indication	"ArriVent Biopharma, Inc."
A potent negative allosteric modulator (NAM) of human alpha5-GABAA receptor		1/31/2024	Treatment of trigeminal neuralgia	Designated	Not FDA Approved for Orphan Indication	"Shanghai SIMR Biotechnology Co., Ltd."
Sodium Hypochlorite		1/31/2024	Treatment of walled-off pancreatic necrosis	Designated	Not FDA Approved for Orphan Indication	Johns Hopkins University School of Medicine
autologous anti-CD19 chimeric antibody receptor T cells designed to deplete CD19+ B cells		1/31/2024	Treatment of Idiopathic Inflammatory Myopathies (IIM)	Designated	Not FDA Approved for Orphan Indication	"Cabaletta Bio, Inc"
"(4R)-3-(4-fluoro-2-hydroxyphenyl)-4-methyl-4,5-dihydro- 1H-pyrazole-1-carboximidamide hydrochloride"		1/30/2024	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	AnaMar AB
"5-BROMO-N-(PROP-2-YN-1-YL)-2-(1H-1,2,4-TRIAZOL-1-YL) PYRIMIDINE-4,6-DIAMINE"		1/30/2024	Treatment of Prader-Willi syndrome	Designated	Not FDA Approved for Orphan Indication	Palobiofarma S.L.
enriched CD34+ hematopoietic stem and progenitor cells / highly purified CD34-CD25+CD4+CD127-regulatory T cells / conventional T cells (Orca-T)		1/30/2024	Prevention of graft-versus-host disease and/or death in patients undergoing hematopoietic stem cell transplant.	Designated	Not FDA Approved for Orphan Indication	"Orca Biosystems, Inc."
CD30-Targeted Genetically-modified Autologous T-cell immunotherapy		1/29/2024	Treatment of Anaplastic Large Cell Lymphoma	Designated	Not FDA Approved for Orphan Indication	"Wu Han Bio-raid Biotech Co., Ltd."
ocifisertib		1/29/2024	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	Treadwell Therapeutics
lanraplenib		1/29/2024	Treatment of Acute Myeloid Leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	"Kronos Bio, Inc."
Signal regulatory protein alpha (SIRPalpha)-Exosome		1/25/2024	Treatment of acute liver failure regardless of etiology	Designated	Not FDA Approved for Orphan Indication	SHIFTBIO INC.
Imiquimod-Ferulic Acid		1/23/2024	Treatment of Cutaneous Leishmaniasis	Designated	Not FDA Approved for Orphan Indication	Celista Pharmaceuticals LLC
Antisense oligonucleotide targeting TUBB4A mRNA		1/23/2024	Treatment of TUBB4A related Isolated Hypomyelination	Designated	Not FDA Approved for Orphan Indication	SynaptixBio Ltd.
Recombinant adeno-associated virus type 5 vector containing codon optimized human RPGR^ORF15 protein coding gene (rAAV5-hRPGR^ORF15)		1/22/2024	Treatment of Retinal Dystrophies Due to Defects in the RPGR Gene	Designated	Not FDA Approved for Orphan Indication	"Frontera Therapeutics, Inc"
An anti-Claudin18.2 monoclonal antibody conjugated with Duostatin-5 (DUO-5) payload		1/22/2024	"Treatment of Gastric Cancer, including cancer of the gastroesophageal junction (GEJ)"	Designated	Not FDA Approved for Orphan Indication	"Shandong Boan Biotechnology Co., Ltd."
antisense oligonucleotide (ASO) binding SMN2 pre-mRNA		1/22/2024	Treatment of Spinal Muscular Atrophy	Designated	Not FDA Approved for Orphan Indication	Biogen
Human monoclonal IgG1 antibody against the isoform 2 of human Claudin 18 protein (Claudin 18.2)		1/22/2024	"Treatment of Gastric Cancer, including Cancer of the Gastroesophageal Junction"	Designated	Not FDA Approved for Orphan Indication	"Shandong Boan Biotechnology Co., Ltd."
"2-(4-(((4-methoxyphenyl)thio)methyl)-1H-1,2,3-triazol-1-yl)-N,N-dimethylethan-1-aminium hydrochloride"		1/22/2024	Treatment of retinal dystrophy associated with PDE6 mutation	Designated	Not FDA Approved for Orphan Indication	Miramoon Pharma SL
regulatory T cell activating peptide		1/19/2024	Treatment of eosinophilic esophagitis	Designated	Not FDA Approved for Orphan Indication	Revolo Biotherapeutics
Prime edited CD34+ cell-based drug product targeting the delGT mutation in the NCF1 gene		1/19/2024	Treatment of Chronic Granulomatous Disease	Designated	Not FDA Approved for Orphan Indication	Prime Medicine
Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc)		1/18/2024	Treatment of Pancreatic Cancer (PC)	Designated	Not FDA Approved for Orphan Indication	NeoImmuneTech
autologous CAR-T cell targeting HER2 and IL13Ralpha2 that simultaneously secrete CD3 EGFR/EGFRvIII bispecific T cell engagers		1/18/2024	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Shanghai Simnova Biotechnology Co., Ltd."
"replication-incompetent human mastadenovirus C serotype 5, with E1 and partial E3 deletions that encodes a hTERT RNA-targeting trans-splicing ribozyme with HSVtk transgene"		1/18/2024	Treatment of hepatocellular carcinoma (HCC)	Designated	Not FDA Approved for Orphan Indication	Rznomics
recombinant human N-acetylglucosamine-6-sulfatase enzyme (rhGNS)		1/16/2024	Treatment of Sanfilippo Syndrome type D (also known as Mucopolysaccharidosis MPS IIID)	Designated	Not FDA Approved for Orphan Indication	Phoenix Nest Inc.
mitogen-activated protein kinase / phosphatidylinositol 3-kinase / mammalian target of rapamycin inhibitor		1/12/2024	Treatment of Myelofibrosis	Designated	Not FDA Approved for Orphan Indication	Lympharma LLC
"N-(2,6-diethyphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2- methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate"		1/11/2024	Treatment of hepatocellular carcinoma (HCC)	Designated	Not FDA Approved for Orphan Indication	Nerviano Medical Sciences S.r.l.
Adeno-associated virus serotype SLB101 containing the human microdystrophin gene (h-muD5)		1/11/2024	Treatment of Duchenne muscular dystrophy (DMD)	Designated	Not FDA Approved for Orphan Indication	Solid Biosciences Inc.
Thrombin-preconditioned allogeneic Wharton's Jelly-derived mesenchymal stem cells		1/11/2024	Treatment of neonatal intraventricular hemorrhage (IVH)	Designated	Not FDA Approved for Orphan Indication	Medinno Inc.
polyethylene glycol-3350		1/11/2024	Treatment of peripheral nerve injury requiring repair	Designated	Not FDA Approved for Orphan Indication	"Neuraptive Therapeutics, Inc."
"4-(3-(4-(1H-imidazo[4,5-b]pyridin-5-yl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride dihydrate"		1/9/2024	Treatment of small cell lung cancer (SCLC)	Designated	Not FDA Approved for Orphan Indication	"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd."
adeno-associated virus serotype 9/rh74 containing the human Capn3 gene and a target sequence of cardiac-specific microRNA		1/4/2024	Treatment of autosomal recessive disorder Limb Girdle Muscular Dystrophy R1 Calpain-related (LGMDR1)	Designated	Not FDA Approved for Orphan Indication	Atamyo Therapeutics
A recombinant adeno-associated virus serotype 9 (rAAV9) vector carrying a compact high-fidelity Cas12i (hfCas12Max) and a CRISPR RNA (crRNA) targeting human DMD exon 51 SD site		1/4/2024	Treatment of Duchenne Muscular Dystrophy (DMD)	Designated	Not FDA Approved for Orphan Indication	"Cholgene Therapeutics, Inc."
Recombinant anti-SIRPalpha humanized monoclonal antibody		1/4/2024	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	BioRay Pharmaceutical Corp.
"4-[[(1S)-1-(4, 8-dichloro-1-oxo-2-phenyl-3-isoquinolyl) ethyl] amino]-8H-pyrido[2,3-d] pyrimidin-5-one]"		1/3/2024	Treatment of angioimmunoblastic T-cell lymphoma (AITL)	Designated	Not FDA Approved for Orphan Indication	"Boryung Co., Ltd."
"Glycine, L-prolyl-L-prolyl-L-leucyl-L-seryl-L-glutaminyl-L-alpha-glutamyl-L-threonyl-L-phenylalanyl-L-seryl-L-alpha-aspartyl-L-leucyl-L-tryptophyl-L-lysyl-L-leucyl-L-leucyl-L-lysyl-L-lysyl-L-tryptophyl-L-lysyl-L-methionyl-L-arginyl-L-arginyl-L-asparaginyl-L-glutaminyl-L-phenylalanyl-L-tryptophyl-L-valyl-L-lysyl-L-valyl-L-glutaminyl-L-arginyl-"		12/28/2023	Treatment of Osteosarcoma	Designated	Not FDA Approved for Orphan Indication	"Oncolyze, Inc."
Thrombin-preconditioned allogeneic Wharton's Jelly-derived mesenchymal stem cells		12/28/2023	Treatment of neonatal hypoxic ischemic encephalopathy	Designated	Not FDA Approved for Orphan Indication	Medinno Inc.
carboplatin		12/28/2023	Treatment of malignant glioma.	Designated	Not FDA Approved for Orphan Indication	Carthera
lixumistat		12/27/2023	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"ImmunoMet Therapeutics, Inc."
lipophilic derivative of dimercaptosuccinic acid sulfur containing chelator		12/27/2023	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	Pleco Therapeutics USA Inc.
Autologous T cells transduced with natural T cell receptor (TCR) that recognizes the HLA-A-restricted HBsAg epitope		12/27/2023	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	SCG Cell Therapy Pte. Ltd.
"Pseudomonas aeruginosa-specific Bacteriophage Mixture, Live consisting of 3 bacteriophages (IHMA-2121771-1, IHMA-2121771-2, IHMA-2121908-1)"		12/27/2023	Treatment of chronic pulmonary infection caused by Pseudomonas aeruginosa in patients with Cystic Fibrosis	Designated	Not FDA Approved for Orphan Indication	BiomX Inc.
Small molecule chaperone to stabilize and rescue the activity of dysfunctional phenylalanine variants		12/27/2023	Treatment of Phenylketonuria	Designated	Not FDA Approved for Orphan Indication	Pluvia AS
Amphotericin B		12/26/2023	Treatment of Cystic Fibrosis	Designated	Not FDA Approved for Orphan Indication	"cystetic Medicines, Inc."
Aldafermin		12/21/2023	Treatment of Primary Sclerosing Cholangitis	Designated	Not FDA Approved for Orphan Indication	NGM Biopharmaceuticals Inc.
anti-Claudin18.2 monoclonal antibody conjugated with Duostatin-5 payload		12/21/2023	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	"Shandong Boan Biotechnology Co., Ltd."
Dual recombinant adeno-associated viral vectors encoding the human otoferlin gene		12/21/2023	Treatment of otoferlin-mediated hearing loss	Designated	Not FDA Approved for Orphan Indication	"Shanghai Refreshgene Therapeutics Co., Ltd."
small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5)		12/21/2023	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"Tango Therapeutics, Inc."
Sonrotoclax		12/21/2023	Treatment of Mantle Cell Lymphoma	Designated	Not FDA Approved for Orphan Indication	"BeiGene USA, Inc"
Human monoclonal IgG1 antibody against the isoform 2 of human Claudin 18 protein (Claudin 18.2)		12/21/2023	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	"Shandong Boan Biotechnology Co., Ltd."
Corneal Endothelial Cells Substitute derived from human allogeneic iPS Cells		12/20/2023	Treatment of bullous keratopathy	Designated	Not FDA Approved for Orphan Indication	"Cellusion, Inc."
4-[[[4-[5-chloro-2-[[trans-4-[[(1R)-2-methoxy-1-methyl ethyl] amino] cyclohexyl] amino] -4-pyridinyl]-2-thiazolyl] amino] methyl] tetrahydro-2H-pyran-4-carbonitrile dimaleate		12/20/2023	Treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"SELLAS Life Sciences Group, Inc."
A rAAV8 capsid containing a single-stranded DNA template encoding wild-type human coagulation factor IX protein and LNP1265: a lipid nanoparticle encapsulating a Cas9 mRNA and a single guide RNA		12/20/2023	Treatment of Hemophilia B	Designated	Not FDA Approved for Orphan Indication	Regeneron Pharmaceuticals Inc
"Recombinant, Humanized, Aglycosylated, Immunoglobulin G1 kappa Anti-Factor Bb Monoclonal Antibody"		12/20/2023	Treatment of paroxysmal nocturnal hemoglobinuria	Designated	Not FDA Approved for Orphan Indication	"NovelMed Therapeutics, Inc."
sonrotoclax		12/19/2023	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	"BeiGene USA, Inc"
Adeno-associated viruses 8 (AAV8)-based gene therapy vector that expresses B domain-deleted human factor VIII under the control of human liver-specific promoters		12/19/2023	Treatment of Hemophilia A	Designated	Not FDA Approved for Orphan Indication	"Gritgen Therapeutics Co., Ltd."
an IgG1(Immunoglobulin G1) subclass antibody targeting CCR8(C-C Motif Chemokine Receptor 8)		12/18/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	LaNova Medicines Limited
a phosphoramidate oral prodrug of a unique 6-modified purine nucleotide		12/18/2023	Treatment of disease caused by dengue virus	Designated	Not FDA Approved for Orphan Indication	Atea Pharmaceuticals Inc.
selective inhibitor of mechanistic target of rapamycin complex 1		12/18/2023	Treatment of autosomal Dominant Polycystic Kidney Disease (ADPKD)	Designated	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
vamorolone		12/18/2023	Treatment of Becker muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	ReveraGen BioPharma Inc.
recombinant fusion protein composed of a recombinant human arylsulfatase A (rhARSA) fused with a variable domain of the heavy chain of heavy chain-only antibody fragment targeting human transferrin		12/15/2023	Treatment of metachromatic leukodystrophy	Designated	Not FDA Approved for Orphan Indication	"Linno Pharmaceuticals, Inc."
N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)benzyl)amino)benzenesulfonamide		12/14/2023	Treatment of Epithelioid hemangioendothelioma	Designated	Not FDA Approved for Orphan Indication	Ikena Oncology
Iloprost		12/14/2023	Treatment of Systemic Sclerosis	Designated	Not FDA Approved for Orphan Indication	"Pharmosa Biopharm, Inc."
"[Phe^2,Ile^3,Dab(PhAc-D-Tyr(Me)-Phe-Gln-Asn-Ala-Pro-Arg-iGln-Lys(Ac)-Epsilon-Lys)^8]vasopressin"		12/14/2023	Treatment of ascites due to all etiologies except cancer	Designated	Not FDA Approved for Orphan Indication	"Ocelot Bio, Inc."
adeno-associated virus serotype rh.10 encoding for the human PKP2 gene (AAVrh.10hPKP2)		12/14/2023	Treatment of arrhythmogenic cardiomyopathy due to a PKP2 pathogenic variant	Designated	Not FDA Approved for Orphan Indication	"LEXEO Therapeutics, Inc."
trastuzumab-rezetecan		12/14/2023	Treatment of biliary tract cancer	Designated	Not FDA Approved for Orphan Indication	"Jiangsu Hengrui Pharmaceuticals Co., Ltd."
nipocalimab		12/14/2023	Prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT)	Designated	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
Beta-nicotinamide mononucleotide		12/14/2023	Treatment of Sickle Cell Disease	Designated	Not FDA Approved for Orphan Indication	LGD SARL
Sonrotoclax		12/14/2023	Treatment of Waldenstrom Macroglobulinemia	Designated	Not FDA Approved for Orphan Indication	"BeiGene USA, Inc."
a non-replicating recombinant adeno- associated virus serotype 9 (AAV9) based gene therapy vector containing the DNA of Streptococcus pyogenes Cas9 (SpCas9) protein and single guide RNA (sgRNA) designed to target the TATA-box of the PMP22 P1 promoter		12/14/2023	Treatment of Charcot-Marie-Tooth Disease Type 1A	Designated	Not FDA Approved for Orphan Indication	"ToolGen, Inc."
4-(4-Methyl-piperazin-1-yl)-N-{6-[2-(4-trifluoromethyl-benzyloxy)-ethoxy]- 1H-indazol-3-yl}-benzamide hemioxalat		12/14/2023	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Nerviano Medical Sciences S.r.l.
(-)-Huperzine A		12/12/2023	Treatment of Myasthenia Gravis	Designated	Not FDA Approved for Orphan Indication	"Wanbangde Pharmaceutical Group Co, Ltd."
oxoindoline carboxamide compound		12/12/2023	Treatment of alpha-1 antitrypsin deficiency	Designated	Not FDA Approved for Orphan Indication	BioMarin Pharmaceutical Inc.
recombinant humanized anti-human tissue factor monoclonal antibody conjugated with a cytotoxic small molecule MMAE		12/12/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Shanghai Miracogen Inc.
Human N-sulfoglucosamine sulfohydrolase fused to a humanised monoclonal antibody targeting human transferrin receptor		12/12/2023	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A)	Designated	Not FDA Approved for Orphan Indication	"JCR Pharmaceuticals Co., Ltd."
Nanatinostat and valganciclovir combination		12/11/2023	Treatment of nasopharyngeal carcinoma	Designated	Not FDA Approved for Orphan Indication	"Viracta Therapeutics, Inc."
"Tetrahydro-2H-pyran-4-yl 7-(2-(cyclopropanecarboxamido)- imidazo[1,2-a]pyridin-6-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate hydrochloride"		12/11/2023	Treatment of acute graft-versus-host disease	Designated	Not FDA Approved for Orphan Indication	Accro Bioscience (Suzhou) Limited
"a bispecific antibody composed of a Light Chain and a Heavy Chain pair targeting HER2, and a Light Chain and a Heavy Chain pair targeting CD47"		12/7/2023	"Treatment of patients with gastric cancer, including cancer of the gastroesophageal junction"	Designated	Not FDA Approved for Orphan Indication	"D3 Bio (Wuxi) Co., Ltd."
pravibismane		12/7/2023	Treatment of non-tuberculous mycobacterial (NTM) infections	Designated	Not FDA Approved for Orphan Indication	Microbion Corporation
Sepantronium Bromide		12/7/2023	Treatment of Burkitt lymphoma	Designated	Not FDA Approved for Orphan Indication	"Cothera Bioscience, Inc."
maplirpacept		12/6/2023	Treatment of Acute Myeloid Leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	Pfizer Inc.
A self-complementary recombinant adeno-associated virus (scAAV) serotype 6 vector that expresses NeuroD1 under the control of the CMV promoter		12/6/2023	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	NeuExcell Therapeutics Inc.
Adeno-associated Virus Vector Expressing Human SERCA2a Gene		12/6/2023	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	Sardocor Corp.
[68Ga]FAPI-46		12/5/2023	Diagnostic for the management of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	SOFIE Co. dba SOFIE
"3-tert-butyl-N-{(1R)-1-[4-(6-{6-[4-({1-[4-(2,4-dioxo-1,3-diazinan-1-yl)phenyl]piperidin-4-yl}methyl)piperazin-1-yl]pyridin-3-yl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-methylphenyl]ethyl}-1,2,4-oxadiazole-5-carboxamide"		12/5/2023	treatment of mantle cell lymphoma	Designated	Not FDA Approved for Orphan Indication	BeiGene USA Inc
"(2S,4R)-1-((S)-2-(7-(4-((R)-3-((4-(N-(4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoyl)sulfamoyl)-2-((trifluoromethyl)sulfonyl)phenyl)amino)-4-(phenylthio)butyl)piperazin-1-yl)-7-oxoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide"		12/5/2023	treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Dialectic Therapeutics, Inc."
"Recombinant AAV9 viral vector containing the transgene encoding the human WW domain-containing oxidoreductase (WWOX) protein, under the control of a human Synapsin I promoter"		12/5/2023	Treatment of WW domain-containing oxidoreductase (WWOX)-related developmental and epileptic encephalopathy	Designated	Not FDA Approved for Orphan Indication	Mahzi Therapeutics
Cutamesine dihydrochloride		12/5/2023	Treatment of Alpha-thalassemia X-linked disability (ATRX) syndrome	Designated	Not FDA Approved for Orphan Indication	"BioPharma Global, a division of Pace Life Sciences"
Chaenomelis Fructus Extract		11/29/2023	Treatment of BAG3-related myofibrillar myopathy	Designated	Not FDA Approved for Orphan Indication	Centre for Chinese Herbal Medicine Drug Development Limited
type II fast skeletal myosin inhibitor		11/29/2023	Treatment of Duchenne and Becker Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	Edgewise Therapeutics
small molecule PRMT5/MTA cooperative inhibitor		11/28/2023	Treatment of Biliary Tract Cancers	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
Epirubicin		11/28/2023	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Beijing Inno Medicine Co., Ltd."
(+)N-hydroxy-N-(methylacylfulvene)urea		11/28/2023	Treatment of diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements	Designated	Not FDA Approved for Orphan Indication	Lantern Pharma
recombinant fusion protein (biologic) made by linking human serum albumin to a human Insulin-like growth factor 2 sequence		11/27/2023	Treatment of myotonic dystrophy type 1	Designated	Not FDA Approved for Orphan Indication	"Juvena Therapeutics, Inc."
mRNA plus Lysate-Loaded Dendritic Cell Vaccine		11/27/2023	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Joseph Georges, D.O., Ph.D."
Human pooled allogenic umbilical cord mesenchymal stromal cells		11/22/2023	Treatment of hypoxic ischemic encephalopathy	Designated	Not FDA Approved for Orphan Indication	ESPL Regulatory Consulting Limited
Allogenic spinal motor neuron precursor cell		11/22/2023	Treatment of amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	"XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd"
AAV8_ABCA4 RNA Exon Editor		11/22/2023	Treatment of ABCA4-related retinopathies	Designated	Not FDA Approved for Orphan Indication	"Ascidian Therapeutics, Inc."
Allogeneic CAR-T cells that is engineered to express a CAR targeting the B cell maturation antigen (BCMA)		11/22/2023	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	"Caribou Biosciences, Inc."
Coagulation Factor X Human		11/21/2023	Treatment of acquired factor X deficiency	Designated	Not FDA Approved for Orphan Indication	Bio Products Laboratory Limited
"single-stranded mRNA consisting of a 5 cap, a 5 untranslated region (UTR), reading frame of the transgene encoding for the human CFTR (hCFTR), the 3 UTR, and poly A tail"		11/21/2023	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Arcturus Therapeutics, Inc."
Sonrotoclax		11/21/2023	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	"BeiGene USA, Inc"
selumetinib		11/21/2023	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc."
Ricin Immune Fab		11/16/2023	Treatment of Ricin Poisoning	Designated	Not FDA Approved for Orphan Indication	BTG International Inc
Recombinant human IgG1 anti-B7H3 monoclonal antibody conjugated to topoisomerase I inhibitor YL0010014		11/16/2023	Treatment of esophageal cancer	Designated	Not FDA Approved for Orphan Indication	MediLink Therapeutics
"2-(6-(6-((6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-methyl-N-(5-methyl-1Hpyrazol-3-yl)pyrimidin-4-amine fumarate"		11/15/2023	Treatment of tissue-agnostic RET fusion-positive solid tumors	Designated	Not FDA Approved for Orphan Indication	Ellipses Pharma Ltd
tenapanor hydrochloride		11/14/2023	Treatment of pediatric hyperphosphatemia	Designated	Not FDA Approved for Orphan Indication	"Ardelyx, Inc."
mocravimod		11/14/2023	Treatment to improve outcome following hematopoietic stem cell transplantation in hematologic malignancies	Designated	Not FDA Approved for Orphan Indication	Priothera SAS
Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc)		11/14/2023	Treatment of acute radiation syndrome (ARS)	Designated	Not FDA Approved for Orphan Indication	"NeoImmuneTech, Inc."
"humanized IgG1 monoclonal VpreB1 antibody conjugated to N-acetyl gamma-calicheamicin 1, 2-dimethyl hydrazine dichloride (NAc gamma-calicheamicin DMH) via an acid-labile 4-(4-acetylphenoxy) butanoic acid linker (acetyl butyrate)"		11/14/2023	Treatment of acute lymphoblastic leukemia/acute lymphoblastic lymphoma	Designated	Not FDA Approved for Orphan Indication	Children's Minnesota
Adeno-Associated Viral Vector Expressing Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/dCas-based Gene Therapy consisting of a Single Guide RNA targeting the Human D4Z4 Locus and a messenger RNA encoding dCasONYX		11/14/2023	Treatement of facioscapulohumeral muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	"EpiCrispr Biotechnologies, Inc."
H-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-OH (acetate)		11/14/2023	Treatment of Hypoxic Ischemic Encephalopathy	Designated	Not FDA Approved for Orphan Indication	Argenica Therapeutics Ltd.
Tacrolimus		11/8/2023	Treatment of graft versus host disease	Designated	Not FDA Approved for Orphan Indication	"Lipella Pharmaceuticals, Inc."
Pyridine derivative containing pyridazine that inhibits lysophospholipase		11/8/2023	Treatment of Idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
6-thio-2¿-deoxyguanosine		11/8/2023	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"MAIA Biotechnology, Inc."
Recombinant human signal regulating protein alpha (SIRPalpha) fragment crystallizable (Fc)-fusion protein		11/7/2023	Treatment of chronic myelomonocytic leukemia	Designated	Not FDA Approved for Orphan Indication	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
autologous peripheral blood mononuclear cells manipulated ex vivo to produce macrophages with markedly reduced signal-regulatory protein alpha (SIRPalpha) expression		11/6/2023	Treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	SIRPant Immunotherapeutics
"an autologous, epigenetically modified cell therapy product which contains expanded tumor-infiltrating lymphocytes (TIL)"		11/6/2023	Treatment of Stage IIB-IV Melanoma	Designated	Not FDA Approved for Orphan Indication	"Lyell Immunopharma, Inc."
alprostadil		11/6/2023	Prevention of ischemia/reperfusion injury resulting from solid organ transplantation.	Designated	Not FDA Approved for Orphan Indication	Institut Georges Lopez
allogeneic natural killer cells that originated from human cord blood mononuclear cells		11/6/2023	Treatment of patients with refractory/relapsed after at least 3 prior multiple myeloma treatment regimens or BCMA based CAR-T therapy	Designated	Not FDA Approved for Orphan Indication	"Cure Therapeutics, Inc."
alpibectir and ethionamide fixed-dose combination drug		11/6/2023	Treatment of tuberculosis	Designated	Not FDA Approved for Orphan Indication	Bioversys SAS
BMEDA-chelated Rhenium-186 nanoliposomes		11/2/2023	Treatment of breast cancer with leptomeningeal metastases (LM)	Designated	Not FDA Approved for Orphan Indication	"Plus Therapeutics, Inc."
selective gamma secretase inhibitor of Notch-mediated signaling		11/2/2023	Treatment of desmoid tumors	Designated	Not FDA Approved for Orphan Indication	Ayala Pharmaceuticals Inc.
Multicyclic 2-aminothiazole carboxamide that inhibits tubulin polymerization		10/31/2023	Treatment of Glioblastoma	Designated	Not FDA Approved for Orphan Indication	"Reglagene, Inc."
dovramilast		10/31/2023	Treatment of leprosy (Hansen disease).	Designated	Not FDA Approved for Orphan Indication	Medicines Development for Global Health
Indotecan		10/31/2023	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Gibson Oncology, LLC"
"recombinant adeno-associated virus serotype 9 vector carrying high-fidelity Cas13Y (hfCas13Y), an RNA editor, gene expression cassette, and guide RNAs targeting human MECP2"		10/30/2023	Treatment of methyl-CpG binding protein 2 (MECP2) duplication syndrome	Designated	Not FDA Approved for Orphan Indication	"Cholgene Therapeutics, Inc."
Autologous blood outgrowth endothelial cells transduced with lentiviral vector to restore factor VIII function		10/30/2023	Treatment of Hemophilia A	Designated	Not FDA Approved for Orphan Indication	Sernova Corp
Mesenchymal stem cell (MSC) derived small extracellular vesicles (EVs) loaded with short and modified interfering RNA (siRNA) against the phosphatase and tensin homolog (PTEN) protein		10/26/2023	Treatment of Acute Spinal Cord Injury	Designated	Not FDA Approved for Orphan Indication	"NurExone Biologic, Ltd."
{PEG2}-Val1-Leu2-Thr3-Thr4-Gly5-Leu6-Pro7-Ala8-Leu9-Ile10Ser11Trp12-Ile13- Lys14Arg15-Lys16-Arg17-Gln18-Gln19-Gly20-Gly21-Gly22-Gly23-Ser24-dLys25-dLeu26-		10/23/2023	Treatment of Hepatocellular Carcinoma	Designated	Not FDA Approved for Orphan Indication	"Twinpig Biolab, Inc."
"10,11-methylenedioxy-20(S)-camptothecin (10,11-MD-CPT)"		10/23/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Canget BioTekpharma, LLC"
clofazimine		10/18/2023	Treatment of non-tuberculous mycobacterial infections	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
"N-(2-(4-Fluorophenyl)-5,7-dimethyl-1,2,3,4-tetrahydro isoquinolin-6-yl)-2-(1-methylcyclopropyl) acetamide"		10/18/2023	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"Shanghai Zhimeng Biopharma, Inc."
Autologous CD34+ hematopoietic stem and progenitor cells modified ex vivo with a lentiviral vector that restores endogenously regulated expression of WASp		10/18/2023	Treatment of Wiskott-Aldrich Syndrome	Designated	Not FDA Approved for Orphan Indication	ImmunoVec
humanized IgG-like T cell engager (TcE) comprised of 2 polypeptide chains specific for human Delta-like 3 (DLL3) and human CD3 (BI 764532)		10/16/2023	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
recombinant humanized anti-interleukin 36R monoclonal antibody		10/16/2023	Treatment of generalized pustular psoriasis	Designated	Not FDA Approved for Orphan Indication	"Shanghai Huaota Biopharmaceutical Co., Ltd."
"(3beta,24S)-25,25,25-trifluoro-3-methyl-26,27-dinorergost-5-ene-3,24-diol"		10/16/2023	Treatment of Huntington’s disease	Designated	Not FDA Approved for Orphan Indication	Sage Therapeutics
adeno-associated virus (AAV) vector-based gene therapy delivering a therapeutic transgene of RJK002		10/16/2023	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	Rejukon Biopharm Inc.
durvalumab		10/12/2023	"Treatment of gastric cancer, including gastroesophageal junction cancer"	Designated	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals
PIKFYVE antisense oligonucleotide		10/11/2023	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Takeda Development Centers America
dovitinib		10/11/2023	Treatment of Osteosarcoma	Designated	Not FDA Approved for Orphan Indication	Oncoheroes Biosciences Inc.
4-[[[4-[5-chloro-2-[[trans-4-[[(1R)-2-methoxy-1-methyl ethyl] amino] cyclohexyl] amino] -4-pyridinyl]-2-thiazolyl] amino] methyl] tetrahydro-2H-pyran-4-carbonitrile dimaleate		10/10/2023	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	"SELLAS Life Sciences Group, Inc."
Recombinant adeno associated virus vector targeting human PHD 2 protein		10/10/2023	Treatment of Rhodopsin and Pde6-associated retinopathy	Designated	Not FDA Approved for Orphan Indication	Trustees of Columbia University in the city of New York
(E)-2-[[3-[(3-Methoxy-4-(prop-2-ynyloxy))phenyl]-1-oxo-2-propen-1-yl]amino]benzoic acid		10/10/2023	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	Certa Therapeutics Pty Ltd
recombinant adeno-associated virus vector serotype 8 carrying the coding sequence of human GBA1 gene		10/5/2023	Treatment of Gaucher disease	Designated	Not FDA Approved for Orphan Indication	Lingyi Biotech Co. Ltd.
Virus-like particle containing Cas9/gRNA ribonucleoprotein targeting the human HTT gene		10/5/2023	Treatment of Huntington’s Disease	Designated	Not FDA Approved for Orphan Indication	"Shanghai BDgene Co., Ltd."
"an injectable cancer vaccine consisting of a mixture of three synthetic peptides (alrefimotide, tapderimotide, and riletamotide)"		10/5/2023	Treatment of Mesothelioma	Designated	Not FDA Approved for Orphan Indication	Ultimovacs ASA
gallium maltolate		10/5/2023	Treatment of atypical teratoid/rhabdoid tumors	Designated	Not FDA Approved for Orphan Indication	"Imaging Biometrics, LLC"
methotrexate		10/4/2023	"Treatment of non-infectious intermediate, posterior, or pan uveitis or chronic non-infectious anterior uveitis"	Designated	Not FDA Approved for Orphan Indication	Nordic Group B.V.
AAV-based engineered microRNA targeting conserved regions on the human PMP22 transcript		10/4/2023	Treatment of Charcot-Marie-Tooth Disease Type 1A	Designated	Not FDA Approved for Orphan Indication	Armatus Bio
N-(4-Methyl-3-(4-(5-(4-methylisoxazol-5-yl)pyridine-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide succinate		10/3/2023	Treatment of Multiple System Atrophy	Designated	Not FDA Approved for Orphan Indication	"Inhibikase Theapeutics, Inc."
Ulinastatin		10/2/2023	Treatment of Phosgene Inhalation	Designated	Not FDA Approved for Orphan Indication	"RNR Biomedical, Inc."
Urokinase plasminogen activator receptor binding peptide attached to fluorophore indocyanine green		10/2/2023	diagnostic for the management of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Fluoguide A/S
"Functionalized benzodihydropyran or chroman closely related to triphendiol, cantrixil and trilexium"		10/2/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Noxopharm Ltd
"((2S,5S)-5-(4-amino-5-(4-(2,3-difluorophenoxy)phenyl)imidazo[5,1-f][1,2,4]triazin-7-yl)tetrahydro-2H-pyran-2-yl)methanol"		10/2/2023	Treatment of Central Nervous System Lymphoma	Designated	Not FDA Approved for Orphan Indication	"Dizal (Jiangsu) Pharmaceutical Co., Ltd."
recombinant human anti-ATTR-immunoglobulin G1 monoclonal antibody		10/2/2023	Treatment of transthyretin amyloidosis	Designated	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc."
Fixed-dose combination of Donepezil hydrochloride and Nebivolol hydrochloride		9/28/2023	Treatment of Amyotrophic Lateral Sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	"Dr. Noah Biotech, Inc."
"A (recombinant) disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13) protein"		9/27/2023	Treatment of Thrombotic Thrombocytopenic Purpura (TTP)	Designated	Not FDA Approved for Orphan Indication	GC Biopharma Corp.
"Autologous human regulatory T cells transduced with a retroviral vector encoding an FVIII C2 T cell receptor (TCR), which specifically binds FVIII C2 2213-2227 epitope in the context with HLA DRB1*01:01"		9/26/2023	Treatment of hemophilia A with inhibitors	Designated	Not FDA Approved for Orphan Indication	"TeraImmune, Inc."
setanaxib		9/26/2023	Treatment of Alport syndrome	Designated	Not FDA Approved for Orphan Indication	Calliditas Therapeutics Suisse SA
non-replicating AAV-based gene therapy vector with a single stranded DNA genome engineered to carry an expression cassette encoding for human cardiac myosin binding protein-C (cMyBP-C; hMYBPC3 transgene)		9/26/2023	Treatment of patients with hypertrophic cardiomyopathy (HCM) with a mutation in the MYBPC3 gene	Designated	Not FDA Approved for Orphan Indication	BioMarin Pharmaceutical Inc.
mRNA encoding the ciliary protein CCDC40		9/26/2023	Treatment of primary ciliary dyskinesia	Designated	Not FDA Approved for Orphan Indication	Ethris GmbH
resminostat mesilate		9/22/2023	Treatment of Cutaneous T-Cell Lymphoma (CTCL)	Designated	Not FDA Approved for Orphan Indication	4SC AG
trastuzumab biosimilar conjugated with TLR7/8 via a non-cleavable linker		9/22/2023	"Treatment of gastric cancer, including gastroesophageal junction cancer"	Designated	Not FDA Approved for Orphan Indication	Bolt Biotherapeutics
"(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl) pyrrolidin-1-yl)(5-fluoropyridin-2-yl)methanone"		9/21/2023	Treatment of Olmsted Syndrome	Designated	Not FDA Approved for Orphan Indication	Kamari Pharma Ltd.
Atibuclimab		9/21/2023	Treatment of arrhythmogenic cardiomyopathy	Designated	Not FDA Approved for Orphan Indication	Implicit Bioscience Ltd.
A Lipid Nanoparticle Suspension of Akt-1 Antisense Oligonucleotide		9/20/2023	Treatment of Hepatocellular Carcinoma	Designated	Not FDA Approved for Orphan Indication	"Zhejiang Haichang Biotech Co., Ltd."
donidalorsen		9/19/2023	Treatment of hereditary angioedema	Designated	Not FDA Approved for Orphan Indication	Ionis Pharmaceuticals
Human Retinal Pigment Epithelial Cell Injection		9/19/2023	Treatment of Retinitis Pigmentosa	Designated	Not FDA Approved for Orphan Indication	Eyecure Therapeutics Inc.
autologous B cells engineered to secrete intact alpha-galactosidase A enzyme		9/19/2023	Treatment of Fabry disease	Designated	Not FDA Approved for Orphan Indication	Walking Fish Therapeutics
Human transferrin 1 receptor (TfR1) targeting humanized IgG 1 kappa fragment antibody conjugated to an antisense oligonucleotide (ASO)		9/19/2023	Treatment of Myotonic Dystrophy Type I	Designated	Not FDA Approved for Orphan Indication	"Dyne Therapeutics, Inc."
Folate-TRPV6-peptide exatecan drug conjugate		9/19/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Coherent Biophanna (Hefei) Co., Ltd."
Piperlongumine (PL) Hydrogel		9/19/2023	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	TargTex S.A.
Autologous T cells expressing anti-B cell maturation agent chimeric antigen receptor		9/19/2023	Treatment of amyloid light chain (AL) amyloidosis	Designated	Not FDA Approved for Orphan Indication	"Nexcella, Inc."
"(R)-3-(5,5-dimethyl-4,5-dihydro-1,2,4-oxadiazol-3-yl)-N-(1-(2,3,5-trifluorophenyl) ethyl) pyrazolo[1,5-a] pyrimidin-5-amine hydrate"		9/19/2023	"Treatment of ALK-positive, ROS1-positive, NTRK fusion-positive, or LTK positive non-small cell lung cancer"	Designated	Not FDA Approved for Orphan Indication	"TYK Medicines, Inc."
alisertib		9/19/2023	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Puma Biotechnology, Inc."
adeno-associated viral vector serotype 9 containing the human PLA2G6 gene		9/15/2023	Treatment of PLA2G6-associated neurodegeneration	Designated	Not FDA Approved for Orphan Indication	Bloomsbury Genetic Therapies Ltd.
2'-O-(2-methoxyethyl) modified antisense oligonucleotide targeting PLP1 pre-mRNA		9/15/2023	Treatment of Pelizaeus-Merzbacher disease	Designated	Not FDA Approved for Orphan Indication	"Ionis Pharmaceuticals, Inc."
Humanized IgG1 monoclonal antibody against annexin-A1		9/15/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Medannex Ltd
"N( 4{[ 5fluoro7( 2methoxyethoxy) 4quinazolinyl] amino}phenyl)2( 4isopropyl1H1,2,3triazol1yl) acetamide 4-methylbenzenesulfonate (1:1)"		9/13/2023	Treatment of Gastrointestinal Stromal Tumors (GIST)	Designated	Not FDA Approved for Orphan Indication	"Ningbo NewBay Technology Development Co., Ltd."
N-Acetyl-Leucine		9/13/2023	Treatment of Multiple Systems Atrophy	Designated	Not FDA Approved for Orphan Indication	IntraBio Inc.
Adeno-associated virus (AAV)-based vector with an engineered capsid serotype SNY001 harboring human phenylalanine hydroxylase (hPAH) cDNA		9/8/2023	Treatment of phenylketonuria (PKU)	Designated	Not FDA Approved for Orphan Indication	"Sanofi US Services, Inc."
Adeno-associated viral vector serotype 9 containing the human NPC1 gene		9/6/2023	"Treatment of Niemann-Pick disease, type C"	Designated	Not FDA Approved for Orphan Indication	Bloomsbury Genetic Therapies Ltd.
Microencapsulated Interleukin-10		9/5/2023	Treatment of Familial Adenomatous Polyposis	Designated	Not FDA Approved for Orphan Indication	"Therapyx, Inc."
"a humanized immunoglobulin G (IgG)1kappa monoclonal antibody targeting IL1RAP that has been designed to inhibit signal transduction from IL?1 alpha, IL?1beta, IL?33, IL?36 alpha, IL?36 beta, and IL?36 gamma"		9/5/2023	Treatment of Systemic Sclerosis	Designated	Not FDA Approved for Orphan Indication	Cantargia AB
autologous T-cells ex vivo modified with a lentiviral vector encoding a chimeric antigen receptor specific for CD1a		9/5/2023	Treatment of acute lymphoblastic leukemia/lymphoblastic lymphoma	Designated	Not FDA Approved for Orphan Indication	OneChain Immunotherapeutics S.L.
pitolisant		9/5/2023	Treatment of idiopathic hypersomnia	Designated	Not FDA Approved for Orphan Indication	"Harmony Biosciences, LLC"
"A replication-defective, non-integrating herpes simplex virus type 1-based vector engineered to express full-length, functional human alpha-1 antitrypsin"		9/1/2023	Treatment of Alpha-1 antitrypsin deficiency	Designated	Not FDA Approved for Orphan Indication	"Krystal Biotech, Inc."
1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone		8/31/2023	Treatment of myelofibrosis	Designated	Not FDA Approved for Orphan Indication	"Telios Pharma, Inc."
autologous chimeric antigen receptor (CAR) T cells targeting CD7		8/31/2023	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma	Designated	Not FDA Approved for Orphan Indication	Hebei Senlang Biotechnology Co. Ltd.
tregalizumab		8/31/2023	Prevention of acute graft versus host disease	Designated	Not FDA Approved for Orphan Indication	T-Balance Therapeutics GmbH
Gotistobart		8/29/2023	Treatment of adenoid cystic carcinoma	Designated	Not FDA Approved for Orphan Indication	"OncoC4, Inc."
CD200 activation receptor ligand (CD200AR-L)		8/29/2023	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	OX2 Therapeutics
Apilimod		8/29/2023	Treatment of amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	"AI Therapeutics, Inc."
a genetically modified Salmonella comprising of methioninase		8/28/2023	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Guangzhou Sinogen Pharmaceutical Co., Ltd."
Autologous synthetic NKG2D receptor armored CLDN18.2 specific CAR-T cell injection		8/28/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Suzhou Immunofoco Biotechnology Co., Ltd"
pozelimab and cemdisiran combiantion		8/28/2023	Treatment of myasthenia gravis	Designated	Not FDA Approved for Orphan Indication	"Regeneron Pharmaceuticals, Inc."
Bexmarilimab		8/24/2023	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Faron Pharmaceuticals Ltd.
"a recombinant, humanized single variable domain on a heavy chain (VHH) bispecific antibody that binds with high affinity to human properdin and human serum albumin"		8/21/2023	Treatment of Sickle Cell Disease	Designated	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc."
Adeno-associated viral vector serotype 2.NN encoding the human cyclic nucleotide-gated channel subunit A1 gene		8/17/2023	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	ViGeneron GmbH
Autologous T cells expressing anti-B cell maturation agent chimeric antigen receptor		8/16/2023	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	"Nexcella, Inc."
"N-[5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl]-2-[(4-ethylpiperazin-1-yl)methyl]quinoline-6-carboxamide"		8/16/2023	Treatment of cholangiocarcinoma	Designated	Not FDA Approved for Orphan Indication	"Nuvectis Pharma, Inc."
Autologous EpCAM specific CAR-T cell injection		8/16/2023	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	"Suzhou Immunofoco Biotechnology Co., Ltd"
Autologous synthetic NKG2D receptor armored CLDN18.2 specific CAR-T cell injection		8/15/2023	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	"Suzhou Immunofoco Biotechnology Co., Ltd"
Ulefnersen		8/15/2023	Treatment of amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	"Ionis Pharmaceuticals, Inc."
zelasudil		8/14/2023	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	Redx Pharma Plc
recombinant adeno-associated virus vector that contains a bioengineered capsid (AAV-Spark100) and a codon-optimized expression cassette to drive expression of a secretable form of alpha-galactosidase A		8/11/2023	Treatment of Fabry disease	Designated	Not FDA Approved for Orphan Indication	"Spark Therapeutics, Inc."
an oral inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1)		8/11/2023	Treatment of Mantle Cell Lymphoma (MCL)	Designated	Not FDA Approved for Orphan Indication	"Schrödinger, Inc."
murine IgG1(kappa) subtype monoclonal antibody MAb-AR20.5 that binds to MUC1		8/10/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	CanariaBio Inc.
"An antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector function null, humanized IgG1 antibody and a phosphorodiamidate morpholino oligonucleotide targeting exon 44 of the human DMD pre-mRNA"		8/10/2023	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	"Avidity Biosciences, Inc."
quaratusugene ozeplasmid		8/9/2023	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Genprex, Inc."
"N-(2-Methoxyethyl)-6-methyl-N-[(3-methyl-2-thienyl)methyl]-2-oxo-1,2-dihydropyridine-4-carboxamide"		8/9/2023	Treatment of Glycogen Storage Disease type IV (GSD-IV)	Designated	Not FDA Approved for Orphan Indication	"Golden Heart Flower, Ltd."
human umbilical cord-derived mesenchymal stem cells		8/9/2023	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"Wuhan Optics Valley Vcanbiopharma Co., Ltd."
Vonafexor		8/9/2023	Treatment of Alport Syndrome	Designated	Not FDA Approved for Orphan Indication	ENYO Pharma
Mezagitamab		8/9/2023	Treatment of immune thrombocytopenia (ITP)	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
adeno-associated viral vector serotype LK03 containing the human ornithine transcarbamylase gene		8/8/2023	Treatment of Ornithine Transcarbamylase Deficiency	Designated	Not FDA Approved for Orphan Indication	Bloomsbury Genetic Therapies Ltd.
heterologous swine glyco-humanized polyclonal antibody against T lymphocytes		8/7/2023	Treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	Xenothera
Ac-Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys-NH2 (Cys:Cys disulfide linkage)		8/3/2023	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Lisata Therapeutics, Inc"
Elesclomol copper		8/3/2023	Treatment of Menkes Disease	Designated	Not FDA Approved for Orphan Indication	"Engrail Therapeutics, Inc."
humanized bispecific anti-C5 minibody		8/3/2023	Treatment of Myasthenia Gravis	Designated	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc."
recombinant adeno-associated virus serotype 9 vector containing the codon optimized human alpha-N-acetylglucosaminidase (NAGLU) gene		8/1/2023	"Treatment of mucopolysaccharidosis (MPS) IIIB, also called Sanfilippo syndrome B"	Designated	Not FDA Approved for Orphan Indication	"NeuroGT, Inc."
heterocyclic small molecule kinase inhibitor of a Notch associated kinase that enhances satellite cell driven regeneration of muscle		8/1/2023	Treatment of Duchenne Muscular Dystrophy (DMD)	Designated	Not FDA Approved for Orphan Indication	Satellos Bioscience Inc.
nimodipine intravenous		8/1/2023	Treatment of subarachnoid hemorrhage	Designated	Not FDA Approved for Orphan Indication	Cipla Ltd.
a synthetic peptide-oligonucleotide conjugate in which a phosphorodiamidate morpholino oligonucleotide is conjugated to a cell penetrating peptide		8/1/2023	Treatment of Myotonic Dystrophy type 1 (also known as Steinert disease)	Designated	Not FDA Approved for Orphan Indication	PepGen Inc.
vosoritide		8/1/2023	Treatment of hypochondroplasia	Designated	Not FDA Approved for Orphan Indication	BioMarin Pharmaceutical Inc.
DTPA[Indium-111]-dinutuximab-IRDye800CW		7/31/2023	Diagnostic for the management of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	University of Pittsburgh
Brogidirsen		7/31/2023	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	"NS Pharma, Inc."
"N-(2-chloro-3-((3,4-dihydro-2H-pyrimido[1,2-c] quinazolin-10- yl) oxy) phenyl) propane-1-sulfonamide hydrochloride"		7/26/2023	Treatment of Malignant Glioma	Designated	Not FDA Approved for Orphan Indication	ABM Therapeutics Corporation
"Maytansine bound via linker to bacterial derived, negatively charged modified Gyrase inhibitor"		7/25/2023	Treatment of Glioblastoma Multiforme	Designated	Not FDA Approved for Orphan Indication	CyGenica Ltd.
Paclitaxel/Polyoligo(ethylene glycol)methacrylate-co-poly(vinylbenzyldithiodibutyric acid-gemcitabine) fixed-dose combination		7/25/2023	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	DUO Oncology
Small molecule fibroblast growth factor receptor 3 selective tyrosine kinase inhibitor		7/25/2023	Treatment of Achondroplasia	Designated	Not FDA Approved for Orphan Indication	Tyra Biosciences
"Alpha 1 anti-trypsin (AAT), human alpha 1 anti-trypsin, alpha 1 proteinase inhibitor"		7/25/2023	Treatment of Charcot-Marie-Tooth Disease	Designated	Not FDA Approved for Orphan Indication	Ageronix SA
A replication-deficient adeno-associated virus serotype 9 vector containing the ornithine transcarbamylase gene within the transposon and a lipid nanoparticle containing messenger RNA for the transposase		7/24/2023	Treatment of ornithine transcarbamylase deficiency	Designated	Not FDA Approved for Orphan Indication	"Poseida Therapeutics, Inc."
Lusvertikimab		7/20/2023	Treatment of acute lymphoblastic leukemia (ALL)	Designated	Not FDA Approved for Orphan Indication	OSE Immunotherapeutics
meropenem		7/20/2023	Treatment of bacterial keratitis	Designated	Not FDA Approved for Orphan Indication	"IBIOTICA, LLC"
7-ethyl-10-hydroxycamptothecin and irinotecan hydrochloride trihydrate		7/18/2023	Treatment of Small-Cell Lung Carcinoma	Designated	Not FDA Approved for Orphan Indication	SN BioScience Inc.
elraglusib		7/18/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Actuate Therapeutics, Inc."
Nitroxoline		7/17/2023	Treatment of Neurofibromatosis type 1 (NF1)	Designated	Not FDA Approved for Orphan Indication	Healx Limited
Primary Human Satellite cell-derived muscle stem cells		7/13/2023	Treatment of Exstrophy-Epispadias Complex	Designated	Not FDA Approved for Orphan Indication	MyoPax Denmark ApS
exosomes purified from primed human bone marrow derived mesenchymal stem cells and methacrylated hyaluronic acid		7/5/2023	Treatment of neurotrophic keratitis	Designated	Not FDA Approved for Orphan Indication	"Pandorum Technologies, Inc."
cemdisiran		7/5/2023	Treatment of Myasthenia Gravis (MG)	Designated	Not FDA Approved for Orphan Indication	"Regeneron Pharamecuticals, Inc."
Lactobacillus reuteri		6/30/2023	Treatment of Gastroschisis	Designated	Not FDA Approved for Orphan Indication	Infant Bacterial Therapeutics AB
Trispecific antibody targeting tumor associated antigens CD38 and BCMA and CD3 on human T cells		6/28/2023	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Ichnos Sciences SA
Genetically modified human adenovirus encoding human PH20		6/27/2023	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	Theriva Biologics S.L.
"(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate"		6/27/2023	Treatment of Myelodysplastic Syndrome (MDS)	Designated	Not FDA Approved for Orphan Indication	"Hemavant Sciences, GmbH"
Pegylated Iron Oxide Nanoparticles		6/26/2023	As a diagnostic for the management of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"MegaPro Biomedical Company, Ltd."
vancomycin		6/22/2023	Treatment of periprosthetic joint infection	Designated	Not FDA Approved for Orphan Indication	"ForCast Orthopedics, Inc."
"autologous T cells transduced with lentiviral vector encoding a G protein-coupled receptor class C, group 5, member D (GPRC5D)-specific chimeric antigen receptor"		6/21/2023	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company"
chimeric antigen receptor (CAR) modified recombinant T cells targeting B7-H3		6/21/2023	Treatment of Malignant Glioma	Designated	Not FDA Approved for Orphan Indication	Fuzhou Tcelltech Biological Science and Technology Inc.
Inobrodib		6/21/2023	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	CellCentric Ltd.
Flucytosine Injection for intravenous Infusion		6/21/2023	Treatment of cryptococcal meningitis	Designated	Not FDA Approved for Orphan Indication	Cipla Ltd.
a fully humanized immunoglobulin gamma 1 (IgG1) agonistic monoclonal antibody (mAb) that specifically targets and activates MuSK		6/21/2023	Treatment of congenital myasthenic syndrome	Designated	Not FDA Approved for Orphan Indication	argenx BV
"(2-Fluoro-5-trifluoromethoxy-phenyl)-carbamic acid 2-(2,6-dioxo-piperidin-3-yl)-3-oxo-2,3-dihydro-1H-isoindol-5-ylmethyl ester"		6/21/2023	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Monte Rosa Therapeutics, Inc."
Corticotropin (ACTH) porcine (synthetic)		6/21/2023	Treatment of membranous nephropathy	Designated	Not FDA Approved for Orphan Indication	"Cerium Pharmaceuticals, Inc."
Insulin-like Growth Factor-1		6/21/2023	Treatment of Spinal Bulbar Muscular Atrophy	Designated	Not FDA Approved for Orphan Indication	Sarcomed AB
recombinant human IgG1 neutralizing monoclonal antibody (mAb) that recognizes the dengue virus (DENV) envelope (E) protein		6/21/2023	Treatment of dengue	Designated	Not FDA Approved for Orphan Indication	AbViro LLC
"(7S)-N-(3-bromo-2-fluorophenyl)-7-[(4-methylpiperazin-1-yl)methyl]-7H,8H-[1,4]dioxino[2,3-g]quinazolin-4-amine"		6/21/2023	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Erasca, Inc."
Autologous delta-like-ligand 3 (DLL3)-targeted chimeric antigen receptor (CAR) T-cells		6/21/2023	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Legend Biotech USA, Inc."
"A ligand binding moiety to MDM2, a chemical linker, and a ligand binding moiety to an E3 ligase that leads to MDM2 degradation."		6/21/2023	Treatment of Acute Myeloid Leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	Kymera Therapeutics
autologous CD34+ hematopoietic stem and progenitor cells transduced with lentiviral vector containing the human DCLRE1C complementary DNA		6/20/2023	Treatment of patients with Artemis-deficient Severe Combined Immunodeficiency	Designated	Not FDA Approved for Orphan Indication	"Morton J Cowan, M.D."
cladribine		6/14/2023	Treatment of myasthenia gravis	Designated	Not FDA Approved for Orphan Indication	"EMD Serono, Inc."
Immune Globulin (Human)		6/12/2023	Treatment of Systemic Sclerosis	Designated	Not FDA Approved for Orphan Indication	"CSL Behring, L.L.C."
nitisinone		6/12/2023	Treatment of alkaptonuria	Designated	Not FDA Approved for Orphan Indication	Cycle Pharmaceuticals Ltd.
"(R)-1-[4'-(5-chloro-3-{[(1-phenylethoxy)carbonyl] amino}thiophen-2-yl)-2'-methoxy-[1,1'-biphenyl]-4-yl]cyclopropanecarboxylic acid"		6/12/2023	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"HiLung, Inc."
Denatonium acetate monohydrate		6/8/2023	Treatment of Prader Willi Syndrome	Designated	Not FDA Approved for Orphan Indication	"Aardvark Therapeutics, Inc."
"Spiro[3H-Indole-3,2¿-pyrrolidin]-2(1H)-one derivative"		6/8/2023	Treatment of biliary tract cancer	Designated	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
"(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol D-tartrate salt (1:1)"		6/8/2023	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	K36 Therapeutics Inc.
Adeno-associated virus serotype rh.74 vector containing the human Plakophilin-2a transgene (AAVrh.74-PKP2a)		6/5/2023	Treatment of PKP2-associated arrhythmogenic cardiomyopathy	Designated	Not FDA Approved for Orphan Indication	"Rocket Pharmaceuticals, Inc."
"an encapsulated, engineered human ARPE-19 cell line that constitutively expresses the native human IL-2 cytokine (hIL 2)fcx v"		6/5/2023	Treatment of mesothelioma	Designated	Not FDA Approved for Orphan Indication	"Avenge Bio, Inc."
N-myristoylated -Glu-Ala-Val-Ser-Leu-Lys-Pro-Thr		5/31/2023	Prevention of ischemia/reperfusion injury in kidney transplantation	Designated	Not FDA Approved for Orphan Indication	"Young Therapeutics, LLC"
Epstein-Barr Virus envelope glycoprotein 350 (gp350)-directed genetically modified autologous chimeric antigen receptor (CAR)-T cells		5/31/2023	Treatment of Nasopharyngeal Carcinoma	Designated	Not FDA Approved for Orphan Indication	Biosyngen Pte. Ltd.
synthetic 2'-O-methoxyethyl phosphorothioate oligoribonucleotide sodium salt consisting of 19 nucleotide residues with the sequence 5'-MeCMeUGMeUGGAAGMeUGAGGGMeCMeCAG-3'		5/31/2023	"Treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S)"	Designated	Not FDA Approved for Orphan Indication	Vanda Pharmaceuticals Inc.
recombinant anti-human activated protein C humanized monoclonal antibody		5/30/2023	Treatment of hemophilia A and B	Designated	Not FDA Approved for Orphan Indication	Equilibra Bioscience LLC
antibody drug conjugate targeting Claudin 18.2 (CLDN 18.2) consisting of a humanized monoclonal antibody against CLDN 18.2 and a conjugated linker-payload VC-MMAE (maleimidocaproyl-valine-citrulline-p-aminobenzylalcohol-Monomethyl Auristatin E)		5/22/2023	Treatment of Gastric Cancer	Designated	Not FDA Approved for Orphan Indication	"Antengene (Hangzhou) Biologics Co., Ltd."
Double-stranded small-interfering ribonucleic acid (siRNA) comprised of an antisense strand complementary to a targeted sequence within human PMP22 messenger RNA and a nucleotide sense strand linked to a fatty acid motif		5/22/2023	Treatment of Charcot-Marie-Tooth Disease Type 1A	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
Recombinant humanized anti-MSLN monoclonal antibody- monomethyl auristatin E conjugate		5/22/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"RemeGen Co., Ltd."
Mitazalimab		5/17/2023	Treatment of Pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Alligator Biosciences AB
Rucosopasem manganese		5/17/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Galera Therapeutics, Inc."
ivosidenib		5/17/2023	Treatment of Chondrosarcoma	Designated	Not FDA Approved for Orphan Indication	Servier Pharmaceuticals
"(R)-N-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a] pyrimidin-3-yl)-4-((4-methylpiperazin-1-yl)methyl)benzamide sulfate hydrate"		5/17/2023	Treatment of NTRK fusion-positive solid tumors	Designated	Not FDA Approved for Orphan Indication	Teligene US LLC
"(5R)-5-ethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione"		5/17/2023	Treatment of progressive myoclonic epilepsy-7	Designated	Not FDA Approved for Orphan Indication	Autifony Therapeutics Ltd.
felzartamab		5/17/2023	Treatment of membranous nephropathy	Designated	Not FDA Approved for Orphan Indication	Human Immunology Biosciences
"N-[3-fluoro-4-[[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-6-(1-methylethoxy)-2-oxo-3-pyridinecarboxamide"		5/16/2023	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Tyligand Bioscience (Shanghai) Limited
Obeticholic Acid; Bezafibrate		5/16/2023	Treatment of primary biliary cholangitis	Designated	Not FDA Approved for Orphan Indication	"Intercept Pharmaceuticals, Inc."
autologous CD3+ T cell product transduced with transgene constructs expressing anti-human mesothelin (MSLN) CAR and self-secreting anti-human PD-1 nanobody		5/16/2023	Treatment of Mesothelioma	Designated	Not FDA Approved for Orphan Indication	"Shanghai Cell Therapy Group Pharmaceutical Technology Co., Ltd."
avasimibe		5/16/2023	Treatment of Prader-Willi syndrome	Designated	Not FDA Approved for Orphan Indication	EFIL BioScience Inc.
Antibody drug conjugate targeting Claudin 18.2 (CLDN 18.2) consisting of a humanized monoclonal antibody against CLDN 18.2 and a conjugated linker-payload VC-MMAE (maleimidocaproyl-valine-citrulline-p-aminobenzylalcohol-Monomethyl Auristatin E)		5/16/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Antengene (Hangzhou) Biologics Co., Ltd."
Autologous Chimeric Antigen Receptor (CAR) Modified Recombinant T Cells Targeting EGFRvIII		5/9/2023	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Beijing DCTY® Biotech Co., Ltd."
Ampreloxetine		5/9/2023	Treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy	Designated	Not FDA Approved for Orphan Indication	Theravance Biopharma Ireland Limited
a phenylalanine consuming engineered bacteria		5/8/2023	Treatment of Phenylketonuria (PKU)	Designated	Not FDA Approved for Orphan Indication	"Synlogic Operating Company, Inc."
double stranded small interfering RNA composed of a CLCN7G215R allele-specific siRNA		5/8/2023	Treatment of Autosomal Dominant Osteopetrosis (ADO)	Designated	Not FDA Approved for Orphan Indication	SiSaf Ltd.
(68-Ga)-Trivehexin		5/8/2023	Diagnostic for the management of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Radiopharm Theranostics, Inc."
Bispecific antibody against CLDN18.2 and T cell receptor complex CD3		5/3/2023	Treatment of Gastric/GEJ Cancer	Designated	Not FDA Approved for Orphan Indication	"Astellas Pharma Global Development, Inc."
Fasudil hydrochloride		5/3/2023	Fasudil hydroTreatment of amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	"BioPharma Global, a division of Pace® Life Sciences"
allogeneic umbilical cord mesenchymal stem cells		5/3/2023	Treatment of ocular graft-versus-host-disease	Designated	Not FDA Approved for Orphan Indication	"Guangdong ProCapZoom Biosciences Co., Ltd."
multi-species cross-reactive anti-extra domain-B splice variant of fibronectin (EDB+FN) fully human IgG1 antibody engineered with 4 reactive cysteines to enable site-specific conjugation (kC183 + C290) to 4 Auristatin010		5/3/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Pyxis Oncology
Antibody-drug conjugate (ADC) consisting of a claudin 18.2 (CLDN18.2)-directed monoclonal antibody conjugated to monomethyl auristatin E (MMAE)		5/3/2023	Treatment of patients with claudin18.2-positive gastric adenocarcinoma	Designated	Not FDA Approved for Orphan Indication	"TORL Biotherapeutics, LLC"
luminol monosodium		5/1/2023	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	MetrioPharm AG
4-Hydroxy-4'-methyoxytolan		5/1/2023	Treatment of Epidermolysis Bullosa	Designated	Not FDA Approved for Orphan Indication	"BioMendics, LLC"
a fully humanized immunoglobulin G1 (IgG1) monoclonal antibody against CLDN18.2		5/1/2023	Treatment of patients with claudin18.2-positive pancreatic adenocarcinoma.	Designated	Not FDA Approved for Orphan Indication	"TORL Biotherapeutics, LLC"
Fully humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against claudin 18.2 (CLDN18.2)		5/1/2023	Treatment of patients with claudin18.2-positive gastric adenocarcinoma	Designated	Not FDA Approved for Orphan Indication	"TORL Biotherapeutics, LLC"
recombinant self-complementary adeno-associated virus9 gene therapy expressing codon-optimized human N-Sulfoglucosamine Sulfohydrolase gene		4/26/2023	Treatment of mucopolysaccharidosis (MPS) IIIA	Designated	Not FDA Approved for Orphan Indication	"NeuroGT, Inc."
Autologous CD34+ hematopoietic stem and progenitor cells edited by CRISPR/CAS12a at the HBG1 and HBG2 promoters		4/26/2023	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"Editas Medicine, Inc."
Ifinatamab deruxtecan		4/26/2023	Treatment of small-cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Daiichi Sankyo, Inc."
Trypan Blue and Brilliant Blue G Ophthalmic Solution		4/26/2023	To selectively stain the epiretinal membrane and internal limiting membrane	Designated	Not FDA Approved for Orphan Indication	D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.
Adeno-Associated Virus Serotype 5 capsid protein containing gene construct encoding human Retinoic Acid Receptor-Related Orphan Receptor Alpha		4/26/2023	Treatment of ABCA4-associated retinopathies	Designated	Not FDA Approved for Orphan Indication	"Ocugen, Inc."
Anagrelide		4/24/2023	Treatment of Gastrointestinal Stromal Tumors	Designated	Not FDA Approved for Orphan Indication	Sartar Therapeutics Oy
"a cysteine conjugated ADC, where the mc-vc-PAB-MMAE linker/payload is conjugated to mAb intermediate, an immunoglobulin G1(IgG1) molecule;"		4/24/2023	Treatment of patients with claudin18.2-positive pancreatic adenocarcinoma	Designated	Not FDA Approved for Orphan Indication	"TORL Biotherapeutics, LLC"
Pegcetacoplan		4/24/2023	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"Apellis Pharmaceuticals, Inc."
Edralbrutinib		4/24/2023	Treatment of neuromyelitis optica spectrum disorder	Designated	Not FDA Approved for Orphan Indication	Reistone Biopharma Company Limited
"Expanded, activated methylguanine methyltransferase (MGMT) gene-modified gamma-delta T cells drug resistant immunotherapy"		4/24/2023	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	IN8bio Inc.
Pemafibrate		4/20/2023	Treatment of primary biliary cholangitis	Designated	Not FDA Approved for Orphan Indication	"Kowa Research Institute, Inc."
oxypurinol		4/20/2023	Treatment of autosomal dominant polycystic kidney disease	Designated	Not FDA Approved for Orphan Indication	XORTX Therapeutics Inc.
"(2M)-2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1- methyl-1H-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3- fluorobenzonitrile"		4/20/2023	Treatment of Mesothelioma	Designated	Not FDA Approved for Orphan Indication	"Mirati Therapeutics, Inc."
O-(2-[18F]fluoroethyl)-L-tyrosine		4/20/2023	Diagnostic for the management of malignant glioma	Designated	Not FDA Approved for Orphan Indication	UCSF Radiopharmaceutical Facility
"(2-(6-(2-(4-cyclopropylpyrimidin-5-yl)-4-fluorophenoxy)-1,2,4-triazin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)((1S,3aR,6aS)-octahydrocyclopenta[c]pyrrol-1-yl)methanone"		4/17/2023	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	BioNova Pharmaceuticals (Shanghai) Limited
lisocabtagene maraleucel		4/17/2023	Treatment of extranodal marginal zone lymphoma	Designated	Not FDA Approved for Orphan Indication	"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company"
lisocabtagene maraleucel		4/17/2023	Treatment of splenic marginal zone lymphoma	Designated	Not FDA Approved for Orphan Indication	"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company"
Methyl 4-{[2-(acetamino)ethyl]sulfanyl}-4-oxobutanoate		4/14/2023	Treatment of mitochondrial disease	Designated	Not FDA Approved for Orphan Indication	Abliva AB
A plasmid encoding a rabies virus glycoprotein tag & lysosome-associated membrane glycoprotein 2 fusion protein gene and a mutant huntingtin small interfering RNA		4/10/2023	Treatment of Huntington’s disease	Designated	Not FDA Approved for Orphan Indication	ExoRNA Bioscience Nanjing Co. Ltd.
Padeliporfin		4/5/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	IMPACT Biotech Ltd
IgG4 monoclonal antibody directed against protein S		4/5/2023	Treatment of von Willebrand disease	Designated	Not FDA Approved for Orphan Indication	"Vega Therapeutics, Inc."
lisocabtagene maraleucel		3/30/2023	Treatment of nodal marginal zone lymphoma	Designated	Not FDA Approved for Orphan Indication	"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company"
Adeno-associated viral vector serotype 9 (AAV9) containing human RPE65 gene		3/30/2023	Treatment of inherited retinal disease caused by RPE65 mutations	Designated	Not FDA Approved for Orphan Indication	"Cholgene Therapeutics, Inc."
vepafestinib		3/30/2023	Treatment of RET alteration-positive non-small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	Helsinn Healthcare SA
1-O-octadecyl-2-arachidonoyl-sn-glycerol-3-phosphoethanolamine		3/29/2023	Treatment of Rett Syndrome	Designated	Not FDA Approved for Orphan Indication	Institute of Rheological Functions of Food
Glucagon like peptide-1 (GLP-1) Elastin like peptide (ELP)-120 fusion protein		3/29/2023	Treatment of Dermatomyositis (DM)	Designated	Not FDA Approved for Orphan Indication	"ImmunoForge Co., Ltd."
Adeno-associated virus vector expressing human iduronate-2-sulfatase		3/28/2023	"Treatment of mucopolysaccharidosis (MPS) II, also called Hunter syndrome"	Designated	Not FDA Approved for Orphan Indication	"NeuroGT, Inc."
"2,5,6,11,12,13-Hexahydro-2-methyl-11-(2-methylpropyl)-8-(2-pyrimidinylamino)-4H-indazolo[5,4-c]pyrrolo[3,4-c]carbazol-4-one mono(4-methylbenzenesulfonate)"		3/27/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Esanik Therapeutics, Inc."
parsaclisib and ruxolitinib		3/27/2023	Treatment of myelofibrosis	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA		3/27/2023	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	BioMarin Pharmaceutical Inc.
a multiple substituted pyrimidoheterocycle small molecule inhibitor that covalently binds to the Switch II pocket of KRAS p.G12C and locks the oncogenic protein in its GDP-bound inactive form		3/27/2023	Treatment of patients with advanced pancreatic cancer harboring KRAS p.G12C mutant protein	Designated	Not FDA Approved for Orphan Indication	"D3 Bio (Wuxi) Co., Ltd."
3-(5-cyano-4-(cyclopropylamino)pyridin-2-yl)-1-(6-formyl-5-((4-methyl-2-oxopiperazin-1-yl)methyl)pyridin-2-yl)-1-methylurea		3/27/2023	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"Wuxi Abbisko Biomedical Technology Co., Ltd."
Autologous CD4+/CD8+ T cells transduced with lentiviral vector directed against MAGE-A4 antigen		3/23/2023	Treatment of Stage III to IV Melanoma	Designated	Not FDA Approved for Orphan Indication	TCRx (KeShiHua.Shenzhen) Therapeutics Ltd.
"Humanized, Low-fucose Anti-Claudin 18.2 IgG1 Antibody"		3/23/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Suzhou Transcenta Therapeutics Co., Ltd."
human anti-CD94 IgG1 monoclonal antibody (non-fucosylated)		3/23/2023	Treatment of large granular lymphocyte leukemia (LGLL)	Designated	Not FDA Approved for Orphan Indication	"Dren Bio, Inc"
zagociguat		3/23/2023	Treatment of mitochondrial diseases	Designated	Not FDA Approved for Orphan Indication	"Tisento Therapeutics, Inc."
tirabrutinib		3/21/2023	Treatment of primary central nervous system lymphoma	Designated	Not FDA Approved for Orphan Indication	"Ono Pharma USA, Inc"
"Glycine, L-prolyl-L-prolyl-L-leucyl-L-seryl-L-glutaminyl-L-(i-circumflex plus/minus)-glutamyl-L-threonyl-L-phenylalanyl-L-seryl-L-(i-circumflex plus/minus)-aspartyl-L-leucyl-L-tryptophyl-L-lysyl-L-leucyl-L-leucyl-L-lysyl-L-lysyl-L-tryptophyl-L-lysyl-L-methionyl-L-arginyl-L-arginyl-L-asparaginyl-L-glutaminyl-L-phenylalanyl-L-tryptophyl-L-valyl-L-lysyl-L-valyl-L-glutaminyl-L-arginyl-"		3/21/2023	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	"Oncolyze, Inc."
"N-(4-(1-cyclopropyl-4-fluoro-2-methyl-1H-benzo[d]imidazol-6-yl)-5-fluoropyrimidin-2-yl)-6-(2-(dimethylamino)ethyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine maleate"		3/21/2023	Treatment of Liposarcoma	Designated	Not FDA Approved for Orphan Indication	Shanghai Pharma Biotherapeutics USA Inc.
a Fab drug targeting the human TfR1 and conjugated to a PMO designed to bind to DMD exon 51		3/21/2023	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	"Dyne Therapeutics, Inc."
ganaxolone		3/21/2023	Treatment of Lennox-Gastaut Syndrome (LGS)	Designated	Not FDA Approved for Orphan Indication	"Marinus Pharmaceuticals, Inc."
Alpelisib		3/21/2023	Treatment of lymphatic malformations	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
an orally bioavailable ALK inhibitor (a macrocyclic compound containing nitrogen heterocycles)		3/20/2023	"Treatment of ALK-positive, ROS1-positive, and LTK-positive non-small cell lung cancer (NSCLC)"	Designated	Not FDA Approved for Orphan Indication	"Nuvalent, Inc."
Bezuclastinib		3/17/2023	Treatment of Mastocytosis	Designated	Not FDA Approved for Orphan Indication	"Cogent Biosciences, Inc."
selective rapidly accelerated fibrosarcoma (RAF) murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor		3/17/2023	Treatment of primary brain and CNS malignancies	Designated	Not FDA Approved for Orphan Indication	Fore Biotherapeutics U.S. Inc.
"Ethenesulfonamide, 2-[(2R)-1,2-dimethyl-2- pyrrolidinyl]-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4- yl)amino]carbonyl]-, (1E)-"		3/17/2023	Treatment of Cryopyrin Associated Periodic Syndromes (CAPS)	Designated	Not FDA Approved for Orphan Indication	Zydus Therapeutics Inc.
fluciclovine (18F)		3/17/2023	Diagnostic for the management of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Blue Earth Diagnostics Ltd
"allogeneic CD3-depleted, CD56-enriched activated natural killer-cell product"		3/16/2023	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	"Wugen, Inc."
Parathyroid Hormone Inverse Agonist (PTH-IA)		3/16/2023	Treatment of patients with Jansen’s Metaphyseal Chondrodysplasia	Designated	Not FDA Approved for Orphan Indication	"National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)"
N-Acetyl-Leucine		3/14/2023	Treatment of Ataxia-oculomotor apraxia-4 (AOA4)	Designated	Not FDA Approved for Orphan Indication	IntraBio Inc.
"2-(2-chlorophenyl)-5-hydroxy-8-((3S,4R)-3-hydroxy-1-methylpiperidin-4-yl)-4-oxo-4H-chromen-7-yl dihydrogen phosphate"		3/14/2023	Treatment of Ewing sarcoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sumitomo Pharma America, Inc."
Arginine butyrate		3/9/2023	Treatment of Short Bowel Syndrome	Designated	Not FDA Approved for Orphan Indication	Baxter Healthcare Corporation
Rifampin		3/7/2023	Treatment of Frontotemporal Dementia	Designated	Not FDA Approved for Orphan Indication	"Medilabo RFP, Inc."
Autologous CD34+ cells edited with CRISPR/Cas9 and transduced with an adeno-associated virus vector serotype 6 containing the codon-optimized version of PKLR gene		3/7/2023	Treatment of Pyruvate Kinase Deficiency	Designated	Not FDA Approved for Orphan Indication	Consorcio Centro de Investigación Biomédica en Red (CIBER)
ex vivo expanded allogeneic cord blood-derived NK cells that have been genetically modified to express a HER2-directed CAR and secrete IL-15		3/7/2023	Treatment of gastric and gastroesophageal junction cancer	Designated	Not FDA Approved for Orphan Indication	"Artiva Biotherapeutics, Inc."
2-{[2-benzyl-4-(5-methyl-3H-imidazol-4-ylmethyl)-3-oxo-piperazine-1-carbonyl]- amino}-4methyl-pentanoic acid		3/7/2023	Treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Prescient Therapeutics, LTD"
"6-Chloro-7-[4-[4-chlorophenyl)methyl]piperazin-1-yl]-2-(1,3-dimethylpyrazol-4-yl)-3H- imidazo[4,5-b]pyridine-3-ium fumarate"		3/1/2023	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	"Ellipses Pharma, Ltd."
Autologous CD34+ cell enriched haematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding for human Interferon-alpha2 cDNA (Temferon)		3/1/2023	Treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	Genenta Sciences
siRNA oligonucleotide designed to target and knockdown the expression of SOD1		3/1/2023	Treatment of Amyotrophic Lateral Sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	Ractigen Therapeutics
Autologous CD34+ cells transduced with a lentiviral vector that encodes for the human NCF1 cDNA sequence		3/1/2023	Treatment of chronic granulomatous disease	Designated	Not FDA Approved for Orphan Indication	Somagenetix AG
Mefuparib		2/28/2023	Treatment of Biliary Tract Cancer	Designated	Not FDA Approved for Orphan Indication	"Convalife (Shanghai) Co., Ltd."
crofelemer		2/27/2023	Treatment of microvillus inclusion disease	Designated	Not FDA Approved for Orphan Indication	Napo Pharmaceuticals Inc.
Gallium maltolate		2/27/2023	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	"Imaging Biometrics, LLC"
"Recombinant serotype 9 adeno-associated virus (AAV) encoding an intron encoding a miRNA generating sequence, complementary miRNA binding sites and a full-length human methyl cytosine binding protein 2 (MECP2)"		2/27/2023	Treatment of Rett syndrome	Designated	Not FDA Approved for Orphan Indication	Neurogene Inc.
"Dextran-coated, nanoparticle-conjugated stabilized synthetic antisense oligonucleotide targeting miR-10b"		2/27/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"TransCode Therapeutics, Inc."
"bispecific, biparatopic antibody targeting CD38 and CD47"		2/27/2023	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	Ichnos Sciences SA
a recombinant human IgG1 with minimized Fc effector function that selectively binds to BMP9 with high affinity and inhibits its interaction with Type II receptors on endothelial cells thereby blocking downstream signaling		2/24/2023	Treatment of Pulmonary Arterial Hypertension	Designated	Not FDA Approved for Orphan Indication	Pfizer Inc.
5-Arylnicotinamide ABCA1 inducer		2/22/2023	Treatment of Alport syndrome (AS)	Designated	Not FDA Approved for Orphan Indication	River 3 Renal Corp.
"an IgG1 humanized antibody directed against Carcinoembryonic Antigen-related Cell Adhesion Molecule (CEACAM)1, 3 and 5"		2/22/2023	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Ymmunobio AG
batiraxcept		2/22/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Aravive, Inc."
"a B-cell maturation antigen (BCMA)-directed, genetically engineered T cell immunotherapy product derived from an autologous leukapheresis"		2/21/2023	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
an orally bioavailable ROS1 inhibitor (a macrocyclic compound containing nitrogen heterocycles)		2/21/2023	"Treatment of ROS1-positive, LTK-positive, and ALK-positive non-small cell lung cancer"	Designated	Not FDA Approved for Orphan Indication	"Nuvalent, Inc."
a fully human monoclonal antibody that binds and activates the Tie2 receptor		2/21/2023	Treatment of systemic capillary leak syndrome	Designated	Not FDA Approved for Orphan Indication	"PharmAbcine, Inc."
"a humanized, immunoglobulin G subtype 4 anti-Amphiregulin monoclonal antibody"		2/16/2023	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	"Pulmongene (Hong Kong) Co., Limited"
allogeneic T cells genetically modified to express anti-B7-H3 chimeric antigen receptor (CAR)		2/16/2023	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"T-MAXIMUM Pharmaceutical (Suzhou) Co., Ltd."
(-)-B-Elemene		2/14/2023	Treatment of Glioblastoma Multiforme (GBM)	Designated	Not FDA Approved for Orphan Indication	"Sichuan Honghe Biotechnology Co., Ltd."
"An antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector function null, humanized IgG1 antibody, a MCC maleimide linker, and a double-stranded siRNA oligonucleotide targeting DUX4"		2/13/2023	Treatment of facioscapulohumeral muscular dystrophy (FSHD)	Designated	Not FDA Approved for Orphan Indication	"Avidity Biosciences, Inc."
humanized immunoglobulin G1 anti-integrin beta-6 monoclonal antibody conjugated to monomethyl auristatin E		2/13/2023	Treatment of Esophageal Cancer	Designated	Not FDA Approved for Orphan Indication	Seagen Inc.
Red blood cell-derived microparticles		2/9/2023	Treatment of intracerebral hemorrhage	Designated	Not FDA Approved for Orphan Indication	"RxMP Therapeutics, Inc."
rituximab		2/7/2023	Treatment of autoimmune hemolytic anemia	Designated	Not FDA Approved for Orphan Indication	Mabion S.A.
"(R)-1-(3,3-difluoro-1-methlypiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one"		2/7/2023	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Wayshine Biopharm, INC"
Ketamine		2/1/2023	Treatment of Rett Syndrome	Designated	Not FDA Approved for Orphan Indication	PharmaTher Inc.
"5¿-(4-fluorophenyl)-3¿-isopropyl-N-(4-(4-methylpiperazin-1-yl) phenyl)-1H,3¿H-[2,4¿-biimidazole]-4-carboxamide acetate"		2/1/2023	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	InSilico Medicine Hong Kong Limited
"Human decorin, natural anti-fibrotic protein, fused to the C-terminal vascular homing peptide tCRK"		1/31/2023	Treatment of epidermolysis bullosa (EB)	Designated	Not FDA Approved for Orphan Indication	Tampereen Korkeakoulusäätiö sr.
H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt		1/26/2023	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"CanBas Co., Ltd."
rituximab		1/26/2023	Treatment of membranous nephropathy	Designated	Not FDA Approved for Orphan Indication	Mabion S.A.
"2-[(3S)-2,6-dioxopiperidin-3-yl]-4-{[(2-fluoro-4-{[3-(morpholin-4-yl)azetidin-1-yl]methyl} phenyl) methyl]amino}-1H-isoindole-1,3(2H)-dione-hydrogen chloride (1/1)"		1/25/2023	Treatment of Follicular Lymphoma (FL)	Designated	Not FDA Approved for Orphan Indication	Celgene Coporation
Degrader of Lysine-specific histone demethylase 1A and REST Corepressor 1		1/25/2023	Treatment of Glioblastoma	Designated	Not FDA Approved for Orphan Indication	Beactica Therapeutics AB
adeno-associated viral vector serotype 2 containing the human SLC6A3 gene		1/24/2023	Treatment of dopamine transporter deficiency syndrome (DTDS)	Designated	Not FDA Approved for Orphan Indication	Bloomsbury Genetic Therapies Ltd.
belimumab		1/24/2023	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	GSK LLC
Recombinant Human Heparan N-sulfatase (rhHNS)		1/24/2023	Treatment of Mucopolysaccharidosis type IIIA (MPS IIIA)	Designated	Not FDA Approved for Orphan Indication	GC Biopharma Corp.
recombinant human IL12/15-PDL1B HSV-1 oncolytic virus injection		1/23/2023	"Treatment of Intrahepatic cholangiocarcinoma (ICC, iCCA)"	Designated	Not FDA Approved for Orphan Indication	Virogin Biotech Canada Ltd
Piperidine-containing autotaxin inhibitor		1/19/2023	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	NextGen Bioscience
ezurpimtrostat		1/18/2023	Treatment of hepatocellular carcinoma (HCC)	Designated	Not FDA Approved for Orphan Indication	Genoscience Pharma
"(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide"		1/18/2023	Treatment of Glioblastoma (GBM)	Designated	Not FDA Approved for Orphan Indication	Jubilant Therapeutics Inc.
"(S)-N-(5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide"		1/18/2023	Treatment of Behcet’s disease	Designated	Not FDA Approved for Orphan Indication	"Ganzhou Hemay Pharmaceutical Co., Ltd."
"N-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(3,3-dimethylpiperazin-1-yl)benzamide hydrochloride"		1/12/2023	Treatment of gastric cancer and gastro-esophageal junction cancer	Designated	Not FDA Approved for Orphan Indication	"3D Medicines (Beijing) Co., Ltd"
"N-(3-(2-cyanopropan-2-yl)-5-(4-methyl-1H-imidazol-1-yl)phenyl)-2-fluoro-4-methyl-5-((8-((1-methyl-1H-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethynyl)benzamide dihydrochloride"		1/12/2023	Treatment of Chronic myeloid leukemia (CML)	Designated	Not FDA Approved for Orphan Indication	"ImmunoForge Co., Ltd."
Budoprutug		1/12/2023	Treatment of Membranous Nephropathy	Designated	Not FDA Approved for Orphan Indication	"Tenet Medicines, Inc."
"a humanized IgG4 monoclonal antibody, produced in CHO cells, that binds to and inhibits the activated form of the classical complement pathway (CP) specific serine protease, C1s"		1/12/2023	Treatment of Autoimmune Hemolytic Anemia (AIHA)	Designated	Not FDA Approved for Orphan Indication	Bioverativ USA Inc
Therapeutic Inducers of Natural Killer cell Killing Immunotherapy expanded from cord blood-derived hematopoietic progenitors		1/12/2023	Treatment of Acute Lymphoblastic Leukemia (ALL)	Designated	Not FDA Approved for Orphan Indication	Centre Hospitalier Universitaire Sainte-Justine
Golexanolone		1/12/2023	Treatment of primary biliary cholangitis	Designated	Not FDA Approved for Orphan Indication	Umecrine Cognition AB
recombinant adeno-associated virus serotype 8 vector encoding human phenylalanine hydroxylase (PAH)		1/9/2023	Treatment of Phenylketonuria (PKU)	Designated	Not FDA Approved for Orphan Indication	NGGT INC.
Trineumin		1/9/2023	Treatment of neurofibromatosis type 2	Designated	Not FDA Approved for Orphan Indication	"PRG S&T Co., Ltd"
"2,7-bis(3-morpholinopropyl)-4-((2-(pyrrolidin-1-yl)ethyl)amino)-9-(4-(pyrrolidin-1-ylmethyl)phenyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone"		1/9/2023	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	"Qualigen Therapeutics, Inc."
"Lyophilized microbiota purified from the stool of screened, healthy human donors"		1/3/2023	Treatment of Pitt Hopkins Syndrome	Designated	Not FDA Approved for Orphan Indication	Gut-Brain Axis Therapeutics
Cannabidiol acid methyl ester (CBDA-ME)		1/3/2023	Treatment of Prader-Willi Syndrome	Designated	Not FDA Approved for Orphan Indication	EPM Group Inc.
(+)N-hydroxy-N-(methylacylfulvene)urea		1/3/2023	Treatment of Mantle Cell Lymphoma	Designated	Not FDA Approved for Orphan Indication	Lantern Pharma
Ivaltinostat		1/3/2023	Treatment of Idiopathic Pulmonary Fibrosis.	Designated	Not FDA Approved for Orphan Indication	"Machaon Biotherapeutics, Inc."
"1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl] ethanone"		1/3/2023	Treatment of Stage IIB to Stage IV Melanoma	Designated	Not FDA Approved for Orphan Indication	"Linnaeus Therapeutics, Inc."
Humanized one-armed monoclonal antibody with high affinity for NMDA receptor		12/29/2022	Treatment of anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis	Designated	Not FDA Approved for Orphan Indication	"Arialys Therapeutics, Inc."
L-Ergothioneine		12/28/2022	Treatment of Cystinuria	Designated	Not FDA Approved for Orphan Indication	AVEROA SAS
"N-hydroxy-4-((4-((((1R,2S)-2-phenylcyclopropyl) amino)methyl)-1H-pyrazol-1-yl)methyl)benzamide hydrogen bromide"		12/27/2022	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	Jubilant Therapeutics Inc.
bitopertin		12/22/2022	Treatment of Erythropoietic Protoporphyria	Designated	Not FDA Approved for Orphan Indication	Disc Medicine
Adenine		12/22/2022	Treatment of Epidermolysis Bullosa	Designated	Not FDA Approved for Orphan Indication	Energenesis Biomedical Co. Ltd.
a fusion protein comprised of genetically engineered human serine peptidase inhibitor and human immunoglobulin G1 Fc		12/21/2022	Treatment of Netherton Syndrome	Designated	Not FDA Approved for Orphan Indication	"Daiichi Sankyo, Inc."
Adeno-associated Virus Vector Containing an Expression Cassette of the Human Factor VIII Transgene		12/21/2022	Treatment of Hemophilia A	Designated	Not FDA Approved for Orphan Indication	Belief BioMed Limited
azeliragon		12/20/2022	Treatment of Glioblastoma	Designated	Not FDA Approved for Orphan Indication	Cantex Pharmaceuticals
Tegavivint		12/20/2022	Treatment of Hepatocellular Carcinoma	Designated	Not FDA Approved for Orphan Indication	Iterion Therapeutics
a modified version of a leucine decarboxylase enzyme from Planctomycetaceae bacterium		12/20/2022	Treatment of Maple Syrup Urine Disease	Designated	Not FDA Approved for Orphan Indication	"Codexis, Inc."
"a DMD exon 44 skipping PMO and a proprietary cyclic peptide, EEV, that is designed to enable robust muscle tissue uptake, high cellular internalization and endosomal escape of oligonucleotide therapeutics"		12/16/2022	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	"Entrada Therapeutics, Inc."
Taldefgrobep Alfa		12/16/2022	Treatment of spinal muscular atrophy	Designated	Not FDA Approved for Orphan Indication	"Biohaven Pharmaceuticals, Inc."
T cell therapeutic product obtained from transduction of chimeric T cell receptor synthetic T cell receptor and antigen receptor (STAR)		12/15/2022	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	Bristar Immunotech Limited
Human Nuclear Hormone Receptor Subfamily 2 Group E Member 3 (hNR2E3)		12/15/2022	Treatment of Retinitis Pigmentosa	Designated	Not FDA Approved for Orphan Indication	"Ocugen, Inc."
Human Nuclear Hormone Receptor Subfamily 2 Group E Member 3 (hNR2E3)		12/15/2022	Treatment of Leber congenital amaurosis	Designated	Not FDA Approved for Orphan Indication	"Ocugen, Inc."
ketamine hydrochloride		12/14/2022	Prevention of ischemia/reperfusion injury during solid organ transplantation.	Designated	Not FDA Approved for Orphan Indication	PharmaTher Inc.
anifrolumab		12/14/2022	Treatment of Idiopathic Inflammatory Myopathies	Designated	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals LP
"1,2:5,6-dianhydrogalactitol"		12/14/2022	Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)	Designated	Not FDA Approved for Orphan Indication	"Kintara Therapeutics, Inc."
"Hemi L-glutarate salt of 7-[(3R,4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5- dihydro-pyrrolo [3,2-d] pyrimidin-4-one"		12/14/2022	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	Laevoroc Immunology
a genetically modified salmonella comprising of methioninase		12/14/2022	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"Guangzhou Sinogen Pharmaceutical Co., Ltd."
(H-L-Arginyl-L-Valyl-L-Isoleucyl-L-Arginyl-L-Alanyl-L-Cysteinyl-L-Leucyl-Glycyl-L-Valyl-Glycyl-L-Leucyl-L-Leucyl-Glycyl-L-Asparaginyl-L-Leucyl-D-Alanyl-Glycyl-L-Lysyl-amino-PEG12-propionic acid)2 (Disulfide bond at Cys)		12/13/2022	Treatment of idiopathic pulmonary fibrosis (IPF)	Designated	Not FDA Approved for Orphan Indication	"CohBar, Inc."
cannabidiol		12/12/2022	Treatment of Glioblastoma	Designated	Not FDA Approved for Orphan Indication	Transpire Bio Inc.
fixed-dose combination of potassium citrate and potassium bicarbonate		12/9/2022	Treatment of primary/inherited distal renal tubular acidosis	Designated	Not FDA Approved for Orphan Indication	Advicenne
Imiquimod		12/8/2022	Treatment of Stage IIB-IV melanoma	Designated	Not FDA Approved for Orphan Indication	Celista Pharmaceuticals LLC
conditionally-replicative CD40L-expressing adenovirus		12/8/2022	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Adze Biotechnology, Inc."
1-[12-(1 Carboxycyclopropyl) dodecyl] cyclopropane-1-carboxylic acid		12/7/2022	Treatment of Congenital X-linked Nephrogenic Diabetes Insipidus	Designated	Not FDA Approved for Orphan Indication	"NephroDI Therapeutics, Inc."
"6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl) phenyl)-1-ethyl-7- phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one L-Tartrate salt"		12/7/2022	Treatment of Hereditary Hemorrhagic Telangiectasia	Designated	Not FDA Approved for Orphan Indication	Vaderis Therapeutics AG
"N-[(1S)-1-(4- fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N'-(pyrazin-2-yl)pyridine-2,6- diamine maleate"		12/7/2022	Treatment of myelofibrosis	Designated	Not FDA Approved for Orphan Indication	"NS Pharma, Inc."
luveltamab tazevibulin		12/7/2022	Treatment of pediatric acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Sutro Biopharma, Inc."
Small molecule inhibitor of PRMT5 (protein arginine methyl transferase 5)		12/5/2022	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Tango Therapeutics, Inc."
Live biotherapeutic product consisting of a single bacterial strain (Leuconostoc citreum [L. citreum])		12/1/2022	Treatment of Primary Sclerosing Cholangitis	Designated	Not FDA Approved for Orphan Indication	LISCure Biosciences Inc.
Recombinant humanized IgG1 anti-Claudin18.2 monoclonal antibody conjugated to MMAE		12/1/2022	"Treatment of Gastric cancer (GC), including cancer of the gastroesophageal junction (GEJ)"	Designated	Not FDA Approved for Orphan Indication	"RemeGen Co., Ltd."
Recombinant humanized IgG1 anti-Claudin18.2 monoclonal antibody conjugated to MMAE		12/1/2022	Treatment of Pancreatic cancer (PC)	Designated	Not FDA Approved for Orphan Indication	"RemeGen Co., Ltd."
"single stranded, synthetic, hybrid RNA/DNA antisense oligonucleotide (ASO) gapmer targeting the TUBB4A gene"		12/1/2022	Treatment of hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC)	Designated	Not FDA Approved for Orphan Indication	SynaptixBio Ltd.
Self-complimentary adeno-associated virus 9 gene therapy containing codon optimized human AP4M1		12/1/2022	Treatment of patients with Spastic Paraplegia Type 50 (SPG50) caused by the AP4M1 gene mutation	Designated	Not FDA Approved for Orphan Indication	CureSPG50
ifenprodil		12/1/2022	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	Algernon Pharmaceuticals Inc.
A dual vector gene therapy product containing AAV8 vectors expressing the 5¿ and 3¿ portion of human otoferlin (OTOF) gene		11/29/2022	Treatment of otoferlin related hearing loss	Designated	Not FDA Approved for Orphan Indication	Sensorion S.A.
dasatinib		11/29/2022	Treatment of acute lymphoblastic leukemia (ALL)	Designated	Not FDA Approved for Orphan Indication	Xspray Pharma AB
incobotulinumtoxinA		11/28/2022	Treatment of hemifacial spasm	Designated	Not FDA Approved for Orphan Indication	"Merz Pharmaceuticals, LLC"
autologous cell therapy product manufactured from tumor-infiltrating lymphocytes that have been harvested from surgically resected tumor tissue and expanded ex vivo		11/28/2022	Treatment of stage IB2 (tumor size >2 cm) to stage IV cervical cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Instil Bio, Inc."
radgocitabine		11/28/2022	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	"Delta-Fly Pharma, Inc."
Pigment Epithelium Derived Factor derived short peptide (Ac-Ser-Leu-Gly-Ala-Glu-Gln-Arg-Thr-Glu-Ser-Ile-Ile-His-Arg-Ala- Leu-Tyr-Tyr-Asp-Leu-Ile-Ser-Ser-Pro-Asp-Ile-His-Gly-Thr-NH2)		11/28/2022	Treatment of Neurotrophic Keratitis	Designated	Not FDA Approved for Orphan Indication	BRIM Biotechnology
ribociclib		11/25/2022	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
A native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene		11/22/2022	Treatment for arrhythmogenic right ventricular cardiomyopathy (ARVC) due to PKP2 mutations.	Designated	Not FDA Approved for Orphan Indication	Tenaya Therapeutics
"[4-[(2R)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxy-propyl]-8-[(1-methyl-4-piperidyl)oxy]-2,3-dihydro-1,4-benzoxazepin-5-one]"		11/22/2022	Treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	SK Life Science Inc.
An immunoglobulin subclass 1 (IgG1) human monoclonal antibody that targets the Marburg virus (MARV) glycoprotein		11/22/2022	Treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).	Designated	Not FDA Approved for Orphan Indication	"Mapp Biopharmaceutical, Inc."
tegavivint		11/22/2022	Treatment of Osteosarcoma	Designated	Not FDA Approved for Orphan Indication	"Iterion Therapeutics, Inc"
synthetic double-strand small interfering ribonucleic acid (siRNA) oligonucleotide drug directed against C3 messenger RNA		11/22/2022	Treatment of C3 Glomerulopathy	Designated	Not FDA Approved for Orphan Indication	Silence Therapeutics plc
live biotherapeutic consisting of metP and metDC genes which are incorporated into the genome of a probiotic strain of E. coli Nissie 1917		11/22/2022	Treatment of homocystinuria	Designated	Not FDA Approved for Orphan Indication	"Synlogic Operating Company, Inc."
mebendazole		11/22/2022	Treatment of Autosomal Dominant Polycystic Kidney Disease	Designated	Not FDA Approved for Orphan Indication	Healx Technology Limited
Autologous Claudin18.2-targeted CAR-T cells		11/22/2022	Treatment of gastric cancer (GC) including gastroesophageal junction (GEJ) cancer	Designated	Not FDA Approved for Orphan Indication	"Legend Biotech USA, Inc."
serdexmethylphenidate		11/17/2022	Treatment of Idiopathic hypersomnia	Designated	Not FDA Approved for Orphan Indication	KemPharm Inc.
Recombinant adeno-associated virus (rAAV) vector expressing human retinoschisis protein RS1		11/15/2022	Treatment of juvenile X-linked retinoschisis	Designated	Not FDA Approved for Orphan Indication	"Langxin Qisheng (Suzhou) Biopharmaceutical Co., Ltd."
Single Protein Encapsulated Doxorubicin		11/15/2022	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	Sunstate Biosciences LLC
"3-([3,3-dibutyl-7-(methylsulfanyl)-1,1-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-1Lambda6,2,5-benzothiadiazepin-8-yl]oxy)propanoic acid"		11/15/2022	Treatment of Primary Sclerosing Cholangitis	Designated	Not FDA Approved for Orphan Indication	Albireo AB
Iodine (I124) evuzamitide		11/14/2022	Diagnostic for the management of immunoglobulin light chain amyloidosis	Designated	Not FDA Approved for Orphan Indication	"Attralus, Inc."
"5-[2-[(3,4-dichlorobenzoyl)amino]ethyl]-N-hydroxy-3-isoxazolecarboxamide"		11/8/2022	Treatment of Stage IIb to IV melanoma	Designated	Not FDA Approved for Orphan Indication	Avstera Therapeutics Corp.
a genetically modified Salmonella comprising of methioninase		11/8/2022	Treatment for osteosarcoma	Designated	Not FDA Approved for Orphan Indication	"Guangzhou Sinogen Pharmaceutical Co., Ltd."
autologous T-cells expressing a chimeric antigen receptor directed against B-Cell maturation antigen		11/8/2022	Treatment of Myasthenia Gravis	Designated	Not FDA Approved for Orphan Indication	"Cartesian Therapeutics, Inc."
recombinant human interleukin-10 fusion protein		11/8/2022	Treatment of pouchitis	Designated	Not FDA Approved for Orphan Indication	"Applied Molecular Transport, Inc."
vibostolimab and pembrolizumab		11/8/2022	Treatment of Small Cell Lung Cancer (SCLC)	Designated	Not FDA Approved for Orphan Indication	"Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc."
"64-fluoro-36-methox-27-methyl-5-thia-4,8-diaza-2(4,6)-tieno[3,2-d]pyrimidine-3(3,5)-pyridina-1(2,5)-thiophena-6(1,3)-benzeneacyclononaphan-7-one 5,5-dioxide"		11/8/2022	Treatment of Neuroblastoma	Designated	Not FDA Approved for Orphan Indication	AUM Biosciences
"Immunoglobulin G [27-histidine,57-histidine,253-tyrosine,255- threonine,257-glutamic acid], anti-(human complement C5) (human monoclonal CAN106 hybrid y2-chain CH1-hinge region/y4-chain CH2- CH3 region), disulfide with human monoclonal CAN106 Kappa-chain, dimer"		11/8/2022	Treatment of myasthenia gravis	Designated	Not FDA Approved for Orphan Indication	"CANbridge Pharmaceuticals, Inc."
zanubrutinib	Brukinsa	11/8/2022	Treatment of follicular lymphoma	Designated/Approved		"BeiGene, Ltd., c/o BeiGene USA, Inc."
Nitric Oxide		11/8/2022	To selectively reduce pulmonary arterial pressures in patients at elevated risk for developing hemodynamically unstable pulmonary hypertension after cardiovascular surgery	Designated	Not FDA Approved for Orphan Indication	Mallinckrodt Pharmaceuticals
"DNA, (Cm-Gm-Gm-Gm-G-T-G-T-G-G-G-T-T-C-G-T-C-G-T-T-A-G-C-T-T-G-A-T-T-T-G-G-C-A-G-C-Um-Gm-Cm-Cm-(5'->3')-dT), 5'-ester with (29S)-29-(tert-butoxycarbonyl)-1-((hydroxyphosphoryl)oxy)-8,17,26,31-tetraoxo-10,13,19,22-tetraoxa-7,16,25,30-tetraazaoctatetracontan-48-oic acid"		11/3/2022	Treatment of Osteogenesis Imperfecta	Designated	Not FDA Approved for Orphan Indication	Aptacure Therapeutics Limited
dasatinib monolauryl sulfate		11/3/2022	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	"Handa Oncology, LLC"
dimethylaminomicheliolide Fumarate		11/3/2022	Treatment of Diffuse Midline Glioma	Designated	Not FDA Approved for Orphan Indication	Accendatech AU Pty Ltd.
blarcamesine		11/3/2022	Treatment of Fragile X syndrome	Designated	Not FDA Approved for Orphan Indication	Anavex Life Sciences Corp.
a humanized immunoglobulin IgG1 antibody with a kappa light chain (LC) with high selectivity and specificity for cancer-specific plectin		11/3/2022	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	ZielBio Incorporated
"[6-Fluoro-1-(4-morpholin-4-ylmethyl-phenyl)-5,5-dioxo-4,5-dihydro-1H-5Lambda6-thiochromeno[4,3-c]pyrazol-3-yl]-morpholin-4-yl-methanone hemi-fumarate"		11/1/2022	Treatment of uveal melanoma	Designated	Not FDA Approved for Orphan Indication	iOnctura SA
Imvotamab		10/31/2022	Treatment of Follicular Lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"IGM Biosciences, Inc."
"bicistronic messenger ribonucleic acid (mRNA) encoding for ZF-DNMT and ZF-KRAB proteins, encapsulated in a lipid nanoparticle (LNP)"		10/31/2022	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"Omega Therapeutics, Inc."
Rintatolimod		10/31/2022	Treatment of Ebola Virus Disease	Designated	Not FDA Approved for Orphan Indication	AIM ImmunoTech Inc.
mazindol		10/31/2022	Treatment of idiopathic hypersomnia	Designated	Not FDA Approved for Orphan Indication	NLS Pharmaceutics AG
H-Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys-OH		10/27/2022	Treatment of Hemophilia A	Designated	Not FDA Approved for Orphan Indication	Worg Pharmaceuticals (Hangzhou) Co. Ltd
"a tumor lysate-pulsed dendritic cell vaccine, enhanced by addition of a TLR 2, 4, 9 ligand adjuvant cocktail (Pam3cys, LPS, CpG ODN)"		10/25/2022	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	NovAccess Global
Human allogeneic umbilical cord mesenchymal stromal cells-derived extracellular vesicles.		10/25/2022	Prevention of bronchopulmonary dysplasia	Designated	Not FDA Approved for Orphan Indication	Exo Biologics SA
"N-hydroxy-4-((4-((((1R,2S)-2-phenylcyclopropyl) amino)methyl)-1H-pyrazol-1-yl)methyl)benzamide hydrogen bromide."		10/24/2022	Treatment of the acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	Jubilant Therapeutics Inc.
Crisdesalazine		10/24/2022	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"GNT Pharma Co., Ltd."
Lisuride Maleate		10/24/2022	Treatment of Fragile X Syndrome.	Designated	Not FDA Approved for Orphan Indication	NeuroVenti Inc.
Chimeric antigen receptor (CAR)-T cell therapy targeting G protein-coupled receptor class-C group-5 member-D (GPRC5D).		10/24/2022	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	"OriCell Therapeutics, Inc."
A Humanized Bispecific Antibody Neutralizing Both Sclerostin and Dickkopf-1		10/20/2022	Treatment of Osteogenesis imperfecta (OI)	Designated	Not FDA Approved for Orphan Indication	Angitia Biopharmaceuticals Guangzhou Limited
H-L-tryphophanyl-L-seryl-glycyl-L-tryptophanyl-L-seryl-L-seryl-L-cysteinyl-L-seryl-L-arginyl-L-seryl-L-cysteinyl-glycyl-OH (disulfide bond)		10/20/2022	Treatment of Amyotrophic Lateral Sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	AXOLTIS Pharma
antisense oligonucleotide consisting of 18 nucleotide residues with a sequence of 5¿-5MeC-5MeU-5MeU-5MeU-5MeC-5MeC-5MeU-5MeU-5MeC-A-5MeC-5MeU-G-5MeU- 5MeU-G-5MeC-A-3¿		10/20/2022	Treatment of cystic fibrosis patients carrying the W1282X CFTR mutation	Designated	Not FDA Approved for Orphan Indication	SpliSense Ltd.
Allogeneic JC polyomavirus-specific T-cell therapy		10/19/2022	Treatment of progressive multifocal leukoencephalopathy	Designated	Not FDA Approved for Orphan Indication	Cellevolve Bio Inc.
a humanized immunoglobulin IgG1 antibody with a kappa light chain (LC) which has high selectivity and specificity for cancer-specific plectin		10/19/2022	Treatment of Cholangiocarcinoma	Designated	Not FDA Approved for Orphan Indication	ZielBio Incorporated
"(+-)-9-(5-bromofuran-2-yl)-12,14-dimethyl-13,15-dioxo-17-phenyl-8-oxa-1,12,14-triazatetracyclo[8.7.0.02,7.011,16]heptadeca-2(7),3,5,10,16-pentaene-4-carboxylic acid"		10/19/2022	Treatment of Cholera	Designated	Not FDA Approved for Orphan Indication	Vanda Pharmaceuticals Inc.
Rifamycin		10/18/2022	Treatment of Pouchitis	Designated	Not FDA Approved for Orphan Indication	"Cosmo Technologies, Ltd."
Mezagitamab		10/17/2022	Treatment of myasthenia gravis	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
synthetic polymer PEG conjugated to a phospholipid anchor (2-dipalmitoyl-sn-glycerol-3-phosphatidylethanolamine)		10/17/2022	Prevention of ischemia reperfusion injury during solid organ transplantation	Designated	Not FDA Approved for Orphan Indication	iCoat Medical AB
Recombinant humanized anti-transforming growth factor (TGF) beta 3 antibody		10/17/2022	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc"
imiquimod (IMQ)-ferulic acid (FA) co-crystal (IMQ API and FA coformer)		10/17/2022	Treatment of vulvar intraepithelial neoplasia	Designated	Not FDA Approved for Orphan Indication	Celista Pharmaceuticals LLC
bi-specific fragment crystallizable region (Fc) fusion protein containing cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety conjugated with human immunoglobulin G4 Fc		10/17/2022	Treatment of Merkel cell carcinoma	Designated	Not FDA Approved for Orphan Indication	"GI Innovation, Inc."
"1-Pyrrolidinecarboximidamide, N-[imino[[4-(trifluoromethoxy)phenyl]amino]methyl]-, acetate (1:1)"		10/17/2022	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"ImmunoMet Therapeutics, Inc."
"anti-human transforming growth factor beta (TGF-Beta) monoclonal antibody (mAb), based on the amino acid sequence of the human monoclonal antibody fresolimumab (GC1008) with the exception of one serine to proline substitution"		10/15/2022	Treatment of Osteogenesis Imperfecta	Designated	Not FDA Approved for Orphan Indication	"Sanofi Genzyme, A Sanofi Company"
"2,6-Dichloro-N-(3-isobutyl-1,5-dimethyl-1H-pyrazol-4-yl)-4-(2-(piperazin-1-yl)pyridin-4-yl)benzenesulfonamide"		10/12/2022	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Pacylex Pharmaceuticals
Vinblastine N-Oxide		10/12/2022	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	"Cascade Prodrug, Inc."
Bevacizumab		10/12/2022	Treatment of hereditary hemorrhagic telangiectasia	Designated	Not FDA Approved for Orphan Indication	Laboratoires Delbert SAS
a polymer based prodrug of bortezomib		10/12/2022	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Window Therapeutics, Inc"
Positive transcription elongation factor b (PTEFb) inhibitor		10/12/2022	Treatment of Diffuse large B-cell lymphoma/high grade B-cell lymphoma with MYC and BCL2 rearrangements	Designated	Not FDA Approved for Orphan Indication	"Vincerx Pharma, Inc."
vigabatrin	Vigafyde	10/12/2022	Treatment of Infantile Spasms	Designated/Approved		"Pyros Pharmaceuticals, Inc."
"N-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(3,3-dimethylpiperazin-1-yl)benzamide hydrochloride"		10/11/2022	Treatment of cholangiocarcinoma	Designated	Not FDA Approved for Orphan Indication	"3D Medicines (Beijing) Co., Ltd"
brodalumab		10/11/2022	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	Bausch Health
"4-[[(1S)-1-(4, 8-Dichloro-1-oxo-2-phenyl-3-isoquinolyl) ethyl] amino]-8H- pyrido[2,3-d] pyrimidin-5-one]"		10/11/2022	"Treatment of Peripheral T-Cell Lymphoma, Not Otherwise Specified"	Designated	Not FDA Approved for Orphan Indication	"Boryung Co., LTD"
an autologous T-cell immunotherapy (ET140203)		10/7/2022	Treatment of Hepatoblastoma (HB)	Designated	Not FDA Approved for Orphan Indication	"Eureka Therapeutics, Inc."
autologous Muscle-Specific tyrosine Kinase Autoantibody Receptor T cells (MuSK-CAART)		10/7/2022	Treatment of muscle-specific tyrosine kinase (MuSK) myasthenia gravis	Designated	Not FDA Approved for Orphan Indication	"Cabaletta Bio, Inc"
"Recombinant, Humanized, aglycosylated, IgG1 Kappa Anti-Properdin Monoclonal Antibody"		10/5/2022	Treatment of Paroxysmal Nocturnal Hemoglobinuria	Designated	Not FDA Approved for Orphan Indication	"NovelMed Therapeutics, Inc."
Velusetrag		10/4/2022	Treatment of chronic intestinal pseudo-obstruction	Designated	Not FDA Approved for Orphan Indication	ALFASIGMA S.P.A.
Human induced pluripotent stem cell derived myogenic progenitor cells (GIVI-MPC)		10/3/2022	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	IPS Heart
"(R)-2-amino-N-((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide, tris hydrochloride"		10/3/2022	Treatment of amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	Stealth Biotherapeutics Inc.
"((S)-3-(1-Cyclopentyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrazole-3-carboxamido)-5-(3,3-difluoropiperidin-1-yl)pentanoic acid hydrochloride)"		9/29/2022	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	APIE Therapeutics
Olverembatinib		9/29/2022	Treatment of gastrointestinal stromal tumor (GIST)	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
AAV9-Synapsin-Caveolin-1		9/28/2022	Treatment of Amyotrophic Lateral Sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	"Eikonoklastes Therapeutics, Inc."
"2-N,O-dimethylhydroxylamino-4,6-bispropylamino-s-triazine, hydrogen sulfate salt"		9/28/2022	Treatment of Apnea of Prematurity	Designated	Not FDA Approved for Orphan Indication	Enalare Therapeutics Inc.
eculizumab		9/28/2022	Treatment of Guillain Barre syndrome (GBS)	Designated	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc."
telitacicept		9/27/2022	Treatment of Myasthenia Gravis	Designated	Not FDA Approved for Orphan Indication	"RemeGen Co., Ltd."
"Sodium ({(2S)-1,4-bis[2-(4-chloro-3- fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2- yl}oxy)methyl hydrogen phosphate - 2-amino-2- (hydroxymethyl)propane-1,3-diol (1/1/1)"		9/27/2022	Treatment of Vanishing White Matter Disease	Designated	Not FDA Approved for Orphan Indication	Calico Life Sciences LLC
An autologous chimeric antigen receptor (CAR) T-cell therapy engineered to express an antibody-derived single-chain variable fragment that recognizes C-type lectin-like molecule-1 (CLL-1)		9/27/2022	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	"Kite Pharma, Inc."
EBV-induced natural T cell [EBViNT Cell]		9/27/2022	"Treatment of extranodal NK/T cell lymphoma, nasal-type"	Designated	Not FDA Approved for Orphan Indication	Eutilex Co. Ltd
polyinosinic:polycytidylic acid		9/27/2022	Treatment of Stage IIB-IV melanoma	Designated	Not FDA Approved for Orphan Indication	Highlight Therapeutics
Autologous T cells genetically engineered to express an anti-mesothelin killer immunoglobulin-like receptor-chimeric antigen receptor (KIR-CAR)		9/27/2022	Treatment of Mesothelioma	Designated	Not FDA Approved for Orphan Indication	Verismo Therapeutics
recombinant human insulin		9/21/2022	Treatment of intestinal malabsorption in preterm infants	Designated	Not FDA Approved for Orphan Indication	"Elgan Pharma, Ltd."
Recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E		9/20/2022	Treatment of patients with nasopharyngeal carcinoma (NPC)	Designated	Not FDA Approved for Orphan Indication	Shanghai Miracogen Inc.
Arginyl-Glutamine Dipeptide		9/20/2022	Prevention of Retinopathy of Prematurity	Designated	Not FDA Approved for Orphan Indication	Infant Bacterial Therapeutics AB
Humanized IgG1kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin		9/16/2022	Treatment of Gastric and Gastroesophageal Junction cancer	Designated	Not FDA Approved for Orphan Indication	"Bliss Biopharmaceutical (Hangzhou) Co., Ltd."
"a bispecific antibody that binds human programmed death-ligand 1 (PD-L1; CD274) and 4-1BB (CD137, tumor necrosis factor receptor superfamily 9) proteins"		9/16/2022	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	Antengene Biologics Limited
"a ligand binding moiety to STAT3, a chemical linker, and a ligand binding moiety to an E3 ligase that leads to STAT3 degradation"		9/14/2022	Treatment of Cutaneous T-Cell Lymphoma (CTCL)	Designated	Not FDA Approved for Orphan Indication	Kymera Therapeutics
"potassium 2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo- 5-phenyl-6,7-dihydrothieno[2, 3-b]pyridin-4-olate hydrate"		9/14/2022	Treatment of Autosomal Dominant Polycystic Kidney Disease	Designated	Not FDA Approved for Orphan Indication	Poxel S.A.
a protein based on human alpha-1-antitrypsin (a1AT) with three mutations in the reactive center loop (RCL) conferring specificity for APC over other plasma proteases		9/13/2022	Treatment of Hemophilia B	Designated	Not FDA Approved for Orphan Indication	ApcinteX Limited
Recombinant oncolytic virus based on the backbone of Alphavirus M1		9/12/2022	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Guangzhou Virotech Pharmaceutical Co., Ltd."
bromophenoxyazole propanoic acid		9/12/2022	Treatment of Myasthenia Gravis	Designated	Not FDA Approved for Orphan Indication	"NMD Pharma, INCUBA"
"(S)-7-(dimethylphosphoryl)-3-(2-((6,6-dimethylpiperidin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)-1H-indole-6-carbonitrile"		9/12/2022	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	Syros Pharmaceuticals
Lutetium-177 labeled humanized monoclonal antibody targeting leucine rich repeat containing 15 (LRRC15)		9/7/2022	Treatment of osteosarcoma (OS)	Designated	Not FDA Approved for Orphan Indication	"Radiopharm Theranostics, Inc."
Recombinant oncolytic virus M1-c6v1		9/7/2022	Treatment of primary liver cancer	Designated	Not FDA Approved for Orphan Indication	"Guangzhou Virotech Pharmaceutical Co., Ltd."
ezurpimtrostat		9/7/2022	Treatment of cholangiocarcinoma	Designated	Not FDA Approved for Orphan Indication	Genfit SA
"2-[(1,3-Benzoxazol-2-yl)amino]-N-[2-(2-hydroxyethoxy)ethyl]-1-methyl-1H-benzimidazole-5- carboxamide monophosphate"		9/1/2022	Treatment of Sickle Cell Disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Astellas Pharma Global Development, Inc."
lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9		9/1/2022	Treatment of hereditary angioedema	Designated	Not FDA Approved for Orphan Indication	"Intellia Therapeutics, Inc."
"Sodium (1-hydroxy-4-(((2-((4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl)oxy)ethoxy)carbonyl)amino)butane-1,1-diyl)bis(hydrogen phosphonate)"		9/1/2022	Treatment of Camurati-Engelmann disease	Designated	Not FDA Approved for Orphan Indication	"Brise Pharmaceuticals Co., Ltd."
Edited allogeneic chimeric antigen receptor T Cells (CAR-T)		9/1/2022	Treatment of follicular lymphoma (FL)	Designated	Not FDA Approved for Orphan Indication	"Caribou Biosciences, Inc."
"3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole"		9/1/2022	Treatment of Multiple System Atrophy	Designated	Not FDA Approved for Orphan Indication	"Teva Branded Pharmaceutical Products R&D, Inc."
non-replicating recombinant adeno-associated virus serotype rh79 (AAVrh.79) vectors: AAVrh79.TBG.M2PCSK9.WPRE.bGH and AAVrh79.hHDR.TBG.hOTCco.bGH		9/1/2022	Treatment of Ornithine Transcarbamylase Deficiency	Designated	Not FDA Approved for Orphan Indication	"iECURE, Inc."
human monoclonal antibody based on an IgG1 lambda framework against human interferon gamma		9/1/2022	Treatment of hemophagocytic lymphohistiocytosis	Designated	Not FDA Approved for Orphan Indication	Elixiron Immunotherapeutics (Hong Kong) Limited
"N-[(2R)-1-[(2S)-2-[(3-hydroxy-2-methyl-6-{[(3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl]oxy}oxan-4-yl)carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]pyridine-4-carboxamide"		9/1/2022	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	Avacta Life Sciences Ltd.
"N-[(1R,2R)-2-(3-chloro-4-cyclopropoxyphenyl)-2-hydroxy-1-(pyrrolidinylmethyl)ethyl]-2-(6-chloro(2-naphthyl))-2-(hydroxyimino)acetamide."		9/1/2022	Treatment of Fabry disease	Designated	Not FDA Approved for Orphan Indication	"AceLink Therapeutics, Inc."
"(S)-1-(4-(1-(3,4,5-trimethyloxyphenyl)-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide citrate"		8/29/2022	Treatment of fibrodysplasia ossificans progressiva	Designated	Not FDA Approved for Orphan Indication	"BioCryst Pharmaceuticals, Inc."
Trastuzumab vedotin		8/29/2022	Treatment of patients with gastric cancer (GC) and gastroesophageal junction (GEJ) cancer	Designated	Not FDA Approved for Orphan Indication	Shanghai Miracogen Inc.
Elemene Emulsion Injection		8/29/2022	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"Dalian Holley Kingkong Pharmaceutical Co., Ltd."
an acetic acid diester of 2-deoxy-D-glucose		8/29/2022	treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	"Moleculin Biotech, Inc."
tucidinostat		8/26/2022	Treatment of patients with of stage IIb-IV melanoma	Designated	Not FDA Approved for Orphan Indication	"HUYABIO International, LLC"
garadacimab		8/16/2022	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	CSL Behring
vebreltinib		8/16/2022	Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations	Designated	Not FDA Approved for Orphan Indication	"Apollomics, Inc."
sotuletinib		8/16/2022	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
Ex-vivo conditioned medium from cultured adult human mesenchymal stem cells		8/15/2022	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	Summa Bio-Solutions Inc.
4'-chloro-2'-cyano-N-(trans-4-hydroxy-4-methylcyclohexyl)-biphenyl-4-sulfonamide		8/15/2022	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	Modern Biosciences Ltd
Ganaplacide and Lumefantrine fixed-dose combination		8/15/2022	Treatment of Malaria	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
Rovatirelin		8/15/2022	Treatment of spinocerebellar ataxia	Designated	Not FDA Approved for Orphan Indication	"BioPharma Global, a division of Pace Life Sciences"
A thienopyrimidine derivative that preferentially inhibits Phosphodiesterase 4B		8/15/2022	Treatment Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
An Adeno-associated Virus Vector Containing an Expression Cassette of the Human Factor IX Transgene		8/15/2022	Treatment of Hemophilia B	Designated	Not FDA Approved for Orphan Indication	Belief BioMed Limited
Recombinant fully humanized anti-IL 6 monoclonal antibody		8/15/2022	Treatment of uveitic macular edema	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc"
selective inhibitor of GYS1		8/12/2022	Treatment of Pompe Disease	Designated	Not FDA Approved for Orphan Indication	Shionogi Inc.
"(R,E)-3-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-1-(piperazin-1-yl)prop-2-en-1-on hemi-oxalate"		8/11/2022	Treatment of Solid Tumors with the NTRK fusion gene	Designated	Not FDA Approved for Orphan Indication	AUM Biosciences Pty Ltd.
Venadaparib		8/5/2022	Treatment of Gastric Cancer	Designated	Not FDA Approved for Orphan Indication	"Idience Co., Ltd."
Allogeneic umbilical cord-derived mesenchymal stem cell drug		8/5/2022	Prevention of Bronchopulmonary Dysplasia	Designated	Not FDA Approved for Orphan Indication	Meribank Biotech Co. Ltd.
"a fixed-dose combination containing two active ingredients, senaparib and temozolomide"		8/3/2022	Treatment of Small Cell Lung Cancer	Designated	Not FDA Approved for Orphan Indication	"IMPACT Therapeutics, Inc."
Oncolytic Type 1 Herpes Simplex Virus (HSV-1) Expressing Human Cytokine Interleukin 12 (IL-12) and Fab Fragment of Anti-PD-1 Antibody		8/1/2022	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"ImmVira Pharma Co., Limited"
CD71 Binding Centyrin-GYS1 siRNA		8/1/2022	Treatment of Pompe Disease	Designated	Not FDA Approved for Orphan Indication	Aro Biotherapeutics Company
18?mer antisense oligonucleotide complementary to OPA1 pre-mRNA		7/29/2022	Treatment of autosomal dominant optic atrophy	Designated	Not FDA Approved for Orphan Indication	"Stoke Therapeutics, Inc."
Recombinant Oncolytic Herpes Simplex Virus Type II (OH2) Therapeutic Injection (Vero Cell) for Human Use (rHSV2hGM-CSF)		7/28/2022	Treatment of stage IIb to IV melanoma	Designated	Not FDA Approved for Orphan Indication	"Binhui Biopharmaceutical Co., Ltd."
Humanized immunoglobulin G4 monoclonal antibody directed against mannan-binding lectin-associated serine protease-3 (MASP-3)		7/28/2022	Treatment of Paroxysmal Nocturnal Hemoglobinuria	Designated	Not FDA Approved for Orphan Indication	Omeros Corporation
small molecule agonist of 5-hydroxytryptamine serotonergic receptors		7/27/2022	Treatment of Dravet Syndrome	Designated	Not FDA Approved for Orphan Indication	Xenon Pharmaceuticals Inc.
efgartigimod alfa and hyaluronidase-qvfc	Vyvgart Hytrulo	7/27/2022	Treatment of myasthenia gravis	Designated/Approved		argenx BV
Human monoclonal IgG1 TREM2 agonist antibody		7/27/2022	Treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia	Designated	Not FDA Approved for Orphan Indication	"Vigil Neuroscience, Inc."
Selective Colony Stimulating Factor-1 Receptor kinase inhibitor		7/27/2022	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	Elixiron Immunotherapeutics Inc.
3-bromopyruvic acid		7/27/2022	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Ko Discovery LLC
"[Phe^2,Ile^3,Dab(PhAc-D-Tyr(Me)-Phe-Gln-Asn-Ala-Pro-Arg-iGln-Lys(Ac)-Epsilon-Lys)^8]vasopressin"		7/26/2022	Treatment of Hepatorenal Syndrome	Designated	Not FDA Approved for Orphan Indication	"Ocelot Bio, Inc"
Small molecule kinase inhibitor		7/26/2022	Treatment of gastrointestinal stromal tumors (GIST)	Designated	Not FDA Approved for Orphan Indication	"IDRX, Inc."
Iodine (I-124) evuzamitide		7/26/2022	Diagnostic for the management of transthyretin amyloidosis	Designated	Not FDA Approved for Orphan Indication	"Attralus, Inc."
Mesenchymal stem cells (MSCs) primed with interferon gamma (IFNgamma)		7/25/2022	Prevention of acute graft-versus-host disease (GVHD)	Designated	Not FDA Approved for Orphan Indication	"Ossium Health, Inc."
Small molecule inhibitor of PRMT5 (protein arginine methyl transferase 5)		7/25/2022	Treatment of malignant peripheral nerve sheath tumor	Designated	Not FDA Approved for Orphan Indication	Tango Therapeutics
fatty acylated parathyroid (prodrug) hormone agonist		7/25/2022	Treatment of hypoparathyroidism	Designated	Not FDA Approved for Orphan Indication	MBX Biosciences
aspacytarabine		7/25/2022	Treatment of Myelodysplastic Syndromes	Designated	Not FDA Approved for Orphan Indication	"BioSight, Ltd."
Docetaxel albumin bound		7/20/2022	Treatment of gastric cancer Including cancer of gastroesophageal junction	Designated	Not FDA Approved for Orphan Indication	"Conjupro Biotherapeutics, Inc."
Recombinant IgG-fusion protein containing a humanized anti-C5 monoclonal antibody fused with a truncated human complement FH to the heavy chain C-terminus		7/20/2022	Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)	Designated	Not FDA Approved for Orphan Indication	"Kira Pharmaceuticals, LLC"
Pioglitazone hydrochloride		7/20/2022	Treatment of childhood onset idiopathic nephrotic syndrome (defined as steroid dependent or frequently relapsing NS).	Designated	Not FDA Approved for Orphan Indication	"NephKey Therapeutics, Inc."
satralizumab-mwge		7/18/2022	Treatment of N-methyl-D-asparatate receptor (NMDAR) antibody autoimmune encephalitis (AIE)	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
Autologous Claudin 18.2 specific chimeric antigen receptor (CAR)-T cell therapy		7/18/2022	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	"Suzhou Immunofoco Biotechnology Co., Ltd"
adeno-associated virus serotype 8 expressing Cas9 gene and single guide RNA targeting R135W mutation in Rhodopsin gene		7/14/2022	Treatment of retinal dystrophy associated with R135W mutation in rhodopsin gene	Designated	Not FDA Approved for Orphan Indication	"Chigenovo Co., Ltd."
Recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS)		7/14/2022	"Treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Homology Medicines, Inc"
Prednisone		7/13/2022	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	Sarcomed AB
Cisplatin transmucosal system		7/13/2022	Treatment of carcinoma in situ (CIS) of the anterior 2/3 of the oral cavity	Designated	Not FDA Approved for Orphan Indication	Privo Technologies
Tetrahydronaphthyl urea based selective TRPV1 antagonist		7/13/2022	Treatment of Erythromelalgia	Designated	Not FDA Approved for Orphan Indication	Pila Pharma AB
2-{[2-benzyl-4-(5-methyl-3H-imidazol-4-ylmethyl)-3-oxo-piperazine-1-carbonyl]- amino}-4methyl-pentanoic acid		7/13/2022	Treatment of peripheral T-cell lymphomas	Designated	Not FDA Approved for Orphan Indication	"Prescient Therapeutics, LTD"
Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc).		7/11/2022	Treatment of advanced/metastatic glioblastoma multiforme (GBM) who have undergone prior chemo-radiation therapy	Designated	Not FDA Approved for Orphan Indication	NeoImmuneTech
autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)		7/11/2022	Treatment of acute lymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	"Unicar Bio-Therapy, Ltd"
Trypan Blue Ophthalmic Solution		7/8/2022	For use as an aid in ophthalmic surgery by staining the Descemet membrane during Descemet membrane endothelial keratoplasty (DMEK)	Designated	Not FDA Approved for Orphan Indication	D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.
Melatonin / ethanol		7/7/2022	Treatment of neonatal hypoxic ischemic encephalopathy	Designated	Not FDA Approved for Orphan Indication	ESPL Regulatory Consulting Limited
solution of protein-free hemodialysate of calf blood		7/6/2022	Treatment of cutaneous sulfur mustard-induced injury	Designated	Not FDA Approved for Orphan Indication	"DermDefense, Inc."
"5-((S)-1-(3,5-bis(trifluoromethyl)phenoxy)ethyl)-3-hydroxycyclohex-2-en-1-one"		7/6/2022	Amyotrophic Lateral Sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	"Akava Therapeutics, LLC"
aldesleukin		7/6/2022	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	ILTOO Pharma
Selective KIT Inhibitor		7/1/2022	Treatment of Mastocytosis	Designated	Not FDA Approved for Orphan Indication	Blueprint Medicines
alpha-L-iduronidase (IDUA) - ricin transport subunit B (RTB) lectin protein fusion		7/1/2022	Treatment of mucopolysaccharidosis type I (MPS-I)	Designated	Not FDA Approved for Orphan Indication	BioStrategies LC
"2-[[(4-Methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-ol or 5-O-desmethyl-omeprazole"		7/1/2022	Treatment of Multiple System Atrophy (MSA)	Designated	Not FDA Approved for Orphan Indication	Yoda Therapeutics Inc.
mavorixafor		7/1/2022	Treatment of Waldenstrom’s Macroglobulinemia	Designated	Not FDA Approved for Orphan Indication	"X4 Pharmaceuticals, Inc."
Octreotide (acetate)		6/30/2022	Treatment of carcinoid syndrome	Designated	Not FDA Approved for Orphan Indication	"Chiesi USA, Inc."
iloprost	Aurlumyn	6/29/2022	Treatment of frostbite	Designated/Approved		"Eicos Sciences, Inc."
menin inhibitor		6/29/2022	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Sumitomo Pharma America, Inc."
"A CD47-binding, fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha variant 1 genetically linked to a modified and inactive Fc domain of human IgG"		6/28/2022	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	ALX Oncology Inc.
Vilobelimab		6/27/2022	Treatment of pyoderma gangrenosum	Designated	Not FDA Approved for Orphan Indication	InflaRx N.V.
"Spiro[3H-Indole-3,2¿-pyrrolidin]-2(1H)-one derivative"		6/24/2022	Treatment of soft tissue sarcoma (STS).	Designated	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
trametinib	Mekinist	6/24/2022	Treatment of malignant glioma with BRAF V600 mutation	Designated/Approved		Novartis Pharmaceuticals Corporation
HSV-1-erasing lentivirus-like particle delivering gRNA-expressing cassette and SpCas9 mRNA		6/24/2022	Treatment of herpes simplex (HSV-1) infected keratitis (HSK)	Designated	Not FDA Approved for Orphan Indication	Shanghai BDgene Therapeutics Co. LTD
5-aminolevulinic acid hydrochloride		6/23/2022	Treatment of malignant glioma.	Designated	Not FDA Approved for Orphan Indication	"Alpheus Medical, Inc."
AAV2.adalimumab		6/22/2022	"Treatment of non-infectious intermediate, posterior, or panuveitis or chronic non-infectious anterior uveitis"	Designated	Not FDA Approved for Orphan Indication	"Kriya Therapeutics, Inc."
Bivalent cytomeglaovirus gB/pp65 enveloped virus-like particles		6/17/2022	Treatment of Glioblastoma	Designated	Not FDA Approved for Orphan Indication	"VBI Vaccines, Inc."
rencofilstat		6/17/2022	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"Hepion Pharmaceuticals, Inc."
dasatinib		6/16/2022	Treatment of chronic myeloid leukemia (CML)	Designated	Not FDA Approved for Orphan Indication	Xspray Pharma AB
replication-incompetent adeno-associated virus serotype 9 vector encoding the human fragile x mental retardation 1 gene		6/16/2022	Treatment of Fragile X Syndrome	Designated	Not FDA Approved for Orphan Indication	"Forge Biologics, Inc."
a chemically modified full phosphorothioate-backbone anti-miR-17 oligonucleotide		6/16/2022	Autosomal dominant polycystic kidney disease (ADPKD)	Designated	Not FDA Approved for Orphan Indication	Regulus Therapeutics Inc.
Autologous T-Cells transduced with a lentiviral vector (LVV) expressing CD20-specific chimeric antigen receptor (CAR) gene (CD20 CAR-T Cells)		6/16/2022	Treatment of Waldenstrom Macroglobulinemia	Designated	Not FDA Approved for Orphan Indication	"Mustang Bio, Inc."
2-(4-Tert-butylphenyl)-1H-benzimidazole		6/16/2022	Treatment of Amyotrophic Lateral Sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	"Tranquis Therapeutics, Inc."
Paxalisib (INN and USAN)		6/15/2022	Treatment of atypical teratoid/rhabdoid tumors (AT/RT)	Designated	Not FDA Approved for Orphan Indication	Kazia Therapeutics Limited
Ibudilast		6/15/2022	Treatment of Fragile X syndrome	Designated	Not FDA Approved for Orphan Indication	Healx Limited
"(R)-5-(2-(2,5-difluorophenyl) pyrrolidin-1-yl)-3-(4-(trifluoromethyl)-1H-pyrazol-1-yl) pyrazolo[1,5-a] pyrimidine"		6/15/2022	Treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumors	Designated	Not FDA Approved for Orphan Indication	Pyramid Biosciences
Magnetic nanocarrier-conjugated small interfering RNA against programmed death ligand 1		6/14/2022	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"TransCode Therapeutics, Inc"
Bispecific antibody against Claudin 18.2 and cluster of differentiation 47 (CD47)		6/13/2022	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	"Phanes Therapeutics, Inc."
hetrombopag		6/13/2022	Treatment for chemotherapy-induced thrombocytopenia	Designated	Not FDA Approved for Orphan Indication	"Jiangsu Hengrui Pharmaceuticals Co., Ltd."
"cis-diamminedichloroplatinum(II) (CDDP), vinblastine sulfate, 8-((2-hydroxybenzoyl)amino)octanoate (SHAO-FA)"		6/13/2022	Treatment of Soft Tissue Sarcoma	Designated	Not FDA Approved for Orphan Indication	"Intensity Therapeutics, Inc."
"5-[[trans-4-[(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid"		6/8/2022	Treatment of primary hyperoxaluria type 1	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	BioMarin Pharmaceutical Inc.
CD20-CD47 bispecific fusion protein		6/8/2022	Treatment of Burkitt Lymphoma	Designated	Not FDA Approved for Orphan Indication	"Conjupro Biotherapeutics, Inc."
"2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-9H-purin-6-amine A triazole purine analogue"		6/8/2022	Treatment of Non-24 Sleep Wake Rhythm Disorder (N24SWRD) in blind individuals without light perception	Designated	Not FDA Approved for Orphan Indication	Circadian Therapeutics Ltd.
tegoprubart		6/7/2022	Prevention of allograft rejection in pancreatic islet cell transplantation	Designated	Not FDA Approved for Orphan Indication	"Eledon Pharmaceuticals, Inc."
fenfluramine hydrochloride		6/7/2022	Treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder	Designated	Not FDA Approved for Orphan Indication	"UCB, Inc."
ilixadencel		6/7/2022	Treatment of gastrointestinal stromal tumors	Designated	Not FDA Approved for Orphan Indication	Mendus AB
(-)-Huperzine A		6/7/2022	Treatment of SCN8A Developmental and Epileptic Encephalopathy	Designated	Not FDA Approved for Orphan Indication	"Supernus Pharmaceuticals, Inc."
pegcetacoplan		6/7/2022	Treatment of immune complex-membranoproliferative glomerulonephritis	Designated	Not FDA Approved for Orphan Indication	"Apellis Pharmaceuticals, Inc."
AAV2/8-SaCas9-sgRNA RHO-T17M		6/7/2022	Treatment of Retinitis pigmentosa (RP)	Designated	Not FDA Approved for Orphan Indication	"Chigenovo Co., Ltd."
"(6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-((3-(pyridin-2-yl)isoxazol-5-yl)methyl)-8-(quinolin-5-ylmethyl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide methane sulfonic acid"		6/7/2022	Treatment of Idiopathic Pulmonary Fribrosis (IPF)	Designated	Not FDA Approved for Orphan Indication	"3Plus2 Pharma, LLC"
human IgG4-based anti-CD3 x anti-BCMA bispecific monoclonal antibody that binds to CD3 and BCMA		6/6/2022	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	"Regeneron Pharmaceuticals, Inc."
"8-((6-iodobenzo[d][1,3]dioxol-5-yl)thio)-9-(2-(neopentylamino)ethyl)-9H-purin-6-amine, dihydrochloride salt"		6/6/2022	Treatment of Malignant Glioma	Designated	Not FDA Approved for Orphan Indication	"Samus Therapeutics, Inc."
Ketamine		6/6/2022	Treatment of Complex Regional Pain Syndrome	Designated	Not FDA Approved for Orphan Indication	"Vitalis Analgesics, LLC"
"1,4Lambda6, 3-Oxathiazinane-4,4-dione"		6/6/2022	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Geistlich Pharma North America
oral melanocortin 4 receptor agonist		6/6/2022	Treatment for Pro-opiomelanocortin (POMC) deficiency.	Designated	Not FDA Approved for Orphan Indication	"Rhythm Pharmaceuticals, Inc."
azithromycin		6/6/2022	Prevention of bronchopulmonary dysplasia in neonates.	Designated	Not FDA Approved for Orphan Indication	Iorek Pharma Limited
iadademstat		6/6/2022	Treatment of small cell lung cancer (SCLC)	Designated	Not FDA Approved for Orphan Indication	Oryzon Genomics S.A.
Bispecific Antibody against DLL3 and CD47		6/6/2022	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Phanes Therapeutics, Inc."
Two immunoglobulin subclass 1 (IgG1) human monoclonal antibodies that target the Sudan ebolavirus glycoprotein		6/3/2022	"Treatment of ebolavirus disease caused by Sudan Ebolavirus (SUDV) infection, otherwise termed Sudan Virus Disease"	Designated	Not FDA Approved for Orphan Indication	"Mapp Biopharmaceutical, Inc."
"15(S)-hydroxy-(5Z,8Z,11Z,13E,17Z)-eicosapentaenoic acid ethyl ester (15(S)-HEPE-EE)"		6/3/2022	Treatment of sickle cell disease (SCD)	Designated	Not FDA Approved for Orphan Indication	Afimmune
Granulocyte colony-stimulating-factor (G-CSF)		6/3/2022	Treatment of thromboangiitis obliterans (Buerger’s disease)	Designated	Not FDA Approved for Orphan Indication	Vasogenesis Inc
Masked immunocytokine comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a		5/31/2022	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Nammi Therapeutics, Inc"
"a ligand binding moiety to STAT3, a chemical linker, and a ligand binding moiety to an E3 ligase that leads to STAT3 degradation"		5/31/2022	Peripheral T-cell Lymphoma (PTCL)	Designated	Not FDA Approved for Orphan Indication	Kymera Therapeutics
Masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a		5/31/2022	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Nammi Therapeutics, Inc"
"Recombinant adeno-associated viral vector serotype HSC15, containing homology arms targeting the human phenylalanine hydroxylase genomic locus, and expressing human phenylalanine hydroxylase"		5/27/2022	Treatment of phenylalanine hydroxylase deficiency	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Homology Medicines, Inc."
"4-(3-cyano-6-ethoxyquinolin-2-yl)-N- (2-fluorophenyl)-1,4-diazepane-1-carbothiomide"		5/26/2022	Treatment of Fragile X syndrome (FXS)	Designated	Not FDA Approved for Orphan Indication	"Neuronascent, Inc."
Selinexor		5/26/2022	Treatment of Myelofibrosis	Designated	Not FDA Approved for Orphan Indication	"Karyopharm Therapeutics, Inc."
2'-O-(2-methoxyethyl) modified antisense oligonucleotide targeting UBE3A antisense transcript RNA		5/26/2022	Treatment of Angelman Syndrome	Designated	Not FDA Approved for Orphan Indication	"Ionis Pharmaceuticals, Inc."
adeno-associated viral vector 9 delivering human Glutaryl-CoA Dehydrogenase (GCDH) gene		5/26/2022	Treatment of glutaric aciduria type I	Designated	Not FDA Approved for Orphan Indication	"Shanghai Vitalgen BioPharma Co., Ltd."
a synthetic PEGylated thrombopoietin (TPO) mimetic (TPOm) peptide with no sequence homology to endogenous TPO		5/26/2022	To treat patients undergoing myeloablative hematopoietic stem cell transplant conditioning to improve platelet recovery and reduce myeloablative bone marrow conditioning-related toxicities.	Designated	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
PTH(1-34)-Cys(succinimido-PEG-vitamin D) amide (human) acetate salt		5/25/2022	Treatment of hypoparathyroidism	Designated	Not FDA Approved for Orphan Indication	Extend Biosciences Inc.
buprenorphine		5/25/2022	Treatment of opioid withdrawal syndrome in the pediatric population	Designated	Not FDA Approved for Orphan Indication	Chiesi Farmaceutici S.p.A.
a synthetic PEGylated thrombopoietin (TPO) mimetic (TPOm) peptide with no sequence homology to endogenous		5/24/2022	Treatment of primary failure of platelet recovery (PFPR) or secondary failure of platelet recovery (SFPR) in patients who have undergone allogeneic hematopoietic stem cell transplant (HSCT).	Designated	Not FDA Approved for Orphan Indication	"Janssen R&D, LLC"
Inclacumab		5/24/2022	Treatment of Sickle Cell Disease	Designated	Not FDA Approved for Orphan Indication	"Global Blood Therapeutics, Inc."
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu- Gly-Pro-Pro-Pro-Ala-Leu-Ala-Leu-Ala-NH2		5/24/2022	Treatment of primary sclerosing cholangitis	Designated	Not FDA Approved for Orphan Indication	"Sterotherapeutics, LLC"
"N-[3-[2-[(1R)-1-Hydroxypropan-2-ylamino]-6-(4- morpholinyl)-4-pyridinyl]-4-methylphenyl]-(3S)-3-(2,2,2-trifluoroethyl)-1- pyrrolidine carboxamide hydrochloride."		5/19/2022	Treatment of BRAF Mutation-positive Stage IIb-IV Melanoma	Designated	Not FDA Approved for Orphan Indication	Pierre Fabre Medicament
selpercatinib	Retevmo	5/19/2022	Treatment of tissue-agnostic RET fusion-positive solid tumors	Designated/Approved		"Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company"
selpercatinib	Retevmo	5/19/2022	Treatment of tissue-agnostic RET fusion-positive solid tumors	Designated/Approved		"Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company"
"(4'aR,10'bR)-8'-chloro-1-[2-(1H-imidazol-1-yl)ethyl]-5',5'-dimethyl-4'a,10'b-dihydro-2'H,4'H,5'H-spiro[piperidine-4,3'-pyrano[3,2-c][1]benzopyran] diphosphate"		5/17/2022	Treatment of Brain Cancer	Designated	Not FDA Approved for Orphan Indication	"Sumitomo Pharma America, Inc."
HER2 targeted antibody-drug conjugate (ADC) consisting of a HER2 targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload		5/17/2022	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	"Mersana Therapeutics, Inc."
Attenuated Salmonella typhimurium containing the gene for human interleukin-2 (IL-2)		5/17/2022	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	Salspera Inc.
Tasquinimod		5/16/2022	Treatment of myelofibrosis	Designated	Not FDA Approved for Orphan Indication	Active Biotech AB
(S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin- 3-yl)methoxy)benzaldehyde		5/16/2022	Treatment of Sickle Cell Disease	Designated	Not FDA Approved for Orphan Indication	"Global Blood Therapeutics, Inc."
"(1E,4E,6E)-1-(3,5-dimethoxyphenyl)-7-(4-hydroxy-3,5dimethoxyphenyl)hepta-1,4,6-trien-3-one"		5/16/2022	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	Agastiya Biotech
"methyl (R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-2-ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate"		5/12/2022	Treatment of Wilson's Disease	Designated	Not FDA Approved for Orphan Indication	DepYmed Inc.
Mesenchymal stem cells		5/12/2022	Treatment of acute Graft-versus-host disease	Designated	Not FDA Approved for Orphan Indication	"Ossium Health, Inc."
"potassium 2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo- 5-phenyl-6,7-dihydrothieno[2, 3-b]pyridin-4-olate hydrate"		5/12/2022	Treatment of X-Linked Adrenoleukodystrophy (ALD)	Designated	Not FDA Approved for Orphan Indication	Poxel S.A.
Elamipretide HCl		5/10/2022	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	Stealth Biotherapeutics Inc.
Aloxistatin		5/10/2022	Treatment of GM1-gangliosidosis	Designated	Not FDA Approved for Orphan Indication	DORPHAN SA
Live attenuated Salmonella enterica Serovar Typhimurium (S. Typhimurium)		5/10/2022	Treatment of schwannoma	Designated	Not FDA Approved for Orphan Indication	"Mulberry Biotherapeutics, Inc."
valbenazine	Ingrezza	5/10/2022	Treatment of Huntington disease	Designated/Approved		Neurocrine Biosciences Inc.
a lyophilized modified oligonucleotide of 16 nucleotides conjugated to a molecule of oleic acid		5/10/2022	Treatment of myotonic dystrophy type 1	Designated	Not FDA Approved for Orphan Indication	Arthex Biotech S.L.
valbenazine	Ingrezza	5/10/2022	Treatment of Huntington disease	Designated/Approved		Neurocrine Biosciences Inc.
"2-(trans-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin6-yl)amino)cyclohexyl)propan-2-ol hydrochloride"		5/10/2022	Treatment of Myelofibrosis	Designated	Not FDA Approved for Orphan Indication	"Sumitomo Pharma America, Inc."
allogenic fetal mesenchymal stem cells		5/6/2022	Treatment of Osteogenesis Imperfecta	Designated	Not FDA Approved for Orphan Indication	BOOST Pharma Aps
autologous CD34+ hematopoietic stem and progenitor cells edited by CRISPR/Cas12a ribonucleoprotein (RNP) at the HBG1 and HBG2 promoters		5/4/2022	Treatment of beta thalassemia	Designated	Not FDA Approved for Orphan Indication	"Editas Medicine, Inc."
Sodium 4-amino-3- [6-( 4-fluoro-2-methylphenyl)pyridine-3-ylazo] naphthalene-1-sulfonate dihydrate		5/3/2022	Treatment of retinal artery occlusion (RAO).	Designated	Not FDA Approved for Orphan Indication	"Kyoto Drug Discovery & Development Co., Ltd."
6-thio-2'-deoxyguanosine		5/2/2022	Treatment of Small Cell Lung Cancer (SCLC)	Designated	Not FDA Approved for Orphan Indication	"MAIA Biotechnology, Inc."
"4,4',4''-(Ethane-1,1,1- triyl)tris(2,6-diethoxyphenol)"		4/29/2022	Treatment of Amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	Neuromagen Pharma Ltd.
darovasertib		4/27/2022	Treatment of Uveal Melanoma	Designated	Not FDA Approved for Orphan Indication	IDEAYA Biosciences Inc.
Clemizole Hydrochloride		4/26/2022	Treatment of Ohtahara Syndrome	Designated	Not FDA Approved for Orphan Indication	"Epygenix Therapeutics, Inc."
"2,3,5-Trimethyl-6-nonyl-2,5-cyclohexadiene-1,4-dione"		4/26/2022	Treatment of amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
umbilical cord mesenchymal stem cell secretome		4/26/2022	Treatment of sarcoidosis	Designated	Not FDA Approved for Orphan Indication	NRG Sciences LLC
Amnion-derived Cellular Cytokine Solution		4/26/2022	Treatment of Necrotizing Enterocolitis	Designated	Not FDA Approved for Orphan Indication	"Noveome Biotherapeutics, Inc."
autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD123		4/26/2022	Treatment of blastic plasmacytoid dendritic cell neoplasm	Designated	Not FDA Approved for Orphan Indication	INSERM UMR 1098
Allogeneic Turbo Chimeric Antigen Receptor (Turbocar) T Cells Targeting B Cell Maturation Antigen		4/26/2022	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	Allogene Therapeutics
H-D-valyl1-D-alanyl-D-glutamyl-D-alanyl-D-arginyl5-D-glutamyl-D-glutamyl-D-leucyl-D-glutamyl-D-arginyl10-D-leucyl-D-glutamyl-D-alanyl-D-arginyl-D-leucyl15-glycyl-D-glutaminyl-D-alanyl-D-arginyl-glycyl20-D-glutamyl-D-leucyl-D-lysyl-D-lysyl-D-tryptophyl25-D-lysyl-D-methionyl-D-arginyl-D-arginyl-D-asparaginyl30-D-glutaminyl-D-phenylalanyl-D-tryptophyl-D-leucyl-D-lysyl35-D-leucyl-D-glutaminyl-D-arginine		4/25/2022	Treatment of stage IIB-IV melanoma	Designated	Not FDA Approved for Orphan Indication	"Sapience Therapeutics, Inc."
sodium bispiperidine-carboxamido-dimethylpenatnamido-methoxycarbonyl-indol-propanamidohexanoate		4/19/2022	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	"ENB Therapeutics, Inc."
Glycolic acid and D-lactic acid		4/19/2022	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Neurevo GmbH
Nanvuranlat		4/19/2022	Treatment of biliary tract cancer	Designated	Not FDA Approved for Orphan Indication	"J-Pharma Co., Ltd."
"N-(1¿,2-dihydroxy-[1,2¿-binapthalen]-4¿-yl)-4-methoxybenzenesulfonamide"		4/19/2022	Treatment of pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"Tvardi Therapeutics, Inc."
"methyl (R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-3- ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate"		4/19/2022	Treatment of Rett Syndrome	Designated	Not FDA Approved for Orphan Indication	"DepYmed, Inc."
N-Acetyl-Leucine		4/13/2022	Treatment of GM1 Gangliosidosis	Designated	Not FDA Approved for Orphan Indication	IntraBio Inc.
efzofitimod		4/12/2022	Treatment of Systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	aTyr Pharma Inc.
"(R)-5-({4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl}methyl)-(5-2H)-1,3-thiazolidine-2,4-dione hydrochloride"		4/11/2022	Treatment of X-Linked Adrenoleukodystrophy	Designated	Not FDA Approved for Orphan Indication	Poxel S.A.
Toripalimab		4/11/2022	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"TopAlliance Biosciences, Inc"
Insulin-like Growth Factor-1		4/11/2022	Treatment of Congenital Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	Sarcomed AB
Echothiophate iodide		4/11/2022	Treatment of Stargardt Disease	Designated	Not FDA Approved for Orphan Indication	"Fera Pharmaceuticals, LLC"
an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payload		4/7/2022	"Treatment of Gastric Cancer, including Gastroesophageal Junction"	Designated	Not FDA Approved for Orphan Indication	AstraZeneca
"(1E, 4E, 6E)-1-(3, 5-dimethoxyphenyl)- 7-(4-hydroxy-3, 5dimethoxyphenyl) hepta- 1, 4, 6-trien-3-one"		3/31/2022	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Agastiya Biotech
serplulimab		3/31/2022	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Hengenix Biotech, Inc."
"(1E, 4E, 6E)-1-(3, 5-dimethoxyphenyl)-7-(4-hydroxy-3, 5 dimethoxyphenyl) hepta-1, 4, 6-trien-3-one"		3/31/2022	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Agastiya Biotech
Beta-Lapachone		3/28/2022	Treatment of Primary Sclerosing Cholangitis (PSC)	Designated	Not FDA Approved for Orphan Indication	"Curome Biosciences Co., Ltd."
besilesomab-CHX-A¿-DTPA-90Y		3/28/2022	Conditioning treatment prior to hematopoietic stem cell transplant	Designated	Not FDA Approved for Orphan Indication	"Telix Pharmaceuticals (US), Inc."
icerguastat		3/23/2022	Treatment of Amyotrophic Lateral Sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	Inflectis Bioscience
elamipretide		3/22/2022	Treatment of Friedreich’s ataxia (FRDA)	Designated	Not FDA Approved for Orphan Indication	"Stealth Biotherapeutics, Inc."
F18-PARPi		3/21/2022	Diagnostic for the management of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	"Theragnostics, Inc."
"N-[(1S)-1-[3-chloro-5-fluoro-2-({[2-methyl-4-(1-methyl-1H-1,2,4-triazol-5-yl)quinolin-8-yl]oxy}methyl)phenyl](1-2H)ethyl]-2-(difluoromethoxy)acetamide"		3/18/2022	Treatment of bradykinin-mediated angioedema	Designated	Not FDA Approved for Orphan Indication	Pharvaris Inc.
Autologous chimeric antigen receptor (CAR) T cells targeting B7-H3		3/18/2022	Treatment for neuroblastoma	Designated	Not FDA Approved for Orphan Indication	PersonGen BioTherapeutics (Suzhou) Co. Ltd.
"Phage-derived, non-replicative delivery vector carrying a DNA payload encoding an RNA-guided nuclease that targets stx genes of Shiga toxin-producing Escherichia coli (STEC)"		3/17/2022	Treatment of Shiga-toxin producing Escherichia coli infection as it relates to the prevention of hemolytic uremic syndrome	Designated	Not FDA Approved for Orphan Indication	Eligo Bioscience SA
dasatinib monolauryl sulfate		3/17/2022	Treatment of chronic myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Handa Oncology, LLC"
alrizomadlin		3/17/2022	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
Idronoxil		3/17/2022	Treatment of soft tissue sarcomas (STS)	Designated	Not FDA Approved for Orphan Indication	Noxopharm Limited
Benzyl ethyl aminoazobenzene quaternary ammonium		3/17/2022	Treatment of Retinitis Pigmentosa (RP)	Designated	Not FDA Approved for Orphan Indication	"Kiora Pharmaceuticals, Inc."
Vancomycin		3/17/2022	Treatment of periprosthetic joint infection	Designated	Not FDA Approved for Orphan Indication	"Osteal Therapeutics, Inc."
a novel synthetic small molecule inhibitor designed to target TEAD		3/14/2022	Treatment of mesothelioma	Designated	Not FDA Approved for Orphan Indication	Ikena Oncology
6-thio-2¿-deoxyguanosine		3/14/2022	Treatment of Hepatocellular Carcinoma	Designated	Not FDA Approved for Orphan Indication	"MAIA Biotechnology, Inc."
"(N-(1¿,2-dihydroxy-[1,2¿-binapthalen]-4¿-yl)-4-methoxybenzenesulfonamide)"		3/14/2022	Treatment of Hepatocellular Carcinoma	Designated	Not FDA Approved for Orphan Indication	"Tvardi Therapeutics, Inc."
a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1) gene		3/14/2022	Treatment of Adrenoleukodystrophy	Designated	Not FDA Approved for Orphan Indication	"SwanBio Therapeutics, Inc."
"c-KIT-targeting, dendrimer-linked phosphorodiamidate morpholino oligonucleotide"		3/10/2022	Treatment of mastocytosis	Designated	Not FDA Approved for Orphan Indication	"Hoth Therapeutics, Inc"
"(2S,4R)-1-((S)-2-(7-(4-((R)-3-((4-(N-(4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoyl)sulfamoyl)-2-((trifluoromethyl)sulfonyl)phenyl)amino)-4-(phenylthio)butyl)piperazin-1-yl)-7-oxoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide"		3/9/2022	Treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Dialectic Therapeutics, Inc."
Autologous ex-vivo CRISPR/Cas9 engineered Wilms¿ tumor 1-specific T-cell receptor T cells		3/9/2022	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Intellia Therapeutics, Inc."
"small molecule composed of a ligand binding moiety to BRD9, a chemical linker, and a ligand binding moiety to the cereblon (CRBN) E3 ligase"		3/8/2022	Treatment of Soft Tissue Sarcoma	Designated	Not FDA Approved for Orphan Indication	"C4 Therapeutics, Inc."
"((S)-3-(1-Cyclopentyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrazole-3-carboxamido)-5-(3,3-difluoropiperidin-1-yl)pentanoic acid hydrochloride)"		3/8/2022	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	APIE Therapeutics
olverembatinib		3/8/2022	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
biphenyl-substituted L-ido configured deoxynojirimycin derivative		3/7/2022	Treatment of Niemann Pick Disease Type C	Designated	Not FDA Approved for Orphan Indication	Azafaros BV
Growth Hormone Releasing Hormone (GHRH) 1-44 Human Amide and Arginine		3/7/2022	Diagnosis of Growth Hormone Deficiency	Designated	Not FDA Approved for Orphan Indication	"Hollenbeck Pharmaceuticals, Inc."
IgG4 Fc linked recombinant human AAT (alpha-1 antitrypsin)		3/2/2022	Treatment of Congenital Alpha-1 Antitrypsin Deficiency (AATD)	Designated	Not FDA Approved for Orphan Indication	Sanofi AATD Inc.
Tislelizumab		3/2/2022	Treatment of nasopharyngeal carcinoma	Designated	Not FDA Approved for Orphan Indication	"BeiGene USA, Inc."
"Small molecular inhibitor of fibroblast growth factor receptor (FGFR)-1,2 and 3 tyrosine kinases"		3/1/2022	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	"Abbisko Therapeutics Co.,Ltd"
"Tri-specific T cell activating construct targeting DLL3, HSA, and CD3e"		3/1/2022	Treatment of Small Cell Lung Cancer	Designated	Not FDA Approved for Orphan Indication	"Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc."
Oxytocin		3/1/2022	Treatment of Prader-Willi Syndrome	Designated	Not FDA Approved for Orphan Indication	"Tonix Pharmaceuticals, Inc."
epcoritamab-bysp	Epkinly	3/1/2022	Treatment of patients with Follicular Lymphoma (FL)	Designated/Approved		"Genmab US, Inc."
an anti-Claudin 18.2 and 4.1BB Bispecific Antibody		3/1/2022	Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ).	Designated	Not FDA Approved for Orphan Indication	"I-Mab Biopharma, Co., Ltd"
Human Insulin (rDNA)		2/28/2022	Prevention of Retinopathy of Prematurity (ROP)	Designated	Not FDA Approved for Orphan Indication	"Elgan Pharma, Ltd."
naproxcinod		2/28/2022	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"Fera Pharmaceuticals, LLC"
"2-{2,6-Dichloro-3-[(2,2-dimethyl-propionylamino)-methyl]-phenylamino}-6-(2,2-difluoroethoxy)-1-methyl-1H-benzoimidazole-5-carboxylic acid (trans-4-trifluoromethylcyclohexyl)-amide, hydrogensulfate"		2/28/2022	Treatment for Systemic Sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Gesynta Pharma AB
Synthetic double-stranded siRNA oligonucleotide directed against TMPRSS6 mRNA and covalently linked to a ligand containing 3 N-acetylgalactosamine residues		2/24/2022	Treatment of Polycythemia Vera (PV)	Designated	Not FDA Approved for Orphan Indication	Silence Therapeutics plc
6-(4-(tert-butyl)phenoxy)pyridin-3-amine hydrochloride		2/23/2022	Treatment of acute lymphoblastic leukemia (ALL)	Designated	Not FDA Approved for Orphan Indication	Cellestia Biotech AG
personalized neoantigen peptide vaccine comprised of 7-25 linear peptides (each peptide containing 20-30 amino acids on average) and poly IC:LC		2/23/2022	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Anda Biology Medicine Development (Shenzhen) Co., Ltd."
darvadstrocel		2/22/2022	Treatment of anal fistulas in patients without Crohn's disease	Designated	Not FDA Approved for Orphan Indication	"Millennium Pharmaceuticals, Inc. (Millennium)"
Glofitamab		2/22/2022	Treatment of Mantle Cell Lymphoma	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
Pralsetinib		2/22/2022	Treatment of metastatic RET fusion-positive solid tumors	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc"
recombinant adeno-associated virus containing human ASPA cDNA (rAAV-Olig001-ASPA)		2/17/2022	Treatment of Canavan Disease	Designated	Not FDA Approved for Orphan Indication	"Myrtelle, Inc."
allogeneic mesenchymal stem cells derived neuronal regeneration promoting cells		2/17/2022	Treatment of Charcot-Marie-Tooth disease type 1	Designated	Not FDA Approved for Orphan Indication	"Cellatoz Therapeutics, Inc."
tiratricol		2/17/2022	Treatment of Resistance to Thyroid Hormone Type Beta (RTH-Beta)	Designated	Not FDA Approved for Orphan Indication	Rare Thyroid Therapeutics International AB
salinomycin		2/15/2022	Treatment of uveal melanoma	Designated	Not FDA Approved for Orphan Indication	"Hillstream Biopharma, Inc."
bucillamine		2/15/2022	Prevention of ischemia-reperfusion injury during liver transplantation	Designated	Not FDA Approved for Orphan Indication	Revive Therapeutics Inc.
allogeneic human placental hematopoietic stem cell derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP)		2/14/2022	Treatment of gastric/gastroesophageal junction cancer	Designated	Not FDA Approved for Orphan Indication	Celularity Inc.
Polihexanide		2/11/2022	Treatment of fungal keratitis infection	Designated	Not FDA Approved for Orphan Indication	SIFI SpA
cemdisiran		2/10/2022	Treatment of paroxysmal nocturnal hemoglobinuria	Designated	Not FDA Approved for Orphan Indication	"Regeneron Pharamecuticals, Inc."
Cannabidiol		2/10/2022	Treatment of chromosome 15q11.2-13.1 duplication syndrome	Designated	Not FDA Approved for Orphan Indication	"Radius Pharmaceuticals, Inc."
Recombinant serotype 9 adeno-associated virus encoding a codon-optimized human galactosylceramidase (GALC) transgene (hGALCopt2)		2/10/2022	Treatment of Krabbe Disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Neurogene Inc.
Pociredir		2/10/2022	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"Fulcrum Therapeutics, Inc."
epetraborole hydrochloride		2/9/2022	Treatment of infections caused by nontuberculous mycobacteria (NTM)	Designated	Not FDA Approved for Orphan Indication	"AN2 Therapeutics, Inc."
Cannabidiol		2/9/2022	Treatment of Angelman Syndrome	Designated	Not FDA Approved for Orphan Indication	"Radius Pharmaceuticals, Inc."
Genetically modified human adenovirus encoding human PH20		2/7/2022	Treatment of Retinoblastoma	Designated	Not FDA Approved for Orphan Indication	VCN Biosciences S.L.
"1,1¿-(1, 12- Dodecanediyl)bis[cyclopropanecarboxamide]"		2/3/2022	Treatment of congenital X-linked nephrogenic diabetes insipidus	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"NephroDI Therapeutics, Inc."
tamibarotene		2/1/2022	Treatment of Myelodysplastic Syndrome (MDS)	Designated	Not FDA Approved for Orphan Indication	Syros Pharmaceuticals
Adeno-associated virus serotype 9 carrying the human Fukutin-Related protein gene and target sequence of the miR-208a		1/31/2022	Treatment of autosomal recessive disorder Limb Girdle Muscular Dystrophy R9 FKRP-related (LGMDR9)	Designated	Not FDA Approved for Orphan Indication	Atamyo Therapeutics
Ketamine Hydrochloride		1/31/2022	Treatment of Status Epilepticus	Designated	Not FDA Approved for Orphan Indication	PharmaTher Inc.
Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A)		1/31/2022	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Nanjing Iaso Biotherapeutics Co., Ltd."
an autologous T-cell immunotherapy (ECT204)		1/31/2022	Treatment of Hepatocellular Carcinoma (HCC)	Designated	Not FDA Approved for Orphan Indication	"Eureka Therapeutics, Inc."
Biphenyl-substituted L-ido configured deoxynojirimycin derivative		1/31/2022	Treatment of GM2 gangliosidoses (Tay-Sachs disease and Sandhoff disease)	Designated	Not FDA Approved for Orphan Indication	Azafaros BV
Small-molecule oral KIT inhibitor targeting activating mutations and resistance mutations		1/28/2022	Treatment of Gastrointestinal Stromal Tumors (GIST)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Theseus Pharmaceuticals, Inc."
"N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide hydrochloride"		1/27/2022	Treatment of Cholangiocarcinoma	Designated	Not FDA Approved for Orphan Indication	Relay Therapeutics Inc.
an autologous T-cell immunotherapy (ET140203)		1/27/2022	Treatment of Hepatocellular Carcinoma	Designated	Not FDA Approved for Orphan Indication	"Eureka Therapeutics, Inc."
"A CD47-binding, fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPalpha) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human IgG"		1/27/2022	Treatment for gastric cancer and gastro-esophageal junction cancer	Designated	Not FDA Approved for Orphan Indication	ALX Oncology Inc.
glumetinib		1/25/2022	Treatment of Non-small Cell Lung Cancer (NSCLC) with MET Genomic Aberration	Designated	Not FDA Approved for Orphan Indication	"Haihe Biopharma Co., Ltd."
Anti-fibroblast growth factor receptor 3 antigen-binding fragment (anti-FGFR3 Fab)		1/25/2022	Treatment of Achondroplasia	Designated	Not FDA Approved for Orphan Indication	"Genzyme Corporation, a Sanofi Company"
"Human recombinant factor VIIa variant (P10Q, K32E, T106N, V253N), desialylated"		1/20/2022	Treatment of postpartum hemorrhage	Designated	Not FDA Approved for Orphan Indication	"Coagulant Therapeutics, Corp."
Recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG		1/20/2022	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Trillium Therapeutics Inc.
Rilpivirine		1/19/2022	Treatment of Neuroblastoma	Designated	Not FDA Approved for Orphan Indication	Aptorum International Limited
flunarizine		1/19/2022	Treatment of Juvenile Absence Epilepsy (JAE)	Designated	Not FDA Approved for Orphan Indication	Xenon Pharmaceuticals Inc.
Norrin-derived growth factor		1/19/2022	Treatment of Familial exudative vitreoretinopathy (FEVR)	Designated	Not FDA Approved for Orphan Indication	"Caeregen Therapeutics, LLC"
Ac-225 alphavbeta3-IAC		1/19/2022	Treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	Advanced Imaging Projects
Explored Claudin 18.2 CAR T Cells		1/19/2022	Treatment of Gastric Cancer	Designated	Not FDA Approved for Orphan Indication	"Nanjing Bioheng Biotech Co., Ltd."
Eltanexor		1/19/2022	Treatment of Myelodysplastic Syndrome	Designated	Not FDA Approved for Orphan Indication	"Karyopharm Therapeutics, Inc."
"Small molecule inhibitor of the enzymatic activity of Su(var), Enhancer-of-zeste, Trithorax domain containing 2 (SETD2)"		1/19/2022	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Epizyme, Inc."
Silmitasertib		1/19/2022	Treatment of Biliary Tract Cancer	Designated	Not FDA Approved for Orphan Indication	"Senhwa Biosciences, Inc."
a modified version of methionine gamma-lyase (MGL) enzyme from the bacterium Pseudomonas entomophila		1/18/2022	Treatment of homocystinuria	Designated	Not FDA Approved for Orphan Indication	"Codexis, Inc."
Autologous multi-tumor-associated antigen-specific T cell product (MultiTAA-specific T cell product)		1/18/2022	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Marker Therapeutics, Inc."
Anti- FcgammaRIIB Monoclonal Antibody		1/18/2022	Treatment of Follicular Lymphoma	Designated	Not FDA Approved for Orphan Indication	BioInvent International AB
Anti-CD19 Chimeric Antigen Receptor T-Cell Injection		1/13/2022	"Treatment of CD19+, relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL)"	Designated	Not FDA Approved for Orphan Indication	Juventas Cell Therapy Ltd.
recombinant adeno-associated virus serotype 2 containing human mitochondrial ND1 codon optimized gene (rAAV2-ND1)		1/13/2022	Treatment of Leber's Hereditary Optic Neuropathy (LHON)	Designated	Not FDA Approved for Orphan Indication	"Neurophth Therapeutics, Inc."
testosterone		1/12/2022	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	Sarcomed AB
N-acetyl-L-leucine		1/11/2022	Treatment of GM2 Gangliosidosis	Designated	Not FDA Approved for Orphan Indication	IntraBio Inc.
Recombinant human apolipoprotein A-I/phospholipid complexes		1/10/2022	Treatment of lecithin-cholesterol acyltransferase (LCAT) deficiency including familial LCAT deficiency and fisheye disease.	Designated	Not FDA Approved for Orphan Indication	Abionyx Pharma
insulin-like growth factor-1		1/10/2022	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	Sarcomed AB
nandrolone		1/6/2022	Treatment of facioscapulohumeral muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	Sarcomed AB
"2-(4-oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid"		1/6/2022	Treatment of sorbitol dehydrogenase deficiency (SORD deficiency)	Designated	Not FDA Approved for Orphan Indication	Applied Therapeutics Inc.
eplontersen	Wainua	1/6/2022	Treatment of transthyretin-mediated amyloidosis	Designated/Approved		"Ionis Pharmaceuticals, Inc."
Human IgG1Fc- iMod domain (amino acids 2-60) of human HARS fusion protein		1/5/2022	Treatment of sarcoidosis	Designated	Not FDA Approved for Orphan Indication	aTyr Pharma
humanized anti-CD-47 mAb		1/3/2022	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"ARCH Oncology, Inc."
"Glycine, L-prolyl-L-prolyl-L-leucyl-L-seryl-L-glutaminyl-L-alpha-glutamyl-L-threonyl-Lphenylalanyl- L-seryl-L-alpha-aspartyl-L-leucyl-L-tryptophyl-L-lysyl-L-leucyl-L-leucyl-L-lysyl-Llysyl- L-tryptophyl-L-lysyl-L-methionyl-L-arginyl-L-arginyl-L-asparaginyl-L-glutaminyl-Lphenylalanyl- L-tryptophyl-L-valyl-L-lysyl-L-valyl-L-glutaminyl-L-arginyl-"		1/3/2022	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Oncolyze, Inc."
adeno-associated virus vector carrying complementary deoxyribonucleic acid encoding the human long-wave-sensitive opsin 1 (AAV.7m8-L-opsin)		1/3/2022	Treatment of blue cone monochromacy (X-linked incomplete achromatopsia)	Designated	Not FDA Approved for Orphan Indication	Blue Gen Therapeutics Foundation
zapnometinib		12/28/2021	Treatment of Hantavirus infection	Designated	Not FDA Approved for Orphan Indication	Atriva Therapeutics GmbH
PEGylated aptamer targeting Von Willebrand Factor A1 domain		12/27/2021	Treatment of Hemophilia A	Designated	Not FDA Approved for Orphan Indication	"Band Therapeutics, LLC"
Sirolimus		12/21/2021	Treatment of Bronchiolitis Obliterans Syndrome	Designated	Not FDA Approved for Orphan Indication	"AI Therapeutics, Inc."
crizotinib	Xalkori	12/20/2021	Treatment of inflammatory myofibroblastic tumor	Designated/Approved		Pfizer Inc.
crizotinib	Xalkori	12/20/2021	Treatment of inflammatory myofibroblastic tumor	Designated/Approved		Pfizer Inc.
IgG-like bispecific monoclonal antibody (mAb) composed of the anti-IL-1beta mAb canakinumab and the anti-IL-18 mAb CMK389		12/20/2021	"Treatment of nucleotide-binding oligomerization domain-like receptor family CARD domain-containing protein 4 - Gain of Function (NLRC4-GOF), also described as autoinflammation with infantile enterocolitis (AIFEC)"	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
adeno-associated virus serotype 5 (AAV5) vector containing the hSERPING cDNA sequence encoding human C1-esterase inhibitor (C1-INH)		12/20/2021	Treatment of hereditary angioedema	Designated	Not FDA Approved for Orphan Indication	"BioMarin Pharmaceutical, Inc."
Nonfucosylated humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting B-cell maturation antigen (SEA-BCMA)		12/16/2021	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	Seagen Inc.
silmitasertib		12/15/2021	Treatment of Medulloblastoma	Designated	Not FDA Approved for Orphan Indication	"Senhwa Biosciences, Inc."
Marzeptacog alfa (activated)		12/15/2021	"Treatment of Bleeding Episodes in Patients with Hemophilia A or B, Including those with Inhibitors"	Designated	Not FDA Approved for Orphan Indication	GC Biopharma Corp.
"a fourth generation activating chimeric receptor (ACR) natural killer (NK) cell therapy engineered with an NKG2D ACR, OX40 costimulatory domain, CD3zeta signaling moiety, and membrane bound IL-15 (mb-IL15)"		12/14/2021	Treatment of acute myeloid lymphoma	Designated	Not FDA Approved for Orphan Indication	"Nkarta, Inc."
Dornase alpha		12/14/2021	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Xenetic Biosciences, Inc."
an adeno-associated viral vector delivering human FIX Padua gene		12/14/2021	Treatment of Hemophilia B	Designated	Not FDA Approved for Orphan Indication	"Shanghai Vitalgen BioPharma Co., Ltd."
"(R)-N2-(4-cyclopropyl-5-fluoro-6-methylpyridin-2-yl)-N4-(1, 5-dimethyl-1H-pyrazol-3-yl)-5-(3,4-dimethylpiperazin-1-yl) pyrimidine-2,4-diamine"		12/14/2021	Treatment of malaria	Designated	Not FDA Approved for Orphan Indication	Cadila Healthcare Limited
N-hydroxy-N-(methylacylfulvene)urea		12/14/2021	Treatment of Atypical Teratoid/Rhabdoid Tumor (ATRT)	Designated	Not FDA Approved for Orphan Indication	Lantern Pharma Inc.
thiostrepton		12/14/2021	Treatment of Mesothelioma	Designated	Not FDA Approved for Orphan Indication	"RS Oncology, LLC"
allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein		12/14/2021	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	Vor Biopharma
olverembatinib		12/14/2021	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
Posaconazole		12/13/2021	Treatment of Mucormycosis (previously called zygomycosis)	Designated	Not FDA Approved for Orphan Indication	"AET Pharma US, Inc."
"an allogeneic, fratricide-resistant genetically modified T cell transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7"		12/8/2021	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	"Wugen, Inc."
recombinant humanized IgG1-based monoclonal antibody which binds to human latent myostatin in a pH dependent manner		12/7/2021	Treatment of spinal muscular atrophy	Designated	Not FDA Approved for Orphan Indication	Genentech Inc.
enzastaurin		12/7/2021	Treatment of Ehlers-Danlos Syndrome	Designated	Not FDA Approved for Orphan Indication	"Aytu BioPharma, Inc."
tacrolimus		12/7/2021	"Treatment of non-infectious intermediate, posterior, pan, and chronic anterior uveitis"	Designated	Not FDA Approved for Orphan Indication	BioNanoSim Ltd.
Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)		12/2/2021	Treatment of Hypoplastic Left Heart Syndrome	Designated	Not FDA Approved for Orphan Indication	"Longeveron, Inc."
"cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments of the hTERT subunit"		12/2/2021	Treatment of Stage IIB - IV melanoma	Designated	Not FDA Approved for Orphan Indication	Ultimovacs ASA
selinexor		12/2/2021	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	"Karyopharm Therapeutics, Inc."
Valemetostat tosylate		12/1/2021	Treatment of Peripheral T-cell lymphoma (PTCL)	Designated	Not FDA Approved for Orphan Indication	"Daiichi Sankyo, Inc."
"an ADC drug against CLDN18.2, containing a recombinant humanized anti-CLDN18.2 IgG1 monoclonal antibody and linker-payload MC-VC-PAB-MMAE"		11/30/2021	Treatment of Cholangiocarcinoma (intrahepatic bile duct cancer)	Designated	Not FDA Approved for Orphan Indication	LaNova Medicines Limited
berbamine		11/29/2021	Treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	IsoQ Therapeutics Inc.
Tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5).		11/24/2021	Treatment of Chondrosarcoma	Designated	Not FDA Approved for Orphan Indication	"Inhibrx, Inc."
Fully Human CD19 / CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection		11/24/2021	Treatment of Acute Lymphoblastic Leukemia	Designated	Not FDA Approved for Orphan Indication	"Nanjing IASO Biotherapeutics Co., Ltd."
"ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate?2? sulfatase (IDS) enzyme to subjects with Hunter syndrome"		11/24/2021	"Treatment of Hunter syndrome (Mucopolysaccharidosis type II, MPS II)"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AVROBIO, Inc."
nanatinostat and valganciclovir		11/24/2021	"Treatment of Epstein Barr Virus-positive diffuse large B-cell lymphoma, not otherwise specified (EBV+ DLBCL, NOS)"	Designated	Not FDA Approved for Orphan Indication	"Viracta Subsidiary, Inc."
Recombinant AAV9 vector encoding the human progranulin (PGRN) gene		11/24/2021	Treatment of frontotemporal dementia (FTD)	Designated	Not FDA Approved for Orphan Indication	AviadoBio Ltd.
autologous anti-CLL-1 CAR T-cell therapy		11/23/2021	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Guangzhou Bio-gene Technology Co., Ltd"
autologous CD34+ hematopoietic stem and progenitor cells with a HBB gene corrected by CRISPR/Cas9 in combination with a gcSCD-AAV6 vector		11/23/2021	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"Graphite Bio, Inc."
obinutuzumab		11/22/2021	"Treatment of childhood-onset idiopathic nephrotic syndrome (NS), defined as steroid dependent or frequently relapsing NS."	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
sodium salt of 19-bp single stranded RNA uniformly modified 2¿-O-(2-methoxyethyl) phosphorothioate Antisense Oligonucleotide (ASO) consisting of 19 nucleotide residues with the sequence 5'-5MeC-5MeU-G-5MeC-A-A-5MeC-A-G-A-5MeU-G-G-A-A-G-A-5MeC-5MeU-3¿		11/10/2021	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	SpliSense Ltd.
Fully human anti-galectin-9 IgG4 monoclonal antibody		11/10/2021	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"PureTech Health, LLC."
Zandelisib		11/9/2021	Treatment of follicular lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"MEI Pharma, Inc."
Chimeric Antigen Receptor T Cells targeting CD7		11/9/2021	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	PersonGen BioTherapeutics (Suzhou) Co. Ltd.
"(R)-2-((1-(2-(4-methoxy-3-(2-morpholinoethoxy) phenyl)-5-methylthiazol-4-yl)ethyl)thio)pyrimidine-4,6-diamine"		11/9/2021	Treatment of Optic Neuritis	Designated	Not FDA Approved for Orphan Indication	Trethera Corporation
"N-(4-methyl-3-(7-methyl-2-((6-methylpyridin-3-yl)amino)-8-oxo-7,8-dihydropyrido[3,4-d]pyrimidin-6-yl)phenyl)-3-(trifluoromethyl)benzamide"		11/8/2021	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Pharos iBio Co., Ltd."
recombinant AAV8 that contains a vector genome encoding a miniaturized dystrophin protein (microdystrophin)		11/8/2021	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	REGENXBIO Inc.
Anti-Beta1 Integrin Monoclonal Antibody		11/8/2021	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	"OncoSynergy, Inc"
Pegylated Liposomal Alendronate with Doxorubicin		11/8/2021	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	LEVCO Pharmaceuticals Ltd.
Adeno-associated viral vector expressing human retinitis pigmentosa GTPase regulator-interacting protein 1 (AAV.Anc80.hRPGRIP1)		11/8/2021	RPGRIP1 Mutation-Associated Retinal Dystrophies	Designated	Not FDA Approved for Orphan Indication	Odylia Therapeutics
Toripalimab		11/8/2021	Treatment of esophageal cancer	Designated	Not FDA Approved for Orphan Indication	"TopAlliance Biosciences, Inc."
efgartigimod alfa and hyaluronidase-qvfc	Vyvgart Hytrulo	11/8/2021	Treatment of Chronic Inflammatory Demyelinating Polyneuropathy	Designated/Approved		argenx BV
H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2-DOTA-225-actinium		11/5/2021	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	NovaCurie AG
Autologous chimeric antigen receptor (CAR)-positive T cells targeting cluster of differentiation 19 (CD19) and B cell maturation antigen (BCMA)		11/4/2021	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Gracell Biopharmaceuticals, Inc."
Ivaltinostat		11/4/2021	Treatment of Alport Syndrome	Designated	Not FDA Approved for Orphan Indication	"Machaon Biotherapeutics, Inc."
"[10-(4,5-dimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl](triphenyl)phosphonium bromide"		11/4/2021	Treatment of Leber Hereditary Optic Neuropathy	Designated	Not FDA Approved for Orphan Indication	Mitotech S.A.
edaravone		11/4/2021	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"Suzhou Auzone Biological Technology Co., Ltd"
rivoceranib		11/4/2021	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"Elevar Therapeutics, Inc."
synthetic 23 amino acid peptide AASSGVSTPGSAGHDIITEQPRS derived from the Huntingtin protein		11/4/2021	Treatment of Huntington’s disease	Designated	Not FDA Approved for Orphan Indication	centre national de la recherche scientifique
L-S-(3-Amino-3-carboxypropyl)-S-methylsulfoximine		11/2/2021	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"William S. Brusilow, Ph.D."
Benralizumab		11/1/2021	Treatment of eosinophilic gastroenteritis	Designated	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals LP
Miltefosine		11/1/2021	Treatment invasive candidiasis	Designated	Not FDA Approved for Orphan Indication	"Profounda, lnc."
Benralizumab		11/1/2021	Treatment of Eosinophilic Gastritis (EG)	Designated	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals LP
"AAV8/TTR-hFVa - Adeno Associated Virus, Serotype 8 with a transthyretin promotor and encoded transgene for human clotting Factor Va."		10/27/2021	Treatment of Hemophilia A or Hemophilia B with or without Inhibitors	Designated	Not FDA Approved for Orphan Indication	"GeneVentiv Therapeutics, Inc."
mocravimod		10/27/2021	Prevention of graft-versus-host disease	Designated	Not FDA Approved for Orphan Indication	Priothera SAS
Idroxioleic acid		10/26/2021	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Laminar Pharma Inc
satralizumab-mwge		10/26/2021	Treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
human anti-LIGHT monoclonal antibody		10/26/2021	Treatment of pediatric Crohn’s disease	Designated	Not FDA Approved for Orphan Indication	Cerecor Inc.
humanized recombinant immunoglobulin G (IgG) 4 monoclonal antibody against C1q		10/25/2021	Treatment of Huntington's Disease	Designated	Not FDA Approved for Orphan Indication	"Annexon, Inc."
Psilocybin		10/25/2021	Treatment of Fragile X Syndrome	Designated	Not FDA Approved for Orphan Indication	Nova Mentis Life Science Corp.
Heterodimeric multi-specific IgG1 antibody targeting human epidermal growth factor receptor 2 (HER2) and NKG2D on natural killer (NK) and cytotoxic T-cells		10/25/2021	Treatment of Esophageal Cancer	Designated	Not FDA Approved for Orphan Indication	"Dragonfly Therapeutics, Inc."
Alvelestat		10/25/2021	Treatment of Alpha-1 Antitrypsin Deficiency	Designated	Not FDA Approved for Orphan Indication	Mereo Biopharma 4 Limited
optimized human tissue-type plasminogen activator		10/21/2021	Treatment of intracerebral hemorrhage	Designated	Not FDA Approved for Orphan Indication	Op2Lysis SAS
clustered regularly interspaced short palindromic repeats CRISPR/ Cas9-based gene therapy consisting of a single guide RNA targeting the human TTR gene and a messenger RNA encoding Cas9		10/19/2021	Treatment of transthyretin amyloidosis	Designated	Not FDA Approved for Orphan Indication	"Intellia Therapeutics, Inc."
nipocalimab		10/14/2021	Treatment of chronic inflammatory demyelinating polyneuropathy	Designated	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
Clemizole		10/14/2021	Treatment of Lennox-Gastaut Syndrome	Designated	Not FDA Approved for Orphan Indication	"Epygenix Therapeutics, Inc."
Biocompatible polymeric PLGA nanofiber membrane containing the active substance 7-ethyl-10-hydroxycamptothecin		10/13/2021	Treatment of Soft Tissue Sarcoma (STS)	Designated	Not FDA Approved for Orphan Indication	Cebiotex S.L.
"immunoglobulin VHH fragment-linker-VHH fragment, anti-CD1d and anti-[Vdelta2 T-cell receptor], humanized monoclonal antibody"		10/13/2021	Treatment of chronic lymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	LAVA Therapeutics
"2-[(3-Methylbutyl)amino]-1,4-naphthalenedione"		10/12/2021	Treatment of Dravet Syndrome	Designated	Not FDA Approved for Orphan Indication	Neuroene Therapeutics
cudetaxestat		10/12/2021	Treatment of systemic sclerosis.	Designated	Not FDA Approved for Orphan Indication	"Blade Therapeutics, Inc."
"haptoglobin (Hp1-1), (Human)"		10/12/2021	Treatment of subarachnoid hemorrhage	Designated	Not FDA Approved for Orphan Indication	CSL Behring
Aminouridyl phenoxypiperidinbenzyl butamide		10/12/2021	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	Anviron Corporation
Recombinant human interleukin-15/IL-15 receptor alpha complex with linked integrin binding motif		10/12/2021	Treatment of cholangiocarcinoma	Designated	Not FDA Approved for Orphan Indication	BJ Bioscience Inc.
E-selectin/Adeno-Associated Virus (E-sel/AAV2) Gene Therapy		10/12/2021	Treatment of Buerger disease	Designated	Not FDA Approved for Orphan Indication	Ambulero Inc
Rituximab		10/12/2021	Treatment of Myasthenia Gravis	Designated	Not FDA Approved for Orphan Indication	Taxon Therapeutics Ltd.
Ketamine		10/12/2021	Treatment of Complex Regional Pain Syndrome (CRPS)	Designated	Not FDA Approved for Orphan Indication	PharmaTher Inc.
"5,6-dibromo-4-nitro-2-(piperidin-4-yl)-1-(propan-2-yl)-1H-1,3-benzodiazole hydrochloride"		10/12/2021	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	"Stemline Therapeutics, Inc."
elranatamab-bcmm	Elrexfio	10/12/2021	Treatment of multiple myeloma	Designated/Approved		Pfizer Inc.
single chain recombinant trispecific killer engager consistent of anti-CD16 scFV spliced to anti-CD33 scFV with a modified IL-15 linker		10/12/2021	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"GT Biopharma, Inc."
Gentulizumab		10/12/2021	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	"Changchun GeneScience Pharmaceutical Co., Ltd."
tezepelumab		10/7/2021	Treatment of Eosinophilic Esophagitis	Designated	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals LP
dasatinib	Phyrago	10/5/2021	Treatment of acute lymphoblastic leukemia	Designated/Approved		"Nanocopoeia, LLC"
dasatinib	Phyrago	10/5/2021	Treatment of chronic myelogenous leukemia	Designated/Approved		"Nanocopoeia, LLC"
"Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpes virus-6, Epstein Barr virus, and adenovirus"		9/29/2021	Treatment for Virus-associated hemorrhagic cystitis	Designated	Not FDA Approved for Orphan Indication	"AlloVir, Inc."
"3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-[(2-fluoro-4-iodophenyl)amino]-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione"		9/28/2021	Treatment of familial adenomatous polyposis	Designated	Not FDA Approved for Orphan Indication	"Recursion Pharmaceuticals, Inc."
Adeno-associated virus 2/9 expressing human GALT gene (AAV2/9-hGALT)		9/28/2021	Treatment of galactosemia	Designated	Not FDA Approved for Orphan Indication	"Jaguar Gene Therapy, LLC"
Marzeptacog alfa (activated)		9/27/2021	Treatment of Factor VII Deficiency	Designated	Not FDA Approved for Orphan Indication	GC Biopharma Corp.
N-acetylcysteine amide		9/27/2021	"Treatment for Gain-of-Function Mutation in ACOX1, Mitchell’s Syndrome."	Designated	Not FDA Approved for Orphan Indication	"Nacuity Pharmaceuticals, Inc."
Polymeric polyethylene glycol-phosphatidyl ethanolamine (PEG-PE) micelles containing Curcumin C3 complex (CUR) and doxorubicin hydrochloride (DOX)		9/27/2021	Treatment of Soft Tissue Sarcoma	Designated	Not FDA Approved for Orphan Indication	"Immix Biopharma, Inc"
"Adeno-Associated Virus 9 human Propionyl-CoA Carboxylase, alpha subunit (AAV9-hPCCA)"		9/27/2021	Treatment of propionic acidemia	Designated	Not FDA Approved for Orphan Indication	"National Institutes of Health, National Center for Advancing Translational Sciences"
PEGylated aptamer targeting Von Willebrand Factor A1 domain		9/27/2021	Treatment of Von Willebrand Disease	Designated	Not FDA Approved for Orphan Indication	"Band Therapeutics, LLC"
Fasudil hydrochloride		9/21/2021	Treatment of 16p11.2 Deletion Syndrome	Designated	Not FDA Approved for Orphan Indication	"Woolsey Pharmaceuticals, Inc."
nadunolimab		9/21/2021	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Cantargia AB
riboflavin 5'-phosphate sodium		9/21/2021	Treatment of corneal ulcers	Designated	Not FDA Approved for Orphan Indication	Glaukos Corporation
anti-thymocyte globulin (rabbit)		9/21/2021	Prophylaxis of graft-versus-host-disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genzyme Corporation
Melatonin		9/21/2021	Treatment of optic neuritis	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
luspatercept		9/21/2021	Treatment of Alpha-thalassemia	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
"fixed set of four ribonucleic acid lipoplex (RNA-LPX) drug products (RBL001.3, RBL002.4, RBL003.3, RBL004.3) which code for four melanoma tumor-associated antigens"		9/15/2021	Treatment of stage IIB through IV melanoma	Designated	Not FDA Approved for Orphan Indication	BioNTech SE
octreotide		9/15/2021	Treatment of autosomal dominant polycystic liver disease	Designated	Not FDA Approved for Orphan Indication	Camurus AB
bis-cyclopropylcarbamoyl-bis-indanedione sulfone		9/15/2021	Treatment of Heparin Induced Thrombocytopenia	Designated	Not FDA Approved for Orphan Indication	"Fox Chase Chemical Diversity Center, Inc."
"3-(4-((3-endo)-3-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4- yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-2-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one"		9/13/2021	Treatment of Primary Sclerosing Cholangitis	Designated	Not FDA Approved for Orphan Indication	"Cascade Pharmaceuticals, Inc"
dextromethadone hydrochloride		9/13/2021	Treatment of Amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"Relmada Therapeutics, Inc."
encorafenib	Braftovi	9/8/2021	Treatment of BRAF-mutant Non-Small Cell Lung Cancer	Designated/Approved		Array BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.)
N-acetyl-L-leucine		9/8/2021	"Treatment of Niemann-Pick Disease, Type C"	Designated	Not FDA Approved for Orphan Indication	IntraBio Inc.
"N-[(3-fluoro-4-methoxypyridin-2-yl) methyl]-3-(methoxymethyl)-1-({4-[(2-oxo-1,2-dihydropyridin-1-yl) methyl]phenyl}methyl)-1H-pyrazole-4-carboxamide"		9/7/2021	Treatment of bradykinin-mediated angioedema	Designated	Not FDA Approved for Orphan Indication	KalVista Pharmaceuticals Ltd
N-acetylcysteine amide		9/7/2021	Treatment of cystinosis	Designated	Not FDA Approved for Orphan Indication	"Nacuity Pharmaceuticals, Inc."
chiauranib		9/2/2021	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Shenzhen Chipscreen Biosciences Co., Ltd."
Synthetic analogue of cyclic Glycine-Proline		9/2/2021	Treatment of Prader-Willi Syndrome	Designated	Not FDA Approved for Orphan Indication	"Neuren Pharmaceuticals, Ltd."
Eliglustat Tartrate		9/2/2021	"Treatment of Gaucher Disease Type 1 patients who are CYP2D6 ultra-rapid metabolizers and patients whose CYP2D6 genotype cannot be determined (i.e., indeterminate metabolizers)."	Designated	Not FDA Approved for Orphan Indication	"Kashiv Biosciences, LLC"
Hypericin		9/2/2021	Treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Soligenix, Inc."
gavocabtagene autoleucel (gavo-cel)		9/1/2021	Treatment of Cholangiocarcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"TCR2 Therapeutics, Inc., a wholly owned"
Stabilized sulforaphane		9/1/2021	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Evgen Pharma plc
Nafamostat		9/1/2021	Treatment of Dengue Fever	Designated	Not FDA Approved for Orphan Indication	RNR Biomedical inc
Glucagon like peptide-1 (GLP-1) Elastin like peptide (ELP)-120 fusion protein		8/31/2021	Treatment of polymyositis	Designated	Not FDA Approved for Orphan Indication	"ImmunoForge Co., Ltd."
Gemfibrozil		8/30/2021	Treatment of Krabbe Disease	Designated	Not FDA Approved for Orphan Indication	"Polaryx Therapeutics, Inc."
citric acid		8/30/2021	Treatment of hyperammonemia in inborn errors of metabolism	Designated	Not FDA Approved for Orphan Indication	Versantis AG
Modified mRNA that encodes human glucose-6-phosphatase-alpha		8/27/2021	Treatment of glycogen storage disease type 1a (GSD1a)	Designated	Not FDA Approved for Orphan Indication	"ModernaTX, Inc."
Gemfibrozil		8/27/2021	Treatment of GM2 gangliosidoses	Designated	Not FDA Approved for Orphan Indication	"Polaryx Therapeutics, Inc."
vactosertib		8/27/2021	Treatment of osteosarcoma	Designated	Not FDA Approved for Orphan Indication	"MedPacto, Inc."
Sivelestat		8/26/2021	Treatment of Myelodysplastic Syndrome	Designated	Not FDA Approved for Orphan Indication	RNR Biomedical inc
begelomab		8/20/2021	Treatment of dermatomyositis	Designated	Not FDA Approved for Orphan Indication	ADIENNE SA
Hydroxyurea methylacylfulvene		8/20/2021	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Lantern Pharma, Inc."
"Anthrax Vaccine Adsorbed, Adjuvanted"	Cyfendus	8/19/2021	Post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure	Designated/Approved		"Emergent Product Development Gaithersburg, Inc."
cemiplimab-rwlc		8/19/2021	Treatment of stage IA2 to stage IV cervical cancer	Designated	Not FDA Approved for Orphan Indication	"Regeneron Pharmaceuticals, Inc."
omadacycline		8/18/2021	Treatment of infections caused by Nontuberculous Mycobacteria (NTM)	Designated	Not FDA Approved for Orphan Indication	"Paratek Pharmaceuticals, Inc."
Infigratinib		8/12/2021	Treatment of achondroplasia	Designated	Not FDA Approved for Orphan Indication	"QED Therapeutics, Inc."
"2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide"		8/12/2021	Treatment of Neurofibromatosis type 1	Designated	Not FDA Approved for Orphan Indication	"Nflection Therapeutics, Inc."
ganaxolone		8/12/2021	Treatment of Tuberous Sclerosis Complex	Designated	Not FDA Approved for Orphan Indication	"Marinus Pharmaceuticals, Inc."
Recombinant adeno-associated viral vector serotype S3 containing codon optimised expression cassette encoding human beta-glucocerebrosidase variant		8/11/2021	Treatment of Gaucher Disease	Designated	Not FDA Approved for Orphan Indication	"Freeline Therapeutics, Inc."
"Samarium (Sm-153) chelate of DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephophonate))"		8/11/2021	Treatment of osteosarcoma	Designated	Not FDA Approved for Orphan Indication	"QSAM Therapeutics, Inc."
Adeno-Associated Viral Vector Serotype 1 containing the human otoferlin gene		8/11/2021	Rescue of hearing function in patients diagnosed with congenital deafness due to biallelic mutations of the OTOF gene	Designated	Not FDA Approved for Orphan Indication	"Decibel Therapeutics, Inc."
cereblon E3 ubiquitin ligase modulating agent		8/10/2021	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	"C4 Therapeutics, Inc."
Allogenic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen (BCMA)		8/10/2021	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	Allogene Therapeutics
Adeno-associated viral 2/5 (AAV2/5) vector expressing the human KCNJ13 gene		8/9/2021	Treatment of inherited retinal dystrophy due to KCNJ13 biallelic mutations	Designated	Not FDA Approved for Orphan Indication	Hubble Therapeutics
N-hydroxy-N-(methylacylfulvene)urea		8/9/2021	Treatment of Pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Lantern Pharma, Inc."
"3', 3, Diseleno Dipropionic Acid"		8/9/2021	Prevention of acute radiation syndrome	Designated	Not FDA Approved for Orphan Indication	"Advanced Innovative Partners, Inc."
Recombinant adeno-associated virus vector carrying human CYP4V2 gene		8/9/2021	Treatment of Bietti crystalline dystrophy (BCD)	Designated	Not FDA Approved for Orphan Indication	"Chigenovo Co., Ltd."
Mixture of delta 9-tetrahydrocannabinol glycosides		8/9/2021	Treatment of pediatric ulcerative colitis between the ages of 0-18 years	Designated	Not FDA Approved for Orphan Indication	"Vitality Biopharma, Inc."
Rapamycin-resistant Autologous Th1/Tc1 T cells		8/5/2021	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	Rapa Therapeutics LLC
a recombinant human monoclonal antibody targeting hantavirus		8/5/2021	Treatment of hantavirus Infection	Designated	Not FDA Approved for Orphan Indication	Ichor Biologics
sirolimus		8/3/2021	Treatment of Lymphatic Malformations	Designated	Not FDA Approved for Orphan Indication	"Palvella Therapeutics, Inc."
IL13 E13K mutation linked to portion of mutated pseudomonas exotoxin		8/3/2021	Treatment of Soft Tissue Sarcoma	Designated	Not FDA Approved for Orphan Indication	Targepeutics
Olorofim		8/3/2021	Treatment of invasive fusariosis	Designated	Not FDA Approved for Orphan Indication	F2G Limited
a humanized IgG1kappa-agonistic anti-CD40 mAb		8/3/2021	Treatment of patients with Soft Tissue Sarcoma (STS).	Designated	Not FDA Approved for Orphan Indication	"Pyxis Oncology, Inc."
Recombinant anti-claudin 18.2 monoclonal antibody		8/3/2021	Treatment of Gastric Cancer	Designated	Not FDA Approved for Orphan Indication	"Hengenix Biotech, Inc."
ketamine		8/3/2021	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	PharmaTher Inc.
an antibody-drug conjugate (ADC) (mAb/N-acetyl-y-calicheamicin)		7/29/2021	Treatment of Small Cell Lung Cancer (SCLC)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AbbVie Inc.
azacitidine	Vidaza	7/28/2021	Treatment of Juvenile myelomonocytic leukemia	Designated/Approved		Celgene Corporation (a Bristol-Myers Squibb Company)
Lisavanbulin		7/27/2021	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Basilea Pharmaceutical International Ltd.
Sirolimus		7/27/2021	Treatment of Sarcoidosis	Designated	Not FDA Approved for Orphan Indication	AI Therapeutics
an antisense oligonucleotide that has been developed to target expanded CAG repeats in messenger ribonucleic acid (mRNA)		7/27/2021	Treatment of Huntington’s disease	Designated	Not FDA Approved for Orphan Indication	Vico Therapeutics B.V.
imatinib		7/26/2021	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	Aerami Therapeutics
19 amino acid synthetic peptide NOS-enhancer		7/26/2021	Treatment of anterior ischemic optic neuropathy	Designated	Not FDA Approved for Orphan Indication	Biozeus Biopharmaceutical SA
"Humanized, Low-fucose Anti-Claudin 18.2 IgG1 Antibody with Enhanced Antibody Dependent Cell-mediated Cytotoxicity"		7/26/2021	Treatment of gastric cancer including cancer of gastroesophageal junction	Designated	Not FDA Approved for Orphan Indication	"Mabspace Biosciences (Suzhou) Co., Limited"
"2?(3,5?dichloro?4?([4?hydroxy?3?(propan?2?yl)phenyl]methyl)phenoxy)?N?methylacetamide"		7/22/2021	Treatment of X-linked Adrenoleukodystrophy	Designated	Not FDA Approved for Orphan Indication	"Autobahn Therapeutics, Inc."
Methotrexate		7/21/2021	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	"Aldeyra Therapeutics, Inc."
Tempol		7/21/2021	Treatment of Ataxia Telangiectasia	Designated	Not FDA Approved for Orphan Indication	"Matrix Biomed, Inc."
"an antibody oligonucleotide conjugate (AOC), comprised of a human transferrin receptor 1 (TfR1) targeting, effector function null, humanized IgG1 antibody (AV01mAb) conjugated to one small interfering RNA (siRNA)."		7/21/2021	Treatment of Myotonic Dystrophy Type 1 (DM1)	Designated	Not FDA Approved for Orphan Indication	Avidity Biosciences
Amisodin		7/21/2021	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"PRG S&T Co., Ltd"
"recombinant human anti-TGFBeta IgG2 monoclonal antibody that belongs to the IgG2/Gamma isotype subclass and binds TGFBeta1 and TGFBeta2 with high affinity and, to a lesser extent, TGFBeta3"		7/21/2021	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
Tesofensine plus metoprolol in a fixed-dose combination		7/21/2021	Treatment of Hypothalamic Obesity	Designated	Not FDA Approved for Orphan Indication	Saniona S/A
Lorcaserin		7/21/2021	Treatment of Lennox-Gastaut syndrome	Designated	Not FDA Approved for Orphan Indication	"Epygenix Therapeutics, Inc."
"3,4-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-5- carboxamide"		7/21/2021	Treatment of gastrointestinal stromal tumors	Designated	Not FDA Approved for Orphan Indication	"Cogent Biosciences, Inc."
Anti-C1s Humanized IgG4 Monoclonal Antibody		7/21/2021	Treatment of chronic inflammatory demyelinating polyneuropathy	Designated	Not FDA Approved for Orphan Indication	Sanofi Genzyme
Vactosertib		7/20/2021	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	"MedPacto, Inc."
magnesium lysinate-bis-resolvin E1		7/20/2021	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	Thetis Pharmaceuticals
(2S)-2-[(2S)-4-cyclohexyl-2-{[(2S)-1-(4-fluorobenzoyl)pyrrolidin-2-yl]formamido}butanamido]-N-(1-{[(1S)-1-{[(1S)-1-({1-[(1-{[2-({1-[(dimethylamino)methyl]cyclobutyl}carbamoyl)ethyl]carbamoyl}-1-methylethyl)carbamoyl]-1-methylethyl}carbamoyl)-3-methylbutyl		7/19/2021	Treatment of cutaneous leishmaniasis (Old World and New World)	Designated	Not FDA Approved for Orphan Indication	Bacoba AG
methotrexate (intravitreal)		7/19/2021	Treatment of Primary Vitreoretinal Lymphoma	Designated	Not FDA Approved for Orphan Indication	"Aldeyra Therapeutics, Inc."
Octreotide Acetate		7/19/2021	Treatment of Idiopathic Intracranial Hypertension	Designated	Not FDA Approved for Orphan Indication	NBO Pharma LLC
Alrizomadlin		7/14/2021	Treatment of Stage III-IV Melanoma	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
Adeno-associated viral vector encoding the human ceroid lipofuscinosis neuronal type 2 (CLN2) gene		7/12/2021	"Treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, Batten disease"	Designated	Not FDA Approved for Orphan Indication	Lexeo Therapeutics
Pridopidine		7/7/2021	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Prilenia Neurotherapeutics LTD
mecasermin rinfabate		7/7/2021	Prevention of bronchopulmonary dysplasia	Designated	Not FDA Approved for Orphan Indication	OHB Neonatology Ltd
"a liposomal formulation of CEBPA-51, an saRNA duplex in sucrose/phosphate buffer"		7/6/2021	Treatment of hepatocellular carcinoma (HCC)	Designated	Not FDA Approved for Orphan Indication	"MiNA Alpha, Ltd"
Iniparib		7/1/2021	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	TriAct Therapeutics
Sodium meta-arsenite		7/1/2021	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Komipharm International Australia Pty Ltd.
opelconazole		7/1/2021	Treatment of invasive aspergillosis	Designated	Not FDA Approved for Orphan Indication	Pulmocide Inc.
T regulatory cells		6/30/2021	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"Coya Therapeutics, Inc."
envafolimab		6/28/2021	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"Tracon Pharmaceuticals, Inc."
Ulinastatin		6/28/2021	Treatment of Acute Radiation Syndrome	Designated	Not FDA Approved for Orphan Indication	RNR Biomedical inc
Bevantolol		6/24/2021	Treatment of Huntington's Disease	Designated	Not FDA Approved for Orphan Indication	SOM Innovation Biotech S.A.
"(1S,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E)-33-(((2S,3S,4S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1,3,4,7,9,11,17,37-octahydroxy-15,16,18,36-tetramethyl-14,39-dioxabicyclo[33. 3.1] nonatriaconta-19,21,23,25,27,29,31-heptaen-13-one"		6/24/2021	Treatment of invasive aspergillosis	Designated	Not FDA Approved for Orphan Indication	Biosergen AS
Fully human anti-human neonatal Fc receptor (hFcRn) IgG1 monoclonal antibody		6/24/2021	Treatment of Myasthenia Gravis	Designated	Not FDA Approved for Orphan Indication	"Immunovant Sciences, GmbH"
Adeno-associated viral vector encoding the human frataxin (FXN) gene		6/24/2021	Treatment of Friedreich’s Ataxia	Designated	Not FDA Approved for Orphan Indication	Lexeo Therapeutics
mRNA encoding the human glycogen debranching enzyme		6/24/2021	Treatment of glycogen storage disease type III	Designated	Not FDA Approved for Orphan Indication	Ultragenyx Pharmaceutical Inc.
Ubidecarenone		6/24/2021	Treatment of Malignant Glioma	Designated	Not FDA Approved for Orphan Indication	"BPGbio, Inc"
Norucholic acid		6/24/2021	Treatment of Primary Sclerosing Cholangitis	Designated	Not FDA Approved for Orphan Indication	Dr. Falk Pharma GmbH
devimistat		6/24/2021	Treatment of liver and intrahepatic bile duct cancer (also known as biliary tract cancer; cholangiocarcinomas of the bile duct and the gall bladder)	Designated	Not FDA Approved for Orphan Indication	"Cornerstone Pharmaceuticals, Inc."
asparaginase erwinia chrysanthemi (recombinant)-rywn	Rylaze	6/22/2021	Treatment of Acute lymphoblastic leukemia	Designated/Approved		Jazz Pharmaceuticals Ireland Limited
cinrebafusp		6/22/2021	Treatment of gastric cancer including cancer of the gastroesophageal junction	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Pieris Pharmaceuticals, Inc."
"2'-O-methylphosphorothioate RNAoligonucleotide, 5'- m5CUGm5CUGm5CUGm5CUGm5CUGm5CUGm5CUG-3'"""		6/22/2021	Treatment of spinocerebellar ataxia	Designated	Not FDA Approved for Orphan Indication	Vico Therapeutics B.V.
"Genetically engineered (alpha-1,3-galactosyltransferase knock-out}, live cell porcine (Sus scrofa) xenotransplantation skin graft"		6/14/2021	"Treatment of severe and extensive, deep partial and full-thickness burn wounds requiring hospitalization, surgical excision, and skin grafting."	Designated	Not FDA Approved for Orphan Indication	"XenoTherapeutics, Inc."
Naltrexone		6/14/2021	Treatment of Complex Regional Pain Syndrome	Designated	Not FDA Approved for Orphan Indication	Soin Theraputics
Sivelestat		6/9/2021	Treatment of ELANE gene related neutropenia	Designated	Not FDA Approved for Orphan Indication	RNR Biomedical inc
Etrasimod L-arginine		6/8/2021	Treatment of Eosinophilic Esophagitis (EoE)	Designated	Not FDA Approved for Orphan Indication	"Arena Pharmaceuticals, Inc."
Doxorubicin		6/8/2021	Treatment of Malignant Glioma	Designated	Not FDA Approved for Orphan Indication	Bionaut Labs
Allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD70 antigen		6/8/2021	Treatment of T-cell Lymphoma	Designated	Not FDA Approved for Orphan Indication	"CRISPR Therapeutics, Inc."
Adeno-associated virus serotype 5 encoding human retinal guanylate cyclase 1 gene (AAV5-GUCY2D)		6/7/2021	Treatment of retinal disease due to autosomal recessive mutations in the human retinal guanylate cyclase 1 (GUCY2D) gene	Designated	Not FDA Approved for Orphan Indication	Atsena Therapeutics Inc.
a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit)		6/7/2021	Conditioning treatment prior to hematopoietic stem cell transplantation	Designated	Not FDA Approved for Orphan Indication	"Jasper Therapeutics, Inc."
quinacrine		6/7/2021	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	Pulmosim Therapeutics
gunagratinib		6/7/2021	Treatment of Cholangiocarcinoma	Designated	Not FDA Approved for Orphan Indication	InnoCare Pharma Inc.
adagrasib	Krazati	6/7/2021	Treatment for KRAS G12C Positive non-small cell lung cancer	Designated/Approved		"Mirati Therapeutics, Inc."
cannabidiol oral solution (CBD-OS)		6/7/2021	Treatment of epilepsy with myoclonic-atonic seizures	Designated	Not FDA Approved for Orphan Indication	GW Research Ltd
Adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression cassette containing the human NGLY1 gene coding sequence		5/28/2021	Treatment of NGLY1 deficiency	Designated	Not FDA Approved for Orphan Indication	"Grace Science, LLC"
tesevatinib		5/26/2021	Treatment of autosomal dominant polycystic kidney disease	Designated	Not FDA Approved for Orphan Indication	Kadmon Corporation
Diazoxide choline		5/26/2021	Treatment of Glycogen Storage Disease Type 1	Designated	Not FDA Approved for Orphan Indication	"Soleno Therapeutics, Inc."
linperlisib		5/26/2021	Treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Shanghai Yingli Pharmaceutical Co., Ltd."
an antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE		5/26/2021	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	LaNova Medicines Limited
an antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE		5/26/2021	"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma."	Designated	Not FDA Approved for Orphan Indication	LaNova Medicines Limited
apraglutide		5/25/2021	Prevention of acute graft-versus-host disease	Designated	Not FDA Approved for Orphan Indication	VectivBio AG
UCART cells targeting CD7		5/25/2021	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	"Nanjing Bioheng Biotech Co., Ltd"
"(7S)-3-Amino-14-ethyl-11-fluoro-7-methyl-4-oxo-4,5,6,7,13,14-hexahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecine-12-carbonitrile"		5/25/2021	"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma"	Designated	Not FDA Approved for Orphan Indication	Bristol Myers Squibb
Bone Marrow Derived Mesenchymal Stem Cell Secretome		5/24/2021	Treatment of Persistent Corneal Epithelial Defects	Designated	Not FDA Approved for Orphan Indication	"Combangio, Inc."
2-(2-{2-(2-{4-Benzothiazol-2- y1-phenoxy}-ethoxy]-ethoxy}-ethoxy}-ethanol		5/24/2021	Treatment of Amyotrophic Lateral Sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	"Spinogenix, Inc"
"(2R,3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol hydrogen chloride"		5/20/2021	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	"Daewoong Pharmaceutical Co., Ltd."
RCH4 synthesized dimer peptide that links a lipid raft receptor to the extracellular matrix		5/19/2021	Treatment of Amyotrophic Lateral Sclerosis (ALS) also known as Motor Neurone Disease (MND)	Designated	Not FDA Approved for Orphan Indication	R. Curran (a.k.a. The RC Charity)
an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR		5/17/2021	Treatment of Follicular Lymphoma	Designated	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
Pegylated Glucagon Receptor Agonist		5/17/2021	Treatment of Congenital Hyperinsulinism	Designated	Not FDA Approved for Orphan Indication	Pegbio Co. Ltd.
a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human MYBPC3 gene		5/12/2021	Treatment of hypertrophic cardiomyopathy (HCM) due to loss-of-function mutations in the MYBPC3 gene encoding cardiac myosin-binding protein C	Designated	Not FDA Approved for Orphan Indication	Tenaya Therapeutics
Hyaluronic Acid-Paclitaxel Conjugate		5/12/2021	Treatment of Malignant Mesothelioma	Designated	Not FDA Approved for Orphan Indication	Fidia Farmaceutici S.p.A.
flunarizine		5/12/2021	Treatment of Childhood Absence Epilepsy	Designated	Not FDA Approved for Orphan Indication	Xenon Pharmaceuticals Inc.
Sulindac		5/10/2021	Treatment of Fragile X syndrome	Designated	Not FDA Approved for Orphan Indication	Healx Limited
"6-fluoro-9-methyl-9H-pyrido[3,4-b]-indole"		5/10/2021	Treatment of Sudden Sensorineural Hearing Loss	Designated	Not FDA Approved for Orphan Indication	AudioCure Pharma GmbH
Pre-Morula Stem Cells		5/10/2021	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	ReoStem L.L.C.
romosozumab		5/10/2021	Treatment of Osteogenesis Imperfecta	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
Gadolinium-chelated polysiloxane based nanoparticles		5/10/2021	Radiosensitizer to be used during radiation treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	NH TherAguix
glucagon-like peptide-1/glucagon/gastric inhibitory polypeptide triple agonist linked to human IgG4 Fc fragment		5/10/2021	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"Hanmi Pharmaceutical Co., Ltd."
recombinant bispecific human IgG4 antibody which functionally mimics the procoagulant properties of activated FVIII		5/10/2021	Treatment of Hemophilia A	Designated	Not FDA Approved for Orphan Indication	"Novo Nordisk, Inc."
ketamine		5/10/2021	Treatment of Complex Regional Pain Syndrome	Designated	Not FDA Approved for Orphan Indication	iX Biopharma Ltd.
Melatonin		5/10/2021	Treatment of Retinitis Pigmentosa	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
Anti-Claudin 18.2 Antibody Drug Conjugate with MMAE and LND1002 linker		5/5/2021	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	"Elevation Oncology, Inc."
talquetamab-tgvs	Talvey	5/3/2021	Treatment of Multiple Myeloma	Designated/Approved		"Janssen Biotech, inc."
copanlisib		5/3/2021	Treatment of patients with Lymphoplasmacytoid lymphoma (LPL)/ Waldenstrom macroglobulinemia (WM)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bayer HealthCare Pharmaceuticals Inc.
autologous CD34+ hematopoietic stem and progenitor cells modified ex-vivo with a lentiviral vector which restores endogenously regulated expression of FOXP3		4/27/2021	Treatment of Immune Dysregulation Polyendocrinopathy X-linked (IPEX) Syndrome	Designated	Not FDA Approved for Orphan Indication	ImmunoVec
olorofim		4/27/2021	Treatment of invasive scopulariopsis/microascus	Designated	Not FDA Approved for Orphan Indication	F2G Limited
"Small molecule, non-isoform selective NaV persistent current inhibitor"		4/27/2021	Treatment of SCN2A Developmental and Epileptic Encephalopathy	Designated	Not FDA Approved for Orphan Indication	"Praxis Precision Medicines, Inc."
camrelizumab		4/27/2021	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"Jiangsu Hengrui Medicine Co., Ltd"
dimethyltryptamine		4/27/2021	Prevention of ischemia-reperfusion injury in patients undergoing solid organ transplantation.	Designated	Not FDA Approved for Orphan Indication	Sairiyo Therapeutics Inc.
Sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]		4/27/2021	Treatment of Gastric Cancer	Designated	Not FDA Approved for Orphan Indication	"Bold Therapeutics, Inc."
an autologous cell therapy product manufactured from tumor-infiltrating lymphocytes (TILs) that have been harvested from surgically resected tumor tissue and expanded ex vivo.		4/26/2021	Treatment of malignant melanoma stages IIB to IV	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Instil Bio, Inc."
cobimetinib	Cotellic	4/26/2021	Treatment for histiocytic neoplasms	Designated/Approved		"Genentech, Inc."
copanlisib		4/16/2021	Treatment of patients with Small lymphocytic lymphoma (SLL)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bayer HealthCare Pharmaceuticals Inc.
"(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide"		4/16/2021	Treatment of myelodysplastic syndrome	Designated	Not FDA Approved for Orphan Indication	"Curis, Inc."
Small molecule inhibitor of kinase mediators of the Wnt pathway		4/16/2021	Treatment of Retinitis Pigmentosa	Designated	Not FDA Approved for Orphan Indication	"Endogena Therapeutics, Inc,"
Izaflortaucipir (proposed INN)		4/12/2021	Diagnosis of Corticobasal Degeneration	Designated	Not FDA Approved for Orphan Indication	Life Molecular Imaging Ltd.
A recombinant adeno-associated viral (AAV) vector encoding the human otoferlin (hOTOF) gene.		4/12/2021	Treatment of otoferlin gene (OTOF)-mediated hearing loss	Designated	Not FDA Approved for Orphan Indication	"Akouos, Inc."
a peptidomimetic protein peptide with sequence H-Gly-Arg-Arg-Ala-Ala-Pro-Gly-Arg-Aib-Gly-Gly-NH2		4/8/2021	Treatment of Lennox- Gastaut Syndrome	Designated	Not FDA Approved for Orphan Indication	CuroNZ Ltd
N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl-phenyl]-acetamide		4/8/2021	Treatment of epileptic encephalopathy with continuous spike-wave discharges during sleep (EECSWS)	Designated	Not FDA Approved for Orphan Indication	Neurocrine Biosciences Inc.
"Small molecule, non-isoform selective NaV persistent current inhibitor"		4/8/2021	Treatment of SCN8A Developmental and Epileptic Encephalopathy	Designated	Not FDA Approved for Orphan Indication	"Praxis Precision Medicines, Inc."
autologous CD34+ hematopoietic stem and progenitor cells modified ex-vivo with a lentiviral vector that restores expression of Gp91phox		4/7/2021	Treatment of Chronic Granulomatous Disease	Designated	Not FDA Approved for Orphan Indication	ImmunoVec
axatilimab		4/7/2021	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	"Syndax Pharmaceuticals, Inc."
eprenetapopt		4/7/2021	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	"Aprea Therapeutics, Inc."
fully human monoclonal IgG1 antibody against the type 2 isoform of human Claudin 18 protein (Claudin 18.2).		4/6/2021	"Treatment of gastric cancer, including cancer of gastroesophageal junction"	Designated	Not FDA Approved for Orphan Indication	"Leap Therapeutics, Inc."
taniraleucel		4/6/2021	Treatment of Malignant Glioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celularity Inc.
bempedoic acid		4/5/2021	Treatment of homozygous familial hypercholesterolemia	Designated	Not FDA Approved for Orphan Indication	"Esperion Therapeutics, Inc."
"(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide"		4/5/2021	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Curis, Inc."
Synthetic DNA aptamer-nucleoside drug conjugate targeting nucleolin-expression cancer cells		3/31/2021	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Samjin Pharmaceutical Co., Ltd."
"(5-(3-(2-amino-4-oxo-4,7-dihydro-3 H-pyrrolo[2,3- d]pyrimidin-6-yl)propyl)thiophene-2-carbonyl)- L-glutamic acid)"		3/30/2021	Treatment of Mesothelioma	Designated	Not FDA Approved for Orphan Indication	"FLAG Therapeutics, Inc."
alpha-CD39 IgG4 monoclonal antibody		3/29/2021	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Coherus BioSciences, Inc."
lithium carbonate		3/29/2021	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	Lispiro LLC
axatilimab		3/29/2021	Treatment of chronic graft versus host disease.	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
5-Aminolevulinic Acid		3/29/2021	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Hemerion Therapeutics
cereblon enzyme 3 (E3) ligase modulating agent		3/25/2021	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene Corporation (a Bristol-Myers Squibb Company)
spartalizumab		3/24/2021	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
canakinumab		3/24/2021	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
Cannabidiol		3/22/2021	Treatment of Angelman syndrome	Designated	Not FDA Approved for Orphan Indication	Biom Therapeutics
"Retinyl Palmitate, Alisitol (herbal extract), Zn Gluconate"		3/18/2021	Treatment of Microvillus Inclusion Disease.	Designated	Not FDA Approved for Orphan Indication	"Dmitry V. Kravtsov, M.D."
adenoviral vector expressing human papillomavirus (HPV) 6 and HPV 11 antigens		3/17/2021	Treatment of recurrent respiratory papillomatosis	Designated	Not FDA Approved for Orphan Indication	"Precigen, Inc."
(+)-5-chloro-1-ethyl-3-(2-hydroxy-3-methoxybenzyl)-2-oxoindolin-3-yl dimethylcarbamate		3/16/2021	Treatment of Retinitis Pigmentosa	Designated	Not FDA Approved for Orphan Indication	"MitoChem Therapeutics, Inc."
vedolizumab		3/15/2021	Treatment of Pouchitis	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
Dodecyl Creatine Ester		3/9/2021	Treatment of Creatine Transporter Deficiency	Designated	Not FDA Approved for Orphan Indication	CERES BRAIN Therapeutics
nemvaleukin alfa		3/9/2021	Treatment of Mucosal Melanoma	Designated	Not FDA Approved for Orphan Indication	"Mural Oncology, Inc."
monosialotetrahexosylganglioside		3/9/2021	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	Innomedica Schweiz AG
Ubenimex		3/8/2021	Treatment of Chronic Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical inc
GCSF-mobilized autologous CD34 cells for intramuscular injection		3/4/2021	Treatment of Buerger's disease (thromboangiitis obliterans)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Lisata Therapeutics
Sepiapterin		3/4/2021	Treatment of hyperphenylalaninemia (HPA)	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
CDK inhibitor (CDKI) of CDK2/4/6		3/3/2021	"Treatment of patients with malignant gliomas (including glioblastoma, astrocytoma, and oligodendroglioma)"	Designated	Not FDA Approved for Orphan Indication	"Nuvation Bio, Inc."
"Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express Human alpha-galactosidase A (h alpha-Gal A), encapsulated within two-layer modified alginate spheres"		3/2/2021	Treatment of Alpha-galactosidase A deficiency (Fabry’s Disease)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sigilon Therapeutics, Inc."
Tesofensine plus metoprolol in a fixed-dose combination		3/2/2021	Treatment of Prader-Willi Syndrome	Designated	Not FDA Approved for Orphan Indication	Saniona S/A
padeliporfin		3/2/2021	Treatment of upper tract urothelial cancer	Designated	Not FDA Approved for Orphan Indication	Steba Biotech S.A
Fomepizole		3/2/2021	Treatment of acetaminophen overdose	Designated	Not FDA Approved for Orphan Indication	Denver Health - Rocky Mountain Poison & Drug Safety
"6-(4-((5-oxo-1,2,3,4,5,6-hexahydrobenzo[h][1,6]naphthyridin-8-yl)methyl)piperazin-1-yl)nicotinonitrile mono citrate"		3/2/2021	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	Onconic Therapeutics
Allogeneic enriched variable delta 1 gamma delta T-cell therapy		3/1/2021	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	GammaDelta Therapeutics Limited
cavrotolimod		3/1/2021	Treatment of merkel cell carcinoma	Designated	Not FDA Approved for Orphan Indication	"Exicure, Inc."
humanized IgG1anti-AXL-antibody conjugated to monomethyl auristatin E		3/1/2021	Treatment of Soft Tissue Sarcoma	Designated	Not FDA Approved for Orphan Indication	"BioAtla, Inc."
Gadolinium-chelated polysiloxane based nanoparticles		2/25/2021	Radiosensitizer to be used during radiation treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Nh TherAguix
satralizumab-mwge		2/23/2021	Treatment of myasthenia gravis	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
Penpulimab		2/23/2021	Treatment of nasopharyngeal carcinoma	Designated	Not FDA Approved for Orphan Indication	"Akeso Biopharma, Inc."
antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 humanized antibody conjugated covalently to the dibenzocyclooctyne (DBCO) noncleavable linker maytansinoid warhead		2/23/2021	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
"Sodium-3-((2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoate"		2/23/2021	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	"Blade Therapeutics, Inc."
Fc-fusion protein comprised of an anti-CXCR4 i-body tethered at its C-terminus to constant domains 2 and 3 of the Fc region of a mutated human IgG1		2/22/2021	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	AdAlta Limited
Stiripentol		2/22/2021	Treatment of Primary Hyperoxaluria	Designated	Not FDA Approved for Orphan Indication	Biocodex
"1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl] ethanone"		2/19/2021	Treatment of uveal melanoma	Designated	Not FDA Approved for Orphan Indication	"Linnaeus Therapeutics, Inc."
Trodusquemine HCl		2/19/2021	Treatment of Dystrophinopathies	Designated	Not FDA Approved for Orphan Indication	Revidia Therapeutics. Inc.
Carmustine		2/18/2021	Treatment prior to hematopoietic stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma	Designated	Not FDA Approved for Orphan Indication	Vivus LLC
"3-Acetyl-1-cyclopentyl-7-{[(3S,4R)-3-hydroxyoxan-4-yl]amino }-4-methyl-1,6-naphthyridin-2(1H)-one"		2/18/2021	Treatment of pulmonary arterial hypertension	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
Chemically induced photoreceptor-like cells		2/18/2021	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	"CiRC Biosciences, Inc."
recombinant bispecific humanized anti-programmed cell death 1 (PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody		2/18/2021	Treatment of Stage IA2-IV cervical cancer	Designated	Not FDA Approved for Orphan Indication	"Akeso Biopharma, Inc."
adeno-associated virus serotype 9 gene transfer vector expressing human AP4B1 cDNA		2/16/2021	Treatment of hereditary spastic paraplegia 47	Designated	Not FDA Approved for Orphan Indication	BlackfinBio Limited
allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD19 antigen		2/16/2021	Treatment of acute lymphoblastic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"CRISPR Therapeutics, Inc."
nipocalimab		2/11/2021	Treatment of myasthenia gravis	Designated	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
adeno-associated virus serotype rhesus 10 vector expressing the human galactocerebrosidase (GALC) gene		2/10/2021	Treatment of Krabbe disease	Designated	Not FDA Approved for Orphan Indication	"Forge Biologics, Inc."
iadademstat		2/10/2021	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	Oryzon Genomics S.A.
A chimeric antigen receptor (CAR) immunotherapy directed against the target protein CD7		2/8/2021	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	"iCell Gene Therapeutics, LLC"
Recombinant fusion protein of human alpha-L-iduronidase (IDUA) and Fab fragment of a humanized monoclonal antibody targeting human transferrin receptor (hTfR).		2/8/2021	Treatment of Mucopolysaccharidosis Type I (MPS I)	Designated	Not FDA Approved for Orphan Indication	"JCR Pharmaceuticals Co., Ltd."
"hexasodium salt of myo-inositol hexaphosphate (IP6, phytate) hexasodium phytate"		2/8/2021	Treatment of peripheral arterial disease in patients with end-stage kidney disease	Designated	Not FDA Approved for Orphan Indication	"Vifor Pharma, Inc."
Mesenchymal Stem Cell-derived Extracellular Vesicles		2/8/2021	Prevention of Bronchopulmonary Dysplasia in neonates	Designated	Not FDA Approved for Orphan Indication	"Stella Kourembanas, M.D."
"(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide"		2/8/2021	Treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Alexion Pharmaceuticals Inc.
Recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1		2/4/2021	Treatment of adenosine triphosphate binding cassette subfamily C member 6 deficiency (ABCC6 deficiency)	Designated	Not FDA Approved for Orphan Indication	"Inozyme Pharma, Inc."
cevostamab		2/3/2021	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
Trans-Cinnamic Acid		2/3/2021	Treatment of Krabbe disease	Designated	Not FDA Approved for Orphan Indication	"Polaryx Therapeutics, Inc."
Chimeric Antigen Receptor immunotherapy directed against CLL-1 and CD33		2/2/2021	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	"iCell Gene Therapeutics, LLC"
Miglustat		2/2/2021	Treatment of Niemann-Pick Disease Type C	Designated	Not FDA Approved for Orphan Indication	Edenbridge Pharmaceuticals LLC
denosumab		2/2/2021	Treatment of Osteogenesis Imperfecta	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
Rivoceranib		2/2/2021	Treatment of Adenoid Cystic Carcinoma	Designated	Not FDA Approved for Orphan Indication	"Elevar Therapeutics, Inc."
N-(N-(4-(trifluoromethoxy)phenyl) carbamimidoyl)pyrrolidine-1-carboximidamide acetate (Or N1-(4-trifluoromethoxy)phenyl-N5-pyrrolidine biguanide acetate)		2/1/2021	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	ImmunoMet Therapeutics Inc.
"(2R,3R,4S)-2-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol"		2/1/2021	Treatment of Primary Biliary Cholangitis	Designated	Not FDA Approved for Orphan Indication	"Future Medicine Co., Ltd."
Sivelestat		1/27/2021	Treatment of Acute Radiation Syndrome	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical
saroglitazar magnesium		1/26/2021	Treatment of Primary Biliary Cholangitis	Designated	Not FDA Approved for Orphan Indication	Zydus Discovery DMCC
dexamethasone		1/26/2021	Prevention of Proliferative Vitreoretinopathy (PVR)	Designated	Not FDA Approved for Orphan Indication	"TherOptix, Inc."
Talabostat		1/26/2021	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	BioXcel Therapeutics
romiplostim		1/25/2021	Treatment of chemotherapy-induced thrombocytopenia	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
ilixadencel		1/25/2021	Treatment of soft tissue sarcoma (STS)	Designated	Not FDA Approved for Orphan Indication	Mendus AB
ferroportin inhibitor		1/25/2021	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"Vifor Pharma, Inc."
suramin		1/25/2021	Treatment of human African trypanosomiasis	Designated	Not FDA Approved for Orphan Indication	"PaxMedica, Inc."
carfilzomib		1/21/2021	Treatment of Acute Lymphoblastic Leukemia	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
AAV9 gene vector construct expressing the human Frataxin gene (scAAV9.CB.hFRXN isoform 1)		1/21/2021	Treatment of Friedreich`s Ataxia (FA).	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Novartis Institute for BioMedical Research, Inc."
"ATI-450, an orally available small molecule inhibitor of the p38alpha mitogen activated protein kinase (MAPK)/MAPK-activated protein kinase 2 (MK2) inflammatory signaling pathway"		1/21/2021	Treatment of cryopyrin-associated periodic syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Aclaris Theapeutics Inc.
miglustat		1/19/2021	Treatment of CLN Batten Disease	Designated	Not FDA Approved for Orphan Indication	Beyond Batten Disease Foundation
L-pyroglutamyl-L-asparaginyl-L-prolyl-D-tyrosyl-D-tryptophan amide		1/19/2021	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Neuropath Therapeutics Limited
human T-lymphoid progenitors derived from CD34+ hematopoietic stem and progenitor cells		1/19/2021	Treatment to enhance cell engraftment in patients receiving hematopoietic stem cell transplant	Designated	Not FDA Approved for Orphan Indication	Smart Immune
uttroside B		1/19/2021	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Q BioMed
"4-{4-{[6-(4-Chlorophenyl)spiro[3.5]non-6-en-7-yl]methyl}-piperazin-1-yl}-N-{{3-nitro-4-[((2S)-1,4-dioxan-2-ylmethyl)amino]phenyl}sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide"		1/19/2021	Treatment of follicular lymphoma	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
"N-((2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-(4-nitrophenoxy)tetrahydro-2H-pyran-3-yl)acetamide"		1/18/2021	Prevention of bronchopulmonary dysplasia.	Designated	Not FDA Approved for Orphan Indication	"AyuVis Research, Inc."
Cepharanthine		1/14/2021	Treatment of Esophageal Cancer	Designated	Not FDA Approved for Orphan Indication	Sairiyo Therapeutics Inc.
humanized HER2 targeting monoclonal antibody conjugated to a cytotoxic tubulin inhibitor amberstatin		1/14/2021	Treatment of gastric cancer including cancer at the gastroesophageal junction	Designated	Not FDA Approved for Orphan Indication	"Ambrx, Inc."
Telacebec		1/13/2021	Treatment of Buruli ulcer	Designated	Not FDA Approved for Orphan Indication	"The Global Alliance for TB Drug Development, Inc."
alitretinoin		1/12/2021	Treatment of systemic (non-cutaneous) kaposi sarcoma	Designated	Not FDA Approved for Orphan Indication	"Galephar Pharmaceutical Research, Inc."
chimeric IgG4 monoclonal antibody targeting CD14		1/11/2021	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Implicit Bioscience Ltd.
Sitaxentan (also known as sitaxsentan)		1/11/2021	Treatment of Systemic Sclerosis	Designated	Not FDA Approved for Orphan Indication	"Timber Pharmaceuticals, Inc."
sparsentan	Filspari	1/11/2021	Treatment of immunoglobulin A (IgA) nephropathy	Designated/Approved		"Travere Therapeutics, Inc."
Ivaltinostat		1/8/2021	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"CG Pharmaceuticals, Inc."
"Trispecific T cell activating construct targeting BCMA, HSA, and CD3"		1/8/2021	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	"Merck & Co., Inc."
"genetically recombinant, non-pathogenic polio:rhinovirus chimera with a tumor--specific conditional replication phenotype"		1/8/2021	Treatment of stage IIB-IV melanoma	Designated	Not FDA Approved for Orphan Indication	"Istari Oncology, Inc."
pyrindinyl benzaldehyde		1/7/2021	Treatment of sickle cell disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Illexcor Therapeutics, LLC"
Atezolizumab		1/7/2021	Treatment of esophageal cancer	Designated	Not FDA Approved for Orphan Indication	Genentech Inc.
tafasitamab-cxix		1/7/2021	Treatment of patients with Follicular Lymphoma	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
"(R)-2-((1-(2-(4-methoxy-3-(2-morpholinoethoxy) phenyl)-5-methylthiazol-4-yl)ethyl)thio)pyrimidine-4,6-diamine"		1/7/2021	Treatment of acute disseminated encephalomyelitis	Designated	Not FDA Approved for Orphan Indication	Trethera Corporation
Non-replicating recombinant adeno-associated virus serotype 1 vector delivering human GRN gene encoding the protein progranulin		1/7/2021	Treatment of frontotemporal dementia	Designated	Not FDA Approved for Orphan Indication	"Passage Bio, Inc."
Fasudil hydrochloride		1/7/2021	Treatment of Corticobasal Syndrome	Designated	Not FDA Approved for Orphan Indication	"Woolsey Pharmaceuticals, Inc."
zinflavonoids		1/7/2021	Treatment of anatomical sites of squamous cell carcinoma of oral cavity and oropharynx accessible for local and topical administration	Designated	Not FDA Approved for Orphan Indication	"Aveta Biomics, Inc."
Tiragolumab		1/7/2021	Treatment of Esophageal Cancer	Designated	Not FDA Approved for Orphan Indication	Genentech Inc.
izaflortaucipir (proposed INN)		1/5/2021	1) In the initial diagnosis of progressive supranuclear palsy (PSP) and 2) Diagnostic in the clinical management of PSP.	Designated	Not FDA Approved for Orphan Indication	Life Molecular Imaging Ltd.
SCN2A mRNA knockdown antisense oligonucleotide		1/5/2021	Treatment of SCN2A Developmental and Epileptic Encephalopathy	Designated	Not FDA Approved for Orphan Indication	"Praxis Precision Medicines, Inc."
Cu-64 anti CD99		1/5/2021	Diagnostic for the clinical management of Ewing Sarcoma	Designated	Not FDA Approved for Orphan Indication	"Advanced Imaging Projects, LLC"
aficamten		1/5/2021	Treatment of symptomatic hypertrophic cardiomyopathy (HCM)	Designated	Not FDA Approved for Orphan Indication	Cytokinetics Inc.
Adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human SLC13A5 protein.		1/4/2021	Treatment of SLC13A5 Deficiency	Designated	Not FDA Approved for Orphan Indication	Taysha Gene Therapies
baclofen		12/31/2020	Prevention of baclofen withdrawal syndrome	Designated	Not FDA Approved for Orphan Indication	Saol Therapeutics Research Limited
Adeno Associate Virus carried Multi Characteristic Opsin		12/30/2020	Treatment of Stargardt Disease	Designated	Not FDA Approved for Orphan Indication	Nanoscope Therapeutics Inc.
Ilixadencel		12/30/2020	Treatment of hepatocellular carcinoma (HCC).	Designated	Not FDA Approved for Orphan Indication	Mendus AB
N-Benzothiazol-2-yl-4-(2-hydroxy-3-methoxy-benzylamino)-bezenesulfonamide		12/30/2020	Prophylaxis of thrombosis in patients with heparin-induced thrombocytopenia	Designated	Not FDA Approved for Orphan Indication	Veralox Therapeutics
Orelabrutinib		12/30/2020	Treatment of Mantle Cell Lymphoma	Designated	Not FDA Approved for Orphan Indication	InnoCare Pharma Inc.
Glucagon like peptide-1 Elastin like peptide-120 fusion protein		12/30/2020	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	"ImmunoForge Co., Ltd."
nilotinib oral formulation		12/28/2020	Treatment of chronic myeloid leukemia (CML).	Designated	Not FDA Approved for Orphan Indication	Xspray Pharma AB
"4-{4-{[6-(4-Chlorophenyl)spiro[3.5]non-6-en-7-yl]methyl}-piperazin-1-yl}-N-{{3-nitro-4-[((2S)-1,4-dioxan-2-ylmethyl)amino]phenyl}sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide"		12/28/2020	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
liposomal annamycin		12/28/2020	Treatment of soft tissue sarcomas	Designated	Not FDA Approved for Orphan Indication	"Moleculin Biotech, Inc."
Nilotinib ONCORE		12/23/2020	Treatment of Chronic Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	"Handa Oncology, LLC"
Fasudil		12/21/2020	Treatment of progressive supranuclear palsy	Designated	Not FDA Approved for Orphan Indication	"Woolsey Pharmaceuticals, Inc."
FC-fusion bispecific antibody targeting extracellular domains II and IV of HER 2 and FC-fusion bispecific IgG1 antibody inhibiting PD-L1 and CTLA-4		12/21/2020	"Treatment of Gastric Cancer, including Cancer of the Gastroesophageal Junction"	Designated	Not FDA Approved for Orphan Indication	"Jiangsu Alphamab Biopharmaceuticals Co., Ltd."
Imatinib		12/21/2020	Treatment of Pulmonary Arterial Hypertension	Designated	Not FDA Approved for Orphan Indication	"Aerovate Therapeutics, Inc"
Highly branched poly(beta-amino ester) complexed with a nanoplasmid containing the human COL7A1 gene		12/21/2020	Treatment of dystrophic epidermolysis bullosa	Designated	Not FDA Approved for Orphan Indication	Amryt Genetics Limited
Adeno-associated virus serotype 5 containing the human RDH12 gene		12/18/2020	Treatment of RDH12 mutation associated retinal dystrophy	Designated	Not FDA Approved for Orphan Indication	MeiraGTx UK II Limited
Rintatolimod		12/17/2020	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	AIM ImmunoTech Inc.
"Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express human native alpha-L-iduronidase enzyme (hIDUA), encapsulated within two-layer modified alginate spheres"		12/14/2020	Mucopolysaccharidosis I (MPS I; alpha-L-iduronidase deficiency)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sigilon Therapeutics, Inc."
H-Ala-Val-Ala-Glu-Ile-Gln-Leu-Met-His-Gln-Arg-Ala-Lys-Trp-Ile-Gln-Asp-Ala-Arg-Arg-Arg-Ala-Phe-Leu-His-Lys-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-Glu-Ile-OH		12/14/2020	Treatment of Hypoparathyroidism	Designated	Not FDA Approved for Orphan Indication	Amolyt Pharma SAS (formerly Alize Pharma III SAS)
Jaktinib		12/14/2020	Treatment of myelofibrosis	Designated	Not FDA Approved for Orphan Indication	"Suzhou Zelgen Biopharmaceuticals Co., Ltd."
"2,2-dimethylbutanoic acid"		12/10/2020	Treatment of propionic acidemia	Designated	Not FDA Approved for Orphan Indication	"HemoShear Therapeutics, LLC"
"2,2-dimethylbutanoic acid"		12/10/2020	Treatment of methylmalonic acidemia	Designated	Not FDA Approved for Orphan Indication	"HemoShear Therapeutics, LLC"
durvalumab	Imfinzi	12/10/2020	Treatment of biliary tract cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
Teduglutide		12/8/2020	Prevention of acute graft versus host disease	Designated	Not FDA Approved for Orphan Indication	9 Meters Biopharma Inc.
Treprostinil		12/7/2020	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	United Therapeutics Corporation
Adeno-associated viral vector serotype 9 encoding human ATP7B		12/7/2020	Treatment of Wilson's Disease	Designated	Not FDA Approved for Orphan Indication	Ultragenyx Pharmaceutical Inc.
"ARQ 531, a reversible non-covalent ATP competitive inhibitor of BTK"		12/7/2020	Treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)	Designated	Not FDA Approved for Orphan Indication	"ArQule, Inc., a wholly owned subsidiary of Merck Sharp & Dohme, LLC"
Human autologous CD4+ and CD8+ T cells engineered ex vivo to express a T cell receptor that recognizes amino acids 11-19 of the human papillomavirus (HPV)16 E7 protein when bound to human leukocyte antigen-A*02:01		12/1/2020	Treatment of patients with human papillomavirus (HPV)+ cervical cancer who are human leukocyte antigen (HLA)-A*02+	Designated	Not FDA Approved for Orphan Indication	"Kite Pharma, Inc."
"5-{[(5-amino-3,3-dihydroxyoxolan-2-yl)oxy][5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl}-N-(4-butylphenyl)-4,7-dimethyl-6-oxocyclohept-1-ene-1-carboxamide"		12/1/2020	Treatment of Tuberculosis	Designated	Not FDA Approved for Orphan Indication	PAI Life Sciences Inc.
Anti-Claudin 18.2 Antibody consisting of a fully human monoclonal IgG1 antibody to the type 2 isoform of human Claudin 18 protein		12/1/2020	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	"Leap Therapeutics, Inc."
Ravulizumab		11/25/2020	Treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy	Designated	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc."
Homodimeric fragment crystallizable fusion protein comprised of the extracellular domain of the human transforming growth factor beta receptor type II linked to a human IgG1 Fc domain		11/25/2020	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	"Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc."
Trans-Cinnamic Acid		11/24/2020	Treatment of GM2 gangliosidosis	Designated	Not FDA Approved for Orphan Indication	"Polaryx Therapeutics, Inc."
Encaleret sulfate		11/24/2020	Treatment for Autosomal Dominant Hypocalcemia Type 1 (ADH1)	Designated	Not FDA Approved for Orphan Indication	"Calcilytix Therapeutics, Inc."
teclistamab-cqyv	Tecvayli	11/24/2020	Treatment of multiple myeloma	Designated/Approved		"Janssen Biotech, Inc."
Humanized Recombinant Anti-Tumor Necrosis Factor ? Monoclonal Antibody		11/24/2020	Treatment of sarcoidosis	Designated	Not FDA Approved for Orphan Indication	"Xentria, Inc."
Murine double minute-2 (MDM2) or Human double minute-2 (HDM2)		11/24/2020	Treatment of Retinoblastoma	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
UBE3A antisense oligonucleotide with locked nucleic acids (UBE3A-ATS-LNA)		11/24/2020	Treatment of Angelman Syndrome	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
Trans-Cinnamic Acid		11/24/2020	treatment for Niemann-Pick disease Type A and Type B	Designated	Not FDA Approved for Orphan Indication	"Polaryx Therapeutics, Inc."
"Single-stranded, non-replicating recombinant adeno-associated viral vector serotype 9 containing the human immunoglobulin u-binding protein 2 cDNA"		11/24/2020	Treatment for Spinal Muscular Atrophy with Respiratory Distress Type 1 (SMARD1)	Designated	Not FDA Approved for Orphan Indication	"Abigail Wexner Research Institute, Nationwide Children’s Hospital"
AAV9 gene therapy encoding the Dok7 protein		11/19/2020	Treatment of congenital myasthenic syndrome	Designated	Not FDA Approved for Orphan Indication	Amplo Biotechnology Inc.
"Anti-Claudin 18.2 antibody drug conjugate comprised of a Claudin 18.2 targeting monoclonal IgG1 antibody, a linker LND1002, and monomethyl auristatin E"		11/19/2020	Treatment for gastric cancer including cancer of gastroesophageal junction	Designated	Not FDA Approved for Orphan Indication	"Elevation Oncology, Inc."
trehalose		11/18/2020	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"Seelos Therapeutics, Inc."
IL13 E13K mutation linked to portion of pseudomonas exotoxin		11/18/2020	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Targepeutics
Antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a CL2A linker		11/18/2020	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
Indolino-benzodiazepine compound (sulfonated DGN549-C) conjugated to the humanized anti-CD123 monoclonal antibody (G4723A)		11/17/2020	Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm	Designated	Not FDA Approved for Orphan Indication	"ImmunoGen, Inc."
itraconazole		11/17/2020	Treatment of coccidioidomycosis	Designated	Not FDA Approved for Orphan Indication	Mayne Pharma International Pty Ltd. c/o Mayne Pharma Inc.
"(R)-6-(2-hydroxy-3-(4-(4-(trifluoromethyl)phenyl)piperazin- 1-yl)propoxy)-3,4-dihydroquinolin-2(1H)-one"		11/17/2020	treatment of subarachnoid hemorrhage	Designated	Not FDA Approved for Orphan Indication	NeurOp Inc.
peptide conjugated phosphorodiamidate morpholino oligomer		11/12/2020	treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	"Sarepta Therapeutics, Inc."
rituximab		11/12/2020	Treatment of autoimmune hemolytic anemia	Designated	Not FDA Approved for Orphan Indication	Taxon Therapeutics Ltd.
afatanib and palbociclib		11/12/2020	Treatment of chordoma	Designated	Not FDA Approved for Orphan Indication	"Collaborations Pharmaceuticals, Inc"
mitapivat		11/12/2020	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"Agios Pharmaceuticals, Inc."
5-aminolevulinic acid		11/12/2020	Diagnostic for the visualization of tumor tissue in patients undergoing surgical resection for meningioma	Designated	Not FDA Approved for Orphan Indication	NX Development Corp.
Mizoribine		11/9/2020	Treatment of membranous nephropathy	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
"peritoneal dialysis solution containing combination of D-xylitol, D-glucose, L-carnitine"		11/9/2020	Treatment of patients with end stage renal disease who are undergoing peritoneal dialysis	Designated	Not FDA Approved for Orphan Indication	CoreQuest Sagl
"2-(4-(4-((1-(107- (4-(fluorophenyl)methoxy)-polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5- diiodophenoxy)-3,5-diiodophenyl)acetic acid"		11/5/2020	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	NanoPharmaceuticals LLC
"Immunotherapeutic vaccine consisting of pAc/emm55, a plasmid DNA (pDNA), which codes for a modified immunogenic, streptococcal Emm55 protein, complexed with in vivo-jetPEI® polymer-based reagent linear polyethylenimine)"		11/5/2020	Treatment of stage IIB to stage IV melanoma	Designated	Not FDA Approved for Orphan Indication	"Morphogenesis, Inc."
"Recombinant humanized monoclonal antibody (immunoglobulin gamma-1 with kappa light chains, IgG1kappa) directed against human soluble cytokine interferon beta."		11/5/2020	Ttreatment of DM (including improvements in cutaneous and muscle manifestations of the disease) in adult and adolescent (aged >/=12 to	Designated	Not FDA Approved for Orphan Indication	Pfizer Inc.
epidermal stem cells genetically modified with a gamma-retroviral (rv) vector expressing the full-length LAMB3 cDNA		11/5/2020	Treatment of Epidermolysis Bullosa	Designated	Not FDA Approved for Orphan Indication	Holostem S.r.l.
Venetoclax		11/5/2020	Treatment for small cell lung cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
"D,L-3-hydroxybutyrate"		11/3/2020	Treatment of multiple acyl-CoA dehydrogenase deficiency	Designated	Not FDA Approved for Orphan Indication	"Orpha Labs, AG"
L-Citrulline		11/3/2020	Treatment of Ornithine Transcarbamylase deficiency	Designated	Not FDA Approved for Orphan Indication	"Orpha Labs, AG"
allosteric MEK 1/2 inhibitor		11/3/2020	Treatment of neurofibromatosis type 1	Designated	Not FDA Approved for Orphan Indication	Pasithea Therapeutics Corp.
"EXE-346, a Live Biotherapeutic Product (LBP), contains eight strains of probiotic bacteria."		11/2/2020	Treatment of pouchitis	Designated	Not FDA Approved for Orphan Indication	"ExeGi Pharma, LLC."
butyl ((2-(5-((1H-imidazol-1-yl)methyl)pyridin-2-yl)-4-(trifluoromethoxy)phenyl)sulfonyl) carbamate		11/2/2020	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Capacity Bio Inc.
Pirarubicin		10/29/2020	Treatment of osteosarcoma	Designated	Not FDA Approved for Orphan Indication	"Hillstream BioPharma, Inc."
"4-((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamido)bicyclo [2.2.2]octane-1-carboxylic acid"		10/28/2020	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
Rifaximin		10/28/2020	treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)"
tricaprilin		10/27/2020	Treatment of infantile spasms also known as West's syndrome	Designated	Not FDA Approved for Orphan Indication	"Cerecin, Inc."
Devimistat		10/26/2020	Treatment of relapsed or refractory clear cell sarcoma of the soft tissues.	Designated	Not FDA Approved for Orphan Indication	"Cornerstone Pharmaceuticals, Inc."
A recombinant adeno-associated virus (rAAV) vector-based gene therapy expressing the methylmalonyl-CoA mutase (MMUT) transgene		10/26/2020	Treatment of patients with isolated methylmalonic acidemia (IMMA) due to methylmalonyl-Coenzyme A mutase (mut) deficiency	Designated	Not FDA Approved for Orphan Indication	"Cartesian Therapeutics, Inc."
Venetoclax		10/26/2020	Treatment of Acute Lymphoblastic Leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AbbVie Inc.
tepotinib	Tepmetko	10/26/2020	Treatment of non-small cell lung cancer with MET genomic tumor aberrations	Designated/Approved		"EMD Serono, Inc."
Dasatinib		10/26/2020	Treatment of Noonan syndrome-associated hypertrophic cardiomyopathy	Designated	Not FDA Approved for Orphan Indication	"IGIA Pharmaceuticals, Inc."
autologous patients¿ CD4+ T cells that have been subjected to lentivirus mediated gene transfer of healthy FOXP3		10/26/2020	Treatment of Immune dysregulation Polyendocrinopathy Enteropathy X-linked (IPEX) Syndrome	Designated	Not FDA Approved for Orphan Indication	Stanford University
retifanlimab-dlwr	Zynyz	10/26/2020	Treatment of Merkel cell carcinoma	Designated/Approved		Incyte Corporation
cystic fibrosis transmembrane conductance regulator protein corrector (VX-121)/tezacaftor/deutivacaftor		10/26/2020	Treatment of cystic fibrosis (CF)	Designated	Not FDA Approved for Orphan Indication	Vertex Pharmaceuticals Incorporated
"a non-replicating recombinant adeno-associated virus serotype hu68 vector, containing a transgene encoding the human galactosylceramidase (GALC) enzyme"		10/22/2020	Treatment of Krabbe disease (globoid cell leukodystrophy)	Designated	Not FDA Approved for Orphan Indication	"Passage Bio, Inc."
Methoxyamine hydrochloride		10/22/2020	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"TRACON Pharmaceuticals, Inc."
"3alpha,6beta,7beta,12alpha-tetrahydroxy-5beta-cholan-24-oic acid"		10/22/2020	Treatment of Progressive Familial Intrahepatic Cholestasis	Designated	Not FDA Approved for Orphan Indication	"Qing Bile Therapeutics, Inc."
"PEGylated, Engineered, Human Cystathionine gamma-Lyase"		10/22/2020	Treatment of Homocystinuria	Designated	Not FDA Approved for Orphan Indication	"Spyre Therapeutics, Inc."
Recombinant adeno-associated virus vector containing the active biological substance AAV-GTX-hUBE3A		10/22/2020	Treatment of Angelman Syndrome	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
a single-stranded adeno-associated virus serotype 8 gene therapy containing codon optimized human alpha-1-iduronidase cDNA.		10/22/2020	Treatment of mucopolysaccharidosis type I (MPS I)	Designated	Not FDA Approved for Orphan Indication	"Rain Bio, Inc."
"(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide maleate"		10/22/2020	treatment of dermatomyositis	Designated	Not FDA Approved for Orphan Indication	"Kezar Life Sciences, Inc."
Trehalose		10/21/2020	Treatment of CLN Batten disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Beyond Batten Disease Foundation
"a highly purified unmodified carbohydrate polymer which consists of (1,3) and (1,4)-beta-glycosidic linkages"		10/21/2020	Treatment of Osteosarcoma	Designated	Not FDA Approved for Orphan Indication	University Hospitals Cleveland Medical Center
"(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide maleate"		10/21/2020	treatment of polymyositis	Designated	Not FDA Approved for Orphan Indication	"Kezar Life Sciences, Inc."
Anti-LILRB4 humanized IgG1 monoclonal antibody		10/21/2020	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Immune-Onc Therapeutics, Inc."
CD34+ cells that have been transduced in vitro with a lentiviral vector carrying a codon-optimized sequence for expressing the wild type RPS19 protein		10/21/2020	Treatment Diamond-Blackfan Anemia	Designated	Not FDA Approved for Orphan Indication	Apriligen LLC
2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49d RNA		10/21/2020	treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	Antisense Therapeutics Limited
AAV9 capsid encapsulating a bicistronic vector encoding for a unique combination of a recombinant human ?-glucocerebrosidase enzyme with the S1S3 variant of the N-acetylglucosamine-Phosphotransferase (S1S3 PTase)		10/21/2020	treatment of Gaucher disease	Designated	Not FDA Approved for Orphan Indication	M6P Therapeutics
maralixibat		10/21/2020	Treatment of Biliary Atresia	Designated	Not FDA Approved for Orphan Indication	"Mirum Pharmaceuticals, Inc."
adeno-associated viral vector type 9 with S1S3 gene encoding S1S3 variant of N-acetylglucosamine-1-phosphotransferase		10/20/2020	treatment of mucolipidosis	Designated	Not FDA Approved for Orphan Indication	M6P Therapeutics
"TGTX-102, an adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human SURF1 protein."		10/20/2020	Treatment of SURF1-associated Leigh Syndrome.	Designated	Not FDA Approved for Orphan Indication	"Taysha Gene Therapies, Inc."
CHO cell line produced human alpha-1 antitrypsin (CHO-AAT) protein		10/19/2020	treatment of alpha-1 antitrypsin deficiency	Designated	Not FDA Approved for Orphan Indication	Caravella Biopharma SA
Branaplam		10/19/2020	treatment of Huntington’s disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
Dabrafenib		10/19/2020	treatment of Kabuki Syndrome	Designated	Not FDA Approved for Orphan Indication	Rescindo Therapeutics Inc.
Setanaxib		10/16/2020	Treatment of primary biliary cholangitis	Designated	Not FDA Approved for Orphan Indication	Calliditas Therapeutics Suisse SA
adeno-associated virus 2/9 expressing human BBS1 gene		10/16/2020	treatment of Bardet-Biedl Syndrome	Designated	Not FDA Approved for Orphan Indication	Axovia Therapeutics
adeno-associated virus 2/8 expressing human BBS1 gene		10/16/2020	treatment of Bardet-Biedl Syndrome	Designated	Not FDA Approved for Orphan Indication	Axovia Therapeutics
immunoglobulin G (IgG) polyclonal antibody that binds to human T cells		10/15/2020	Prevention of graft rejection following solid organ transplantation	Designated	Not FDA Approved for Orphan Indication	Xenothera
humanized secreted frizzled-related protein-2 monoclonal antibody		10/15/2020	treatment of osteosarcoma	Designated	Not FDA Approved for Orphan Indication	Innova Therapeutics
"synthetic 2?-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a tri-antennary cluster of N-acetyl galactosamine (GalNAc3) sugars targeting transmembrane protease, serine 6 messenger ribonucleic acid"		10/15/2020	Treatment of beta-thalassemia	Designated	Not FDA Approved for Orphan Indication	"Ionis Pharmaceuticals, Inc."
Bacteriophage		10/14/2020	Treatment for prosthetic Joint Infection	Designated	Not FDA Approved for Orphan Indication	"Adaptive Phage Therapeutics, Inc."
"(R)-2-allyl-1-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one"		10/14/2020	Treatment of osteosarcoma	Designated	Not FDA Approved for Orphan Indication	"K-Group Beta, Inc."
"APG-2575, a novel, orally active, selective and potent BCL-2 inhibitor"		10/14/2020	Treatment for multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
"an antibiotic combination product consisting of 3 antimicrobial agents (clarithromycin, rifabutin, and clofazimine)."		10/13/2020	Treatment for Nontuberculous Mycobacteria Disease	Designated	Not FDA Approved for Orphan Indication	RedHill Biopharma Ltd.
atezolizumab	Tecentriq	10/8/2020	treatment of soft tissue sarcoma	Designated/Approved		"Genentech, Inc."
Disulfiram and Copper		10/8/2020	treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Cantex Pharmaceuticals, Inc."
Volasertib		10/8/2020	treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	Oncoheroes Biosciences Inc.
2¿-O-(2-methoxyethyl) modified antisense oligonucleotide targeting glycogen synthase 1 (GYS1) pre mRNA		10/8/2020	treatment of Lafora disease	Designated	Not FDA Approved for Orphan Indication	"Ionis Pharmaceuticals, Inc."
O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic acid amidoxime dihydrochloride		10/8/2020	Treatment of familial dysautonomia	Designated	Not FDA Approved for Orphan Indication	Mitochon Technologies Kft.
Pre-Morula Stem Cells		10/8/2020	treatment for amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	ReoStem L.L.C.
sacituzumab govitecan (SG)		10/8/2020	Treatment for adult and pediatric patients with glioblastoma	Designated	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
sulfo butyl ether beta-cyclodextrin		10/8/2020	treatment of Stargardt disease	Designated	Not FDA Approved for Orphan Indication	"reVision Therapeutics, Inc."
"fully human, antagonistic IgG1 monoclonal antibody targeting IL-27 subunit alpha (p28)"		10/8/2020	Treatment of hepatocellular carcinoma (HCC)	Designated	Not FDA Approved for Orphan Indication	"Coherus BioSciences, Inc."
sugemalimab		10/8/2020	treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"CStone Pharmaceuticals (Suzhou) Co., Ltd."
Small molecule activator of pantothenate kinases		10/7/2020	treatment for pantothenate kinase-associated neurodegeneration	Designated	Not FDA Approved for Orphan Indication	CoA Therapeutics
L-citrulline		10/7/2020	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"Asklepion Pharmaceuticals, LLC"
recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene		10/7/2020	Treatment for Rett syndrome	Designated	Not FDA Approved for Orphan Indication	Taysha Gene Therapies
Fibromun / Onfekafusp alfa		10/7/2020	treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Philogen S.p.A.
daratumumab and hyaluronidase-fihj	Darzalex Faspro	10/6/2020	treatment of light-chain (AL) amyloidosis	Designated/Approved		"Janssen Research & Development, LLC"
"APX005M,a 10 mg/mL preservative-free solution (pH 5.5) containing 25 mM sodium acetate, 248 mM trehalose, and 0.02% polysorbate 20 in water for injection in a singleuse, 20 mL Type 1 clear glass vials."		10/5/2020	Treatment of esophageal and gastroesophageal junction cancer	Designated	Not FDA Approved for Orphan Indication	"Pyxis Oncology, Inc."
O-(2-[18F]fluoroethyl)-L-tyrosine		10/5/2020	Diagnostic for the management of glioma	Designated	Not FDA Approved for Orphan Indication	Telix Pharmaceuticals Limited (Telix)
Phenobarbital Sodium		9/30/2020	Treatment of neonatal seizures	Designated	Not FDA Approved for Orphan Indication	"Hikma Pharmaceuticals USA, Inc."
Humanized Anti-claudin18.2 Autologous Chimeric Antigen Receptor (CAR) T Cells		9/30/2020	Treatment of gastric cancer including cancer of the gastroesophageal junction	Designated	Not FDA Approved for Orphan Indication	CARsgen Therapeutics Corporation
Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells		9/30/2020	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Glycostem Therapeutics B.V.
Sodium phenylbutyrate and tauroursodeoxycholic acid dihydrate		9/30/2020	Treatment of Wolfram syndrome	Designated	Not FDA Approved for Orphan Indication	Amylyx Pharmaceuticals Inc.
"allogeneic, expanded, engineered human umbilical cord E4ORF1+ CD31+ cells (E-CEL UVEC® cells)"		9/30/2020	Prevention (reduction) of morbidity and mortality associated with hematopoietic stem cell transplantation	Designated	Not FDA Approved for Orphan Indication	"Angiocrine Bioscience, Inc."
apadamtase alfa		9/28/2020	Treatment of Sickle Cell Disease	Designated	Not FDA Approved for Orphan Indication	Baxalta US Inc.
Vactosertib		9/28/2020	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	"MedPacto, Inc"
Emapalumab		9/25/2020	Prevention of graft failure following hematopoietic stem cell transplantation	Designated	Not FDA Approved for Orphan Indication	Sobi AG
Synthetic adrenocorticotropic hormone		9/25/2020	Treatment of infantile spasms	Designated	Not FDA Approved for Orphan Indication	Amzell B.V.
Nivatrotamab		9/25/2020	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	"Y-mAbs Therapeutics, Inc."
DNA plasmid encoding the human transferrin gene		9/25/2020	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	"Eyevensys, Inc."
tovorafenib	Ojemda	9/24/2020	Treatment of malignant glioma	Designated/Approved		"Day One Biopharmaceuticals, Inc."
"Human Engrailed-1 homeoprotein, recombinant"		9/24/2020	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	BrainEver SAS
Pelcitoclax		9/23/2020	Treatment of Small Cell Lung Cancer	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
Hemopexin (Human)		9/23/2020	Treatment of Sickle Cell Disease	Designated	Not FDA Approved for Orphan Indication	CSL Behring
N-Acetylglucosamine		9/23/2020	Treatment for Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	"Wellesley Therapeutics, Inc."
Excindogen		9/23/2020	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	CarcinEx Inc.
Cepharanthine		9/22/2020	Treatment of immune thrombocytopenia (ITP)	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
Recombinant Human Adeno-Associated Virus Serotype 2 Containing Human Mitochondrial ND4 gene (rAAV2-ND4)		9/22/2020	Treatment of Leber's Hereditary Optic Neuropathy	Designated	Not FDA Approved for Orphan Indication	"Neurophth Therapeutics, Inc."
Small molecule melanocortin 4 receptor agonist		9/21/2020	Treatment for leptin receptor deficiency	Designated	Not FDA Approved for Orphan Indication	"Rhythm Pharmaceuticals, Inc."
"2-(4-oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid"		9/21/2020	Treatment of phosphomannomutase 2 deficiency	Designated	Not FDA Approved for Orphan Indication	Applied Therapeutics Inc.
Gabexate		9/18/2020	Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
2¿-O-(2-methoxyethyl) modified antisense oligonucleotide targeting glial fibrillary acidic protein pre mRNA		9/18/2020	Treatment of Alexander disease	Designated	Not FDA Approved for Orphan Indication	Ionis Pharmaceuticals
Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor		9/18/2020	Treatment of Esophageal Cancer	Designated	Not FDA Approved for Orphan Indication	"Jacobio Pharmaceuticals Co., Ltd."
aspirin for injection (acetylsalicylic acid)		9/18/2020	Treatment of Kawasaki Disease	Designated	Not FDA Approved for Orphan Indication	Rhoshan Pharmaceuticals Inc.
"Mobilized peripheral blood-derived autologous CD34+ hematopoietic stem cells, that have been genetically modified, ex vivo, with self-inactivating lentiviral vector CL20-4i-EF1a-hyc-OPT containing a normal version of the coding region of the IL2RG gene."		9/18/2020	Treatment of severe combined immunodeficiency	Designated	Not FDA Approved for Orphan Indication	"Mustang Bio, Inc."
6-{(1S)-1-[(2-Amino-6-fluoroquinolin-3-yl)oxy]ethyl}-5-(1H-pyrazol-1-yl)pyridin-2(1H)-one		9/18/2020	Treatment for Sickle Cell Disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
a recombinant humanized Fc effector function null IgG1 antibody with kappa light chains (IgG1) that selectively binds to E-selectin to inhibit binding to cellular proteins containing carbohydrate structures with a sialyl Lewis X (sLex) deter		9/18/2020	Treatment of Sickle Cell Disease	Designated	Not FDA Approved for Orphan Indication	Pfizer Inc.
tisagenlecleucel	Kymriah	9/16/2020	Treatment of follicular lymphoma	Designated/Approved		Novartis Pharmaceuticals Corporation
Cannabidiol		9/16/2020	Treatment of 22q.11.2 deletion syndrome	Designated	Not FDA Approved for Orphan Indication	"Zynerba Pharmaceuticals, Inc."
Toripalimab		9/15/2020	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"TopAlliance Biosciences, Inc."
Autologous Anti-CD22 CAR T-Cells		9/14/2020	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	"Center for Cancer Research, National Cancer Institute"
pirtobrutinib	Jaypirca	9/14/2020	Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma	Designated/Approved		"Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company"
Pexastimogene Devacirepvec		9/14/2020	Treatment of stage IIB-IV melanoma	Designated	Not FDA Approved for Orphan Indication	"SillaJen, Inc."
Autologous blood derived natural killer cells		9/14/2020	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"CHA Biotech. Co., Ltd"
"N-[4-[[2-(1,1-Dimethylethyl)phenyl]sulfonyl]phenyl]-2,3,4-trihydroxy-5-[[2-(1-methylethyl)phenyl]methyl]benzamide"		9/14/2020	Treatment of retinoblastoma	Designated	Not FDA Approved for Orphan Indication	Oxular Ltd
"APG-115, an orally bioavailable small molecule."		9/14/2020	Treatment of acute myeloid leukemia (AML).	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
mavrilimumab		9/14/2020	Treatment of Giant Cell Arteritis	Designated	Not FDA Approved for Orphan Indication	"Kiniksa Pharmaceuticals, GmbH"
(S)-4-((1-Benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzenesulfonamide		9/10/2020	"Treatment of sodium channel, voltage-gated, type VIII, alpha subunit (SCN8A) developmental and epileptic encephalopathy syndrome"	Designated	Not FDA Approved for Orphan Indication	Neurocrine Biosciences Inc.
(R)-N-(3-(2-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propenamide hemi ethyl acetate solvate		9/10/2020	Treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Dizal (Jiangsu) Pharmaceutical Co., Ltd."
glycolate oxidase inhibitor		9/10/2020	Treatment of primary hyperoxaluria	Designated	Not FDA Approved for Orphan Indication	"Cantero Therapeutics, Inc."
Aminolevulinic acid hydrochloride		9/9/2020	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"SonALAsense, Inc."
Bioartificial liver system utilizing encapsulated human Hep G2 hepatoblastoma cells in a fluidised bed bioreactor (BAL).		9/9/2020	Treatment of Acute Liver failure.	Designated	Not FDA Approved for Orphan Indication	ESPL Regulatory Consulting Limited
Fasudil		9/9/2020	Treatment of Frontotemporal Dementia	Designated	Not FDA Approved for Orphan Indication	"Woolsey Pharmaceuticals, Inc.Woolsey Pharmaceuticals, Inc."
Caveolin-1 Scaffolding Domain 7-Mer		9/9/2020	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"Lung Therapeutics, Inc."
Proglumide		9/9/2020	Treatment of Chronic Pancreatitis	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
Autologous Osteogenic Stem Cells		9/9/2020	Treatment of Congenital Pseudarthrosis of Long Bones	Designated	Not FDA Approved for Orphan Indication	Novadip Biosciences
Lumacaftor		9/9/2020	Treatment of subarachnoid hemorrhage	Designated	Not FDA Approved for Orphan Indication	Qanatpharma AG
peptide conjugated phosphorodiamidate morpholino oligomer		9/8/2020	Treatment for Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies	Designated	Not FDA Approved for Orphan Indication	
Adeno-associated viral vector expressing a cystic fibrosis transmembrane conductance regulator with a partial deletion in the R domain gene		9/8/2020	Treatment of Cystic Fibrosis	Designated	Not FDA Approved for Orphan Indication	"Spirovant Sciences, Inc."
"2,4 dinitrophenol"		9/8/2020	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"Mitochon Phannaceuticals, Inc."
Pozelimab/Cemdisiran Combination		9/8/2020	Treatment of Paroxysmal Nocturnal Hemoglobinuria	Designated	Not FDA Approved for Orphan Indication	"Regeneron Pharamecuticals, Inc."
"5-fluoro-4-(7''-fluoro-2''-methylspiro[cyclopentane-1,3''-indol]-5''-yl)-N-(5-(1-methylpiperidin-4-yl)pyridin-2-yl)pyrimidin-2-amine fumarate"		9/8/2020	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Gan & Lee Pharmaceuticals USA Corporation
Biotin		9/8/2020	Treatment of Charcot-Marie-Tooth disease	Designated	Not FDA Approved for Orphan Indication	MedDay Pharmaceuticals
Small molecule mitofusin allosteric activator		9/4/2020	Treatment of Charcot-Marie-Tooth Disease Type 2A	Designated	Not FDA Approved for Orphan Indication	Mitochondria Emotion Inc.
Belumosudil		9/4/2020	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	Kadmon Corporation
humanized bispecific IgG1 antibody that can simultaneously bind to both programmed death-ligand 1 and cytotoxic T-lymphocyte-associated protein 4		9/2/2020	Treatment of Thymic Epithelial Tumors	Designated	Not FDA Approved for Orphan Indication	"Jiangsu Alphamab Biopharmaceuticals Co., Ltd."
"APG-115, a novel orally available small molecule MDM2 inhibitor"		9/2/2020	Treatment of Gastric Cancer	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
firolimogene autotemcel		8/31/2020	treatment X-linked severe combined immunodeficiency.	Designated	Not FDA Approved for Orphan Indication	"Mustang Bio, Inc."
Lorcaserin		8/31/2020	Treatment of Dravet syndrome	Designated	Not FDA Approved for Orphan Indication	Eisai Inc.
chemically synthesized molecule which is composed of two binding sites (a CD38 binder and a universal antibody binding terminus binder) connected by a linker chain.		8/31/2020	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	Kleo Pharmaceuticals
nedaplatin		8/31/2020	Treatment of esophageal cancer	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
20-alphaHydroxycholesterol		8/31/2020	Prevention of White Matter Injury in Preterm Infants less than or equal to 32 Weeks Gestational Age	Designated	Not FDA Approved for Orphan Indication	"Tellus Therapeutics, Inc."
"2-(4-(4-((1-(107-(4-(fluorophenyl)methoxy)-(polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid"		8/28/2020	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"NanoPharmaceuticals, LLC"
"2-(4-(4-((1-(107-(4-(guanidinomethyl)phenoxy)-(polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid"		8/28/2020	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	"NanoPharmaceuticals, LLC"
"[6-(4-Chlorophenyl)-spiro[3.5]non-6-en-7-yl]methyl}-piperazin-1-yl}-N-{{3-nitro-4-[((2S)-1,4-dioxan-2-ylmethyl)amino]phenyl}sulfonyl}-2-(1H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide"		8/28/2020	Treatment of Chronic Lymphocytic Leukemia	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
"2-(4-(4-((1-(107-(4-(fluorophenyl)methoxy)-polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid"		8/28/2020	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"NanoPharmaceuticals, LLC"
211At-4-astato-L-phenylalanine (4-[211At]APA)		8/28/2020	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Telix Pharmaceuticals Limited (Telix)
BCX9930 is a small molecule inhibitor of human complement factor D.		8/28/2020	Treatment of paroxysmal nocturnal hemoglobinuria	Designated	Not FDA Approved for Orphan Indication	"BioCryst Pharmaceuticals, Inc."
pirtobrutinib	Jaypirca	8/28/2020	Treatment of mantle cell lymphoma	Designated/Approved		"Loxo Oncology, Inc."
"1-{6-[(4-fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1H,2H,3H-pyrrolo[3,2-b]pyridin-1-yl}-2-[(2R,5R)-5-methyl-2-{[(3R)-3-methylmorpholin-4-yl]methyl}piperazin-1-yl]ethan-1-one, L-(+)-lactic acid salt"		8/28/2020	Treatment of T-Cell Lymphoma	Designated	Not FDA Approved for Orphan Indication	"Astex Pharmaceuticals, Inc."
BMEDA-chelated Rhenium-186 nanoliposomes		8/26/2020	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	University of Texas Health Science Center at San Antonio
Adeno-Associated Viral Vector Expressing Codon-optimized Human PCCA cDNA		8/26/2020	Treatment of Propionic Acidemia	Designated	Not FDA Approved for Orphan Indication	Mayo Clinic
"Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (mc-vc-PAB), and a monomethyl auristatin E (MMAE) cytotoxin."		8/26/2020	Treatment of mantle cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Merck Sharp & Dohme, LLC"
Autologous ex-vivo-expanded peripheral polyclonal lymphocytes enriched in activated natural killer cells		8/25/2020	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	XNK Therapeutics AB
fasudil HCL		8/25/2020	Treatment of Huntington’s Disease	Designated	Not FDA Approved for Orphan Indication	"Woolsey Pharmaceuticals, Inc."
"Bis-(3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-B-D-galactopyranosyl) sulfane"		8/25/2020	Treatment of idiopathic pulmonary fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Galecto Biotech AB
zanubrutinib	Brukinsa	8/24/2020	Treatment of splenic marginal zone lymphoma	Designated/Approved		"BeiGene USA, Inc."
zanubrutinib	Brukinsa	8/24/2020	Treatment of nodal marginal zone lymphoma	Designated/Approved		"BeiGene USA, Inc."
zanubrutinib	Brukinsa	8/24/2020	Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue	Designated/Approved		"BeiGene USA, Inc."
Ivaltinostat		8/21/2020	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"CG Pharmaceuticals, Inc."
Paxalisib		8/21/2020	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Kazia Therapeutics Limited
cannabidiol		8/21/2020	Treatment of Prader Willi Syndrome	Designated	Not FDA Approved for Orphan Indication	"Radius Pharmaceuticals, Inc."
"(R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone"		8/18/2020	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"Corcept Therapeutics, Inc."
"A replication-defective, non-integrating herpes simplex virus type 1 vector expressing human cystic fibrosis transmembrane conductance regulator"		8/17/2020	Treatment of Cystic Fibrosis	Designated	Not FDA Approved for Orphan Indication	"Krystal Biotech, Inc."
Disufenton sodium		8/14/2020	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Oblato, Inc."
cannabidiol covalently linked to temozlomide		8/14/2020	Treatment of malignant glioma.	Designated	Not FDA Approved for Orphan Indication	"Diverse Biotech, Inc."
Small molecule activator of pantothenate kinases		8/14/2020	Treatment of Propionic Acidemia	Designated	Not FDA Approved for Orphan Indication	CoA Therapeutics
venglustat malate		8/13/2020	Treatment of GM2 gangliosidosis	Designated	Not FDA Approved for Orphan Indication	"Genzyme Corporation, a SANOFI COMPANY"
Urinary-derived human chorionic gonadotropin and epidermal growth factor		8/12/2020	Treatment of acute graft-versus-host disease	Designated	Not FDA Approved for Orphan Indication	University of Minnesota
Edaravone and (+)-Borneol		8/11/2020	Treatment of Amyotrophic Lateral Sclerosis.	Designated	Not FDA Approved for Orphan Indication	"Yantai Yenepharma. Co., Ltd"
Adeno-associated virus serotype HSC15 expressing human arylsulfatase A		8/11/2020	Treatment of Metachromatic Leukodystrophy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Homology Medicines, Inc."
vatiquinone		8/10/2020	Treatment of seizures in patients with mitochondrial disease	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting B-cell maturation antigen		8/10/2020	Treatment of multiple myeloma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"CRISPR Therapeutics, Inc."
Trehalose + miglustat		8/10/2020	Treatment of CLN Batten disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Beyond Batten Disease Foundation
Adeno-Associated Virus containing the gene for human Nuclear Hormone Receptor NR2E3 (AAV-hNR2E3)		8/7/2020	Treatment of retinal dystrophies due to mutations in PDE6B gene	Designated	Not FDA Approved for Orphan Indication	Ocugen Inc.
Ubenimex		8/7/2020	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
Nedaplatin		8/5/2020	Treatment of Small Cell Lung Cancer	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
Dystrophin Expressing Chimeric Cells derived from allogenic normal human myoblast and autologous DMD myoblast from Duchenne muscular dystrophy affected donor		8/5/2020	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	Dystrogen Therapeutics Corporation
Prosetin		8/4/2020	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	Project ALS
sulindac		8/4/2020	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	"Prolindox, Inc."
"Cl-CAR-135 (FLT3 CAR), RRV-FLT3-CAR-tCD19 transduced autologous T cells derived from patients with acute myeloid leukemia"		7/31/2020	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Cytoimmune Therapeutics
"6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)-paromamine sulfate"		7/31/2020	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"ELOXX Pharmaceuticals, Inc."
An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8		7/31/2020	Treatment of neuronal ceroid lipofuscinosis type 7	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Neurogene Inc.
Racemetyrosine		7/31/2020	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Tyme Technologies, Inc."
half-life extended bispecific T cell engager (BiTE®) antibody construct designed to target both CLDN18.2 and CD3		7/31/2020	"Treatment of gastric cancer, including cancer of gastroesophageal junction"	Designated	Not FDA Approved for Orphan Indication	"Amgen, Inc."
iptacopan	Fabhalta	7/31/2020	Treatment of paroxysmal nocturnal hemoglobinuria	Designated/Approved		Novartis Pharmaceuticals Corporation
"trans-4-[4-Amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazine-7-yl]-cyclohexanecarboxylic acid, tromethamine salt"		7/30/2020	Treatment of lymphatic malformations	Designated	Not FDA Approved for Orphan Indication	"Avalo Therapeutics, Inc."
Celecoxib		7/30/2020	Treatment of hemophilic arthropathy	Designated	Not FDA Approved for Orphan Indication	"Upex-Med Co., Ltd."
a chemically modified full phosphorothioate-backboned anti-miR-17 oligonucleotide.		7/28/2020	Treatment of autosomal dominant polycystic kidney disease	Designated	Not FDA Approved for Orphan Indication	"Regulus Therapeutics, Inc."
parsaclisib		7/28/2020	Treatment of autoimmune hemolytic anemia	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
A recombinant plasmid-derived DNA-based vaccine targeting the E6 and E7 antigens of both HPV6 and HPV11		7/28/2020	Treatment of recurrent respiratory papillomatosis	Designated	Not FDA Approved for Orphan Indication	"Inovio Pharmaceuticals, Inc."
"3,5-diiodothyropropionic acid"		7/28/2020	Treatment of monocarboxylate transporter (MCT) 8 deficiency (Allan-Herndon-Dudley syndrome)	Designated	Not FDA Approved for Orphan Indication	"Prizm, LLC"
Low molecular weight dextran sulfate (LMW-DS)		7/28/2020	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	TikoMed AB
Proglumide		7/23/2020	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
adeno-Associated Virus containing human Nuclear Hormone Receptor NR2E3 (AAV-hNR2E3) gene therapy		7/23/2020	Treatment of RHO gene mutation associated retinal degenerative disease	Designated	Not FDA Approved for Orphan Indication	Ocugen Inc.
Aviptadil		7/23/2020	Treatment of sarcoidosis	Designated	Not FDA Approved for Orphan Indication	AdVita Lifescience GmbH
Zenocutuzumab		7/22/2020	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Merus N.V.
cobomarsen		7/21/2020	Treatment of T-cell lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Viridian Therapeutics, Inc."
"2-Amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide fumarate dihydrate"		7/21/2020	Treatment of fibrodysplasia ossificans progressiva	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
Pax7+ Satellite Stem Cell Therapy		7/21/2020	Treatment of Duchenne Muscular Dystrophy.	Designated	Not FDA Approved for Orphan Indication	Vita Therapeutics
Alidornase alfa		7/21/2020	Treatment of sarcoidosis	Designated	Not FDA Approved for Orphan Indication	"SarcoMed USA, Inc."
adeno-associated viral vector serotype 9 encoding a codon-optimized human SLC6A1 transgene		7/17/2020	Treatment of SLC6A1-related disorder.	Designated	Not FDA Approved for Orphan Indication	Taysha Gene Therapies
adeno-associated viral vector serotype 9 (AAV9) carrying both HEXA and HEXB		7/17/2020	Treatment of GM2 gangliosidosis	Designated	Not FDA Approved for Orphan Indication	Taysha Gene Therapies
rilonacept	Arcalyst	7/14/2020	Treatment of pericarditis	Designated/Approved		"Kiniksa Pharmaceuticals, Ltd."
Humanized Recombinant IgG4 Anti-PD-1 Monoclonal Antibody		7/14/2020	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"CStone Pharmaceuticals (Suzhou) Co., Ltd."
(Z)-3-fluoro-4-(quinolin-8-ylsulfonyl)but-2-en-1-amine		7/10/2020	Treatment of myelofibrosis	Designated	Not FDA Approved for Orphan Indication	Pharmaxis Ltd.
Mitochondria		7/10/2020	Prevention of ischemia-reperfusion injury during solid organ transplantation	Designated	Not FDA Approved for Orphan Indication	cellvie Inc.
Dehydrated alcohol		7/10/2020	Treatment of methanol poisoning	Designated	Not FDA Approved for Orphan Indication	Eton Pharmaceuticals
Dihydrotestosterone Gel		7/9/2020	Treatment of micropenis	Designated	Not FDA Approved for Orphan Indication	Besins Healthcare Ireland Ltd.
a novel humanized bispecific XmAb® T cell recruiting antibody cross-reactive to human and nonhuman primate STEAP1 and CD3		7/7/2020	Treatment of Ewing Sarcoma	Designated	Not FDA Approved for Orphan Indication	"Amgen, Inc."
imsidolimab		7/7/2020	Treatment of generalized pustular psoriasis	Designated	Not FDA Approved for Orphan Indication	"AnaptysBio, Inc."
"N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl) amino]carbonyl]-1-(1-methylethyl)-1H-Pyrazole-3-sulfonamide"		7/7/2020	Treatment of cryopyrin-associated periodic syndromes	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc., a Member of the Roche Group"
Nadofaragene firadenovec		7/7/2020	Treatment of malignant mesothelioma	Designated	Not FDA Approved for Orphan Indication	Trizell Ltd
"N,N-dimethyl-N-(2-{[(2R,3R,4S,5R,6R)-3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl]oxy}ethyl)cyclopropylammonium"		7/7/2020	Treatment of Trimethylaminuria	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Kintai Therapeutics, Inc."
"5-fluoro-2-(6-fluoro-2-methyl-1H-benzo[d]imidazole-1-yl)-N4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine"		7/7/2020	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
Paltusotine		7/7/2020	Treatment of acromegaly	Designated	Not FDA Approved for Orphan Indication	"Crinetics Pharmaceuticals, Inc."
Humanized afucosylated IgG1 monoclonal antibody binding to KLRG1		7/7/2020	Treatment of inclusion body myositis	Designated	Not FDA Approved for Orphan Indication	"Abcuro, Inc."
Engineered cationic antibiotic peptide		7/1/2020	Treatment of prosthetic joint infections	Designated	Not FDA Approved for Orphan Indication	"Peptilogics, Inc."
"[6-(4-Chlorophenyl)-spiro[3.5]non-6-en-7-yl]methyl}-piperazin-1-yl}-N-{{3-nitro-4-[((2S)-1,4-dioxan-2-ylmethyl)amino]phenyl}sulfonyl}-2-(1H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide"		7/1/2020	Treatment of Waldenström macroglobulinemia	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
Enriched CD34+ hematopoietic stem and progenitor cells/highly puridied CD34-CD25+CD4+CD127-regulatory T cells/conventional T cells		7/1/2020	Treatment to enhance cell engraftment in patients receiving hematopoietic stem cell transplant.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Orca Biosystems Inc.
recombinant human IgG monoclonal HPA-1a antibody		7/1/2020	Prevention of fetal and neonatal alloimmune thrombocytopenia	Designated	Not FDA Approved for Orphan Indication	"Rallybio IPA, LLC"
anakinra	Kineret	6/29/2020	Treatment of Deficiency of IL-1 Receptor Antagonist	Designated/Approved		Swedish Orphan Biovitrum AB (PUBL)
Synthetic double-stranded siRNA oligonucleotide directed against TMPRSS6 mRNA and covalently linked to a ligand containing 3 N-acetylgalactosamine residues		6/26/2020	Treatment of ß-thalassemia	Designated	Not FDA Approved for Orphan Indication	Silence Therapeutics GmbH
nipocalimab		6/26/2020	Prevention of hemolytic disease of the fetus and newborn	Designated	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
A therapeutic vaccine targeting the HPV16 E6/E7 proteins		6/26/2020	Treatment of HPV16-positive cervical cancer	Designated	Not FDA Approved for Orphan Indication	ISA Therapeutics BV
geranylgeranylacetone		6/26/2020	Treatment of spinal and bulbar muscular atrophy	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
belzutifan	Welireg	6/24/2020	Treatment of von Hippel-Lindau disease	Designated/Approved		"Merck Sharp & Dohme, LLC"
Humanized immunoglobulin G1 kappa monoclonal antibody targeting PAUF		6/24/2020	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Prestige Biopharma Ltd
nanatinostat and valganciclovir		6/22/2020	Treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Viracta Therapeutics, Inc."
cirmtuzumab		6/22/2020	Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.	Designated	Not FDA Approved for Orphan Indication	"Oncternal Therapeutics, Inc."
"6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3- tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one"		6/22/2020	Treatment of beta-thalassemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"IMARA, Inc."
cirmtuzumab		6/22/2020	Treatment of mantle cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Oncternal Therapeutics, Inc."
Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene		6/22/2020	Treatment of Mucopolysaccharidosis Type I (MPS-I)	Designated	Not FDA Approved for Orphan Indication	Orchard Therapeutics (Europe) Limited
Proglumide		6/16/2020	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Jill P Smith, MD"
Geranylgeranylacetone		6/16/2020	Prevention of post-hepatectomy liver failure	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
tacrolimus		6/16/2020	Prophylaxis of lung allograft rejection	Designated	Not FDA Approved for Orphan Indication	"TFF Pharmaceuticals, Inc."
Humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated Thr231-Pro232 motif in tau		6/16/2020	Treatment of Progressive supranuclear palsy	Designated	Not FDA Approved for Orphan Indication	Pinteon Therapeutics Inc.
(-)-huperzine A		6/15/2020	Treatment of Lennox-Gastaut Syndrome	Designated	Not FDA Approved for Orphan Indication	"Supernus Pharmaceuticals, Inc."
imatinib mesylate		6/15/2020	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	"PHPrecisionMed, LLC"
Ubenimex		6/12/2020	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
Ulinastatin		6/12/2020	Treatment of Kawasaki Disease	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
Hepcidin mimetic peptide		6/12/2020	Treatment of Polycythemia vera	Designated	Not FDA Approved for Orphan Indication	"Protagonist Therapeutics, Inc."
Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc).		6/11/2020	Treatment of progressive multifocal leukoencephalopathy	Designated	Not FDA Approved for Orphan Indication	"NeoImmuneTech, Inc."
geranylgeranylacetone		6/10/2020	Prevention of Acute Radiation Syndrome	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
guadecitabine SC		6/10/2020	Treatment of myelodysplastic syndromes including chronic myelomonocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Astex Pharmaceuticals, Inc."
"humanized IgG4 monoclonal antibody optimized for neutralizing activity against DKK1, a secreted modulator of Wnt signaling"		6/10/2020	Treatment of gastric and gastroesophageal junction cancer	Designated	Not FDA Approved for Orphan Indication	"Leap Therapeutics, Inc"
Berubicin		6/9/2020	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"CNS Pharmaceuticals, Inc."
L-fucose		6/8/2020	Treatment of Leukocyte Adhesion Deficiency Type- II	Designated	Not FDA Approved for Orphan Indication	"Orpha Labs, AG"
treprostinil		6/8/2020	Treatment of Systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	"LutaFlo Therapeutics, LLC"
obinutuzumab		6/8/2020	Treatment of Membranous Nephropathy	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc., A Member of the Roche Group"
"(1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-caroxylic acid-phosphoric acid (1/1)"		6/8/2020	treatment of cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease)	Designated	Not FDA Approved for Orphan Indication	"Mitsubishi Tanabe Pharma Development America, Inc."
Mitapivat		6/8/2020	Treatment of thalassemia	Designated	Not FDA Approved for Orphan Indication	"Agios Pharmaceuticals, Inc."
sivelestat		6/5/2020	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
Tacrolimus		6/3/2020	Treatment of vernal keratoconjunctivitis	Designated	Not FDA Approved for Orphan Indication	"CN2 Therapeutics, Inc."
progesterone		6/3/2020	Treatment of ocular graft versus host disease	Designated	Not FDA Approved for Orphan Indication	"GLIA, LLC"
Adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 gene		6/3/2020	Treatment of neuronal ceroid lipofuscinosis type 5	Designated	Not FDA Approved for Orphan Indication	Neurogene Inc.
margetuximab		6/3/2020	Treatment of gastric and gastroesophageal junction cancer.	Designated	Not FDA Approved for Orphan Indication	"MacroGenics, Inc."
Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop-1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate		6/2/2020	Treatment of primary mitochondrial myopathy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Reneo Pharmaceuticals Inc.
half-life extended bispecific T-cell engager antibody construct targeting MUC17 and CD3		6/2/2020	"Treatment of gastric cancer, including cancer of gastroesophageal junction"	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
Telomerase Specific Replication-competent Oncolytic Adenovirus		6/1/2020	Treatment of esophageal cancer	Designated	Not FDA Approved for Orphan Indication	Oncolys BioPharma Inc.
Human Placental Extract		5/28/2020	Prevention of necrotizing enterocolitis in early preterm infants (gestational age less than 34 weeks).	Designated	Not FDA Approved for Orphan Indication	"Plakous Therapeutics, Inc."
nilotinib oral tablets		5/28/2020	Treatment of chronic myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	"Nanocopoeia, LLC"
Amitriptyline		5/27/2020	Treatment of Erythromelalgia	Designated	Not FDA Approved for Orphan Indication	Algo Therapeutix S.A.S
pralsetinib	Gavreto	5/26/2020	"Treatment of RET-fusion, RET-mutation, and TRKC-positive poorly differentiated thyroid cancer, undifferentiated or anaplastic thyroid cancer, medullary thyroid cancer, and locally advanced or metastatic follicular or papillary thyroid cancer"	Designated/Approved		"Rigel Pharmaceuticals, Inc."
ivosidenib	Tibsovo	5/20/2020	Treatment of myelodysplastic syndromes	Designated/Approved		Servier Pharmaceuticals LLC
PEGylated recombinant human tumor necrosis factor-related apoptosis inducing ligand		5/20/2020	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	"Theraly Fibrosis, Inc."
fam-trastuzumab deruxtecan-nxki	Enhertu	5/20/2020	"Treatment of gastric cancer, including gastroesophageal junction cancer"	Designated/Approved		"Daiichi Sankyo, Inc."
"4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl) benzoic acid"		5/18/2020	Treatment of C3 glomerulopathy	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
toripalimab-tpzi	Loqtorzi	5/18/2020	Treatment of nasopharyngeal carcinoma	Designated/Approved		"Coherus BioSciences, Inc."
Gemcitabine		5/18/2020	Treatment of cholangiocarcinoma	Designated	Not FDA Approved for Orphan Indication	RenovoRx
"Benzeneacetamide, 2-[2-[2-[[2-methoxy-4-(1-methyl-4-piperidinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]ethyl]-"		5/18/2020	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	Amplia Therapeutics
GRObeta (a truncated form of the human CXC motif chemokine 2)		5/18/2020	Mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent transplant	Designated	Not FDA Approved for Orphan Indication	"Ensoma, Inc."
Poly (Phenyl Sulfoglucuronate Galactoside)		5/14/2020	Treatment of anti-myelin-associated glycoprotein (MAG) neuropathy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Polyneuron Pharmaceuticals AG
"non-replicating recombinant adeno associated viral vector, serotype 9, designed to promote increased transcription of SCN1A gene"		5/14/2020	Treatment of Dravet Syndrome.	Designated	Not FDA Approved for Orphan Indication	Encoded Therapeutics
defibrotide		5/14/2020	Prevention of acute graft versus host disease	Designated	Not FDA Approved for Orphan Indication	Jazz Pharmaceuticals Ireland Limited
tislelizumab		5/14/2020	"Treatment of gastric cancer, including cancer of the gastroesophageal junction"	Designated	Not FDA Approved for Orphan Indication	"BeiGene USA, Inc."
"{(3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[ (2S)-3 -methyl-1-(propan-2- ylsulfonyl)butan-2-yl]-2-oxopiperidin-3-yl}acetic acid"		5/13/2020	Treatment of myelofibrosis.	Designated	Not FDA Approved for Orphan Indication	"Kartos Therapeutics, Inc."
hydrocortisone		5/13/2020	Prevention of bronchopulmonary dysplasia	Designated	Not FDA Approved for Orphan Indication	LABORATOIRE AGUETTANT
Allogeneic gene-edited CD19-directed CAR T cells/azercabtagene zapreleucel		5/13/2020	Treatment of mantle cell lymphoma	Designated	Not FDA Approved for Orphan Indication	Imugene Limited
Nafamostat		5/11/2020	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
Autologous T-cells genetically modified using a lentiviral vector encoding for CD19 CD3e TRuC		5/11/2020	Treatment of acute lymphoblastic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"TCR2 Therapeutics, Inc."
exagamglogene autotemcel	Casgevy	5/11/2020	Treatment of sickle cell disease	Designated/Approved		Vertex Pharmaceuticals Inc.
fixed dose combination of Pyronaridine and Benznidazole		5/11/2020	Treatment of Chagas Disease	Designated	Not FDA Approved for Orphan Indication	"Collaborations Pharmaceuticals, Inc."
human platelet derived hemostatic agent		5/7/2020	Treatment of Acute Radiation Syndrome	Designated	Not FDA Approved for Orphan Indication	"Cellphire, Inc."
[64Cu]Cu-[MeCOSar0-Tyr3]-octreotate		5/6/2020	Diagnostic for the clinical management of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	Clarity Pharmaceuticals Ltd.
"3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl((2S,3R,4R, 5R)-2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)-carbamimidoyl)pyrazine-2-carboxamide"		5/5/2020	Treatment of Primary Ciliary Dyskinesia	Designated	Not FDA Approved for Orphan Indication	"Parion Sciences, Inc."
"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate"		5/5/2020	Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia	Designated	Not FDA Approved for Orphan Indication	"ARMGO Pharma, Inc."
spherical carbon absorbent		5/5/2020	Treatment of urea cycle disorders	Designated	Not FDA Approved for Orphan Indication	"CT Development One, LLC"
"1-((2S,4S)-2-((((S) -(4-bromophenoxy)(((S)-1-oxo-1-(((S)- pentan-2-yl)oxy)propan-2-yl)amino)phosphoryl)oxy)methyl)-1,3-dioxolan-4-yl)-2-oxo-1,2-dihydropyrimidin-4- aminium chloride"		5/4/2020	Treatment of Hepatocellular Carcinoma	Designated	Not FDA Approved for Orphan Indication	Medivir AB
cipargamin		5/1/2020	Treatment of malaria	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
3-bromo-2-oxopropanoic acid		5/1/2020	Treatment of stage IIb-IV melanoma	Designated	Not FDA Approved for Orphan Indication	"NewG Lab Pharma, Inc."
garadacimab		4/30/2020	Treatment of bradykinin-mediated angioedema	Designated	Not FDA Approved for Orphan Indication	CSL Behring
Trehalose		4/29/2020	"Treatment of mucopolysaccharidosis type III (MPS III), or Sanfilippo syndrome"	Designated	Not FDA Approved for Orphan Indication	"Seelos Therapeutics, Inc."
Allogeneic multi-tumor-associated antigen-specific T cell product		4/28/2020	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Marker Therapeutics, Inc."
cannabidiol		4/28/2020	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	"Diverse Biotech, Inc."
pentosan polysulfate		4/28/2020	Treatment of mucopolysaccharidosis type 1	Designated	Not FDA Approved for Orphan Indication	Paradigm Biopharmaceuticals Ltd.
nanovesicle containing Saposin C and dioleoylphosphatidylserine		4/28/2020	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Bexion Pharmaceuticals, Inc"
exagamglogene autotemcel	Casgevy	4/28/2020	Treatment of beta-thalassemia	Designated/Approved		Vertex Pharmaceuticals Inc.
Recombinant adeno-associated viral vector serotype S3 containing DNA encoding for human alpha-galactosidase A		4/22/2020	Treatment of Fabry disease	Designated	Not FDA Approved for Orphan Indication	Freeline Therapeutics Limited
olverembatinib		4/22/2020	Treatment of chronic myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Ascentage Pharma Group Inc.
Aldesleukin		4/22/2020	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"Iovance Biotherapeutics, Inc."
pentagastrin		4/21/2020	Diagnostic for the management of medullary thyroid cancer	Designated	Not FDA Approved for Orphan Indication	"Exela Pharma Sciences, LLC"
epoprostenol		4/20/2020	Treatment of Frostbite	Designated	Not FDA Approved for Orphan Indication	"LutaFlo Therapeutics, LLC"
intravenous baclofen		4/20/2020	Prevention of baclofen withdrawal syndrome	Designated	Not FDA Approved for Orphan Indication	"Allaysis, LLC"
solution stable glucagon analog		4/20/2020	Treatment of congenital hyperinsulinism	Designated	Not FDA Approved for Orphan Indication	AmideBio
cannabidiol		4/20/2020	Treatment of Epidermolysis Bullosa	Designated	Not FDA Approved for Orphan Indication	Tetra Bio-Pharma Inc.
"trans N-ethyl-2-((4-(7-((4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide sesquifumarate salt"		4/20/2020	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Syndax Pharmaceuticals, Inc."
Melatonin		4/20/2020	Prevention of retinopathy of prematurity	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
Melatonin		4/20/2020	Treatment of retinopathy of prematurity	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
4-Methylumbelliferone		4/20/2020	Treatment of Esophageal Carcinoma	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
bempegaldesleukin		4/17/2020	Treatment of Stage IIb to Stage IV melanoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Nektar Therapeutics
"non-replicating recombinant adeno-associated virus serotype hu68 vector, which contains human GLB1 transgene encoding the galactosidase beta 1 enzyme"		4/16/2020	Treatment of GM1 gangliosidosis	Designated	Not FDA Approved for Orphan Indication	"Passage Bio, Inc."
"N-(bromoacetyl)-3,3-dinitroazetidine"		4/15/2020	Prevention of acute radiation syndrome	Designated	Not FDA Approved for Orphan Indication	"EpicentRx, Inc."
Monoclonal anti-IL-7R alpha antibody		4/15/2020	Treatment of Acute Lymphoblastic Leukemia	Designated	Not FDA Approved for Orphan Indication	Allterum Therapeutics
Near-infrared monoamine oxidase inhibitor (conjugate of clorgyline and cyanine dye MHI-148)		4/15/2020	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"Jean C. Shih, Ph.D."
docarpamine		4/14/2020	Treatment of ascites due to all etiologies except cancer	Designated	Not FDA Approved for Orphan Indication	"Martin Pharmaceuticals, Inc."
delta-9-tetrahydrocannabinol and cannabidiol		4/14/2020	Treatment of Epidermolysis Bullosa	Designated	Not FDA Approved for Orphan Indication	Tetra Bio-Pharma Inc.
Sintilimab		4/14/2020	Treatment of esophageal cancer	Designated	Not FDA Approved for Orphan Indication	Innovent Biologics (Suzhou) Co. Ltd
carbon monoxide		4/14/2020	Prevention of Primary Graft Dysfunction in transplant recipients receiving a lung or heart+ lung transplant.	Designated	Not FDA Approved for Orphan Indication	"Proterris, Inc."
[67Cu]Cu-[MeCOSar0-Tyr3]-octreotate		4/14/2020	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	Clarity Pharmaceuticals Ltd.
racecadotril		4/13/2020	Treatment of Microvillus inclusion disease	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
"[(1S,2S,5S)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol"		4/13/2020	Prevention of proliferative vitreoretinopathy	Designated	Not FDA Approved for Orphan Indication	Tetra Bio-Pharma Inc.
pozelimab-bbfg	Veopoz	4/13/2020	Treatment of CD55-deficient protein-losing enteropathy	Designated/Approved		"Regeneron Pharmaceuticals, Inc."
lonapegsomatropin-tcgd	Skytrofa	4/13/2020	Treatment of growth hormone deficiency	Designated/Approved		Ascendis Pharma Endocrinology Division A/S
navtemadlin		4/8/2020	Treatment of Merkel cell carcinoma	Designated	Not FDA Approved for Orphan Indication	"Kartos Therapeutics, Inc."
florbetaben F18		4/7/2020	Diagnostic for the management of amyloid light chain (AL) amyloidosis	Designated	Not FDA Approved for Orphan Indication	Life Molecular Imaging Ltd.
tipifarnib		4/6/2020	Treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Kura Oncology, Inc."
Fixed combination of monomethyl fumarate and aspirin		4/6/2020	Treatment of patients with multiple sclerosis who experience the fumarate flush	Designated	Not FDA Approved for Orphan Indication	"Vitalis, LLC"
bis-choline tetrathiomolybdate		4/6/2020	Treatment of primary biliary cholangitis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc."
fixed combination of diroximel fumarate and aspirin		4/6/2020	Treatment of patients with multiple sclerosis who experience the fumarate flush	Designated	Not FDA Approved for Orphan Indication	"Vitalis, LLC"
synthetic double-stranded small interfering RNA (siRNA) oligonucleotide directed against TMPRSS6 mRNA		4/6/2020	Treatment of Myelodysplastic Syndrome	Designated	Not FDA Approved for Orphan Indication	Silence Therapeutics GmbH
(+)-Epicatechin		4/6/2020	Treatment of Duchenne and Becker muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	Epirium Bio Inc.
tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct		4/1/2020	Treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	Affimed GmbH
Gallium-68 DOTANOC		4/1/2020	Diagnostic for the management of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	"Advanced Imaging Projects, LLC"
lisocabtagene maraleucel	Breyanzi	4/1/2020	Treatment of mantle cell lymphoma	Designated/Approved		"Juno Therapeutics, Inc."
Magnesium lysinate bis Resolvin E1		3/30/2020	Treatment of pediatric ulcerative colitis	Designated	Not FDA Approved for Orphan Indication	Thetis Pharmaceuticals
combination of p-Tolylmethylcarbinol nicotinic acid ester and a-naphthylacetic acid		3/30/2020	Treatment of primary biliary cholangitis	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
4-Methylumbelliferone		3/30/2020	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
Thymidine phosphorylase-cCPP-PEG		3/30/2020	Treatment of mitochondrial neurogastrointestinal encephalomyopathy	Designated	Not FDA Approved for Orphan Indication	"Pierrepont Therapeutics, Inc."
ansuvimab		3/30/2020	Post-exposure prophylaxis against Ebola virus infection	Designated	Not FDA Approved for Orphan Indication	Emergent Manufacturing Operations Baltimore LLC
"Sodium (4Z,7Z,10R,11E,13E,15Z,17S,19Z) 10,17-dihydroxy-docosa-4,7,11,13,15,19-hexaenoate"		3/30/2020	Prevention of retinopathy of prematurity	Designated	Not FDA Approved for Orphan Indication	Anida Pharma Inc.
Cerium dioxide nanoparticles		3/26/2020	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	Cerion Nanomaterials
"7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4H-imidazo[4,5,1-ij] quinoline hydrochloride"		3/26/2020	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Ryvu Therapeutics S.A.
epalrestat		3/26/2020	"Treatment of phosphomannomutase-2 deficiency, a congenital disorder of glycosylation"	Designated	Not FDA Approved for Orphan Indication	Maggie's Pearl
technetium-99m radiolabeled heparin		3/25/2020	Diagnostic for the management of Eosinophilic Esophagitis	Designated	Not FDA Approved for Orphan Indication	"NexEos Diagnostics, Inc."
toripalimab in combination with axitinib		3/25/2020	Treatment of mucosal melanoma	Designated	Not FDA Approved for Orphan Indication	"TopAlliance Biosciences, Inc."
Sodium Nitrite		3/25/2020	Treatment of Sickle Cell Disease	Designated	Not FDA Approved for Orphan Indication	AdimaBio LLC
axicabtagene ciloleucel		3/24/2020	Treatment of nodal marginal zone lymphoma	Designated	Not FDA Approved for Orphan Indication	"Kite Pharma, Inc."
retifanlimab		3/24/2020	Treatment of anal cancer	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
sintilimab		3/24/2020	Treatment of T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	Innovent Biologics (Suzhou) Co. Ltd
"benzeneacetamide, 2-[2-[2-[[2-methoxy-4-(1-methyl-4-piperidinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]ethyl]-"		3/23/2020	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Amplia Therapeutics
"L-serine, L-threonine, L-leucine, glycine, L-alanine, L-arginine, L-cysteine, L-glutamine, L-histidine, L-aspartic acid, L-proline, L-isoleucine, L-lysine, L-tryptophan, L-valine, L-methionine, L-tyrosine, carnitine and taurine"		3/23/2020	Treatment of phenylketonuria	Designated	Not FDA Approved for Orphan Indication	APR Applied Pharma Research
axicabtagene ciloleucel		3/23/2020	Treatment of extranodal marginal zone lymphoma	Designated	Not FDA Approved for Orphan Indication	"Kite Pharma, Inc."
interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker		3/23/2020	Treatment of Graft-Versus-Host-Disease	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
remdesivir		3/23/2020	Treatment of coronavirus disease 2019 (COVID-19)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
colistimethate sodium		3/19/2020	Treatment of respiratory infection in patients with Cystic Fibrosis	Designated	Not FDA Approved for Orphan Indication	"EnBiotix, Inc."
highly selective histone deacetylase 6 inhibitor		3/17/2020	Treatment of Charcot-Marie-Tooth disease	Designated	Not FDA Approved for Orphan Indication	"Chong Kun Dang Pharmaceutical Co., Ltd."
elezanumab		3/17/2020	Treatment of acute spinal cord injury	Designated	Not FDA Approved for Orphan Indication	AbbVie Inc.
a synthetic double-stranded RNA oligonucleotide conjugated to N-acetyl-D-galactosamine aminosugar residues		3/16/2020	Treatment of alpha-1 antitrypsin deficiency	Designated	Not FDA Approved for Orphan Indication	"Dicerna Pharmaceuticals, Inc."
acazicolcept		3/16/2020	Treatment of Acute Graft versus Host Disease	Designated	Not FDA Approved for Orphan Indication	Alpine Immune Sciences
"Autologous modified RNA transfected myeloid cells that express a fusion protein composed of humanized scFv that recognizes human CD5, a CD8 alpha transmembrane domain, and Fc gamma and PI3K intracellular signaling domains (CD5-ATAK-Fcy-PI3K Myeloid Cells)"		3/16/2020	Treatment of T-cell Lymphoma	Designated	Not FDA Approved for Orphan Indication	"Myeloid Therapeutics, Inc."
acazicolcept		3/16/2020	Prevention of acute graft versus host disease	Designated	Not FDA Approved for Orphan Indication	Alpine Immune Sciences
Adeno-associated viral vector encoding human multidrug resistance protein 3A (MDR3A)		3/16/2020	Treatment of progressive familial intrahepatic cholestasis	Designated	Not FDA Approved for Orphan Indication	Vivet Therapeutics SAS
mexiletine		3/16/2020	Treatment of myotonic disorders	Designated	Not FDA Approved for Orphan Indication	Lupin Europe GmbH
4-Methylumbelliferone		3/13/2020	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
olorofim		3/11/2020	Treatment of coccidioidomycosis	Designated	Not FDA Approved for Orphan Indication	F2G Limited
pirfenidone		3/11/2020	Treatment of Unclassifiable-interstitial lung disease	Designated	Not FDA Approved for Orphan Indication	"Genentech Inc., A Member of the Roche Group"
Glucagon-like peptide-1/Glucagon/Gastric inhibitory polypeptide triple agonist linked to human IgG4 Fc fragment		3/9/2020	Treatment of primary biliary cholangitis	Designated	Not FDA Approved for Orphan Indication	"Hanmi Pharmaceutical Company, Ltd."
Adeno-associated viral vector serotype 8 containing cDNA of the human PDE6A protein		3/9/2020	Treatment of Retinitis Pigmentosa	Designated	Not FDA Approved for Orphan Indication	Universitätsklinikum Tübingen (UKT)
Purified Human Allogeneic Pancreatic Islets of Langerhans		3/9/2020	Treatment of Brittle Type 1 Diabetes	Designated	Not FDA Approved for Orphan Indication	University of Minnesota
sodium valproate		3/9/2020	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	Cereno Scientific AB
Sodium (R)-2-(5-(2-(3-ethylureido)-5-fluoro-4-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)propan-2-yl hydrogen phosphate		3/9/2020	Treatment of Nontuberculous mycobacteria infection	Designated	Not FDA Approved for Orphan Indication	"Spero Therapeutics, Inc."
Adeno-Associated Virus Serotype 2 capsid variant (4D-C102) carrying a transgene encoding a codon-optimized human alpha-galactosidase A gene		3/9/2020	Treatment of Fabry Disease	Designated	Not FDA Approved for Orphan Indication	"4D Molecular Therapeutics, Inc."
sotigalimab		3/9/2020	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Pyxis Oncology, Inc."
umbralisib	Ukoniq	3/4/2020	Treatment of Follicular Lymphoma	Designated/Approved		"TG Therapeutics, Inc."
Phosphorodiamidate morpholino oligomer (5¿- CTATATATAGTTATTCAACA -3¿)		3/4/2020	Treatment of Spinal Muscular Atrophy	Designated	Not FDA Approved for Orphan Indication	"Shift Pharmaceuticals Holdings, Inc."
Glucagon-like peptide-1/Glucagon/Gastric inhibitory polypeptide triple agonist linked to human IgG4 Fc fragment		3/4/2020	Treatment of primary sclerosing cholangitis	Designated	Not FDA Approved for Orphan Indication	"Hanmi Pharmaceutical Company, Ltd."
setmelanotide		3/4/2020	Treatment of Alström syndrome	Designated	Not FDA Approved for Orphan Indication	"Rhythm Pharmaceuticals, Inc"
autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin		3/4/2020	Treatment of cystinosis	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
"Particles comprised ofmethacrylic acid based co-polymer, cross-linked with a bi-functional cross-linker, purified to bind L-phenylalanine and L-phenylalanine containing peptides"		2/27/2020	Treatment of hyperphenylalaninemia	Designated	Not FDA Approved for Orphan Indication	MipSalus ApS
phenobarbital sodium		2/27/2020	Treatment of neonatal seizures	Designated	Not FDA Approved for Orphan Indication	"Nivagen Pharmaceuticals, Inc."
Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signaling domains		2/26/2020	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	"Arcellx, Inc."
vidutolimod		2/26/2020	Treatment of Stage IIb to IV Melanoma	Designated	Not FDA Approved for Orphan Indication	Regeneron Pharmaceuticals Inc.
Phenobarbital		2/26/2020	Treatment of Neonatal seizures	Designated	Not FDA Approved for Orphan Indication	Accord Healthcare Inc.
anti-EGFR VHH Fragment Fused to Cytosine Deaminase		2/26/2020	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Lumosa Therapeutics Co., Ltd."
phenobarbital sodium		2/26/2020	Treatment of status epilepticus	Designated	Not FDA Approved for Orphan Indication	Accord Healthcare Inc.
Adeno Associated Virus Serotype 8 Encoding the Collagen Q Gene		2/24/2020	Treatment of Collagen Q Congenital Myasthenia	Designated	Not FDA Approved for Orphan Indication	Amplo Biotechnology Inc.
fibrinogen-depleted human platelet lysate		2/24/2020	Treatment of ocular graft-versus-host disease	Designated	Not FDA Approved for Orphan Indication	Cambium Medical Technologies LLC
sepiapterin		2/19/2020	Treatment of primary tetrahydrobiopterin deficiency	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc. (PTC)"
Recombinant human alpha-1 antitrypsin from Oryza sativa		2/19/2020	Treatment of alpha-1 antitrypsin deficiency	Designated	Not FDA Approved for Orphan Indication	Wuhan Healthgen Biotechnology Corporation
etavopivat		2/19/2020	Treatment of Sickle Cell Disease	Designated	Not FDA Approved for Orphan Indication	"FORMA Therapeutics, Inc."
A recombinant humanized IgG1 monoclonal antibody targeting programmed death-ligand 1		2/13/2020	Treatment of Nasopharyngeal carcinoma	Designated	Not FDA Approved for Orphan Indication	"Harbour BioMed US, Inc."
"5-fluoro-2-(6-fluoro-2-methyl-1H-benzo[d]imidazole-1-yl)-N4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine"		2/13/2020	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
sodium fusidate		2/13/2020	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	Arnasi LLC
Pyronaridine tetraphosphate		2/11/2020	Treatment of Malaria	Designated	Not FDA Approved for Orphan Indication	"Collaborations Pharmaceuticals, Inc."
Progranulin		2/10/2020	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"Alpha Cognition, Inc."
cell-penetrating CCAAT-enhancer-binding protein ß antagonist		2/5/2020	Treatment of Glioma	Designated	Not FDA Approved for Orphan Indication	"Sapience Therapeutics, Inc"
Progerinin		2/5/2020	Treatment of Werner syndrome	Designated	Not FDA Approved for Orphan Indication	"PRG S&T Co., Ltd."
small interfering RNA targeting TGF-Beta1 and COX-2 mRNA		2/5/2020	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"Sirnaomics, Inc."
"4-fluoro-5-((6-methylhexahydropyrrolo[3,4-b] pyrrol-5(1H)-yl) sulfonyl) isoquinoline"		2/5/2020	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"The National Institutes of Pharmaceutical R&D Co., Ltd"
Aggregated polymer of protein magnesium ammonium phospholinoleate-palmitoleate anhydride		2/4/2020	Treatment of Schistosomiasis	Designated	Not FDA Approved for Orphan Indication	Farmabrasilis
Peptide Inhibitor of Complement C1		1/29/2020	Treatment of neonatal hypoxic-ischemic encephalopathy	Designated	Not FDA Approved for Orphan Indication	"ReAlta Life Sciences, Inc."
"(2R,4R)-1-(3-chloro-2-fluorobenzyl)-4-((3-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)methyl)-2-methylpiperidine-4-carboxylic acid; 2- methylpropan-2-amine"		1/29/2020	Treatment of Neuroblastoma	Designated	Not FDA Approved for Orphan Indication	Eli Lilly and Company
di-deuterated linoleic acid		1/28/2020	Treatment of Progressive Supranuclear Palsy	Designated	Not FDA Approved for Orphan Indication	"Retrotope, Inc."
Umbilical Cord Mesenchymal Stem Cells		1/28/2020	Treatment of Huntington’s disease	Designated	Not FDA Approved for Orphan Indication	"Acen Regenerative Medicine Sci-Tech Co., Ltd."
Immune Globulin Intravenous (Human)		1/28/2020	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	CSL Behring
Autologous Desmoglein 3 (DSG3) Chimeric Autoantibody Receptor-directed (CAAR) T cells		1/28/2020	Treatment of pemphigus vulgaris	Designated	Not FDA Approved for Orphan Indication	"Cabaletta Bio, Inc."
recombinant adeno-associated virus serotype 9 constitutively expressing codon optimized coding sequence of human GBA1		1/27/2020	Treatment of Gaucher disease	Designated	Not FDA Approved for Orphan Indication	Prevail Therapeutics
Ziritaxestat		1/27/2020	Treatment of systemic sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Galapagos NV
losmapimod		1/27/2020	Treatment of Facioscapulohumeral muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	"Fulcrum Therapeutics, Inc."
"(1S)-6-chloro-1,3,4,9-tetrahydro-1-(4-methoxyphenyl)-2H-pyrido[3,4-b]indole-2-carboxylic acid, 4-chlorophenyl ester"		1/27/2020	Treatment of Acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
dual E-selectin and C-X-C chemokine receptor Type 4 (CXCR4) antagonist that targets both E-selectin and CXCR4		1/27/2020	Treatment of osteosarcoma	Designated	Not FDA Approved for Orphan Indication	"GlycoMimetics, Inc."
Recombinant adeno-associated virus serotype 8 (rAAV2/8) vector expressing bioengineered B domain deleted liver-codon-optimized human factor VIII		1/27/2020	Treatment of Hemophilia A	Designated	Not FDA Approved for Orphan Indication	"ASC Therapeutics, Inc."
Adeno-associated virus serotype 9 vector encoding the Dok7 protein		1/23/2020	Treatment of Dok7 Myasthenia	Designated	Not FDA Approved for Orphan Indication	Amplo Biotechnology Inc.
Melatonin		1/22/2020	Treatment of primary intracerebral hemorrhage	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
Allogeneic CD3+ T lymphocytes ex vivo expanded expressing the Vgamma9Vdelta2 T-cell receptor		1/16/2020	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	TC BioPharm Ltd
olorofim		1/16/2020	Treatment of invasive aspergillosis	Designated	Not FDA Approved for Orphan Indication	F2G Limited
Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human gp91phox gene		1/16/2020	Treatment of X-linked chronic granulomatous disease (X-CGD)	Designated	Not FDA Approved for Orphan Indication	Orchard Therapeutics (Europe) Limited
luspatercept		1/16/2020	Treatment of myelofibrosis	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
Envafolimab		1/16/2020	Treatment of biliary tract cancer	Designated	Not FDA Approved for Orphan Indication	"3D Medicines (Sichuan) Co., Ltd"
Humanized Anti-Globo H Monoclonal Antibody Monomethyl Auristatin E Conjugate		1/15/2020	Treatment of Gastric cancer	Designated	Not FDA Approved for Orphan Indication	"OBI Pharma USA, Inc."
Adeno-associated virus serotype 9 vector containing human Nacetylgalactosamine-6-sulfate sulfatase gene		1/15/2020	Treatment of mucopolysaccharidosis type IVA (Morquio A Syndrome)	Designated	Not FDA Approved for Orphan Indication	"Esteve Pharmaceuticals, S.A."
Olorofim		1/15/2020	Treatment of lomentospora/scedosporium infections	Designated	Not FDA Approved for Orphan Indication	F2G Limited
tremelimumab-actl	Imjudo	1/15/2020	Treatment of hepatocellular carcinoma	Designated/Approved		AstraZeneca Pharmaceuticals LP
durvalumab	Imfinzi	1/15/2020	Treatment of hepatocellular carcinoma	Designated/Approved		AstraZeneca Pharmaceuticals LP
Fasudil		1/15/2020	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"Woolsey Pharmaceuticals, Inc."
"5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine"		1/14/2020	Treatment of sarcoidosis	Designated	Not FDA Approved for Orphan Indication	Molecure S.A. (previously OncoArendi S.A.)
(R)-3-[(4-{1-[1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-8-yl)-pyrrolidin-3-yl-cyclopropyl]-methylamino}-piperidin-1-ylimino)-methylenyl]-rifamycin		1/14/2020	Treatment of prosthetic joint infection	Designated	Not FDA Approved for Orphan Indication	TenNor Therapeutics Limited
Autologous CD34+ cells transduced with gamma globin lentiviral vector		1/14/2020	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	Cincinnati Children’s Hospital Medical Center
An Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua (AAV8.ss-3xCRM8-TTRFIX_R338Lopt)		1/13/2020	Treatment of Hemophilia B	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Baxalta US Inc.
Manganese butoxyethyl pyridyl porphyrin		1/9/2020	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"BioMimetix JV, LLC"
fixed-dose combination of celecoxib and ciprofloxacin.		1/8/2020	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	NeuroSense Therapeutics
"Autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane bound Interleukin-15, and a truncated form of human HER1t (kill switch) on the cell surface."		12/31/2019	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Precigen
recombinant adeno-associated viral vector serotype 8 encoding human acid alpha-glucosidase		12/31/2019	Treatment of Pompe Disease	Designated	Not FDA Approved for Orphan Indication	"Astellas Gene Therapies, Inc."
upadacitinib		12/30/2019	Treatment of pediatric ulcerative colitis	Designated	Not FDA Approved for Orphan Indication	AbbVie
"Natural Regulatory T Cells (T-Regs), Expanded with Interleukin-2, ExpAct Beads (CD3/CD28; Miltenyi), Rapamycin and Transforming Growth Factor-beta"		12/23/2019	Prevention of graft rejection following solid organ transplantation	Designated	Not FDA Approved for Orphan Indication	"TRACT Therapeutics, Inc."
18-(p-[131I]-iodophenyl)octadecyl phosphocholine		12/23/2019	Treatment of Lymphoplasmacytic Lymphoma/Waldenstrom macroglobulinemia	Designated	Not FDA Approved for Orphan Indication	"Cellectar Biosciences, Inc."
"Anti-vascular endothelial growth factor, anti-hepatocyte growth factor Designed Ankyrin Repeat Protein"		12/23/2019	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Molecular Partners AG
Mycobacterium vaccae		12/23/2019	Treatment of Tuberculosis	Designated	Not FDA Approved for Orphan Indication	Immunitor Inc.
"atoltivimab, odesivimab and maftivimab"		12/23/2019	Post-exposure prophylaxis against Ebola virus infection	Designated	Not FDA Approved for Orphan Indication	"Regeneron Pharmaceuticals, Inc."
Humanized Anti-Globo H Monoclonal Antibody Monomethyl Auristatin E Conjugate		12/23/2019	Treatment of Pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"OBI Pharma USA, Inc."
Self complimentary adeno-associated virus serotype 9 expressing human aspartoacylase transgene		12/23/2019	Treatment of Canavan Disease	Designated	Not FDA Approved for Orphan Indication	"Aspa Therapeutics, Inc."
fusion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein		12/19/2019	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	"Molecular Templates, Inc."
recombinant human growth hormone fused to alpha1-antitrypsin variant		12/19/2019	Treatment of Growth Hormone Deficiency	Designated	Not FDA Approved for Orphan Indication	"Alteogen, Inc."
avatrombopag maleate		12/19/2019	Treatment of chemotherapy-induced thrombocytopenia	Designated	Not FDA Approved for Orphan Indication	"Sobi, Inc."
zanidatamab		12/18/2019	Treatment of Biliary Tract Cancer	Designated	Not FDA Approved for Orphan Indication	Jazz Pharmaceuticals Ireland Limited
Allogeneic gene edited BCMA-directed CAR T cells		12/18/2019	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Precision BioSciences, Inc."
autologous T cells expressing a transmembrane chimeric antigen receptor (CAR) to target anti-delta-like ligand 3		12/18/2019	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
Magrolimab		12/18/2019	Treatment of Myelodysplastic Syndrome	Designated	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
mobocertinib	Exkivity	12/17/2019	"Treatment of non-small cell lung cancer with genetic alterations in EGFR including EGFR mutations and/or EGFR gene amplifications, HER2 mutations, or BRAF G466V mutations"	Designated/Approved		"Takeda Development Center Americas, Inc."
Salinomycin		12/12/2019	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Hillstream Biopharma, Inc."
dantrolene		12/12/2019	Treatment of organophosphate exposure	Designated	Not FDA Approved for Orphan Indication	"Eagle Pharmaceuticals, Inc."
pioglitazone		12/12/2019	Treatment of sudden sensorineural hearing loss	Designated	Not FDA Approved for Orphan Indication	Strekin AG
Reldesemtiv		12/11/2019	Treatment of Amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"Cytokinetics, Inc."
Oncolytic Herpes Simplex Virus Expressing IL-12 - M032		12/11/2019	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	University of Alabama at Birmingham
Placenta-Derived Decidua Stromal Cells		12/9/2019	Treatment of graft versus host disease	Designated	Not FDA Approved for Orphan Indication	"ASC Therapeutics, Inc."
nipocalimab		12/5/2019	Treatment of autoimmune hemolytic anemia	Designated	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
Non-replicating recombinant adeno-associated virus serotype 9 containing the progranulin gene		12/5/2019	Treatment of frontotemporal dementia	Designated	Not FDA Approved for Orphan Indication	Prevail Therapeutics
nandrolone		12/4/2019	Treatment of limb-girdle muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	Sarcomed AB
brivaracetam		12/3/2019	Treatment of Childhood Absence Epilepsy	Designated	Not FDA Approved for Orphan Indication	"UCB, Inc."
brivaracetam		12/3/2019	Treatment of Juvenile Absence Epilepsy	Designated	Not FDA Approved for Orphan Indication	"UCB, Inc."
Romiplostim		11/27/2019	Treatment of aplastic anemia	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
delta-9-tetrahydrocannabinol		11/27/2019	Treatment of Hepatocellular Carcinoma	Designated	Not FDA Approved for Orphan Indication	Tetra Bio-Pharma Inc.
"Non-replicating recombinant, self-complementary adeno-associated virus serotype 9 containing the human CLN6 gene"		11/27/2019	Treatment of CLN6 Batten Disease	Designated	Not FDA Approved for Orphan Indication	Nationwide Children's Hospital
"Hypotonic, acid oxidizing solution containing hypochlorous acid (HClO)"		11/26/2019	Treatment of Epidermolysis Bullosa	Designated	Not FDA Approved for Orphan Indication	APR Applied Pharma Research s.a.
"4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4- methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide, (2Z)-2-butenedioate (1:2), Sesquihydrate"		11/26/2019	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Shanghai Fosun Pharmaceutical Development Co., Ltd."
"1-(4-Chloro-3,5-diphenyl-pyrazolo[3,4-c]pyridazin-1-yl)-2-methyl-propan-2-ol"		11/26/2019	Treatment of Usher syndrome	Designated	Not FDA Approved for Orphan Indication	"Usher III Initiative, Inc."
Recombinant Bispecific antibody targeting CD123 and CD3		11/26/2019	Treatment of acute myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	Aptevo Research and Development
"Non-replicating recombinant, self-complementary adeno-associated virus serotype 9 containing the human CLN3 gene"		11/26/2019	Treatment of CLN3 Batten Disease	Designated	Not FDA Approved for Orphan Indication	Nationwide Children's Hospital
nicardipine		11/26/2019	Treatment of Pitt-Hopkins Syndrome	Designated	Not FDA Approved for Orphan Indication	"Collaborations Pharmaceuticals, Inc."
dalfampridine		11/25/2019	Treatment of Transverse Myelitis	Designated	Not FDA Approved for Orphan Indication	Magnum Therapeutics
selpercatinib	Retevmo	11/21/2019	"Treatment of RET fusion-positive or RET mutant thyroid cancers including poorly differentiated thyroid cancer, undifferentiated or anaplastic thyroid cancer, medullary thyroid cancer, and locally advanced or metastatic follicular or papillary thyroid canc"	Designated/Approved		"Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company"
"5-(3,6-dibromo-9H-carbazol-9-yl)-N,N,N-trimethylpentan-1-aminium chloride"		11/21/2019	Treatment of Dercum’s disease (adiposis dolorosa)	Designated	Not FDA Approved for Orphan Indication	"Raziel Therapeutics, Inc."
zotiraciclib		11/21/2019	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"Cothera Bioscience, Inc."
surufatinib		11/21/2019	Treatment of pancreatic neuroendocrine tumors	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Hutchison MediPharma Ltd.
selpercatinib	RETEVMO	11/21/2019	"Treatment of RET fusion-positive or RET mutant thyroid cancers including poorly differentiated thyroid cancer, undifferentiated or anaplastic thyroid cancer, medullary thyroid cancer, and locally advanced or metastatic follicular or papillary thyroid canc"	Designated/Approved		"Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company"
Tislelizumab		11/20/2019	Treatment of Hepatocellular Carcinoma	Designated	Not FDA Approved for Orphan Indication	"BeiGene USA, Inc."
"2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl) acetamide monohydrate"		11/20/2019	Treatment of myelofibrosis	Designated	Not FDA Approved for Orphan Indication	Constellation Pharmaceuticals
Purified bovine Type V Collagen		11/20/2019	Prevention of Primary Graft Dysfunction in Lung Transplant Patients.	Designated	Not FDA Approved for Orphan Indication	Magnolia Therapeutics LLC
navitoclax		11/18/2019	Treatment of myelofibrosis	Designated	Not FDA Approved for Orphan Indication	AbbVie Inc.
antisense oligonucleotide targeting the P23H mutation of the RHO gene		11/18/2019	Treatment of retinal dystrophy dut to the P23H gene mutation (retinitis pigmentosa)	Designated	Not FDA Approved for Orphan Indication	ProQR Therapeutics IV B.V.
alpelisib	Vijoice	11/18/2019	Treatment of PIK3CA-related overgrowth spectrum	Designated/Approved		Novartis Pharmaceuticals Corporation
alpelisib	Vijoice	11/18/2019	Treatment of PIK3CA-related overgrowth spectrum	Designated/Approved		Novartis Pharmaceuticals Corporation
humanized bi-specific XmAb(R) T cell recruiting antibody construct directed against CD3 and CD38		11/14/2019	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Xencor, Inc."
Single stranded adeno-associated virus vector encoding beta-galactosidase-1		11/14/2019	Treatment of GM1 gangliosidosis	Designated	Not FDA Approved for Orphan Indication	Axovant Sciences
tislelizumab-jsgr	Tevimbra	11/6/2019	Treatment of Esophageal Cancer	Designated/Approved		"BeiGene USA, Inc."
Autologous auricular cartilage construct for subcutaneous implantation		11/6/2019	Treatment of microtia (including anotia)	Designated	Not FDA Approved for Orphan Indication	"PrintBio, Inc."
"4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b] pyrido[4,3-e][1,4]diazepin-8-yl) morpholine"		11/6/2019	treatment of cholangiocarcinoma	Designated	Not FDA Approved for Orphan Indication	"TransThera Sciences (Nanjing), Inc."
autologous enriched T cells transduced with a lentiviral vector to express an anti-CD19 Chimeric Antigen Receptor		11/4/2019	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	"Autolus Incorporated, US subsidiary of Autolus Limited"
selpercatinib	RETEVMO	10/30/2019	Treatment of RET-fusion-positive non-small cell lung cancer	Designated/Approved		"Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company"
selpercatinib	Retevmo	10/30/2019	Treatment of RET-fusion-positive non-small cell lung cancer	Designated/Approved		"Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company"
"Recombinant humanized, non-fucosylated IgG1 anti-Siglec-8 monoclonal antibody"		10/30/2019	Treatment of eosinophilic esophagitis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Allakos, Inc."
vasopressin 1a receptor antagonist		10/30/2019	Treatment of Huntington's disease	Designated	Not FDA Approved for Orphan Indication	"Azevan Pharmaceuticals, Inc."
Proliferation arrested myelomonocytic leukemic cell line-derived cells with a mature dendritic cell phenotype		10/30/2019	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	Mendus BV
"Lu-177(3+),2-[[5-(2,6-dimethoxyphenyl)-1-[2-isopropyl-4-[methyl-[3-[methyl-[3-[methyl-[2-[4,7,10- tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]propyl]amino]propyl]carbamoyl]phenyl]pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid"		10/28/2019	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Fusion Pharmaceuticals Inc.
monobenzone and imiquimod		10/28/2019	Treatment of stage IIB-IV melanoma	Designated	Not FDA Approved for Orphan Indication	"Learmont Pharmaceuticals, Inc."
Human Alpha1-proteinase inhibitor		10/22/2019	Treatment of graft versus host disease	Designated	Not FDA Approved for Orphan Indication	CSL Behring
hydroxypropyl-B-cyclodextrin-panobinostat complex		10/22/2019	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Biodexa Ltd.
"acetic acid, propionic acid, and butyric acid"		10/22/2019	Treatment of Hepatocellular Carcinoma	Designated	Not FDA Approved for Orphan Indication	"SFA Therapeutics, Inc."
crenolanib		10/21/2019	"Treatment of gastric cancer, including cancer of the gastroesophageal junction"	Designated	Not FDA Approved for Orphan Indication	"AROG Pharmaceuticals, Inc."
recombinant human interleukin 22-human immunoglobulin Fc fusion protein		10/21/2019	Treatment of acute graft versus host disease	Designated	Not FDA Approved for Orphan Indication	Generon (Shanghai) Corporation Ltd.
adeno-associated virus serotype 2/6 encoding a human alpha-galactosidase A cDNA		10/21/2019	Treatment of Fabry Disease	Designated	Not FDA Approved for Orphan Indication	"Sangamo Therapeutics, Inc."
Pyronaridine		10/21/2019	Treatment of Chagas Disease	Designated	Not FDA Approved for Orphan Indication	"Collaborations Pharmaceuticals, Inc."
Recombinant complement-specific multimerized human IgG1 Fc		10/21/2019	Treatment of autoimmune hemolytic anemia	Designated	Not FDA Approved for Orphan Indication	"Gliknik, Inc."
adeno-associated virus vector encoding human phenylalanine hydroxylase		10/21/2019	Treatment of phenylketonuria	Designated	Not FDA Approved for Orphan Indication	"BioMarin Pharmaceutical, Inc."
CD3 and B-cell maturation antigen T-cell engaging bispecific antibody		10/17/2019	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	"TeneoOne, Inc."
Cyclo(-L-Glycyl-L-2-Allylproline)		10/15/2019	Treatment of Pitt-Hopkins Syndrome	Designated	Not FDA Approved for Orphan Indication	"Neuren Pharmaceuticals, Ltd."
Cyclo(-L-Glycyl-L-2-Allylproline)		10/15/2019	Treatment of Phelan-McDermid syndrome	Designated	Not FDA Approved for Orphan Indication	"Neuren Pharmaceuticals, Ltd."
glyceryl tribenzoate		10/15/2019	Treatment of nonketotic hyperglycinemia	Designated	Not FDA Approved for Orphan Indication	Liberyx Therapeutics Limited
"(S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 4-(2-(5-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)-1H-indol-1-yl)ethyl)piperidine-1-carboxylate"		10/10/2019	Treatment of Small Cell Lung Cancer	Designated	Not FDA Approved for Orphan Indication	"Tarveda Therapeutics, Inc."
cyclo(-L-Glycyl-L-2-Allylproline)		10/9/2019	Treatment of Angelman syndrome	Designated	Not FDA Approved for Orphan Indication	"Neuren Pharmaceuticals, Ltd."
pazopanib		10/9/2019	Treatment of hereditary hemorrhagic telangiectasia	Designated	Not FDA Approved for Orphan Indication	HHT Foundation International (d/b/a Cure HHT)
parsaclisib		10/9/2019	Treatment of extranodal marginal zone lymphoma	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
pembrolizumab	Keytruda	10/9/2019	Treatment of Biliary Tract Carcinoma	Designated/Approved		"Merck Sharp & Dohme, LLC"
melatonin		10/9/2019	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
a small molecule tissue-nonspecific alkaline phosphatase inhibitor		10/7/2019	Treatment of Pseudoxanthoma elasticum	Designated	Not FDA Approved for Orphan Indication	"Daiichi Sankyo, Inc."
parsaclisib		10/7/2019	Treatment of nodal marginal zone lymphoma	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
Encochleated oral Amphotericin B suspension		10/3/2019	Treatment of cryptococcosis	Designated	Not FDA Approved for Orphan Indication	"Matinas BioPharma Nanobiotechnologies, Inc."
phenobarbital sodium	Sezaby	10/2/2019	Treatment of neonatal seizures	Designated/Approved		"Sun Pharmaceutical Industries, Inc."
duvelisib		10/2/2019	Treatment of T-Cell Lymphoma	Designated	Not FDA Approved for Orphan Indication	"Secura Bio, Inc."
autologous CD34+ cell enriched hematopoietic stem cells genetically modified ex vivo with a lentiviral vector to contain codon-optimized complementary deoxyribonucleic acid that encodes human beta-glucocerebrosidase		9/25/2019	Treatment of Gaucher disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AVROBIO, Inc."
Parsaclisib		9/25/2019	Treatment of Follicular Lymphoma	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
Caflanone		9/25/2019	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	Flavocure Biotech
"(1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione and [(1E,4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]"		9/24/2019	Treatment of spinocerebellar ataxia	Designated	Not FDA Approved for Orphan Indication	AnnJi Pharmaceutical Co. Ltd.
setmelanotide	Imcivree	9/19/2019	Treatment of Bardet-Biedl syndrome	Designated/Approved		"Rhythm Pharmaceuticals, Inc."
"L-Lysinamide,N2,N6-bis(L-lysylglycyl-L-valyl-L-seryl-L-leucyl-L-seryl-L-tyrosyl-L-arginyl)-hexa-acetate salt"		9/18/2019	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	TCM Biotech International Corp.
linerixibat		9/18/2019	Treatment of Primary Biliary Cholangitis	Designated	Not FDA Approved for Orphan Indication	GlaxoSmithKline
Humanized connexin 43 (hCx43) monoclonal antibody		9/18/2019	Treatment of Osteosarcoma	Designated	Not FDA Approved for Orphan Indication	"AlaMab Therapeutics, Inc."
10-nitro-9(E)-octadec-9-enoic acid		9/12/2019	Treatment of pulmonary arterial hypertension	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Complexa, Inc."
nomacopan		9/12/2019	Treatment of bullous pemphigoid	Designated	Not FDA Approved for Orphan Indication	Akari Therapeutics Plc
tacrolimus	Prograf	9/12/2019	Prevention of rejection in lung transplantation	Designated/Approved		"Astellas Pharma Global Development, Inc."
bispecific Antibody simultaneously targeting CD38 and CD3		9/11/2019	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Ichnos Sciences, Inc."
infigratinib	Truseltiq	9/11/2019	Treatment of cholangiocarcinoma	Designated/Approved/Designation Withdrawn or Revoked		"QED Therapeutics, Inc."
"2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate"		9/11/2019	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	"Ategrin, Inc."
allogeneic gene edited CD20-directed CAR (Chimeric Antigen Receptor) T cells		9/11/2019	Treatment of Mantle Cell Lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Precision BioSciences, Inc."
bispecific T cell engager antibody construct with a half-life extension Fc moiety capable of binding to the neonatal Fc receptor		9/11/2019	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
deoxynucleogen		9/10/2019	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"CLS Therapeutics, Inc"
"drug component, inhaled nitric oxide, of the inhaled nitric oxice/INOpulse® Device combination product"		9/10/2019	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	Bellerophon Therapeutics
parsaclisib		9/10/2019	Treatment of splenic marginal zone lymphoma	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
glycerol tribenzoate		9/10/2019	Treatment of Huntington’s disease	Designated	Not FDA Approved for Orphan Indication	Forest Hills Partners Hong Kong Limited
quinacrine		9/10/2019	Treatment of Ebola Infection	Designated	Not FDA Approved for Orphan Indication	"Collaborations Pharmaceuticals, Inc."
fasudil		9/5/2019	Treatment of subarachnoid hemorrhage	Designated	Not FDA Approved for Orphan Indication	"Aneuryst, Inc."
sotatercept-csrk	Winrevair	9/5/2019	Treatment of pulmonary arterial hypertension	Designated/Approved		Merck Sharp & Dohme LLC
PEGylated recombinant human tumor necrosis factor-related apoptosis inducing ligand		9/5/2019	Treatment of chronic pancreatitis.	Designated	Not FDA Approved for Orphan Indication	"Theraly Fibrosis, Inc."
nomacopan		8/28/2019	Treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy	Designated	Not FDA Approved for Orphan Indication	Akari Therapeutics Plc
"An asymmetric immunoglobulin G1 (IgG1)-based, B-cell maturation antigen (BCMA) x CD3 T-cell bispecific monoclonal antibody"		8/28/2019	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	CELGENE INTERNATIONAL II SARL
Fully Human Anti-BCMA (B-Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cell		8/28/2019	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	CARsgen Therapeutics Corporation
Chimeric locked nucleic acid and ribonucleic-deoxyribonucleic antisense oligonucleotide specific for the human UBE3A-antisense transcript		8/28/2019	Treatment of Angelman syndrome	Designated	Not FDA Approved for Orphan Indication	Ultragenyx Pharmaceutical Inc.
sirolimus		8/26/2019	Treatment of tuberous sclerosis complex	Designated	Not FDA Approved for Orphan Indication	"AI Therapeutics, Inc."
(E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate		8/26/2019	Treatment of Pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"CG Pharmaceuticals, Inc."
zilucoplan	Zilbrysq	8/26/2019	Treatment of myasthenia gravis	Designated/Approved		"UCB, Inc."
benralizumab		8/26/2019	Treatment of eosinophilic esophagitis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals LP
Specific Peptide Enhanced Affinity Receptor T cell product comprised of autologous CD4 and CD8 positive T cells genetically engineered with an affinity-enhanced T cell receptor to target cancer-testis antigen MAGE-A4		8/26/2019	Treatment of Soft Tissue Sarcoma	Designated	Not FDA Approved for Orphan Indication	"Adaptimmune, LLC"
neratinib		8/26/2019	Treatment of breast cancer patients with brain metastases	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Puma Biotechnology Inc.
Propranolol		8/23/2019	Treatment of retinopathy of prematurity	Designated	Not FDA Approved for Orphan Indication	"Recordati Rare Diseases, SARL"
"(1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione and [(1E,4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]"		8/23/2019	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	Allianz Pharmascience Limited
pemigatinib	Pemazyre	8/21/2019	"Treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2"	Designated/Approved		Incyte Corporation
"Cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer modified alginate spheres"		8/21/2019	Treatment of Hemophilia A	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sigilon Therapeutics, Inc."
18F-meta-fluorobenzylguanidine		8/21/2019	Diagnostic for the management of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	"Innervate Radiopharmaceuticals, LLC"
dupilumab		8/21/2019	Treatment of bullous pemphigoid	Designated	Not FDA Approved for Orphan Indication	"Regeneron Pharmaceuticals, Inc."
small molecule inhibitor of the pro-survival protein Myeloid Cell Leukemia sequence 1 (MCL1)		8/21/2019	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
cedazuridine and decitabine	Inqovi	8/21/2019	Treatment of myelodysplastic syndromes (including chronic myelomonocytic leukemia)	Designated/Approved		"Astex Pharmaceuticals, Inc."
Talabostat		8/21/2019	Treatment of acute myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	"BioXcel Therapeutics, Inc."
Romilkimab		8/21/2019	Treatment of systemic sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Sanofi U.S. Service Inc.
"Bismuth-1,2-ethanedithiol; 1,2-Bis-((1,3-dithia-2-bismolan)-2-yl) thioethane"		8/21/2019	Treatment (management) of pulmonary infections in patients with Cystic Fibrosis	Designated	Not FDA Approved for Orphan Indication	Microbion Corporation
Adeno-Associated Virus containing the gene for human Nuclear Hormone Receptor NR2E3 (AAV-hNR2E3)		8/20/2019	Treatment of CEP290 mutation associated retinal disease.	Designated	Not FDA Approved for Orphan Indication	Ocugen Inc.
"DNA, (Cm-Gm-Gm-Gm-G-T-G-T-G-G-G-T-T-C-G-T-C-G-T-T-A-G-C-T-T-G-A-T-T-T-G-G-C-A-G-C-Um-Gm-Cm-Cm-(3'¿3')-dT), 5'-ester with [[5-(phosphoonoxy) pentyl] amino] carbonyl-oxy-1, 2-ethanediyl, sodium salt"		8/19/2019	Treatment of Osteogenesis Imperfecta	Designated	Not FDA Approved for Orphan Indication	Aptacure Therapeutics Limited
neutralizing equine anti-Stx hyperimmune immunoglobulin F(ab')2 fragment		8/19/2019	Treatment of Shiga-toxin producing bacterial infection as it relates to the prevention of hemolytic uremic syndrome	Designated	Not FDA Approved for Orphan Indication	Inmunova SA
cannabidiol		8/15/2019	Treatment of childhood absence epilepsy	Designated	Not FDA Approved for Orphan Indication	"Radius Pharmaceuticals, Inc."
Lentiviral vector expressing human fumarylacetoacetate hydrolase		8/8/2019	Treatment of hereditary tyrosinemia type I	Designated	Not FDA Approved for Orphan Indication	"Castle Creek Biosciences, LLC"
"4-(4-((4-chloro-3-(trifluoromethyl)phenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione"		8/8/2019	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"Neuropore Therapies, Inc."
clazakizumab		8/8/2019	Treatment of chronic antibody-mediated rejection in kidney transplant recipients	Designated	Not FDA Approved for Orphan Indication	CSL Behring
"1-(((Z)-hexadec-1-en-1-yl)oxy)-3-((2-oxido-1,3,2-oxazaphospholidin-2-yl)oxy)propan-2-yl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate"		8/8/2019	Treatment of Rhizomelic Chondrodysplasia Punctata	Designated	Not FDA Approved for Orphan Indication	"Med-Life Discoveries, LP"
perfluorooctyl-bromide		8/8/2019	Treatment of congenital pulmonary hypoplasia in infancy	Designated	Not FDA Approved for Orphan Indication	Children’s Hospital of Pennsylvania
"(R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4-yl)pyridin-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate"		8/8/2019	Treatment of fibrodysplasia ossificans progressiva	Designated	Not FDA Approved for Orphan Indication	"Clementia Pharmaceuticals, Inc."
sargramostim		8/8/2019	Treatment of Stage IIb-IV melanoma	Designated	Not FDA Approved for Orphan Indication	"Partner Therapeutics, Inc."
5¿-cEtG-sp-cEt5MeU-sp-cEt5MeU-sp-dT-sp-dA-sp-dT-sp-dT-sp-dA-sp-dT-sp-dA-sp-dG-sp-dG-sp-dG-sp-cEt5MeC-sp-cEt5MeU-sp-cEt5MeU-3¿		8/5/2019	Treatment of centronuclear myopathies	Designated	Not FDA Approved for Orphan Indication	Dynacure SAS
18-mer antisense oligonucleotide complementary to SCN1A mRNA		8/5/2019	Treatment of Dravet syndrome	Designated	Not FDA Approved for Orphan Indication	"Stoke Therapeutics, Inc."
"(2R,3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol Hydrogen Chloride"		8/5/2019	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"Daewoong Pharmaceutical Co., Ltd."
Temozolomide		8/1/2019	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	ORPHELIA Pharma
"(2S,3R,4R,5S)-2-(hydroxymethyl)-1-pentylpiperidine-3,4,5-triol"		8/1/2019	Treatment of GM2 gangliosidosis	Designated	Not FDA Approved for Orphan Indication	Idorsia Pharmaceuticals Ltd
leriglitazone		8/1/2019	Treatment of Friedreich´s ataxia	Designated	Not FDA Approved for Orphan Indication	Minoryx Therapeutics S.L.
1-{4-[2-(5-ethoxymethyl-2-methyl-phenylamino)-oxazol-5-yl]-phenyl}-imidazolidin-2-one		8/1/2019	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	AB Science
"calcium, magnesium, potassium, and sodium oxybates"	Xywav	7/31/2019	Treatment of idiopathic hypersomnia	Designated/Approved		Jazz Pharmaceuticals Ireland Limited
heparin sodium		7/29/2019	Treatment of Cystic Fibrosis	Designated	Not FDA Approved for Orphan Indication	Vectura Limited
elafibranor	Iqirvo	7/25/2019	Treatment of Primary Biliary Cholangitis	Designated/Approved		Ipsen Bioscience Inc.
Episcleral Topotecan		7/24/2019	Treatment of retinoblastoma	Designated	Not FDA Approved for Orphan Indication	"Targeted Therapy Technologies, LLC., DBA: 3T Ophthalmics"
"(S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 4-(2-(5-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)-1H-indol-1-yl)ethyl)piperidine-1-carboxylate"		7/24/2019	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Tarveda Therapeutics, Inc."
"(R)-6-((3,3-difluoro-1-methylpiperidine-4-yl)oxy-N-(3-ethynyl-2-fluorophenyl)-7-methoxyquinazolin-4-amine-,fumerate (2:1) (salt)"		7/24/2019	Treatment of glioma (including glioblastoma and anaplastic astrocytoma)	Designated	Not FDA Approved for Orphan Indication	Wayshine Biopharm Inc.
aflibercept	Eylea	7/23/2019	Treatment of Retinopathy of Prematurity	Designated/Approved		"Regeneron Pharmaceuticals, Inc."
a recombinant adeno-associated virus pseudotyped with serotype 5 viral capsid encoding CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) gene editing constructs		7/23/2019	Treatment of CEP290 gene mutations including Leber congenital amaurosis.	Designated	Not FDA Approved for Orphan Indication	Editas Medicine
artesunate		7/22/2019	Treatment of malaria	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	La Jolla Pharmaceutical Company
Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop-1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate		7/22/2019	Treatment of fatty acid oxidation disorders	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Reneo Pharma Ltd
Aripiprazole		7/22/2019	Treatment of N-glycanase 1 (NGLY1) deficiency	Designated	Not FDA Approved for Orphan Indication	Perlara PBC
"recombinant human anti-human sortilin (SORT1) IgG1 G1m17,1 [or G1m (z,a)] kappa monoclonal antibody"		7/22/2019	Treatment of Frontotemporal Dementia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Alector, Inc."
pozelimab		7/22/2019	Treatment of Paroxysmal Nocturnal Hemoglobinuria	Designated	Not FDA Approved for Orphan Indication	Regeneron Pharmaceuticals Inc
concizumab		7/22/2019	Treatment of hemophilia B	Designated	Not FDA Approved for Orphan Indication	"Novo Nordisk, Inc."
Allogeneic Human Pancreatic Islets of Langerhans		7/22/2019	Treatment of Brittle Type 1 Diabetes	Designated	Not FDA Approved for Orphan Indication	Hospital of the University of Pennsylvania (Penn Medicine)
"autologous T-cells genetically modified to express a CD123-specific, hinge-optimized, CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor"		7/22/2019	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Mustang Bio, Inc."
"(S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile"		7/22/2019	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Kura Oncology
"N-(4-amino-3,4-dioxo-1-phenylbutan-2-yl)-4-(2-fluorophenyl)-2-methyloxazole-5-carboxamide"		7/22/2019	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	"Blade Therapeutics, Inc."
Imidazopyridine		7/22/2019	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"1ST Biotherapeutics, Inc."
"(R)-N-(1-(1-(1H-indazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4,5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide"		7/18/2019	Treatment of idiopathic pulmonary fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"X-Rx, Inc."
humanized non-fucosylated anti-Siglec-8 monoclonal antibody (IgG1)		7/15/2019	Treatment of Mastocytosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Allakos Inc.
Zamicastat		7/15/2019	Treatment of pulmonary arterial hypertension (PAH) (pulmonary hypertension WHO Group 1)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bial-Portela & Cª., S.A."
"PEGylated 24-amino acid peptide inhibitor of Interleukin-2, Interleukin-9 and Interleukin-15"		7/15/2019	Treatment of cutaneous T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Equillium, Inc."
Double stranded oligomer RNA interference-based liver targeted therapeutic directed against the ANGPTL3 gene		7/15/2019	Treatment of homozygous familial hypercholesterolemia	Designated	Not FDA Approved for Orphan Indication	"Arrowhead Pharmaceuticals, Inc."
durvalumab	IMFINZI	7/10/2019	Treatment of small cell lung cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
afatinib		7/9/2019	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
bispecific T-cell engager (BiTE) antibody targeting CD33 and CD3		7/1/2019	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
apilimod dimesylate		7/1/2019	Treatment of follicular lymphoma	Designated	Not FDA Approved for Orphan Indication	"AI Therapeutics, Inc."
"non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the short hairpin RNA (shRNA) sequence against human SOD1 under the H1 promoter"		7/1/2019	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"AveXis, Inc."
Regorafenib		7/1/2019	Treatment of glioblastoma multiforme	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bayer HealthCare Pharmaceuticals, Inc."
mometasone furoate		6/26/2019	Treatment of eosinophilic esophagitis	Designated	Not FDA Approved for Orphan Indication	EsoCap AG
riociguat		6/26/2019	Treatment of Fontan-palliated patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bayer U.S. LLC
Ornithine transcarbamylase messenger RNA		6/26/2019	Treatment of Ornithine Transcarbamylase Deficiency	Designated	Not FDA Approved for Orphan Indication	"Arcturus Therapeutics, Inc."
Human monoclonal IgG2 antibody against tissue factor pathway inhibitor		6/25/2019	Treatment of Hemophilia B	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bayer HealthCare LLC
Kallikrein 7 and elastase 2 inhibitor		6/25/2019	Treatment of Netherton Syndrome	Designated	Not FDA Approved for Orphan Indication	"LifeMax Laboratories, Inc."
5-iodo-2-pyrimidinone-2¿deoxyribose		6/25/2019	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	"Shuttle Pharmaceuticals, LLC"
CD34+ hematopoietic stem and progenitor cells with CD3+ T-cells		6/25/2019	Prevention of graft rejection following solid organ transplantation	Designated	Not FDA Approved for Orphan Indication	"Medeor Therapeutics, Inc."
gallium citrate		6/24/2019	Treatment of lung infections in patients with cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Aridis Pharmaceuticals, Inc."
Double stranded oligomer ARO-APOC3 RNA interference-based liver targeted therapeutic		6/20/2019	Treatment of Familial Chylomicronemia Syndrome	Designated	Not FDA Approved for Orphan Indication	"Arrowhead Pharmaceuticals, Inc."
"L-Leucyl-L-prolyl-L-prolyl-L-leucyl-L-prolyl-L-tyrosyl-L-proline, acetate salt"		6/19/2019	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"Immunity Pharma, Ltd."
rexlemestrocel-L		6/19/2019	Prevention of post-LVAD (left ventricular assist device) implantation mucosal bleeding	Designated	Not FDA Approved for Orphan Indication	Mesoblast
Balipodect		6/19/2019	Treatment of CDKL5 deficiency disorder	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
"2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride"		6/17/2019	Treatment of beta-thalassemia	Designated	Not FDA Approved for Orphan Indication	"Vifor Pharma, Inc."
"adoptive, anti-FLT3 chimeric antigen receptor T cell therapy generated through transduction of autologous T-cells with a self-inactivating human immunodeficiency virus-1 based lentiviral vector"		6/13/2019	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
Balipodect		6/13/2019	Treatment of Fragile X Syndrome	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
parsaclisib		6/12/2019	Treatment of mantle cell lymphoma	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
4-((L-valyl)oxy)butanoic acid		6/12/2019	Treatment of Narcolepsy	Designated	Not FDA Approved for Orphan Indication	XWPharma Incorporated
Venetoclax		6/12/2019	Treatment of myelodysplastic syndromes	Designated	Not FDA Approved for Orphan Indication	AbbVie Inc.
Autologous CD34+ hematopoietic stem and progenitor cells transfected with zinc finger nuclease messenger RNAs SB-mRENH1 and SB-mRENH2		6/11/2019	Treatment of Sickle Cell Disease	Designated	Not FDA Approved for Orphan Indication	"Sangamo Therapeutics, Inc."
adeno-associated virus serotype rh10 encoding artificial anti-SOD1 miRNA		6/11/2019	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	uniQure Biopharma BV
fosgemcitabine palabenamide		6/11/2019	Treatment of biliary tract cancer	Designated	Not FDA Approved for Orphan Indication	NuCana plc
humanized anti CD20 monoclonal antibody		6/11/2019	Treatment of Dermatomyositis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Biocon Limited
"Insulin producing cells (autologous liver cells transduced by Ad5-CMV-MafA, Ad5-CMV-NeuroD1, and Ad5-CMV-PDX1)"		6/11/2019	Treatment of diabetes due to total pancreatectomy.	Designated	Not FDA Approved for Orphan Indication	"Orgenesis, Ltd."
flubrobenguane (18F)		6/4/2019	Diagnostic for the management of neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	"Lantheus Medical Imaging, Inc."
dornase alfa		6/4/2019	Treatment of sarcoidosis	Designated	Not FDA Approved for Orphan Indication	"SarcoMed USA, LLC"
72 amino acid proprietary recombinant protein antagonist for the CXCR1 and CXCR2 receptors of interleukin-8		6/4/2019	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	Rise Biopharmaceutical Ltd.
casimersen	Amondys 45	6/4/2019	Treatment of Duchenne muscular dystrophy	Designated/Approved		"Sarepta Therapeutics, Inc."
Allogeneic Human Pancreatic Islets of Langerhans		6/4/2019	Treatment of Brittle Type 1 Diabetes	Designated	Not FDA Approved for Orphan Indication	"University of California, San Francico"
autologous CD34+ hematopoietic stem and progenitor cells transfected with zinc finger nuclease messenger RNAs SB-mRENH1 and SB-mRENH2		6/4/2019	Treatment of beta-thalassemia	Designated	Not FDA Approved for Orphan Indication	"Sangamo Therapeutics, Inc."
4-Methyl-3-quinolin-3-ylethynylbenzoic acid N'-(2-chloro-6- methylbenzoyl) hydrazide		6/3/2019	Treatment of chronic myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Sun Pharma Advanced Research Company Ltd.
bardoxolone methyl		6/3/2019	Treatment of autosomal dominant polycystic kidney disease	Designated	Not FDA Approved for Orphan Indication	"Reata Pharmaceuticals, Inc."
Ac-Nle-cyclo-(Glu-His-D-Phe-Arg-Dap)-Trp-NH2		6/3/2019	"Treatment of non-infectious intermediate, posterior, pan, and chronic anterior uveitis"	Designated	Not FDA Approved for Orphan Indication	"Palatin Technologies, Inc."
"6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one"		5/23/2019	Treatment of KRAS (Kirsten rat sarcoma viral oncogene homolog) p.G12C-positive Colorectal Cancer.	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
"2-(4-oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid"		5/23/2019	Treatment of Galactosemia	Designated	Not FDA Approved for Orphan Indication	Applied Therapeutics Inc.
"N-(4,4-difluorocyclohexyl)-2-(3-methyl-1H-pyrazol-1-yl)-6-morpholinopyrimidin-4-amine"		5/22/2019	Treatment of spinocerebellar ataxia	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
Murine IgG1 monoclonal antibody binding to site II on G protein of rabies virus envelope and murine IgG2b monoclonal antibody binding to site III on G protein of rabies virus envelope		5/15/2019	Post-exposure prophylaxis against rabies virus infection.	Designated	Not FDA Approved for Orphan Indication	"Cadila Healthcare Limited, India"
esomeprazole		5/15/2019	Treatment of Eosinophilic Esophagitis	Designated	Not FDA Approved for Orphan Indication	"Adare Pharmaceuticals US, L.P."
cytarabine-beta-L-aspartic acid		5/14/2019	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	BioSight Ltd.
cereblon enzyme 3 (E3) ubiquitin ligase modulating agent		5/14/2019	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
"(1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione OR [(1E,4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]"		5/14/2019	Treatment of Huntington’s Disease	Designated	Not FDA Approved for Orphan Indication	AnnJi Pharmaceutical Co. Ltd.
genetically engineered herpes simplex virus		5/9/2019	Treatment of medulloblastoma	Designated	Not FDA Approved for Orphan Indication	"Aettis, Inc."
genetically engineered herpes simplex virus		5/9/2019	Treatment of primitive neuroectodermal brain tumors	Designated	Not FDA Approved for Orphan Indication	"Aettis, Inc."
Human cytomegalovirus (HCMV) internal repeat short 1 (IRS1)-expressing oncolytic Herpes Simplex Virus		5/9/2019	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Nationwide Children's Hospital
iloprost		5/9/2019	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	"Eicos Sciences, Inc., a CiVi Biopharma, Inc. affiliated company"
Autologous T cells transfected with PiggyBac transposon plasmid vector expressing B-cell maturation antigen (CAR-T cells)		5/8/2019	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	"Poseida Therapeutics, Inc."
faceted gold nanocrystals		5/8/2019	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"Clene Nanomedicine, Inc."
A potent and selective inhibitor of Gamma Secretase-mediated NOTCH signaling		5/8/2019	Treatment of Adenoid cystic carcinoma	Designated	Not FDA Approved for Orphan Indication	"Ayala Pharmaceuticals, Inc."
O-18F-fluoroethyl-L-tyrosine		5/8/2019	Diagnostic for the management of Malignant Rhabdoid Tumors	Designated	Not FDA Approved for Orphan Indication	"Advanced Imaging Projects, LLC"
"(6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1-methyl-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone"		5/8/2019	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	"Beijing Tide Pharmaceutical Co., Ltd"
ansuvimab-zykl	EBANGA™	5/8/2019	Treatment of Ebola Virus Disease	Designated/Approved		Emergent Manufacturing Operations Baltimore LLC
sotorasib	Lumakras	5/1/2019	Treatment of KRAS p.G12C-positive non-small cell lung cancer	Designated/Approved		Amgen Inc.
human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment (ready to use pre-filled syringe)		5/1/2019	Treatment of short bowel syndrome	Designated	Not FDA Approved for Orphan Indication	Hanmi Pharmaceutical Co. Ltd.
allogeniec Human Pancreatic Islets of Langerhans		5/1/2019	Treatment of brittle type 1 diabetes	Designated	Not FDA Approved for Orphan Indication	"Diabetes Research Institute & Cell Transplant Center, Univ of Miami"
Purified Allogeneic Human Pancreatic Islets of Langerhans		5/1/2019	Treatment of Brittle Type 1 Diabetes	Designated	Not FDA Approved for Orphan Indication	University of Chicago
allogeneic skin-derived ABCB5-positive mesenchymal stem cells		5/1/2019	Treatment of Epidermolysis Bullosa	Designated	Not FDA Approved for Orphan Indication	RHEACELL GmbH & Co. KG
N-{2-[N-((3S)(3-piperidyl))carbamoyl]-5-[2-(3-fluorophenyl)ethynyl](3-thienyl)}aminoamide		4/29/2019	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Pharos iBio Co., Ltd."
Dexpramipexole		4/22/2019	Treatment of hypereosinophilic syndrome (HES)	Designated	Not FDA Approved for Orphan Indication	Areteia Therapeutics
Melatonin		4/22/2019	Treatment of heat stroke	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
vardenafil		4/22/2019	Treatment of Pulmonary Arterial Hypertension	Designated	Not FDA Approved for Orphan Indication	"Respira Therapeutics, Inc"
"3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-pyrazol-1-yl) propanoic acid"		4/22/2019	Treatment of Stargardt’s disease.	Designated	Not FDA Approved for Orphan Indication	"Stargazer Pharmaceuticals, Inc."
recombinant adeno-associated viral vector with human methylmalonyl-COA mutase (MUT) gene		4/22/2019	Treatment of methylmalonic acidemia	Designated	Not FDA Approved for Orphan Indication	"LogicBio Therapeutics, Inc."
a long-acting interleukin-11 analog comprised of 178 amino acids covalently modified wiht a 40-kDa branched maleimide-polyethylene glycol at the added cysteine residue following the carboxy-terminal amino acid		4/17/2019	Treatment of acute radiation syndrome	Designated	Not FDA Approved for Orphan Indication	"Bolder BioTechnology, Inc."
Autologous enriched T-cells genetically modified with a retroviral vector to express two chimeric antigen receptors (CARs) targeting cluster of differentiation (CD) 19 and CD 22.		4/17/2019	Treatment of Acute Lymphoblastic Leukemia	Designated	Not FDA Approved for Orphan Indication	Autolus Limited
6-[18F] fluoro-L-m-tyrosine		4/17/2019	Diagnostic for the management of Aromatic L-Amino Acid Decarboxylase Deficiency	Designated	Not FDA Approved for Orphan Indication	"Advanced Imaging Projects, LLC"
"a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter."		4/17/2019	Treatment of Rett Syndrome (RTT)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Novartis Institute for BioMedical Research, Inc."
etranacogene dezaparvovec-drlb	Hemgenix	4/17/2019	Treatment of Hemophilia B	Designated/Approved		CSL Behring LLC
Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc)		4/11/2019	Treatment of Idiopathic CD4+ Lymphocytopenia.	Designated	Not FDA Approved for Orphan Indication	"NeoImmuneTech, Inc."
cromolyn solution		4/11/2019	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"Respivant Sciences, Inc."
"2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one"		4/11/2019	Treatment of Myelodysplastic Syndrome	Designated	Not FDA Approved for Orphan Indication	Aprea Therapeutics AB
umbralisib	Ukoniq	4/11/2019	Treatment of nodal marginal zone lymphoma	Designated/Approved		"TG Therapeutics, Inc."
umbralisib	Ukoniq	4/11/2019	Treatment of splenic marginal zone lymphoma	Designated/Approved		"TG Therapeutics, Inc."
umbralisib	Ukoniq	4/11/2019	Treatment of extranodal marginal zone lymphoma	Designated/Approved		"TG Therapeutics, Inc."
pamrevlumab		4/11/2019	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	"FibroGen, Inc."
autologous chimeric antigen receptor (CAR) T cells targeting intercellular adhesion molecule-1 (ICAM-1)		4/9/2019	"Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer"	Designated	Not FDA Approved for Orphan Indication	"AffyImmune Therapeutics, Inc."
estetrol		3/28/2019	Treatment of neonatal hypoxic ischemic encephalopathy	Designated	Not FDA Approved for Orphan Indication	Mithra Pharmaceuticals S.A.
allogeneic ABCB5-positive limbal stem cells		3/28/2019	Treatment of limbal stem cell deficiency	Designated	Not FDA Approved for Orphan Indication	RHEACELL GmbH & Co. KG
alpha tocopherol and ascorbic acid		3/28/2019	Treatment of Fragile X syndrome	Designated	Not FDA Approved for Orphan Indication	GenCo Pharmaceuticals LLC
sodium bispiperidine-carboxamido-dimethylpenatnamido-methoxycarbonyl-indol-propanamidohexanoate		3/28/2019	Treatment of malignant melanoma stages IIB to IV	Designated	Not FDA Approved for Orphan Indication	"ENB Therapeutics, INC"
"expanded human autologous chondrocytes in a biopolymer (sodium alginate, gellan gum) matrix"		3/25/2019	Treatment of microtia (including anotia)	Designated	Not FDA Approved for Orphan Indication	Auregen BioTherapeutics SA
Varespladib		3/25/2019	Treatment of snakebite	Designated	Not FDA Approved for Orphan Indication	"Ophirex, Inc."
methotrexate		3/25/2019	Treatment of ectopic pregnancy	Designated	Not FDA Approved for Orphan Indication	"Antares Pharma, Inc"
Anti-transforming growth factor beta (TGF-ß) trap fusion protein		3/25/2019	Treatment of systemic sclerosis.	Designated	Not FDA Approved for Orphan Indication	Formation Biologics
human monoclonal IgG2 antibody against tissue factor pathway inhibitor (TFPI)		3/25/2019	Treatment of Hemophilia A	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bayer HealthCare LLC
deferoxamine		3/15/2019	Treatment of sickle cell leg ulcers	Designated	Not FDA Approved for Orphan Indication	Theris Medical
encapsulated rapamycin		3/15/2019	Treatment of familial adenomatous polyposis	Designated	Not FDA Approved for Orphan Indication	Emtora Biosciences Inc
calmangafodipir		3/15/2019	Treatment of acetaminophen overdose.	Designated	Not FDA Approved for Orphan Indication	Egetis Therapeutics AB
crinecerfont		3/15/2019	Treatment of congenital adrenal hyperplasia	Designated	Not FDA Approved for Orphan Indication	"Neurocrine Biosciences, Inc."
capmatinib		3/15/2019	Treatment of non-small cell lung cancer with MET genomic tumor aberrations	Designated/Approved		Novartis Pharmaceuticals Corp.
meplazumab		3/15/2019	Treatment of malaria	Designated	Not FDA Approved for Orphan Indication	"Jiangsu Pacific-Meinuoke Bio-pharmaceutical Co., Ltd."
tinostamustine hydrochloride		3/15/2019	Treatment of T-cell prolymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	Mundipharma EDO GmbH
nanatinostat and valganciclovir		3/15/2019	Treatment of angioimmunoblastic T-cell lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Viracta Therapeutics, Inc."
"recombinant adeno-associated virus, serotype 1, containing a transgene that encodes a microRNA targeting huntingtin messenger RNA"		3/15/2019	Treatment of Huntington’s Disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Voyager Therapeutics
saracatinib		3/11/2019	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"AstraZeneca Pharmaceuticals, LP"
tecarfarin		3/7/2019	Prevention of systemic thromboembolism of cardiac origin in patients with End Stage Renal Disease and atrial fibrillation	Designated	Not FDA Approved for Orphan Indication	"Cadrenal Therapeutics, Inc."
small molecule inhibitor of the pro-survival protein Myeloid Cell Leukemia sequence 1 (MCL 1)		2/28/2019	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
pyronaridine tetraphosphate		2/28/2019	Treatment of Ebola infection	Designated	Not FDA Approved for Orphan Indication	"Collaborations Pharmaceuticals, Inc."
sorafenib		2/28/2019	Treatment of desmoid tumors/aggressive fibromatosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bayer HealthCare Pharmaceuticals, Inc."
efmitermant alfa		2/28/2019	Treatment of Charcot-Marie-Tooth disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Acceleron Pharma Inc.
src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor JAB-3068		2/28/2019	Treatment of esophageal cancer	Designated	Not FDA Approved for Orphan Indication	"Jacobio Pharmaceuticals Co., Ltd."
nanatinostat and valganciclovir		2/28/2019	Treatment of plasmablastic lymphoma	Designated	Not FDA Approved for Orphan Indication	"Viracta Therapeutics, Inc."
nanatinostat and valganciclovir		2/28/2019	Treatment of post-transplant lymphoproliferative disorder	Designated	Not FDA Approved for Orphan Indication	"Viracta Therapeutics, Inc."
Ac-225-4-PHenylbutyryl-His-D-Phe-Arg-Trp-Gly-Lys(eAhx-DOTA)-NH2		2/28/2019	Treatment of Uveal Melanoma	Designated	Not FDA Approved for Orphan Indication	Modulation Therapeutics Incorporated
melatonin		2/28/2019	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
modakafusp alfa		2/28/2019	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
[11C]Acetic Acid		2/28/2019	Diagnostic for the management of hepatoblastoma	Designated	Not FDA Approved for Orphan Indication	"Advanced Imaging Projects, LLC"
Autologous genetically modified CD34+ hematopoietic cells transduced with a lentiviral vector (LV-EFS-TCIRG1-WPRE) that encodes for the human TCIRG1 transgene		2/28/2019	Treatment of infantile malignant osteopetrosis	Designated	Not FDA Approved for Orphan Indication	"Rocket Pharmaceuticals, Inc."
"4-(((3-chloro-1,4-dioxo-1,4 dihydronaphthalen-2-yl)amino)methyl)-N-(pyridine-3-yl)benzamide"		2/28/2019	Treatment of Multiple Myeloma	Designated	Not FDA Approved for Orphan Indication	Sino-American Cancer Foundation
C-type natriuretic peptide conjugated to a multi-arm polyethylene glycol carrier molecule through a cleavable linker		2/27/2019	Treatment of Achondroplasia	Designated	Not FDA Approved for Orphan Indication	Ascendis Pharma Growth Disorders A/S
recombinant botulinum vaccine A/B		2/26/2019	"Prevention of botulism caused by inhalational intoxication with botulinum neurotoxin (BoNT) serotype A, subtype A1, and BoNT serotype B, subtype B1."	Designated	Not FDA Approved for Orphan Indication	"The Surgeon General, Department of the Army"
autologous CD34+ Cells Enriched with Blood Derived Mitochondria		2/26/2019	Treatment of Pearson Syndrome	Designated	Not FDA Approved for Orphan Indication	Minovia Therapeutics Ltd.
dexamethasone		2/26/2019	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Fera Pharmaceuticals
"5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine"		2/25/2019	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	Molecure S.A. (previously OncoArendi S.A.)
"6-{[(1R,2S)-2-aminocyclohexyl]amino-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate"		2/25/2019	Treatment of follicular lymphoma	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
peritoneal dialysis solution containing combination of D-glucose and L-carnitine		2/21/2019	Treatment of patients with end stage renal disease who require peritoneal dialysis	Designated	Not FDA Approved for Orphan Indication	CoreQuest Sagl
enzyme transport vehicle specific for the transferrin receptor fused to iduronate 2-sulfatase		2/19/2019	Treatment of mucopolysaccharidosis type II	Designated	Not FDA Approved for Orphan Indication	Denali Therapeutics Inc.
A small molecule inhibitor of the pro-survival protein Myeloid Cell Leukemia sequence 1 (MCL 1)		2/15/2019	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
verdiperstat		2/15/2019	Treatment of multiple system atrophy (MSA).	Designated	Not FDA Approved for Orphan Indication	"Biohaven Pharmaceuticals, Inc."
"peptide-drug conjugate combining [(Tyr3,Cys8) octreotate amide] and N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl) maytansine"		2/15/2019	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Tarveda Therapeutics, Inc."
recombinant adeno-associated viral vector serotype S3 containing codon-optimized expression cassette encoding human coagulation factor IX variant		2/15/2019	Treatment of hemophilia B	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Freeline Therapeutics Limited
etoposide toniribate		2/11/2019	Treatment of biliary tract cancer	Designated	Not FDA Approved for Orphan Indication	CellAct Pharma GmbH
rose bengal disodium		2/11/2019	Treatment of ocular melanoma	Designated	Not FDA Approved for Orphan Indication	"Provectus BioPharmaceuticals, Inc."
"2,4-dinitrophenol"		2/11/2019	Treatment of Huntington disease	Designated	Not FDA Approved for Orphan Indication	"Mitochon Pharmaceuticals, Inc."
budesonide		2/11/2019	Treatment of primary biliary cholangitis	Designated	Not FDA Approved for Orphan Indication	Calliditas Therapeutics AB
"Extracts of herbs Scutellaria baicalensis Geori, Glycyrrhiza uralensis Fisch, Paeonia lactiflora Pall, and Ziziphus jujuba Mill"		2/11/2019	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Yiviva Inc.
"2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate"		2/11/2019	Treatment of esophageal cancer	Designated	Not FDA Approved for Orphan Indication	"Millennium Pharmaceuticals, Inc."
Bispecific T-cell engager (BiTE) containing two single-chain variable fragment (scFv) domains directed against the B cell maturation antigen (BCMA) surface receptor on tumor cells and the cluster of differentiation 3 (CD3) receptor on T-cells		2/8/2019	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Amgen, Inc."
adeno-associated virus serotype 5 capsid containing the gene for human Nuclear Hormone Receptor NR2E3		2/8/2019	Treatment of NR2E3 mutation-associated retinal degenerative disease	Designated	Not FDA Approved for Orphan Indication	Ocugen Inc.
itolizumab		2/5/2019	Prevention of acute graft versus host disease	Designated	Not FDA Approved for Orphan Indication	"Equillium, Inc."
pegcetacoplan		2/1/2019	Treatment of autoimmune hemolytic anemia	Designated	Not FDA Approved for Orphan Indication	"Apellis Pharmaceuticals, Inc."
ketamine		2/1/2019	Treatment of Complex Regional Pain Syndrome	Designated	Not FDA Approved for Orphan Indication	"Bexson Biomedical, Inc."
rozanolixizumab-noli	Rystiggo	2/1/2019	Treatment of myasthenia gravis	Designated/Approved		"UCB, Inc."
nivolumab		2/1/2019	Treatment of primary mediastinal B-cell lymphoma.	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Company
ciltacabtagene autoleucel	Carvykti	2/1/2019	Treatment of multiple myeloma (MM)	Designated/Approved		"Janssen Research & Development, LLC"
recombinant adeno-associated viral (AAV) vector that contains a bio-engineered capsid (AAV-Spark100) and a codon-optimized expression cassette to drive expression of a secretable form of human acid a-glucosidase (GAA)		2/1/2019	Treatment of Pompe Disease	Designated	Not FDA Approved for Orphan Indication	"Spark Therapeutics, Inc."
budesonide		2/1/2019	Treatment of Autoimmune Hepatitis	Designated	Not FDA Approved for Orphan Indication	Calliditas Therapeutics AB
autologous genetically engineered T cells that express a single-domain antibody that recognizes human mesothelin fused to the cluster of differentiation 3e subunit of the T cell receptor		2/1/2019	Treatment of mesothelioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"TCR2 Therapeutics, Inc., a wholly owned subsidiary of Adaptimmune Therapeutics plc"
(E)-3-(6-Bromo-pyridin-2-yl)-2-cyano-N-((S)-1-phenyl-ethyl)-acryl amide		2/1/2019	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	"Moleculin Biotech, Inc."
benralizumab		2/1/2019	Treatment of hypereosinophilic syndrome	Designated	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals LP
Adeno-associated virus serotype 9 vector containing the human lysosome-associated membrane glycoprotein 2 isoform B transgene (AAV9.LAMP2B)		2/1/2019	Treatment of Danon Disease	Designated	Not FDA Approved for Orphan Indication	"Rocket Pharmaceuticals, Inc."
motixafortide		2/1/2019	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"BioLineRx, Ltd."
efgartigimod		2/1/2019	Treatment of Primary Immune Thrombocytopenia (ITP)	Designated	Not FDA Approved for Orphan Indication	argenx BVBA
itolizumab		2/1/2019	Treatment of acute graft versus host disease	Designated	Not FDA Approved for Orphan Indication	"Equillium, Inc."
autologous adult bone marrow-derived and unexpanded CD133+ hematopoietic stem cells (CD133+ BMDSCs) mobilized from peripheral blood (PB)		2/1/2019	Treatment of women with infertility and a thin endometrium seeking pregnancy	Designated	Not FDA Approved for Orphan Indication	Asherman Therapy S.L.U.
ciltacabtagene autoleucel	Carvykti	2/1/2019	Treatment of multiple myeloma (MM)	Designated/Approved		"Janssen Research & Development, LLC"
Fully human immunoglobulin G1 monoclonal antibody that targets CD32b		1/29/2019	Treatment of mantle cell lymphoma	Designated	Not FDA Approved for Orphan Indication	BioInvent International AB
Losartan		1/29/2019	Treatment of epidermolysis bullosa	Designated	Not FDA Approved for Orphan Indication	Crowd Pharma Losartan GmbH & Co. KG
"5,7-Dichloro-2-((ethylamino)methyl)-8-hydroxy-3-methylquinazolin-4(3H)-one mesylate"		1/29/2019	Treatment of multiple system atrophy	Designated	Not FDA Approved for Orphan Indication	"Alterity Therapeutics, Limited"
delta-9-tetrahydrocannabinol and cannabidiol		1/29/2019	Treatment of Huntington's Disease	Designated	Not FDA Approved for Orphan Indication	MMJ International Holdings
certepetide		1/29/2019	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Lisata Therapeutics, Inc."
clofarabine		1/24/2019	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Boyen Therapeutics, Inc."
fosmanogepix		1/22/2019	Treatment of cryptococcosis	Designated	Not FDA Approved for Orphan Indication	"Basilea Pharmaceutica Ltd, Allschwil"
Human IgG1 monoclonal antibody to human CD38		1/22/2019	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
recombinant Mitsugumin 53		1/17/2019	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	"Axolo Pharma, Inc."
ribitol		1/16/2019	Treatment of limb-girdle muscular dystrophy type 2I	Designated	Not FDA Approved for Orphan Indication	"ML Bio Solutions, Inc."
odevixibat		1/16/2019	Treatment of Biliary Atresia	Designated	Not FDA Approved for Orphan Indication	"Ipsen Biopharmaceuticals, Inc."
"N-(bromoacetyl)-3,3-dinitroazetidine"		1/16/2019	Treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	EpicentRx Inc.
tiratricol		1/16/2019	Treatment of Monocarboxylate 8 Transporter (MCT8) Deficiency (Allan-Herndon-Dudley-Syndrome)	Designated	Not FDA Approved for Orphan Indication	Rare Thyroid Therapeutics
adeno-associated viral vector 9-containing the human heparan-alpha-glucosaminide N-acetyltransferase (HGSNAT) gene (AAV9- HGSNAT)		1/16/2019	Treatment of Sanfilippo Syndrome IIIC (also known as Mucopolysaccharidosis IIIC/MPS IIIC)	Designated	Not FDA Approved for Orphan Indication	"Phoenix Nest, Inc."
L-fucose		1/14/2019	Treatment of Congenital Disorder of Glycosylation IIc	Designated	Not FDA Approved for Orphan Indication	"AUG Therapeutics, LLC"
D-mannose		1/14/2019	Treatment of Mannose Phosphate Isomerase Deficiency	Designated	Not FDA Approved for Orphan Indication	"AUG Therapeutics, LLC"
D-Galactose		1/14/2019	Treatment of Phosphoglucomutase 1 Deficiency	Designated	Not FDA Approved for Orphan Indication	"AUG Therapeutics, LLC"
Autotaxin inhibitor		1/14/2019	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	"Bridge Biotherapeutics, Inc"
cusatuzumab		1/14/2019	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	OncoVerity
tarlatamab-dlle	Imdelltra	12/27/2018	Treatment of small cell lung cancer (SCLC)	Designated/Approved		Amgen Inc.
bromelain + acetylcysteine		12/27/2018	Treatment of pseudomyxoma peritonei with Bromelain and Acetylcysteine	Designated	Not FDA Approved for Orphan Indication	MUCPharm Pty Ltd.
apraglutide		12/20/2018	Treatment of short bowel syndrome (SBS)	Designated	Not FDA Approved for Orphan Indication	VectivBio AG
Autologous adult live cultured osteoblasts		12/20/2018	Treatment of osteonecrosis	Designated	Not FDA Approved for Orphan Indication	Regrow Biosciences Pvt. Ltd.
small interfering RNA agent that targets human transforming growth factor-Eszett1 messenger RNA		12/19/2018	Treatment of Idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"Toray Industries, Inc."
pegcetacoplan		12/19/2018	Treatment of C3 glomerulopathy	Designated	Not FDA Approved for Orphan Indication	"Apellis Pharmaceuticals, Inc."
iberdomide		12/19/2018	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
Synthetic PreImplantation Factor		12/19/2018	Treatment of Acute Radiation Syndrome	Designated	Not FDA Approved for Orphan Indication	"BioIncept, LLC"
conditionally active biologics-anti-ROR2-antibody drug conjugate consisting of a humanized IgG1 antibody specific for ROR2 tyrosine kinase conjugated to a peptide linker coupled with monomethyl auristatin E		12/18/2018	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	BioAtla LLC
Fibromun		12/18/2018	Treatment of Soft Tissue Sarcoma	Designated	Not FDA Approved for Orphan Indication	Philogen S.p.A.
ceramide		12/18/2018	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	"Keystone Nano, Inc."
"(1S,3S)-3-((2-methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid"		12/17/2018	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Company
autologous CD34+ cell- enriched population transduced with lentiviral vector encoding the codon-optimized human alpha-galactosidase A complementary deoxyribonucleic acid sequence.		12/17/2018	Treatment of Fabry Disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AVROBIO, Inc."
mosunetuzumab-axgb	Lunsumio	12/17/2018	Treatment of follicular lymphoma	Designated/Approved		"Genentech, Inc."
"15(S)-hydroxy-(5Z,8Z,11Z,13E,17Z)-eicosapentaenoic acid ethyl ester"		12/17/2018	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	Afimmune
autologous T cells genetically modified to express CD123 specific hinge-optimized CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor		12/17/2018	Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm	Designated	Not FDA Approved for Orphan Indication	"Mustang Bio, Inc."
CDC-like kinase inhibitor of the Wnt Pathway		12/17/2018	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Biosplice Therapeutics, Inc."
poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin		12/17/2018	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	Cancer Research and Life Foundation
venetoclax + idasanutlin		12/17/2018	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Genentech Inc. (A Member of the Roche Group)
"((1r, 4r)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate)-Expanded cord blood"		12/13/2018	Prevention of Graft-versus-Host-Disease	Designated	Not FDA Approved for Orphan Indication	ExCellThera Inc.
"5-(3,5-Dimethyl-4-hydroxybenzylamino)-3-(4-morpholin-4-yl-phenylamino)-1H-pyrazole-4-carboxylic acid amide"		12/7/2018	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	Metagone Biotech Inc.
transforming growth factor beta trap/anti-programmed death ligand-1 antibody bifunctional fusion protein		12/7/2018	Treatment of biliary tract cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"EMD Serono Research & Development Institute, Inc."
"99mTc-HYNIC-[D-Phe1,Tyr3-Octreotide] trifluoroacetate"		12/5/2018	Diagnostic for the management of neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	Narodowe Centrum Badan Jadrowych
(+)-alpha-dihydrotetrabenazine		12/5/2018	Treatment of Huntington's disease.	Designated	Not FDA Approved for Orphan Indication	"Adeptio Pharmaceuticals, Ltd"
messenger ribonucleic acid-based therapeutic agent encoding human propionyl-CoA carboxylase alpha and beta subunits		12/5/2018	Treatment of propionic acidemia.	Designated	Not FDA Approved for Orphan Indication	"Moderna Therapeutics, Inc."
"self-complementary non-replicating, recombinant adeno-associated virus serotype rhesus 74 expressing the human alpha-sarcoglycan gene under a triple E-box muscle creatine kinase muscle specific promoter (scAAVrh74.tMCK.hSGCA)"		12/5/2018	Treatment of limb girdle muscular dystrophy Type 2D	Designated	Not FDA Approved for Orphan Indication	Sarepta Therapeutics
recombinant human interleukin 12		12/5/2018	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	TherapyX Inc.
"(1S, 4R, 5R, 7S)-3, 4-dibenzyl-2-oxo-6, 8-dioxa- 3-azabyciclo [3.2.1] octane-7-carboxylic acid-L-lysine"		11/30/2018	Treatment of Neurotrophic keratopathy	Designated	Not FDA Approved for Orphan Indication	"Recordati Rare Diseases, SARL"
doranidazole		11/30/2018	radiosensitizer to be used during radiation treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Shuttle Pharmaceuticals, Inc."
povidone iodine		11/30/2018	Treatment of Endophthalmitis	Designated	Not FDA Approved for Orphan Indication	Cumulus Pharmaceutical LLC
recombinant adeno-associated virus vector containing DNA encoding INT41 intrabody		11/30/2018	Treatment of Huntington’s Disease	Designated	Not FDA Approved for Orphan Indication	Vybion Inc.
benralizumab		11/21/2018	Treatment of eosinophilic granulomatosis with polyangiitis	Designated	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals LP
terlipressin		11/21/2018	Treatment of hepatorenal syndrome	Designated	Not FDA Approved for Orphan Indication	BioVie Inc.
recombinant adeno-associated virus (AAV) vector based on the AAV serotype hu37 containing a single stranded DNA genome encoding a form of human Factor VIII		11/20/2018	Treatment of Hemophilia A	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bayer HealthCare LLC
humanized connexin 43 monoclonal antibody		11/20/2018	Treatment of acute spinal cord injury	Designated	Not FDA Approved for Orphan Indication	"AlaMab Therapeutics, Inc."
flunarizine		11/20/2018	Treatment of Alternating Hemiplegia	Designated	Not FDA Approved for Orphan Indication	"Xenon Pharmaceuticals, Inc."
"peptide-drug conjugate combining [(Tyr3,Cys8) octreotate amide] and N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl) maytansine"		11/20/2018	Treatment of neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	"Tarveda Therapeutics, Inc."
humanized anti-Globo H monoclonal antibody		11/20/2018	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"OBI Pharma USA, Inc."
hydromethylthionine mesylate		11/20/2018	Treatment of frontotemporal dementia	Designated	Not FDA Approved for Orphan Indication	TauRx Therapeutics Ltd
"8-bromo-2-(1-methylpiperidin-4-yl) amino)-4-(4-phenoxyphenyl) amino) pyrido[4,3-d] pyrimidin-5(6H)-one hydrochloride"		11/20/2018	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	Oscotec Inc.
humanized IgG1 antibody specifific for the AXL tyrosine kinase conjugated to monomethyl auristatin E		11/19/2018	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	BioAtla LLC
small molecule inhibitor of integrins avß6 and avß1		11/19/2018	Treatment of primary sclerosing cholangitis	Designated	Not FDA Approved for Orphan Indication	"Pliant Therapeutics, Inc."
ceramide		11/13/2018	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	"Keystone Nano, Inc."
brentuximab vedotin		11/13/2018	Treatment of extranodal NK/T-cell lymphoma (ENKTL)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Seattle Genetics, Inc."
ipilimumab		11/7/2018	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Company
bomedemstat		11/7/2018	Treatment of essential thrombocythemia.	Designated	Not FDA Approved for Orphan Indication	"Merck & Co., Inc."
cannabidiol		11/5/2018	Prevention of ischemia/reperfusion Injury resulting from solid organ transplantation	Designated	Not FDA Approved for Orphan Indication	Revive Therapeutics Ltd.
Rose bengal disodium		11/2/2018	Treatment of Neuroblastoma	Designated	Not FDA Approved for Orphan Indication	"Provectus BioPharmaceuticals, Inc."
Diacerein		11/2/2018	Treatment of epidermolysis bullosa	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
human astrocytes derived from astrocyte progenitor cells originating from clincial-grade human embryonic stem cells		11/1/2018	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"Kadimastem, Ltd."
"N-[(2R)-2,3 dihydroxypropoxyl]-3,4 difluro-2 -[(2-fluoro-4-iodophenyl)amino] benzamide"		10/30/2018	Treatment of Neurofibromatosis type I	Designated	Not FDA Approved for Orphan Indication	"SpringWorks Therapeutics, Inc."
trimetazidine		10/30/2018	Treatment of dilated cardiomyopathy	Designated	Not FDA Approved for Orphan Indication	"Martin Pharmaceuticals, Inc."
autologous dendritic cells pulsed with hepatitis B virus antigens		10/25/2018	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"Jiangsu Antae Biological Technology Co., Ltd."
"non-replicating, recombinant adeno-associated virus (AAV) serotype 9 (AAV9) vector containing an hCLN2 expression cassette encoding for the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1)"		10/25/2018	Treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease.	Designated	Not FDA Approved for Orphan Indication	REGENXBIO Inc. (REGENXBIO)
"5-Chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazine-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine·monohydrate"		10/25/2018	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	Aptose Biosciences Inc.
"2-[3-(2-chloro-4-{[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy}phenyl)-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid¿2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1)"		10/25/2018	Treatment of Primary Sclerosing Cholangitis (PSC)	Designated	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
humanized monoclonal antibody targeting interleukin-15		10/25/2018	Treatment of eosinophilic esophagitis	Designated	Not FDA Approved for Orphan Indication	CALYPSO BIOTECH BV
adipose-derived mesenchymal stem cells in a hydrogel sheet		10/25/2018	Treatment of Epidermolysis Bullosa	Designated	Not FDA Approved for Orphan Indication	"Anterogen Co., Ltd."
"(1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II)"		10/25/2018	Treatment of thymoma and thymic carcinoma	Designated	Not FDA Approved for Orphan Indication	"Promontory Therapeutics, Inc."
human monoclonal antibody inhibitor of mannan binding lectin-associated serine protease-2 (MASP-2)		10/22/2018	Treatment of Hematopoietic Stem-Cell Transplant-Associated Thrombotic Microangiopathy	Designated	Not FDA Approved for Orphan Indication	Omeros Corporation
concizumab		10/22/2018	Treatment of hemophilia A	Designated	Not FDA Approved for Orphan Indication	"Novo Nordisk, Inc."
sargramostim		10/22/2018	Treatment of pulmonary alveolar proteinosis (PAP).	Designated	Not FDA Approved for Orphan Indication	"Partner Therapeutics, Inc."
melatonin		10/22/2018	Treatment of Acute Radiation Syndrome	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
spartalizumab		10/18/2018	Treatment of Stage IIB-IV melanoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
"[4-(4-{1-[2-(2-{2-[2-(2-{2-[2-(4-guanidinomethyl-phenoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethyl]-1H-[1,2,3]triazol-4-ylmethoxy}-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-acetic acid"		10/17/2018	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	"NanoPharmaceuticals, LLC"
Humanized IgG-1 antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase		10/15/2018	Treatment of Mucopolysaccharidosis Type II (MPS II) or Hunter Syndrome	Designated	Not FDA Approved for Orphan Indication	"JCR Pharmaceuticals Co., Ltd."
rilzabrutinib		10/15/2018	Treatment of immune thrombocytopenic purpura (ITP)	Designated	Not FDA Approved for Orphan Indication	Principia Biopharma Inc.
odevixibat	Bylvay	10/15/2018	Treatment of Alagille syndrome	Designated/Approved		"Ipsen Biopharmaceuticals, Inc."
recombinant lentivirus vector expressing the human phenylalanine hydroxylase (PAH) gene under control of a liver-specific promoter		10/15/2018	Treatment of Phenylketonuria	Designated	Not FDA Approved for Orphan Indication	American Gene Technologies International Inc.
reboxetine		10/15/2018	Treatment of narcolepsy	Designated	Not FDA Approved for Orphan Indication	"Axsome Therapeutics, Inc."
relacorilant		10/15/2018	Treatment of endogenous Cushing syndrome	Designated	Not FDA Approved for Orphan Indication	"Corcept Therapeutics, Inc."
heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IgG1 and part of human IL1 receptor accessory protein		10/15/2018	Treatment of Schnitzler Syndrome	Designated	Not FDA Approved for Orphan Indication	R-Pharm Overseas
Glucagon-Like Peptide 2 fused to hyFc		10/11/2018	Treatment of short bowel syndrome	Designated	Not FDA Approved for Orphan Indication	Genexine
N-[5-(6-fluoro-8-{[4-(2-hydroxypropan-2-yl) piperidin-1-yl]methyl}-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-]methanesulfonamide		10/11/2018	Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Designated	Not FDA Approved for Orphan Indication	"Shanghai Yingli Pharmaceutical Co., Ltd."
Lead-212 DOTAMTATE		10/11/2018	Treatment of neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	"RadioMedix, Inc."
Monoclonal antibody targeting CCL24		10/11/2018	Treatment of primary sclerosing cholangitis	Designated	Not FDA Approved for Orphan Indication	"ChemomAb, Ltd."
olaparib	Lynparza	10/11/2018	Treatment of pancreatic cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
mavorixafor	Xolremdi	10/10/2018	"Treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome"	Designated/Approved		"X4 Pharmaceuticals, Inc."
N-[5-(6-fluoro-8-{[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl}-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-yl]methanesulfonamide		10/10/2018	Treatment Follicular Lymphoma	Designated	Not FDA Approved for Orphan Indication	"Shanghai Yingli Pharmaceutical Co., Ltd."
antibody-drug conjugate comprised of a human aglycosylated anti-CD74 IgG1 antibody (SP7219) and two non-cleavable maytansinoid linker warheads		10/10/2018	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Sutro Biopharma, Inc."
Indolino-benzodiazepine compound (sulfonated DGN549-C) conjugated to the humanized anti-CD123 monoclonal antibody (G4723A)		10/10/2018	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"ImmunoGen, Inc."
"6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile"		10/10/2018	Treatment of pancreatic cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Loxo Oncology, Inc."
bispecific T-cell engager antibody with a single chain Fc moiety that binds to B cell maturation antigen surface receptor and CD3		10/10/2018	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
clervonafusp alfa		10/4/2018	Treatment of Pompe Disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Valerion Therapeutics, LLC"
spesolimab-sbzo	Spevigo	10/3/2018	Treatment of generalized pustular psoriasis	Designated/Approved		"Boehringer Ingelheim Pharmaceuticals, Inc. (BI)"
spesolimab-sbzo	Spevigo	10/3/2018	Treatment of generalized pustular psoriasis	Designated/Approved		"Boehringer Ingelheim Pharmaceuticals, Inc. (BI)"
"poly (acetyl, arginyl) glucosamine"		10/2/2018	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Synedgen, Inc."
N-Acetyl-Leucine		10/2/2018	Treatment of Ataxia Telangiectasia	Designated	Not FDA Approved for Orphan Indication	IntraBio Inc.
"3-(3-(3,5-Dimethyl-1H-pyrazol-4- yl)propoxy)-4-fluorobenzoic acid"		10/2/2018	Treatment of transthyretin amyloidosis	Designated	Not FDA Approved for Orphan Indication	"BridgeBio Pharma, Inc."
selexipag		10/2/2018	Treatment of Chronic Thromboembolic Pulmonary Hypertension	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Janssen Research & Development LLC
clenbuterol		10/2/2018	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Duke University Medical Center
Ibudilast		10/2/2018	Treatment of Glioblastoma	Designated	Not FDA Approved for Orphan Indication	"MediciNova, Inc."
S-[+]-apomorphine		10/2/2018	Treatment of amyotrophic lateral sclerosis (ALS).	Designated	Not FDA Approved for Orphan Indication	Aclipse One Inc
progerinin		10/2/2018	Treatment of Hutchinson-Gilford progeria syndrome	Designated	Not FDA Approved for Orphan Indication	"PRG S&T Co., Ltd."
fixed combination of dimethyl fumarate and aspirin (162mg)		9/27/2018	Treatment of multiple sclerosis in patients who experience dimethyl fumarate flushing	Designated	Not FDA Approved for Orphan Indication	"Vitalis, LLC"
sodium 2-hydroxylinoleate		9/27/2018	Treatment of biliary tract cancer	Designated	Not FDA Approved for Orphan Indication	"Ability Pharmaceuticals, SL"
Adeno-associated viral vector serotype 8 containing the human RPGR gene		9/27/2018	Treatment of inherited retinal dystrophies due to defects in the RPGR gene	Designated	Not FDA Approved for Orphan Indication	Biogen
relacorilant		9/27/2018	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	"Corcept Therapeutics, Inc."
fixed dose combination of pyronaridine tetraphosphate and artesunate		9/27/2018	Treatment of malaria	Designated	Not FDA Approved for Orphan Indication	"Shin Poong Pharmaceutical Co., Ltd."
"(13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one"		9/24/2018	Treatment of solid tumors with neurotrophic tyrosine receptor kinase (NTRK)-fusion proteins	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bayer Healthcare Pharmaceuticals, Inc."
18-(p-[131I]-iodophenyl)octadecyl phosphocholine		9/24/2018	Treatment of osteosarcoma	Designated	Not FDA Approved for Orphan Indication	"Cellectar Biosciences, Inc."
ex-vivo expanded placental adherent stromal cells		9/24/2018	"Treatment of graft failure and incomplete hematopoietic recovery, following hematopoietic cell transplantation (HCT)"	Designated	Not FDA Approved for Orphan Indication	Pluri Biotech Ltd.
Autologous dendritic cells ex vivo incubated with zebularine and factor VIII		9/24/2018	Treatment to reduce factor VIII neutralizing antibodies (inhibitors)	Designated	Not FDA Approved for Orphan Indication	Idogen AB
cerdulatinib		9/21/2018	Treatment of peripheral T-cell lymphoma (PTCL).	Designated	Not FDA Approved for Orphan Indication	"Portola Pharmaceuticals, Inc."
imidazolyl ethanamide pentandioic acid		9/17/2018	Treatment of Acute Radiation Syndrome	Designated	Not FDA Approved for Orphan Indication	Myelo Therapeutics GmbH
"3-[5-[(1R)-1-[bis(aziridin-1-yl(phosphoryloxy]ethyl]-2-nitrophenoxy]-N,N-dimethylbenzamide"		9/17/2018	Treatment of Acute Lymphoblastic Leukemia	Designated	Not FDA Approved for Orphan Indication	"OBI Pharma USA, Inc."
Methanesulfonate-1-sec-butoxycarbonyloxymethyl-1-methyl-4-{4-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-benzyl}-piperazin-1-ium		9/13/2018	Treatment of chronic myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Inhibikase Therapeutics, Inc."
docetaxel encapsulated in an albumin-stabilized liposome		9/12/2018	Treatment of small cell lung cancer (SCLC)	Designated	Not FDA Approved for Orphan Indication	"Plus Therapeutics, Inc."
"4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidin-4-ylcarbonyl)-3-pyridinyl]-3-(trifluoromethyl)benzenesulfonamide, sodium salt"		9/12/2018	Treatment of focal segmental glomerulosclerosis	Designated	Not FDA Approved for Orphan Indication	"ChemoCentryx, Inc."
immune globulin subcutaneous (Human)		9/12/2018	Treatment of Dermatomyositis	Designated	Not FDA Approved for Orphan Indication	CSL Behring
autologous engineered T-cell product that targets B-cell maturation antigen (BCMA)		9/10/2018	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Kite Pharma, Inc."
autologous Cytokine-Induced Killer Cells (Cytokine-induced Killer Cells plus Cytotoxic T Lymphocytes)		9/10/2018	Treatment of Pancreatic Cancer.	Designated	Not FDA Approved for Orphan Indication	Green Cross Cell Corporation
vorasidenib		9/10/2018	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	Servier Pharmaceuticals LLC
disitamab vedotin		9/10/2018	Treatment of Gastric Cancer	Designated	Not FDA Approved for Orphan Indication	Seagen Inc.
orilanolimab		9/10/2018	Treatment of pemphigus	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc."
adeno-associated virus vector expressing human 21-hydroxylase		8/30/2018	Treatment of congenital adrenal hyperplasia 21-hydroxylase deficiency	Designated	Not FDA Approved for Orphan Indication	Adrenas Therapeutics Inc
"elexacaftor, tezacaftor, and ivacaftor; ivacaftor"	Trikafta	8/29/2018	Treatment of Cystic Fibrosis	Designated/Approved		Vertex Pharmaceuticals Inc.
"elexacaftor, tezacaftor, and ivacaftor; ivacaftor"	Trikafta	8/29/2018	Treatment of Cystic Fibrosis	Designated/Approved		Vertex Pharmaceuticals Inc.
"elexacaftor, tezacaftor, and ivacaftor; ivacaftor"	Trikafta	8/29/2018	Treatment of Cystic Fibrosis	Designated/Approved		Vertex Pharmaceuticals Inc.
"elexacaftor, tezacaftor, and ivacaftor; ivacaftor"	Trikafta	8/29/2018	Treatment of Cystic Fibrosis	Designated/Approved		Vertex Pharmaceuticals Inc.
Adeno-Associated Viral Vector encoding C1 Esterase Inhibitor		8/22/2018	Treatment of Angioedema due to C1-Inhibitor Deficiency	Designated	Not FDA Approved for Orphan Indication	"Adverum Biotechnologies, Inc."
fully human nicotine-specific monoclonal antibody		8/22/2018	Treatment of thromboangiitis obliterans (Buerger’s disease)	Designated	Not FDA Approved for Orphan Indication	"Antidote Therapeutics, Inc."
bertilimumab		8/17/2018	Treatment of bullous pemphigoid	Designated	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc."
"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate"		8/17/2018	Treatment of Ryanodine receptor type 1-related myopathies	Designated	Not FDA Approved for Orphan Indication	"ARMGO Pharma, Inc."
clofazimine		8/17/2018	Treatment of Pulmonary Nontuberculous Mycobacterial Infections	Designated	Not FDA Approved for Orphan Indication	MannKind Corporation
"2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid"		8/16/2018	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"ASLAN Pharmaceuticals Pte, Ltd."
(1-hydroxy-2-oxopiperidin-3-yl)phosphonic acid		8/9/2018	Treatment of Glioblastoma	Designated	Not FDA Approved for Orphan Indication	The University of Texas MD Anderson Cancer Center
trimetazidine		8/7/2018	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	"Martin Pharmaceuticals, Inc."
"A replication-incompetent, non-integrating Herpes simplex type 1 (HSV-1) vector expressing the human transglutaminase-1 (TGM-1) enzyme"		8/7/2018	Treatment of TGM-1-deficient autosomal recessive congenital ichthyosis (ARCI)	Designated	Not FDA Approved for Orphan Indication	"Krystal Biotech, Inc."
monosialotetrahexosylganglioside		8/7/2018	Treatment of Huntington’s Disease	Designated	Not FDA Approved for Orphan Indication	"Qilu Pharmaceutical Co., Ltd."
[(4-benzylpiperazin-1-yl)(2-(isopentylamino)pyridin-3-yl)methanone]-phosphate		8/7/2018	Treatment of Angelman Syndrome	Designated	Not FDA Approved for Orphan Indication	"Seneca Biopharma, Inc."
Synthetic stereopure antisense oligonucleotide specific for human dystrophin pre-messenger ribonucleic acid (mRNA)		8/7/2018	Treatment of Duchenne muscular dystrophy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Wave Life Sciences Ltd.
adenovirus associated viral vector serotype 8 containing the human Cyclic Nucleotide Gated Channel Alpha 3 subunit (CNGA3) gene		8/7/2018	Treatment of achromatopsia due to CNGA3 gene mutations.	Designated	Not FDA Approved for Orphan Indication	MeiraGTx LLC
"interleukin-1 receptor antagonist (IL-1Ra, sequence-homologous anakinra)"		8/7/2018	Treatment of Bronchiolitis Obliterans	Designated	Not FDA Approved for Orphan Indication	"Onspira Therapeutics, Inc., a wholly owned subsidiary of Sumitomo Pharma America, Inc."
lurbinectedin	Zepzelca	8/1/2018	Treatment of small cell lung cancer (SCLC)	Designated/Approved		Jazz Pharmaceuticals Ireland Limited
"4-amino-1-[(2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl] pyrimidin-2(1H)-one"		8/1/2018	Treatment of cholangiocarcinoma	Designated	Not FDA Approved for Orphan Indication	"FUJIFILM Pharmaceutical U.S.A., Inc."
Autologous Cytokine-Induced Killer Cells (Cytokine-Induced Killer Cells Plus Cytotoxic T Lymphocytes)		8/1/2018	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	Green Cross Cell Corporation
carbon monoxide		8/1/2018	Prevention of delayed graft function in renal transplant recipients	Designated	Not FDA Approved for Orphan Indication	"Proterris, Inc."
small molecule inhibitor of integrins avb6 and avb1		8/1/2018	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	"Pliant Therapeutics, Inc."
lenzumestrocel		8/1/2018	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"Corestem, Inc."
anti-CD47 monoclonal antibody		7/30/2018	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Surface Oncology, Inc."
human Alpha1-Proteinase inhibitor		7/30/2018	Prevention of graft-versus-host disease (GVHD)	Designated	Not FDA Approved for Orphan Indication	CSL Behring LLC
antibody drug conjugate of metal-binding motif-introduced trastuzumab antibody variant and monomethyl auristatin E		7/30/2018	Treatment of Gastric Cancer	Designated	Not FDA Approved for Orphan Indication	"Alteogen, Inc."
arsenic trioxide		7/30/2018	Treatment of Graft-versus-host disease	Designated	Not FDA Approved for Orphan Indication	Medsenic
ascorbic acid		7/30/2018	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Renovion, Inc."
lenabasum		7/18/2018	Treatment of dermatomyositis	Designated	Not FDA Approved for Orphan Indication	"Corbus Pharmaceuticals, Inc."
recombinant adeno-associated viral vector containing a single-stranded transgene encoding a codon-optimized human SMN1 complementary deoxyribonucleic acid under the control of the chicken beta actin promoter		7/16/2018	Treatment of Spinal Muscular Atrophy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Biogen Inc.
lisocabtagene maraleucel	Breyanzi	7/12/2018	Treatment of primary mediastinal large B-cell lymphoma	Designated/Approved		"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company"
lisocabtagene maraleucel	Breyanzi	7/12/2018	Treatment of primary mediastinal large B-cell lymphoma	Designated/Approved		"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company"
Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein		7/12/2018	"Treatment of Mucopolysaccharidosis Type IIIA, Sanfilippo A Syndrome"	Designated	Not FDA Approved for Orphan Indication	"ArmaGen, Inc."
Daromun		7/10/2018	Treatment of Melanoma Stages IIb through IV.	Designated	Not FDA Approved for Orphan Indication	Philogen S.p.A.
competitive and reversible small molecule inhibitor of the O-linked-B-N-acetylglucosaminidase enzyme		7/10/2018	Treatment of progressive supranuclear palsy	Designated	Not FDA Approved for Orphan Indication	"Ferrer Internacional, S.A."
ivabradine		7/9/2018	Treatment of post-cardiac transplant heart dysfunction	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Amgen, Inc.,"
"soidum (5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxypyridin-3-yl)((2,4-difluorophenyl)sulfonyl)amide"		7/9/2018	Treatment of idiopathic pulmonary fibrosis (IPF)	Designated	Not FDA Approved for Orphan Indication	"Sunshine Lake Pharma Co., Ltd"
Dilanubicel		7/9/2018	Reduction of morbidity and mortality associated with hematopoietic stem cell transplantation	Designated	Not FDA Approved for Orphan Indication	"Nohla Therapeutics, Inc."
Follistatin291-IgG2 Fc fusion protein		7/3/2018	Treatment of facioscapulohumeral muscular dystrophy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Acceleron Pharma Inc.
Imlifidase		7/3/2018	Treatment of anti-glomerular basement membrane (anti-GBM) disease	Designated	Not FDA Approved for Orphan Indication	Hansa Medical AB
"3-[5-[(1R)-1-[bis(aziridin-1-yl(phosphoryloxy]ethyl]-2-nitrophenoxy]-N,N-dimethylbenzamide"		7/3/2018	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"OBI Pharma USA, Inc."
18-(p-[131I]-iodophenyl)octadecyl phosphocholine		7/3/2018	Treatment of Ewing’s Sarcoma	Designated	Not FDA Approved for Orphan Indication	"Cellectar Biosciences, Inc."
allogeneic anti-CD19 chimeric antigen receptor (CAR)-T cells		7/2/2018	Treatment of acute lymphoblastic leukemia (ALL)	Designated	Not FDA Approved for Orphan Indication	Imugene Limited
small molecule selective inhibitor of c-Jun N-terminal kinase		6/27/2018	Treatment of idiopathic pulmonary fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene Corporation
cannabidiol		6/25/2018	Treatment of autoimmune hepatitis	Designated	Not FDA Approved for Orphan Indication	Revive Therapeutics Ltd.
delandistrogene moxeparvovec-rokl	Elevidys	6/21/2018	Treatment of Duchenne Muscular Dystrophy	Designated/Approved		"Sarepta Therapeutics, Inc."
Autologous Cytokine-Induced Killer Cells (Cytokine-Induced Killer Cells plus Cytotoxic T Lymphocytes)		6/21/2018	Treatment of Hepatocellular Carcinoma	Designated	Not FDA Approved for Orphan Indication	GC Cell Corporation
ezogabine		6/21/2018	Treatment of KCNQ2 epileptic encephalopathy	Designated	Not FDA Approved for Orphan Indication	"Xenon Pharmaceuticals, Inc."
L-alanoyl-D-glutamate endopeptidase from Bacillus-infected bacteriophages		6/21/2018	Treatment of inhalational anthrax	Designated	Not FDA Approved for Orphan Indication	"iNtRON Biotechnology, Inc."
recombinant adeno-associated virus vector encoding human CYP4V2 protein		6/21/2018	Treatment of Bietti's crystalline dystrophy	Designated	Not FDA Approved for Orphan Indication	Reflection Biotechnologies Limited
delandistrogene moxeparvovec-rokl	Elevidys	6/21/2018	Treatment of Duchenne Muscular Dystrophy	Designated/Approved		"Sarepta Therapeutics, Inc."
Fixed dose combination of relatlimab and nivolumab		6/18/2018	Treatment of gastric cancer (GC) and gastro-esophageal junction cancer (GEJ).	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Co.
"recombinant human anti-human Sortilin (SORT1) monoclonal IgG1 G1m17,1 [or G1m (z,a)] kappa monoclonal antibody"		6/18/2018	Treatment of Frontotemporal Dementia	Designated	Not FDA Approved for Orphan Indication	Alector
deuterated S-lisofylline		6/18/2018	Treatment of Necrobiosis Lipoidica	Designated	Not FDA Approved for Orphan Indication	Processa Pharmaceuticals Inc
indralin		6/13/2018	Prevention of acute radiation syndrome (ARS)	Designated	Not FDA Approved for Orphan Indication	"Advanced Innovative Partners, Inc."
extracellular domain of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 fused to the Fc region of human IgG1		6/11/2018	Treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency (generalized arterial calcification of infancy and autosomal recessive hypophosphatemic rickets type 2)	Designated	Not FDA Approved for Orphan Indication	Inozyme Pharma Inc.
nirogacestat	Ogsiveo	6/7/2018	Treatment of desmoid tumor (aggressive fibromatosis)	Designated/Approved		"SpringWorks Therapeutics, Inc."
Recombinant humanized IgG1 anti-HER2 monoclonal antibody conjugated to Duostatin-5		6/7/2018	Treatment of gastric cancer.	Designated	Not FDA Approved for Orphan Indication	"Klus Pharma, Inc."
N-acetyl-DL-leucine		6/6/2018	Treatment of Spinocerebellar Ataxia (SCA)	Designated	Not FDA Approved for Orphan Indication	IntraBio Inc.
nitric oxide		6/5/2018	Treatment of non-tuberculous mycobacterial lung disease	Designated	Not FDA Approved for Orphan Indication	"Novoteris, LLC"
brincidofovir	Tembexa	6/5/2018	Treatment of smallpox	Designated/Approved		Emergent BioDefense Operations Lansing LLC
liposomal mannose-1-phosphate		6/4/2018	Treatment of Phosphomannomutase 2-Congenital Disorder of Glycosylation	Designated	Not FDA Approved for Orphan Indication	"Glycomine, Inc."
"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one"		6/4/2018	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Chimerix, Inc."
olinciguat		6/4/2018	Treatment of Sickle Cell Disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Cyclerion Therapeutics, Inc."
L-cystine bis(N'-methylpiperazide)		6/4/2018	Treatment of cystinuria.	Designated	Not FDA Approved for Orphan Indication	PharmaKrysto Ltd
TransCon Parathyroid Hormone (mPEG conjugated parathyroid hormone 1-34)		6/4/2018	Treatment of hypoparathyroidism	Designated	Not FDA Approved for Orphan Indication	Ascendis Pharma Bone Diseases A/S
apomorphine palmitate		6/4/2018	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	Leukos Biotech
vutrisiran	Amvuttra	5/25/2018	Treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis)	Designated/Approved		Alnylam Pharmaceuticals
teicoplanin		5/24/2018	Treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	Neupharma srl
photochlor		5/24/2018	Treatment of Esophageal Cancer	Designated	Not FDA Approved for Orphan Indication	"Ami Onco-Theranostics, LLC"
romiplostim	Nplate	5/24/2018	Treatment of patients acutely exposed to myelosuppressive doses of radiation following radiological/nuclear incident	Designated/Approved		Amgen Inc.
"N-(2-chloro-6-propoxypyridin-4-yl)-2-(2-hydroxyethyl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazinecarboxamide"		5/23/2018	Treatment of Idiopathic pulmonary fibrosis (IPF)	Designated	Not FDA Approved for Orphan Indication	"Arroyo Biosciences, LLC"
"potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide/tezacaftor/ivacaftor"		5/23/2018	Treatment of Cystic Fibrosis	Designated	Not FDA Approved for Orphan Indication	Vertex Pharmaceuticals Inc.
"trans-4-({2-(aminocarbonyl)-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}amino)cyclohexyl glycinate mesylate"		5/23/2018	Treatment of neuroendocrine tumors (NETs).	Designated	Not FDA Approved for Orphan Indication	Esanex Inc.
omidubicel-onlv	Omisirge	5/23/2018	Enhancement of cell engraftment and immune reconstitution in patients receiving hematopoietic stem cell transplant	Designated/Approved		Gamida Cell Ltd.
rebastinib		5/23/2018	Treatment of Facioscapulohumeral Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	Genea Biocells US Inc.
tazemetostat		5/23/2018	Treatment of chordoma	Designated	Not FDA Approved for Orphan Indication	"Epizyme, Inc."
futibatinib	Lytgobi	5/23/2018	Treatment of cholangiocarcinoma (CCA)	Designated/Approved		"Taiho Oncology, Inc."
diazepam		5/23/2018	Treatment of Dravet syndrome	Designated	Not FDA Approved for Orphan Indication	"Xeris Pharmaceutical, Inc."
autologous human adipose perivascular stromal cells genetically modified to secrete soluble Tumor Necrosis Factor-related Apoptosis-inducing Ligand (sTRAIL)		5/22/2018	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	Rigenerand Srl
golodirsen	VYONDYS 53	5/22/2018	Treatment of Duchenne muscular dystrophy (DMD)	Designated/Approved		"Sarepta Therapeutics, Inc."
"8-(6-iodobenzo[1,3]dioxol-5-ylsufanyl)-9-(3-isopropylamino propyl)adenine dihydrochloride"		5/16/2018	Treatment of Myelofibrosis	Designated	Not FDA Approved for Orphan Indication	"Samus Therapeutics, Inc."
nedosiran	Rivfloza	5/15/2018	Treatment of primary hyperoxaluria	Designated/Approved		"Dicerna Pharmaceuticals, Inc. (a wholly owned subsidiary of Novo Nordisk)"
diosmin		5/15/2018	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	"Primus Pharmaceuticals, Inc."
olaparib	Lynparza	5/15/2018	Treatment of primary peritoneal cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
olaparib	Lynparza	5/15/2018	Treatment of Fallopian Tube Cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
olaparib	Lynparza	5/15/2018	Treatment of primary peritoneal cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
olaparib	Lynparza	5/15/2018	Treatment of primary peritoneal cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
olaparib	Lynparza	5/15/2018	Treatment of Fallopian Tube Cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
olaparib	Lynparza	5/15/2018	Treatment of Fallopian Tube Cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
carboxyamidotriazole orotate		5/10/2018	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Tactical Therapeutics, Inc."
20-hydroxyecdysone		5/10/2018	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	Biophytis SA
galinpepimut-S		5/8/2018	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"SELLAS Life Sciences Group, Inc."
synthetic preImplantation factor		5/8/2018	Prevention of graft versus host disease	Designated	Not FDA Approved for Orphan Indication	"BioIncept, LLC"
18-(p-[131I]-iodophenyl)octadecyl phosphocholine		5/8/2018	Treatment of soft tissue sarcomas including rhabdomyosarcoma	Designated	Not FDA Approved for Orphan Indication	"Cellectar Biosciences, Inc."
budesonide		5/8/2018	Treatment of eosinophilic esophagitis	Designated	Not FDA Approved for Orphan Indication	Dr. Falk Pharma GmbH
peptide fraction derived from porcine brain protein		5/8/2018	Treatment of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)	Designated	Not FDA Approved for Orphan Indication	EVER Neuro Pharma GmbH
Indolino-benzodiazepine compound (sulfonated DGN462) conjugated to the humanized anti-CD33 monoclonal antibody (Z4681A) via the sulfo-SPDB linker		5/2/2018	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ImmunoGen, Inc."
venglustat		5/1/2018	Treatment of Autosomal Dominant Polycystic Kidney Disease	Designated	Not FDA Approved for Orphan Indication	"Genzyme Corporation, a SANOFI COMPANY"
ivosidenib		5/1/2018	Treatment of glioma.	Designated	Not FDA Approved for Orphan Indication	Servier Pharmaceuticals LLC
BN-Brachyury; a heterologous prime/boost therapeutic cancer vaccine composed of MVA-BN-Brachyury (prime) and FPV-Brachyury (boost)		4/30/2018	Treatment of chordoma	Designated	Not FDA Approved for Orphan Indication	Bavarian Nordic A/S
autologous tumor infiltrating lymphocytes (TIL)		4/30/2018	Treatment of cervical cancer with a tumor size greater than 2 cm. in diameter	Designated	Not FDA Approved for Orphan Indication	"Iovance Biotherapeutics, Inc."
Rozanolixizumab		4/30/2018	Treatment of immune thrombocytopenic purpura (ITP)	Designated	Not FDA Approved for Orphan Indication	"UCB, Inc."
Cell-penetrating activating transcription factor 5 mimetic		4/30/2018	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	"Sapience Therapeutics, Inc"
Ursodeoxycholic acid		4/26/2018	"Treatment of Niemann-Pick disease, type C"	Designated	Not FDA Approved for Orphan Indication	IntraBio Inc.
ex vivo expanded autologous human corneal epithelial cells containing stem cells		4/26/2018	Treatment of limbal stem cell deficiency	Designated	Not FDA Approved for Orphan Indication	Holostem S.r.l.
"5-{(1R,2R)-2-[(Cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride"		4/26/2018	Treatment of Kabuki Syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
"6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate"		4/26/2018	Treatment of Cystinosis	Designated	Not FDA Approved for Orphan Indication	"ELOXX Pharmaceuticals, Inc."
gemcitabine intra-arterial infusion via the RenovoCath¿ RC120 catheter		4/24/2018	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	RenovoRx
Ciclopirox		4/17/2018	Treatment of congenital erythropoietic porphyria	Designated	Not FDA Approved for Orphan Indication	Atlas Molecular Pharma S.L.
Oraxol		4/16/2018	Treatment of angiosarcoma	Designated	Not FDA Approved for Orphan Indication	Health Hope Pharma
ubidecarenone		4/16/2018	Treatment of Epidermolysis Bullosa	Designated	Not FDA Approved for Orphan Indication	"BPGbio, Inc"
"2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione"		4/16/2018	Treatment of inherited mitochondrial respiratory chain disease	Designated	Not FDA Approved for Orphan Indication	Abliva AB
Allogeneic umbilical cord blood (UCB) cell therapy product consisting of two cell fractions (CD34 enriched and CD34 depleted) derived from the same UCB unit		4/11/2018	For the enhancement of cell engraftment in patients receiving hematopoietic stem cell transplantation (HSCT)	Designated	Not FDA Approved for Orphan Indication	Magenta Therapeutics
pralsetinib	GAVRETO™	4/11/2018	"Treatment of rearranged during transfection (RET)-rearranged non-small cell lung cancer (NSCLC), JAK1/2-positive NSCLC, or TRKC-positive NSCLC."	Designated/Approved		"Rigel Pharmaceuticals, Inc."
methotrexate		4/11/2018	Prevention of proliferative vitreoretinopathy (PVR)	Designated	Not FDA Approved for Orphan Indication	"Aldeyra Therapeutics, Inc."
human glial restricted progenitor cells and their progeny		4/11/2018	Treatment of transverse myelitis	Designated	Not FDA Approved for Orphan Indication	"Q Therapeutics, Inc."
tegavivint		4/11/2018	Treatment of Desmoid Tumors	Designated	Not FDA Approved for Orphan Indication	Beta Cat Pharmaceuticals
"4-{[4-Amino-3-(4-cyclohexylpiperazin-1-yl)-9,10-dioxo-9,10-dihydroanthracen-1-yl]amino}benzoic acid"		4/11/2018	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"VM Oncology, LLC"
human immunoglobulin (IgG1K) monoclonal antibody that binds to interleukin 15		4/10/2018	Treatment of refractory celiac disease.	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
"C1 esterase inhibitor, human"		4/5/2018	Treatment of antibody mediated rejection (AMR) of solid organ transplants	Designated	Not FDA Approved for Orphan Indication	CSL Behring
"6-(4-(4-(2,3-Dicholorophenyl) piperazin-1-yl) butoxy)-2H-benzo [b] [1,4] oxazin-3(4H)-one hydrochloride"		4/4/2018	Treatment of Idiopathic Pulmonary Fibrosis	Designated	Not FDA Approved for Orphan Indication	"Reviva Pharmaceuticals, Inc."
tegoprubart		4/4/2018	Treatment of Amyotrophic Lateral Sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	"Eledon Pharmaceuticals, Inc."
tenalisib		4/4/2018	Treatment of Cutaneous T-Cell Lymphoma	Designated	Not FDA Approved for Orphan Indication	Rhizen Pharmaceuticals SA
pomalidomide	POMALYST®	4/4/2018	Treatment of Kaposi sarcoma	Designated/Approved		Celgene Corporation
Brevenal		4/2/2018	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Silurian Pharmaceuticals, Inc."
tinostamustine hydrochloride		4/2/2018	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Mundipharma EDO GmbH
anti-EGFRvIII x anti-CD3 bispecific T cell engager antibody construct		4/2/2018	Treatment of glioblastoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Amgen Inc.
elamipretide		4/2/2018	Treatment of Leber’s Hereditary Optic Neuropathy	Designated	Not FDA Approved for Orphan Indication	Stealth BioTherapeutics Inc.
"Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s"		3/28/2018	Treatment of immune thrombocytopenia	Designated	Not FDA Approved for Orphan Indication	Bioverativ USA Inc.
Phenobarbital sodium		3/28/2018	Treatment of neonatal seizures	Designated	Not FDA Approved for Orphan Indication	Genus Lifesciences
melatonin		3/28/2018	Treatment of subarachnoid hemorrhage	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
fluasterone		3/28/2018	"Treatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis)"	Designated	Not FDA Approved for Orphan Indication	"Sterotherapeutics, LLC"
Nanoparticle suspension containing biosynthetic codon-optimized human ornithine transcarbamylase messenger RNA		3/28/2018	Treatment of ornithine transcarbamylase (OTC) deficiency	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Translate Bio, Inc."
Autologous Activated T Lymphocytes (ATL)		3/28/2018	Treatment of hepatocellular carcinoma (HCC)	Designated	Not FDA Approved for Orphan Indication	Lukas Biomedical Inc.
(3R)-3-Methyl-6-[2-({5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-1-yl}methyl)phenoxy]hexanoic acid hemisulfate		3/28/2018	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	"Astellas Pharma Global Development, Inc."
"7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl) thieno [3,2-d]pyrimidin-2-amine semi-fumarate"		3/26/2018	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"MaxiNovel Pharmaceutical Co.,Ltd"
dexamethasone		3/26/2018	Treatment of multiple myeloma (MM)	Designated/Approved		Dexcel Pharma Technologies Ltd
Allogeneic mesenchymoangioblast-derived mesenchymal stem cells		3/26/2018	Treatment of acute graft versus host disease	Designated	Not FDA Approved for Orphan Indication	Cynata Therapeutics Limited
N-acetyl-DL-leucine		3/26/2018	Treatment of GM2 Gangliosidosis	Designated	Not FDA Approved for Orphan Indication	IntraBio Inc.
zatolmilast		3/26/2018	Treatment of Fragile X Syndrome	Designated	Not FDA Approved for Orphan Indication	"Tetra Discovery Partners, Inc."
"Powdered extracts of the herbs Scutellaria baicalensis Geori, Glycyrrhiza uralensis Fisch, Paeonia lactiflora Pall, and Ziziphus jujuba Mill"		3/22/2018	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Yiviva Inc.
elamipretide		3/22/2018	Treatment of Barth syndrome	Designated	Not FDA Approved for Orphan Indication	"Stealth Biotherapeutics, Inc."
fully human anti-proMyostatin monoclonal antibody of the IgG4/lambda isotype that binds to human pro- and latent myostatin with high affinity		3/22/2018	Treatment of spinal muscular atrophy	Designated	Not FDA Approved for Orphan Indication	Scholar Rock
perfluorooctyl-bromide (PFOB)		3/22/2018	Treatment of respiratory distress syndrome (RDS)	Designated	Not FDA Approved for Orphan Indication	Children’s Hospital of Pennsylvania
Sleeping Beauty Transposon-Engineered Autologous Plasmablasts for Expression and Delivery of Alpha-L-Iduronidase		3/19/2018	Treatment of mucopolysaccharidosis type I (MPS I)	Designated	Not FDA Approved for Orphan Indication	Immusoft Corporation
nicotinamide riboside and pterostilbene		3/19/2018	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	Elysium Health Inc.
18-(p-[131]-iodophenyl)octadecyl phosphocholine		3/15/2018	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	"Cellectar Biosciences, Inc."
"2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one"		3/15/2018	Treatment of Tuberculosis (TB)	Designated	Not FDA Approved for Orphan Indication	Klinikum der Universität München
PEGASEMP¿(doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31 aminoacid peptide targeting nucleolin)		3/15/2018	Treatment of Mesothelioma	Designated	Not FDA Approved for Orphan Indication	"TREAT U, S.A."
antisense oligonucleotide specific to the antisense transcript of UBE3A		3/15/2018	Treatment of Angelman Syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"GeneTx Biotherapeutics, LLC"
Trimetazidine		3/15/2018	Treatment of acute-on-chronic liver failure	Designated	Not FDA Approved for Orphan Indication	"Martin Pharmaceuticals, Inc."
Cannabidiol and delta-9-tetrahydrocannabinol		3/15/2018	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"AXIUM Pharmaceuticals, Inc."
sirolimus		3/13/2018	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	Rare Partners srl Impresa Sociale
avadomide		3/12/2018	Treatment of follicular lymphoma	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
Pemigatinib	PEMAZYRE	3/12/2018	Treatment of cholangiocarcinoma	Designated/Approved		Incyte Corporation
melatonin		3/8/2018	Treatment of perinatal asphyxia	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
Recombinant Human Monoclonal Antibody To Vascular Endothelial Growth Factor Receptor-2		3/8/2018	Treatment of Glioblastoma	Designated	Not FDA Approved for Orphan Indication	PharmAbcine Inc.
atidarsagene autotemcel	Lenmeldy	3/8/2018	Treatment of the Metachromatic Leukodystrophy (including pre-symptomatic metachromatic leukodystrophy)	Designated/Approved		Orchard Therapeutics Ltd.
tianeptine		3/8/2018	Treatment of Rett syndrome (RTT)	Designated	Not FDA Approved for Orphan Indication	AMO Pharma Ltd.
"1-118-signal regulatory protein alpha (human) fusion protein with immunoglobulin G1 (human Fc fragment), dimer"		3/8/2018	Treatment of Cutaneous T-Cell Lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Trillium Therapeutics Inc.
messanger ribonucleic acid (mRNA)-based therapeutic agent encoding human methylmalonyl-coenzyme A mutase		3/7/2018	Treatment of isolated methylmalonic academia (MMA) due to methylmalonyl-Coenzyme A mutase (MUT) deficiency	Designated	Not FDA Approved for Orphan Indication	"Moderna Therapeutics, Inc."
granaticin B		3/7/2018	Treatment of Acute Lymphoblastic Leukemia (ALL)	Designated	Not FDA Approved for Orphan Indication	Lin BioScience
Bacillus thuringiensis crystal protein (Cry5B)		3/7/2018	"Treatment of gastroinstestinal infections caused by ascaris lumbricoides (roundworm), trichuris trichiura (whipworm), ancylostoma duodenale, necator americanus, and ancylostoma ceylanicum (hookworms)"	Designated	Not FDA Approved for Orphan Indication	University of Massachusetts Medical School
anhydrous enol-oxaloacetate		3/7/2018	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Terra Biological LLC
delta-9-tetrahydrocannabinol and cannabidiol		3/7/2018	Treatment of complex regional pain syndrome	Designated	Not FDA Approved for Orphan Indication	PhytoPain Pharma Inc.
"N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide"		3/7/2018	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Proteostasis Therapeutics, Inc."
hepcidin mimetic peptide		3/1/2018	Treatment of beta-thalassemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Protagonist Therapeutics
"N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide"		3/1/2018	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	ATXA Therapeutics Limited
allogeneic Fecal Microbiota		2/28/2018	Treatment of Graft-Versus-Host Disease	Designated	Not FDA Approved for Orphan Indication	MaaT Pharma
DL-3-n-butylphthalide		2/28/2018	Treatment of amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	"CSPC NBP Pharmaceutical Co, Ltd, subsidiary of CSPC Pharma Group"
devimistat		2/28/2018	Treatment of Peripheral T-cell Lymphoma (PTCL)	Designated	Not FDA Approved for Orphan Indication	"Cornerstone Pharmaceuticals, Inc."
davunetide		2/22/2018	Treatment of Activity-Dependent Neuroprotective Protein (ADNP) Syndrome	Designated	Not FDA Approved for Orphan Indication	Ramot at Tel Aviv University Ltd.
N-acetyl-DL-leucine		2/22/2018	"Treatment of Niemann-Pick disease, type C"	Designated	Not FDA Approved for Orphan Indication	IntraBio Inc.
16 base single stranded peptide nucleic acid oligonucleotide ¿ 7 aminoacids peptide		2/22/2018	Treatment of Small Cell Lung Cancer	Designated	Not FDA Approved for Orphan Indication	BIOGENERA SpA
taurolidine		2/22/2018	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	"CorMedix, Inc."
"5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[3,4-e]purin-2-yl)pyrimidin-2-amine"		2/21/2018	Treatment of glioblastoma multiforme (GBM)	Designated	Not FDA Approved for Orphan Indication	Kazia Therapeutics Limited
tenofovir exalidex		2/20/2018	Treatment of pediatric chronic hepatitis B infection (age 0 through 11 years of age)	Designated	Not FDA Approved for Orphan Indication	"ContraVir Pharmaceuticals, Inc."
"Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Polyinosinic-polycyidylic acid, kanamycin and calcium)"		2/15/2018	Treatment of Pancreatic Cancer	Designated	Not FDA Approved for Orphan Indication	"Yisheng US Biopharma, Inc."
adeno-associated virus serotype 6 containing human LAMAN cDNA		2/15/2018	Treatment of alpha-mannosidosis	Designated	Not FDA Approved for Orphan Indication	"Stephen G. Kaler, MD"
"self-complementary non-replicating, recombinant adeno-associated virus serotype rhesus 74 (rh 74) expressing the human beta-sarcoglycan gene under the control of the muscle creatine kinase (MHCK7) promoter"		2/15/2018	Treatment of Limb Girdle Muscular Dystrophy Type 2E (LGMD2E)	Designated	Not FDA Approved for Orphan Indication	Sarepta Therapeutics
human coagulation factor XI		2/15/2018	Treatment of congenital factor XI deficiency	Designated	Not FDA Approved for Orphan Indication	Bio Products Laboratory Limited
Siplizumab		2/15/2018	Prevention of solid organ transplant rejection	Designated	Not FDA Approved for Orphan Indication	ITB-MED AB
humanized IgG1 low affinity allergic reactivity inhibiting (LARI) monoclonal antibody		2/15/2018	Treatment for mastocytosis	Designated	Not FDA Approved for Orphan Indication	Sixal Inc.
double stranded oligomer ADS-001 RNA interference-based liver targeted therapeutic		2/14/2018	Treatment of alpha-1 antitrypsin deficiency	Designated	Not FDA Approved for Orphan Indication	Takeda Development Center Americas Inc.
selumetinib		2/14/2018	Treatment of Neurofibromatosis Type 1	Designated/Approved		AstraZeneca Pharmaceuticals LP
imlifidase		2/14/2018	Treatment of Guillain-Barré Syndrome (GBS)	Designated	Not FDA Approved for Orphan Indication	Hansa Medical AB
recombinant humanized IgG4 monoclonal antibody against pHERV-W Envelope protein		2/14/2018	Treatment of chronic inflammatory demyelinating polyradiculoneuropathy/polyneuropathy (CIDP)	Designated	Not FDA Approved for Orphan Indication	GeNeuro S.A.
inter-Alpha-Inhibitor-Proteins (IaIp) (Human)		2/13/2018	Treatment of necrotizing enterocolitis (NEC)	Designated	Not FDA Approved for Orphan Indication	"ProThera Biologics, Inc."
a self-complementary adeno-associated virus serotype 9 expressing human codon-optimized CLN1 under control of CBh		2/7/2018	Treatment of neuronal ceroid lipofuscinosis type 1 (CLN1)	Designated	Not FDA Approved for Orphan Indication	"Taysha Gene Therapies, Inc."
tilorone dihydrochloride		2/7/2018	Treatment of Ebola infection	Designated	Not FDA Approved for Orphan Indication	"Collaborations Pharmaceuticals, Inc."
human IgG2 monoclonal antibody directed against the mucosal addressin cell adhesion molecule		2/7/2018	Treatment of Crohn’s Disease (CD) in the pediatric population	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Shire Human Genetic Therapies, Inc. (Shire)"
humanized non-fucosylated Anti-Siglec-8 Monoclonal Antibody (IgG1)		2/1/2018	Treatment of eosinophilic gastroenteritis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Allakos, Inc."
humanized non-fucosylated anti-siglec-8 monoclonal antibody (IgG1)		2/1/2018	Treatment of eosinophilic gastritis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Allakos, Inc."
ibrutinib		2/1/2018	"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma"	Designated	Not FDA Approved for Orphan Indication	"Pharmacyclics, LLC"
adenovirus associated viral vector serotype 8 containing the human AIPL1 gene		2/1/2018	"Treatment of inherited retinal dystrophy due to defects in AIPL1 gene, including Leber congenital amaurosis, retinitis pigmentosa, and cone-rod dystrophy"	Designated	Not FDA Approved for Orphan Indication	MeiraGTx UK II Ltd
glucagon analog conjugated with human immunoglobulin G4 fragment		2/1/2018	Treatment of congenital hyperinsulinism (CHI)	Designated	Not FDA Approved for Orphan Indication	"Hanmi Pharmaceutical Company, Ltd."
anti-human epidermal growth factor receptor 2 (HER2) antibody drug conjugate		2/1/2018	Treatment of gastric cancer including cancer of gastroesophageal junction	Designated	Not FDA Approved for Orphan Indication	"CSPC Dophen Corporation, subsidiary within CSPC Pharmaceutical Group"
"2-(3,7-Dimethyl-octa-2, 6-dienyl)¿6-ethylamino-3-hydroxy-5-pentyl-[1,4]benzoquinone"		2/1/2018	Treatment of Huntington’s Disease (HD)	Designated	Not FDA Approved for Orphan Indication	Emerald Health Pharmaceuticals Inc.
fostamatinib disodium		1/31/2018	Treatment of autoimmune hemolytic anemia (AIHA)	Designated	Not FDA Approved for Orphan Indication	"Rigel Pharmaceuticals, INc."
recombinant humanized monoclonal antibody targeting the anti-müllerian hormone receptor II		1/30/2018	Treatment of Anti -Mullerian Hormone Receptor II (AMHRII)-expressing ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Exelixis, Inc."
leniolisib	Joenja	1/30/2018	"Treatment of activated P13Kdelta Syndrome/p110delta-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency"	Designated/Approved		Pharming Technologies B.V.
midazolam		1/30/2018	Treatment of status epilepticus	Designated	Not FDA Approved for Orphan Indication	Crossject SA
neihulizumab		1/25/2018	Treatment of acute graft-versus-host disease (aGvHD)	Designated	Not FDA Approved for Orphan Indication	"AltruBio Inc. (formerly AbGenomics International, Inc.)"
humanized IgG4-based anti-CD20 x anti-CD3 bispecific monoclonal antibody		1/25/2018	Treatment of follicular lymphoma	Designated	Not FDA Approved for Orphan Indication	"Regeneron Pharmaceuticals, Inc."
"6,8-bis(benzylthio)octanoic acid"		1/25/2018	Treatment of Burkitt’s Lymphoma (BL)	Designated	Not FDA Approved for Orphan Indication	"Cornerstone Pharmaceuticals, Inc."
glucagon (ready-to-use)		1/24/2018	Treatment of hyperinsulinemic hypoglycemia	Designated	Not FDA Approved for Orphan Indication	"Xeris Pharmaceuticals, Inc."
SF-RI-1 bovine surfactant for inhalation		1/23/2018	Treatment of respiratory distress syndrome (RDS)	Designated	Not FDA Approved for Orphan Indication	Aerogen Pharma Corporation
branaplam		1/23/2018	Treatment of spinal muscular atrophy (SMA)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
riluzole oral film	EXSERVAN	1/23/2018	Treatment of amyotrophic lateral sclerosis (ALS)	Designated/Approved		Aquestive Therapeutics
2-{4-[(9R)-9-Hydroxy-2-(3-hydroxy-3-methylbutyloxy)-9-(trifluoromethyl)-9H-fluoren-4-yl]-1H-pyrazol-1-yl}-2-methylpropanamide monohydrate		1/23/2018	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	Akros Pharma Inc.
octreotide acetate (intranasal)		1/23/2018	Treatment of acromegaly	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Dauntless Pharmaceuticals, Inc."
dihydroxyphenylalanine F 18/Fluorodopa (F18)		1/22/2018	Diagnostic for the management of congenital hyperinsulinism	Designated	Not FDA Approved for Orphan Indication	Society of Nuclear Medicine and Molecular Imaging
humanized immunoglobulin G1 (IgG1) T-cell bispecific (TCB) antibody targeting carcinoembryonic antigen (CEA)		1/22/2018	"Treatment of gastric cancer, including gastroesophageal junction cancer"	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
inclisiran		1/22/2018	Treatment of homozygous familial hypercholesterolemia (HoFH)	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
apremilast		1/17/2018	Treatment of pediatric patients with ulcerative colitis	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
cyclocreatine phosphate		1/17/2018	Prevention of ischemic injury to enhance cardiac graft recovery and survival in heart transplantation.	Designated	Not FDA Approved for Orphan Indication	"Nour Heart Therapeutics, LLC"
tin ethyl etiopurpurin		1/16/2018	Treatment of basal cell carcinoma nevus syndrome (BCCNS)	Designated	Not FDA Approved for Orphan Indication	"Adgero Biopharmaceuticals, Inc"
recombinant adeno-associated viral (AAV) vector that contains a bioengineered capsid (AAV-Spark200) and a codon-optimized expression cassette to drive expression of the SQ form of a B-domain deleted human coagulation factor VIII (hFVIII)		1/16/2018	Treatment of hemophilia A	Designated	Not FDA Approved for Orphan Indication	"Spark Therapeutics, Inc."
sodium oxybate	Lumryz	1/8/2018	Treatment of narcolepsy	Designated/Approved		Flamel Ireland Limited dba Avadel Ireland
cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)		1/8/2018	Treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	"AXIUM Pharmaceuticals, Inc."
atezolizumab + bevacizumab	Tecentriq and Avastin	1/8/2018	Treatment of hepatocellular carcinoma (HCC)	Designated/Approved		"Genentech, Inc."
atezolizumab + bevacizumab	Tecentriq and Avastin	1/8/2018	Treatment of hepatocellular carcinoma (HCC)	Designated/Approved		"Genentech, Inc."
milrinone		1/8/2018	Treatment of right heart failure (RHF) in left ventricular assist device (LVAD) patients	Designated	Not FDA Approved for Orphan Indication	Hyloris Developments SA
eflornithine + sulindac		1/8/2018	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Panbela Therapeutics, Inc."
cryopreserved human umbilical cord		1/8/2018	Treatment of spina bifida	Designated	Not FDA Approved for Orphan Indication	"TissueTech, Inc."
antibody drug conjugate targeting dipeptidase 3 (DPEP3)		1/8/2018	"Treatment of DPEP3-positive ovarian, fallopian tube, and primary peritoneal cancers"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie Stemcentrx, LLC"
"genetically modified, non-self replicating Adeno-Associated Virus serotype 9 expressing shRNA to knock down mutant PABP1 as well as a codon optimized, shRNA-insensitive, wildtype PABN1"		1/8/2018	Treatment of oculopharyngeal muscular dystrophy (OPMD)	Designated	Not FDA Approved for Orphan Indication	Benitec Biopharma Limited
resatorvid		1/2/2018	Treatment of acute-on-chronic liver failure	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
partial myostatin antigen displayed on the surface of Lactobacillus casei		12/28/2017	Treatment of Duchenne Muscular Dystrophy (DMD)	Designated	Not FDA Approved for Orphan Indication	BioLeaders Corporation
"ICG140:CD19-CD123 cCAR T-cells, a chimeric antigen receptor (CAR) on the surface of T-cells directed against the target proteins CD19 and CD 123"		12/26/2017	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	iCell Gene Therapeutics
NP-CSIC002		12/26/2017	Treatment of anterior ischemic optic neuropathy (AION)	Designated	Not FDA Approved for Orphan Indication	Neurizon Pharma
Arylalkyl 3-ketoindole		12/26/2017	Treatment of dengue virus infection	Designated	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
abatacept	Orencia	12/26/2017	Prevention of graft versus host disease	Designated/Approved		Bristol-Myers Squibb Co.
"Urea, N-[4-[2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl]-3-fluorophenyl]-N¿-(2,4,6-trifluorophenyl)-"		12/22/2017	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	"Aptose Biosciences, Inc."
soraprazan		12/22/2017	Treatment of Stargardt Disease (StD)	Designated	Not FDA Approved for Orphan Indication	Katairo GmbH
fenretinide		12/22/2017	Treatment of peripheral T-cell lymphoma (including follicular T-cell lymphoma)	Designated	Not FDA Approved for Orphan Indication	"SciTech Development, LLC"
three-dimensional bioprinted therapeutic liver tissue		12/21/2017	Treatment of alpha-1 antitrypsin deficiency	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Organovo Inc.
sirolimus protein-bound particles for injectable suspension (albumin-bound)	Fyarro	12/21/2017	Treatment of perivascular epithelioid cell tumors (PEComa)	Designated/Approved		"Aadi Bioscience, Inc."
"2-O, 3-O, desulfated heparin"		12/21/2017	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Chimerix, Inc."
cannabidiol		12/21/2017	Treatment of Dravet syndrome	Designated	Not FDA Approved for Orphan Indication	"AXIUM Pharmaceuticals, Inc."
trafermin in combination with plasma and platelet rich plasma		12/21/2017	Treatment of alopecia areata in pediatric patients	Designated	Not FDA Approved for Orphan Indication	"HCell, Inc."
"methyl (2R,3S)-3-[(methylsulfonyl)amino]-2-{[(cis-4-phenylcyclohexyl)oxy]methyl}piperidine-1-carboxylate"		12/19/2017	Treatment of narcolepsy	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
fenretinide		12/19/2017	Treatment of cutaneous T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"SciTech Development, LLC"
"sodium sulfate, magnesium sulfate, potassium chloride"		12/19/2017	For the cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in pediatric patients	Designated	Not FDA Approved for Orphan Indication	"Braintree Laboratories, Inc."
mosedipimod		12/19/2017	Treatment of acute radiation syndrome	Designated	Not FDA Approved for Orphan Indication	Enzychem Lifesciences Corporation
(S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one)		12/18/2017	Treatment of peripheral T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	Rhizen Pharmaceuticals SA
diacetyl(N(4)-methylthiosemicarbazonato) copper (II)		12/18/2017	Treatment of amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	Collaborative Medicinal Development Pty. Ltd. (CMD)
lentiviral transfected chimeric antigen receptor T-cells modified to target B-cell maturation antigen and CS1		12/14/2017	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	iCell Gene Therapeutics
"(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide"		12/14/2017	Treatment of C3 glomerulopathy (C3G)	Designated	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc"
"2-(4-(2,4-dichlorophenethyl)-3,6-dioxo-1-(2-(thiophen-2-yl)ethyl)piperazin-2-yl)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl) acetamide"		12/14/2017	Prevention of platinum-induced ototoxicity in pediatric patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Spiral Therapeutics
metformin		12/14/2017	Treatment of progressive myoclonus epilepsy type 2 (Lafora disease)	Designated	Not FDA Approved for Orphan Indication	"Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER)"
plasminogen (Human)		12/14/2017	Treatment of idiopathic pulmonary fibrosis (IPF)	Designated	Not FDA Approved for Orphan Indication	Kedrion Biopharma Inc.
dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL)		12/13/2017	Treatment of diffuse large B-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"KAHR Medical, LTD"
3-(1¿-butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-N-butylimide methyl ester		12/6/2017	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"Photolitec, LLC"
cholesterol 24S-hydroxylase inhibitor		12/6/2017	Treatment of Lennox-Gastaut syndrome	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
gemfibrozil and vitamin A		12/6/2017	Treatment of neuronal ceroid lipofuscinoses	Designated	Not FDA Approved for Orphan Indication	"Polaryx Therapeutics, Inc."
D-amino acid oxidase inhibitor		12/6/2017	Treatment of Friedreich's ataxia (FRDA)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
cotsiranib		11/29/2017	Treatment of cholangiocarcinoma (CCA)	Designated	Not FDA Approved for Orphan Indication	"Sirnaomics, Inc."
cholesterol 24S-hydroxylase inhibitor		11/29/2017	Treatment of Dravet syndrome	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
idasanutlin		11/29/2017	Treatment of polycythemia vera	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Hoffmann-La Roche Inc.
CD4-mediated activated regulatory T cells		11/27/2017	Treatment of graft-versus-host disease	Designated	Not FDA Approved for Orphan Indication	"ActiTrexx GmbH, University Medical Center of Johannes Gutenberg-University"
setmelanotide	Imcivree	11/27/2017	Treatment of leptin receptor deficiency	Designated/Approved		"Rhythm Pharmaceuticals, Inc."
"Eubacterial Spores, Purified Suspension, Encapsulated"		11/27/2017	Treatment of pediatric ulcerative colitis	Designated	Not FDA Approved for Orphan Indication	"Seres Therapeutics, Inc."
povidone iodine		11/27/2017	Treatment of endophthalmitis	Designated	Not FDA Approved for Orphan Indication	Veloce BioPharma LLC
eflornithine	Iwilfin	11/22/2017	Treatment of neuroblastoma	Designated/Approved		"USWM, LLC"
"(1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II)"		11/22/2017	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Phosplatin Therapeutics LLC
Synthetic PreImplantation Factor (H-Met-Val-Arg-Ile-Lys-Pro-Gly-Ser-Ala-Asn-Lys-Pro-Ser-Asp-Asp-OH		11/22/2017	Treatment of autoimmune hepatitis (AIH)	Designated	Not FDA Approved for Orphan Indication	"BioIncept, LLC"
2¿-O-(2-methoxyethyl) modified antisense oligonucleotide targeting exon 13 in the USH2A gene		11/20/2017	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	Laboratoires Théa
human IgG2 anti-monoclonal antibody directed against mucosal addressin cell adhesion molecule (MAdCAM)		11/16/2017	Treatment of pediatric patients with Ulcerative Colitis (UC)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Shire Human Genetic Therapies, Inc. (Shire)"
daxibotulinumtoxinA-lanm	Daxxify	11/16/2017	Treatment of cervical dystonia	Designated/Approved		"Revance Therapeutics, Inc."
cholera toxin B subunit		11/16/2017	Treatment of ulcerative colitis in pediatric patients	Designated	Not FDA Approved for Orphan Indication	Aliment Wellness LLC
tazemetostat	Tazverik	11/14/2017	Treatment of follicular lymphoma	Designated/Approved		"Epizyme, Inc."
adeno-associated virus type 2 encoding human aromatic L-amino acid decarboxylase		11/14/2017	Treatment of aromatic L-amino acid decarboxylase deficiency	Designated	Not FDA Approved for Orphan Indication	University of California San Francisco
Recombinant adeno-associated virus serotype 2/1 vector encoding human beta-hexosaminidase alpha & beta subunits (rAAV2/1 Hex alpha & beta)		11/14/2017	Treatment of GM2 gangliosidosis (Tay-Sachs & Sandhoff diseases)	Designated	Not FDA Approved for Orphan Indication	University of Cambridge
ubidecarenone		11/8/2017	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"BPGbio, Inc"
VLA-4 and LFA-1 integrin activator		11/8/2017	Treatment of malignant melanoma stages IIB to IV	Designated	Not FDA Approved for Orphan Indication	"7 Hills Pharma, LLC"
"(3R,3aS,9R,9aS,9bS)-3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one fumarate"		11/8/2017	Treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	Accendatech USA Incorporated
corticotropin-releasing factor receptor-1 antagonist containing an unfused thiazole ring		11/8/2017	Treatment of congenital adrenal hyperplasia	Designated	Not FDA Approved for Orphan Indication	Spruce Biosciences
3-aminopyridine-2-carboxaldehyde thiosemicarbazone		11/8/2017	Treatment of stage 1B to IV cervical cancer	Designated	Not FDA Approved for Orphan Indication	"National Cancer Institute, Div of Cancer Treatment & Diagnosis (DCTD)"
palovarotene		11/6/2017	Treatment of multiple osteochondromas	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Clementia Pharmaceuticals, Inc."
alanyl-glutamine dipeptide		11/6/2017	Prevention of complications associated with peritoneal dialysis (PD) treatment in end stage renal disease (ESRD)	Designated	Not FDA Approved for Orphan Indication	Zytoprotec GmbH
polyhexanide		11/6/2017	Treatment of Acanthamoeba keratitis	Designated	Not FDA Approved for Orphan Indication	Società Industria Farmaceutica Italiana S.p.A.
baricitinib		11/2/2017	Treatment of pediatric systemic lupus erythematosus	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Eli Lilly and Company
danicopan	Voydeya	11/2/2017	Treatment of paroxysmal nocturnal hemoglobinuria	Designated/Approved		"Alexion Pharmaceuticals, Inc"
beremagene geperpavec-svdt	Vyjuvek	11/2/2017	Treatment of dystrophic epidermolysis bullosa	Designated/Approved		"Krystal Biotech, Inc."
arimoclomol		11/2/2017	Treatment of inclusion body myositis	Designated	Not FDA Approved for Orphan Indication	KemPharm Denmark A/S
live bacterial product consisting of defined consortia of Clostridium clusters live bacterial product consisting of defined consortia of Clostridium clusters		11/2/2017	Prevention of recurrent Clostridium difficile infection in individuals with prior recurrent Clostridium difficile infection	Designated	Not FDA Approved for Orphan Indication	"Vedanta Biosciences, Inc."
"1-(fluoro-18F)-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol"		11/1/2017	A diagnostic for the management of progressive supranuclear palsy	Designated	Not FDA Approved for Orphan Indication	Aprinoia Therapeutics
ozanimod		11/1/2017	Treatment of pediatric Crohn’s disease	Designated	Not FDA Approved for Orphan Indication	Celgene International II Sarl
berotralstat	ORLADEYO™	11/1/2017	Treatment of C1-inhibitor-dependent angioedema (including prevention and treatment of attacks)	Designated/Approved		"BioCryst Pharmaceuticals, Inc."
recombinant fragment human surfactant protein-D		11/1/2017	Prevention of bronchopulmonary dysplasia	Designated	Not FDA Approved for Orphan Indication	Trimunocor Ltd.
vigabatrin and cosyntropin		11/1/2017	Treatment of infantile spasms	Designated	Not FDA Approved for Orphan Indication	"West Therapeutic Development, LLC"
ravulizumab-cwvz	Ultomiris	10/27/2017	Treatment of atypical hemolytic uremic syndrome (aHUS)	Designated/Approved		"Alexion Pharmaceuticals, Inc."
copper sulfate		10/26/2017	Treatment of keratoconus	Designated	Not FDA Approved for Orphan Indication	Glaukos Corporation
indoximod		10/26/2017	Treatment of Stage IIB to IV melanoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Lumos Pharma, Inc."
phenobarbital		10/25/2017	Treatment of neonatal seizures	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Renaissance SSA, LLC"
seribantumab		10/25/2017	Treatment of heregulin-positive non-small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Elevation Oncology, Inc."
16 base single stranded PNA oligonucleotide¿7 aminoacids peptide		10/25/2017	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	BIOGENERA SpA
"THIOMAB antibody drug conjugate comprised of humanized IgG1 anti-C-type lectin-like molecule-1 monoclonal antibody and DNA alkylating cross-linking agent pyrrolo [2,1-c][1,4] benzodiazepine dimer"		10/24/2017	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
cannabidiol (CBD)		10/24/2017	Treatment of Lennox-Gastaut syndrome	Designated	Not FDA Approved for Orphan Indication	"AXIUM Pharmaceuticals, Inc."
"9-cis,12-cis-11,11-D2-linoleic acid ethyl ester"		10/24/2017	Treatment of PLA2G6-associated neurodegeneration	Designated	Not FDA Approved for Orphan Indication	"Retrotope, Inc."
dopamine hydrochloride		10/24/2017	Prevention of intraventricular hemorrhage in hypotensive premature neonates	Designated	Not FDA Approved for Orphan Indication	"Brepco Biopharma, Ltd."
glasdegib		10/20/2017	Treatment of myelodysplastic syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
glepaglutide		10/20/2017	Treatment of short bowel syndrome	Designated	Not FDA Approved for Orphan Indication	Zealand Pharma A/S
valbenazine		10/19/2017	Treatment of pediatric patients with Tourette syndrome (TS).	Designated	Not FDA Approved for Orphan Indication	"Neurocrine Biosciences, Inc."
a strain of modified live probiotic bacterium Escherichia coli (E.coli) Nissle 1917 that has been modified to treat phenylketonuria by consuming phenylalanine within the gastrointestinal tract		10/18/2017	Treatment of phenylketonuria (PKU)	Designated	Not FDA Approved for Orphan Indication	"Synlogic, Inc."
vatiquinone		10/18/2017	Treatment of pontocerebellar hypoplasia	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue		10/18/2017	Treatment of fistulizing Crohn's disease	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
human IgG1 anti-human cytomegalovirus monoclonal antibodies LJP538 and LJP539		10/18/2017	Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
autologous human peripheral blood mononuclear cells incubated ex vivo with protein TBX-4000 (Tat-MYC)		10/16/2017	Treatment of malignant melanoma Stages IIb to IV	Designated	Not FDA Approved for Orphan Indication	"Taiga Biotechnologies, Inc."
upamostat		10/16/2017	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	RedHill Biopharma Ltd.
chimeric Antigen Receptor (CAR) directed against the target protein CD5		10/16/2017	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	iCell Gene Therapeutics
adeno-associated virus (AAV2) capsid variant carrying a transgene encoding a codon-optimized human choroideremia (CHM) gene		10/12/2017	Treatment of choroideremia (CHM)	Designated	Not FDA Approved for Orphan Indication	"4D Molecular Therapeutics, Inc."
synthetic cyclic 8 amino acid analog of human unacylated ghrelin		10/12/2017	Treatment of Prader-Willi syndrome (PWS)	Designated	Not FDA Approved for Orphan Indication	"Millendo Therapeutics, Inc."
autologous glioma tumor cells treated with 18-mer oligodeoxynucleotide sequence complementary to insulin-like growth factor type 1 receptor (IGF-1R) codons 2-7 in the IG-1R gene		10/11/2017	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Imvax, Inc."
avelumab		10/11/2017	Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ)	Designated	Not FDA Approved for Orphan Indication	"EMD Serono Research & Development Institute, Inc."
carmustine		10/11/2017	Conditioning treatment prior to hematopoietic progenitor cell transplantation	Designated	Not FDA Approved for Orphan Indication	ADIENNE S.A.
belumosudil	Rezurock	10/5/2017	Treatment of graft versus host disease (GVHD)	Designated/Approved		"Kadmon Pharmaceuticals, LLC"
filgotinib maleate		10/5/2017	Treatment of pediatric ulcerative colitis (UC)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
autologous T lymphocyte enriched population cultured in the rpesence of phosphatidylinositol 3-kinase inhibitor (bb007) that contains cells transduced with an anti-human B cell maturation antigen (BCMA02) chimeric antigen receptor (CAR) lentiviral vector		10/5/2017	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"bluebird bio, Inc."
humanized monoclonal antibody to CCR5		10/4/2017	Prevention of graft versus host disease	Designated	Not FDA Approved for Orphan Indication	"CytoDyn, Inc."
Adeno Associated Virus carried Multi Characteristic Opsin		10/3/2017	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	Nanoscope Therapeutics Inc.
Gaboxadol		10/3/2017	Treatment of Fragile X syndrome	Designated	Not FDA Approved for Orphan Indication	Ovid Therapeutics
pembrolizumab	Keytruda	10/3/2017	Treatment of Small Cell Lung Cancer	Designated/Approved		"Merck Sharp & Dohme, LLC"
"6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate"		10/3/2017	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
Recombinant humanized immunoglobulin gamma 1 monoclonal antibody (mAb) directed against the CemX segment of human membrane-bound immunoglobulin E (mIgE)		9/28/2017	Treatment of hyperimmunoglobulin E syndrome (HIES)	Designated	Not FDA Approved for Orphan Indication	"Oneness Biotech Co., Ltd."
Givinostat		9/28/2017	Treatment of polycythemia vera (PV)	Designated	Not FDA Approved for Orphan Indication	Italfarmaco SpA
tazemetostat		9/28/2017	Treatment of mesothelioma	Designated	Not FDA Approved for Orphan Indication	Epizyme Inc.
"1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt"		9/28/2017	Treatment of Acute Myeloid Leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Cardiff Oncology, Inc."
Autologous CD4+/CD8+ T cells expressing a BCMA-specific chimeric antigen receptor (CAR)		9/28/2017	Treatment of Multiple Myeloma (MM)	Designated	Not FDA Approved for Orphan Indication	"Juno Therapeutics, Inc."
adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene		9/27/2017	Treatment of Huntington's disease	Designated	Not FDA Approved for Orphan Indication	uniQure Inc.
Anti-STAT3 B VHH13 single domain antibody		9/27/2017	Treatment of osteosarcoma	Designated	Not FDA Approved for Orphan Indication	"Singh Biotechnology, LLC"
fimaporfin		9/27/2017	Treatment of cholangiocarcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	PCI Biotech AS
Nitric oxide		9/26/2017	Treatment of non-tuberculosis mycobacterial (NTM) infections	Designated	Not FDA Approved for Orphan Indication	Advanced Inhalation Therapies Ltd.
rofecoxib		9/26/2017	Treatment of hemophilic arthropathy (HA)	Designated	Not FDA Approved for Orphan Indication	"Tremeau Pharmaceuticals, Inc."
efgartigimod alfa-fcab	Vyvgart	9/20/2017	Treatment of myasthenia gravis	Designated/Approved		argenx BV
ex-vivo expanded placental adherent stromal cells		9/20/2017	Treatment of acute radiation syndrome	Designated	Not FDA Approved for Orphan Indication	Pluri Biotech Ltd.
Dalcinonacog Alfa		9/20/2017	Treatment for hemophilia B	Designated	Not FDA Approved for Orphan Indication	GC Biopharma Corp.
Mitoxantrone hydrochloride liposome		9/20/2017	Treatment of peripheral T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd."
Prismocitrate 18		9/19/2017	Use as replacement solution (includes regional anticoagulation of the extracorporeal circuit) in patients undergoing continuous renal replacement therapy (CRRT)	Designated	Not FDA Approved for Orphan Indication	Baxter Healthcare Corporation
non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA		9/19/2017	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	Nationwide Children's Hospital
ICG136:CD123-CD33cCAR T-cells		9/19/2017	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	iCell Gene Therapeutics
4-demethyl-4-cholesteryloxycarbonylpenclomedine		9/19/2017	Treatment of non-small cell lung cancer with CNS metastases	Designated	Not FDA Approved for Orphan Indication	"DEKK-TEC, Inc."
rimeporide		9/19/2017	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	EspeRare Foundation
"1-(3-{4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl}-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridin-6-yl)ethan-1-one"		9/19/2017	Treatment of Stargardt disease	Designated	Not FDA Approved for Orphan Indication	"Belite Bio, LLC"
Adeno-associated virus serotype 8 vector expressing B domain deleted codon optimized factor VIII		9/18/2017	Treatment of hemophilia A	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
liposomal oxaliplatin		9/18/2017	Treatment of pancreatic adenocarcinoma	Designated	Not FDA Approved for Orphan Indication	"KC Specialty Therapeutics, LLC"
lixivaptan		9/18/2017	Treatment of autosomal dominant polycystic kidney disease (ADPKD)	Designated	Not FDA Approved for Orphan Indication	"Palladio Biosciences, Inc."
priliximab		9/18/2017	Treatment of mycosis fungoides (MF)	Designated	Not FDA Approved for Orphan Indication	"Onco Therapies, Inc."
nelatimotide and adegramotide (DSP-7888 dosing emulsion)		9/18/2017	Treatment of brain cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sumitomo Pharma Oncology, Inc."
mRNA encoding human argininosuccinate lyase		9/18/2017	Treatment of argininosuccinate lyase deficiency	Designated	Not FDA Approved for Orphan Indication	"PhaseRx, Inc."
tucatinib	Tukysa	9/18/2017	Treatment of HER2+ colorectal cancer	Designated/Approved		Seagen Inc.
iclaprim		9/14/2017	Treatment of Staphylococus aureus lung infections in patients with cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	Motif Bio PLC
N-{2-[4-(2-Amino-5-chloropyridin-3-yl)phenoxy]pyrimidin-5-yl}-N'-[2-(methanesulfonyl)-5-(trifluoromethyl)phenyl]urea mono-4-toluenesulfonate		9/13/2017	Treatment of tropomyosin receptor kinase (Trk) gene fusion-positive cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Ono Pharmaceuticals Co. Ltd.
cipaglucosidase alfa-atga and miglustat	Pombiliti and Opfolda	9/13/2017	Treatment of Pompe disease	Designated/Approved		"Amicus Therapeutics, Inc."
antisense oligonucleotide targeting exon 73 in the COL7A1 gene		9/13/2017	Treatment of dystrophic epidermolysis bullosa	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Phoenicis Therapeutics, Inc."
cipaglucosidase alfa-atga and miglustat	Pombiliti and Opfolda	9/13/2017	Treatment of Pompe disease	Designated/Approved		"Amicus Therapeutics, Inc."
adeno-associated viral vector serotype 3B encoding shortened human ATP7B		9/7/2017	Treatment of Wilson's disease	Designated	Not FDA Approved for Orphan Indication	Vivet Therapeutics SAS
lisocabtagene maraleucel	Breyanzi	9/7/2017	Treatment of follicular lymphoma (FL)	Designated/Approved		"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company"
lisocabtagene maraleucel	Breyanzi	9/7/2017	Treatment of follicular lymphoma (FL)	Designated/Approved		"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company"
lisocabtagene maraleucel	Breyanzi	9/7/2017	Treatment of follicular lymphoma (FL)	Designated/Approved		"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company"
rusalatide acetate		9/7/2017	Treatment of acute radiation syndrome (ARS)	Designated	Not FDA Approved for Orphan Indication	"Chrysalis BioTherapeutics, Inc."
"(N-{2-[(6-{[(2,6-Dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4- yl)amino]-5-(4-ethylpiperazin-1-yl)phenyl}prop-2-enamide)"		9/7/2017	Treatment of hepatocellular carcinoma (HCC)	Designated	Not FDA Approved for Orphan Indication	Eisai Inc.
"N-(3-(2-(2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)quinazolin-8-yl)phenyl)acrylamide"		9/5/2017	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)	Designated	Not FDA Approved for Orphan Indication	"Checkpoint Therapeutics, Inc."
dupilumab	Dupixent	9/5/2017	Treatment of eosinophilic esophagitis	Designated/Approved		"Regeneron Pharmaceuticals, Inc."
dupilumab	Dupixent	9/5/2017	Treatment of eosinophilic esophagitis	Designated/Approved		"Regeneron Pharmaceuticals, Inc."
omaveloxolone		9/5/2017	Treatment of stage IIb through IV malignant melanoma	Designated	Not FDA Approved for Orphan Indication	"Reata Pharmaceuticals, Inc."
daratumumab		9/5/2017	Treatment of systemic amyloid light-chain (AL) amyloidosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
recombinant humanized IgG4P monoclonal antibody with specificity for human tau		9/5/2017	Treatment of progressive supranuclear palsy (PSP)	Designated	Not FDA Approved for Orphan Indication	"UCB, Inc."
crovalimab-akkz	Piasky	9/5/2017	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	Designated/Approved		Genentech Inc.
elamipretide		9/5/2017	Treatment of primary mitochondrial myopathy	Designated	Not FDA Approved for Orphan Indication	Stealth BioTherapeutics
synthetic stereopure antisense oligonucleotide specific to the mutant huntingtin mRNA transcript at the U variant of single nucleotide polymorphism rs326331		9/5/2017	Treatment of Huntington's disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Wave Life Sciences Ltd.
Artesunate		9/5/2017	Treatment of malaria	Designated	Not FDA Approved for Orphan Indication	"Guilin Pharmaceutical Co., Ltd."
Allogeneic cytomegalovirus cytotoxic T lymphocytes		8/31/2017	Treatment of cytomegalovirus viremia and disease in immunocompromised patients	Designated	Not FDA Approved for Orphan Indication	Memorial Sloan Kettering Cancer Center (MSKCC)
venetoclax		8/31/2017	Treatment of mantle cell lymphoma	Designated	Not FDA Approved for Orphan Indication	AbbVie Inc.
Salmonella Typhi strain Ty21a transfected with a plasmid vector encoding for the human vascular endothelial growth factor receptor 2		8/31/2017	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Vaximm GmbH
5-(4-carboxymethyl-phenylazo)-2-hydroxybenzoic acid disodium salt		8/31/2017	Treatment of pediatric ulcerative colitis (UC)	Designated	Not FDA Approved for Orphan Indication	"9 Meters Biopharma, Inc."
Peginterferon lambda-1a		8/25/2017	Treatment of hepatitis Delta virus infection	Designated	Not FDA Approved for Orphan Indication	"Eiger BioPharmaceuticals, Inc."
trazodone		8/18/2017	Treatment of Dravet syndrome	Designated	Not FDA Approved for Orphan Indication	"Epygenix Therapeutics, Inc."
nivolumab and relatlimab-rmbw	Opdualag	8/18/2017	Treatment of stage IIb to IV melanoma	Designated/Approved		Bristol-Myers Squibb Company
"2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-¿{6}-sulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine"		8/18/2017	Treatment of malaria	Designated	Not FDA Approved for Orphan Indication	"Paul Maher, MD"
"O,O'-Bis({4-[3,5-diiodo-4-(1-methylene-1,2,3-triazol-4-ylmethoxy)phenoxy]-3,5-diiodophenyl}acetic acid)polyethylene glycol"		8/18/2017	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"NanoPharmaceuticals, LLC"
"3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5 f]indol-7-yl)-pyrrole-2,5-dione"		8/18/2017	Treatment of Neuroblastoma	Designated	Not FDA Approved for Orphan Indication	Actuate Therapeutics
nevanimibe HCL		8/17/2017	Treatment of congenital adrenal hyperplasia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Millendo Therapeutics, Inc."
"humanized IgG4 Monoclonal Antibody against total complement component 1, subcomponent s (C1s)"		8/17/2017	Treatment of bullous pemphigoid (BP).	Designated	Not FDA Approved for Orphan Indication	Bioverativ USA Inc.
tetravalent tandem diabody binding both CD3 and CD33		8/17/2017	Treatment of patients with acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	"Amphivena Therapeutics, Inc."
obinutuzumab		8/17/2017	Treatment of splenic marginal zone lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech Inc., a member of the Roche Group"
nivolumab and ipilimumab	OPDIVO® and YERVOY®	8/16/2017	Treatment of mesothelioma	Designated/Approved		Bristol-Myers Squibb Company
tamibarotene		8/16/2017	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	"Syros Pharmaceuticals, Inc."
upadacitinib		8/16/2017	Treatment of pediatric systemic juvenile idiopathic arthritis	Designated	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
trans-resveratrol		8/16/2017	Treatment of Friedreich’s Ataxia (FRDA)	Designated	Not FDA Approved for Orphan Indication	Jupiter Orphan Therapeutics
nivolumab and ipilimumab	OPDIVO® and YERVOY®	8/16/2017	Treatment of mesothelioma	Designated/Approved		Bristol-Myers Squibb Company
nivolumab		8/16/2017	Treatment of mesothelioma	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Company
(R)-Azasetron besylate		8/16/2017	Prevention of platinum-induced ototoxicity in pediatric patients	Designated	Not FDA Approved for Orphan Indication	Sensorion SA
bitopertin		8/16/2017	Treatment of ß-thalassemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Hoffmann-La Roche Inc.
mobilized perioheral blood cells that have undergone ex-vivo negative functionial selection of GvHD-causing T-cells by short term incubation with Fas-ligand		8/15/2017	Prevention of graft versus host disease (GvHD)	Designated	Not FDA Approved for Orphan Indication	Cellect Biotherapeutics
dasiglucagon		8/10/2017	Treatment of hypoglycemia in patients with congenital hyperinsulinism (CH)	Designated	Not FDA Approved for Orphan Indication	Zealand Pharma A/S
entospletinib		8/10/2017	Prevention of chronic graft-versus-host disease	Designated	Not FDA Approved for Orphan Indication	"Kronos Bio, Inc."
nimodipine intravenous		8/10/2017	Treatment of subarachnoid hemorrhage	Designated	Not FDA Approved for Orphan Indication	Acasti Pharma Inc.
Recombinant human antibody directed against human misfolded superoxide dismutase 1		8/10/2017	Treatment of amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	AL-S Pharma SA
yinfenidone		8/10/2017	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"Sunshine Lake Pharma Co., Ltd"
cadazolid		8/8/2017	Treatment of clostridium difficile infection in pediatric patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Actelion Pharmaceuticals Ltd
cobitolimod		8/8/2017	Treatment of ulcerative colitis in pediatric patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	InDex Pharmaceuticals AB
apolipoprotein E mimetic peptide (AEM-28(R)-14)		8/7/2017	Treatment of homozygous familial hypercholesterolemia (HoFH)	Designated	Not FDA Approved for Orphan Indication	"LipimetiX Development, LLC"
blisibimod		8/7/2017	Treatment of patients with immunoglobulin A nephropathy	Designated	Not FDA Approved for Orphan Indication	"Anthera Pharmaceuticals, Inc."
oxfendazole		8/7/2017	Treatment of cysticercosis	Designated	Not FDA Approved for Orphan Indication	Oxfendazole Development Group
Leu-Lys-Gly-Gln-Leu-Arg-Cys-Ile		8/7/2017	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Kalos Therapeutics, Inc."
KIT and PDGFR inhibitor		8/7/2017	Treatment of glioblastoma multiforme and anaplastic astrocytomas	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Deciphera Pharmaceuticals, LLC"
nivolumab		8/7/2017	Treatment of anal cancer	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Company
"1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene"		8/3/2017	Treatment of subarachnoid hemorrhage (SAH)	Designated	Not FDA Approved for Orphan Indication	Edvince AB
human monoclonal antibody inhibitor of mannan binding lectin-associated serine protease-2		8/3/2017	Treatment of immunoglobulin A nephropathy (IgAN)	Designated	Not FDA Approved for Orphan Indication	Omeros Corporation
tesevatinib		8/3/2017	Treatment of non-small cell lung cancer with epithelial growth factor receptor-activating mutations	Designated	Not FDA Approved for Orphan Indication	"Kadmon Corporation, LLC"
brimonidine		8/3/2017	Treatment of ocular graft versus host disease	Designated	Not FDA Approved for Orphan Indication	"Ocugen, Inc."
seletalisib		8/3/2017	Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"UCB, Inc."
Granexin gel (aCTI peptide)		8/3/2017	Treatment of cutaneous radiation injury due to radiation disaster	Designated	Not FDA Approved for Orphan Indication	"Xequel Bio, Inc."
papaverine		8/3/2017	Treatment of mesenteric ischemia	Designated	Not FDA Approved for Orphan Indication	RNR BioMedical Inc.
"antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl"	Altuviiio	8/3/2017	Treatment of hemophilia A	Designated/Approved		"Bioverativ Therapeutics, Inc."
odiparcil		8/3/2017	Treatment of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome)	Designated	Not FDA Approved for Orphan Indication	Inventiva SA
gemfibrozil		8/2/2017	Treatment of neuronal ceroid lipofuscinoses	Designated	Not FDA Approved for Orphan Indication	"Polaryx Therapeutics, Inc."
crofelemer		8/2/2017	Treatment of short bowel syndrome	Designated	Not FDA Approved for Orphan Indication	"Napo Pharmaceuticals, Inc."
synthetic survivin peptide SVN53-67/M57-keyhole limpet hemocyanin		8/2/2017	treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"MimiVax, LLC"
cosyntropin		8/2/2017	Treatment of infantile spasms.	Designated	Not FDA Approved for Orphan Indication	"West Therapeutic Development, LLC"
miltefosine		8/2/2017	Treatment of schistosomiasis	Designated	Not FDA Approved for Orphan Indication	"Profounda, Inc."
carisbamate		8/2/2017	Treatment of Lennox-Gastaut syndrome	Designated	Not FDA Approved for Orphan Indication	"SK Life Sciences, Inc."
"1-{2-[3-(3,4-Dichlorophenyl)ureido]-6-methyl-pyrimidin-4-yl}-amino-3(dimethylamino)propane Di methansulfonate"		8/2/2017	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"Curtana Pharmaceuticals, Inc."
tocilizumab	Actemra	8/1/2017	Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome	Designated/Approved		"Genentech Inc., a member of the Roche Group"
recombinant adeno-associated virus vector expressing the retinitis pigmentosa GTPase regulator		7/31/2017	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	Beacon Therapeutics
canakinumab		7/31/2017	Treatment of adult-onset Still's Disease	Designated/Approved		Novartis Pharmaceuticals Corporation
alpha-1 proteinase inhibitor (human)		7/31/2017	Prevention of graft versus host disease	Designated	Not FDA Approved for Orphan Indication	"Kamada, Ltd."
Picropodophyllin		7/27/2017	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	MAX Kemikonsult AB
Bedaquiline		7/27/2017	Treatment of Nontuberculosis Mycobacteria infection	Designated	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
humanized immunoglobulin G1 (IgG1) T-cell bispecific (TCB) antibody targeting carcinoembryonic antigen (CEA) and CD3 epsilon chain (CD3e) on T-cells		7/27/2017	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
(s)-perillyl alcohol temozolomide carbamate		7/27/2017	Treatment of nasopharyngeal carcinoma	Designated	Not FDA Approved for Orphan Indication	"NeOnc Technologies, Inc."
antisense oligonucleotide targeting exon 13 of the USH2A gene		7/27/2017	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	ProQR Therapeutics IV B.V.
Cis-diamminedichloroplatinum (II) polyethylene glycol-polyglutamate (cis platinum PEG-pGlu) polymeric micelles		7/27/2017	Treatment of biliary tract carcinoma	Designated	Not FDA Approved for Orphan Indication	"NanoCarrier Co., Ltd"
Cipargamin		7/27/2017	Treatment of malaria	Designated	Not FDA Approved for Orphan Indication	"Paul Maher, MD"
sodium phenylbutyrate and taurursodiol	Relyvrio	7/27/2017	Treatment of amyotrophic lateral sclerosis (ALS)	Designated/Approved		"Amylyx Pharmaceuticals, Inc."
"(R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl) butanamide"		7/27/2017	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
Pro-Pro-Thr-Val-Pro-Thr-Arg		7/27/2017	Treatment of xeroderma pigmentosum	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	ProGeLife S.A.S
thalidomide		7/19/2017	Treatment of hereditary hemorrhagic telangiectasia	Designated	Not FDA Approved for Orphan Indication	PlumeStars s.r.l.
Fusion protein linking human frataxin to a cell-penetrant peptide		7/19/2017	Treatment of Friedreich's ataxia	Designated	Not FDA Approved for Orphan Indication	"Larimar Therapeutics, Inc."
Recombinant adenovirus carrying the cDNA coding sequence for the human interferon gamma gene		7/19/2017	"Treatment of basal cell carcinomas in individuals with basal cell nevus syndrome (BCNS), also known as Gorlin syndrome"	Designated	Not FDA Approved for Orphan Indication	Ascend Biopharmaceuticals Ltd
patidegib		7/19/2017	Treatment of nevoid basal cell carcinoma syndrome (Gorlin syndrome)	Designated	Not FDA Approved for Orphan Indication	"Sol-Gel Technologies, Ltd."
artemisone		7/19/2017	Treatment of malaria	Designated	Not FDA Approved for Orphan Indication	"Artemis Therapeutics, Inc."
recombinant adeno-associated viral vector serotype HSC expressing human phenylalanine hydroxylase		7/19/2017	Treatment of phenylalanine hydroxylase deficiency	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Homology Medicines, Inc."
"(R)-3-[3-Fluoro-4-(1-methyl-1,4,5,6-tetrahydro-1,2,4-triazin-4-yl)phenyl]-5(R)-(hydroxymethyl)oxazolidin-2-one"		7/19/2017	Treatment of tuberculosis	Designated	Not FDA Approved for Orphan Indication	"LigaChem Biosciences Inc.,"
Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol palmitoylated linker		7/19/2017	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	Designated	Not FDA Approved for Orphan Indication	"Ra Pharmaceuticals, Inc."
"One, two, three, or four antisense oligonucleotides of Phosphorodiamidate morpholino oligomer combination that skips exons 4, 5, 6, and 7 of the gamma sarcoglycan (SGCG) gene"		7/18/2017	"Treatment of limb-girdle muscular dystrophy type 2C that have mutations or deletions in exons 4, 5, 6, or 7of gamma sarcoglycan gene"	Designated	Not FDA Approved for Orphan Indication	Kurt+Peter Foundation
filgotinib maleate		7/18/2017	Treatment of pediatric Crohn's disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
ustekinumab		7/18/2017	Treatment of pediatric systemic lupus erythematosus	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Biotech, Inc."
Ranpirnase		7/14/2017	Treatment of Ebola virus disease (EVD)	Designated	Not FDA Approved for Orphan Indication	"Tamir Biotechnology, Inc."
etrolizumab		7/13/2017	Treatment of pediatric Crohn's disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
gilteritinib	XOSPATA	7/13/2017	Treatment of acute myeloid leukemia (AML)	Designated/Approved		"Astellas Pharma US, Inc."
autologous mononuclear cells derived from umbilical cord blood		7/13/2017	Treatment of severe pediatric congenital heart disease	Designated	Not FDA Approved for Orphan Indication	"Timothy Nelson, MD, PhD"
epirubicin-conjugated polymer micelles		7/13/2017	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"NanoCarrier Co., Ltd"
liposomal vinorelbine		7/13/2017	Treatment of soft tissue carcinoma	Designated	Not FDA Approved for Orphan Indication	"Taiwan Liposome Company, Ltd."
(20S)-7-tert-butyldimethysilyl-10-hydroxycamptothecin		7/13/2017	Treatment of glioblastoma multiforme (GBM)	Designated	Not FDA Approved for Orphan Indication	"Vivacitas Oncology, Inc."
tbo-filgrastim		7/10/2017	For the mobilization of peripheral blood progenitor cells (PBPCs) in healthy donors prior to allogeneic PBPC transplantation	Designated	Not FDA Approved for Orphan Indication	Sicor Biotech UAB
electrokinetically altered saline solution with an elevated dissolved oxygen concentration		7/10/2017	Treatment of amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	Revalesio Corporation
humanized immunoglobulin G4-variant monoclonal antibody directed against the p19 subunit of interleukin (IL)-23		7/6/2017	Treatment of pediatric Crohn's disease	Designated	Not FDA Approved for Orphan Indication	Eli Lilly & Company
"5-cholesten-3ß, 25-diol 3-sulfate sodium salt (25HC3S)"		7/6/2017	Treatment of primary sclerosing cholangitis (PSC)	Designated	Not FDA Approved for Orphan Indication	DURECT Corporation
"(1'R,6'R)-3-(Benzylamine)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)-[1,1'-bi(cyclohexane)]-2',3,6-triene-2,5-dione"		7/6/2017	Treatment of systemic scleroderma (SSc)	Designated	Not FDA Approved for Orphan Indication	Emerald Health Pharmaceuticals Inc.
blinatumomab		7/6/2017	Treatment of diffuse large B-cell lymphoma (DLBCL)	Designated	Not FDA Approved for Orphan Indication	Amgen Inc.
cosyntropin		7/6/2017	Treatment of Duchenne muscular dystrophy.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Mallinckrodt ARD Inc.
entrectinib	Rozlytrek	7/5/2017	Treatment of NTRK fusion-positive solid tumors	Designated/Approved		"Genentech, Inc."
entrectinib	Rozlytrek	7/5/2017	Treatment of NTRK fusion-positive solid tumors	Designated/Approved		"Genentech, Inc."
benznidazole		7/5/2017	Treatment of Chagas disease	Designated	Not FDA Approved for Orphan Indication	"Taran Therapeutics, Inc."
Autologous T cells transfected with mRNA encoding hepatitis B virus antigen-specific T cell receptor		7/3/2017	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Lion TCR Pte. Ltd.
"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride"		7/3/2017	Treatment of hepatocellular carcinoma (HCC)	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
tadekinig alfa		7/3/2017	"Treatment of Still's disease, including adult-onset Still's disease (AoSD) and systemic juvenile idiopathic arthritis (sJIA)"	Designated	Not FDA Approved for Orphan Indication	AB2 Bio Ltd
sirukumab		7/3/2017	Treatment of juvenile idiopathic arthritis (JIA) in pediatric patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
autologous T cells transduced with retroviral vector encoding a hepatitis B virus antigen-specific T cell receptor		7/3/2017	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Lion TCR Pte. Ltd.
antagonist of chemokine Ligand-2		7/3/2017	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
bardoxolone methyl		7/3/2017	Treatment of Alport Syndrome	Designated	Not FDA Approved for Orphan Indication	"Reata Pharmaceuticals, Inc."
Angiotensin II type 2 receptor agonist		7/3/2017	Treatment of pediatric cardiomyopathy	Designated	Not FDA Approved for Orphan Indication	"Novopyxis, Inc."
Small Molecule Bruton's Agammaglobulinemia Tyrosine Kinase (BKT) Inhibitor		6/29/2017	Treatment of Pemphigus Vulgaris	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Principia Biopharma Inc.
chemically modified recombinant sulfamidase		6/28/2017	Treatment of mucopolysaccharidosis type IIIA (MPS IIIA)	Designated	Not FDA Approved for Orphan Indication	Swedish Orphan Biovitrum AB (publ)
"O,O'-Bis({4-[3,5-diiodo-4-(1-methylene-1,2,3-triazol-4-ylmethoxy)phenoxy]-3,5-diiodophenyl}acetic acid)polyethylene glycol"		6/28/2017	Treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	"NanoPharmaceuticals, LLC"
retinol palmitate (vitamin A palmitate)		6/28/2017	Prevention of retinopathy of prematurity (ROP)	Designated	Not FDA Approved for Orphan Indication	orphanix GmbH
Glasdegib	DAURISMO	6/28/2017	Treatment of acute myeloid leukemia (AML)	Designated/Approved		"Pfizer, Inc."
ganaxolone	Ztalmy	6/28/2017	Treatment of cyclin-dependent kinase-like 5 (CDKL5) gene-related early-onset infantile epileptic encephalopathy	Designated/Approved		Marinus Pharmaceuticals
"(2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide"		6/28/2017	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Paul Maher, MD"
antisense oligonucleotide targeting the c.7595-2144A>G mutation in intron 40 of the USH2A gene		6/28/2017	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	ProQR Therapeutics IV B.V.
oral tyrosine kinase inhibitor		6/28/2017	Treatment of chronic myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Fusion Pharma, LLC"
hydrocortisone acetate		6/27/2017	Treatment of pediatric ulcerative colitis	Designated	Not FDA Approved for Orphan Indication	"Cristcot HCA, LLC"
(R)-praziquantel		6/27/2017	Treatment of schistosomiasis	Designated	Not FDA Approved for Orphan Indication	"Tongli Biomedical Co., Ltd. (TLB)"
"scAAV9.MeCP2.hCLN3, a self-complementary AAV serotype 9 expressing human CLN3 (hCLN3)"		6/27/2017	Treatment of neuronal ceroid lipofuscinosis Type 3 (CLN3)	Designated	Not FDA Approved for Orphan Indication	UNeMed Corporation
bomedemstat		6/26/2017	Treatment of myelofibrosis	Designated	Not FDA Approved for Orphan Indication	"Merck & Co., Inc."
chrysoeriol		6/22/2017	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Flavocure Biotech
[(S)-1-(L-valyl)-N_((S)-1-phenyl-2-(pyridin-2-yl)ethyl)pyrrolidine-2-carboxamide fumarate]		6/22/2017	Treatment of Rett Syndrome	Designated	Not FDA Approved for Orphan Indication	"Biohaven Pharmaceutical Holding Company, Ltd."
repotrectinib	Augtyro	6/22/2017	Treatment of non-small cell lung cancer with adenocarcinoma histology	Designated/Approved		Bristol Myers Squibb Company
belantamab mafodotin-blmf	BLENREP	6/22/2017	Treatment of multiple myeloma	Designated/Approved		GlaxoSmithKline Intellectual Property Development Ltd.
"(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate"		6/22/2017	Treatment of chronic myelomonocytic leukemia (CMML)	Designated	Not FDA Approved for Orphan Indication	Pharmavant 7 Sciences GmBH
tipifarnib		6/22/2017	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Paul Maher, MD"
bendamustine		6/22/2017	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Paul Maher, MD"
tilsotolimod sodium		6/21/2017	Treatment of melanoma stages IIb-IV.	Designated	Not FDA Approved for Orphan Indication	"Idera Pharmaceuticals, Inc."
"(S)-3-((S)-2-(2-((2,6-difluorophenyl)amino)-2-oxoacetamido)propanamido-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid"		6/21/2017	Treatment of primary sclerosing cholangitis (PSC)	Designated	Not FDA Approved for Orphan Indication	Conatus Pharmaceuticals
anti-angiogenic peptide		6/21/2017	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	Almac Group
"(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate"		6/21/2017	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	Pharmavant 7 Sciences GmBH
citric acid monohydrate		6/21/2017	Treatment of acute-on-chronic liver failure	Designated	Not FDA Approved for Orphan Indication	Versantis AG
miltefosine		6/19/2017	Treatment of disseminated amebiasis	Designated	Not FDA Approved for Orphan Indication	"Profounda, Inc."
miltefosine		6/19/2017	Treatment of granulomatous amebic encephalitis (GAE)	Designated	Not FDA Approved for Orphan Indication	"Profounda, Inc."
NELATIMOTIDE AND ADEGRAMOTIDE combination		6/19/2017	Treatment of myelodysplastic syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sumitomo Pharma Oncology, Inc."
fenfluramine	Fintepla	6/19/2017	Treatment of Lennox-Gastaut syndrome	Designated/Approved		"UCB, Inc."
omaveloxolone	Skyclarys	6/19/2017	Treatment of Friedreich's Ataxia	Designated/Approved		"Reata Phamaceuticals, Inc."
Tideglusib		6/19/2017	Treatment of myotonic dystrophy type 1 (DM1)	Designated	Not FDA Approved for Orphan Indication	AMO Pharma Ltd.
Anlotinib		6/19/2017	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"Advenchen Laboratories, LLC"
Trypsinogen/Chymotrypsinogen		6/19/2017	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Propanc Pty Ltd.
pamrevlumab		6/19/2017	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"FibroGen, Inc."
Cotsiranib		6/15/2017	Treatment of primary sclerosing cholangitis	Designated	Not FDA Approved for Orphan Indication	"Sirnaomics, Inc."
humanized immunoglobulin G4-variant monoclonal antibody directed against the p19 subunit of interleukin (IL)-23		6/15/2017	Treatment of ulcerative colitis in pediatric patients	Designated	Not FDA Approved for Orphan Indication	Eli Lilly & Company
burosumab-twza	Crysvita	6/15/2017	Treatment of tumor-induced osteomalacia (TIO) syndrome	Designated/Approved		"Kyowa Kirin, Inc."
tezacaftor/ivacaftor; ivacaftor	Symdeko	6/15/2017	Treatment of cystic fibrosis (CF)	Designated/Approved		Vertex Pharmaceuticals Inc.
apatinib mesylate		6/15/2017	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	"Elevar Therapeutics, Inc."
ibutamoren mesylate		6/15/2017	Treatment of growth hormone deficiency	Designated	Not FDA Approved for Orphan Indication	Lumos Pharma
Human monoclonal antibody against phosphorylcholine		6/15/2017	Prevention of arteriovenous fistula or arteriovenous graft failure in patients with end stage renal disease receiving hemodialysis or preparing for hemodialysis	Designated	Not FDA Approved for Orphan Indication	"Athera Biotechnologies, AB"
"N-(bromoacetyl)-3,3-dinitroazetidine"		6/15/2017	Treatment of neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	"EpicentRx, Inc."
tazemetostat		6/15/2017	Treatment of soft tissue sarcoma	Designated/Approved		"Epizyme, Inc."
entospletinib		6/15/2017	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Kronos Bio, Inc."
oxytocin		6/15/2017	Treatment of Prader-Willi syndrome	Designated	Not FDA Approved for Orphan Indication	"Eric Hollander, MD"
cobicistat	Tybost®	6/15/2017	Treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients	Designated/Approved		"Gilead Sciences, Inc."
"(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate"		6/15/2017	Treatment of Pediatric Crohn's disease	Designated	Not FDA Approved for Orphan Indication	AbbVie
pembrolizumab	Keytruda	6/15/2017	Treatment of esophageal carcinoma	Designated/Approved		"Merck Sharp & Dohme, LLC"
pembrolizumab	Keytruda	6/15/2017	Treatment of esophageal carcinoma	Designated/Approved		"Merck Sharp & Dohme, LLC"
"N-(bromoacetyl)-3,3-dinitroazetidine"		6/15/2017	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"EpicentRx, Inc."
monomethoxypolyethylene glycol recombinant adenosine deaminase		6/15/2017	Treatment of systemic sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Chiesi USA Inc.
tezacaftor/ivacaftor; ivacaftor	Symdeko	6/15/2017	Treatment of cystic fibrosis (CF)	Designated/Approved		Vertex Pharmaceuticals Inc.
cobicistat	Tybost®	6/15/2017	Treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients	Designated/Approved		"Gilead Sciences, Inc."
deferiprone		6/15/2017	Treatment of neurodegeneration with brain iron accumulation (NBIA)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Chiesi USA, Inc."
tezacaftor/ivacaftor; ivacaftor	Symdeko	6/15/2017	Treatment of cystic fibrosis (CF)	Designated/Approved		Vertex Pharmaceuticals Inc.
alirocumab	Praluent	6/15/2017	Treatment of homozygous familial hypercholesterolemia	Designated/Approved		"Regeneron Pharmaceuticals, Inc."
macitentan		6/15/2017	Treatment of chronic thromboembolic pulmonary hypertension (CTEPH)	Designated	Not FDA Approved for Orphan Indication	"Actelion Clinical Research, Inc."
"N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline"		6/14/2017	Treatment of hepatocellular carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"MedPacto, Inc."
humanized IgG1 monoclonal antibody targeting KIR3DL2		6/14/2017	Treatment of cutaneous T-cell lymphoma.	Designated	Not FDA Approved for Orphan Indication	Innate Pharma
Active calcium sensing receptor antagonist derived from tetrahydropyrazolopyrimidine		6/13/2017	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Centre Europe, Ltd."
nandrolone		6/13/2017	Treatment of Duchenne and Becker Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	Sarcomed AB
palm tocotrienol complex		6/13/2017	Treatment of cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)	Designated	Not FDA Approved for Orphan Indication	Hovid Berhad
pembrolizumab	Keytruda	6/12/2017	Treatment of hepatocellular carcinoma (HCC)	Designated/Approved		Merck Sharp & Dohme LLC
pembrolizumab	Keytruda	6/12/2017	Treatment of hepatocellular carcinoma (HCC)	Designated/Approved		Merck Sharp & Dohme LLC
ibrutinib		6/12/2017	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Pharmacyclics, LLC"
Bacillus subtilis oxalate decarboxylase		6/12/2017	Treatment of primary hyperoxaluria	Designated	Not FDA Approved for Orphan Indication	"Allena Pharmaceuticals, Inc."
adenovirus-associated viral vector serotype 5 containing the human RLBP1 gene		6/12/2017	Treatment of retinitis punctata albescens due to RLBP1 gene mutation	Designated	Not FDA Approved for Orphan Indication	"HORAMA, SAS"
"5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione"		6/12/2017	Treatment of fragile X syndrome	Designated	Not FDA Approved for Orphan Indication	Autifony Therapeutics Limited
Human alpha-1-antitrypsin		6/12/2017	Treatment of acute graft versus host disease	Designated	Not FDA Approved for Orphan Indication	"Paul Maher, MD"
loncastuximab tesirine-lpyl	Zynlonta	6/8/2017	Treatment of diffuse large B-cell lymphoma	Designated/Approved		ADC Therapeutics SA
Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through a protease cleavable valine-alanine linker		6/8/2017	Treatment of mantle cell lymphoma	Designated	Not FDA Approved for Orphan Indication	ADC Therapeutics SA
humanized monoclonal antibody against human PD-1		6/8/2017	Treatment of neuroendocrine tumors	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corp.
Oleoylethanolamide		6/8/2017	Treatment of Prader-Willi syndrome	Designated	Not FDA Approved for Orphan Indication	"NutriForward, LLC"
4¿-(p-fluorobenzyl)tylosin A		6/8/2017	Treatment of onchocerciasis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AbbVie Inc.
"2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile"		6/8/2017	Treatment of idiopathic pulmonary fibrosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Galapagos NV
sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]		6/8/2017	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Bold Therapeutics Inc.
20% Lipid emulsion solution		6/8/2017	Treatment of local anesthetic systemic toxicity	Designated	Not FDA Approved for Orphan Indication	ResQ Pharma
human IgG4-based anti-CD20 x anti-CD3 bispecific monoclonal antibody		6/6/2017	Treatment of diffuse large b-cell lymphoma.	Designated	Not FDA Approved for Orphan Indication	"Regeneron Pharmaceuticals, Inc."
DNA Plasmid Vector encoding IL-12 (pUMVC3-hIL-12-NGVL331)		6/6/2017	"Treatment of Stage IIB, IIc, III, and IV melanoma (which includes use in combination with pembrolizumab)"	Designated	Not FDA Approved for Orphan Indication	OncoSec Medical Incorporated
4¿-(p-fluorobenzyl)tylosin A		6/6/2017	Treatment of lymphatic filariasis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AbbVie Inc.
emtricitabine and tenofovir alafenamide	Descovy	6/6/2017	Treatment of HIV-1 infection in pediatric patients under 12 years of age	Designated/Approved		"Gilead Sciences, Inc."
Cannabidivarin		6/6/2017	Treatment of Fragile X syndrome	Designated	Not FDA Approved for Orphan Indication	GW Research Ltd.
pembrolizumab		6/6/2017	Treatment of follicular lymphoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Merck, Sharp & Dohme Corp"
small molecule inhibitor of the Wnt pathway		6/6/2017	Treatment of idiopathic pulmonary fibrosis (IPF).	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Biosplice Therapeutics, Inc."
emtricitabine and tenofovir alafenamide	Descovy	6/6/2017	Treatment of HIV-1 infection in pediatric patients under 12 years of age	Designated/Approved		"Gilead Sciences, Inc."
Humanized IgG4 monoclonal antibody that antagonizes endothelin-1 receptor subtype A		6/6/2017	Treatment of pulmonary arterial hypertension (PAH)	Designated	Not FDA Approved for Orphan Indication	"GenThera, Inc."
macitentan		6/6/2017	Treatment of Fontan-Palliated patients	Designated	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
bis-choline tetrathiomolybdate		6/5/2017	Treatment of Amyotrophic Lateral Sclerosis (ALS)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Alexion Pharmaceutical Inc.
recombinant human palmitoyl-protein thioeserase-1 (rhPPT1)		6/5/2017	Treatment of PPT1-deficient neuronal ceroid lipofuscinoses	Designated	Not FDA Approved for Orphan Indication	"Collaborations Pharmaceuticals, Inc."
"6-Amino-9-[(3R)-1-(but-2-ynoyl)pyrrolidin-3-yl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one monohydrochloride"		6/5/2017	Treatment of chronic lymphocytic leukemia.	Designated	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
Sodium Stibogluconate		6/5/2017	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	BioXcel Corporation
tucatinib		6/5/2017	Treatment of breast cancer patients with brain metastases.	Designated/Approved		Seagen Inc.
Recombinant human fibroblast growth factor receptor 3		6/2/2017	Treatment of achondroplasia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pfizer Inc.
etelcalcetide		5/31/2017	Treatment of pediatric hyperparathyroidism	Designated	Not FDA Approved for Orphan Indication	"Amgen, Inc."
"L-3,4-Dihydroxy-6-[18F]fluorophenylalanine"		5/31/2017	Diagnostic agent for the management of patients with aromatic L-amino acid decarboxylase deficiency (AADC).	Designated	Not FDA Approved for Orphan Indication	"Advanced Imaging Projects, LLC"
autologous Epstein-Barr specific T-cells		5/31/2017	Treatment of post-transplant lymphoproliferative disorder	Designated	Not FDA Approved for Orphan Indication	BCM Center for Cell and Gene Therapy
irinotecan liposome injection		5/24/2017	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Ipsen Bioscience, Inc."
resiquimod		5/24/2017	Treatment of cutaneous T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Galderma Research and Development, LLC"
ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the human COL7A1 gene.		5/24/2017	Treatment of dystrophic Epidermolysis Bullosa	Designated	Not FDA Approved for Orphan Indication	Abeona Therapeutics
Recombinant adeno-associated virus serotype 9 vector expressing codon-optimized miniaturized version of DMD gene		5/22/2017	Treatment of Duchenne Muscular Dystrophy (DMD)	Designated	Not FDA Approved for Orphan Indication	"Bamboo Therapeutics, w wholly owned subsidiary of Pfizer"
"bictegravir, emtricitabine, and tenofovir alafenamide"	Biktarvy	5/17/2017	Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients	Designated/Approved		"Gilead Sciences, Inc."
"bictegravir, emtricitabine, and tenofovir alafenamide"	Biktarvy	5/17/2017	Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients	Designated/Approved		"Gilead Sciences, Inc."
"bictegravir, emtricitabine, and tenofovir alafenamide"	Biktarvy	5/17/2017	Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients	Designated/Approved		"Gilead Sciences, Inc."
sirolimus	Hyftor	5/17/2017	Treatment of angiofibroma associated with tuberous sclerosis	Designated/Approved		"NobelPharma Co., LTD"
exenatide		5/16/2017	Treatment of idiopathic intracranial hypertension	Designated	Not FDA Approved for Orphan Indication	Boyd Consultants Ltd
Ritanserin		5/11/2017	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	The University of Virginia/Benjamin Purow
fast skeletal muscle troponin activator		5/11/2017	Treatment of spinal muscular atrophy	Designated	Not FDA Approved for Orphan Indication	"Cytokinetics, Inc."
"2-amino-1-[2-(4-fluoro-phenyl)-3-(4-fluoro-phenyl)amino)-8,8-dimethyl-5,6-dihydro-imidazo[1,2-a]pyrazin-7(8H)-yl)-ethanone diphosphate"		5/11/2017	Treatment of malaria.	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
povidone-iodine 0.5% (w/w) in dimethylsulfoxide 44% (w/w)		5/11/2017	Treatment of microbial keratitis (which includes Acanthamoeba keratitis).	Designated	Not FDA Approved for Orphan Indication	"Veloce BioPharma, LLC"
"humanized anti-CD19, Fc engineered, monoclonal antibody with enhanced binding to FcyRIIb"		5/9/2017	Treatment of immunoglobulin G4-related disease	Designated	Not FDA Approved for Orphan Indication	Zenas BioPharma (USA) LLC.
larotrectinib	VITRAKVI	5/9/2017	Treatment of solid tumors with NTRK-fusion proteins	Designated/Approved		Bayer HealthCare Pharmaceuticals Inc.
rilonacept		5/9/2017	Treatment of deficiency of interleukin-1 receptor antagonist (DIRA)	Designated	Not FDA Approved for Orphan Indication	"Regeneron Pharmaceuticals, Inc."
Autologous CD34+ hematopoietic stem cells transduced with an hCD11b lentiviral vector encoding for the human N-sulfoglucosamine sulfohydrolase (SGSH) gene		5/3/2017	Treatment of mucopolysaccharidosis IIIA	Designated	Not FDA Approved for Orphan Indication	Orchard Therapeutics Ltd.
"Recombinant adeno-associated viral vector, AAV2 serotype 6 (rAAv2/6), expressing human factor 8 (hf8) cDNA"		5/3/2017	Treatment of hemophilia A	Designated	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
macromolecular conjugate of heparin sodium on a polymer backbone		5/2/2017	Prevention of ischemia-reperfusion injury associated with solid organ tranplantation	Designated	Not FDA Approved for Orphan Indication	Corline Biomedical AB
Cisplatin loaded hyaluronate film for implant		5/2/2017	Treatment of mesothelioma	Designated	Not FDA Approved for Orphan Indication	PlumeStars s.r.l.
olutasidenib	Rezlidhia	4/27/2017	Treatment of acute myeloid leukemia	Designated/Approved		"Rigel Pharmaceuticals, Inc."
ivosidenib	Tibsovo	4/26/2017	Treatment of cholangiocarcinoma	Designated/Approved		Servier Pharmaceuticals LLC
small molecule Mas receptor agonist		4/25/2017	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	"Capacity Bio, Inc."
Triciribine phosphate		4/24/2017	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Prescient Therapeutics LTD
Immune Globulin Intravenous (Human)	Octagam 10%	4/19/2017	Treatment of dermatomyositis	Designated/Approved		"OCTAPHARMA USA, Inc."
clemizole		4/19/2017	Treatment of Dravet syndrome	Designated	Not FDA Approved for Orphan Indication	"Epygenix Therapeutics, Inc."
Peptide inhibiting murine double minute 2 (MDM2) and murine double minute X (MDMX)		4/19/2017	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Aileron Therapeutics, Inc."
modified vitamin D binding protein		4/17/2017	Treatment of recurrent respiratory papillomatosis.	Designated	Not FDA Approved for Orphan Indication	"Efranat, Ltd."
2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol		4/17/2017	Treatment of congenital ichthyosis	Designated	Not FDA Approved for Orphan Indication	Aldeyra Therapeutics
trifluridine/tipiracil	LONSURF	4/17/2017	Treatment of gastric cancer including cancer of the gastroesophageal junction	Designated/Approved		"Taiho Oncology, Inc."
triclabendazole	Egaten	4/17/2017	Treatment of fascioliasis	Designated/Approved		Novartis Pharmaceuticals Corporation
lorcaserin		4/17/2017	Treatment of Dravet syndrome	Designated	Not FDA Approved for Orphan Indication	"Epygenix Therapeutics, Inc."
itacitinib		4/17/2017	Treatment of graft versus host disease	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
Human major histocompatibility complex (MHC) non-restricted T-cell line 104		4/17/2017	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Galileo Research srl
Huperzine A		4/12/2017	Treatment of Dravet syndrome	Designated	Not FDA Approved for Orphan Indication	"Supernus Pharmaceuticals, Inc."
Redaporfin		4/12/2017	Treatment of cholangiocarcinoma	Designated	Not FDA Approved for Orphan Indication	"Luzitin, S.A."
Tasquinimod		4/10/2017	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Active Biotech AB
levosimendan		4/10/2017	Treatment of amyotrophic lateral sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Orion Corporation
tubimod		4/10/2017	Treatment of active tuberculosis	Designated	Not FDA Approved for Orphan Indication	"Immunitor, Inc."
merestinib		4/10/2017	Treatment of biliary tract cancer	Designated	Not FDA Approved for Orphan Indication	Eli Lilly and Company
recombinant human club cell protein		4/10/2017	Treatment of bronchiolitis obliterans	Designated	Not FDA Approved for Orphan Indication	"Trove Therapeutics, Inc."
bromodomain and Extra-Terminal (BET) Inhibitor		4/5/2017	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene Corporation
4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide		3/30/2017	Treatment of cholangiocarcinoma	Designated	Not FDA Approved for Orphan Indication	RedHill Biopharma Ltd.
"3,4-diaminopyridine"		3/30/2017	Treatment of congenital myasthenic syndrome (CMS)	Designated	Not FDA Approved for Orphan Indication	"Catalyst Pharmaceuticals, Inc."
liposomal oxaliplatin		3/30/2017	Treatment of cholangiocarcinoma	Designated	Not FDA Approved for Orphan Indication	"KC Specialty Therapeutics, LLC"
MRG-106 oligonucleotide inhibitor of microRNA miR-155-5p		3/30/2017	Treatment of mycosis fungoides	Designated	Not FDA Approved for Orphan Indication	"miRagen Therapeutics, Inc."
(+)-a-dihydrotetrabenazine		3/30/2017	Treatment pediatric patients with Tourette's syndrome	Designated	Not FDA Approved for Orphan Indication	"Adeptio Pharmaceuticals, Ltd"
Valproic acid		3/30/2017	Treatment of diffuse large B-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	Valcuria AB
"generation 4 hydroxyl-terminated polyamidoamine dendrimer containing an ethylene diamine (EDA) core, amidoamine repate units, and 64 hydroxyl end groups"		3/22/2017	Treatment of x-linked adrenoleukodystrophy	Designated	Not FDA Approved for Orphan Indication	Ashvattha Therapeutics
Vedolizumab		3/21/2017	Treatment of graft versus host disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
ganitumab		3/21/2017	Treatment of Ewing sarcoma.	Designated	Not FDA Approved for Orphan Indication	"NantCell, Inc., a wholly-owned subsidiary of ImmunityBio, Inc."
N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine disulphate salt		3/20/2017	Treatment of progressive supranuclear palsy	Designated	Not FDA Approved for Orphan Indication	Alzprotect sas
Cell-penetrating dominant-negative activating transcription factor 5		3/20/2017	Treatment of glioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sapience Therapeutics, Inc"
avacopan		3/20/2017	Treatment of C3 glomerulopathy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ChemoCentryx, Inc."
liposomal annamycin		3/20/2017	Treatment of acute myeloid leukemia.	Designated	Not FDA Approved for Orphan Indication	"Moleculin Biotech, Inc."
Talabostat		3/20/2017	Treatment of stages IIb through IV melanoma	Designated	Not FDA Approved for Orphan Indication	BioXcel Corporation
1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane		3/20/2017	Treatment of infantile spasms	Designated	Not FDA Approved for Orphan Indication	"Bio-Pharm Solutions, Co., Ltd."
pentetrazol		3/16/2017	Treatment of narcolepsy	Designated	Not FDA Approved for Orphan Indication	"Balance Therapeutics, Inc."
Recombinant human placental growth factor		3/16/2017	Treatment of severe preeclampsia	Designated	Not FDA Approved for Orphan Indication	"Aggamin, LLC"
"synthetic, single stranded, fully phosphorothioated 2¿-OMethyl-RNA and DNA mixmer oligonucleotide-based compound targeted against natural antisense transcripts (NATs)"		3/16/2017	Treatment of Dravet Syndrome	Designated	Not FDA Approved for Orphan Indication	Camp4 Therapeutics
Talabostat		3/16/2017	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	BioXcel Corporation
Mutated form of human acetylcholine receptor a1 extracellular domain subunit		3/16/2017	Treatment of myasthenia gravis	Designated	Not FDA Approved for Orphan Indication	Toleranzia AB
activated natural killer[aNK])		3/15/2017	Treatment of Merkel cell carcinoma	Designated	Not FDA Approved for Orphan Indication	"ImmunityBio, Inc."
fixed dose combination of methimazole and liothyronine		3/6/2017	Treatment of brain metastases in patients with primary lung cancer	Designated	Not FDA Approved for Orphan Indication	Musli Thyropeutics Ltd.
melatonin		3/2/2017	Treatment of acute acetaminophen overdose	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
cabozantinib	CABOMETYX	3/2/2017	Treatment of hepatocellular carcinoma.	Designated/Approved		"Exelixis, Inc."
hydroxyurea	Xromi	3/2/2017	Treatment of sickle cell anemia in pediatric patients	Designated/Approved		Nova Laboratories Limited
(s)-perillyl alcohol temozolomide carbamate		2/28/2017	Treatment of intracranially located metastases from breast cancer	Designated	Not FDA Approved for Orphan Indication	"NeOnc Technologies, Inc."
3-pentylbenzeneacetic acid sodium salt		2/28/2017	Treatment of Alström syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Liminal BioSciences Limited
asciminib	Scemblix	2/27/2017	Treatment of chronic myelogenous leukemia	Designated/Approved		Novartis Pharmaceutical Corporation
asciminib	Scemblix	2/27/2017	Treatment of chronic myelogenous leukemia	Designated/Approved		Novartis Pharmaceutical Corporation
Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human iduronate 2-sulfatase (hIDS) gene		2/27/2017	Treatment of mucopolysaccharidosis type II	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sangamo Therapeutics, Inc."
Fully human IgG1 antibody specific for CD33		2/27/2017	Treatment of myelodysplastic syndromes (MDS)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
"6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro[cyclohexane-1,3'-imidazo[1,5a]pyridine]-1',5'-dione hydrochloride"		2/23/2017	Treatment of diffuse large B-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	eFFECTOR Therapeutics
Recombinant human histidyl-tRNA synthetase		2/23/2017	Treatment of patients with limb girdle muscular dystrophy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	aTyr Pharma
sofosbuvir and velpatasvir	Epclusa	2/22/2017	Treatment of pediatric chronic hepatitis C virus (HCV) infection	Designated/Approved		"Gilead Sciences, Inc."
abatacept		2/22/2017	Treatment of idiopathic inflammatory myopathy (IIM)	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Research & Development
Abatacept		2/22/2017	Treatment of giant cell arteritis	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Research & Development
ustekinumab		2/22/2017	Treatment of pediatric ulcerative colitis	Designated	Not FDA Approved for Orphan Indication	"Janssen Biotech, Inc."
sofosbuvir and velpatasvir	Epclusa	2/22/2017	Treatment of pediatric chronic hepatitis C virus (HCV) infection	Designated/Approved		"Gilead Sciences, Inc."
"5-aza-2'-dexocytidine combined with 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one"		2/16/2017	Treatment of thalassemia	Designated	Not FDA Approved for Orphan Indication	Novo Nordisk Inc.
melatonin		2/14/2017	Treatment of short bowel syndrome	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
"6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridine-3-one monocitrate"		2/14/2017	Treatment of diffuse large B-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
Glucopyranosyl lipid A stable emulsion		2/14/2017	Treatment of follicular lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Immune Design Corp.
nelfinavir		2/14/2017	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Swiss Group for Clinical Cancer Research (SAKK)
EnGeneIC delivery vehicles loaded with doxorubicin and targeted to tumor with sequences from Vectibix and mouse monoclonal antibody		2/14/2017	Treatment glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	EnGeneIC Ltd
dextromethorphan hydrobromide/quinidine sulfate		2/14/2017	Treatment of amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	Avanir Pharmaceuticals
sirolimus		2/13/2017	Treatment of tuberous sclerosis complex-related facial angiofibromas	Designated	Not FDA Approved for Orphan Indication	"Aucta Pharmaceuticals, Inc."
milademetan		2/13/2017	Treatment of liposarcoma	Designated	Not FDA Approved for Orphan Indication	Rain Oncology Inc.
Atezolizumab		2/13/2017	"Treatment of patients with stage IIb, IIc, III, and IV melanoma"	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
atezolizumab	TECENTRIQ®	2/13/2017	"Treatment of Stage llb, llc, lll and IV melanoma"	Designated/Approved		"Genentech, Inc."
copanlisib		2/7/2017	Treatment of nodal marginal zone lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bayer HealthCare Pharmaceuticals, Inc."
copanlisib		2/7/2017	Treatment of extranodal marginal zone lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bayer HealthCare Pharmaceuticals, Inc."
Modified cholera toxin		2/7/2017	Treatment of Gaucher disease	Designated	Not FDA Approved for Orphan Indication	"ERAD Therapeutics, Inc."
"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one-2HCL"		2/7/2017	Treatment of mantle cell lymphoma (MCL)	Designated	Not FDA Approved for Orphan Indication	"Chimerix, Inc."
copanlisib		2/7/2017	Treatment of splenic marginal zone lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bayer HealthCare Pharmaceuticals, Inc."
bomedemstat		2/7/2017	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	"Merck & Co., Inc."
Brentuximab vedotin		2/6/2017	Treatment of cutaneous T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	Seagen Inc.
Anti-HER2 bispecific antibody		2/6/2017	"Treatment of gastric cancer, including cancer of the gastroesophageal junction"	Designated	Not FDA Approved for Orphan Indication	Jazz Pharmaceuticals Ireland Limited
donislecel-jujn	Lantidra	2/1/2017	Treatment of Brittle Type 1 Diabetes	Designated/Approved		CellTrans Inc.
"6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-one"		1/31/2017	Treatment of sickle cell disease (SCD)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Imara Inc.
laquinimod sodium		1/31/2017	Treatment of Huntington's Disease	Designated	Not FDA Approved for Orphan Indication	Active Biotech AB
nitric oxide		1/31/2017	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	VERO Biotech
adeno-associated virus (AAV) serotype rh.10 expressing beta-galactosidase		1/30/2017	Treatment of GM1 gangliosidosis	Designated	Not FDA Approved for Orphan Indication	"Lysogene, Inc."
hydroxypioglitazone		1/30/2017	Treatment of X-linked adrenoleukodystrophy	Designated	Not FDA Approved for Orphan Indication	Minoryx Therapeutics S.L.
Para-toluenesulfonamide		1/30/2017	Treatment of adenoid cystic carcinoma	Designated	Not FDA Approved for Orphan Indication	PTS International Inc.
vixotrigine		1/30/2017	Treatment of erythromelalgia	Designated	Not FDA Approved for Orphan Indication	"Biogen, Inc."
melatonin		1/25/2017	Treatment of necrotizing enterocolitis	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
Dendritic cell/tumor cell fusion vaccine + recombinant human interleukin 12		1/25/2017	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	CyTIX Inc.
3-[4-(lH-imidazol-l-ylmethyl)phenyl]-5-(2-methylpropyl) thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt		1/25/2017	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	Vicore Pharma AB
"(R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl)phenyl)-N,N,N-trimethylethanaminium methanesulfonate dehydrate"		1/25/2017	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	Chiesi Farmaceutici S.p.A.
nicotinamide riboside		1/25/2017	"Treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS)"	Designated	Not FDA Approved for Orphan Indication	Rejuvenation Therapeutics
adeno-associated viral vector serotype 2.7m8 containing the chrimsonR-tdTomato gene		1/25/2017	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	GenSight Biologics
nitric oxide		1/25/2017	Treatment of pulmonary arterial hypertension excluding persistent pulmonary hypertension of the newborn	Designated	Not FDA Approved for Orphan Indication	"GeNo, LLC"
Human monoclonal antibody directed against human Activin A		1/19/2017	Treatment of fibrodysplasia ossificans progressiva	Designated	Not FDA Approved for Orphan Indication	"Regeneron Pharmaceuticals, Inc."
humanized IgG4 monoclonal antibody binding to human C1q		1/19/2017	Treatment of Guillain-Barre Syndrome	Designated	Not FDA Approved for Orphan Indication	"Annexon, Inc."
D-tagatose		1/19/2017	Treatment of Prader-Willi Syndrome	Designated	Not FDA Approved for Orphan Indication	Biospherics.net LLC
umbralisib in combination with ublituximab		1/19/2017	Treatment of diffuse large B-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"TG Therapeutics, Inc."
D9-ivacaftor		1/18/2017	Treatment of cystic fibrosis (CF)	Designated	Not FDA Approved for Orphan Indication	"Vertex Pharmaceuticals, Inc."
hyaluronic acid		1/18/2017	Treatment of emphysema due to alpha1-antitrypsin deficiency.	Designated	Not FDA Approved for Orphan Indication	"Gerard M. Turino, MD"
3-[3-(6-guanidino-1-oxoisoindolin-2yl) propanamido]-3-(pyridine-3yl) propanoic acid dihydrochloride		1/17/2017	Treatment of retinopathy of prematurity	Designated	Not FDA Approved for Orphan Indication	"Advanced Imaging Projects, LLC"
"2-Amino-4-[11C]methylsulfanyl-butanoic acid, l-[S methyl[11C]methionine"		1/17/2017	Diagnostic agent for the Clinical Management of Medulloblastoma	Designated	Not FDA Approved for Orphan Indication	"Advanced Imaging Projects, LLC"
(E)-N¿-(1-(5-Chloro-2-hydroxy phenyl)Ethylidene)-3-((4-Methyl Piperazin-1-yl) Sulfonyl) Benzohydrazide Mesylate		1/12/2017	Treatment of Ewing's sarcoma.	Designated	Not FDA Approved for Orphan Indication	Salarius Pharmaceuticals
viltolarsen	VILTEPSO	1/12/2017	Treatment of Duchenne Muscular Dystrophy	Designated/Approved		"NS Pharma, Inc."
anti-interleukin 21 (NNC0114-0006) in combination with liraglutide		1/12/2017	Treatment of Type I Diabetes Mellitus with residual beta cell function.	Designated	Not FDA Approved for Orphan Indication	"Novo Nordisk, Inc."
tadekinig alfa		1/12/2017	Treatment of hemophagocytic lymphohistiocytosis	Designated	Not FDA Approved for Orphan Indication	AB2 Bio Ltd
Glyburide		1/12/2017	Treatment of severe cerebral edema in patients with acute ischemic stroke	Designated	Not FDA Approved for Orphan Indication	"Remedy Pharmaceuticals, Inc."
methyldopa		1/12/2017	Treatment of type 1 diabetes in DQ8 positive patients with residual beta cell function	Designated	Not FDA Approved for Orphan Indication	IM Therapeutics LLC
Non-replicating recombinant adeno-associated viral vector expressing the human acid alpha-glucosidase gene		1/11/2017	Treatment of Pompe disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Asklepios Biopharmaceutics, Inc"
4-methylpiperazine-1-carboxylic acid [1-(3-benzenesufonyl-1-phenethylallyl-carbamoyl)-2-phenylethyl] amide		1/11/2017	Treatment of Chagas disease.	Designated	Not FDA Approved for Orphan Indication	Center for Discovery & Innovation in Parasitic Diseases
"Monovalent replication-incompetent adenovirus serotype 26 (Ad26) vaccine, AD26.ZEBOV in combination with multivalent replication-defective Modified Vaccinia Ankara (MVA)-Bavarian Nordic (BN) vaccine, MVA-mBN226B"		1/11/2017	Pre-exposure prophylaxis of Ebola virus disease	Designated	Not FDA Approved for Orphan Indication	Janssen Vaccines and Prevention B.V.
Ritonavir powder for oral suspension	Norvir Powder for Oral Suspension	1/11/2017	Use with other antiretroviral agents for the treatment of pediatric HIV-1 infection	Designated/Approved/Designation Withdrawn or Revoked		AbbVie Inc.
human single domain antibody-like protein inhibitor of the chemokine receptor type 4		1/11/2017	Treatment of idiopathic pulmonary fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AdAlta Limited
"protoplasmic protein matrix, omega-3 fatty oils, vitamins, minerals and trace elements, cell membrane matrix phospholipid, entracellular matrix, lipids, medium chain triglycerides, longer chain triglycerides, carbohydrates, probiotic, and phytonutrients"		1/11/2017	Treatment of juvenile rheumatoid arthritis.	Designated	Not FDA Approved for Orphan Indication	"Leonard S. Girsh, MD"
glecaprevir and pibrentasvir	MAVYRET	1/9/2017	Treatment of pediatric patients with chronic hepatitis C virus infection	Designated/Approved		"AbbVie, Inc."
Clenbuterol		1/9/2017	Treatment of Pompe disease (glycogen storage disease type II)	Designated	Not FDA Approved for Orphan Indication	"Dwight D. Koeberl, MD, PhD"
adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human alpha-L-iduronidase (hIDUA) gene		1/9/2017	Treatment of mucopolysaccharidosis type I (MPS I)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sangamo Therapeutics, Inc."
glecaprevir and pibrentasvir	Mavyret	1/9/2017	Treatment of pediatric patients with chronic hepatitis C virus infection	Designated/Approved		"AbbVie, Inc."
Vancomycin HCL and Tobramycin sulfate multi-pack component of the Joint Purification Systems X7 Spacer		1/9/2017	Treatment of periprosthetic joint infection	Designated	Not FDA Approved for Orphan Indication	Joint Purification Systems LLC
L-citrulline		1/9/2017	Prevention of clinical sequelae of acute lung injury induced by cardiopulmonary bypass in pediatric patients	Designated	Not FDA Approved for Orphan Indication	"Asklepion Pharmaceuticals, LLC"
umbralisib in combination with ublituximab		1/5/2017	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"TG Therapeutics, Inc."
echinomycin		1/5/2017	Treatment of graft-versus-host disease (GVHD)	Designated	Not FDA Approved for Orphan Indication	"OncoC4, Inc."
"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile"		1/5/2017	Treatment of epidermolysis bullosa acquisita	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Almirall, S.A."
Celecoxib oral liquid suspension		1/5/2017	Treatment of pediatric juvenile idiopathic arthritis	Designated	Not FDA Approved for Orphan Indication	"NuBioPharma, LLC"
cytomegalovirus specific cytotoxic T lymphocytes		1/5/2017	Treatment of cytomegalovirus infection in severely immunocompromised patients	Designated	Not FDA Approved for Orphan Indication	"ViraCyte, LLC"
ravulizumab-cwvz	Ultomiris	1/4/2017	Treatment of paroxysmal nocturnal hemoglobinuria	Designated/Approved		"Alexion Pharmaceuticals, Inc."
risdiplam	Evrysdi	1/4/2017	Treatment of spinal muscular atrophy	Designated/Approved		"Genentech, Inc., a Member of the Roche Group"
ravulizumab-cwvz	Ultomiris	1/4/2017	Treatment of paroxysmal nocturnal hemoglobinuria	Designated/Approved		"Alexion Pharmaceuticals, Inc."
ravulizumab-cwvz	Ultomiris	1/4/2017	Treatment of paroxysmal nocturnal hemoglobinuria	Designated/Approved		"Alexion Pharmaceuticals, Inc."
emixustat		1/4/2017	Treatment of Stargardt disease (STGD)	Designated	Not FDA Approved for Orphan Indication	Acucela Inc.
risdiplam	Evrysdi	1/4/2017	Treatment of spinal muscular atrophy	Designated/Approved		"Genentech, Inc., a Member of the Roche Group"
lenalidomide	Revlimid	1/4/2017	Treatment of nodal marginal zone lymphoma	Designated/Approved		Celgene Corporation
lenalidomide	Revlimid	1/4/2017	Treatment of splenic marginal zone lymphoma	Designated/Approved		Celgene Corporation
pyridoxal-5¿ phosphate monohydrate (P5P)		1/4/2017	Treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency	Designated	Not FDA Approved for Orphan Indication	Medicure International Inc.
ravulizumab-cwvz	Ultomiris	1/4/2017	Treatment of paroxysmal nocturnal hemoglobinuria	Designated/Approved		"Alexion Pharmaceuticals, Inc."
"Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium)"		12/29/2016	Prevention of rabies virus infection including post-exposure prophylaxis (PEP) for rabies	Designated	Not FDA Approved for Orphan Indication	"Yisheng US Biopharma, Inc."
pembrolizumab	Keytruda	12/28/2016	Treatment of Merkel cell carcinoma	Designated/Approved		Merck Sharp & Dohme LLC
ganaxolone		12/28/2016	Treatment of Fragile X Syndrome	Designated	Not FDA Approved for Orphan Indication	Marinus Pharmaceuticals
flotetuzumab		12/22/2016	Treatment of acute myeloid leukemia (AML)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"MacroGenics, Inc."
Silmitasertib		12/22/2016	Treatment of cholangiocarcinoma	Designated	Not FDA Approved for Orphan Indication	"Senhwa Biosciences, Inc."
nivolumab	Opdivo	12/20/2016	Treatment of gastric cancer and gastro-esophageal junction cancer	Designated/Approved		Bristol-Myers Squibb Company
nivolumab	Opdivo	12/20/2016	Treatment of gastric cancer and gastro-esophageal junction cancer	Designated/Approved		Bristol-Myers Squibb Company
Nivolumab and Ipilimumab		12/20/2016	Treatment of gastric cancer and gastric-esophageal junction cancer.	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Company
eflornithine		12/14/2016	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"Panbela Therapeutics, Inc."
tetrandrine		12/13/2016	Treatment of acute myeloid leukemia.	Designated	Not FDA Approved for Orphan Indication	"Escend Pharmaceuticals, Inc."
3-aminopropyl-butyl phosphinic acid		12/13/2016	Treatment of succinic semialdehyde dehydrogenase deficiency.	Designated	Not FDA Approved for Orphan Indication	"Speragen, Inc."
polatuzumab vedotin-piiq	POLIVY	12/12/2016	Treatment of diffuse large B-cell lymphoma	Designated/Approved		"Genentech, Inc."
Nintedanib		12/12/2016	Treatment of mesothelioma	Designated	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
immune globulin (human)		12/12/2016	Treatment of Myasthenia Gravis	Designated	Not FDA Approved for Orphan Indication	"Grifols Therapeutics, Inc."
polatuzumab vedotin-piiq	Polivy	12/12/2016	Treatment of diffuse large B-cell lymphoma	Designated/Approved		"Genentech, Inc."
ascorbic acid		12/12/2016	Treatment of lung dysfunction following lung transplant	Designated	Not FDA Approved for Orphan Indication	"Renovion, Inc."
avexitide		12/8/2016	Treatment of hyperinsulinemic hypoglycemia	Designated	Not FDA Approved for Orphan Indication	"Eiger BioPharmaceuticals, Inc."
miltefosine		12/6/2016	Treatment of primary amebic encephalitis (PAM)	Designated	Not FDA Approved for Orphan Indication	"Profounda, Inc."
miltefosine		12/6/2016	Treatment of Acanthamoeba keratitis	Designated	Not FDA Approved for Orphan Indication	"Profounda, Inc."
"5-{[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxypiperidin-4-yl]methoxy}-8-fluoro-3,4-dihydroquinolin-2(1H)-one"		12/5/2016	Treatment of active tuberculosis	Designated	Not FDA Approved for Orphan Indication	"Otsuka Pharmaceutical Company, Ltd"
"((4-(3-benzyl-4-hydroxybenzyl)-3,5-dimethylphenoxy)methyl)phosphonic acid"		12/5/2016	Treatment of X-linked adrenoleukodystrophy	Designated	Not FDA Approved for Orphan Indication	"Viking Therapeutics, Inc."
C1 esterase inhibitor (Human)		11/30/2016	Treatment of acute antibody mediated rejection following kidney transplantation	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
cannabidivarin		11/30/2016	Treatment of Rett syndrome	Designated	Not FDA Approved for Orphan Indication	GW Research Ltd.
Yersinia pestis plague recombinant antigen (rF1V; F1 capsular protein fused to V antigen; E. coli) vaccine with aluminum hydroxide		11/30/2016	Prevention of plague (Yersinia pestis)	Designated	Not FDA Approved for Orphan Indication	"The Surgeon General, Department of the Army"
lactobacillus plantarum		11/30/2016	Treatment of amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	"New Biotic, LLC"
riluzole orally disolving tablet		11/30/2016	Treatment of amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	"Biohaven Pharmaceutical Holding Company, Ltd"
nanoparticles containing Zoledronic acid		11/29/2016	Treatment of Glioma	Designated	Not FDA Approved for Orphan Indication	Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA
(2-((2-chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide)		11/29/2016	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Acetylon Pharmaceuticals, Inc. (Celgene Subsidiary)"
risankizumab		11/29/2016	Treatment of pediatric Crohn's disease	Designated	Not FDA Approved for Orphan Indication	AbbVie Inc.
adenovirus associated viral vector serotype 5 containing the RPGR gene		11/29/2016	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
cellspan esophageal implant		11/29/2016	"Restore the structure and function of the esophagus subsequent to esophageal damage due to cancer, injury, or congenital abnormality"	Designated	Not FDA Approved for Orphan Indication	"Biostage, Inc."
cannabidiol		11/29/2016	Treatment of Graft versus Host Disease	Designated	Not FDA Approved for Orphan Indication	"Kalytera Therapeutics Israel, Ltd."
sodium 2-hydroxylinoleate		11/23/2016	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"Ability Pharmaceuticals, SL"
mRNA encoding human ornithine transcarbamylase		11/23/2016	Treatment of ornithine transcarbamylase deficiency	Designated	Not FDA Approved for Orphan Indication	"PhaseRx, Inc."
"Isoindolin-1,3-Di Thione"		11/21/2016	Treatment of Frontotemporal dementia	Designated	Not FDA Approved for Orphan Indication	"P2D, Inc."
"5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-pyridin-2-amine"		11/21/2016	Treatment of primary central nervous system lymphoma.	Designated	Not FDA Approved for Orphan Indication	"Torqur AG, a subsidiary of Swiss Rockets AG"
diazepam	Libervant	11/10/2016	"Treatment of selected, refractory patients with epilepsy who are on stable regimens of antiepileptic drugs (AED) and who require intermittent use of diazepam to control bouts of increased seizure activity (acute repetitive seizures)"	Designated/Approved		Aquestive Therapeutics
hematopoietic stem cells modified with a lentiviral vector containing the CD18 (Integrin Beta 2) gene		11/9/2016	Treatment of leukocyte adhesion deficiency Type I	Designated	Not FDA Approved for Orphan Indication	"Rocket Pharmaceuticals, Inc."
rituximab		11/9/2016	Treatment of Rasmussen's encephalitis	Designated	Not FDA Approved for Orphan Indication	Keck Graduate Institute of Applied Life Sciences
"6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one hydrochloride"		11/9/2016	Treatment of pulmonary arterial hypertension (WHO Group 1)	Designated	Not FDA Approved for Orphan Indication	"Reviva Pharmaceuticals, Inc."
NiCord (cord blood-derived exvivo expanded CD34+ cells and the non-expanded cell fraction of the same cord blood unit)		11/9/2016	Treatment of chronic myelogenous leukemia (CML)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Gamida Cell Ltd.
sargramostim	Leukine	11/9/2016	Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome)	Designated/Approved		"Partner Therapeutics, Inc."
recombinant growth hormone fused to hyFc		11/9/2016	Treatment of growth hormone deficiency.	Designated	Not FDA Approved for Orphan Indication	"Genexine, Inc."
Autologous stromal vascular cell fraction from adipose tissue (central facitily processed)		11/9/2016	Treatment of impaired hand function due to systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	"Lorem Cytori USA, Inc."
riboflavin-vitamin E-TPGS topical solution		11/8/2016	Treatment of keratoconus in patients undergoing crosslinking procedure	Designated	Not FDA Approved for Orphan Indication	Institute of Refractive & Ophthalmic Surgery
aganirsen		11/7/2016	Prevention of corneal graft rejection.	Designated	Not FDA Approved for Orphan Indication	Gene Signal International SA
seladelpar		11/7/2016	Treatment of primary biliary cholangitis	Designated	Not FDA Approved for Orphan Indication	CymaBay Therapeutics
ruxolitinib	JAKAFI	11/3/2016	Treatment of graft versus host disease	Designated/Approved		Incyte Corporation
fosmanogepix		11/3/2016	Treatment of coccidioidomycosis	Designated	Not FDA Approved for Orphan Indication	"Basilea Pharmaceutica Ltd, Allschwil"
veliparib		11/3/2016	Treatment of squamous non-small cell lung cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AbbVie Inc.
ruxolitinib	Jakafi	11/3/2016	Treatment of graft versus host disease	Designated/Approved		Incyte Corporation
H-(4-amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2		11/3/2016	Treatment of acromegaly	Designated	Not FDA Approved for Orphan Indication	Amryt Research Ltd.
melatonin		11/3/2016	Treatment of smith-magenis syndrome in combination with a beta-blocker	Designated	Not FDA Approved for Orphan Indication	WORPHMED Srl
"6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate"		11/3/2016	Treatment of Rett syndrome	Designated	Not FDA Approved for Orphan Indication	"Eloxx Pharmaceuticals, Ltd."
fosmanogepix		11/2/2016	"Treatment of invasive rare mold infections caused by scedosporium spp., fusarium spp., and mucorales fungi (including mucor spp., and rhizopus spp.)"	Designated	Not FDA Approved for Orphan Indication	"Basilea Pharmaceutica Ltd, Allschwil"
fosmanogepix		10/26/2016	Treatment of invasive aspergillosis	Designated	Not FDA Approved for Orphan Indication	"Basilea Pharmaceutica Ltd, Allschwil"
sofosbuvir	Sovaldi	10/25/2016	Treatment of pediatric chronic hepatitis C virus infection	Designated/Approved		"Gilead Sciences, Inc."
napabucasin		10/25/2016	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sumitomo Dainippon Pharma Oncology, Inc."
sofosbuvir	Sovaldi	10/25/2016	Treatment of pediatric chronic hepatitis C virus infection	Designated/Approved		"Gilead Sciences, Inc."
sofosbuvir	Sovaldi	10/25/2016	Treatment of pediatric chronic hepatitis C virus infection	Designated/Approved		"Gilead Sciences, Inc."
rapamycin		10/20/2016	Treatment of pulmonary arterial hypertention	Designated	Not FDA Approved for Orphan Indication	Lam Therapeutics
fosmanogepix		10/19/2016	Treatment of invasive candidiasis	Designated	Not FDA Approved for Orphan Indication	"Basilea Pharmaceutica Ltd, Allschwil"
macitentan and tadalafil	Opsynvi	10/19/2016	Treatment of pulmonary arterial hypertension	Designated/Approved		"Actelion Pharmaceuticals US, Inc."
Partial agonist at the opioid receptor-like 1 receptor with amino acid sequence Ac-Arg-Tyr-Tyr-Arg-Trp-Lys-Lys-Lys-Lys-Lys-Lys-Lys-NH2		10/19/2016	Treatment of pulmonary arterial hypertension	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Serodus ASA
"6-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate"		10/18/2016	Treatment of mucopolysaccharidosis type 1 (MPS I)	Designated	Not FDA Approved for Orphan Indication	"Eloxx Pharmaceuticals, Ltd."
"Combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium)"		10/13/2016	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"Yisheng US Biopharma, Inc."
atezolizumab	TECENTRIQ	10/13/2016	Treatment of small cell lung cancer (SCLC)	Designated/Approved		"Genentech, Inc."
vorinostat		10/13/2016	"Treatment of advanced melanoma (stages IIb, IIc, III, and IV)"	Designated	Not FDA Approved for Orphan Indication	Qameleon Therapeutics
Vibrio alginolyticus collagenase		10/12/2016	Treatment of advanced Dupuytren's disease (Dupuytren's contracture)	Designated	Not FDA Approved for Orphan Indication	Fidia Farmaceutici S.p.A.
liposomal vinorelbine		10/12/2016	Treatment of cutaneous t-cell lymphoma (CTCL)	Designated	Not FDA Approved for Orphan Indication	"Taiwan Liposome Company, Ltd."
ledipasvir/sofosbuvir	Harvoni	10/12/2016	Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients	Designated/Approved		"Gilead Sciences, Inc."
ledipasvir/sofosbuvir	Harvoni	10/12/2016	Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients	Designated/Approved		"Gilead Sciences, Inc."
ledipasvir/sofosbuvir	Harvoni	10/12/2016	Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients	Designated/Approved		"Gilead Sciences, Inc."
pembrolizumab		10/11/2016	Treatment of nasopharyngeal carcinoma	Designated	Not FDA Approved for Orphan Indication	Merck Sharp & Dohme LLC
ibudilast		10/6/2016	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"MediciNova, Inc."
Recombinant human monoclonal antibody against human complement component C5a		10/6/2016	Treatment of acute graft versus host disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc."
lisocabtagene maraleucel	Breyanzi	10/4/2016	Treatment of chronic lymphocytic leukemia	Designated/Approved		"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company"
posaconazole	Noxafil	10/4/2016	Treatment of invasive aspergillosis	Designated/Approved		Merck Sharp & Dohme LLC
tacrolimus extended-release capsules	Astagraf XL	10/4/2016	"Prevention of rejection in kidney, liver or heart transplant in pediatric patients"	Designated/Approved		"Astellas Pharma Global Development, Inc."
tacrolimus	Prograf	10/4/2016	"Prevention of rejection in kidney, liver or heart transplant in pediatric patients"	Designated/Approved		"Astellas Pharma Global Development, Inc."
tacrolimus	Prograf	10/4/2016	"Prevention of rejection in kidney, liver or heart transplant in pediatric patients"	Designated/Approved		"Astellas Pharma Global Development, Inc."
tacrolimus	Prograf	10/4/2016	"Prevention of rejection in kidney, liver or heart transplant in pediatric patients"	Designated/Approved		"Astellas Pharma Global Development, Inc."
Atrasentan		9/29/2016	Treatment of pediatric nephrotic syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AbbVie Inc.
recombinant adeno-associated virus serotype 8 vector encoding human glucose-6-phosphatase-alpha (G6Pase or G6PC)		9/28/2016	Treatment of glycogen storage disease type Ia (von Gierke Disease)	Designated	Not FDA Approved for Orphan Indication	"Ultragenyx Pharmaceutical, Inc."
Wharton's jelly mesenchymal stem cells		9/27/2016	Treatment of graft-versus-host disease	Designated	Not FDA Approved for Orphan Indication	Midwest Stem Cell Therapy Center
Autologous dendritic cell/tumor antigens		9/27/2016	Treatment of glioblastoma multiforme (GBM)	Designated	Not FDA Approved for Orphan Indication	"Ever Supreme Bio Technology, Co. Ltd."
tenofovir disoproxil fumarate		9/27/2016	Prevention of mother to child transmission of hepatitis B virus	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
decitabine and tetrahydrouridine		9/19/2016	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	Novo Nordisk Inc.
recombinant adeno-associated virus serotype rhesus 74 expressing the human dysferin gene (AAVrh74.MHCK7.DYSF.DV)		9/19/2016	Treatment of Limb Girdle Muscular Dystrophy Type 2B	Designated	Not FDA Approved for Orphan Indication	Sarepta Therapeutics
Adeno-associated virus delivered transgene of follistatin		9/19/2016	Treatment of inclusion body myositis	Designated	Not FDA Approved for Orphan Indication	Milo Biotechnology
fixed dose combination of modafinil and flecainide		9/19/2016	Treatment of narcolepsy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Theranexus S.A
ProTmune (ex vivo Programmed Mobilized Peripheral Blood)		9/19/2016	Prevention of graft-versus-host disease in patients undergoing allogenic hematopoietic cell transplantation	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Fate Therapeutics
tofersen	Qalsody	9/19/2016	Treatment of amyotrophic lateral sclerosis	Designated/Approved		Biogen Inc.
methylprednisolone oral suspension		9/19/2016	Treatment of adrenal insufficiency in pediatric patients	Designated	Not FDA Approved for Orphan Indication	Generic Specialty Pharma
"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride"		9/19/2016	Treatment of diffuse large B-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
"disulfide-stabilized single-chain variable region fragment of the anti-EGFR wild type/EGFRvIII dual specificity monoclonal antibody with variable fragments fused to a truncated version of the Pseudomonas exotoxin A, PE38, and KDEL"		9/19/2016	Treatment of glioma.	Designated	Not FDA Approved for Orphan Indication	"Darell D. Bigner, MD, PhD"
riluzole oral suspension	Tiglutik	9/15/2016	Treatment of amyotrophic lateral sclerosis (ALS).	Designated/Approved		Italfarmaco SpA
riluzole oral suspension	Tiglutik	9/15/2016	Treatment of amyotrophic lateral sclerosis (ALS).	Designated/Approved		Italfarmaco SpA
poly(lactide-co-glycolide) carboxylated microparticle		9/13/2016	Treatment of malaria	Designated	Not FDA Approved for Orphan Indication	"Cour Pharmaceutical Development Company, Inc."
emodepside		9/13/2016	"Treatment of onchocerhiasis (""river blindness"") caused by the filarial nematode onchocerca volvulus"	Designated	Not FDA Approved for Orphan Indication	"Bayer HealthCare Pharmaceuticals, Inc."
terlipressin		9/8/2016	Treatment of ascites due to all etiologies except cancer	Designated	Not FDA Approved for Orphan Indication	Bio Vie Inc.
Coversin		9/8/2016	Treatment of paroxysmal nocturnal hemoglobinuria	Designated	Not FDA Approved for Orphan Indication	Akari Therapeutics Plc
rituximab and recombinant human hyaluronidase	Rituxan SC	9/7/2016	Treatment of diffuse large B-cell lymphoma	Designated/Approved		"Genentech, Inc."
"6-fluoro-(18F)-L-3,4-dihydroxyphenylalanine"		9/7/2016	A diagnostic for management of patients with Lesch-Nyhan syndrome	Designated	Not FDA Approved for Orphan Indication	"Advanced Imaging Projects, LLC"
Brentuximab vedotin	Adcetris	9/7/2016	Treatment of primary cutaneous CD30-positive T-cell lymphoproliferative disorders	Designated/Approved		Seagen Inc.
cinacalcet		9/7/2016	Treatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease receiving dialysis	Designated	Not FDA Approved for Orphan Indication	"Amgen, Inc."
autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor and a truncated epidermal growth factor receptor		9/7/2016	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	"Juno Therapeutics, Inc."
Cisplatin		9/6/2016	Treatment of anal cancer	Designated	Not FDA Approved for Orphan Indication	Privo Technologies
"4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol"		9/6/2016	Treatment of Angelman syndrome.	Designated	Not FDA Approved for Orphan Indication	Ovid Therapeutics
"bilayer, engineered collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts"		9/6/2016	Treatment of partial deep dermal and full thickness burn wounds	Designated	Not FDA Approved for Orphan Indication	Curtiss AG
mesylate synthetic small molecule inhibitor of HDAC and PI3K		9/6/2016	Treatment of nuclear protein in testis (NUT) midline carcinoma	Designated	Not FDA Approved for Orphan Indication	"Curis, Inc."
recombinant adeno-associated virus vector serotype 9 expressing human N-Sulfoglucosamine Sulfohydrolase		9/1/2016	"Treatment of mucopolysaccharidosis type III A, also called Sanfilippo syndrome A"	Designated	Not FDA Approved for Orphan Indication	Research Institute at Nationwide Children's Hospital
dabrafenib and trametinib	Tafinlar(r) Capsules a nd Mekinist(r) Tablets	9/1/2016	Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.	Designated/Approved		Novartis Pharmaceuticals Corporation
Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and human factor 9 gene (SB-FIX)		9/1/2016	Treatment of hemophilia B	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sangamo Therapeutics, Inc."
recombinant adeno-associated virus vector serotype 9 expressing human iduronate-2-sulfatase		9/1/2016	"Treatment of mucopolysaccharidosis II, also called Hunter syndrome A."	Designated	Not FDA Approved for Orphan Indication	University of North Carolina at Chapel Hill
Angiotensin (1-7)		9/1/2016	Treatment of recessive dystrophic epidermolysis bullosa (RDEB).	Designated	Not FDA Approved for Orphan Indication	Constant Therapeutics LLC
dabrafenib and trametinib	Tafinlar(r) Capsules a nd Mekinist(r) Tablets	9/1/2016	Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.	Designated/Approved		Novartis Pharmaceuticals Corporation
amifampridine phosphate		8/31/2016	Treatment of myasthenia gravis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Catalyst Pharmaceuticals, Inc."
zildistrogene varoparvovec		8/31/2016	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	"Solid Biosciences, Inc."
humanized IgG4 monoclonal antibody to Toll-Like Receptor 2 (TLR2)		8/30/2016	Treatment of myelodysplastic syndrome	Designated	Not FDA Approved for Orphan Indication	"TLR Therapeutics, Inc."
S-ethylisothiourea diethylphosphate		8/29/2016	"Treatment of symptomatic intradialytic hypotension, including symptomatic hypotension in the immediate post-dialytic period."	Designated	Not FDA Approved for Orphan Indication	"TrioxBio, Inc."
berberine ursodeoxycholate		8/29/2016	Treatment of primary sclerosing cholangitis	Designated	Not FDA Approved for Orphan Indication	HighTide Biopharma Pty. Ltd.
anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single domain antibody		8/29/2016	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Singh Biotechnology, LLC"
131-I-8H9 monoclonal antibody		8/29/2016	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	"Y-mAbs Therapeutics, Inc."
venetoclax		8/29/2016	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	AbbVie Inc.
givosiran	GIVLAARI	8/29/2016	Treatment of acute hepatic porphyria	Designated/Approved		"Alnylam Pharmaceuticals, Inc."
"recombinant, fully-human, IgG4 immunoglobulin with antigen-binding specificity for human vascular adhesion protein-1 (VAP-1)"		8/25/2016	Treatment of primary sclerosing cholangitis.	Designated	Not FDA Approved for Orphan Indication	"Acorda Therapeutics, Inc."
ublituximab		8/25/2016	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Designated	Not FDA Approved for Orphan Indication	"TG Therapeutics, Inc."
umbralisib		8/23/2016	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"TG Therapeutics, Inc."
rituximab and recombinant human hyaluronidase	Rituxan SC	8/22/2016	Treatment of chronic lymphocytic leukemia (CLL)	Designated/Approved		"Genentech, Inc."
stabilized sulforaphane		8/22/2016	Treatment of subarachnoid hemorrhage	Designated	Not FDA Approved for Orphan Indication	Evgen Pharma PLC
nivolumab	Opdivo	8/22/2016	Treatment of esophageal cancer	Designated/Approved		Bristol-Myers Squibb Company
ambrisentan/tadalafil fixed combination		8/22/2016	Treatment of pulmonary arterial hypertension	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
etrolizumab		8/22/2016	Treatment of pediatric patients with ulcerative colitis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
ibrexafungerp		8/22/2016	Treatment of invasive Aspergillus infections	Designated	Not FDA Approved for Orphan Indication	"SCYNEXIS, Inc."
recombinant human interleukin-12		8/22/2016	Treatment of acute radiation syndrome	Designated	Not FDA Approved for Orphan Indication	"Neumedicines, Inc."
cultured skin substitute (CSS)		8/22/2016	Treatment of burns requiring skin grafting.	Designated	Not FDA Approved for Orphan Indication	Regenicin Inc.
rituximab and recombinant human hyaluronidase	Rituxan SC	8/22/2016	Treatment of follicular lymphoma	Designated/Approved		"Genentech, Inc."
disufenton sodium		8/22/2016	Treatment of glioblastoma multiforme	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Oblato, Inc."
nivolumab	Opdivo	8/22/2016	Treatment of esophageal cancer	Designated/Approved		Bristol-Myers Squibb Company
nivolumab	Opdivo	8/22/2016	Treatment of esophageal cancer	Designated/Approved		Bristol-Myers Squibb Company
nivolumab	Opdivo	8/22/2016	Treatment of esophageal cancer	Designated/Approved		Bristol-Myers Squibb Company
live E. coli Nissle bacterium modified to assimilate ammonia		8/22/2016	Treatment of urea cycle disorders	Designated	Not FDA Approved for Orphan Indication	"Synlogic, Inc."
nivolumab	Opdivo	8/22/2016	Treatment of esophageal cancer	Designated/Approved		Bristol-Myers Squibb Company
propofol hemisuccinate		8/19/2016	Treatment of acute repetitive seizures	Designated	Not FDA Approved for Orphan Indication	EpaleX Corporation
humanized IgG4 monoclonal antibody that binds to the SEMA4D antigen		8/16/2016	Treatment of Huntington's disease	Designated	Not FDA Approved for Orphan Indication	"Vaccinex, Inc."
carbon monoxide		8/16/2016	Treatment of idiopathic pulmonary fibrosis (IPF).	Designated	Not FDA Approved for Orphan Indication	"Proterris, Inc."
itraconazole inhalation powder		8/16/2016	Treatment of pulmonary fungal infections in patients with cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Pulmatrix, Inc"
dusquetide		8/10/2016	Treatment of macrophage activation syndrome	Designated	Not FDA Approved for Orphan Indication	"Soligenix, Inc."
ceramide		8/8/2016	Treatment of liver cancer	Designated	Not FDA Approved for Orphan Indication	"Keystone Nano, Inc."
Retinol palmitate		8/8/2016	Prevention of bronchopulmonary dysplasia.	Designated	Not FDA Approved for Orphan Indication	Orphanix GmbH
vedolizumab		8/4/2016	Prevention of graft versus host disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
vemurafenib	Zelboraf	8/2/2016	Treatment of Erdheim-Chester Disease	Designated/Approved		"Genentech, Inc."
chimeric antigen receptor directed against the target protein CD4 lentivirally transfected T cells		7/28/2016	Treatment of peripheral T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	iCell Gene Therapeutics
sutimlimab-jome	Enjaymo	7/27/2016	Treatment of autoimmune hemolytic anemia	Designated/Approved		Bioverativ USA Inc. (a fully owned subsidiary of Sanofi)
sutimlimab-jome	Enjaymo	7/27/2016	Treatment of autoimmune hemolytic anemia	Designated/Approved		Bioverativ USA Inc. (a fully owned subsidiary of Sanofi)
"recombinant, adeno-associated virus serotype 5 vector, containing the transgene, which encodes for the human protein, frataxin"		7/25/2016	Treatment of Friedreich's Ataxia	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
zanubrutinib	Brukinsa	7/20/2016	Treatment of chronic lymphocytic leukemia	Designated/Approved		"BeiGene USA, Inc."
flunarizine		7/20/2016	Treatment of hemiplegic migraine	Designated	Not FDA Approved for Orphan Indication	"Xenon Pharmaceuticals, Inc."
Ruxolitinib		7/18/2016	Treatment of acute lymphoblastic leukemia.	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
pegylated recombinant human interleukin-10		7/18/2016	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Eli Lilly and Company
"atoltivimab, maftivimab, and odesivimab-ebgn"	INMAZEB™	7/14/2016	Treatment of ebola virus infection	Designated/Approved		"Regeneron Pharmaceuticals, Inc."
tolfenamic acid		7/13/2016	Treatment of progressive supranuclear palsy	Designated	Not FDA Approved for Orphan Indication	Nasser H. Zawia
tolfenamic acid		7/13/2016	Treatment of Frontotemporal Dementia	Designated	Not FDA Approved for Orphan Indication	Nasser H. Zawia
recombinant human biglycan		7/13/2016	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	"Tivorsan Pharmaceuticals, Inc."
[F18] florilglutamic acid		7/13/2016	For the diagnosis of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Life Molecular Imaging Ltd.
[F18] florilglutamic acid		7/13/2016	Diagnostic for the management of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Life Molecular Imaging Ltd.
1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane		7/7/2016	Treatment of status epilepticus	Designated	Not FDA Approved for Orphan Indication	"Bio-Pharm Solutions Co., Ltd."
selinexor		7/7/2016	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"Karyopharm Therapeutics, Inc."
deoxythymidine monophosphate and deoxycytidine monophosphate		7/7/2016	Treatment of thymidine kinase 2 deficiency.	Designated	Not FDA Approved for Orphan Indication	"UCB, Inc."
brentuximab vedotin		7/7/2016	Treatment of enteropathy-associated T-cell lymphoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Seattle Genetics, Inc."
mazindol		7/6/2016	Treatment of narcolepsy	Designated	Not FDA Approved for Orphan Indication	NLS-0 Pharma AG
"metavert, N-hydroxy-4-(5-((4-methoxyphenyl)amino)-1,3,4-oxadiazol-2-yl)benzamide"		7/6/2016	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Avenzoar Pharmaceuticals, Inc."
anti-HER2 bispecific antibody drug conjugate		7/6/2016	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Zymeworks Inc.
nintedanib	OFEV	7/6/2016	Treatment of systemic sclerosis (including the associated interstitial lung disease).	Designated/Approved		"Boehringer Ingelheim Pharmaceuticals, Inc."
"modified mRNA encoding UGT1A1 protein, formulated in lipid nanoparticles"		7/5/2016	Treatment of Crigler-Najjar syndrome	Designated	Not FDA Approved for Orphan Indication	"Moderna Therapeutics, Inc."
bortezomib		7/5/2016	Treatment of neurofibromatosis type 2 (NF2)	Designated	Not FDA Approved for Orphan Indication	BioXcel Corporation
adenovirus-associated viral vector serotype 5 containing the human pde6B gene		7/5/2016	Treatment of retinitis pigmentosa due to pde6B gene mutations	Designated	Not FDA Approved for Orphan Indication	eyeDNA Therapeutics
Small molecule Ewing Sarcoma breakpoint region 1/Friend leukemia virus integration 1 fusion protein inhibitor		6/30/2016	Treatment of Ewing sarcoma	Designated	Not FDA Approved for Orphan Indication	"Oncternal Therapeutics, Inc"
autologous osteogenic cells cultured from adipose tissue derived stem cells embedded in extracellular matrix with demineralized bone matrix.		6/30/2016	Treatment of congenital pseudarthrosis of the tibia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novadip Biosciences
Peptide consisting of L-amino acids with the sequence H-lys-glu-phe-leu-his-pro-ser-lys-val-asp-leu-pro-arg-OH		6/29/2016	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"Soricimed Biopharma, Inc."
"recombinant, glycoenfineered humanized IgG1 kappa monoclonal antibody directed against Fibroblast Growth Factor Receptor 2b"		6/29/2016	Treatment of gastric cancer including cancer of the gastroesophageal junction.	Designated	Not FDA Approved for Orphan Indication	"Five Prime Therapeutics, Inc."
zanubrutinib	Brukinsa	6/29/2016	Treatment of Waldenstrom's macroglobulinemia	Designated/Approved		"BeiGene USA, Inc."
triclabendazole		6/27/2016	Treatment of fascioliasis	Designated	Not FDA Approved for Orphan Indication	"Tropicalis Pharmaceuticals, LLC"
"high molecular weight multimer of E3-Fc, an endostatin C-terminus and IgG1-Fc fusion protein"		6/27/2016	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	"iBio, Inc."
ibrutinib	Imbruvica	6/23/2016	Treatment of chronic Graft versus Host disease	Designated/Approved		"Pharmacyclics, LLC"
zanubrutinib	BRUKINSA	6/23/2016	Treatment of mantle cell lymphoma	Designated/Approved		"BeiGene USA, Inc."
ibrutinib	Imbruvica	6/23/2016	Treatment of chronic Graft versus Host disease	Designated/Approved		"Pharmacyclics, LLC"
"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one*2HCl"		6/23/2016	Treatment of glioblastoma.	Designated	Not FDA Approved for Orphan Indication	"Chimerix, Inc."
sirolimus		6/21/2016	Treatment of beta-thalassemia.	Designated	Not FDA Approved for Orphan Indication	Rare Partners srl Impresa Sociale
Sperm Protein-17 oral microparticle vaccine		6/21/2016	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Kiromic, LLC"
"tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride"		6/20/2016	Treatment of infantile spasms	Designated	Not FDA Approved for Orphan Indication	Anavex Life Sciences Corp.
napabucasin		6/20/2016	Treatment of gastric cancer including gastroesophageal junction cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Boston Biomedical, Inc."
varlitinib		6/20/2016	Treatment of gastric cancer.	Designated	Not FDA Approved for Orphan Indication	ASLAN Pharmaceuticals
hydromorphone hydrochloride (intrathecal infusion)		6/16/2016	Treatment of complex regional pain syndrome	Designated	Not FDA Approved for Orphan Indication	"Piramal Critical Care, Inc."
antisense oligonucleotide targeting the U isoform of SNP rs362307		6/16/2016	Treatment of Huntington's disease (prodromal stage Huntington's disease and diagnosed Huntington's disease)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Wave LIfe Sciences
L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser		6/13/2016	Treatment to increase survival and improve functioning of pancreatic islets following transplantation	Designated	Not FDA Approved for Orphan Indication	"Araim Pharmaceuticals, Inc."
cannabidiol		6/13/2016	Treatment of infantile spasms	Designated	Not FDA Approved for Orphan Indication	GW Research Ltd.
L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser		6/13/2016	Treatment of sarcoidosis.	Designated	Not FDA Approved for Orphan Indication	"Araim Pharmaceuticals, Inc."
Folate Binding Protein Peptide: Glu-Ile-Trp-Thr-Phe-Ser-Thr-Lys-Val		6/8/2016	Treatment (including prevention of recurrence) of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Galena Biopharma, Inc."
eladocagene exuparvovec		6/8/2016	treatment of aromatic L-amino acid decarboxylase deficiency	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
glibentek (glibenclamide oral suspension)		6/8/2016	Treatment of neonatal diabetes (monogenic forms of diabetes that present in infancy)	Designated	Not FDA Approved for Orphan Indication	AMMTeK
fosbretabulin tromethamine		6/8/2016	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"Mateon Therapeutics, Inc."
recombinant human cerebral dopamine neurotrophic factor		6/8/2016	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Herantis Pharma Plc
folate binding protein peptide: Glu-Ile-Trp-Thr-His-Ser-Tyr-Lys-Val		6/8/2016	Treatment (including prevention of recurrence) of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Galena Biopharma, Inc."
d-methadone		6/2/2016	Treatment of postherpetic neuralgia	Designated	Not FDA Approved for Orphan Indication	"Relmada Therapeutics, Inc."
human donor hematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with TBX-4000		6/2/2016	Enhancement of cell engraftment in patients receiving hematopoietic stem cell transplant.	Designated	Not FDA Approved for Orphan Indication	"Taiga Biotechnologies, Inc."
methimazole and liothyronine sodium		6/2/2016	Treatment of glioblastoma multiforme.	Designated	Not FDA Approved for Orphan Indication	Musli Thyropeutics Ltd
oral testosterone		6/2/2016	Treatment of constitutional delay of growth and puberty in adolescent boys 14 to 17 years of age.	Designated	Not FDA Approved for Orphan Indication	"TesoRx Pharma, LLC"
bupivacaine hydrochloride		5/31/2016	treatment of pain associated with postherpetic neuralgia.	Designated	Not FDA Approved for Orphan Indication	Acasti Pharma Inc.
diazepam subcutaneous injection		5/26/2016	Treatment of acute repetitive seizures.	Designated	Not FDA Approved for Orphan Indication	"Xeris Pharmaceuticals, Inc."
"recombinant, non-pathogenic poliovirus:rhinovirus chimera that consists of the genome of the live attenuated poliovirus serotype 1 vaccine with its cognate IRES element replaced with that of HRV2"		5/26/2016	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"Istari Oncology, Inc."
antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA		5/25/2016	Treatment of Leber's congenital amaurosis.	Designated	Not FDA Approved for Orphan Indication	Laboratoires Théa
"non-replicating recombinant adeno-associated viral vector, serotype 8, expressing the 1A1 isoform of the bilirubin-uridine diphosphate glucuronosyltransferase gene"		5/24/2016	Treatment of Crigler Najjar syndrome.	Designated	Not FDA Approved for Orphan Indication	"Audentes Therapeutics, Inc."
brentuximab vedotin		5/23/2016	Treatment of adult T-cell leukemia/lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Seattle Genetics, Inc."
Nanocomplex consisting of a small interfering RNA that targets the human EV11 oncogenic transcription factor and an elastin-like polypeptide drug carrier.		5/23/2016	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	PeptiMed
"9-cis, 12-cis-11,11-d2-linoleic acid ethyl ester"		5/23/2016	Treatment of Friedreich's Ataxia	Designated	Not FDA Approved for Orphan Indication	"Retrotope, Inc."
ropidoxuridine		5/19/2016	Radiosensitizer to be used during radiation treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"EMEK, Inc."
Itraconazole		5/19/2016	Treatment of basal cell carcinoma nevus syndrome.	Designated	Not FDA Approved for Orphan Indication	Mayne Pharma LLC
tetrandrine		5/19/2016	Treatment of chronic myeloid leukemia.	Designated	Not FDA Approved for Orphan Indication	"Escend Pharmaceuticals, Inc."
anti-HER2 bispecific antibody		5/18/2016	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Zymeworks Inc.
combination of disulfiram and copper gluconate		5/18/2016	Treatment of glioblastoma multiforme.	Designated	Not FDA Approved for Orphan Indication	"Cantex Pharmaceuticals, Inc."
ustekinumab		5/18/2016	Treatment of pediatric Crohn's disease (0 through 16 years of age)	Designated	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
"(2,2-diphenyl-tetrahydro-furan-3-yl-methyl)-dimethylamine hydrochloride"		5/18/2016	Treatment of Rett Syndrome.	Designated	Not FDA Approved for Orphan Indication	Anavex Life Sciences Corporation
copper Cu 64 dotatate	Detectnet	5/18/2016	Diagnostic for the management of neuroendocrine tumors.	Designated/Approved		RadioMedix Inc.
2-amino-N-({methyl-[(6-trifluoromethoxy-benzothiazol-2-ylcarbamoyl)-methyl]-carbamoyl}-methyl)-acetamide monohydrochloride		5/18/2016	Treatment of spinocerebellar ataxia.	Designated	Not FDA Approved for Orphan Indication	"Biohaven Pharmaceuticals, Inc."
liposomal glutathione		5/18/2016	Treatment of Dengue Virus infection.	Designated	Not FDA Approved for Orphan Indication	"Your Energy Systems, LLC"
marstacimab		5/18/2016	"Treatment of hemophilia A and hemophilia B patients with or without inhibitors, which includes routine prophylaxis to prevent or reduce the frequency of bleeding in hemophilia A and hemophilia B patients."	Designated	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
taurolidine		5/16/2016	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"Geistlich Pharma NA, Inc."
Naratuximab emtansine		5/12/2016	Treatment of diffuse large B-cell lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Debiopharm International S.A.
Ceclazepide		5/12/2016	Treatment of gastric neuroendocrine tumors (gastric NETs).	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Trio Medicines Ltd.
florilglutamic acid		5/11/2016	Diagnostic for the management of glioma	Designated	Not FDA Approved for Orphan Indication	Life Molecular Imaging Ltd.
idecabtagene vicleucel	Abecma	5/11/2016	Treatment of multiple myeloma	Designated/Approved		"Celgene Corporation, a Bristol-Myers Squibb Company"
idecabtagene vicleucel	Abecma	5/11/2016	Treatment of multiple myeloma	Designated/Approved		"Celgene Corporation, a Bristol-Myers Squibb Company"
"6-methoxy-3-(3',4',5'-trimethoxybenzoyl) indole"		5/11/2016	Treatment of cholangiocarcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	SynCore Biotechnology Co. Ltd.
ibrexafungerp		5/10/2016	"Treatment of invasive Candida infections, including candidemia"	Designated	Not FDA Approved for Orphan Indication	"SCYNEXIS, Inc."
clotrimazole otic solution		5/10/2016	Treatment of fungal otitis externa (otomycosis)	Designated	Not FDA Approved for Orphan Indication	Laboratorios SALVAT S.A.
2'-O-(2-methoxyethyl)phosphorothioate antisense oligonucleotide		5/10/2016	Treatment of acromegaly	Designated	Not FDA Approved for Orphan Indication	Antisense Therapeutics Limited
autologous ex vivo expanded polyclonal CD4+CD25+CD1271o/-FOXP3+ Regulatory T cells		5/10/2016	Treatment of type 1 diabetes mellitus with residual beta cell function	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Caladrius Biosciences
Recombinant protein inhibitor of complement factor 5		5/10/2016	Treatment of Guillain-Barre Syndrome.	Designated	Not FDA Approved for Orphan Indication	Akari Therapeutics Plc
selumetinib		5/10/2016	Adjuvant treatment of patients with stage III or stage IV differentiated thyroid cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals LP
human recombinant bone morphogenetic protein 4		5/4/2016	Treatment of glioblastoma multiforme.	Designated	Not FDA Approved for Orphan Indication	Stemgen Spa
autologous adipose tissue derived mesenchymal stem cells		5/4/2016	Treatment of Buerger's disease (thromboangiitis obliterans).	Designated	Not FDA Approved for Orphan Indication	Biostar Stem Cell Research Institute
acyclovir		5/3/2016	Treatment of herpetic keratitis.	Designated	Not FDA Approved for Orphan Indication	Cumulus Pharmaceuticals LLC
Fancalen (lentiviral vector containing the Fanconi anemia-A (FANCA) gene		5/2/2016	Treatment of Fanconi anemia type A patients.	Designated	Not FDA Approved for Orphan Indication	"Rocket Pharmaceuticals, Inc."
combinatorial regimen of LV305 (lentiviral vector encoding NY-ESO-1 gene) and G305 (NY-ESO-1 recombinant protein plus GLA-SE)		5/2/2016	Treatment of soft tissue sarcoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Immune Design Corp.
brigatinib	Alunbrig	4/28/2016	"Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC)."	Designated/Approved		"Takeda Development Center Americas, Inc."
brexucabtagene autoleucel	TECARTUS™	4/28/2016	Treatment of mantle cell lymphoma	Designated/Approved		"Kite Pharma, Inc."
brigatinib	Alunbrig	4/28/2016	"Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC)."	Designated/Approved		"Takeda Development Center Americas, Inc."
lisocabtagene maraleucel	Breyanzi	4/27/2016	Treatment of diffuse large B-cell lymphoma	Designated/Approved		"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company"
lisocabtagene maraleucel	Breyanzi	4/27/2016	Treatment of diffuse large B-cell lymphoma	Designated/Approved		"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company"
mavacamten	Camzyos	4/27/2016	Treatment of symptomatic hypertrophic cardiomyopathy	Designated/Approved		"MyoKardia, Inc. (A Wholly-Owned Subsidiary of Bristol Myers Squibb)"
"(3S)-3-[({1-(2-Chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3yl}amino)carbonyl]amino-3-(4-methylphenyl)propanoic acid monosodium salt"		4/25/2016	For mobilization of hematopoietic stem cells	Designated	Not FDA Approved for Orphan Indication	"Aviara Pharmaceuticals, Inc/"
axicabtagene ciloleucel	Yescarta	4/25/2016	Treatment of follicular lymphoma.	Designated/Approved		"Kite Pharma, Inc."
axicabtagene ciloleucel	Yescarta	4/25/2016	Treatment of follicular lymphoma.	Designated/Approved		"Kite Pharma, Inc."
axicabtagene ciloleucel	Yescarta	4/25/2016	Treatment of follicular lymphoma.	Designated/Approved		"Kite Pharma, Inc."
"(E, Z)-4,5,9-trithiadodeca-1, 6, 11-triene 9-oxide (Ajoene)"		4/21/2016	Treatment of Pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Neem Biotech Ltd.
brexucabtagene autoleucel	Tecartus	4/20/2016	Treatment of acute lymphoblastic leukemia	Designated/Approved		"Kite Pharma, Inc."
brexucabtagene autoleucel		4/20/2016	Treatment of chronic lymphocytic leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Kite Pharma, Inc."
axicabtagene ciloleucel	Yescarta	4/20/2016	Treatment of primary mediastinal B-cell lymphoma.	Designated/Approved		"Kite Pharma, inc."
axicabtagene ciloleucel	Yescarta	4/20/2016	Treatment of primary mediastinal B-cell lymphoma.	Designated/Approved		"Kite Pharma, inc."
aphidicolin		4/20/2016	Treatment of Ebola virus infection	Designated	Not FDA Approved for Orphan Indication	Biospherics.net LLC
allogeneic ex-vivo generated CD56+CD3-natural killer cells from CD34+ umbilical cord blood progenitor cells		4/20/2016	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	IPD-Therapeutics BV
HDF-LV-RTS-MMP1 (human dermal fibroblasts genetically modified with LV-RTS-MMP1) and Veledimex		4/19/2016	Treatment of localized scleroderma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Castle Creek Biosciences, LLC"
cannabidiol	Epidiolex	4/19/2016	Treatment of tuberous sclerosis complex.	Designated/Approved		GW Research Ltd.
"1,2:5,6-dianhydrogalactitol"		4/19/2016	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	"DelMar Pharmaceuticals, Inc. (Clinical Operations)"
Adenovirus encoding the recombinant CD40 ligand		4/19/2016	Treatment of stage IIb through IV melanoma.	Designated	Not FDA Approved for Orphan Indication	Memgen LLC
ganaxolone		4/14/2016	Treatment of status epilepticus.	Designated	Not FDA Approved for Orphan Indication	"Marinus Pharmaceuticals, Inc."
"(5S,8S, 10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5] diazocine-8-carboxyamide"		4/14/2016	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"EMD Serono, Inc., a business of Merck Healthcare KGaA"
7-ethyl-10-hydroxycamptothecin (EHC)		4/13/2016	Treatment of small cell lung cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Nippon Kayaku Co., Ltd."
pritumumab		4/6/2016	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"Nascent Biotech, Inc."
"1-(2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one"		4/6/2016	Treatment of frontotemporal dementia.	Designated	Not FDA Approved for Orphan Indication	Anavex Life Sciences Corp.
1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol; 1H-1-(3-[18F]fluoro-2-hydroxypropyl0-2-nitroimidazole (18F-Misonidazole)		4/6/2016	Diagnostic for management of glioma.	Designated	Not FDA Approved for Orphan Indication	"Advanced Imaging Projects, LLC"
"poly-N,N'-hexamethyleneguanidine-poly-N1,N4-hexamethyleneaminoguanidine"		4/5/2016	"Treatment of pulmonary infections in patients with cystic fibrosis including infections due to pseudomonas aeruginosa,Burkholderia cepacia and other bacteria"	Designated	Not FDA Approved for Orphan Indication	"TGV-Inhalonix, Inc."
peptide fraction derived from porcine brain protein		4/5/2016	"Treatment of frontotemporal dementia, including all subvariants"	Designated	Not FDA Approved for Orphan Indication	EVER Neuro Pharma GmbH
metronidazole		4/5/2016	Treatment of clostridium difficile infection in pediatric patients (0 through 16 years of age).	Designated	Not FDA Approved for Orphan Indication	"Appili Therapeutics, Inc."
setmelanotide	Imcivree	4/4/2016	Treatment of pro-opiomelanocortin (POMC) deficiency due to mutations in the POMC gene	Designated/Approved		"Rhythm Pharmaceuticals, Inc."
fexinidazole		4/4/2016	Treatment of human African trypanosomiasis (HAT) or sleeping sickness	Designated/Approved		"Sanofi US Services Inc., A SANOFI COMPANY"
Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase	HyQvia	3/31/2016	Treatment of chronic inflammatory demyelinating polyneuropathy	Designated/Approved		"Takeda Development Center Americas, Inc."
gentamicin C2 congener		3/29/2016	Treatment of cystic fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	La Jolla Pharmaceuticals Company
"3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-pyrrole-2,5-dione"		3/29/2016	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	Actuate Therapeutics
131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I		3/28/2016	Treatment of Acute Myeloid Leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	"Actinium Pharmaceuticals, Inc."
letetresgene autoleucel		3/28/2016	Treatment of soft tissue sarcoma.	Designated	Not FDA Approved for Orphan Indication	"Adaptimmune, LLC"
ivabradine	CORLANOR	3/23/2016	Treatment of pediatric patients (0 through 16 years of age) with dilated cardiomyopathy.	Designated/Approved		"Amgen, Inc.,"
lentiviral vector containing the human liver and erythroid pyruvate kinase gene		3/23/2016	Treatment of pyruvate kinase deficiency.	Designated	Not FDA Approved for Orphan Indication	"Rocket Pharmaceuticals, Inc."
guanfacine and amphetamine		3/17/2016	Treatment of pediatric patients with Tourette's syndrome (0 through 16 years of age)	Designated	Not FDA Approved for Orphan Indication	"KemPharm, Inc."
adeno-associated viral serotype 2 vector under the regulatory control of a CMV promoter encoding the human tripeptidyl peptidase-1 (hTPP1) cDNA		3/16/2016	Treatment of CLN2 disease (neuronal ceroid lipofuscinosis (NCL)) caused by TPP1 deficiency.	Designated	Not FDA Approved for Orphan Indication	"Spark Therapeutics, Inc."
"1,2:5,6-dianhydrogalactitol"		3/10/2016	Treatment of medulloblastoma.	Designated	Not FDA Approved for Orphan Indication	"DelMar Pharmaceuticals, Inc."
bevacizumab		3/10/2016	Treatment of Coat's disease	Designated	Not FDA Approved for Orphan Indication	"MicroSert, Ltd."
adenovirus associated viral vector serotype 5 containing the human RPE65 gene		3/10/2016	Treatment of Leber congenital amaurosis	Designated	Not FDA Approved for Orphan Indication	MeiraGTx Limited
adenovirus associated viral vector serotype 8 containing the human CNGB3 gene		3/10/2016	Treatment of achromatopsia due to mutations in the CNGB3 gene.	Designated	Not FDA Approved for Orphan Indication	MeiraGTx LLC
trientine tetrahydrochloride	Cuvrior	3/10/2016	Treatment of Wilson's disease excluding patients intolerant to penicillamine	Designated/Approved		Orphalan
Rosomidnar		3/10/2016	Treatment of diffuse large B-cell lymphoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ProNAi Therapeutics, Inc."
competetive small molecule inhibitor of the enzyme O-GlcNAcase		3/10/2016	Treatment of progressive supranuclear palsy.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Merck & Company, Inc."
anfibatide		3/10/2016	Treatment of thrombotic thrombocytopenic purpura.	Designated	Not FDA Approved for Orphan Indication	Lee's Pharmaceutical (Hong Kong) Limited
encochleated amikacin		3/3/2016	Treatment of non-tuberculous mycobacteria (NTM) infections	Designated	Not FDA Approved for Orphan Indication	"Matinas BioPharma Nanotechnologies, Inc"
selective inhibitor of fungal CYP51		3/3/2016	Treatment of coccidioidomycosis.	Designated	Not FDA Approved for Orphan Indication	"NQP 1598, Ltd."
Tesevatinib		3/1/2016	Treatment of patients with autosomal recessive polycystic kidney disease (ARPKD)	Designated	Not FDA Approved for Orphan Indication	"Kadmon Corporation, LLC"
valoctocogene roxaparvovec-rvox	Roctavian	2/29/2016	Treatment of Hemophilia A.	Designated/Approved		"BioMarin Pharmaceutical, Inc."
human monoclonal antibody targeting human sclerostin		2/29/2016	Treatment of osteogenesis imperfecta.	Designated	Not FDA Approved for Orphan Indication	"Ultragenyx Pharmaceutical, Inc."
Bacillus subtilis oxalate decarboxylase		2/29/2016	Treatment of pediatric hyperoxaluria	Designated	Not FDA Approved for Orphan Indication	"Allena Pharmaceuticals, Inc."
sodium alginate oligosaccharide		2/24/2016	Treatment of cystic fibrosis.	Designated	Not FDA Approved for Orphan Indication	AlgiPharma AS
Ombitasvir/Paritaprevir/Ritonavir		2/24/2016	Treatment of pediatric patients with chronic hepatitis C virus infection	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AbbVie Inc.
rapamycin		2/24/2016	Treatment of facial angiofibromas (FA) associated with tuberous sclerosis complex (TSC).	Designated	Not FDA Approved for Orphan Indication	AFT Pharmaceuticals Ltd.
riluzole		2/23/2016	Treatment of spinocereballar ataxia	Designated	Not FDA Approved for Orphan Indication	"Biohaven Pharmaceutical Holding Company, Ltd."
cannabidiol		2/23/2016	Treatment of Fragile X syndrome	Designated	Not FDA Approved for Orphan Indication	"Zynerba Pharmaceuticals, Inc."
"growth hormone releasing hormone, 1-44 human amide"		2/23/2016	Treatment of growth hormone deficiency	Designated	Not FDA Approved for Orphan Indication	"Hollenbeck Pharmaceuticals, Inc."
Human wilms tumor protein 1 peptides		2/23/2016	treatment of mesothelioma	Designated	Not FDA Approved for Orphan Indication	SELLAS Life Sciences Group
midazolam		2/18/2016	Treatment of status epilepticus	Designated	Not FDA Approved for Orphan Indication	"Laboratorios Lesvi, S.L."
CaspaCIDe System (combination product) consisting of allogeneic T Cell genetically modified to contain an inducible caspase 9 gene and Rimiducid		2/18/2016	Replacement T-cell therapy for the treatment of immunodeficiency and graft versus host disease after allogeneic hematopoietic stem cell transplant	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bellicum Pharmaceuticals, Inc."
"N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d] pyrimidin-4-amine"		2/18/2016	Treatment of glioma.	Designated	Not FDA Approved for Orphan Indication	"Flag Therapeutics, Inc."
pembrolizumab		2/17/2016	Treatment of multiple myeloma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Merck, Sharp & Dohme Corp."
"1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione or [(1E, 4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]"		2/17/2016	Treatment of spinal and bulbar muscular atrophy	Designated	Not FDA Approved for Orphan Indication	AnnJi Pharmaceutical Co. Ltd.
dantrolene sodium		2/17/2016	Treatment of Wolfram Syndrome	Designated	Not FDA Approved for Orphan Indication	Washington University in St. Louis
epacadostat		2/11/2016	Treatment of stage IIB-IV melanoma.	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
"6-{4-[l-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide"		2/11/2016	Treatment of glioblastoma multiforme (GBM).	Designated	Not FDA Approved for Orphan Indication	"Proximagen, LLC"
dodecafluoropentane emulsion		2/11/2016	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	NuvOx Pharma
inebilizumab	Uplizna	2/10/2016	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders	Designated/Approved		Horizon Therapeutics Ireland DAC
"4-[(2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide"		2/8/2016	Treatment of retinitis pigmentosa	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Shire HGT, Inc."
lumasiran	Oxlumo	2/8/2016	Treatment of primary hyperoxaluria type 1	Designated/Approved		"Alnylam Pharmaceuticals, Inc."
solnatide		2/8/2016	Treatment of generalized systemic pseudohypoaldosteronism type 1 (also known as autosomal recessive PHA-I or PHA-IB)	Designated	Not FDA Approved for Orphan Indication	Apeptico Forschung und Entwicklung GmbH (APEPTICO)
midazolam		2/8/2016	Treatment of seizures induced by organophosporous insecticide poisoning.	Designated	Not FDA Approved for Orphan Indication	"Meridian Medical Technologies, Inc."
eltoprazine HCl		2/8/2016	Treatment of levodopa-induced dyskinesia associated with Parkinson's disease.	Designated	Not FDA Approved for Orphan Indication	"Amarantus BioScience Holdings, Inc."
glyburide		2/8/2016	Treatment of acute subarachnoid hemorrhage	Designated	Not FDA Approved for Orphan Indication	"Remedy Pharmaceuticals, Inc."
dabrafenib	Tafinlar	2/8/2016	Treatment of malignant glioma with BRAF V600 mutation	Designated/Approved		Novartis Pharmaceuticals Corporation
evinacumab-dgnb	Evkeeza	2/8/2016	Treatment of homozygous familial hypercholesterolemia	Designated/Approved		"Regeneron Pharmaceuticals, Inc."
evinacumab-dgnb	Evkeeza	2/8/2016	Treatment of homozygous familial hypercholesterolemia	Designated/Approved		"Regeneron Pharmaceuticals, Inc."
Angiotensin (1-7)		2/8/2016	Treatment of LAMA2-related muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	Constant Therapeutics LLC
rezafungin	Rezzayo	2/8/2016	Treatment of candidemia and invasive candidiasis infections caused by susceptible Candida spp.	Designated/Approved		Mundipharma GmbH
lumasiran	Oxlumo	2/8/2016	Treatment of primary hyperoxaluria type 1	Designated/Approved		Alnylam Pharmaceuticals
human recombinant dual-variable domain immunoglobulin G1 monoclonal antibody that selectively neutralizes tumor necrosis factor-alpha and interkeukin-17A		2/4/2016	Treatment of pediatric patients 0 to	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
tabelecleucel		2/4/2016	Treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disorders	Designated	Not FDA Approved for Orphan Indication	"ATARA Biotherapeutics, Inc."
venetoclax	VENCLEXTA	2/4/2016	Treatment of acute myeloid leukemia.	Designated/Approved		AbbVie Inc.
midazolam	SEIZALAM	2/4/2016	Treatment of status epilepticus	Designated/Approved		Meridian Medical Technologies
solnatide		2/4/2016	Treatment of primary graft dysfunction following lung transplantation	Designated	Not FDA Approved for Orphan Indication	Apeptico Forschung und Entwicklung GmbH
afamelanotide		2/4/2016	Treatment of cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease)	Designated	Not FDA Approved for Orphan Indication	Clinuvel Inc.
tazemetostat		2/4/2016	Treatment of malignant rhabdoid tumors (MRTs)	Designated	Not FDA Approved for Orphan Indication	Epizyme Inc.
Synthesized peptide of the L-amino acids with the sequence H-Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg-OH		2/4/2016	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	Soricimed Biopharma Inc.
"somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells."		2/4/2016	Prevention of organ rejection in living donor kidney transplant recipients	Designated	Not FDA Approved for Orphan Indication	Regenerex LLC
oligodendrocyte progenitor cells		2/2/2016	Treatment of acute spinal cord injury	Designated	Not FDA Approved for Orphan Indication	"Lineage Cell Therapeutics, Inc."
ibrutinib	Imbruvica	2/2/2016	Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma)	Designated/Approved		"Pharmacyclics, LLC"
bevacizumab		1/27/2016	Treatment of mesothelioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
Endothelin receptor B antagonist		1/21/2016	Treatment of malignant melanoma Stages IIB to IV.	Designated	Not FDA Approved for Orphan Indication	"ENB Therapeutics, LLC"
tebentafusp-tebn	Kimmtrak	1/21/2016	Treatment of uveal melanoma	Designated/Approved		Immunocore Ltd
avapritinib	Ayvakit	1/21/2016	Treatment of mastocytosis	Designated/Approved		Blueprint Medicines Corporation
avapritinib	Ayvakit	1/21/2016	Treatment of mastocytosis	Designated/Approved		Blueprint Medicines Corporation
90Y-DOTA-tyr3-Octreotide		1/20/2016	Treatment of neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	"M. Sue O'Dorisio, MD, PhD"
thioureidobutyronitrile		1/20/2016	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"Innovation Pharmaceuticals, Inc."
Human/Murine Chimeric Monoclonal antibody to Endoglin		1/20/2016	Treatment of soft tissue sarcoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Tracon Pharmaceuticals, Inc."
mifepristone		1/14/2016	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	"Corcept Therapeutics, Inc."
pembrolizumab	Keytruda	1/14/2016	Treatment of primary mediastinal B cell lymphoma.	Designated/Approved		Merck Sharp & Dohme LLC
His-His- Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr-NH2		1/13/2016	Treatment of retinal detachment	Designated	Not FDA Approved for Orphan Indication	"ONL Therapeutics, Inc"
recombinant human serum albumin human growth hormone		1/13/2016	Treatment of growth hormone deficiency	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"TEVA Branded Pharmaceutical Products R&D, Inc."
S-nitrosoglutathione reductase inhibitor		1/13/2016	Treatment of cystic fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Alpine Immune Sciences
gemcitabine		1/11/2016	Treatment of cholangiocarcinoma.	Designated	Not FDA Approved for Orphan Indication	"InnoPharmax, Inc."
Cabiralizumab		1/11/2016	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Five Prime Therapeutics, Inc."
recombinant NY-ESO-1 protein mixed with glucopyranosyl lipid A		1/6/2016	Treatment of soft tissue sarcoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Immune Design Corp.
avapritinib	Ayvakit	1/6/2016	Treatment of gastrointestinal stromal tumors	Designated/Approved		Blueprint Medicines Corporation
"dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 gene"		1/6/2016	Treatment of soft tissue sarcoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Immune Design Corp.
1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol;1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole		1/6/2016	"As a diagnostic for clinical management of soft tissue sarcoma, including rhabdomyosarcoma."	Designated	Not FDA Approved for Orphan Indication	"Advanced Imaging Projects, LLC"
5-imino-13-deoxydoxorubicin HCl		12/31/2015	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"Monopar Therapeutics, Inc."
anlotinib hydrochloride		12/31/2015	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Advenchen Laboratories, LLC"
adeno-associated viral vector expressing the human vascular endothelial growth factor gene		12/31/2015	"Treatment of critical limb ischemia in no-option patients where other procedures, grafts, or angioplasty are not indicated"	Designated	Not FDA Approved for Orphan Indication	"Integene International Holding, LLC"
pembrolizumab	KEYTRUDA	12/30/2015	Treatment of Hodgkin lymphoma.	Designated/Approved		Merck Sharp & Dohme LLC
gemcitabine		12/30/2015	Treatment of upper tract urothelial carcinoma	Designated	Not FDA Approved for Orphan Indication	TARIS Biomedical LLC
recombinant adeno-associated virus serotype AAV8 vector encoding human ornithine transcarbamylase		12/29/2015	Treatment of ornithine transcarbamylase deficiency	Designated	Not FDA Approved for Orphan Indication	Dimension Therapeutics
ozanimod		12/29/2015	Treatment of pediatric (0 through 16 years of age) ulcerative colitis	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
fluticasone propionate		12/29/2015	Treatment of eosinophilic esophagitis	Designated	Not FDA Approved for Orphan Indication	"Banner Life Sciences, LLC"
noscapine		12/29/2015	Treatment of amyotrophic lateral sclerosis.	Designated	Not FDA Approved for Orphan Indication	KineMed Inc.
fosbretabulin tromethamine		12/29/2015	Treatment of neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	"Mateon Therapeutics, Inc."
voxelotor	Oxbryta	12/29/2015	Treatment of sickle cell disease	Designated/Approved		"Global Blood Therapeutics, Inc."
dipraglurant		12/29/2015	Treatment of levodopa-induced dyskinesias	Designated	Not FDA Approved for Orphan Indication	Addex Pharma SA
Tominersen		12/29/2015	Treatment of Huntington's disease	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
voxelotor	Oxbryta	12/29/2015	Treatment of sickle cell disease	Designated/Approved		"Global Blood Therapeutics, Inc."
Cyclo{-Asn-Leu-d-Phe-Al[(N5-acetyl-N5-hydroxy-Orn)-(N5-acetyl-N5-hydroxy-Orn)-(N5-hydroxy-Orn)]-} . Al(III)		12/29/2015	Treatment of invasive aspergillosis.	Designated	Not FDA Approved for Orphan Indication	"Basilea Pharmaceutica International, Ltd., Allschwil"
allogeneic ex-vivo expanded placental adherent stromal cells		12/29/2015	For the treatment of severe preeclampsia	Designated	Not FDA Approved for Orphan Indication	Pluri Biotech Ltd.
"treprostinil sodium solution enclosed within a pre-filled, pre-programmed, single-use, electronically-controlled infusion pump"		12/29/2015	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	SteadyMed Therapeutics
imetelstat	Rytelo	12/23/2015	Treatment of myelodysplastic syndrome	Designated/Approved		Geron Corporation
Human Wilms tumor protein 1 peptides		12/23/2015	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	SELLAS Life Sciences Group
magnesium lysinate bis eicosapentaenoate		12/23/2015	Treatment of familial adenomatous polyposis.	Designated	Not FDA Approved for Orphan Indication	Thetis Pharmaceuticals
rovalpituzumab tesirine		12/22/2015	Treatment of small cell lung cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AbbVie Inc.
Substituted imidazopyridine amide		12/22/2015	Treatment of active tuberculosis (TB).	Designated	Not FDA Approved for Orphan Indication	"The Global Alliance for TB Drug Development, Inc."
carbon dioxide		12/17/2015	Treatment of trigeminal neuralgia	Designated	Not FDA Approved for Orphan Indication	"Capnia, Inc."
stemchymal		12/16/2015	Treatment of polyqlutamine spinocerebellar ataxia	Designated	Not FDA Approved for Orphan Indication	"Steminent Biotherapeutics, Inc."
propagermanium and irbesartan		12/9/2015	Treatment of focal segmental glomerulosclerosis.	Designated	Not FDA Approved for Orphan Indication	Dimerix Bioscience Ltd.
cromolyn sodium for inhalation		12/9/2015	Treatment of mastocytosis.	Designated	Not FDA Approved for Orphan Indication	"Patara Pharma, LLC"
"(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one"		12/9/2015	Treatment of Fragile X Syndrome.	Designated	Not FDA Approved for Orphan Indication	Centre National de la Recherche Scientifique (CNRS)
non-replicating recombinant adeno-associated virus (AAV) vector of serotype 9 expressing human iduronate-2-sulfatase		12/8/2015	Treatment of Mucopolysaccharidosis Type II	Designated	Not FDA Approved for Orphan Indication	"REGENXBIO, Inc."
multi-epitope folate receptor alpha peptide vaccine with GM-CSF adjuvant (TPIV200)		12/7/2015	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	"Marker Therapeutics, Inc. (formerly Tapimmune, Inc.)"
delta-9-tetrahydrocannibinol and cannabidiol		12/3/2015	Treatment of glioma.	Designated	Not FDA Approved for Orphan Indication	GW Research Ltd.
Azurin-p28		12/2/2015	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"CDG Therapeutics, Inc."
dodecafluoropentane emulsion (DDFPe)		12/2/2015	Radiosensitizer to be used during radiation treatment of glioblastoma multiforme (GBM).	Designated	Not FDA Approved for Orphan Indication	NuvOx Pharma
tirapazamine		11/30/2015	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Teclison Limited
temozolomide		11/25/2015	Treatment glioblastoma multiforme in pediatric patients	Designated	Not FDA Approved for Orphan Indication	"AmpliPharm Pharmaceuticals, LLC"
acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cystenyl-D-arginyl-D-arginyl-D-lysyl-D-asparaginylmaide disulfide		11/24/2015	Treatment of acute myeloid leukemia.	Designated	Not FDA Approved for Orphan Indication	"Genus Oncology, LLC"
necitumumab		11/20/2015	Treatment of squamous non-small cell lung cancer	Designated/Approved		Eli Lilly and Company
ubenimex		11/19/2015	Treatment of pulmonary arterial hypertension.	Designated	Not FDA Approved for Orphan Indication	"Eiger BioPharmaceuticals, Inc."
"(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride"		11/19/2015	Treatment of cholangiocarcinoma.	Designated	Not FDA Approved for Orphan Indication	Basilea Pharmaceutical International Ltd.
Vasomera		11/19/2015	"Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and X-linked dilated cardiomyopathy (XL-dCMP)."	Designated	Not FDA Approved for Orphan Indication	ImmunoForge Co. Ltd.
oxaloacetic acid		11/18/2015	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Terra Biological LLC
"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate"		11/18/2015	Treatment of patients with Duchenne Muscular Dystrophy.	Designated	Not FDA Approved for Orphan Indication	"ARMGO Pharma, Inc."
adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)		11/18/2015	Treatment of mucopolysaccharidosis type IIIA or Sanfilippo type A syndrome	Designated	Not FDA Approved for Orphan Indication	LYSOGENE
thioureidobutyronitrile		11/17/2015	Treatment of retinoblastoma.	Designated	Not FDA Approved for Orphan Indication	"Innovation Pharmaceuticals, Inc."
diazepam (intranasal)	VALTOCO	11/16/2015	Management of acute repetitive seizures	Designated/Approved		"Neurelis Pharmaceuticals, Inc."
adeno-associated virus type 8 delivering a vector genome with human retinoschisin promoter (RS/IRBP) and the human retinoschisin cDNA (hRS)		11/16/2015	Treatment of X-linked retinoschisis	Designated	Not FDA Approved for Orphan Indication	"VegaVect, Inc."
recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel alpha subunit (CNGA3)		11/16/2015	Treatment of achromatopsia caused by mutations in the CNGA3 gene	Designated	Not FDA Approved for Orphan Indication	Beacon Therapeutics
"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide"		11/16/2015	Treatment of C3 glomerulopathy.	Designated	Not FDA Approved for Orphan Indication	Amyndas Pharmaceuticals S.A
sodium nitrite and EDTA		11/10/2015	Treatment of Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Arch Biopartners, Inc."
vadastuximab talirine		11/10/2015	Treatment of acute myeloid leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Seattle Genetics, Inc."
daratumumab		11/9/2015	Treatment of diffuse large B-cell lymphoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
human allogeneic bone marrow derived osteoblastic cells		11/9/2015	Treatment of osteogenesis imperfecta.	Designated	Not FDA Approved for Orphan Indication	Biosenic SA
"3-{3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl}cpyridin-2-amine bis-mesylate"		11/9/2015	Treatment of Proteus Syndrome.	Designated	Not FDA Approved for Orphan Indication	Merck Sharp & Dohme LLC
Bendamustine oral doseage formulation		11/5/2015	Treatment of chronic lymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	Exinda Theapeutics LLC
Cisplatin ChemoThin Wafer		11/3/2015	"Treatment of anatomically accessible oral cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)"	Designated	Not FDA Approved for Orphan Indication	Privo Technologies
human cystic fibrosis transmembrane conductance regulator (hCFTR) messenger RNA (mRNA) complexed with branched polyethyleneimine (bPEI)		11/3/2015	Treatment of patients with cystic fibrosis.	Designated	Not FDA Approved for Orphan Indication	Translate Bio
arsenic trioxide capsule (oral)		11/2/2015	Treatment of acute promyelocytic leukemia.	Designated	Not FDA Approved for Orphan Indication	"Syros Pharmaceuticals, Inc."
dabrafenib and trametinib	Mekinist	10/29/2015	Treatment of patients with BRAF mutation positive non-small cell lung cancer.	Designated/Approved		Novartis Pharmaceuticals Corporation
monoclonal antibody targeting eotaxin-2		10/29/2015	Treatment of idiopathic pulmonary fibrosis.	Designated	Not FDA Approved for Orphan Indication	"ChemomAb, Ltd."
recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP		10/29/2015	Treatment of Angelman Syndrome.	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
"N'-(7-Chloroquinolin-4-yl)-N,N-diethyl-propane-1,3-diamine"		10/29/2015	Treatment of malaria.	Designated	Not FDA Approved for Orphan Indication	"Donald J. Krogstad, MD"
lucerastat		10/29/2015	Treatment of Fabry Disease.	Designated	Not FDA Approved for Orphan Indication	Idorsia Pharmaceuticals US Inc.
baclofen		10/28/2015	Treatment of complex regional pain syndrome	Designated	Not FDA Approved for Orphan Indication	"Piramal Critical Care, Inc."
nano-diamino-tetraiodothyroacetic acid		10/28/2015	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"NanoPharmaceuticals, LLC"
ABCA4 DNA nanoparticles		10/28/2015	Treatment of Stargardt Macular Degeneration	Designated	Not FDA Approved for Orphan Indication	"Copernicus Therapeutics, Inc."
valsartan oral solution		10/28/2015	Treatment of hypertension in pediatric patients 0 through 16 years of age	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Carmel Biosciences
paricalcitol	Zemplar	10/27/2015	Treatment of pediatric hyperparathyroidism	Designated/Approved		"Abbvie, inc."
bucillamine		10/22/2015	Treatment of cystinuria	Designated	Not FDA Approved for Orphan Indication	"Revive Therapeutics, Ltd."
acalabrutinib		10/22/2015	Treatment of Waldenstrom macroglobulinemia.	Designated	Not FDA Approved for Orphan Indication	"Acerta Pharma, LLC (a member of the AstraZeneca Group)"
deflazacort		10/22/2015	Treatment of pediatric (0 through 16 years of age) juvenile idiopathis arthritis (JIA) International League of Associations for Rheumatology (ILAR) categories excluding systemic JIA.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
"(2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1h-pyrazolo [4,3-c] pyridine-3,6(2h,5h)-dione)"		10/14/2015	Treatment of systemic sclerosis.	Designated	Not FDA Approved for Orphan Indication	Calliditas Therapeutics Suisse SA
human soluble receptor-Fc fusion protein that targets human activin A		10/14/2015	Treatment of ovarian cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Atara Biotherapeutics
lisinopril oral solution		10/14/2015	Treatment of hypertension in pediatric patients 0 through 16 years of age.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Silvergate Pharmaceuticals, Inc."
ondansetron inhalation powder		10/14/2015	Prevention of chemotherapy-induced nausea and vomiting due to highly emetogenic chemotherapy in pediatric patients (0 through 16 years of age) .	Designated	Not FDA Approved for Orphan Indication	"Luxena Pharmaceuticals, Inc."
"(6aR, 10aR)-3-(1¿,1¿-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid"		10/13/2015	Treatment of cystic fibrosis.	Designated	Not FDA Approved for Orphan Indication	"Corbus Pharmaceuticals, Inc."
betamethasone		10/7/2015	Treatment of Ataxia Telangiectasia.	Designated	Not FDA Approved for Orphan Indication	Acasti Pharma Inc.
Mixture of 2 anti-rabies humanized monoclonal immunoglobulin (Ig)G1k antibodies		10/7/2015	Post-exposure prophylaxis against rabies virus infection	Designated	Not FDA Approved for Orphan Indication	"Synermore Biologics Co., Ltd"
recombinant fusion protein comprising exenatide and XTEN		10/7/2015	Treatment of short bowel syndrome.	Designated	Not FDA Approved for Orphan Indication	"9 Meters Biopharma, Inc."
nanoparticulate paclitaxel		10/6/2015	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"NanOlogy, LLC"
"2-amino-2-[2-[2-chloro-4-[[3-(phenylmethoxy) phenyl] thio]phenyl]ethyl]1,3-propanediol hydrochloride"		10/6/2015	Prevention of graft versus host disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
rodatristat ethyl		10/6/2015	Treatment of pulmonary arterial hypertension (PAH).	Designated	Not FDA Approved for Orphan Indication	Altavant Sciences GmbH
"2-[(4S)-6-(4-chlorophenyl)-1,7,8-trimethylthiophenol[3,2-f]1,2,4-triazolo[4,3-a]1,4-diazepin-4-yl]-N-[3-(4-methylpiperazinyl)propyl]acetamide"		9/29/2015	Treatment of nuclear protein in testis (NUT) midline carcinoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc (a Roche Group Member)"
guadecitabine		9/29/2015	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Astex Pharmaceuticals, Inc."
glyburide		9/29/2015	Treatment of acute spinal cord injury	Designated	Not FDA Approved for Orphan Indication	"Remedy Pharmaceuticals, Inc."
aden-associated virus vector serotype 9 expressing human a-L-iduronidase		9/29/2015	Treatment of mucopolysaccharidosis Type I (MSP I).	Designated	Not FDA Approved for Orphan Indication	"REGENXBIO, Inc."
"4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl"		9/29/2015	Treatment of cerebral cavernous malformation.	Designated	Not FDA Approved for Orphan Indication	"Recursion Pharmaceuticals, LLC"
acalabrutinib	Calquence	9/21/2015	Treatment of mantle cell lymphoma.	Designated/Approved		"Acerta Pharma, LLC (a member of the AstraZeneca Group)"
setmelanotide		9/21/2015	Treatment of Prader-Willi Syndrome.	Designated	Not FDA Approved for Orphan Indication	"Rhythm Metabolics, Inc."
fidanacogene elaparvovec-dzkt	Beqvez	9/21/2015	Treatment of hemophilia B.	Designated/Approved		Pfizer Inc.
marizomib		9/21/2015	Treatment of malignant glioma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene International II S?
"mecasermin, recombinant human insulin-like growth factor-1"		9/21/2015	Treatment of Rett Syndrome.	Designated	Not FDA Approved for Orphan Indication	Keck Graduate Institute of Applied Life Sciences
avelumab (Recombinant human monoclonal IgG1 antibody against programmed death ligand-1)	Bavencio	9/21/2015	Treatment of merkel cell carcinoma.	Designated/Approved		"EMD Serono Research and Development Institute, Inc."
acalabrutinib	CALQUENCE	9/21/2015	Treatment of mantle cell lymphoma.	Designated/Approved		"Acerta Pharma, LLC (a member of the AstraZeneca Group)"
Remdesivir		9/18/2015	Treatment of Ebola virus disease	Designated	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
upadacitinib	Rinvoq	9/18/2015	Treatment of pediatric (aged 0 through 16 years) juvenile idiopathic arthritis (JIA) ILAR categories excluding systemic JIA	Designated/Approved		"AbbVie, Inc."
Mononuclear enriched fraction of human umbilical cord blood		9/15/2015	Treatment of amyotrophic lateral sclerosis (ALS).	Designated	Not FDA Approved for Orphan Indication	"Saneron CCEL Therapeutics, Inc."
nivolumab	OPDIVO	9/15/2015	Treatment of small cell lung cancer.	Designated/Approved		Bristol-Myers Squibb Company
interleukin-1 receptor antagonist anakinra		9/15/2015	Treatment of Still's disease including systemic juvenile idiopathic arithritis and adult-onset Still's disease.	Designated	Not FDA Approved for Orphan Indication	Swedish Orphan Biovitrum AB
small molecule FGFR4 inhibitor		9/14/2015	Treatment of hepatocellular cancer (HCC).	Designated	Not FDA Approved for Orphan Indication	Blueprint Medicines Corporation
masitinib mesylate		9/14/2015	Treatment of gastric cancer including cancer of the gastroesophageal junction	Designated	Not FDA Approved for Orphan Indication	AB Science
2-(2-chlorobenzylidene)hydrazinecarboximidamide acetate		9/10/2015	Treatment of Charcot-Marie Tooth disease.	Designated	Not FDA Approved for Orphan Indication	InFlectis BioScience
"mesencephalic, astrocyte-derived neurotrophic factor"		9/10/2015	Treatment of retinal artery occlusion.	Designated	Not FDA Approved for Orphan Indication	"Amarantus BioScience Holdings, Inc."
immunoglobulin G degrading enzyme of Streptococcus pyogenes		9/10/2015	Prevention of antibody mediated organ rejection in solid organ transplant patients.	Designated	Not FDA Approved for Orphan Indication	Hansa Medical AB
everolimus ointment		9/10/2015	Topical treatment of Tuberous Sclerosis Complex-related skin lesions	Designated	Not FDA Approved for Orphan Indication	"Aucta Pharmaceuticals, LLC"
pentetrazol		9/9/2015	Treatment of idiopathic hypersomnia	Designated	Not FDA Approved for Orphan Indication	"Balance Therapeutics, Inc."
nimotuzumab		9/8/2015	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	InnoCIMab Pte Ltd
hydrocortisone modified release capsules		9/3/2015	Treatment of adrenal insufficiency.	Designated	Not FDA Approved for Orphan Indication	Diurnal Limited
nivolumab; nivolumab	OPDIVO; OPDIVO	9/2/2015	Treatment of hepatocellular carcinoma	Designated/Approved		Bristol-Myers Squibb Company
nivolumab; nivolumab	OPDIVO; OPDIVO	9/2/2015	Treatment of hepatocellular carcinoma	Designated/Approved		Bristol-Myers Squibb Company
purified autologous type 1 regulatory T lymphocytes specific for human type II collagen		9/1/2015	Treatment of chronic non-infectious uveitis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	TxCell SA
ataluren		9/1/2015	Treatment of aniridia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
modified a-cobratoxin		9/1/2015	Treatment of pediatric multiple sclerosis (0 through 16 years of age).	Designated	Not FDA Approved for Orphan Indication	Nutra Pharma Corporation
Larotrectinib		8/31/2015	Treatment of soft tissue sarcoma.	Designated	Not FDA Approved for Orphan Indication	Bayer HealthCare Pharmaceuticals Inc.
udenafil		8/31/2015	Treatment of single ventricle congenital heart disease with Fontan physiology	Designated	Not FDA Approved for Orphan Indication	Mezzion Pharma Co. Ltd.
N-acetylcysteine and sodium thiosulfate		8/31/2015	Prevention of platinum-induced toxicities in pediatric patients (0 through 16 years of age).	Designated	Not FDA Approved for Orphan Indication	"Edward A. Neuwelt, MD"
methotrexate oral solution	Xatmep	8/27/2015	Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who are intolerant of or had an inadequate response to first-line therapy.	Designated/Approved		"Silvergate Pharmaeuticals, Inc."
nivolumab		8/27/2015	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Co
sodium 2-hydroxylinoleate		8/25/2015	Treatment of neuroblastoma.	Designated	Not FDA Approved for Orphan Indication	"Ability Pharmaceuticals, SL"
fostamatinib disodium hexahydrate		8/25/2015	Treatment of immune thrombocytopenic purpura	Designated/Approved		"Rigel Pharmaceuticals, Inc."
Adeno-associated virus serotype rh10 vector encoding the human factor IX gene		8/25/2015	Treatment of hemophilia B.	Designated	Not FDA Approved for Orphan Indication	Ultragenyx Pharmaceuticals
daratumumab		8/20/2015	Treatment of mantle cell lymphoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
humanized monoclonal antibody of the IgG4 kappa isotype targeting CD47		8/20/2015	Treatment of acute myeloid (myelogenous) leukemia.	Designated	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
"fecal microbiota spores, live-brpk"	Vowst	8/19/2015	Treatment of recurrent Clostridium difficile infection (CDI)	Designated/Approved		"Seres Therapeutics, Inc."
daratumumab		8/6/2015	Treatment of follicular lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
butylidenephthalide		8/5/2015	Treatment of Malignant Glioma	Designated	Not FDA Approved for Orphan Indication	"Everfront Biotech, Inc."
varlitinib		8/5/2015	treatment of biliary tract cancer	Designated	Not FDA Approved for Orphan Indication	"ASLAN Pharmaceuticals Pte, Ltd."
sodium valproate		8/5/2015	Treatment of Wolfram syndrome	Designated	Not FDA Approved for Orphan Indication	The University of Birmingham
inecalcitol		8/3/2015	Treatment of acute myeloid leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Hybrigenics, S.A."
afatinib	Gilotrif	8/3/2015	Treatment of non-small cell lung cancer with squamous histology.	Designated/Approved		"Boehringer Ingelheim Pharmaceuticals, Inc."
veltuzumab		7/28/2015	Treatment of immune thrombocytopenic purpura.	Designated	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12 + veledimex		7/23/2015	Treatment of malignant glioma.	Designated	Not FDA Approved for Orphan Indication	"Ziopharm Oncology, Inc."
cannabidiol		7/23/2015	Treatment of infantile spasms	Designated	Not FDA Approved for Orphan Indication	"Radius Pharmaceuticals, Inc."
procaspase-activating compound 1		7/23/2015	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Vanquish Oncology, Inc."
antroquinonol		7/23/2015	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Golden Biotechnology Corporation
Amantadine HCl		7/20/2015	Treatment of levodopa-induced dyskinesia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Osmotica Pharmaceutical Corporation
mongersen		7/20/2015	Treatment of pediatric Crohn's disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene Corporation
ombitasvir/paritaprevir/ritonavir and dasabuvir		7/16/2015	Treatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age)	Designated	Not FDA Approved for Orphan Indication	"Abbvie, Inc."
adeno-associated virus serotype 9 vector containing human Iduronate-2-sulfatase transgene		7/16/2015	Treatment of mucopolysaccharidosis type II (Hunter syndrome).	Designated	Not FDA Approved for Orphan Indication	"Esteve Pharmaceuticals, S.A."
recombinant humanized anti-matrix metalloprotein 9 (MMP9) monoclonal antibody IgG4		7/16/2015	Treatment of gastric cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
vitamin A palmitate		7/14/2015	Prevention of bronchopulmonary dysplasia.	Designated	Not FDA Approved for Orphan Indication	"Advent Therapeutics, Inc."
thioureidobutyronitrile		7/14/2015	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Innovation Pharmaceuticals, Inc."
DPX-Survivac		7/14/2015	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	"Immunovaccine Technologies, Inc."
recombinant multimerized human IgG1 Fc		7/14/2015	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).	Designated	Not FDA Approved for Orphan Indication	Gliknik Inc.
"3-(4-(8-fluoroquinoline)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)"		7/14/2015	Treatment of fibrodysplasia ossificans progressiva.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"La Jolla Pharmaceutical Company, Inc."
"3-(4-(1,5-Napthrydine)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)"		7/14/2015	Treatment of fibrodysplasia ossificans progressiva.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"La Jolla Pharmaceutical Company, Inc."
anisina		7/14/2015	Treatment of neuroblastoma.	Designated	Not FDA Approved for Orphan Indication	Novogen Ltd
cannabidiol		7/14/2015	Prevention of Graft versus Host Disease (GVHD).	Designated	Not FDA Approved for Orphan Indication	"Kalytera Therapeutics Israel, Ltd."
adenovirus vaccine encoding reduced expression in immortalized cell protein		7/14/2015	Treatment of mesothelioma	Designated	Not FDA Approved for Orphan Indication	Momotaro-Gene Inc.
melphalan		7/14/2015	Treatment of cholangiocarcinoma.	Designated	Not FDA Approved for Orphan Indication	"Delcath Systems, Inc."
nano-diamino-tetraiodothyroacetic acid		7/9/2015	Treatment of glioblastoma multiforme (GBM)	Designated	Not FDA Approved for Orphan Indication	"NanoPharmaceuticals, LLC"
propranolol and etodolac		7/8/2015	Treatment of malignant glioma.	Designated	Not FDA Approved for Orphan Indication	"Vicus Therapeutics, LLC"
"1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide"		7/8/2015	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Cleave Biosciences, Inc."
ANA-conjugated dactunomycin nanoemulsion		7/7/2015	Treatment of Ewing sarcoma	Designated	Not FDA Approved for Orphan Indication	"NanoSmart Pharmaceuticals, Inc."
sarizotan		7/7/2015	Treatment of Rett syndrome.	Designated	Not FDA Approved for Orphan Indication	"Newron Pharmaceuticals US, Inc."
Gallium (68Ga) edotreotide		7/1/2015	Diagnostic for the clinical management of neuroendocrine tumors.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Advanced Accelerator Applications, USA"
gemcitabine ready-to-use		6/24/2015	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Sun Pharmaceutical Industries Ltd.
gemcitabine ready-to-use		6/24/2015	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Sun Pharmaceutical Industries Ltd.
"volanesorsen sodium, apolipotrotein C-III antisense oligonucleotide"		6/23/2015	treatment of familial chylomicronemia syndrome	Designated	Not FDA Approved for Orphan Indication	"Akcea Therapeutics, Inc."
"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid"		6/23/2015	Treatment of malignant melanoma stages IIB to IV.	Designated	Not FDA Approved for Orphan Indication	"Rgenix, Inc."
Lorlatinib; lorlatinib	LORBRENA; Lorbrena	6/23/2015	Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer	Designated/Approved		"Pfizer, Inc."
Lorlatinib; lorlatinib	LORBRENA; Lorbrena	6/23/2015	Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer	Designated/Approved		"Pfizer, Inc."
chlorotoxin conjugated to indocyanine green dye		6/23/2015	Diagnostic for the management of primary malignant brain and CNS tumors	Designated	Not FDA Approved for Orphan Indication	"Blaze Bioscience, Inc."
"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one"		6/18/2015	Treatment of Netherton syndrome	Designated	Not FDA Approved for Orphan Indication	Sixera Pharma AB
pembrolizumab	Keytruda	6/16/2015	"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma"	Designated/Approved		Merck Sharp & Dohme LLC
"recombinant adeno-associated virus serotype rhesus 74 (rh74) expressing the human CT GalNac transferase (GALGT2) gene, also called the Sda or Cad GAlNac transferase or b4Galnt2, under control of the muscle creatine kinase (MCK) promoter"		6/16/2015	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	Nationwide Children's Hospital
"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid"		6/16/2015	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	"Rgenix, Inc."
synthetic signal peptide of human mucin-1 (amino acids 1-21)		6/16/2015	Treatment of multiple myeloma.	Designated	Not FDA Approved for Orphan Indication	Vaxil Bio Therapeutics Ltd.
pembrolizumab	Keytruda	6/16/2015	"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma"	Designated/Approved		Merck Sharp & Dohme LLC
"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid"		6/16/2015	Treatment of glioblastoma multiforme.	Designated	Not FDA Approved for Orphan Indication	"Rgenix, Inc."
pembrolizumab	Keytruda	6/16/2015	"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma"	Designated/Approved		Merck Sharp & Dohme LLC
obinutuzumab		6/11/2015	Treatment of splenic marginal zone lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
imetelstat		6/11/2015	Treatment of myelofibrosis	Designated	Not FDA Approved for Orphan Indication	Geron Corporation
staphylococcal aureus protein A		6/10/2015	Treatment of immune thrombocytopenic purpura	Designated	Not FDA Approved for Orphan Indication	"Protalex, Inc."
"(6aR, 10aR)-3-(1â¿¿,1â¿¿-dimethylheptyl)-Î¿8-tetrahydro-cannabinol-9-carboxylic acid"		6/10/2015	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	"Corbus Pharmaceuticals, Inc."
fully human IgG2 monoclonal antibody that binds insulin receptors		6/9/2015	Treatment of congenital hyperinsulinism	Designated	Not FDA Approved for Orphan Indication	"Rezolute, Inc."
ivosidenib	Tibsovo	6/9/2015	Treatment of acute myeloid leukemia (AML)	Designated/Approved		Servier Pharmaceuticals LLC
lifileucel	Amtagvi	6/9/2015	Treatment of malignant melanoma Stages IIb to IV	Designated/Approved		"Iovance Biotherapeutics, Inc."
double stranded oligomer AD00370 RNA interference-based liver targeted therapeutic		6/9/2015	Treatment of Alpha-1 Antitrypsin deficiency	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Arrowhead Research Corporation
recombinant human CD24FcIg (humanized fusion protein consisting of the extracellular domain of CD24 linked to IgG1 Fc domain		6/9/2015	Prevention of graft-versus-host disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Merck Sharp & Dohme LLC
ivosidenib	TIBSOVO	6/9/2015	Treatment of acute myeloid leukemia (AML)	Designated/Approved		Servier Pharmaceuticals LLC
ivosidenib	TIBSOVO	6/9/2015	Treatment of acute myeloid leukemia (AML)	Designated/Approved		Servier Pharmaceuticals LLC
adenoviral vector expressing the E.coli purine nucleoside phosphorylase gene and fludarabine		6/8/2015	"Intratumoral treatment of anatomically accessible oral and pharyngeal cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)"	Designated	Not FDA Approved for Orphan Indication	"GeoVax, Inc."
regorafenib	Stivarga	6/4/2015	Treatment of hepatocellular carcinoma	Designated/Approved		"Bayer HealthCare Pharmaceuticals, Inc."
synthetic 14-mer phosphorothioate antisense oligonucleotide directed against TGF-beta2 mRNA		6/4/2015	Prevention of scarring post glaucoma filtration surgery	Designated	Not FDA Approved for Orphan Indication	Isarna Therapeutics GmbH
"2-(5-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10] phenanthroline"		6/1/2015	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Aptose Biosciences, Inc."
ibudilast		6/1/2015	Treatment of Krabbe disease	Designated	Not FDA Approved for Orphan Indication	"MediciNova, Inc."
immunologically active synthetic peptides		6/1/2015	Treatment of Hemophilia A	Designated	Not FDA Approved for Orphan Indication	Apitope International NV
17-a-hydroxyprogesterone caporate (oral formulation)		6/1/2015	Prevention of preterm birth in women with a singleton pregnancy	Designated	Not FDA Approved for Orphan Indication	"Lipocine, Inc."
docosahexaenoic acid		6/1/2015	Treatment of short bowel syndrome	Designated	Not FDA Approved for Orphan Indication	"Micelle BioPharma, Inc."
intraventricular nimodipine		5/28/2015	Treatment of subarachnoid hemorrhage	Designated	Not FDA Approved for Orphan Indication	"Edge Therapeutics, Inc."
methotrexate oral solution	Xatmep	5/28/2015	Treatment of acute lymphoblastic leukemia in pediatric patients (0 through 16 years of age)	Designated/Approved		"Silvergate Pharmaceuticals, Inc."
idarucizumab		5/28/2015	To reverse the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure	Designated/Approved		"Boehringer Ingelheim Pharmaceuticals, Inc."
adult hemogenic endothelial cells		5/27/2015	Treatment of aplastic anemia	Designated	Not FDA Approved for Orphan Indication	HemoGenyx LLC
prasugrel hydrochloride		5/26/2015	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	Eli Lilly
lutetium (177Lu)-edotreotide		5/21/2015	Treatment of gastro-entero-pancreatic neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	ITM Solucin GmbH
echinomycin		5/21/2015	Treatment of acute myeloid leukemia.	Designated	Not FDA Approved for Orphan Indication	"OncoC4, Inc."
poly-CD-PEG-camptothecin		5/21/2015	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	"Ellipses Pharma, Ltd."
chloroquine		5/20/2015	Treatment of glioblastoma multiforme.	Designated	Not FDA Approved for Orphan Indication	"DualTpharma B.,V."
revusiran		5/18/2015	Treatment of transthyretin amyloidosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Alnylam Pharmaceuticals, Inc."
xenon gas		5/18/2015	To improve neurological outcome in hospitalized cardiac arrest patients.	Designated	Not FDA Approved for Orphan Indication	"Invero Pharma, Inc."
E-selectin antagonist		5/13/2015	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	"GlycoMimetics, Inc."
recombinant human alkaline phosphatase		5/13/2015	Treatment of hypophosphatasia.	Designated	Not FDA Approved for Orphan Indication	-Pharma BV
Anti-eTau Humanized IgG4 Monoclonal Antibody		5/13/2015	Treatment of Progressive Supranuclear Palsy	Designated	Not FDA Approved for Orphan Indication	"Biogen, Inc."
2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide		5/13/2015	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	Flatley Discovery Lab
Hydrocortisone	ALKINDI® SPRINKLE	5/13/2015	Treatment of pediatric adrenal insufficiency (0 through 16 years of age).	Designated/Approved		"Eton Pharmaceuticals, Inc."
adalimumab	HUMIRA	5/13/2015	Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)	Designated/Approved		"AbbVie, Inc."
acalabrutinib		5/13/2015	Treatment of chronic lymphocytic leukemia (CLL).	Designated/Approved		"Acerta Pharma, LLC (a member of the AstraZeneca Group)"
acalabrutinib	Calquence	5/13/2015	Treatment of chronic lymphocytic leukemia (CLL).	Designated/Approved		"Acerta Pharma, LLC (a member of the AstraZeneca Group)"
adalimumab	HUMIRA	5/13/2015	Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)	Designated/Approved		"AbbVie, Inc."
edaravone	Radicava ORS	5/12/2015	Treatment of amyotrophic lateral sclerosis	Designated/Approved		Mitsubishi Tanabe Pharma Corporation
edaravone	Radicava	5/12/2015	Treatment of amyotrophic lateral sclerosis	Designated/Approved		Mitsubishi Tanabe Pharma Corporation
N-t-butylhydroxylamine		5/12/2015	Treatment of infantile neuronal ceroid lipofuscinosis.	Designated	Not FDA Approved for Orphan Indication	Andrew Lim
"autologous tumor cells fused with polyethylene glycol to human allogeneic FO-1, DNA plasmid transfected tumor cell line"		5/6/2015	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	"Sebastiano Gattoni-Celli, MD"
humanized monoclonal antibody that targets the a-subunit of the human IL-3 receptor also known as the CD123 antigen; (JNJ-56022473)		5/5/2015	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
pantothenate phosphate		5/4/2015	Treatment of pantothenate kinase associated neurodegeneration (PKAN).	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Retrophin, Inc."
pelareorep		5/4/2015	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	"Oncolytics Biotech, Inc."
tadalafil		5/4/2015	Treatment of Duchenne Muscular Dystrophy (DMD)	Designated	Not FDA Approved for Orphan Indication	Eli Lilly and Company
"LOAd703, a modified adenovirus 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand (TMZ-CD40L) and full length 4-1BBL"		5/4/2015	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Lokon Pharma AB
"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one"		5/4/2015	Treatment of congenital long QT syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
tacrolimus		5/4/2015	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	Stanford University School of Medicine
antroquinonol		4/30/2015	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Golden Biotechnology Corporation
lenalidomide	Revlimid	4/29/2015	Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue	Designated/Approved		Celgene Corporation
"(S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one"		4/29/2015	Treatment of Hodgkin lymphoma	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
liposomal P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide		4/27/2015	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Bio-Path Holdings, Inc."
docosahexaenoic acid		4/27/2015	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"Micelle BioPharma, Inc."
propranolol and etodolac		4/27/2015	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"Vicus Therapeutics, LLC"
cannabidiol		4/22/2015	Treatment of neonatal hypoxic ischemic encephalopathy	Designated	Not FDA Approved for Orphan Indication	GW Pharma Ltd.
synthetic double-stranded (hybridized duplex) ribonucleic acid oligonucleotide specific to hydroxyacid oxidase 1 gene		4/22/2015	Treatment of primary hyperoxaluria type 1	Designated	Not FDA Approved for Orphan Indication	"Dicerna Pharmaceuticals, Inc."
recombinant human histidyl tRNA synthetase		4/22/2015	Treatment of facioscapulohumeral muscular dystrophy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"aTyr Pharma, Inc."
allogeneic cardiosphere-derived cells		4/21/2015	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	"Capricor, Inc."
cantrixil		4/20/2015	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	Vivesto AB
177-LU-DOTA-GlyGlyNle-CycMSHhex		4/16/2015	Treatment of Stage IIB through IV malignant melanoma	Designated	Not FDA Approved for Orphan Indication	"SolaranRx, Inc."
2-[4-[[(2-R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate		4/15/2015	Treatment of patients with Frederickson Type I or V hyperlipoproteinemia	Designated	Not FDA Approved for Orphan Indication	"CymaBay Therapeutics, Inc."
selumetinib		4/15/2015	Treatment of uveal melanoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals LP
pelareorep		4/15/2015	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Oncolytics Biotech, Inc."
"zoledronate D,L-lysine monohydrate (ZLM)"		4/15/2015	Treatment of complex regional pain syndrome (CRPS)	Designated	Not FDA Approved for Orphan Indication	"Thar Pharma, LLC"
obinutuzumab	GAZYVA	4/15/2015	Treatment of follicular lymphoma	Designated/Approved		"Genentech Inc., a member of the Roche Group"
obinutuzumab	GAZYVA	4/15/2015	Treatment of follicular lymphoma	Designated/Approved		"Genentech Inc., a member of the Roche Group"
triheptanoin	Dojolvi	4/15/2015	Treatment of fatty acid oxidation disorders	Designated/Approved		"Ultragenyx Pharmaceutical, Inc."
Diphenylcyclopropenone gel		4/15/2015	Treatment of malignant melanoma stage IIB to IV	Designated	Not FDA Approved for Orphan Indication	RXi Pharmaceuticals Corp.
[Î±â¿¿N-(2â¿¿succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[Îµâ¿¿N-(2â¿¿succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[Îµâ¿¿N-(2â¿¿succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr		4/15/2015	Treatment of breast cancer patients with brain metastases	Designated	Not FDA Approved for Orphan Indication	"Angiochem, Inc."
sodium ascorbate and menadione sodium bisulfite		4/9/2015	Treatment of noninfected painful total joint without mechanical complication	Designated	Not FDA Approved for Orphan Indication	IC-MedTech Corporation
"2-Pyrazinecarbonitrile, 5-[[5-2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino] monomesylate monohydrate"		4/9/2015	Treatment of anal cancer	Designated	Not FDA Approved for Orphan Indication	"Acrivon Therapeutics, Inc."
Amantadine hydrochloride	Gocovri	4/9/2015	Treatment of levodopa-induced dyskinesia	Designated/Approved		"Adamas Pharmaceuticals, Inc."
treosulfan		4/8/2015	Conditioning treatment prior to hematopoietic stem cell transplantation (HSCT) in malignant and non-malignant diseases in adults and pediatric patients.	Designated	Not FDA Approved for Orphan Indication	Medac GmbH
modified human papillomavirus capsid protein conjugated to a near infrared dye		4/8/2015	Treatment of uveal melanoma	Designated	Not FDA Approved for Orphan Indication	"Aura Biosciences, Inc."
"fluciclovine (18F)(anti-1-amino-3-fluorocyclobutane-1-carboxylic acid, labelled with Fluorine-18)"		4/7/2015	For the diagnosis of glioma	Designated	Not FDA Approved for Orphan Indication	Blue Earth Diagnostics Ltd.
eflornithine HCL		4/7/2015	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	"Panbela Therapeutics, Inc."
human insulin (rDNA)		4/6/2015	Treatment of short bowel syndrome (SBS).	Designated	Not FDA Approved for Orphan Indication	ELGAN Pharma Ltd.
doxorubicin		4/6/2015	Treatment of cutaneous T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Louis D. Falo, Jr."
golimumab	SIMPONI ARIA®	4/2/2015	Treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.	Designated/Approved		"Janssen Research & Development, LLC"
C24H28N8O7S2		4/2/2015	Treatment of diffuse large B-cell lymphoma (DLBCL).	Designated	Not FDA Approved for Orphan Indication	"Curis, Inc."
"PEG-b-PLA micelles containing (1) paclitaxel, (2) sirolimus (rapamycin) and (3) tanespimycin (17-AAG)(also known as: triolimus)"		4/2/2015	Treatment of angiosarcoma	Designated	Not FDA Approved for Orphan Indication	"Co-D Therapeutics, Inc."
bryostatin 1		3/31/2015	Treatment of Fragile X Syndrome.	Designated	Not FDA Approved for Orphan Indication	"Synaptogenix, Inc."
5'-CTATCTGUC*G1TTCTCTGU-3'.17 Na+		3/31/2015	Treatment of diffuse large B-cell lymphoma.	Designated	Not FDA Approved for Orphan Indication	"Idera Pharmaceuticals, Inc."
bulevirtide		3/31/2015	Treatment of hepatitis D virus infection.	Designated	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid		3/31/2015	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	Inventiva Pharma
bardoxolone		3/30/2015	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	"Reata Pharmaceuticals, Inc."
C21H27O10P		3/30/2015	Treatment of gastric cancer.	Designated	Not FDA Approved for Orphan Indication	"Minneamrita Therapeutics, LLC"
dalbavancin		3/30/2015	Treatment of acute osteomyelitis in children (0 through 16 years of age)	Designated	Not FDA Approved for Orphan Indication	Durata Therapeutics International B.V.
Live-attenuated Listeria monocytogenes actA/inlB/human mesothelin (hMeso) Strain hMeso38		3/24/2015	Treatment of mesothelioma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Aduro BioTech, Inc."
avicin d		3/24/2015	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Avicin Therapeutics Ltd.
Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis		3/24/2015	Prevention of necrotizing enterocolitis (NEC) in premature infants with very low birth weight less than or equal to 1500 grams	Designated	Not FDA Approved for Orphan Indication	"Leadiant Biosciences, Inc."
"mouse-human chimeric antibody of the IgG1 isotype, directed against human CD37"		3/24/2015	Treatment of chronic lymphocytic leukemia (CLL).	Designated	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
ganaxolone		3/24/2015	Treatment of Protocadherin 19 (PCDH19) female epilepsy.	Designated	Not FDA Approved for Orphan Indication	"Marinus Pharmaceuticals, Inc."
amylopectin		3/24/2015	Treatment of glycogen storage disease types Ia and Ib	Designated	Not FDA Approved for Orphan Indication	"Voltera Pharmaceuticals, LLC"
4-(4-Methoxy-phenylamino)-6-methylcarbamyl-quinoline-3-carboxylic acid		3/24/2015	Prevention of scarring post ab externo glaucoma surgery	Designated	Not FDA Approved for Orphan Indication	Clanotech AB
mitapivat	Pyrukynd	3/24/2015	Treatment of pyruvate kinase deficiency	Designated/Approved		"Agios Pharmaceuticals, Inc."
sonidegib		3/23/2015	Treatment of medulloblastoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corp.
elapegademase-lvlr	Revcovi	3/19/2015	Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency.	Designated/Approved		Chiesi USA Inc.
cladribine		3/19/2015	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Designated	Not FDA Approved for Orphan Indication	Chord Therapeutics S.a.r.l.
roneparstat		3/19/2015	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Leadiant Biosciences S.p.A
voretigene neparvovec-rzyl	LUXTURNA	3/18/2015	Treatment of inherited retinal dystrophy due to biallelic RPE65 gene mutations	Designated/Approved		"Spark Therapeutics, Inc."
hydrocortisone modified release capsules		3/18/2015	Treatment of congenital adrenal hyperpasia	Designated	Not FDA Approved for Orphan Indication	Diurnal Limited
tremelimumab		3/18/2015	Treatment of malignant mesothelioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"MedImmune, LLC"
2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate		3/18/2015	Treatment of homozygous familial hypercholesterolemia (HoFH)	Designated	Not FDA Approved for Orphan Indication	"CymaBay Therapeutics, Inc."
masitinib mesylate		3/18/2015	Treatment of amyotrophic lateral sclerosis.	Designated	Not FDA Approved for Orphan Indication	AB Science
methotrexate oral liquid formulation		3/18/2015	Treatment of acute lymphoblastic leukemia in pediatric patients aged 0 through 16 years.	Designated	Not FDA Approved for Orphan Indication	Chesapeake Therapeutics
polyethylene glycol modified recombinant C-terminal truncate of human cystathionine beta-synthase		3/17/2015	Treatment of homocystinuria	Designated	Not FDA Approved for Orphan Indication	Travere Therapeutics Switzerland GmbH
sevuparin		3/17/2015	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	Modus Therapeutics
naproxcinod		3/16/2015	Treatment of Duchenne muscular dystrophy.	Designated	Not FDA Approved for Orphan Indication	Nicox SA
tetra-substituted porphyrin derivative containing manganese (III)		3/16/2015	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	Aeolus Pharmaceuticals
melphalan flufenamide	Pepaxto	3/16/2015	"Treatment of plasma cell myeloma, also referred to as multiple myeloma"	Designated/Approved		Oncopeptides AB
tacrolimus		3/16/2015	Treatment of pulmonary arterial hypertension.	Designated	Not FDA Approved for Orphan Indication	"VIVUS, Inc."
pegzilarginase		3/16/2015	Treatment of arginase I deficiency (hyperargininemia).	Designated	Not FDA Approved for Orphan Indication	Immedica Pharma AB
hydroxyurea		3/16/2015	"Treatment of symptomatic sickle cell disease in pediatric patients, less than 17 years of age."	Designated	Not FDA Approved for Orphan Indication	Ebelle D'Ebelle Pharmaceuticals LLC
"phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis (1,1-dimethyethyl) monohydrochloride"		3/16/2015	Treatment of Huntington's disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Ipsen Biopharmaceuticals, Inc."
edaravone		3/12/2015	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Treeway B.V.
ponatinib		3/12/2015	Treatment of gastrointestinal stromal tumors (GIST).	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ARIAD Pharmaceuticals, Inc."
hydrocinnamate-[Orn-Pro-dCha-Trp-Arg](CH3COO)		3/9/2015	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Alsonex Pty Ltd
autologous Epstein-Barr virus specific T-cells		3/9/2015	Treatment of Epstein-Barr virus positive non-Hodgkin lymphomas.	Designated	Not FDA Approved for Orphan Indication	BCM Center for Cell and Gene Therapy
lebrikizumab		3/9/2015	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
alpha1-proteinase inhibitor (human)		3/3/2015	Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.	Designated	Not FDA Approved for Orphan Indication	"Grifols Therapeutics, Inc."
recombinant activated Factor X variant		3/3/2015	Treatment of intracerebral hemorrhage	Designated	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
dacomitinib	VIZIMPRO	3/3/2015	"Treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations."	Designated/Approved		"Pfizer, Inc."
amifampridine phosphate		3/3/2015	Treatment of congenital myasthenic syndromes	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Catalyst Pharmaceuticals
ketotifen		2/25/2015	Treatment of mastocytosis	Designated	Not FDA Approved for Orphan Indication	"Valcrest Pharmaceuticals, LLC"
acetylcysteine effervescent tablets for oral solution	Cetylev	2/24/2015	Preventing hepatic injury from acetaminophin overdose	Designated/Approved		"Arbor Pharmaceuticals, Inc."
deferasirox	Exjade; Jadenu Sprinkles	2/24/2015	Treatment of chronic iron overload in alpha-thalassemia	Designated/Approved		Novartis Pharmaceuticals Corporation
deferasirox	Exjade; Jadenu Sprinkles	2/24/2015	Treatment of chronic iron overload in alpha-thalassemia	Designated/Approved		Novartis Pharmaceuticals Corporation
propranolol hydrochloride and etodolac		2/24/2015	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"Vicus Therapeutics, LLC"
pelareorep		2/24/2015	Treatment of primary peritoneal cancer	Designated	Not FDA Approved for Orphan Indication	"Oncolytics Biotech, Inc."
pelareorep		2/24/2015	Treatment of fallopian tube cancer	Designated	Not FDA Approved for Orphan Indication	"Oncolytics Biotech, Inc."
naltrexone		2/23/2015	Treatment of postherpetic neuralgia	Designated	Not FDA Approved for Orphan Indication	Allodynic Therapeutics LLC
bovine lactoferrin		2/23/2015	Prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams)	Designated	Not FDA Approved for Orphan Indication	"Metrodora Therapeutics, LLC"
"Coagulation factor Xa (recombinant), inactivated-zhzo"	ANDEXXA	2/23/2015	For reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery	Designated/Approved		"Alexion Pharmaceuticals, Inc."
rituximab	Rituxan(r); MabThera(r)	2/23/2015	Treatment of pemphigus vulgaris.	Designated/Approved		"Genentech, Inc."
bovine lactoferrin		2/19/2015	Prevention of late-onset sepsis in very low birth weight infants	Designated	Not FDA Approved for Orphan Indication	"Metrodora Therapeutics, LLC"
polidocanol		2/19/2015	Treatment of congenital venous malformations	Designated	Not FDA Approved for Orphan Indication	Provensis Ltd
"N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide"		2/12/2015	"Treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive, or ALK-positive colorectal cancer"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
defactinib		2/12/2015	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Verastem, Inc."
3-pentylbenzenacetic acid sodium salt		2/11/2015	Treatment of idiopathic pulmonary fibrosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Liminal BioSciences Limited
trofinetide	Daybue	2/11/2015	Treatment of Rett syndrome	Designated/Approved		Acadia Pharmaceuticals Inc.
recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody		2/11/2015	Treatment of eosinophilic esophagitis	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
pelareorep		2/11/2015	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Oncolytics Biotech, Inc."
paromomycin		2/11/2015	Treatment of cutaneous leishmaniasis (Old World and New World)	Designated	Not FDA Approved for Orphan Indication	Appili Therapeutics Inc.
omeprazole-lansoprazole with buffer		2/10/2015	Treatment of esophageal ulcers	Designated	Not FDA Approved for Orphan Indication	"Effexus Pharmaceuticals, LLC"
levomefolate calcium		2/10/2015	Treatment of megaloblastic anemia caused by folate deficiency	Designated	Not FDA Approved for Orphan Indication	Cox Biosciences LLC
5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6yl]-2-pyrimidinamine		2/10/2015	Treatment of malignant mesothelioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Verastem, Inc."
recombinant monoclonal antibody to human serum amyloid P component		2/10/2015	Treatment of AL amyloidosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Glaxo Group Limited, England d/b/a GlaxoSmithKline"
carboxy pyrrolidine hexanoyl pyrrolidine carboxylate		2/10/2015	Treatment of AL amyloidosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Glaxo Group Limited, England d/b/a GlaxoSmithKline"
bivalent anti-human myostatin adnectin-IgG1		2/10/2015	Treatment of duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
pelareorep		2/10/2015	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Oncolytics Biotech, Inc."
ibrutinib	Imbruvica	2/5/2015	Treatment of nodal marginal zone lymphoma	Designated/Approved		"Pharmacyclics, LLC"
tolerogen		2/5/2015	Treatment of myasthenia gravis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Toleranzia AB
ibrutinib	Imbruvica	2/5/2015	Treatment of splenic marginal zone lymphoma	Designated/Approved		"Pharmacyclics, LLC"
copanlisib	ALIQOPA	2/5/2015	Treatment of follicular lymphoma	Designated/Approved		Bayer US LLC
antinuclear antibody conjugated liposomal doxorubicin		2/3/2015	Treatment of Ewing's sarcoma.	Designated	Not FDA Approved for Orphan Indication	"NanoSmart Pharmaceuticals, Inc."
saposin C		2/3/2015	Treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	"Bexion Pharmaceuticals, LLC"
entrectinib	ROZLYTREK	2/3/2015	"Treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive or ALK-positive non-small cell lung cancer"	Designated/Approved		"Genentech, Inc."
tisagenlecleucel-T	Kymriah	2/3/2015	Treatment of diffuse large B-cell lymphoma	Designated/Approved		Novartis Pharmaceuticals Corporation
bortezomib		2/3/2015	Treatment of acute lymphoblastic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Millennium Pharmaceuticals, Inc."
alectinib	Alecensa	1/27/2015	Treatment of ALK-positive non-small cell lung cancer	Designated/Approved		"Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)"
filgrastim		1/27/2015	Treatment of amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	Neurovision Pharma GmbH
recombinant human fucosyltransferase VI [ FTVI ] + GDP-fucose		1/27/2015	To increase the activity of regulatory T-cells (Tregs) used in the prevention of graft versus host disease in patients undergoing hematopoietic stem cell transplantation	Designated	Not FDA Approved for Orphan Indication	"TargaZyme, Inc."
lisinopril oral solution		1/27/2015	Treatment of primary hypertension with complications and secondary hypertension in pediatric patients (ages 0 through 16 years of age)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"BioRamo, LLC"
alectinib	Alecensa	1/27/2015	Treatment of ALK-positive non-small cell lung cancer	Designated/Approved		"Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)"
alectinib	Alecensa	1/27/2015	Treatment of ALK-positive non-small cell lung cancer	Designated/Approved		"Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)"
18Fluorine-N-3-Fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) Nortropane		1/26/2015	Diagnostic to be used in the management of multiple system atrophy (MSA)	Designated	Not FDA Approved for Orphan Indication	"Advanced Imaging Projects, LLC"
human leukocyte antigen-A2 restricted peptides		1/26/2015	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"Stemline Therapeutics, Inc."
double stranded RNA which targets the mutated KRAS oncogene		1/26/2015	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Silenseed Ltd
tarextumab		1/26/2015	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"OncoMed Pharmaceuticals, Inc."
tarextumab		1/26/2015	Treatment of small cell lung cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"OncoMed Pharmaceuticals, Inc."
"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile"		1/26/2015	Treatment of pemphigus vulgaris	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Almirall S.A.
leukotriene A4 hydrolase inhibitor		1/26/2015	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Celltaxis, LLC"
"2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-l-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate"		1/26/2015	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
Theranost 68Ga RGD		1/26/2015	Diagnostic for the clinical management of patients with tuberculosis	Designated	Not FDA Approved for Orphan Indication	"Advanced Imaging Projects, LLC"
recombinant humanized anti-tau antibody		1/22/2015	Treatment of progressive supranuclear palsy	Designated	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
liposomal encapsulated paclitaxel		1/21/2015	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Benuvia Therapeutics, LLC"
antroquinonol		1/21/2015	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Golden Biotechnology Corp.
8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one		1/21/2015	Treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	"Diffusion Pharmaceuticals, Inc."
pegylated carboxyhemoglobin bovine		1/15/2015	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"Prolong Pharmaceuticals, LLC"
autologous CD34+ bone marrow derived stem cells transduced with a self-inactivating gammaretroviral vector encoding the human IL2RG (yc)		1/15/2015	Treatment of severe combined immune deficiency-X1	Designated	Not FDA Approved for Orphan Indication	Boston Children's Hospital
"5-(4-Cyclopropyl-1H-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide"		1/15/2015	Treatment pulmonary arterial hypertension	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
"2,5-dimethyl-3-[2-methyl-4-(methyloxy)phenyl]-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-"		1/15/2015	Treatment of congenital adrenal hyperplasia (CAH)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Neurocrine Biosciences, Inc."
synthetic oligomer of 16 nucleotides		1/13/2015	Treatment of myotonic dystrophy Type I	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Ionis Pharmaceuticals, Inc."
pentapeptide with sequence Ac-VSRRR-NH2		1/13/2015	Treatment of intracerebral hemorrhage	Designated	Not FDA Approved for Orphan Indication	"AegisCN, LLKC"
deutetrabenazine		1/13/2015	Treatment of Tourette syndrome in the pediatric population (defined as 0 through 16 years of age)	Designated	Not FDA Approved for Orphan Indication	TEVA Pharmaceuticals
naltrexone		1/13/2015	Treatment of autoimmune hepatitis	Designated	Not FDA Approved for Orphan Indication	"TaiwanJ Pharmaceuticals Co., Ltd."
arimoclomol citrate		1/13/2015	"Treatment of Neimann-Pick disease, type C"	Designated	Not FDA Approved for Orphan Indication	Zevra Denmark A/S
anti-Beta1 integrin monoclonal antibody		1/13/2015	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"OncoSynergy, Inc."
ulocuplumab		1/12/2015	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Company
"N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt"		1/7/2015	For the treatment of Cushing's Syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Millendo Therapeutics, Inc."
monoclonal antibody targeting eotaxin-2		1/6/2015	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	"ChemomAb, Ltd."
selinexor	Xpovio	1/5/2015	Treatment of multiple myeloma	Designated/Approved		"Karyopharm Therapeutics, Inc."
pyrvinium		1/5/2015	Treatment of familial adenomatous polyposis	Designated	Not FDA Approved for Orphan Indication	"StemSynergy Therapeutics, Inc."
pentosan polysulfate sodium		1/5/2015	Treatment of mucopolysaccharidosis (MPS) type VI	Designated	Not FDA Approved for Orphan Indication	Paradigm Biopharmaceuticals Ltd.
sparsentan		1/5/2015	Treatment of Focal Segmental Glomerulosclerosis	Designated	Not FDA Approved for Orphan Indication	"Travere Therapeutics, Inc."
celiprolol		1/5/2015	Treatment of Ehlers-Danlos syndrome	Designated	Not FDA Approved for Orphan Indication	"Acer Therapeutics, Inc."
selinexor	XPOVIO	1/5/2015	Treatment of multiple myeloma	Designated/Approved		"Karyopharm Therapeutics, Inc."
amikacin sulfate		1/5/2015	Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	Designated	Not FDA Approved for Orphan Indication	PlumeStars s.r.l.
simtuzumab		1/5/2015	Treatment of primary sclerosing cholangitis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
"antagonist of the endosomal Toll-like receptors (TLRs) 7, 8, and 9"		12/23/2014	Treatment of Waldenstrom's macroglobulinemia	Designated	Not FDA Approved for Orphan Indication	"Idera Pharmaceuticals, Inc."
3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid		12/23/2014	Prevention of acute attacks of angioedema in individuals with hereditary angioedema	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"BioCryst Pharmaceuticals, Inc."
pafolacianine	Cytalux	12/23/2014	Detecting folic receptor alpha positive lesions in ovarian cancer patients (diagnostic for the management of ovarian cancer)	Designated/Approved		"On Target Laboratories, LLC"
herpes simplex type 1 virus containing cellular B-myb gene as tumor-specific promoter		12/23/2014	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Karcinolys S.A.S.
"human recombinant mesencephalic, astrocyte derived neurotrophic factor"		12/22/2014	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	"Amarantus BioScience Holdings, Inc."
Oncolytic adenovirus coding for granulocyte macrophage colony stimulating factor (ONCOS-102)		12/22/2014	Treatment of malignant mesothelioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Targovax Solutions AS, a subsidiary of Targovax ASA"
entrectinib		12/22/2014	Treatment of neuroblastoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
pleconaril		12/22/2014	Treatment of symptomatic enteroviral infection in the neonate	Designated	Not FDA Approved for Orphan Indication	"NES Therapeutics, Inc."
chromium picolinate and chromium histidinate		12/22/2014	Treatment of pediatic polycystic ovary syndrome (0 through 16 years of age)	Designated	Not FDA Approved for Orphan Indication	"JDS Therapeutics, LLC"
"docosahexaenoic acid, DHA"		12/17/2014	Treatment of primary sclerosing cholangitis	Designated	Not FDA Approved for Orphan Indication	"Micelle BioPharma, Inc."
hepcortespenlisimut-L		12/17/2014	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"Immunitor, Inc."
cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulphate		12/17/2014	Treatment of pancreatic cancer in combination with ifosfamide	Designated	Not FDA Approved for Orphan Indication	"PharmaCyte Biotech, Inc."
veliparib		12/17/2014	Treatment of brain metastases when used in combination with DNA-damaging agents	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AbbVie Inc.
non-peptide small molecule orally available agonist of the parathyroid hormone receptor type I		12/15/2014	Treatment of hypoparathyroidism	Designated	Not FDA Approved for Orphan Indication	"Chugai Pharma USA, LLC"
ataluren		12/10/2014	Treatment of mucopolysaccharidosis type I	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
recombinant nematode anticoagulant protein c2 (rNAPc2)		12/8/2014	Treatment of viral hemorrhagic fever post-exposure to Ebola virus (treatment of Ebola)	Designated	Not FDA Approved for Orphan Indication	"ARCA Biopharma, Inc."
theranost 68Ga-RGD		12/8/2014	Diagnostic for clinical management of patients with neuroblastoma	Designated	Not FDA Approved for Orphan Indication	"Advanced Imaging Projects, LLC"
1 8-(p[131I]-iodophenyl)octadecyl phosphocholine		12/3/2014	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Cellectar Biosciences, Inc."
"non-replicating adeno-associated viral vector, serotype 8, expressing human myotubularin gene"		12/3/2014	Treatment of x-linked myotubular myopathy	Designated	Not FDA Approved for Orphan Indication	"Astellas Gene Therapies, Inc."
xenon gas		12/3/2014	Treatment of hypoxic ischemic encephalopathy	Designated	Not FDA Approved for Orphan Indication	Neuroprotexeon
liposome encapsulated paclitaxel		12/3/2014	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	"Benuvia Therapeutics, LLC"
Imiquimod		12/3/2014	Treatment of carcinoma in situ (CIS) of the urinary bladder	Designated	Not FDA Approved for Orphan Indication	UroGen Pharma Ltd
tafasitamab	MONJUVI	12/1/2014	Treatment of diffuse large B-cell lymphoma	Designated/Approved		Incyte Corporation
225Ac-lintuzumab		11/25/2014	Treatment of acute myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	"Actinium Pharmaceuticals, Inc."
chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2		11/25/2014	"Treatment of mucopolysaccharidosis III Type B (MPS IIIB, Sanfilippo Syndrome Type B)"	Designated	Not FDA Approved for Orphan Indication	Allievex Corporation
PyNTTTTGT class of oligodeoxynucleotide with a 24-base single chain composed of nucleotide sequence 5'TCATCATTTTGTCATTTTGTCATT 3'		11/24/2014	Treatment of rabies virus infections	Designated	Not FDA Approved for Orphan Indication	"Mid-Atlantic BioTherapeutics, Inc."
oxytocin		11/24/2014	Treatment of Prader-Willi syndrome	Designated	Not FDA Approved for Orphan Indication	OT4B
"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride"		11/17/2014	Treatment of inherited mitochondrial respiratory chain diseases	Designated	Not FDA Approved for Orphan Indication	Khondrion BV
cannabidiol		11/17/2014	Treatment of pediatric schizophrenia (pediatrics is defined as 0 through 16 years of age)	Designated	Not FDA Approved for Orphan Indication	"Benuvia Therapeutics, LLC"
veltuzumab		11/17/2014	Treatment of pemphigus	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
vatiquinone		11/17/2014	Treatment of Rett syndrome	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
avacopan		11/17/2014	Treatment of atypical hemolytic uremic syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ChemoCentryx, Inc."
recombinant neuroglobin (rNgb) containing mutations H64Q/C46G/C55S/C120S		11/17/2014	Treatment of patients with carbon monoxide poisoning	Designated	Not FDA Approved for Orphan Indication	University of Pittsburgh
trehalose		11/17/2014	Treatment of spinal cerebellar ataxia type 3 (also known as SCA3 or Machado Joseph disease)	Designated	Not FDA Approved for Orphan Indication	"Seelos Therapeutics, Inc."
"(S)-3-((3-(1-((6-((3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium"		11/17/2014	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	"GB002, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc."
N-(2-amino-2-oxoethyl)-2-(2-((4-fluorophenethyl)amino)-N-isobutylacetamido)-N-(3-(2-oxopyrrolidin-1-yl)propyl)acetamide N-({Carbamoylmethyl-[3-(2-oxo-pyrrolidin-1-yl)propyl}-carbamoyl}-methyl)-2-[2-(2-fluorophenyl)-ethylamino]-N-isobutyl-acetamide		11/17/2014	Treatment of optic neuritis	Designated	Not FDA Approved for Orphan Indication	Bionure Farma SL
N-(9-methoxynonyl)-1-deoxynojirimycin hydrochloride		11/17/2014	"Treatment of acute dengue illness (inclusive of acute dengue illness, dengue fever, dengue hemorrhagic fever, and dengue shock syndrome)"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Emergent Virology, LLC"
anti-tumor necrosis factor (TNF) polyclonal antibody (bovine)		11/17/2014	Treatment of pediatric ulcerative colitis (0 through 16 years of age)	Designated	Not FDA Approved for Orphan Indication	"Circle33, LLC"
sirolimus		11/17/2014	Treatment of lymphangioleiomyomatosis	Designated	Not FDA Approved for Orphan Indication	"Cote Orphan Consulting, LLC"
Edasalonexent		11/17/2014	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	"Catabasis Pharmaceuticals, Inc."
stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells		11/13/2014	Treatment of myelodysplastic syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Gamida Cell Ltd.
stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells		11/13/2014	Treatment of Hodgkin lymphoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Gamida Cell Ltd.
stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells		11/13/2014	Treatment of acute lymphoblastic leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Gamida Cell Ltd.
Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor)		11/13/2014	Treatment of acute lymphoblastic leukemia (ALL)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Juno Therapeutics, Inc."
(S)-perillyl alcohol temozolomide		11/12/2014	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"NeOnc Technologies, Inc."
autologous CD4+/CD8+ T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19		11/6/2014	Treatment of acute lymphoblastic leukemia (inclusive of B-cell acute lymphoblastic leukemia)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Juno Therapeutics, Inc."
"d6-tetrabenazine, deutetrabenazine"	Austedo	11/5/2014	Treatment of Huntington's Disease	Designated/Approved		"Teva Branded Pharmaceutical Products R&D, Inc."
"(S)-1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine"		11/5/2014	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	BerGenBio AS
adeno-associated viral vector serotype 2 containing the human Rab escort protein 1 gene		11/5/2014	Treatment of choroideremia	Designated	Not FDA Approved for Orphan Indication	Biogen
sodium thiosulfate		10/28/2014	Treatment of dermatomyositis	Designated	Not FDA Approved for Orphan Indication	Hope Pharmaceuticals
pritumumab		10/28/2014	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"Nascent Biotech, Inc."
oprozomib		10/28/2014	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Onyx Therapeutics, Inc."
clenbuterol		10/27/2014	Adjunctive therapy with enzyme replacement therapy in the treatment of Pompe disease	Designated	Not FDA Approved for Orphan Indication	Duke University Medical Center
alpha-1 proteinase inhibitor (human)		10/23/2014	Treatment of graft versus host disease	Designated	Not FDA Approved for Orphan Indication	Kamada Ltd.
bi-shRNA furin and GMCSF Autologous Tumor Cell Vaccine		10/22/2014	Treatment of Ewing's sarcoma	Designated	Not FDA Approved for Orphan Indication	"Gradalis, Inc."
autologous adipose derived mesenchymal stromal cells		10/22/2014	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Mayo Clinic
Istiratumab		10/22/2014	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Merrimack Pharmaceuticals, Inc."
triheptanoin		10/21/2014	Treatment of glucose transporter type-1 deficiency syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Ultragenyx Pharmaceutical, Inc."
N-(4-{3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxy}phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine bis-mesylate dihydrate		10/21/2014	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Amgen, Inc."
"autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA"		10/21/2014	Treatment of adenosine deaminase deficient severe combined immunodeficiency	Designated	Not FDA Approved for Orphan Indication	"Donald B. Kohn, M.D."
isavuconazonium sulfate		10/20/2014	Treatment of invasive candidiasis/candidemia	Designated	Not FDA Approved for Orphan Indication	"Astellas Pharma Global Development, Inc."
non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channelrhodopsin-2 protein		10/20/2014	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	"Allergan, Inc."
ibalizumab	Trogarzo	10/20/2014	Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy	Designated/Approved		Theratechnologies Inc.
alteplase		10/20/2014	Treatment of plastic bronchitis	Designated	Not FDA Approved for Orphan Indication	"Kathleen A Stringer, PharmD, FCCP - Professor"
dabrafenib		10/20/2014	Treatment of patients with BRAF mutation positive non-small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
"[5-Amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone"		10/20/2014	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Synovo GmbH
tipelukast		10/20/2014	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"MediciNova, Inc."
cardiotrophin-1		10/16/2014	Prevention of ischemia-reperfusion injury in kidney transplant recipients	Designated	Not FDA Approved for Orphan Indication	"Digna Biotech, S.L."
N-Methanocarbathymidine		10/15/2014	Treatment of neonatal herpes	Designated	Not FDA Approved for Orphan Indication	"N & N Pharmaceuticals, Inc."
diacerein		10/15/2014	Treatment of epidermolysis bullosa	Designated	Not FDA Approved for Orphan Indication	"TWi Biotechnology, Inc."
"N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide"		10/15/2014	Treatment of AL Amyloidosis	Designated	Not FDA Approved for Orphan Indication	"ProtaMed, Inc."
ipilimumab	Yervoy	10/9/2014	Treatment of Stage IIb to Stage IV melanoma	Designated/Approved		Bristol-Myers Squibb Company
nivolumab	Opdivo	10/9/2014	Treatment of Stage IIb to Stage IV melanoma	Designated/Approved		Bristol-Myers Squibb Company
Combination of nivolumab and ipilimumab		10/9/2014	Treatment of Stage IIb to Stage IV melanoma	Designated/Approved		Bristol-Myers Squibb Company
olaratumab	Lartruvo	10/9/2014	Treatment of soft tissue sarcoma	Designated/Approved		Eli Lilly and Company
"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)"		10/9/2014	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	Designated	Not FDA Approved for Orphan Indication	Amyndas Pharmaceuticals
A-dmDT390-bisFv(UCHT1)		10/9/2014	Treatment of cutaneous T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Angimmune, LLC"
adeno-associated viral vector serotype 8 containing the human cardiac calsequestrin gene		10/2/2014	Treatment of catecholaminergic polymorphic ventricular tachycardia	Designated	Not FDA Approved for Orphan Indication	Solid Biosciences Inc.
Ripretinib		10/2/2014	Treatment of gastrointestinal stromal tumors (GIST)	Designated/Approved		"Deciphera Pharmaceuticals, LLC"
Theranost 68 Ga RGD		10/1/2014	A Diagnostic for the management of Moyamoya disease (MMD)	Designated	Not FDA Approved for Orphan Indication	"Advanced Imaging Projects, LLC (AIP)"
PEGylated recombinant human hyaluronidase PH20		10/1/2014	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Halozyme Therapeutics, Inc."
interferon gamma-1b		10/1/2014	Treatment of Friedreich's Ataxia	Designated	Not FDA Approved for Orphan Indication	Horizon Therapeutic Ireland DAC
"adenovirus delta 24-RGD, an oncolytic adenovirus genetically modified for treatment of glioma"		10/1/2014	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"DNAtrix, Inc."
onasemnogene abeparvovec	ZOLGENSMA	9/30/2014	Treatment of spinal muscular atrophy	Designated/Approved		"AveXis, Inc."
glucagon infusion		9/25/2014	"Prevention of chronic, severe hypoglycemia related to congential hyperinsulinism"	Designated	Not FDA Approved for Orphan Indication	"Xeris Pharmaceuticals, Inc."
satoreotide tetraxetan		9/24/2014	Management of gastroenteropancreatic neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	Ariceum Therapeutics GmbH
cannabidiol		9/24/2014	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"Benuvia Therapeutics, LLC"
aldoxorubicin		9/24/2014	Treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	"NantCell, Inc."
aldoxorubicin		9/24/2014	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"NantCell, Inc."
aldoxorubicin		9/24/2014	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"NantCell, Inc."
nitric oxide		9/23/2014	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Advanced Inhalation Therapies, Ltd."
heat killed whole cell mycobacterium obuense		9/23/2014	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Immodulon Therapeutics Limited
"4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl) cyclopent-2-en-1-yl] pyrimidin-2-one"		9/23/2014	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"Processa Pharmaceuticals, Inc."
"MV-NB-02, its bivalent ganglioside vaccine consisting of GD2-lactone and GD3-lactone each covalently conjugated to keyhole hemocyanin"		9/23/2014	Treatment of Neuroblastoma	Designated	Not FDA Approved for Orphan Indication	"Y-mAbs Therapeutics, Inc."
technetium Tc 99m tilmanocept	LYMPHOSEEK	9/17/2014	"Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck"	Designated/Approved		"Cardinal Health 414, LLC"
Cysteamine		9/11/2014	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	NovaBiotics Ltd.
humanized monoclonal antibodies hu1B7 and hu11E6		9/11/2014	Treatment of Bordetella pertussis	Designated	Not FDA Approved for Orphan Indication	"Synthetic Biologics, Inc."
single chain urokinase plasminogen activator		9/11/2014	Treatment of empyema (pleural)	Designated	Not FDA Approved for Orphan Indication	"Lung Therapeutics, Inc."
venglustat		9/11/2014	Treatment of Gaucher disease	Designated	Not FDA Approved for Orphan Indication	Genzyme
"silibinin-C-2',3-dihydrogensuccinate, disodium salt"		9/11/2014	"Treatment of amatoxin poisoning, which includes the prevention and treatment of amatoxin induced hepatic failure"	Designated	Not FDA Approved for Orphan Indication	Mylan Specialty LP
ibrutinib		9/8/2014	Treatment of follicular lymphoma	Designated	Not FDA Approved for Orphan Indication	"Pharmacyclics, LLC"
mitomycin	Jelmyto	9/8/2014	Treatment of upper tract urothelial cell cancers (transitional cell carcinoma of the renal pelvis and ureter)	Designated/Approved		"UroGen Pharma, Ltd."
vemurafenib		9/8/2014	Treatment of patients with non-small cell lung cancer (NSCLC) with BRAF V600 mutation	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
"6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydro-pyran-4-yl)-1,5-dihydro-pryazolo[3,4-d]pyrimidin-4-one"		9/4/2014	Treatment of sickle cell disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Cardurion Pharmaceuticals, Inc."
osimertinib	Tagrisso	9/4/2014	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
osimertinib	Tagrisso	9/4/2014	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
osimertinib	Tagrisso	9/4/2014	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
inBreath airway transplant system		9/4/2014	"To restore the structure and/or function of the trachea subsequent to tracheal damage due to cancer, injury or infection"	Designated	Not FDA Approved for Orphan Indication	"Biostage, Inc."
"5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride"		9/4/2014	Treatment of Huntington's disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Prana Biotechnology Limited
"Adenovirus serotype-5 (Ad5) vector that contains a modified non-oncogenic fused early 6 (E6) and early 7 (E7) gene of the human papillomavirus (HPV); (Ad5 [E1-, E2b-]-E6/E7)"		9/4/2014	Treatment of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC)	Designated	Not FDA Approved for Orphan Indication	Etubics Corporation
Adenoassociated virus vector (AAV) carrying a modified AAV serotype 2 backbone and coding sequence of human thymidine phosphorylase preceded by a human thyroxin-binding globulin promoter		9/4/2014	For the treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)	Designated	Not FDA Approved for Orphan Indication	Columbia University Medical Center
osimertinib	Tagrisso	9/4/2014	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
mebendazole	VERMOX 500 mg chewable tablets	9/3/2014	"Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm)."	Designated/Approved		"Janssen Pharmaceutical Research & Development, LLC"
Methotrexate		8/28/2014	Treatment of Myasthenia Gravis	Designated	Not FDA Approved for Orphan Indication	The Universtiy of Kanasa Medical Center
"2-{[(1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexy]methoxy} acetic acid"		8/28/2014	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	United Therapeutics Corporation
Spanlecortemlocel		8/27/2014	Hematopoietic support in patients with acute lymphoblastic leukemia (ALL)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
vemurafenib		8/26/2014	Treatment of hairy cell leukemia (HCL).	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
gefitinib	Iressa	8/26/2014	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
recombinant human Pentraxin-2		8/26/2014	Treatment of myelofibrosis	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
Venglustat		8/26/2014	Treatment of Fabry's disease	Designated	Not FDA Approved for Orphan Indication	Genzyme Corporation
oprozomib		8/25/2014	Treatment of Waldenstrom's macroglobulinemia	Designated	Not FDA Approved for Orphan Indication	"Onyx Therapeutics, Inc."
"monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus"		8/25/2014	Treatment of Ebola virus infection	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"LeafBio, Inc."
cannabidiol		8/20/2014	Treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	"Benuvia Therapeutics, LLC"
selective inhibitor of fungal lanosterol demethylase		8/19/2014	Treatment of cryptococcal meningitis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Viamet Pharmaceuticals, Inc."
olaptesed pegol		8/19/2014	Treatment of glioblastoma in conjunction with radiotherapy.	Designated	Not FDA Approved for Orphan Indication	Noxxon Pharma AG
sodium phenylbutyrate		8/19/2014	Treatment of maple syrup urine disease	Designated	Not FDA Approved for Orphan Indication	"Acer Therapeutics, Inc."
dexrazoxane hydrochloride		8/19/2014	Prevention of cardiomyopathy for chilren and adolescents 0 through 16 years of age treated with anthracyclines	Designated	Not FDA Approved for Orphan Indication	"Satiscor, LLC"
altiratinib		8/19/2014	Treatment of glioblastoma multiforme.	Designated	Not FDA Approved for Orphan Indication	"Deciphera Pharmaceuticals, LLC"
Lacnotuzumab		8/19/2014	"Treatment of pigmented villonodular synovitis, including giant cell tumor of the tendon sheath"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corp
recombinant human deoxyribonuclease I (DNase I)		8/18/2014	Prevention of graft-vs-host disease	Designated	Not FDA Approved for Orphan Indication	"CLS Therapeutics, Inc."
recombinant human deoxyribonuclease I		8/18/2014	Treatment of graft-vs-host disease	Designated	Not FDA Approved for Orphan Indication	"CLS Therapeutics, Inc."
"Immune Globulin Subcutaneous (Human), 20% Liquid"	Hizentra	8/18/2014	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)	Designated/Approved		CSL Behring
anti-beta1 integrin monoclonal antibody		8/7/2014	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	"OncoSynergy, Inc."
nivolumab	OPDIVO	8/7/2014	Treatment of Hodgkin lymphoma	Designated/Approved		Bristol-Myers Squibb Company
mocetinostat		8/7/2014	Treatment of diffuse large B-cell lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Mirati Therapeutics, Inc."
nivolumab	OPDIVO	8/7/2014	Treatment of Hodgkin lymphoma	Designated/Approved		Bristol-Myers Squibb Company
birch triterpenes	Filsuvez	8/7/2014	Treatment of epidermolysis bullosa	Designated/Approved		Chiesi Farmaceutici S.p.A.
ivospemin		8/7/2014	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Panbela Therapeutics, Inc."
Roseburia hominis		8/4/2014	Treatment of ulcerative colitis in pediatric patients age 0 through 16 years	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	4D Pharma Research Ltd
pirfenidone		7/31/2014	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"Avalyn Pharma, Inc."
binimetinib		7/31/2014	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Array BioPharma Inc., a wholly-owned subsidiary of Pfizer Inc."
Antibody drug conjugate consisting of a humanized IgG1 anti-NaPi2b monoclonal antibody and monomethyl auristatin E		7/29/2014	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
monomethyl auristatin E conjugated to a monoclonal antibody which targets guanylyl cyclase C		7/29/2014	Treatment of pancreatic cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Millennium Pharmaceuticals, Inc."
riociguat		7/24/2014	Treatment of systemic sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bayer HealthCare Pharmaceuticals, Inc."
triterpenoid saponin		7/23/2014	Treatment of mantle cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Avicin Therapeutics, Ltd."
palovarotene	Sohonos	7/21/2014	Treatment of fibrodysplasia ossificans progressiva	Designated/Approved		"Ipsen Biopharmaceuticals, Inc."
antibody drug conjugate consisting of fully human anti-guanylyl cyclase C monoclonal antibody linked to the cytotoxic drug monomethyl auristatin E		7/21/2014	Treatment of gastric cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Millennium Pharmaceuticals, Inc."
pegargiminase		7/21/2014	Treatment of mesothelioma.	Designated	Not FDA Approved for Orphan Indication	Polaris Group
"single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21"		7/17/2014	Treatment of Alport syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genzyme Corporation
"2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2,-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate"		7/16/2014	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	OncoEthix GmbH (Merck Subsidiary)
paclitaxel-coated buttress		7/15/2014	For use as local administration at the time of curative surgery in the treatment of stage 0 to III non-small cell lung cancer.	Designated	Not FDA Approved for Orphan Indication	Cook Biotech Incorporated
oxfendazole		7/14/2014	Treatment of cysticercosis (including neurocysticercosis)	Designated	Not FDA Approved for Orphan Indication	"Robert H. Gilman, MD, DTMH and"
mirvetuximab soravtansine-gynx	Elahere	7/14/2014	Treatment of ovarian cancer	Designated/Approved		"ImmunoGen, Inc."
adalimumab		7/10/2014	Treatment of Behcet's disease	Designated	Not FDA Approved for Orphan Indication	Mucora
siponimod		7/10/2014	Treatment of dermatomyositis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
carbenoxolone		7/2/2014	Treatment of Huntington's Disease	Designated	Not FDA Approved for Orphan Indication	"Oxalys Pharmaceuticals, Inc."
bendamustine for 50 ml admixture	Bendeka	7/2/2014	Treatment of chronic lymphocytic leukemia	Designated/Approved		"Eagle Pharmaceuticals, Inc."
bendamustine for 50ml admixture	Bendeka	7/2/2014	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively"	Designated/Approved		"Eagle Pharmaceuticals, Inc."
2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt		7/1/2014	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"CASI Pharmaceuticals, Inc."
cannabidiol		7/1/2014	Treatment of Dravet syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Insys Development Company, Inc."
plasmid DNA encoding the human cystic fibrosis transmembrane conductance regulator gene complexed with a nonviral cationic lipid based gene transfer agent		6/30/2014	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	Imperial Innovations Limited
lumacaftor/ivacaftor	Orkambi	6/30/2014	Treatment of cystic fibrosis	Designated/Approved		Vertex Pharmaceuticals Inc.
lumacaftor/ivacaftor	Orkambi	6/30/2014	Treatment of cystic fibrosis	Designated/Approved		Vertex Pharmaceuticals Inc.
lumacaftor and ivacaftor	Orkambi	6/30/2014	Treatment of cystic fibrosis	Designated/Approved		Vertex Pharmaceuticals Inc.
lumacaftor/ivacaftor	Orkambi	6/30/2014	Treatment of cystic fibrosis	Designated/Approved		Vertex Pharmaceuticals Inc.
satralizumab-mwge	Enspryng	6/30/2014	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Designated/Approved		"Genentech, Inc."
sirolimus		6/25/2014	Treatment of lymphangioleiomyomatosis	Designated	Not FDA Approved for Orphan Indication	"LAM Therapeutics, Inc."
clofazimine		6/25/2014	Treatment of active tuberculosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corp.
cannabidiol		6/23/2014	Treatment of Lennox-Gastaut syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Insys Development Company, Inc."
cenegermin-bkbj	Oxervate	6/23/2014	Treatment of neurotrophic keratitis	Designated/Approved		Dompe S.p.A.
recombinant human surfactant protein D		6/23/2014	Prevention of bronchopulmonary dysplasia	Designated	Not FDA Approved for Orphan Indication	Airway Therapeutics LLC
"(2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic,N-tert-butyl ester, 13 ester 5B-20-epoxy-1B,2a,4a,7B,9a,10a,13a-heptahydroxy-4,10-diacetate-2-benzoate-(1""S)-7,9-acrolein acetal-11(15-1)-abeotaxane"		6/23/2014	Treatment of progressive supranuclear palsy	Designated	Not FDA Approved for Orphan Indication	"Cortice Biosciences, Inc."
human fully IgG1 antibody specific for CD33		6/19/2014	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
Re188 P2045 somatostatin peptide analogue		6/19/2014	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"Andarix Pharmaceuticals, Inc."
carglumic acid	Carbaglu	6/17/2014	Treatment of organic acidemias	Designated/Approved		Recordati Rare Diseases
Mocetinostat		6/12/2014	Treatment of myelodysplastic syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Mirati Therapeutics, Inc."
Epstein-Barr virus-specific autologous cytotoxic T lymphocytes		6/12/2014	Treatment of Epstein-Barr virus positive head and neck cancers (which includes nasopharyngeal carcinoma)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Tessa Therapeutics Pte.
"6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine"		6/12/2014	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"DARA Therapeutics, Inc."
small molecule normalizing the p53 function		6/12/2014	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Critical Outcome Technologies, Inc."
eculizumab	Soliris	6/12/2014	Treatment of Myasthenia Gravis	Designated/Approved		"Alexion Pharmaceuticals, Inc."
enasidenib	Idhifa	6/12/2014	Treatment of acute myelogenous leukemia	Designated/Approved		Celgene Corporation
ravulizumab-cwvz	Ultomiris	6/12/2014	Treatment of myasthenia gravis	Designated/Approved		"Alexion Pharmaceuticals, Inc."
autologous genetically modified human dermal fibroblasts		6/10/2014	Treatment of dystrophic epidermolysis bullosa.	Designated	Not FDA Approved for Orphan Indication	"Castle Creek Biosciences, LLC"
trifarotene		6/6/2014	Treatment of congenital ichthyosis	Designated	Not FDA Approved for Orphan Indication	Mayne Pharma LLC.
afatinib		6/4/2014	Treatment of malignant brain and central nervous system tumors	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
vatiquinone		6/4/2014	Treatment of Leigh Syndrome	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
echothiophate iodide		6/2/2014	Treatment of Stargardt's disease	Designated	Not FDA Approved for Orphan Indication	"Makindus, Inc."
everolimus		6/2/2014	Treatment of diffuse large B-cell lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corp.
2-[4-(1-Methyl-4-pyridin-4-yl-lH-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid		6/2/2014	Treatment of Huntington's disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pfizer Inc.
avacopan	Tavneos	6/2/2014	"Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome)"	Designated/Approved		"ChemoCentryx, Inc."
von Willebrand Factor Human Concentrate		5/29/2014	Treatment of Von Willebrand Disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"LFB USA, Inc."
heparan sulfate mimetic		5/29/2014	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Momenta Pharmaceuticals, Inc."
Human Monoclonal Antibody against Epidermal Growth Factor Receptor Linked to Monomethylauristatin F		5/29/2014	Treatment of glioblastoma multiforme	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
metformin		5/29/2014	Treatment of pediatric polycystic ovary syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	EffRx Pharmaceuticals SA
sacituzumab govitecan		5/29/2014	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
p38 mitogen-activated kinase inhibitor		5/27/2014	"Treatment of dilated cardiomyopathy, including dilated cardiomyopathy secondary to lamin A/C gene mutations"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Array BioPharma, Inc."
spironolactone		5/22/2014	Use in pediatric patients with primary hyperaldosteronism	Designated	Not FDA Approved for Orphan Indication	"CMP Pharma, Inc."
isatuximab-irfc	Sarclisa	5/22/2014	Treatment of multiple myeloma	Designated/Approved		"Sanofi U.S. Services, Inc."
isatuximab-irfc	Sarclisa	5/22/2014	Treatment of multiple myeloma	Designated/Approved		"Sanofi U.S. Services, Inc."
miconazole		5/22/2014	Treatment of fungal otitis externa (otomycosis)	Designated	Not FDA Approved for Orphan Indication	"Hill Dermaceuticals, Inc."
"all-cis-docosa-4,7,10,13,16,19-hexaenoic acid"		5/21/2014	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	"Celavista Mitobiogenesis, S.L."
live attenuated bioengineered Listeria monocytogenes immunotherapy		5/21/2014	Treatment of osteosarcoma.	Designated	Not FDA Approved for Orphan Indication	OS Therapies Incorporated
"4-{[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid"		5/19/2014	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	"Genentech, A member of the Roche Group"
recombinant lens epithelium derived growth factor 1-326		5/19/2014	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	"Ocugen, Inc."
selinexor		5/14/2014	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Karyopharm Therapeutics, Inc."
Inecalcitol		5/14/2014	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Hybrigenics, S.A."
recombinant humanized monoclonal antibody of the immunoglobulin G1 subclass directed against colony stimulating factor-1 receptor expressed on macrophages		5/14/2014	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
177Lu-tetraxetan-tetulomab		5/14/2014	Treatment of Follicular Lymphoma	Designated	Not FDA Approved for Orphan Indication	Nordic Nanovector AS
selinexor	Xpovio	5/14/2014	Treatment of diffuse large B-cell lymphoma	Designated/Approved		"Karyopharm Therapeutics, Inc."
[a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr		5/14/2014	Treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	"Angiochem, Inc."
Targeted Gastrin 17 Complexed Peptide		5/14/2014	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Tyg Oncology Ltd
menadione sodium bisulfite		5/14/2014	Treatment of autosomal dominant polycystic liver disease	Designated	Not FDA Approved for Orphan Indication	IC-MedTech Corporation
afamelanotide		5/14/2014	Treatment of familial benign chronic pemphigus (Hailey-Hailey disease)	Designated	Not FDA Approved for Orphan Indication	"Clinuvel, Inc."
Menadione Sodium Bisulfite		5/14/2014	For the treatment of autosomal dominant polycystic kidney disease	Designated	Not FDA Approved for Orphan Indication	IC-MedTech Corporation
adalimumab	Humira	5/13/2014	"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis"	Designated/Approved		"AbbVie, Inc."
vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein		5/13/2014	"Treatment of pulmonary arterial hypertension, WHO Group 1"	Designated	Not FDA Approved for Orphan Indication	ImmunoForge Co. Ltd.
adalimumab	Humira	5/13/2014	"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis"	Designated/Approved		"AbbVie, Inc."
diazoxide choline		5/13/2014	Treatment of Prader-Willi Syndrome	Designated	Not FDA Approved for Orphan Indication	"Soleno Therapeutics, Inc."
ex vivo cultured human mesenchymal stromal cells		5/8/2014	Prevention of graft rejection following solid organ transplantation	Designated	Not FDA Approved for Orphan Indication	iCell Science AB
autologous dendritic cells pulsed with allogeneic tumor cell lysate		5/6/2014	Treatment of malignant mesothelioma	Designated	Not FDA Approved for Orphan Indication	Amphera BV
filanesib		5/6/2014	Treatment of multiple myeloma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Array BioPharma, Inc."
imatinib mesylate		5/6/2014	Treatment of progressive multifocal leukencephalopathy	Designated	Not FDA Approved for Orphan Indication	"Inhibikase Therapeutics, Inc."
18-(p-[124I]-iodophenyl)octadecyl phosphocholine		4/30/2014	Diagnostic for the management of glioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Cellectar Biosciences, Inc."
"(3E,5E)-3,5-bis[(4-fluoro-3-nitrophenyl)methylidene]-1-(prop-2-enoyl)azepan-4-0ne"		4/30/2014	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	VivoLux AB
moxifloxacin hydrochloride		4/30/2014	Treatment of tuberculosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bayer HealthCare Pharmaceuticals, Inc."
demcizumab		4/30/2014	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"OncoMed Pharmaceuticals, Inc."
pegylated granulocyte colony stimulating factor		4/30/2014	Treatment of patients at risk of developing myelosuppression following a radiological or nuclear incident	Designated	Not FDA Approved for Orphan Indication	PharmaEssentia
Ipatasertib		4/30/2014	For the treatment of gastric cancer including cancer of the gastro-esophageal junction.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
Human plasma derived conagulation protein-Factor XI		4/30/2014	For the treatment of congenital Factor XI deficiency	Designated	Not FDA Approved for Orphan Indication	Cambryn Biologics
Recombinant AAV9 expressing human alpha-N-acetylglucosaminidase		4/30/2014	Mucopolysaccharidosis III-B (Sanfilippo Syndrome Type B)	Designated	Not FDA Approved for Orphan Indication	The Research Institute at Nationwide Children's Hospital
recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase		4/29/2014	Treatment of mucopolysaccharidosis type III-A (Sanfilippo Syndrome Type A)	Designated	Not FDA Approved for Orphan Indication	Ultragenyx Pharmaceutical Inc.
humanized Fc engineered monoclonal antibody against CD19		4/29/2014	Treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
3-bromopyruvate		4/29/2014	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"PreScience Labs, LLC"
a live attenuated bioengineered Listeria monocytogenes cancer immunotherapy		4/29/2014	Treatment of Stage II to IV invasive cervical carcinoma	Designated	Not FDA Approved for Orphan Indication	"Advaxis, Inc."
stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells		4/28/2014	For the treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Gamida Cell Ltd
sotatercept		4/28/2014	Treatment of anemias associated with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene Corporation
Tezacaftor		4/24/2014	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	Vertex Pharmaceuticals Inc.
alvocidib		4/21/2014	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sumitomo Dainippon Pharma Oncology, Inc."
allopregnanolone		4/20/2014	Treatment of status epilepticus	Designated	Not FDA Approved for Orphan Indication	Sage Therapeutics
pegcetacoplan	Empaveli	4/20/2014	Treatment of paroxysmal nocturnal hemoglobinuria	Designated/Approved		"Apellis Pharmaceuticals, Inc."
teriparatide		4/18/2014	Treatment of hypoparathyroidism	Designated	Not FDA Approved for Orphan Indication	"Entera Bio, Ltd."
ciprofloxacin dry powder inhaler		4/17/2014	Treatment of non-cystic fibrosis bronchiectasis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bayer HealthCare Pharmaceuticals, Inc."
volasertib		4/14/2014	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
entospletinib		4/14/2014	Treatment of chronic lymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	"Kronos Bio, Inc."
naltrexone/clonidine combination		4/14/2014	Treatment of postherpetic neuralgia	Designated	Not FDA Approved for Orphan Indication	Allodynic Therapeutics LLC
benznidazole		4/14/2014	Treatment of Chagas disease	Designated/Approved		"Chemo Research, S.L."
Anthrax Vaccine Adsorbed	BioThrax	4/11/2014	For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure	Designated/Approved		Emergent BioDefense Operations Lansing LLC
pegylated proline interferon alpha-2b		4/11/2014	Treatment of essential thrombocythemia	Designated	Not FDA Approved for Orphan Indication	PharmaEssentia
carbetocin (nasal spray)		4/11/2014	Treatment of Prader Willi syndrome	Designated	Not FDA Approved for Orphan Indication	Acadia Pharmaceuticals Inc.
H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu- Ser-Asp-Val-OH		4/11/2014	Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onset	Designated	Not FDA Approved for Orphan Indication	"NoNO, Inc."
pegylated proline interferon alpha-2b		4/10/2014	Treatment of myelofibrosis	Designated	Not FDA Approved for Orphan Indication	PharmaEssentia
isotretinoin		4/10/2014	Treatment of congenital ichthyosis	Designated	Not FDA Approved for Orphan Indication	Timber Pharmaceuticals
"{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl](3H-benzo[f]azepin-4-yl)}-N,N-dipropycarboxamide"		4/10/2014	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene Corporation
lenvatinib	LENVIMA	3/27/2014	Treatment of hepatocellular carcinoma	Designated/Approved		Eisai Inc.
axicabtagene ciloleucel	Yescarta	3/27/2014	Treatment of diffuse large B-cell lymphoma	Designated/Approved		"Kite Pharma, Inc."
axicabtagene ciloleucel	Yescarta	3/27/2014	Treatment of diffuse large B-cell lymphoma	Designated/Approved		"Kite Pharma, Inc."
venetoclax		3/27/2014	Treatment of diffuse large B-cell lymphoma.	Designated	Not FDA Approved for Orphan Indication	AbbVie
L-asparaginase		3/27/2014	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	ERYTECH Pharma S.A.
Laromustine		3/27/2014	Treatment of acute myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	NanoSHIFT LLC
lenvatinib		3/26/2014	Treatment of stage IIB to Stage IV melanoma	Designated	Not FDA Approved for Orphan Indication	"Eisai, Inc."
"(RS)-baclofen, naltrexone and D-sorbitol"		3/17/2014	Treatment of Charcot-Marie-Tooth disease type 1A	Designated	Not FDA Approved for Orphan Indication	Pharnext SA
recombinant human collagen alpha-1 (VII) chain homo-trimer (rC7)		3/17/2014	Treatment of dystrophic epidermolysis bullosa	Designated	Not FDA Approved for Orphan Indication	Phoenix Tissue Repair
Ad5/3-D24-granulocyte-macrophage colony stimulating factor (GMCSF)-encoding oncolytic adenovirus		3/17/2014	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Targovax Solutions AS, a subsidiary of Targovax ASA"
adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene		3/14/2014	Treatment of hemophilia B	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
Tisagenlecleucel		3/14/2014	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
"fecal microbiota, live - jslm"	Rebyota	3/10/2014	Prevention of recurrent Clostridium difficile infection (CDI) in individuals with recurrent Clostridium difficile infection	Designated/Approved		"Ferring Pharmaceuticals, Inc."
long acting recombinantFactor VIIa-CTP3		2/27/2014	Treatment and prophylaxis of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX	Designated	Not FDA Approved for Orphan Indication	"OPKO Biotech, Ltd"
cannabidiol	Epidiolex	2/27/2014	Treatment of Lennox-Gastaut syndrome	Designated/Approved		GW Research Ltd.
pracinostat		2/27/2014	Treatment of acute myeloid leulemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Helsinn Healthcare SA
cannabidiol	EPIDIOLEX	2/27/2014	Treatment of Lennox-Gastaut syndrome	Designated/Approved		GW Research Ltd.
oligopeptide containing 6 amino acids (H-Phe-Ser-Arg-Tyr-Ala-Arg-OH)		2/27/2014	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"Genervon Biopharmaceuticals, LLC"
lovotibeglogene autotemcel	Lyfgenia	2/26/2014	For the treatment of Sickle Cell Disease	Designated/Approved		bluebird bio Inc.
gevokizumab		2/21/2014	Treatment of pyoderma gangrenosum	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	XOMA (US) LLC
"(6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl] amino-L-glyceroB-L-manno-heptopyranosyl]amino-9H-purine)"		2/21/2014	"Parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"DARA Therapeutics, Inc."
phoxillum		2/14/2014	For use as a replacement solution in patients undergoing continuous renal replacement therapy	Designated/Approved		"Gambro Renal Products, Inc."
doxofylline		2/14/2014	Treatment of bronchiectasis	Designated	Not FDA Approved for Orphan Indication	"Alitair Pharmaceuticals, Inc."
rosuvastatin	Crestor	2/14/2014	For the treatment of pediatric homozygous familial hypercholesterolemia	Designated/Approved		"iPR Pharmaceuticals, Inc."
bisantrene HCl		2/14/2014	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Race Oncology, Ltd"
pexidartinib	TURALIO	2/14/2014	Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath	Designated/Approved		"Daiichi Sankyo, Inc."
caprine hyperimmune serum against HIV lysate		2/14/2014	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	Aimsco Ltd.
REMUNE HIV 1		2/14/2014	Treatment of pediatric HIV/AIDS (age through 16 years)	Designated	Not FDA Approved for Orphan Indication	"Immune Response BioPharma, Inc."
sotalol hydrochloride		2/10/2014	Treatment of life-threatening ventricular arrhythmias in pediatric patients	Designated	Not FDA Approved for Orphan Indication	"Arbor Pharmaceuticals, LLC"
Bruton's tyrosine kinase inhibitor		2/10/2014	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene Corporation
gemcabene		2/6/2014	Treatment of homozygous familial hypercholesterolemia	Designated	Not FDA Approved for Orphan Indication	"NeuroBo Pharmaceuticals, Inc."
"T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine"		2/6/2014	Treatment of Pediatric Multiple Sclerosis	Designated	Not FDA Approved for Orphan Indication	"Immune Response BioPharma, Inc."
Re188 P2045 somatostatin analog		2/6/2014	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	Andarix Pharmaceuticals
Engineered variant of recombinant human fibroblast growth factor 19		2/6/2014	Treatment of primary biliary cirrhosis	Designated	Not FDA Approved for Orphan Indication	"NGM Biopharmaceuticals, Inc."
DNA plasmid vector (pCK-HGFX7) expressing human hepatocyte growth factor		2/6/2014	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"Helixmith Co., Ltd."
vatiquinone		1/31/2014	Treatment of Friedreich's ataxia	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)]		1/31/2014	Treatment of dermal injury due to nuclear/radiation incident	Designated	Not FDA Approved for Orphan Indication	"US Biotest, Inc."
cobimetinib		1/31/2014	"Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600 mutation"	Designated/Approved		"Genentech, Inc."
(tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	Kymriah (tisagenlecleucel)	1/31/2014	For the treatment of Acute Lymphoblastic Leukemia	Designated/Approved		Novartis Pharmaceuticals Corporation
brentuximab vedotin		1/31/2014	Treatment of patients with diffuse large B-cell lymphoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Seattle Genetics, Inc."
recombinant DNA plasmid		1/31/2014	"Treatment of stage IIb, IIc, III and IV melanoma."	Designated	Not FDA Approved for Orphan Indication	Scancell Ltd.
flubendazole		1/23/2014	"Treatment of lymphatic filariasis caused by nematodes of the family Filariodidea, in children and adults."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
paquinimod		1/17/2014	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	Active Biotech AB
tetra substituted prophyrin derivative containing manganese (III)		1/17/2014	For use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome.	Designated	Not FDA Approved for Orphan Indication	"Aeolus Pharmaceuticals, Inc."
ethanolamine		1/17/2014	Prophylactic use in pediatric patients (age 0 through 16 years) with esophageal varices that are at risk of bleeding to obliterate varices and to prevent bleeding	Designated	Not FDA Approved for Orphan Indication	"QOL Medical, LLC"
Allogeneic motor neuron progenitor cells derived from human embryonic stem cells		1/17/2014	Treatment of Amyotrophic Lateral Sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Caladrius Biosciences
rsATP7A cDNA		1/10/2014	Treatment of Menkes disease	Designated	Not FDA Approved for Orphan Indication	"Cyprium Therapeutics, Inc."
enchochleate amphotericin B		1/10/2014	Treatment of visceral leishmaniasis	Designated	Not FDA Approved for Orphan Indication	"Matinas BioPharma Nanotechnologies, Inc"
monoclonal antibody Hu3F8		1/10/2014	Treatment of osteosarcoma	Designated	Not FDA Approved for Orphan Indication	Y-mAbs Therapeutics A/S
emicizumab-kxwh	Hemlibra	1/10/2014	Treatment of hemophilia A	Designated/Approved		Genentech
emicizumab-kxwh	Hemlibra	1/10/2014	Treatment of hemophilia A	Designated/Approved		Genentech
human allogeneic bone marrow derived osteoblastic cells		1/10/2014	Treatment of osteonecrosis	Designated	Not FDA Approved for Orphan Indication	Biosenic SA
eculizumab		1/10/2014	Prevention of delayed graft function after renal transplantation	Designated	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc."
"Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide"	NETSPOT	12/31/2013	Diagnostic for the clinical management of neuroendocrine tumors	Designated/Approved		"Advanced Accelerator Applications, USA"
NorLeu3-Angiontensin(1-7)) [NorLeu3-A(1-7)]		12/31/2013	Treatment of leakage from the surgical site following penetrating keratoplasty	Designated	Not FDA Approved for Orphan Indication	"US Biotest, Inc."
thymosin beta 4		12/31/2013	Treatment of patients with neurotrophic keratopathy	Designated	Not FDA Approved for Orphan Indication	"ReGenTree, LLC"
nifurtimox		12/31/2013	Treatment of Chagas disease	Designated	Not FDA Approved for Orphan Indication	"MetronomX Therapeutics, LLC"
N-acetyl cysteine amide		12/31/2013	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	"Nacuity Pharmaceuticals, Inc."
radiolabeled somastatin analog		12/31/2013	Diagnostic for the management of neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	"RadioMedix, Inc."
recombinant human acid ceramidase		12/24/2013	Treatment of Farber disease	Designated	Not FDA Approved for Orphan Indication	"Aceragen, Inc."
Tolcapone		12/24/2013	Treatment of transthyretin amyloidosis	Designated	Not FDA Approved for Orphan Indication	"Corino Therapeutics, Inc."
tacrolimus	Envarsus XR	12/20/2013	Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant	Designated/Approved		"Veloxis Pharmaceuticals, Inc."
erdosteine		12/20/2013	Treatment of bronchiectasis.	Designated	Not FDA Approved for Orphan Indication	"Alitair Pharmaceuticals, Inc."
CD40/CD80/CD86 modified autologous dendritic cell therapy		12/20/2013	Treatment Type 1 diabetes mellitus patients with residual beta cell function	Designated	Not FDA Approved for Orphan Indication	"DiaVacs, Inc."
fenfluramine HCI	Fintepla	12/20/2013	For the Treatment of Dravet Syndrome	Designated/Approved		"UCB, Inc."
tacrolimus	Envarsus XR	12/20/2013	Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant	Designated/Approved		"Veloxis Pharmaceuticals, Inc."
Human monoclonal antibody inhibitor of mannan binding lectin-associated serine protease-2 (MASP-2)		12/16/2013	Prevention (inhibition) of complement-mediated thrombotic microangiopathy	Designated	Not FDA Approved for Orphan Indication	Omeros Corporation
vintafolide		12/16/2013	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Endocyte, Inc."
onartuzumab (MetMab)		12/16/2013	Treatment of hepatocellular carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
metadoxine		12/16/2013	Treatment of Fragile X Syndrome	Designated	Not FDA Approved for Orphan Indication	"Alcobra, Inc."
"O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1yl]diazen-1-ium-1,2-diolate"		12/13/2013	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"JSK Therapeutics, Inc."
marizomib		12/13/2013	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene International II S?
sotatercept		12/5/2013	Treatment of beta-thalassemia intermedia and major	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene Corporation
canakinumab	ILARIS	12/5/2013	Treatment of hyperimmunoglobulinemia D and periodic fever syndrome	Designated/Approved		Novartis Pharmaceuticals Corporation
canakinumab	ILARIS	12/5/2013	Treatment of familial mediterranean fever	Designated/Approved		Novartis Pharmaceuticals Corporation
sacituzumab govitecan		11/27/2013	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate		11/26/2013	Treatment of gliomas	Designated	Not FDA Approved for Orphan Indication	"Kinex Pharmaceuticals, Inc."
bendamustine hydrochloride	Treanda	11/26/2013	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively"	Designated/Approved		"Cephalon, Inc."
Siponimod		11/26/2013	Treatment of polymyositis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
vemurafenib		11/26/2013	Treatment of anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a BRAF V600 mutation	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
lanadelumab-flyo	Takhzyro	11/26/2013	Treatment of angioedema	Designated/Approved		"Takeda Pharmaceuticals USA, Inc."
human umbilical cord blood-derived mesenchymal stem cells		11/26/2013	Prevention of bronchopulmonary dysplasia	Designated	Not FDA Approved for Orphan Indication	"MEDIPOST America, Inc."
Angiotensin (1-7)		11/26/2013	Treatment of limb-girdle muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	Constant Therapeutics LLC
lanadelumab-flyo	Takhzyro	11/26/2013	Treatment of angioedema	Designated/Approved		"Takeda Pharmaceuticals USA, Inc."
Pegfilgrastim	Neulasta	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Designated/Approved		"Amgen, Inc."
emricasan		11/20/2013	Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease	Designated	Not FDA Approved for Orphan Indication	Conatus Pharmaceuticals Inc.
filgrastim	Neupogen	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Designated/Approved		"Amgen, Inc."
lenadogene nolparvovec		11/20/2013	Treatment of Leber Hereditary Optic Neuropathy	Designated	Not FDA Approved for Orphan Indication	Gensight Biologics
autologous CD4+CD25hiFoxP3+regulatory T cells		11/19/2013	Prevention of graft rejection following solid organ transplantation	Designated	Not FDA Approved for Orphan Indication	iREG Medical AB
pirfenidone		11/19/2013	Treatment of systemic sclerosis (including the associated interstitial lung disease)	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
binimetinib		11/19/2013	Treatment Stage IIB-IV melanoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Array BioPharma Inc., a wholly-owned subsidiary of Pfizer Inc."
encorafenib		11/19/2013	Treatment of Stage IIB-IV melanoma positive for BRAF mutation	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Array BioPharma Inc., a wholly-owned subsidiary of Pfizer Inc."
encorafenib + binimetinib		11/19/2013	Treatment of Stage IIB-IV melanoma positive for the BRAF mutation.	Designated/Approved		"Array BioPharma, Inc."
human haptoglobin		11/19/2013	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	BioProducts Laboratory Limited
encorafenib + binimetinib		11/19/2013	Treatment of Stage IIB-IV melanoma positive for the BRAF mutation.	Designated/Approved		"Array BioPharma, Inc."
avalglucosidase alfa-ngpt	Nexviazyme	11/19/2013	Treatment of Pompe Disease	Designated/Approved		"Genzyme Corporation, a Sanofi Company"
lonafarnib		11/19/2013	Treatment of Hepatitis Delta Virus (HDV)infection	Designated	Not FDA Approved for Orphan Indication	"Eiger Biopharmaceuticals, Inc."
cannabidiol	Epidiolex	11/14/2013	Treatment of Dravet syndrome	Designated/Approved		GW Research Ltd.
cannabidiol	EPIDIOLEX	11/14/2013	Treatment of Dravet syndrome	Designated/Approved		GW Research Ltd.
eltrombopag	Promacta	11/8/2013	Treatment of aplastic anemia	Designated/Approved		Novartis Pharmaceuticals Corp.
eltrombopag	Promacta	11/8/2013	Treatment of aplastic anemia	Designated/Approved		Novartis Pharmaceuticals Corp.
poloxamer 188		11/8/2013	Treatment of Acute Limb Ischemia	Designated	Not FDA Approved for Orphan Indication	Mast Therapeutics Inc.
monoclonal antibody directed at hepatitis C virus E2 glycoprotein		11/4/2013	Prevention of Hepatitis C recurrence in patients receiving liver transplantation	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	MassBiologics-University of MA Medical School
live attenuated bioengineered Listeria monocytogenes immunotherapy		11/4/2013	Treatment of human papilloma virus-associated head and neck cancer	Designated	Not FDA Approved for Orphan Indication	"Ayala Pharmaceuticals, Inc."
isavuconazonium sulfate	Cresemba	10/25/2013	Treatment of zygomycosis	Designated/Approved		Astellas Pharma Global Development Inc.
trehalose		10/25/2013	Treatment of occulopharyngeal muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	Seelos Therapeutics
3-chloro-4-fluorophenyl-[4-fluoro-4-[[(5-methylpyrimidin-2-ylmethyl)amino]methyl]piperidin-1yl]methanone		10/25/2013	Treatment of Rett syndrome	Designated	Not FDA Approved for Orphan Indication	"Neurolixis, Inc."
isavuconazonium sulfate	Cresemba	10/25/2013	Treatment of zygomycosis	Designated/Approved		Astellas Pharma Global Development Inc.
flubendazole		10/25/2013	Treatment of onchocerciasis caused by Onchocerca volvulus	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
TXA127		10/25/2013	Treament of acute radiation syndrome	Designated	Not FDA Approved for Orphan Indication	"US Biotest, Inc."
recombinant human monoclonal IgM antibody targeting glucose regulated protein 78		10/25/2013	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Patrys Ltd.
Gallium-68 (DOTA0-Phel-Tyr3)octreotide		10/25/2013	The management of neuroendocrine tumors	Designated/Approved		University of Iowa Hospital & Clinics
PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody		10/25/2013	Treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	Designated	Not FDA Approved for Orphan Indication	"KaloBios Pharmaceuticals, Inc."
poly(lactide-co-glycolide) carboxylated microparticle		10/25/2013	Treatment of acute encephalitis syndrome	Designated	Not FDA Approved for Orphan Indication	"Cour Pharmaceutical Development Company, Inc."
trastuzumab emtansine		10/25/2013	For the treatment of gastric cancer including gastroesophageal junction cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genethech, Inc."
oleylphosphocholine		10/25/2013	Treatment of leishmaniasis	Designated	Not FDA Approved for Orphan Indication	Oblita Therapeutics bvba
isavuconazonium sulfate	Cresemba	10/25/2013	Treatment of zygomycosis	Designated/Approved		Astellas Pharma Global Development Inc.
tigecycline		10/23/2013	Treatment of acute myeloid leukemia.	Designated	Not FDA Approved for Orphan Indication	"Trillium Therapeutics, Inc."
phenobarbitol sodium injection		10/23/2013	Treatment of hypoxic-ischemic encephalopathy to prevent siezures in neonates	Designated	Not FDA Approved for Orphan Indication	"Fera Pharmaceuticals, LLC"
ibrutinib		10/23/2013	Treatment of diffuse large B-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Pharmacyclics, LLC"
Trofinetide		10/23/2013	Treatment of Fragile X Syndrome	Designated	Not FDA Approved for Orphan Indication	ACADIA Pharmaceuticals Inc.
sodium fusidate		10/23/2013	Treatment of patients with prosthetic joint infections	Designated	Not FDA Approved for Orphan Indication	"Cempra Pharmaceuticals, Inc."
tivantinib		10/16/2013	Treatment of hepatocellular carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Daiichi Sankyo Pharma Development
olaparib	Lynparza	10/16/2013	Treatment of ovarian cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
anifrolumab		10/16/2013	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals LP
mTOR kinase inhibitor (CC-223)		10/16/2013	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
olaparib	Lynparza	10/16/2013	Treatment of ovarian cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
olaparib	Lynparza	10/16/2013	Treatment of ovarian cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
olaparib	Lynparza	10/16/2013	Treatment of ovarian cancer	Designated/Approved		AstraZeneca Pharmaceuticals LP
somavaratan		10/16/2013	Treatment of growth hormone deficiency	Designated	Not FDA Approved for Orphan Indication	"Versartis, Inc."
human monoclonal antibody againt human interleukin 13 (IL-13)		10/15/2013	Treatment of eosinophilic esophagitis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporaton
6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimdinecarboxamide		10/15/2013	Treatment of stage IIb-IV melanoma	Designated	Not FDA Approved for Orphan Indication	"Millennium Pharmaceuticals, Inc."
idelalisib		10/15/2013	Treatment of splenic marginal zone lymphoma	Designated	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
idelalisib		10/15/2013	Treatment of nodal marginal zone lymphoma.	Designated	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
idelalisib		10/15/2013	Treatment of extranodal marginal zone lymphoma	Designated	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
idelalisib	Zydelig	10/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Designated/Approved		"Gilead Sciences, Inc."
ibrutinib	Imbruvica	10/15/2013	Treatment of Waldenstrom's macroglobulinemia	Designated/Approved		"Pharmacyclics, LLC"
ceritinib	ZYKADIA	9/27/2013	Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive	Designated/Approved		Novartis Pharmaceuticals Corp.
"self-complimentary adeno-associated virus vector, serotype 9, packaging the full lenght GAN gene in the viral capsid"		9/27/2013	Treatment of Giant Axonal Neuropathy	Designated	Not FDA Approved for Orphan Indication	"The National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)"
ceritinib	ZYKADIA	9/27/2013	Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive	Designated/Approved		Novartis Pharmaceuticals Corp.
chimeric monoclonal antibody against claudin-18 splice variant 2		9/26/2013	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Astellas Pharma Global Development Inc.
bacterium Bacteroides thetaiotaomicron		9/26/2013	Treatment of active Crohn's disease in the pediatric population	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	4D Pharma Research Ltd
"6,8-bis-benzylsulfanyl-octanoic acid"		9/26/2013	Treatment of myelodysplastic syndrome	Designated	Not FDA Approved for Orphan Indication	"Cornerstone Pharmaceuticals, Inc."
dovitinib		9/26/2013	Treatment of adenoid cystic carcinoma	Designated	Not FDA Approved for Orphan Indication	Oncology Venture ApS
"1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one"		9/26/2013	Management of postherpetic neuralgia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Zalicus Pharmaceuticals Ltd.
manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption)		9/26/2013	Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where use of gadolinium based contrast agents may be medically inadvisable or where gadolinium based contrast agents cannot be admini	Designated	Not FDA Approved for Orphan Indication	Ascelia Pharma AB
ethiodized oil injection	Lipiodol	9/26/2013	Management of patients with known hepatocellular carcinoma (HCC)	Designated/Approved		Guerbet LLC
small molecule inhibitor of phosphodiesterase 10		9/26/2013	Treatment of Huntington's disease	Designated	Not FDA Approved for Orphan Indication	Omeros Corporation
idelalisib	Zydelig	9/26/2013	Treatment of follicular lymphoma	Designated/Approved		"Gilead Sciences, Inc."
idelalisib		9/26/2013	Treatment of lymphoplasmacytic lymphoma with or without Walenstrom's macroglobulinemia	Designated	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
melphalan hydrochloride		9/26/2013	Treatment of patients with hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"Delcath Systems, Inc."
anti-sense oligonucleotide consisting of 2¿0-Me RNA with a phosphorothioate backbone		9/23/2013	Treatment of cystic fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	ProQR Therapeutics IV B.V.
riociguat	Adempas	9/19/2013	Treatment of chronic thromboembolic pulmonary hypertension	Designated/Approved		"Bayer HealthCare Pharmaceuticals, Inc."
riociguat	Adempas	9/19/2013	Treatment of pulmonary arterial hypertension.	Designated/Approved		"Bayer HealthCare Pharmaceuticals, Inc."
lenalidomide	Revlimid	9/17/2013	Treatment of follicular lymphoma	Designated/Approved		Celgene Corporation
autologous ex vivo expanded CD4+-enriched leukocytes treated with the de-methylating agent 5-aza-2â??-deoxycytidine		9/13/2013	Treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	CytoVac A/S
anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein		9/13/2013	Treatment of graft versus host disease	Designated	Not FDA Approved for Orphan Indication	Philikos BV
melarsoprol-hydroxypropylbetadex		9/13/2013	Treatment of human African trypanosomiasis (sleeping sickness)	Designated	Not FDA Approved for Orphan Indication	"Peter Kennedy, CBE, MD, PhD, DSc, FRCP FMedSci,"
brentuximab vedotin		9/13/2013	Treatment of patients with angioimmunoblastic T-cell lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Seattle Genetics, Inc."
osilodrostat	Isturisa	9/13/2013	Treatment of Cushing's disease	Designated/Approved		"Recordati Rare Diseases, Inc"
"aadeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1"		9/12/2013	Treatment of choroideremia due to mutations in the human choroideremia gene (CHM)	Designated	Not FDA Approved for Orphan Indication	"Sparks Therapeutics, Inc."
evolocumab	Repatha	9/12/2013	Treatment of homozygous familial hypercholesterolemia	Designated/Approved		Amgen Inc.
evolocumab	Repatha	9/12/2013	Treatment of homozygous familial hypercholesterolemia	Designated/Approved		Amgen Inc.
dimethyl fumarate		9/11/2013	Treatment of Friedreich's Ataxia	Designated	Not FDA Approved for Orphan Indication	"Ixchel Pharma, LLC"
human glial restricted progenitor cells and their progeny		9/11/2013	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"Q Therapeutics, Inc."
cysteamine		9/11/2013	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Horizon Therapeutics USA, Inc."
nitric oxide		9/11/2013	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Novoteris, LLC"
L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alanine-amide		9/11/2013	Treatment of acute radiation syndrome	Designated	Not FDA Approved for Orphan Indication	"Soligenix, Inc."
denosumab	XGEVA	9/11/2013	Treatment of hypercalcemia in malignancy	Designated/Approved		"Amgen, Inc."
dehydrated alcohol	Ablysinol	9/11/2013	Treatment of hypertrophic obstructive cardiomyopathy	Designated/Approved		"Belcher Pharmaceuticals, LLC"
bendamustine hydrochloride with betadex sulfobutyl ether sodium		9/10/2013	Treatment of chronic lymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	BendaRx Corp.
motixafortide		9/5/2013	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"BioLineRx, Ltd."
ublituximab		9/5/2013	Treatment of Nodal marginal zone lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"TG Therapeutics, Inc."
listeria monocytogenes		9/5/2013	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Aduro BioTech, Inc."
ublituximab		9/5/2013	"Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"TG Therapeutics, Inc."
fenretinide		9/4/2013	Treatment of peripheral T-cell lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"CerRx, Inc."
maralixibat	Livmarli	9/4/2013	Treatment of alagille syndrome	Designated/Approved		"Mirum Pharmaceuticals, Inc."
"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride"		9/4/2013	Treatment of primary biliary cirrhosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Mirum Pharmaceuticals, Inc."
"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride"		9/4/2013	Treatment of primary sclerosing cholangitis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Mirum Pharmaceuticals, Inc."
fenretinide		9/4/2013	Treatment of cutaneous T-cell lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"CerRx, Inc."
"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride"		9/4/2013	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	Designated	Not FDA Approved for Orphan Indication	"Braintree Laboratories, Inc."
maralixibat	Livmarli	9/4/2013	Treatment of alagille syndrome	Designated/Approved		"Mirum Pharmaceuticals, Inc."
maralixibat	Livmarli	9/4/2013	Treatment of progressive familial intrahepatic cholestasis	Designated/Approved		"Mirum Pharmaceuticals, Inc."
angiotensin (1-7)		8/30/2013	Treatment of patients requiring stem cell transplantation to accelerate the mobilization of hematopoietic stem cells (CD34+) from the bone marrow to the peripheral blood when combined with a granulocyte colony-stimulating factor	Designated	Not FDA Approved for Orphan Indication	"US Biotest, Inc."
trebananib		8/30/2013	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Amgen, Inc."
expanded human allogeneic neural retinal progenitor cells extracted from neural retina		8/22/2013	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	ReNeuron Ltd
pomalidomide		8/22/2013	Treatment of systemic sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene Corporation
ruxolitinib		8/16/2013	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
deflazacort	Emflaza	8/16/2013	Treatment of Duchenne muscular dystrophy	Designated/Approved		"PTC Therapeutics, Inc."
deflazacort	Emflaza	8/16/2013	Treatment of Duchenne muscular dystrophy	Designated/Approved		"PTC Therapeutics, Inc."
synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA		8/16/2013	Treatment of hemophilia A	Designated	Not FDA Approved for Orphan Indication	Genzyme Corporation
dantrolene sodium suspension for injection	RYANODEX	8/16/2013	Treatment of malignant hyperthermia syndrome	Designated/Approved		"Eagle Pharmaceuticals, Inc."
small molecule inhibitor of histone methyltransferase DOT1L		8/15/2013	Treatment of Acute Myeloid Leukemia	Designated	Not FDA Approved for Orphan Indication	Epizyme Inc.
pentamidine		8/12/2013	Treatment of liver and intrahepatic bile duct cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Verlyx Pharma, Inc."
synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA		8/12/2013	Treatment of hemophilia B	Designated	Not FDA Approved for Orphan Indication	Genzyme Corporation
pentamidine		8/12/2013	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Oncozyme Pharma, Inc."
ADXS11-001		8/12/2013	Treatment of HPV-positive associated anal cancer	Designated	Not FDA Approved for Orphan Indication	"Advaxis, Inc."
uridine triacetate		8/9/2013	Treatment of hereditary orotic aciduria	Designated/Approved		BTG International Inc.
small molecule inhibitor of histone methyltransferase DOT1L		8/8/2013	Treatment of acute lymphoblastic leukemia (ALL)	Designated	Not FDA Approved for Orphan Indication	Epizyme Inc.
bispecific antibody (monoclonal antibody)		8/8/2013	Treatment of HER2-expressing advanced adenocarcinoma of the stomach and gastroesophageal junction	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Elevation Oncology, Inc."
bispecific antibody (monoclonal antibody)		8/8/2013	Treatment of HER2-expressing adenocarcinoma of the esophagus	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Elevation Oncology, Inc."
recombinant human nerve growth factor		8/8/2013	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	Dompe S.p.A.
Human Hemin		8/6/2013	Prevention of ischemia reperfusion injury in patients undergoing solid organ transplantation	Designated	Not FDA Approved for Orphan Indication	Borders Technology Management Ltd
Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer		8/6/2013	Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome)	Designated	Not FDA Approved for Orphan Indication	NanoViricides Incorporated
duvelisib	COPIKTRA	8/1/2013	Treatment of follicular lymphoma	Designated/Approved		"Secura Bio, Inc."
L. reuteri		8/1/2013	"Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams"	Designated	Not FDA Approved for Orphan Indication	Infant Bacterial Therapeutics
angiotensin (1-7)[A(1-7)]		7/25/2013	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	Constant Therapeutics LLC
sulthiame		7/25/2013	Treatment of patients with benign epilepsy of childhood with centrotemporal spikes (BECTS) also known as rolandic epilepsy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Marathon Pharmaceuticals, LLC"
bezafibrate		7/24/2013	For therapeutic treatment of Barth syndrome	Designated	Not FDA Approved for Orphan Indication	"Barth Sydrome Foundation, Inc."
vixotrigine		7/24/2013	Treatment of trigeminal neuralgia	Designated	Not FDA Approved for Orphan Indication	"Biogen, Inc."
topiramate injection		7/24/2013	Treatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being treated in an emergency care setting who are unable to take oral topiramate	Designated	Not FDA Approved for Orphan Indication	"CURx Pharmaceuticals, Inc."
"granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF"		7/24/2013	Treatment of soft tissue sarcoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Targovax Solutions AS, a subsidiary of Targovax ASA"
hydroxycarbamide (hydroxyurea)	Siklos	7/24/2013	Treatment of sickle cell disease in patients under 18 years of age	Designated/Approved		Theravia Pharma
N-methyl-4-({4-[({3-methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride		7/18/2013	Treatment of mesothelioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Verastem, Inc."
pertuzumab		7/12/2013	"Treatment of gastric cancer, including gastroesophageal junction cancer"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
allopregnanolone		7/12/2013	"Treatment of Neimann-Pick disease, type C"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"La Jolla Pharmaceutical Company, Inc."
denileukin diftitox		7/12/2013	Treatment of cutaneous T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Citius Pharmaceuticals, Inc."
alisertib		7/12/2013	Treatment of small cell lung cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Millennium Pharmaceuticals, Inc."
repository corticortropin injection		6/28/2013	Treatment of amyotrophic lateral sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Mallinckrodt Pharmaceuticals, Inc."
moxetumomab pasudotox		6/28/2013	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals LP
human platelet antigen-1a immunoglobulin (anti-HPA-1a)		6/27/2013	Prevention of fetal and neonatal alloimmune thrombocytopenia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Rallybio IPA, LLC"
intravenous carbamazepine	CARNEXIV	6/27/2013	Treatment of epilepsy patients who cannot take anything by mouth (NPO)	Designated/Approved		Lundbeck LLC
naxitamab-gqgk	DANYELZA®	6/24/2013	Treatment of neuroblastoma	Designated/Approved		"Y-mAbs Therapeutics, Inc."
Ulixertinib		6/24/2013	Treatment of Stage IIb through Stage IV BRAF mutant melanoma	Designated	Not FDA Approved for Orphan Indication	"BioMed Valley Discoveries, Inc."
"cyclo(-y-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonly-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt"		6/24/2013	Treatment of acromegaly	Designated	Not FDA Approved for Orphan Indication	"Xeris Pharmaceuticals, lnc."
liposomal busulfan		6/24/2013	For use as a conditioning regimen for patients with malignancies undergoing autologous or allogeneic hematopoietic stem cell transplantation	Designated	Not FDA Approved for Orphan Indication	Calliditas Therapeutics AB
flunarizine		6/24/2013	Treatment of alternating hemiplegia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Marathon Pharmaceuticals, LLC"
eculizumab	Soliris	6/24/2013	Treatment of neuromyelitis optica	Designated/Approved		"Alexion Pharmaceuticals, Inc."
ravulizumab-cwvz	Ultomiris	6/24/2013	Treatment of neuromyelitis optica	Designated/Approved		"Alexion Pharmaceuticals, Inc."
IL-12 secreting dendritic cells loaded with autologous tumor lysate		6/24/2013	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Activartis Biotech GmbH
Multi-peptide cancer vaccine		6/23/2013	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"OncoPep, Inc."
Tagraxofusp-erzs	ELZONRIS	6/6/2013	Treatment of blastic plasmacytoid dendritic cell neoplasm	Designated/Approved		"Stemline Therapeutics, Inc."
sodium phenylbutyrate	Pheburane	6/6/2013	Treatment of urea cycle disorders	Designated/Approved		Medunik Canada Inc
"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-broethyl) diamidophosphate"		6/5/2013	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	EMD Serono
diazepam auto-injector		5/30/2013	"Management of selected, refractory patients with epilepsy on stable regimens of antiepileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity"	Designated	Not FDA Approved for Orphan Indication	"Meridian Medical Technologies, Inc."
abatacept		5/30/2013	Treatment of type 1 diabetes mellitus patients with residual beta cell function	Designated	Not FDA Approved for Orphan Indication	Orban Biotech LLC
modified recombinant human Factor VIIa (rFVIIa) molecule		5/30/2013	Treatment of bleeding episodes in hemophilia A or B subjects with inhibitors	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bayer Healthcare Pharmaceuticals, Inc."
ibrutinib	IMBRUVICA	5/30/2013	Treatment of small lymphocytic lymphoma	Designated/Approved		"Pharmacyclics, LLC"
terguride		5/17/2013	Treatment of systemic sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Medac GmbH
ibrutinib		5/16/2013	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Pharmacyclics, LLC"
HIRMAb-IDS		5/15/2013	Treatment of mucopolysaccharidosis Type II (Hunter Syndrome)	Designated	Not FDA Approved for Orphan Indication	"ArmaGen Technologies, Inc."
2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid		5/14/2013	Treatment of patients with systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	Horizon Therapeutics Ireland DAC
H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-alys-aleu-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH		5/14/2013	Treatment of subarachnoid hemorrhage	Designated	Not FDA Approved for Orphan Indication	"NoNO, Inc."
"3,5-diiodothyropropionic acid"		5/14/2013	Treatment of Allan-Herndon-Dudley syndrome	Designated	Not FDA Approved for Orphan Indication	Zarion Pharmaceuticals P/L
DCVAC OvCa		5/14/2013	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	SOTIOS a.s.
rociletinib		5/14/2013	Treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor	Designated	Not FDA Approved for Orphan Indication	"Clovis Oncology, Inc."
daratumumab	Darzalex	5/6/2013	Treatment of multiple myeloma	Designated/Approved		"Janssen Biotech, Inc."
pazopanib		5/6/2013	Treatment of ovarian cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corp.
daratumumab	Darzalex	5/6/2013	Treatment of multiple myeloma	Designated/Approved		"Janssen Biotech, Inc."
daratumumab	Darzalex	5/6/2013	Treatment of multiple myeloma	Designated/Approved		"Janssen Biotech, Inc."
zoledronic acid		5/6/2013	Treatment of complex regional pain syndrome	Designated	Not FDA Approved for Orphan Indication	"Axsome Therapeutics, Inc."
daratumumab	Darzalex	5/6/2013	Treatment of multiple myeloma	Designated/Approved		"Janssen Biotech, Inc."
isavuconazonium sulfate	Cresemba	5/6/2013	Treatment of invasive aspergillosis	Designated/Approved		Astellas Pharma Global Development Inc.
teprotumumab		5/6/2013	Treatment of active thyroid eye disease	Designated/Approved		Horizon Therapeutics Ireland DAC
daratumumab	Darzalex	5/6/2013	Treatment of multiple myeloma	Designated/Approved		"Janssen Biotech, Inc."
daratumumab	Darzalex	5/6/2013	Treatment of multiple myeloma	Designated/Approved		"Janssen Biotech, Inc."
recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)		5/6/2013	Treatment of congenital factor VII deficiency which includes treatment and prophylaxis of bleeding episodes in patients with congenital factor VII deficiency	Designated	Not FDA Approved for Orphan Indication	CSL Behring
adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs		5/6/2013	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome)	Designated	Not FDA Approved for Orphan Indication	Lysogene
hepatitis B virus neutralizing human monoclonal antibody		5/6/2013	Prevention of hepatitis B recurrence following liver transplantation	Designated	Not FDA Approved for Orphan Indication	Green Cross Corp.
budesonide		5/6/2013	Treat of ulcerative colitis in pediatric patients aged 0 through 16 years.	Designated	Not FDA Approved for Orphan Indication	"Santarus, Inc."
pexastimogene devacirepvec		5/6/2013	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"SillaJen Biotherapeutics, Inc."
daratumumab	Darzalex	5/6/2013	Treatment of multiple myeloma	Designated/Approved		"Janssen Biotech, Inc."
isavuconazonium sulfate	Cresemba	5/6/2013	Treatment of invasive aspergillosis	Designated/Approved		Astellas Pharma Global Development Inc.
isavuconazonium sulfate	Cresemba	5/6/2013	Treatment of invasive aspergillosis	Designated/Approved		Astellas Pharma Global Development Inc.
replication-deficient recombinant serotype 2 adeno-associated viral vector containing hAQP1 cDNA		5/3/2013	Treatment of symptoms of Grade 2 and Grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral cavity.	Designated	Not FDA Approved for Orphan Indication	"MeiraGTx, LLC"
tocilizumab	Actemra	4/17/2013	Treatment of systemic sclerosis	Designated/Approved		"Genentech, Inc."
opioid growth factor		4/16/2013	Treatment of liver and intrahepatic bile duct cancer	Designated	Not FDA Approved for Orphan Indication	"Primocure Pharma, Inc."
recombinant human alpha-N-acetylglucosaminidase		4/15/2013	Treatment of mucopolysaccharidosis IIIB (Sanfilippo B syndrome)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc."
brentuximab vedotin		4/15/2013	"Treatment of patients with peripheral T-cell lymphoma, not otherwise specified"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Seattle Genetics, Inc."
"4-(6-(4-(piperazin-1-yl)phenyl_pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride"		4/15/2013	Treatment of fibrodysplasia ossificans progressiva	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"La Jolla Pharmaceutical Company, Inc."
daunorubicin citrate liposome		4/15/2013	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Galen Limited
prolactin receptor antagonist		4/15/2013	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Oncolix, Inc."
sdTD-K6a.513a.12; small interfering RNA composed of 2 strands of hybridized RNAs		4/15/2013	Treatment of pachyonychia congenita	Designated	Not FDA Approved for Orphan Indication	"TransDerm, Inc."
duvelisib	COPIKTRA	4/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Designated/Approved		"Secura Bio, Inc."
sodium ascorbate and menadione sodium bisulfite		4/15/2013	Treatment of autosomal dominant polycystic kidney disease	Designated	Not FDA Approved for Orphan Indication	IC-MedTech Corporation
sodium ascorbate and menadione sodium bisulfite		4/15/2013	Treatment of autosomal dominant polycystic liver disease	Designated	Not FDA Approved for Orphan Indication	IC-Medtech Corporation
methylparaben suberohydroxamic acid phenyl ester		4/15/2013	Treatment of cutaneous T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	Medivir AB
melatonin		4/12/2013	Treatment of neonatal hypoxic ischemic encephalopathy	Designated	Not FDA Approved for Orphan Indication	Scharper S.p.A.
givinostat	Duvyzat	4/12/2013	Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Designated/Approved		Italfarmaco SpA
recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)		4/12/2013	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"NKT Therapeutics, Inc."
anti-inhibitor coagulant complex	FEIBA	4/12/2013	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	Designated/Approved		"Baxalta US, Inc."
transforming growth factor-beta receptor 1 kinase inhibitor		4/1/2013	Treatment of hepatocellular carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Eli Lilly and Company
cerliponase alfa	Brineura	4/1/2013	Treatment of neuronal ceroid lipofuscinosis type 2	Designated/Approved		"BioMarin Pharmaceutical, Inc."
Kre-Celazine		4/1/2013	Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population	Designated	Not FDA Approved for Orphan Indication	All American Pharmaceutical & Natural Foods Corpor
neridronate		3/25/2013	"Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)"	Designated	Not FDA Approved for Orphan Indication	"NovaPharm, LLC"
acamprosate		3/25/2013	Treatment of fragile X syndrome	Designated	Not FDA Approved for Orphan Indication	"Confluence Pharmaceuticals, LLC"
inotuzumab ozogamicin		3/25/2013	Treatment of B-cell acute lymphoblastic leukemia	Designated/Approved		"Wyeth Pharmaceuticals, LLC"
liposomal amikacin	Arikayce	3/25/2013	Treatment of infections caused by non-tuberculous mycobacteria	Designated/Approved		Insmed Incorporated
inotuzumab ozogamicin	Besponsa	3/25/2013	Treatment of B-cell acute lymphoblastic leukemia	Designated/Approved		"Wyeth Pharmaceuticals, LLC"
recombinant adenovirus vector AAV2/rh8 expressing human B-hexosaminidase A & B subunits		3/25/2013	Treatment of Tay-Sachs disease	Designated	Not FDA Approved for Orphan Indication	Na't Tay-Sachs & Allied Diseases Association
recombinant adeno- associated virus vector AAV2/rh8 expressing human B-hexosaminidase A and B subunits		3/25/2013	For the treatment of Sandhoff disease	Designated	Not FDA Approved for Orphan Indication	Nat'l Tay-Sachs & Allied Diseases Association
Fedratinib		3/21/2013	Treatment of polycythemia vera	Designated	Not FDA Approved for Orphan Indication	Impact Biomedicines
cell based therapeutic composed of allogeneic donor apoptotic cells		3/18/2013	Prevention of graft versus host disease	Designated	Not FDA Approved for Orphan Indication	Enlivex Therapeutics Ltd.
neostigmine		3/18/2013	Treatment of acute colonic pseudo-obstruction	Designated	Not FDA Approved for Orphan Indication	"Luitpold Pharmaceuticals, Inc."
"Coagulation Factor IX (Recombinant), GlycoPEGylated"	Rebinyn	3/18/2013	Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease)	Designated/Approved		"Novo Nordisk, Inc."
sirolimus		3/18/2013	Treatment of pachyonychia congenita	Designated	Not FDA Approved for Orphan Indication	"Palvella Therapeutics, Inc."
luspatercept-aamt	Reblozyl	3/18/2013	Treatment of myelodysplastic syndrome	Designated/Approved		"Celgene Corporation, a Bristol-Myers Squibb Company"
luspatercept-aamt	Reblozyl	3/18/2013	Treatment of myelodysplastic syndrome	Designated/Approved		"Celgene Corporation, a Bristol-Myers Squibb Company"
chimeric monoclonal antibody against Claudin 6		3/18/2013	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Astellas Pharma Global Development, Inc."
betibeglogene autotemcel	Zynteglo	3/18/2013	Treatment of B-thalassemia major and intermedia	Designated/Approved		"bluebird bio, Inc."
recombinant elafin		3/18/2013	Prevention of inflammatory complications of transthoracic esophagectomy	Designated	Not FDA Approved for Orphan Indication	tiakis Biotech AG
Luspatercept-aamt	REBLOZYL	3/11/2013	Treatment of B-thalassemia	Designated/Approved		Celgene Corporation
C66H100N6O27		3/11/2013	Treatment of of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"GenSpera, Inc."
aerosolized beractant		3/11/2013	Treatment of respiratory distress syndrome	Designated	Not FDA Approved for Orphan Indication	"Beena G. Sood, MD, MS"
His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr		3/11/2013	Treatment of retinal detachment	Designated	Not FDA Approved for Orphan Indication	"ONL Therapeutics, Inc"
transforming growth factor-beta receptor 1 kinase inhibitor		3/11/2013	Treatment of glioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Eli Lilly and Company
AAV-G6Pase vector		3/11/2013	Treatment of glycogen storage disease type Ia	Designated	Not FDA Approved for Orphan Indication	"GlyGenix Therapeutics, Inc."
3-bromopyruvate		3/5/2013	Treatment of liver and intrahepatic bile duct cancer	Designated	Not FDA Approved for Orphan Indication	"KoDiscovery, LLC"
"plasminogen, human-tvmh"	Ryplazim	3/5/2013	"Treatment of hypoplasminogenemia, or type I plasminogen deficiency"	Designated/Approved		"ProMetic BioTherapeutics, Inc."
recombinant human Naglu- insulin-like growth factor II		3/5/2013	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Shire Human Genetic Therapies, Inc."
2-hydroxypropyl-B-cyclodextrin		2/18/2013	"Treatment of Niemann Pick disease, type C."	Designated	Not FDA Approved for Orphan Indication	Mandos LLC
Minnelide		2/18/2013	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Minneamrita Therapeutics, LLC"
allogeneic ex-vivo expanded placental adherent stromal cells		2/18/2013	Treatment of Aplastic Anemia	Designated	Not FDA Approved for Orphan Indication	Pluri Biotech Ltd.
testosterone undecanoate (oral)		2/13/2013	Treatment of constitutional delay in growth and puberty in adolescent boys (14-17 yrs of age)	Designated	Not FDA Approved for Orphan Indication	"Marius Pharmaceuticals, LLC"
human insulin beta chain peptide with incomplete Freund's adjuvant vaccine		2/11/2013	Treatment of Type 1 diabetes patients with residual beta cell function	Designated	Not FDA Approved for Orphan Indication	"Orban Biotech, LLC"
idursulfase beta		2/11/2013	Treatment of Hunter Syndrome (mucopolysaccharidoses)	Designated	Not FDA Approved for Orphan Indication	Green Cross Corp.
enalapril maleate (powder for oral solution)		1/30/2013	Treatment of hypertension in pediatric patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Silvergate Pharmaceuticals, Inc."
[met5]-enkephalin		1/24/2013	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Statera BioPharma, Inc."
nivolumab	Opdivo	1/23/2013	Treatment of Stage IIb to IV melanoma	Designated/Approved		Bristol-Myers Squibb Co.
Exon 55 specific phosphorothioate oligonucleotide		1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 55	Designated	Not FDA Approved for Orphan Indication	"BioMarin Pharmaceutical, Inc."
Exon 52 specific phosphorothiate oligonucleotide		1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 52	Designated	Not FDA Approved for Orphan Indication	"BioMarin Pharmaceutical, Inc."
Exon 45 specific phosphorothioate oligonucleotide		1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 45	Designated	Not FDA Approved for Orphan Indication	"BioMarin Pharmaceutical, Inc."
exon 53 specific phosphorothioate oligonucleotide		1/23/2013	treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 53	Designated	Not FDA Approved for Orphan Indication	"BioMarin Pharmaceutical, Inc."
nivolumab	Opdivo	1/23/2013	Treatment of Stage IIb to IV melanoma	Designated/Approved		Bristol-Myers Squibb Co.
nivolumab	Opdivo	1/23/2013	Treatment of Stage IIb to IV melanoma	Designated/Approved		Bristol-Myers Squibb Co.
onartuzumab		1/23/2013	Treatment of gastric cancer including gastroesophageal cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
nivolumab	Opdivo	1/23/2013	Treatment of Stage IIb to IV melanoma	Designated/Approved		Bristol-Myers Squibb Co.
nivolumab	Opdivo	1/23/2013	Treatment of Stage IIb to IV melanoma	Designated/Approved		Bristol-Myers Squibb Co.
10 synthetic peptides targeting 5 tumor asociated antigens		1/23/2013	Treatment of non-small cell lung cancer in patients expressing HLA-A2	Designated	Not FDA Approved for Orphan Indication	Orphan Synergy Europe Pharma (OSE Pharma)
eflornithine plus sulindac		1/22/2013	Treatment of familial adenomatous polyposis	Designated	Not FDA Approved for Orphan Indication	"Panbela Therapeutics, Inc."
lisuride		1/17/2013	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	Sinoxa Pharma GmbH
apremilast	OTEZLA®	1/17/2013	Treatment of Behcet's disease	Designated/Approved		Amgen Inc.
vosoritide	Voxzogo	1/17/2013	Treatment of achondroplasia	Designated/Approved		"BioMarin Pharmaceutical, Inc."
vosoritide	Voxzogo	1/17/2013	Treatment of achondroplasia	Designated/Approved		"BioMarin Pharmaceutical, Inc."
synthetic peptide; cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-ALA-Lys-Pro-Trp-Tyr-Cys		1/16/2013	Treatment of high altitude pulmonary edema	Designated	Not FDA Approved for Orphan Indication	Apeptico Forschung und Entwicklung GmbH
beloranib		1/15/2013	Treatment of Prader-Willi syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Zafgen, Inc."
5-aminolevulinic acid	Gleolan	1/15/2013	Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV)	Designated/Approved		NX Development Corporation
Efdispo		1/15/2013	Treatment of Ewings Sarcoma	Designated	Not FDA Approved for Orphan Indication	"TDP Biotherapeutics, Inc."
O-(3-piperidino-2-hydroxyl-1-propyl)-nicotinic acid amidoxime hydrochloride		1/15/2013	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	Vudbenk Life Science Kft.
tafenoquine	Krintafel	1/15/2013	Treatment of malaria	Designated/Approved		GlaxoSmithKline Intellectual Property Development Ltd. England
ezatiostat hydrochloride		1/9/2013	Treatment of myelodysplastic syndrome	Designated	Not FDA Approved for Orphan Indication	"Hessian Pharmaceuticals, Inc."
rilonacept		1/9/2013	Treatment of familial Mediterranean fever	Designated	Not FDA Approved for Orphan Indication	"Philip J Hashkes, MD, MSc."
P140K MGMT transduced human CD34 cells		1/9/2013	For bone marrow protection in the treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	Lentigen Corporation
paclitaxel nanoparticles		1/2/2013	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"CIRJ Co., Ltd."
S-nitrosoglutathione		12/28/2012	Treatment of severe preeclampsia	Designated	Not FDA Approved for Orphan Indication	Salupont Consulting Ltd
tiprelestat		12/28/2012	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	tiakis Biotech AG
vancomycin		12/27/2012	Treatment of endophthalmitis	Designated	Not FDA Approved for Orphan Indication	"Fera Pharmaceuticals, LLC"
PGC-C12E-terlipressin		12/27/2012	Treatment of ascites due to all etiologies except for cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	PharmaIN Corporation
lenvatinib	Lenvima	12/27/2012	"Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer"	Designated/Approved		"Eisai, Inc."
prothrombin complex concentrate (human)	Kcentra	12/27/2012	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	Designated/Approved		CSL Behring
adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene		12/27/2012	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)	Designated	Not FDA Approved for Orphan Indication	"Esteve Pharmaceuticals, S.A."
prothrombin complex concentrate (human)	Kcentra	12/27/2012	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	Designated/Approved		CSL Behring
methylene blue0.5%	ProvayBlue	12/18/2012	Treatment of hereditary and acquired methemoglobinemia	Designated/Approved		Provepharm SAS
adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene		12/13/2012	treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	Spark Therapeutics Ireland Ltd.
perampanel		12/7/2012	Treatment of Lennox-Gastaut Syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Eisai Inc.
glucagon		12/5/2012	Prevention of hypoglycemia in the congenital hyperinsulinism population	Designated	Not FDA Approved for Orphan Indication	"Biodel, Inc."
Yttrium(90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10		12/3/2012	Treatment of soft tissue sarcoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"OncoTherapy Science, Inc."
trans sodium crocetinate		12/3/2012	Treatment of brain metastasis	Designated	Not FDA Approved for Orphan Indication	"Diffusion Pharmaceuticals, LLC"
porcine GM1 ganglioside		12/3/2012	Treatment of acute spinal cord injury	Designated	Not FDA Approved for Orphan Indication	TRB Chemedica International S.A.
afatinib	Gilotrif	12/3/2012	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	Designated/Approved		"Boehringer Ingelheim Pharmaceuticals, Inc."
ibrutinib	Imbruvica	12/3/2012	Treatment of mantle cell lymphoma	Designated/Approved		"Pharmacyclics, LLC"
afatinib	Gilotrif	12/3/2012	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	Designated/Approved		"Boehringer Ingelheim Pharmaceuticals, Inc."
recombinant human gowth hormone in an ocular delivery system		12/3/2012	Treatment of persistent corneal epithelial defects	Designated	Not FDA Approved for Orphan Indication	Jade Therapeutics LLC
diazoxide		12/3/2012	Treatment of Prader Willi Syndrome	Designated	Not FDA Approved for Orphan Indication	"Sedogen, LLC"
apolipoprotein E mimetic peptide		12/3/2012	Treatment of homozygous familial hypercholesterolemia	Designated	Not FDA Approved for Orphan Indication	"LipimetiX Development, LLC"
human coagulation factor VIII		12/3/2012	Immune tolerance induction in hemophilia A patients with inhibitors	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"OCTAPHARMA USA, Inc."
recombinant human monoclonal antibody of the IgG1 kappa class against prostate stem cell antigen		12/3/2012	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Astellas Pharma Global Development, Inc."
hexasodium phytate		12/2/2012	Treatment of calciphylaxis	Designated	Not FDA Approved for Orphan Indication	"Vifor Pharma, Inc."
marzeptacog alfa (activated)		11/30/2012	Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors	Designated	Not FDA Approved for Orphan Indication	GC Biopharma Corp.
chimeric monoclonal antibody to claudin 18 splice variant 2		11/20/2012	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	Astellas Pharma Global Development Inc.
sodium thiosulfate		11/19/2012	Treatment of calciphylaxis	Designated	Not FDA Approved for Orphan Indication	Edinburg BioQuarter
combretastatin A 1 diphosphate		11/19/2012	Treatment of acute myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	"Mateon Therapeutics, Inc."
"beclomethasone 17,21-dipropionate"		11/19/2012	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Designated	Not FDA Approved for Orphan Indication	"Soligenix, Inc"
"1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one"		11/19/2012	Treatment of erythromelalgia	Designated	Not FDA Approved for Orphan Indication	"Flexion Therapeutics, Inc."
melphalan		11/19/2012	Treatment of retinoblastoma	Designated	Not FDA Approved for Orphan Indication	"EyePoint Pharmaceuticals, Inc."
adeno-associated virus transgene of follistatin		11/19/2012	Treatment of Duchennes and Becker's muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	Milo Biotechnology
pembrolizumab	Keytruda	11/19/2012	Treatment of Stage IIB through IV malignant melanoma	Designated/Approved		Merck Sharp & Dohme LLC
tabalumab		11/19/2012	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Eli Lilly and Company
extract of sorghum bicolor extract		11/19/2012	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"Invenux, LLC"
brentuximab vedotin	Adcetris	11/19/2012	Treatment of mycosis fungoides	Designated/Approved		Seagen Inc.
melphalan		11/19/2012	Treatment of Stage IIB through IV melanoma	Designated	Not FDA Approved for Orphan Indication	"OncoTx, LLC"
pembrolizumab	Keytruda	11/19/2012	Treatment of Stage IIB through IV malignant melanoma	Designated/Approved		Merck Sharp & Dohme LLC
pembrolizumab	Keytruda	11/19/2012	Treatment of Stage IIB through IV malignant melanoma	Designated/Approved		Merck Sharp & Dohme LLC
pembrolizumab	Keytruda	11/19/2012	Treatment of Stage IIB through IV malignant melanoma	Designated/Approved		Merck Sharp & Dohme LLC
Hantaan virus and Puumala virus DNA vaccines		11/13/2012	Prevention of hemorrhagic fever with renal syndrome caused by Hantaan virus and Puumala virus	Designated	Not FDA Approved for Orphan Indication	Surgeon General of the U. S. Army
2'-O-methyl phosphorothioate 5'-GCUAGGUUUACGGGACCUCU-3'		10/31/2012	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	LifeSplice Pharma LLC
5'-GCCATGGTTTTTTCTCAGG-3'		10/31/2012	Prophylaxis for patients following documented or suspected exposure to ebolavirus	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sarepta Therapeutics, Inc."
sirolimus	Rapamune	10/31/2012	Treatment of lymphangioleiomyomatosis	Designated/Approved		"Pfizer, Inc."
crenolanib		10/31/2012	Treatment of acute myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	"AROG Pharmaceuticals, LLC"
tetracosactide hexaacetate (beta 1-24-corticotrophin)		10/31/2012	Treatment of infantile spasms	Designated	Not FDA Approved for Orphan Indication	"Cerium Pharmaceuticals, Inc."
"sodium sulfate, potassium sulfate, and magnesium sulfate"	SUPREP Bowel Prep Kit	10/31/2012	For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents	Designated/Approved		"Braintree Laboratories, Inc."
crizotinib		10/31/2012	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
"5ÿ¿ÿÿÿ¢ÿ¿ÿÿ¬""-GAATATTAACAIACTGACAAGTC-3ÿ¿ÿÿÿ¢ÿ¿ÿÿ¬"""		10/31/2012	Prophylaxis following documented or suspected exposure to marburg virus	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sarepta Therapeutics, Inc."
"recombinant human GM-CSF, molgramostim"		10/31/2012	Treatment of pulmonary alveolar proteinosis	Designated	Not FDA Approved for Orphan Indication	Savara Inc.
coagulation factor IX (recombinant); coagulation factor IX (recombinant)	RIXUBIS; RIXUBIS	10/31/2012	Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)	Designated/Approved		"Takeda Pharmaceuticals USA, Inc."
coagulation factor IX (recombinant); coagulation factor IX (recombinant)	RIXUBIS; RIXUBIS	10/31/2012	Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)	Designated/Approved		"Takeda Pharmaceuticals USA, Inc."
"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid"		10/31/2012	Treatment of primary biliary cirrhosis	Designated	Not FDA Approved for Orphan Indication	"Ipsen Biopharmaceuticals, Inc."
odevixibat	Bylvay	10/31/2012	Treatment of progressive familial intrahepatic cholestasis	Designated/Approved		"Ipsen Biopharmaceuticals, Inc."
pralmorelin hydrochloride		10/18/2012	As a diagnostic agent for the detection of growth hormone deficiency	Designated	Not FDA Approved for Orphan Indication	"Sella Pharmaceuticals, Inc."
amatuximab		9/28/2012	Treatment of mesothelioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Eisai Inc.
carbon monoxide		9/28/2012	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"Hillhurst Biopharmaceuticals, Inc."
crizotinib	Xalkori	9/28/2012	Treatment of anaplastic large cell lymphoma	Designated/Approved		"Pfizer, Inc."
liposomal Ã}Â±-galactosylceramide		9/28/2012	Prevention of graft-versus-host disease	Designated	Not FDA Approved for Orphan Indication	REGiMMUNE Corporation
ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS; HLA class I/II binding tumor associated peptides		9/28/2012	Treatment of renal cell carcinoma in HLA-A*2 positive patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Immatics Biotechnologies GmbH
crizotinib	Xalkori	9/28/2012	Treatment of anaplastic large cell lymphoma	Designated/Approved		"Pfizer, Inc."
quinacrine		9/28/2012	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"Cleveland BioLabs, Inc & Incuron, LLC Joint Ventur"
glycosylated recombinant human interleukin-7		9/27/2012	Treatment of progressive multifocal leukoencephalopathy	Designated	Not FDA Approved for Orphan Indication	"Cytheris, Inc."
synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA		9/25/2012	Treatment of ischemic optic neuropathy	Designated	Not FDA Approved for Orphan Indication	"Quark Pharmaceuticals, Inc."
"Japanese encephalitis vaccine, inactivated, adsorbed"	IXIARO	9/25/2012	Prevention of Japanese encephalitis virus in pediatric patients.	Designated/Approved		Intercell AG
metyrapone		9/25/2012	Treatment of Cushing's syndrome	Designated	Not FDA Approved for Orphan Indication	HRA Pharma Rare Diseases
reparixin		9/25/2012	Prevention of graft loss in pancreatic islet transplantation	Designated	Not FDA Approved for Orphan Indication	Dompe S.p.A.
dantrolene sodium		9/25/2012	Treatment of heat stroke	Designated	Not FDA Approved for Orphan Indication	"Eagle Pharmaceuticals, Inc."
vancomycin hydrochloride (inhalational)		9/20/2012	Treatment of persistent methicillin-resistant S. aureus lung infection in patients with cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Savara Pharmaceuticals, Inc."
paclitaxel poliglumex		9/20/2012	Treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	CTI BioPharma Corporation
H-Leu-Pro-Pro-Ser-Arg-OH		9/20/2012	Treatment of Kaposi sarcoma	Designated	Not FDA Approved for Orphan Indication	"Immuno Tech, Inc."
trametinib and dabrafenib	MEKINIST and TAFINLAR	9/20/2012	Treatment of Stage IIb through IV melanoma.	Designated/Approved		Novartis Pharmaceuticals Corporation
trametinib and dabrafenib	MEKINIST and TAFINLAR	9/20/2012	Treatment of Stage IIb through IV melanoma.	Designated/Approved		Novartis Pharmaceuticals Corporation
alfimeprase		9/20/2012	Treatment of ST-elevation myocardial infarcted patients who are undergoing primary percutaneous coronary intervention	Designated	Not FDA Approved for Orphan Indication	"Niche Therapeutics, LLC"
venetoclax	VENCLEXTA	9/20/2012	Treatment of chronic lymphocytic leukemia	Designated/Approved		"AbbVie, Inc"
trametinib and dabrafenib	MEKINIST and TAFINLAR	9/20/2012	Treatment of Stage IIb through IV melanoma.	Designated/Approved		Novartis Pharmaceuticals Corporation
trametinib and dabrafenib	MEKINIST and TAFINLAR	9/20/2012	Treatment of Stage IIb through IV melanoma.	Designated/Approved		Novartis Pharmaceuticals Corporation
venetoclax	VENCLEXTA	9/20/2012	Treatment of chronic lymphocytic leukemia	Designated/Approved		"AbbVie, Inc"
venetoclax	VENCLEXTA	9/20/2012	Treatment of chronic lymphocytic leukemia	Designated/Approved		"AbbVie, Inc"
mecasermin rinfabate		9/20/2012	Prevention of retinopathy of prematurity in premature infants born at risk for the disease	Designated	Not FDA Approved for Orphan Indication	OHB Neonatology Ltd
mouse-human chimeric monoclonal anti-GD2 IgG1 antibody		9/20/2012	Treatment of neuroblastoma.	Designated	Not FDA Approved for Orphan Indication	Recordati Rare Diseases Inc.
milciclib maleate		9/20/2012	Treatment of thymic epithelial tumors.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Tiziana Life Sciences PLC
recilisib sodium		9/4/2012	Treatment of acute radiation syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Onconova Therapeutics, Inc."
menaquinone		9/4/2012	Treatment of calciphylaxis	Designated	Not FDA Approved for Orphan Indication	"Nu Science Trading, LLC"
canakinumab	Ilaris	9/4/2012	Treatment of TNF-receptor associated periodic syndrome (TRAPS)	Designated/Approved		Novartis Pharmaceuticals Corporation
caffeine and sodium benzoate		8/22/2012	Treatment of seizure prolongation in patients undergoing electroconvulsive therapy	Designated	Not FDA Approved for Orphan Indication	"Luitpold Pharmaceuticals, Inc."
triptorelin pamoate	Triptodur	8/20/2012	Treatment of central precocious puberty	Designated/Approved		"Arbor Pharmaceuticals, LLC"
mercaptopurine oral solution	Purixan	8/20/2012	Treatment of acute lymphoblastic leukemia in pediatric patients	Designated/Approved		Nova Laboratories Limited
Solriamfetol	Sunosi	8/20/2012	Treatment of narcolepsy	Designated/Approved		"Axsome Malta, Ltd."
panobinostat	Farydak	8/20/2012	Treatment of multiple myeloma	Designated/Approved		zr pharma& GmbH
modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain		8/20/2012	Treatment of inherited mitochondrial respiratory chain disease	Designated	Not FDA Approved for Orphan Indication	Gencia Corporation
lurbinectedin		8/20/2012	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"PharmaMar USA, Inc."
gevokizumab		8/20/2012	"Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	XOMA (US) LLC
methylene blue injection		8/11/2012	Treatment of congenital and acquired methemoglobinemia	Designated	Not FDA Approved for Orphan Indication	"Luitpold Pharmaceuticals, Inc."
Brilliant Blue G Ophthalmic Solution 0.025%	DORC ILM-Blue	7/31/2012	For use as an aid in ophthalmic surgery by selectively staining the internal limiting membrane	Designated/Approved		Dutch Ophthalmic Research Center International BV
rucaparib	Rubraca	7/31/2012	Treatment of ovarian cancer	Designated/Approved		"Clovis Oncology, Inc."
tocilizumab	Actemra	7/31/2012	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	Designated/Approved		"Genentech, Inc."
rucaparib	Rubraca	7/31/2012	Treatment of ovarian cancer	Designated/Approved		"Clovis Oncology, Inc."
tocilizumab	Actemra	7/31/2012	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	Designated/Approved		"Genentech, Inc."
heat killed mycobacterium w immunomodulator		7/31/2012	Treatment of non-small cell lung cancers that express desmocollin-3	Designated	Not FDA Approved for Orphan Indication	Cadila Pharmaceuticals Limited
diazepam (intranasal)		7/31/2012	Management of patients with acute repetitive seizures	Designated	Not FDA Approved for Orphan Indication	SK Life Sciences Inc.
"DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the nastive eIF5A mRNA, and PEI (polyethyleneimine)"		7/24/2012	Treatment of diffuse large B cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Senesco Technologies, Inc."
Recombinant Fusion Protein		7/24/2012	Treatment of Myelodysplastic Syndrome	Designated	Not FDA Approved for Orphan Indication	Apogenix GmbH
autologous umbilical cord blood		7/24/2012	Treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury	Designated	Not FDA Approved for Orphan Indication	Duke University
"DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)"		7/24/2012	Treatment of mantle cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Senesco Technologies, Inc."
recombinant human anti-GDF-8 monoclonal antibody		7/24/2012	Treatment of Duchenne Muscular Dystrophy.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
acetyl-l-carnitine		7/24/2012	Treatment of Fragile X syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Leadiant Biosciences, Inc."
allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor		7/24/2012	Treatment of macular telangiectasia type 2 (MacTel)	Designated	Not FDA Approved for Orphan Indication	"Neurotech Pharmaceuticals, Inc."
midazolam		7/24/2012	Treatment of nerve agent-induced seizures	Designated	Not FDA Approved for Orphan Indication	"Meridian Medical Technologies, Inc."
oxaloacetate		7/24/2012	Treatment of gliomas	Designated	Not FDA Approved for Orphan Indication	Terra Biological LLC
Inotersen	TEGSEDI™	7/24/2012	Treatment of transthyretin amyloidosis (ATTR amyloidosis)	Designated/Approved		"Akcea Therapeutics, Inc."
cantharidin		7/24/2012	"Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa"	Designated	Not FDA Approved for Orphan Indication	"Orenova Group, LLC"
dexamethasone sodium phosphate encapsulated in autologous erythrocytes		7/24/2012	Treatment of ataxia-telangiectasia	Designated	Not FDA Approved for Orphan Indication	"Quince Therapeutics, S.p.A."
methylene blue		7/24/2012	Treatment of methemoglobinemia	Designated	Not FDA Approved for Orphan Indication	"Fera Pharmaceuticals, LLC"
tralokinumab		7/24/2012	Treatment of idiopathic pulmonary fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	MedImmune Ltd.
human retinal progenitor cells		7/23/2012	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	"jCyte, Inc."
everolimus		7/23/2012	Treatment of hepatocellular carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corp.
mecasermin rinfabate		7/23/2012	Treatment of amyotropic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"PCUT BioPartners, Inc."
N-acetylcysteine		7/19/2012	Prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers	Designated	Not FDA Approved for Orphan Indication	"Edward A. Neuwelt, MD"
tacrolimus		7/6/2012	Treatment of hemorrhagic cystitis	Designated	Not FDA Approved for Orphan Indication	Lipella Pharmaceuticals Inc.
motixafortide	Aphexda	7/6/2012	For use to mobilize hematopoietic stem cells (HSCs) from the marrow to peripheral blood for collection for autologous or allogeneic transplantation	Designated/Approved		"BioLineRx, Ltd."
human MHC non-restricted cytotoxic T-cell line		7/6/2012	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	Galileo Research srl
pamrevlumab		7/6/2012	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"FibroGen, Inc."
benzoate		7/6/2012	Treatment of pediatric schizophrenia	Designated	Not FDA Approved for Orphan Indication	SyneuRx International (Taiwan) Corp.
L-asparaginase encapsulated in red blood cells		7/6/2012	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	ERYTECH Pharma
adult adherent bone marrow-derived multipotent stem cells		7/6/2012	"Treatment of MPS-1, including Hurler syndrome"	Designated	Not FDA Approved for Orphan Indication	"Athersys, Inc."
antimesothelin-ADC (antibody drug conjugate)		7/5/2012	Treatment of mesothelioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bayer HealthCare Pharmaceuticals, Inc."
PG2 (Astragalus polysaccharides extracted and purified from the dry root of Astragalus membranaceus)		7/5/2012	Treatment of idiopathic thrombocytopenic purpura	Designated	Not FDA Approved for Orphan Indication	PhytoHealth Corporation
nitric oxide		6/18/2012	Treatment of persistent pulmonary hypertension in newborns	Designated/Approved		VERO BIOTECH
CNDO-109-activated allogeneic natural killer cells		6/18/2012	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Fortress Biotech, Inc."
cyclocreatine		6/18/2012	Treatment of creatine transporter deficiency	Designated	Not FDA Approved for Orphan Indication	Lumos Pharma
rilotumumab		6/18/2012	Treatment of gastric cancer including gastroesophageal junction adenocarcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Amgen, Inc."
bimagrumab		6/18/2012	Treatment of inclusion body myositis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corp.
pentoxifylline		6/14/2012	Treatment of Behcet's disease	Designated	Not FDA Approved for Orphan Indication	Silk Road Therapeutics
interferon-alpha secreting autologous micro-organ tissue converting into a biopump		6/14/2012	Treatment of chronic hepatitis D	Designated	Not FDA Approved for Orphan Indication	"Medgenics, Inc."
perhexiline maleate		6/14/2012	Treatment of moderate to severe symptomatic hypertrophic cardiomyopathy	Designated	Not FDA Approved for Orphan Indication	"Heart Metabolics, Limited."
patisiran	ONPATTRO	6/14/2012	Treatment of transthyretin-mediated amyloidosis	Designated/Approved		"Alnylam Pharmaceuticals, Inc."
liposomal ciprofloxacin plus ciprofloxacin		6/1/2012	For the management of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	Savara Inc.
recilisib sodium		6/1/2012	Prevention of acute radiation syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Onconova Therapeutics, Inc."
Autologous Engineered Skin Substitute		6/1/2012	Treatment of hospitalized patients with deep partial and full thickness burns requiring grafting.	Designated	Not FDA Approved for Orphan Indication	"Amarantus BioScience Holdings, Inc."
bortezomib	Velcade	5/30/2012	Treatment of mantle cell lymphoma.	Designated/Approved		"Millennium Pharmaceuticals, Inc."
bortezomib	Velcade	5/30/2012	Treatment of mantle cell lymphoma.	Designated/Approved		"Millennium Pharmaceuticals, Inc."
Heat Shock Protein (hsp60) antigen		5/21/2012	For use in type 1 diabetic mellitus patients with residual beta-cell function	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AndromedA Biotech, LTD"
golimumab		5/21/2012	Treatment of sarcoidosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Biotech, Inc."
allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat	StrataGraft	5/21/2012	Treatment of hospitalized patients with complex skin defects resulting from partial and full thickness skin burns requiring excision and grafting	Designated/Approved		"Stratatech Corporation, a Mallinckrodt company"
eribulin mesylate	Halaven	5/14/2012	Treatment of soft tissue sarcoma	Designated/Approved		Eisai Inc.
"Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass"		5/14/2012	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Unicorn Pacific Corporation
alisertib		5/14/2012	Treatment of peripheral T-cell lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Millennium Pharmaceuticals, Inc."
copper histidinate		5/14/2012	Treatment of Menkes disease	Designated	Not FDA Approved for Orphan Indication	"Sentynl Therapeutics, Inc."
sirolimus in an implantable collagen matrix		5/10/2012	"Prevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing for hemodialysis"	Designated	Not FDA Approved for Orphan Indication	"Vascular Therapies, LLC"
recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)	Idelvion	4/27/2012	Treatment of patients with congenital factor IX deficiency (hemophilia B).	Designated/Approved		"CSL Behring, LLC"
eptifibatide and iloprost		4/20/2012	Treatment of purpura fulminans	Designated	Not FDA Approved for Orphan Indication	Thrombologic
elivaldogene autotemcel	Skysona	4/19/2012	Treatment of adrenoleukodystrophy	Designated/Approved		"bluebird bio, Inc."
ibrutinib	Imbruvica	4/6/2012	Treatment of chronic lymphocytic leukemia (CLL)	Designated/Approved		"Pharmacyclics, LLC"
ferumoxytol		4/6/2012	"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)"	Designated	Not FDA Approved for Orphan Indication	"ArsNova Partners, LLC"
emeramide		4/6/2012	Treatment of mercury toxicity	Designated	Not FDA Approved for Orphan Indication	NBMI Science Limited
alpha1-proteinase inhibitor (human)		4/6/2012	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Grifols Therapeutics, Inc."
tolvaptan	Jynarque	4/6/2012	Treatment of autosomal dominant polycystic kidney disease	Designated/Approved		"Otsuka Pharmaceutical Company, Ltd."
ibrutinib	Imbruvica	4/6/2012	Treatment of chronic lymphocytic leukemia (CLL)	Designated/Approved		"Pharmacyclics, LLC"
iloprost		4/6/2012	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	"Algorithum Sciences, LLC"
ibrutinib	Imbruvica	4/6/2012	Treatment of chronic lymphocytic leukemia (CLL)	Designated/Approved		"Pharmacyclics, LLC"
ropeginterferon alfa-2b-njft	Besremi	4/2/2012	Treatment of polycythemia vera	Designated/Approved		PharmaEssentia
adenovirus containing a human FAS-c gene		4/2/2012	Treatment of malignant glioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Vascular Biogenics Ltd, (VBL Therapeutics)"
ibrutinib		3/27/2012	Treatment of chronic lymphocytic leukemia (CLL).	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Pharmacyclics, LLC"
"synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue"		3/16/2012	Treatment of preterm neonatal respiratory distress syndrome	Designated	Not FDA Approved for Orphan Indication	"Chiesi USA, Inc."
"O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate"		3/16/2012	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"JSK Therapeutics, Inc."
carisbamate		3/16/2012	Management of patients with infantile spasms	Designated	Not FDA Approved for Orphan Indication	"SK Life Science, Inc."
dehydrated alcohol		3/16/2012	Treatment of trigeminal neuralgia	Designated	Not FDA Approved for Orphan Indication	"Luitpold Pharmaceuticals, Inc."
ilorasertib		3/16/2012	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
golimumab		3/16/2012	Treatment of pediatric ulcerative colitis	Designated	Not FDA Approved for Orphan Indication	"Janssen Biotech, Inc."
talarazole		3/16/2012	Treatment of congenital ichthyosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Stiefel Laboratories, Inc."
rigosertib		3/16/2012	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Onconova Therapeutics, Inc."
"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate"		3/9/2012	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"Threshold Pharmaceuticals, Inc."
levoketoconazole	Recorlev	3/9/2012	Treatment of endogenous Cushing's syndrome	Designated/Approved		Strongbridge Dublin Limited
nevanimibe HCL		3/9/2012	Treatment of adrenocortical carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Millendo Therapeutics, Inc."
Hanferon		3/9/2012	Treatment of Behcet's disease	Designated	Not FDA Approved for Orphan Indication	"HanAll BioPharma Co., Ltd."
telotristat etiprate	Xermelo	3/9/2012	Treatment of carcinoid syndrome in patients with neuroendocrine tumors	Designated/Approved		"TerSera Therapeutics, LLC"
verteporfin		3/9/2012	Treatment of chronic or recurrent central serous chorioretinopathy	Designated	Not FDA Approved for Orphan Indication	Valeant Pharmaceuticals North America LLC
heterologous human liver derived progenitor cells		3/9/2012	Treatment of Crigler-Najjar syndrome	Designated	Not FDA Approved for Orphan Indication	Promethera Biosciences
linsitinib		3/9/2012	Treatment of adrenocortical carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Astellas Pharma Global Development, Inc."
anti-Lewis Y humanized monoclonal antibody		3/9/2012	Treament of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	Recepta Biopharma S.A.
"2,2'-{2-[1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid (ixazomib citrate)"		3/9/2012	Treatment of systemic light chain (AL) amyloidosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Millennium Pharmaceuticals, Inc."
basimglurant		3/9/2012	Treatment of Fragile X Syndrome	Designated	Not FDA Approved for Orphan Indication	"Hoffmann-La Roche, Inc."
2-Chloro-N6--(3-iodobenzyl)adenosine-5'-N-methyluronamide		2/17/2012	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Can-Fite BioPharma Ltd.
"Silibinin-C-2',3-dihydrogensuccinate, disodium salt"		2/17/2012	Prevention of recurrent hepatitis C in liver transplant patients	Designated	Not FDA Approved for Orphan Indication	Mylan Specialty LP
birtamimab		2/17/2012	Treatment of AA amyloidosis and AL amyloidosis	Designated	Not FDA Approved for Orphan Indication	Prothena Therapeutics Limited
recombinant human Pentraxin-2; recombinant human Serum Amyloid P		2/17/2012	Treatment of idiopathic pulmonary fibrosis.	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
sulfonated monophosphorylated mannose oligosaccharide		2/17/2012	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Cellxpert Biotechnologies Corporation
salicylic acid 6%		2/17/2012	Treatment of rare congenital ichthyoses.	Designated	Not FDA Approved for Orphan Indication	"Orenova Group, LLC"
tafamidis meglumine	VYNDAQEL; VYNDAMAX	2/17/2012	Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.	Designated/Approved		"FoldRx Pharmaceuticals, Inc., a subsidiary of Pfizer Inc."
bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine		2/17/2012	Treatment of stage IIB to IV melanoma	Designated	Not FDA Approved for Orphan Indication	"Gradalis, Inc."
obinutuzumab	GAZYVA	2/17/2012	Treatment of chronic lymphocytic leukemia	Designated/Approved		"Genentech Inc., a member of the Roche Group"
neostigmine methylsulfate		2/17/2012	Treatment of Myasthenia Gravis	Designated	Not FDA Approved for Orphan Indication	"Luitpold Pharmaceuticals, Inc."
Recombinant humanized monoclonal antibody directed against an epidermal growth factor receptor		2/17/2012	Treatment of glioblastoma multiforme	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
obinutuzumab		2/17/2012	Treatment of diffuse large B cell lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech Inc., a member of the Roche Group"
vestronidase alfa-vjbk	Mepsevii	2/16/2012	"Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)"	Designated/Approved		"Ultragenyx Pharmaceutical, Inc."
ramucirumab	CYRAMZA	2/16/2012	Treatment of gastric cancer	Designated/Approved		Eli Lilly and Company
ramucirumab	CYRAMZA	2/16/2012	Treatment of gastric cancer	Designated/Approved		Eli Lilly and Company
Sodium Thiosulfate		2/16/2012	Treatment of uremic and non-uremic calciphylaxis	Designated	Not FDA Approved for Orphan Indication	"Luitpold Pharmaceuticals, Inc."
digoxin immune fab (ovine)		2/3/2012	Treatment of severe preeclampsia and eclampsia	Designated	Not FDA Approved for Orphan Indication	"AMAG Pharmaceuticals, Inc."
"1,2:5,6-Dianhdrogalactitol"		1/31/2012	Treatment of malignant gliomas	Designated	Not FDA Approved for Orphan Indication	"DelMar Pharmaceuticals, Inc."
phenylephrine		1/31/2012	Treatment of Tetralogy of Fallot	Designated	Not FDA Approved for Orphan Indication	"Luitpold Pharmaceuticals, Inc."
Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor		1/31/2012	Treatment of homozygous familial hypercholesterolemia	Designated	Not FDA Approved for Orphan Indication	ReGenX Biosciences LLC
N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide		1/13/2012	Treatment of meningioma	Designated	Not FDA Approved for Orphan Indication	Recursion Pharmaceuticals Inc.
N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide		1/13/2012	Treatment of Schwannoma of the central nervous system	Designated	Not FDA Approved for Orphan Indication	Recursion Pharmaceuticals Inc.
heterologous human adult liver derived progenitor cells (HHALPC)		1/13/2012	Treatment of urea cycle disorders	Designated	Not FDA Approved for Orphan Indication	Promethera Biosciences
sodium nitrite		1/9/2012	Treatment of chlorine gas poisoning	Designated	Not FDA Approved for Orphan Indication	Hope Pharmaceuticals
"1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy) methyl]benzene"		1/9/2012	Treatment of poliovirus infection.	Designated	Not FDA Approved for Orphan Indication	"ViroDefense, Inc."
nitric oxide		12/28/2011	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	Bellerophon Therapeutics
ustekinumab		12/28/2011	Treatment of chronic sarcoidosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Biotech, Inc."
ustekinumab; human monocloncal antibody to interkeukin 12p40		12/22/2011	Treatment of primary biliary cirrhosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Biotech, Inc."
rVIIa-FP		12/22/2011	Treatment and prophyllaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX	Designated	Not FDA Approved for Orphan Indication	CSL Behring
beraprost sodium 314d		12/22/2011	Treatment of pulmonary arterial hypertension	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Lung Biotechnology PBC
sodium benzoate and clozapine		12/22/2011	Treatment of treatment-resistant schizophrenia	Designated	Not FDA Approved for Orphan Indication	SyneuRx International Corp.
an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco)		12/22/2011	Treatment of hemophilia B	Designated	Not FDA Approved for Orphan Indication	"uniQure, B.V."
H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt		12/22/2011	For use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma	Designated	Not FDA Approved for Orphan Indication	"CanBas Company, Ltd."
letermovir	PREVYMIS	12/12/2011	Prevention of human cytomegalovirus viremia and disease in at risk populations	Designated/Approved		Merck Sharp & Dohme LLC
sorafenib	Nexavar	12/12/2011	"Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer"	Designated/Approved		"Bayer HealthCare Pharmaceuticals, Inc."
losartan		12/12/2011	Treatment of Marfan Syndrome	Designated	Not FDA Approved for Orphan Indication	National Marfan Foundation
humanized IgG4 monoclonal antibody		12/12/2011	Prevention of ischemia/reperfusion injury associated with solid organ tranplantation	Designated	Not FDA Approved for Orphan Indication	"Neuramedy Co., Ltd."
letermovir	Prevymis	12/12/2011	Prevention of human cytomegalovirus viremia and disease in at risk populations	Designated/Approved		Merck Sharp & Dohme LLC
recombinant human galactocerebrosidase (rhGALC);		12/12/2011	Treatment of globoid cell leukodystrophy (Krabbe Disease)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Chiesi USA, Inc."
porfimer sodium		12/2/2011	Treatment of malignant mesothelioma	Designated	Not FDA Approved for Orphan Indication	"Concordia Laboratories, Inc., Sarl"
riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation	Photrexa Viscous	12/2/2011	Treatment of corneal ectasia following refractive surgery	Designated/Approved		"Avedro, Inc."
vamorolone	Agamree	12/2/2011	Treatment of Duchenne muscular dystrophy	Designated/Approved		"Catalyst Pharmaceuticals, Inc."
opium tincture		12/2/2011	Treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment	Designated	Not FDA Approved for Orphan Indication	"Valeant Pharmaceuticals International, Inc."
MCMV5322A/MCMV3068A		11/22/2011	Prevention of maternal-fetal transmission of congenital CMV in pregnant women who acquire CMV infection during pregnancy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genentech
5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzp[d]oxazole		11/22/2011	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	Summit (Oxford) Limited
humanized single chain monoclonal antibody(scFV: IgG1 hinge: IgG1 CH2 and CH3 domains)		11/17/2011	Treatment of chronic lymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	"Aptevo Therapeutics, Inc."
sodium thiosulfate		11/9/2011	Treatment of uremic and non-uremic calciphylaxis	Designated	Not FDA Approved for Orphan Indication	Hope Pharmaceuticals
urea		11/7/2011	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	Designated	Not FDA Approved for Orphan Indication	"Orenova Group, LLC"
ramucirumab	CYRAMZA	11/4/2011	Treatment of hepatocellular carcinoma	Designated/Approved		Eli Lilly and Company
interferon gamma		11/4/2011	Treatment of Friedreich's ataxia	Designated	Not FDA Approved for Orphan Indication	"Roberto Testi, MD"
sirolimus		11/4/2011	"Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS)."	Designated	Not FDA Approved for Orphan Indication	Santen Inc.
heparin activated recombinant human fibroblast growth factor 1 (FGF1)in combination with a surgically implanted biodegradable device		10/24/2011	Treatment of patients with a confirmed traumatic complete spinal cord injury where no motor or sensory function is preserved below the injury(Scale A)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	BioArctic Neuroscience AB
Autologous lymphoma-derived immunoglobulin idiotype antigen vaccine conjugated to keyhole limpet hemocyanin		10/18/2011	Treatment of Waldenstrom's macroglobulinemia	Designated	Not FDA Approved for Orphan Indication	"Biovest International, Inc."
eculizumab		10/18/2011	Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome	Designated	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc."
sodium 4-phenylbutyrate		10/18/2011	Treatment of spinal muscular atrophy	Designated	Not FDA Approved for Orphan Indication	GMP-Orphan SAS
sodium thiosulfate		10/13/2011	Prevention of platinum-induced ototoxicity in pediatric patients	Designated	Not FDA Approved for Orphan Indication	Hope Pharmaceuticals
halofuginone hydrobromide		10/13/2011	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	"Akashi Therapeutics, Inc."
"(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester"		10/12/2011	Treatment of Fragile X syndrome	Designated	Not FDA Approved for Orphan Indication	Stalicla SA
sarcosine		10/12/2011	Treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age)	Designated	Not FDA Approved for Orphan Indication	"Guochuan Emil Tsai, MD, PhD"
reltecimod		10/12/2011	Treatment of necrotizing soft tissue infections (NSTI)	Designated	Not FDA Approved for Orphan Indication	"Atox Bio, Inc."
ferumoxytol		10/7/2011	For use in magnetic resonance imaging in brain metastases	Designated	Not FDA Approved for Orphan Indication	Covis Pharma GmbH
abeotaxane inhibitor of microtubules		10/7/2011	Treatment of gliomas	Designated	Not FDA Approved for Orphan Indication	Cortice Biosciences
"4-[2-(3-Propyl-[1,2,4]0xadiazol-5-yl)-vinyl]-benzene-1,2-diol"		10/4/2011	Treatment of chronic myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Piramal Enterprises Limited
lactobacillus brevis CD2		10/4/2011	Treatment Behcet's disease	Designated	Not FDA Approved for Orphan Indication	"VSL Pharmaceuticals, Inc."
aceneuramic acid		9/23/2011	Treatment of hereditary inclusion body myopathy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Ultragenyx Pharmaceutical, Inc."
"4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol"		9/23/2011	Treatment of idiopathic pulmonary fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene Corporation
peretinoin		9/23/2011	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Kowa Pharmaceutical Europe GmbH
human laminin-111		9/23/2011	Treatment of merosin (laminin-alpha2) deficient congential muscular dystrophy type 1A.	Designated	Not FDA Approved for Orphan Indication	"Prothelia, Inc."
dendritic hybrid cell vaccine		9/23/2011	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	"Orbis Health Solutions, LLC"
resminostat		9/16/2011	Treatment of Hodgkin's lymphoma.	Designated	Not FDA Approved for Orphan Indication	4SC AG
pentosan polysulfate sodium		9/16/2011	Treatment of sickle cell disease.	Designated	Not FDA Approved for Orphan Indication	"Vanguard Therapeutics, Inc."
nimodipine	NYMALIZE	9/16/2011	Treatment of subarachnoid hemorrhage.	Designated/Approved		"Arbor Pharmaceuticals, Inc."
bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13)		9/14/2011	Treatment of idiopathic pulmonary fibrosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sanofi US Services, Inc., A SANOFI COMPANY"
Angiotensin-(1-7)		9/13/2011	Treatment of pulmonary arterial hypertension.	Designated	Not FDA Approved for Orphan Indication	"US Biotest, Inc."
L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser		9/13/2011	Treatment of neuropathic pain in patients with sarcoidosis.	Designated	Not FDA Approved for Orphan Indication	"Araim Pharmaceuticals, Inc."
cardiotrophin-1		9/13/2011	Treatment of acute liver failure	Designated	Not FDA Approved for Orphan Indication	"Digna Biotech, S.L."
lanreotide acetate		9/8/2011	Treatment of carcinoid syndrome	Designated/Approved		"Ipsen Biopharmaceuticals, Inc."
domperidone		9/2/2011	"Treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding"	Designated	Not FDA Approved for Orphan Indication	Texas Tech University Health Sciences Center
riboflavin ophthalmic solution & ultraviolet A	Photrexa Viscous	9/2/2011	Treatment of keratoconus	Designated/Approved		"Avedro, Inc."
ribavirin elaidate		9/2/2011	"Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer"	Designated	Not FDA Approved for Orphan Indication	"Translational Therapeutics, Inc."
deferiprone		9/1/2011	Treatment of superficial siderosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Chiesi USA, Inc."
elotuzumab	Empliciti	9/1/2011	Treatment of multiple myeloma	Designated/Approved		Bristol-Myers Squibb Co.
HPV16 E6/E7 synthetic long peptides vaccine		9/1/2011	Treatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16.	Designated	Not FDA Approved for Orphan Indication	ISA Therapeutics BV
elotuzumab	Empliciti	9/1/2011	Treatment of multiple myeloma	Designated/Approved		Bristol-Myers Squibb Co.
avatrombopag maleate		9/1/2011	Treatment of idiopathic thrombocytopenic purpura	Designated/Approved		"Sobi, Inc."
lanreotide acetate	Somatuline Depot	8/25/2011	Treatment of neuroendocrine tumors	Designated/Approved		"Ipsen Biopharmaceuticals, Inc."
choline tetrathiomolybdate		8/25/2011	Treatment of Wilson's disease	Designated	Not FDA Approved for Orphan Indication	Alexion Pharmaceutical Inc.
dinaciclib		8/25/2011	Treatment of chronic lymphocytic leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Merck Sharp & Dohme Ltd.
idelalisib		8/25/2011	Treatment of chronic lymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
"6,8-bis-benzylsulfanyl-octanoic acid"		8/22/2011	Treatment of acute myeloid leukemia.	Designated	Not FDA Approved for Orphan Indication	"Cornerstone Pharmaceuticals, Inc."
menatetrenone and Vitamin D3		8/22/2011	Treatment of myelodysplastic syndrome	Designated	Not FDA Approved for Orphan Indication	"NBI Pharmaceuticals, Inc."
trabedersen		8/22/2011	Treatment of Stage IIB through Stage IV malignant melanoma.	Designated	Not FDA Approved for Orphan Indication	Oncotelic Inc.
corifungin		8/22/2011	Treatment of amebic meningoencephalitis.	Designated	Not FDA Approved for Orphan Indication	Ctr for Discovery & Innovation in Parasitic Diseas
sodium chlorite		8/22/2011	For slowing the progression of amyotrophic lateral sclerosis.	Designated	Not FDA Approved for Orphan Indication	"Neuvivo, Inc."
allogeneic ex-vivo expanded placental adherent stromal cells		8/22/2011	Treatment of thromboangiitis obliterans (Buerger's disease)	Designated	Not FDA Approved for Orphan Indication	Pluri Biotech Ltd.
pyrimethamine		8/16/2011	Treatment of GM-2 gangliosidoses (Tay-Sachs disease and Sandhoff disease).	Designated	Not FDA Approved for Orphan Indication	ExSAR Corporation
alpha-1 proteinase inhibitor (human)		7/28/2011	Treatment of patients with recent onset (	Designated	Not FDA Approved for Orphan Indication	"Kamada, Ltd."
sildenafil	Revatio	7/28/2011	Treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension	Designated/Approved		Viatris Specialty LLC
sildenafil	Revatio	7/28/2011	Treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension	Designated/Approved		Viatris Specialty LLC
plerixafor		7/28/2011	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genzyme Corporation
"1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridine-3-yl}phenyl)-3-(3-fluorophenyl)urea)"		7/28/2011	Treatment of acute myelogenous leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
irinotecan liposome injection	Onivyde	7/21/2011	Treatment of pancreatic cancer	Designated/Approved		"Ipsen Biopharmaceuticals, Inc."
trans sodium crocetinate		7/21/2011	Treatment of glioblastoma in conjunction with radiotherapy	Designated	Not FDA Approved for Orphan Indication	"Diffusion Pharmaceuticals, LLC"
smilagenin		7/21/2011	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"Junaxo, Inc."
laminin-111 (human)		7/21/2011	Treatment of Duchenne Muscular Dystrophy	Designated	Not FDA Approved for Orphan Indication	"Prothelia, Inc."
irinotecan liposome injection		7/21/2011	Treatment of pancreatic cancer	Designated/Approved		"Ipsen Biopharmaceuticals, Inc."
mepolizumab	NUCALA	7/14/2011	Treatment of Churg-Strauss Syndrome	Designated/Approved		GlaxoSmithKline LLC
mepolizumab	NUCALA	7/14/2011	Treatment of Churg-Strauss Syndrome	Designated/Approved		GlaxoSmithKline LLC
mogamulizumab		7/14/2011	Treatment of adult T-cell leukemia/lymphoma (ATLL).	Designated	Not FDA Approved for Orphan Indication	"Kyowa Kirin Pharmaceutical Development, Inc."
low molecular weight dextran sulfate		7/6/2011	Treatment to mobilze progenitor cells prior to stem cell transplantation	Designated	Not FDA Approved for Orphan Indication	TikoMed AB
corifungin		7/6/2011	Treatment of visceral leishmaniasis	Designated	Not FDA Approved for Orphan Indication	Sandler Center for Drug Discovery
Fibronectin Peptide		6/29/2011	"Prevention of burn injury progression of acute, deep dermal burns in hospitalized patients."	Designated	Not FDA Approved for Orphan Indication	"NeoMatrix Therapeutics, Inc."
ambroxol		6/29/2011	Treatment of Gaucher disease	Designated	Not FDA Approved for Orphan Indication	Zywie LLC
nintedanib	OFEV	6/29/2011	Treatment of patients with idiopathic pulmonary fibrosis.	Designated/Approved		"Boehringer Ingelheim Pharmaceuticals, Inc."
resminostat		6/29/2011	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	4SC AG
denileukin diftitox		6/29/2011	Treatment of peripheral T-cell lymphoma (PTCL)	Designated	Not FDA Approved for Orphan Indication	"Citius Pharmaceuticals, Inc."
"botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)"		6/29/2011	Treatment of botulism.	Designated/Approved		Cangene Corporation
Aldoxorubicin		6/29/2011	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"NantCell, Inc."
gusperimus trihydrochloride		6/29/2011	Treatment of Wegener's granulomatosis	Designated	Not FDA Approved for Orphan Indication	Nordic Group B.V.
IgG1 chimeric monoclonal antibody		6/22/2011	Treatment of multiple myeloma.	Designated	Not FDA Approved for Orphan Indication	HaemaLogiX Pty Ltd.
"cytochrome C, flavin mononucleotide and thiamin diphosphate"		6/17/2011	Treatment of mitochondrial disorders	Designated	Not FDA Approved for Orphan Indication	"NBI Pharmaceuticals, Inc."
cyclophosphamide		6/17/2011	Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant	Designated	Not FDA Approved for Orphan Indication	"Accentia Biopharmaceuticals, Inc."
NanoDTPA(tm)		6/17/2011	"Treatment of known or suspected cases of internal contamination with plutonium, americium, or curium"	Designated	Not FDA Approved for Orphan Indication	NanoSHIFT LLC
7-B-Hydroxy Cholesteryl-3-B-Oleate-Ester		6/15/2011	Treatment of gliomas.	Designated	Not FDA Approved for Orphan Indication	Intsel Chimos SA
gabapentin enacarbil	Horizant	6/7/2011	Treatment of postherpetic neuralgia	Designated/Approved		"Arbor Pharmaceuticals, LLC"
cyclophosphamide		6/7/2011	Treatment of systemic sclerosis.	Designated	Not FDA Approved for Orphan Indication	"Accentia Biopharmaceuticals, Inc."
autologous neo-uninary conduit		6/7/2011	Treatment of bladder dysfunction requiring incontinent urinary diversion.	Designated	Not FDA Approved for Orphan Indication	"Tengion, Inc."
maribavir	Livtencity	6/7/2011	Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.	Designated/Approved		"Takeda Pharmaceuticals USA, Inc."
12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21)		6/7/2011	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Targovax Solutions AS, a subsidiary of Targovax ASA"
recombinant human minibody against complement component		6/7/2011	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	ADIENNE S.A
exendin-(9-39)		6/1/2011	Treatment of congential hyperinsulinenic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	The Children's Hospital of Philadelphia
"Recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)"		6/1/2011	Treatment of myelofibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
ciprofloxacin		6/1/2011	The management of bronchiectasis	Designated	Not FDA Approved for Orphan Indication	Savara Inc.
mitomycin		6/1/2011	Prevention of corneal sub-epithelial haze formation following surface ablation laser keratectomy	Designated	Not FDA Approved for Orphan Indication	"Mobius Therapeutics, LLC"
adeno-associated virus vector serotype 9 expressing human sulfamidase		6/1/2011	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).	Designated	Not FDA Approved for Orphan Indication	"Esteve Pharmaceuticals, S.A."
humanized IgG1 monoclonal anti-CD20 antibody		5/26/2011	Treatment of follicular lymphoma	Designated	Not FDA Approved for Orphan Indication	"MENTRIK Biotech, LLC"
recombinant human erythropoietin (rHuEPO)		5/26/2011	Treatment of mutliple myeloma	Designated	Not FDA Approved for Orphan Indication	"XTL Biopharmaceuticals, Ltd"
everolimus		5/24/2011	Treatment of gastric cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corp.
camostat		5/18/2011	Treatment of chronic pancreatitis	Designated	Not FDA Approved for Orphan Indication	NIXS Corporation
"recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)"		5/17/2011	Treatment of pancreatic cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
adalimumab	Humira	5/11/2011	Treatment of pediatric patients with ulcerative colitis	Designated/Approved		"AbbVie, Inc."
human Hepatocarcinoma-Intestine-pancreas/pancreatitis associated protein		5/11/2011	Treatment of acute liver failure	Designated	Not FDA Approved for Orphan Indication	Vivo Bioscience Company Limited
human umbilical tissue derived cells (hUTC)		5/10/2011	Treatment of amyotrophic lateral sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
acadesine		5/4/2011	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Advancell-Advanced In Vitro Cell Technologies S.A.
Humanized monoclonal antibody to TumorEndothelial Marker-1		4/29/2011	Treatment of soft tissue sarcoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Eisai Inc.
immune globulin intravenous (human)	Gammaplex	4/29/2011	Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia)	Designated/Approved		Bio Products Laboratory
ferumoxytol		4/29/2011	For use in MR imaging for the mangement of brain tumors	Designated	Not FDA Approved for Orphan Indication	Covis Pharma GmbH
sobetirome		4/29/2011	Treatment of X-linked adrenoleukodystrophy	Designated	Not FDA Approved for Orphan Indication	"Naftali Kaminski, MD"
humanized monoclonal antibody to tissue factor		4/26/2011	Treatment of pancreatic cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Morphotek, Inc."
levothyroxine sodium		4/26/2011	The preservation of organ function in brain-dead organ donors.	Designated	Not FDA Approved for Orphan Indication	"Fera Pharmaceuticals, LLC"
metronidazole		4/26/2011	Treatment of pouchitis	Designated	Not FDA Approved for Orphan Indication	S.L.A. Pharma Limited (UK)
"clarithromycin, rifabutin, clofazimine"		4/26/2011	Treatment of pediatric Crohn's disease.	Designated	Not FDA Approved for Orphan Indication	RedHill Biopharma Ltd.
rose bengal disodium		4/18/2011	Treatment of hepatocellular carcinoma.	Designated	Not FDA Approved for Orphan Indication	"Provectus BioPharmaceuticals, Inc."
perillyl alcohol		4/18/2011	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"NeOnc Technologies, Inc."
abeotaxane inhibitor of microtubules		4/18/2011	Treatment of pediatric neuroblastoma.	Designated	Not FDA Approved for Orphan Indication	Cortice Biosciences
"5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride"		4/18/2011	Treatment of progressive supranuclear palsy.	Designated	Not FDA Approved for Orphan Indication	"Mithridion, Inc."
Recombinant humanized anti-LOXL2 monoclonal antibody		4/18/2011	Treatment of idiopathic pulmonary fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
DNA plasmid encoding the acetylcholine receptor		4/18/2011	Treatment of myasthenia gravis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bayhill Therapeutics
recombinant IgA protease of bacterium Heamophilus influenzae		4/18/2011	"Treatment of immunoglobulin A nephropathy (IgAN, Berger's disease)."	Designated	Not FDA Approved for Orphan Indication	Shire Human Genetics Therapies
peptide YY		4/18/2011	Treatment of hepatocellular carcinoma.	Designated	Not FDA Approved for Orphan Indication	Mondobiotech Laboratories AG
firtecan pegol		4/18/2011	Treatment of neuroblastoma.	Designated	Not FDA Approved for Orphan Indication	"Enzon Pharmaceuticals, Inc."
etirinotecan pegol		4/18/2011	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	Nektar Therapeutics
Aldoxorubicin		4/18/2011	Treatment of adenocarcinoma of the pancreas.	Designated	Not FDA Approved for Orphan Indication	"NantCell, Inc."
Tissue Plasminogen activator		4/18/2011	Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.	Designated	Not FDA Approved for Orphan Indication	"Catherine Amlie-Lefond, MD"
"Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-?-aspararginyl-4-aminobutanoyl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-L-lysyl]amino]ethoxy]ethoxy]ethoxy]ethyl]-2,3-di-O-methyl-6-O-sulfo-?-D-glucopyranosyl-(1?4)-O-2,3-di-O-methyl-?-D-glucopyranuronosyl-(1?4)-O-2,3,6-tri-O-sulfo- ?-D-glucopyranosyl-(1?4)-O-2,3-di-O-methyl- ?-L-idopyranuronosyl-(1?4)-3-O"		4/18/2011	Prevention of ischemia reperfusion injury associated wth solid organ transplantation	Designated	Not FDA Approved for Orphan Indication	Endotis Pharma
nusinersen	Spinraza	4/18/2011	Treatment of spinal muscular atrophy	Designated/Approved		"Biogen, Inc"
lonafarnib	ZOKINVY	4/18/2011	Treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies	Designated/Approved		"Eiger BioPharmaceuticals, Inc."
bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine		4/18/2011	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Gradalis, Inc."
(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt		4/15/2011	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Company
selective deacylglycerol acyltransferase 1 inhibitor		3/28/2011	"Treatment of hypertriglyceridemia in the setting of Type I hyperlipoproteinemia, also known as Familial Chylomicronemia Syndrome"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
lenalidomide		3/28/2011	Treatment of diffuse large B-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide"		3/18/2011	Treatment of chronic myelogenous leukemia.	Designated	Not FDA Approved for Orphan Indication	NATCO Pharma Limited
"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide"		3/18/2011	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	NATCO Pharma Limited
"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamideNRC-AN-019"		3/18/2011	Treatment of Glioma	Designated	Not FDA Approved for Orphan Indication	NATCO Pharma Limited
crenolanib		3/18/2011	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"AROG Pharmaceuticals, LLC"
rigosertib		3/18/2011	Treatment of pancreatic cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Onconova Therapeutics, Inc"
acetyl-l-carnitine (ALC)		3/18/2011	Treatment of Rett syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Leadiant Biosciences, Inc."
brivanib alaninate		3/18/2011	Treatment of hepatocellular carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb
FTV1+GDP-fucose		3/18/2011	To improve homing to bone (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.	Designated	Not FDA Approved for Orphan Indication	"America Stem Cell, Inc."
Heat Shock Protein 70		3/18/2011	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"ALS Biopharma, LLC"
picibanil		3/17/2011	Treatment of lymphatic malformations	Designated	Not FDA Approved for Orphan Indication	Protara Therapeutics Inc.
hydralazine - magnesium valproate		3/17/2011	Treatment of cutaneous T-cell lymphoma.	Designated	Not FDA Approved for Orphan Indication	Neolpharma S.A.DE C.V.
hydralazine - magnesium valproate		3/17/2011	Treatment of myelodysplastic syndrome	Designated	Not FDA Approved for Orphan Indication	Neolpharma S.A.DE C.V.
adeno associated viral vector containing human ARSB gene		3/17/2011	Treatment of mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome)	Designated	Not FDA Approved for Orphan Indication	Fondazione Telethon
menatetrenone		3/17/2011	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"NBI Pharmaceuticals, Inc."
"Sar9, Met(O2)11-Substance P"		3/16/2011	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	New Amsterdam Sciences
talimogene laherparepvec	IMLYGIC	3/14/2011	Treatment of stage IIb-stage IV melanoma	Designated/Approved		"BioVex, Inc. (subsidiary of Amgen)"
coenzyme Q10 and d-alpha-tocopherol		3/14/2011	Treatment of Friedreich's Ataxia.	Designated	Not FDA Approved for Orphan Indication	"NBI Pharmaceuticals, Inc."
eicosapentaenoic acid		3/8/2011	Treatment of familial adenomatous polyposis	Designated	Not FDA Approved for Orphan Indication	S.L.A. Pharma Ltd. (UK)
acadesine		3/3/2011	Treatment of chronic lymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	"Avanced In Vitro Cell Technologies, S.L."
lomitapide		3/3/2011	Treatment of Familial Chylomicronemia	Designated	Not FDA Approved for Orphan Indication	Chiesi Farmaceutici S.p.A.
sodium thiosulfate		3/3/2011	Treatment of sulfur mustard poisoning	Designated	Not FDA Approved for Orphan Indication	Hope Pharmaceuticals
Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase		3/3/2011	"Treatment of myeloproliferative disorders (polycythemia vera, essential throbocythemia, and myelofibrosis)"	Designated	Not FDA Approved for Orphan Indication	Eli Lilly and Company
pyridoxine; vitamin B6		3/3/2011	Treatment of pyridoxine dependent seizures.	Designated	Not FDA Approved for Orphan Indication	"NBI Pharmaceuticals, Inc."
"ombrabulin; N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethozyphenyl)vinyl]phenyl}-L-serinamide hydrochloride"		3/3/2011	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	"Sanofi-Aventis U.S., Inc."
Revimmune		2/18/2011	Treatment of autoimmune hemolytic anemia.	Designated	Not FDA Approved for Orphan Indication	Accentia Biopharmaceuticals
murine monoclonal antibody against CD26		2/18/2011	Treatment of graft versus host disease	Designated	Not FDA Approved for Orphan Indication	ADIENNE S.A.
ixazomib citrate	Ninlaro	2/18/2011	Treatment of multiple myeloma	Designated/Approved		"Takeda Development Center Americas, Inc."
oral potent and selective antagonist		2/18/2011	Treatment of patients with chondrosarcoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Infinity Pharmaceuticals, Inc."
met-enkephalin; Met-N		2/18/2011	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"NBI Pharmaceuticals, Inc."
human interleukin-3 genetically conjugated to diphtheria toxin protein		2/18/2011	Treatment of acute myeloid leukemia.	Designated	Not FDA Approved for Orphan Indication	"Stemline Therapeutics, Inc."
acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cysteinyl-D-arginyl-D-arginyl-D-lysyl-Dasparaginylamide disulfide		2/18/2011	Treatment of pancreatic cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genus Oncology, LLC"
S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light		2/14/2011	Treatment of thrombotic thrombocytopenic purpura	Designated	Not FDA Approved for Orphan Indication	Cerus Corporation
human heterologous liver cells		2/14/2011	Treatment of urea cycle disorders	Designated	Not FDA Approved for Orphan Indication	Promethera Biosciences
MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)		2/4/2011	Treatment of Myelodysplastic syndrome	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)		2/4/2011	Treatment of acute myelogenous leukemia.	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
eflornithine		2/4/2011	Treatment of Familial Adenomatous Polyposis	Designated	Not FDA Approved for Orphan Indication	"Panbela Therapeutics, Inc."
inhibitor of microRNA-451		2/4/2011	Treatment of polycythemia vera	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"miRagen Therapeutics, Inc."
recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel beta subunit (rAAV-CNGB3)		2/4/2011	Treatment of achromatopsia caused by mutations in the CNGB3 gene.	Designated	Not FDA Approved for Orphan Indication	Beacon Therapeutics
mesenchymal stromal cells secreting neurotrophic factors		2/4/2011	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	BrainStorm Cell Therapeutics Ltd.
menatetrenone		2/4/2011	Treatment of myelodysplastic syndrome.	Designated	Not FDA Approved for Orphan Indication	"NBI Pharmaceuticals, Inc."
D-peptide		2/4/2011	Treatment of acute myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	"Immune System Key, Ltd"
thymopentin		2/4/2011	Treatment of sarcoidosis.	Designated	Not FDA Approved for Orphan Indication	Mondobiotech Laboratories AG
human spinal cord derived neural stem cells		2/4/2011	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"Seneca Biopharma, Inc."
"N-{[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide"		2/4/2011	Treatment of tuberculosis.	Designated	Not FDA Approved for Orphan Indication	"Sequella, Inc."
peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis		2/4/2011	Treatment of myasthenia gravis	Designated	Not FDA Approved for Orphan Indication	CuraVac Europe SA
monoclonal antibody		1/21/2011	Prevention of congential cytomegalovirus (CMV)infection following primary CMV infection in pregnant women.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Theraclone Sciences
iduvec		1/21/2011	Treatment of Mucopolysaccharidosis Type I	Designated	Not FDA Approved for Orphan Indication	Zebraic Corporation
fluticasone propionate		1/19/2011	Treatment of pediatric and adult eosinophilic esophagitis	Designated	Not FDA Approved for Orphan Indication	Ellodi Pharmaceuticals
mitomycin		1/13/2011	Prevention of recurrence of pterygium after its surgical excision.	Designated	Not FDA Approved for Orphan Indication	"Mobius Therapeutics, LLC"
"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride"		1/12/2011	Treatment of acute myeloid leukemia (AML).	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"EMD Serono, Inc."
reslizumab		1/12/2011	Treatment of hypereosinophilic syndrome	Designated	Not FDA Approved for Orphan Indication	"Teva Respiratory, LLC"
glioma derived cell lysates and irradiated cells		1/12/2011	Treatment of glioma.	Designated	Not FDA Approved for Orphan Indication	Epitopoietic Research Corp.
"anti-TCR murine monoclonal antibody (MAB, type IgM)"		1/12/2011	Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age	Designated	Not FDA Approved for Orphan Indication	"Tolera Therapeutics, Inc."
vocimagene amiretrorepvec and flucytosine		1/12/2011	Treatment of malignant glioma in addition to glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	"Tocagen, Inc."
"L-amino acids, vitamins and minerals combined with omega-3 fatty acids"		1/12/2011	Treatment of patients with pediatric Crohn's disease	Designated	Not FDA Approved for Orphan Indication	"Immunopath Profile, Inc."
dabrafenib	TAFINLAR	1/12/2011	Treatment BRAF V600 mutation positive Stage IIB through IV melanoma	Designated/Approved		Novartis Pharmaceuticals Corp.
regorafenib	Stivarga	1/12/2011	Treatment gastrointestinal stromal tumors	Designated/Approved		"Bayer HealthCare Pharmaceuticals, Inc."
cridanimod		1/12/2011	Treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.	Designated	Not FDA Approved for Orphan Indication	"Xenetic Biosciences, Inc."
ricin vaccine		1/7/2011	Prevention of ricin intoxication.	Designated	Not FDA Approved for Orphan Indication	"Soligenix, Inc."
4-[131I]iodo-L-phenylalanine		1/4/2011	Treatment of glioma.	Designated	Not FDA Approved for Orphan Indication	Telix Pharmaceuticals (US) Inc.
bortezomib		1/4/2011	Treatment of follicular non-Hodgkin lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Millennium Pharmaceuticals, Inc."
tranilast		12/23/2010	Prevention of scarring following glaucoma filtration surgery	Designated	Not FDA Approved for Orphan Indication	Esperante Development B.V.
GVAX melanoma		12/23/2010	Treatment of stage IIb to IV melanoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Aduro BioTech, Inc."
ex-vivo expanded autologous bone marrow-derived mesenchymal stem cells		12/20/2010	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"TCA Cellular Therapy, LLC"
Bleomycin		12/20/2010	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	CIRJ Company Ltd.
dinutuximab	Unituxin	12/20/2010	Treatment of neuroblastoma	Designated/Approved		United Therapeutics Corporation
calcium benzoate and risperidone		12/20/2010	Treatment of pediatric patients with schizophrenia	Designated	Not FDA Approved for Orphan Indication	"University of California, Los Angeles"
trametinib	MEKINIST	12/20/2010	Treatment of Stage IIb through Stage IV melanoma	Designated/Approved		Novartis Pharmaceuticals Corp.
crenolanib besylate		12/20/2010	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"AROG Pharmaceuticals, LLC"
denosumab	Xgeva	12/20/2010	Treatment of patients with giant cell tumor of bone	Designated/Approved		"Amgen, Inc."
live attenuated E. Coli expressing Beta catenin shRNA		12/20/2010	Treatment of Familial Adenomatous Polyposis	Designated	Not FDA Approved for Orphan Indication	Marina Biotech
vemurafenib	Zelboraf	12/20/2010	Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation	Designated/Approved		"Hoffmann-La Roche, Inc."
NDX-peptides		12/14/2010	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	NeoDiagnostic Research Ltd
cediranib		12/13/2010	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	National Institutes of Health
acyclovir	Avaclyr	12/13/2010	Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2	Designated/Approved		Fera Pharmaceuticals
iferanserin (S-MPEC)		12/13/2010	For use in pulmonary arterial hypertension.	Designated	Not FDA Approved for Orphan Indication	"Sam Amer & Company, Inc."
Dermagraft		12/13/2010	Treatment of epidermolysis bullosa	Designated	Not FDA Approved for Orphan Indication	"Shire Regenerative Medicine, Inc."
lithium citrate tetrahydrate (in reverse micelle formulation)		12/13/2010	Treatment of Huntington's disease.	Designated	Not FDA Approved for Orphan Indication	Medesis Pharma
DNA plasmid vector expressing eIF5Ak50		12/13/2010	Treatment of multiple myeloma.	Designated	Not FDA Approved for Orphan Indication	"Senesco Technologies, Inc."
recombinant thymidine phosphorylase encapsulated with autologous erythrocytes		12/13/2010	Treatment of mitochondrial neurogastrointestinal encephalomyopathydue to thymidine phosphorylase deficiency.	Designated	Not FDA Approved for Orphan Indication	St. George's University of London
fidaxomicin	Dificid	12/13/2010	Treatment of pediatric Clostridium difficile infection	Designated/Approved		"Cubist Pharmaceuticals LLC, a subsidiary of Merck Sharp & Dohme LLC"
zuretinol acetate		12/2/2010	Treatment of inherited retinal dystrophies caused by confirmed biallelic RPE65 or LRAT mutations	Designated	Not FDA Approved for Orphan Indication	"Eluminex Biosciences, Inc."
"allogeneic cord blood cells, ex vivo modulated with 16,16 dimethyl prostaglandin E2 (dmPGE2)"		12/2/2010	"Enhancement of stem cell engraftment through ex vivo treatment of human allogeneic hematopoietic stem cells (treatment of neuropenia, thrombocytopenia, lymphopenia, and anemia)."	Designated	Not FDA Approved for Orphan Indication	"Fate Therapeutics, Inc."
sodium thiosulfate		12/2/2010	Treatment of extravasation of meclorethamine hydrochloride into subcutaneous tissues.	Designated	Not FDA Approved for Orphan Indication	Hope Pharmaceuticals
zuretinol acetate		12/2/2010	Treatment of retinitis pigmentosa	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Retinagenix LLC
ustekinumab		11/29/2010	Treatment of type 1 diabetes mellitus patients with residual beta-cell function.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Johnson & Johnson Pharmaceutical & Development LLC
cabozantinib	Cometriq	11/29/2010	"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer."	Designated/Approved		"Exelixis, Inc."
filociclovir		11/29/2010	Treatment of active cytomegalovirus infections	Designated	Not FDA Approved for Orphan Indication	"Microbiotix, Inc."
maytansinoid DM1-conjugated humanized monoclonal antibody N901		11/29/2010	Treatment of multiple myeloma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ImmunoGen, Inc."
cabozantinib	Cabometyx	11/29/2010	"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer."	Designated/Approved		"Exelixis, Inc."
sodium dichloroacetate		11/29/2010	For pulmonary arterial hypertension.	Designated	Not FDA Approved for Orphan Indication	"Peter W. Stackpoole, PhD, MD"
bevacizumab	Avastin	11/23/2010	Treatment of fallopian tube carcinoma	Designated/Approved		"Genentech, Inc."
bevacizumab	Avastin	11/23/2010	Treatment of fallopian tube carcinoma	Designated/Approved		"Genentech, Inc."
recombinant von Willebrand factor (rhVWF)	Vonvendi	11/23/2010	Treatment of von Willebrand disease	Designated/Approved		"Takeda Pharmaceuticals USA, Inc."
recombinant kallikrein inhibitor		11/23/2010	Treatment of Netherton Syndrome.	Designated	Not FDA Approved for Orphan Indication	Dermadis SA
"antihemophilic factor (recombinant), Fc fusion protein"	Eloctate	11/23/2010	Treatment of hemophilia A	Designated/Approved		"Bioverativ Therapeutics, Inc."
recombinant von Willebrand factor (rhVWF)		11/23/2010	Treatment of von Willebrand disease	Designated/Approved		"Takeda Pharmaceuticals USA, Inc."
naloxone		11/23/2010	Topical treatment of pruritus associated with mycosis fungoides	Designated	Not FDA Approved for Orphan Indication	"Elorac, Inc."
bevacizumab	Avastin	11/23/2010	Treatment of fallopian tube carcinoma	Designated/Approved		"Genentech, Inc."
entolimod		11/23/2010	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Designated	Not FDA Approved for Orphan Indication	"Statera BioPharma, Inc."
cyclosporine; ciclosporin		11/23/2010	Treatment of moderate to severe traumatic brain injury.	Designated	Not FDA Approved for Orphan Indication	Owl Therapeutics
recombinant von Willebrand factor (rhVWF)		11/23/2010	Treatment of von Willebrand disease	Designated/Approved		"Takeda Pharmaceuticals USA, Inc."
ganitumab		11/23/2010	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"NantCell, Inc., a wholly-owned subsidiary of ImmunityBio, Inc."
eflornithine		11/23/2010	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	Cancer Prevention Pharmaceuticals
gabapentin	Gralise	11/8/2010	Management of postherpetic neuralgia	Designated/Approved		Golf Acquiror LLC
menatetrenone		11/2/2010	Treatment of acute promyelocytic leukemia.	Designated	Not FDA Approved for Orphan Indication	"NBI Pharmaceuticals, Inc."
bevacizumab	Avastin	11/2/2010	Treatment of primary peritoneal carcinoma.	Designated/Approved		"Genentech, Inc."
bevacizumab	Avastin	11/2/2010	Treatment of primary peritoneal carcinoma.	Designated/Approved		"Genentech, Inc."
mogamulizumab		11/2/2010	Treatment of peripheral T-cell lymphoma.	Designated	Not FDA Approved for Orphan Indication	"Kyowa Kirin Pharmaceutical Development, Inc."
mogamulizumab	POTELIGEO	11/2/2010	Treatment of patients with cutaneous T-cell lymphoma.	Designated/Approved		Kyowa Kirin Pharmaceutical Development Inc.
menatetrenone		11/2/2010	Treatment of hepatocellular carcinoma (HCC).	Designated	Not FDA Approved for Orphan Indication	"NBI Pharmaceuticals, Inc."
bevacizumab	Avastin	11/2/2010	Treatment of primary peritoneal carcinoma.	Designated/Approved		"Genentech, Inc."
4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide		11/2/2010	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	Apogee Biotechnology Corporation
trientine hydrochloride		11/2/2010	Treatment of manganism	Designated	Not FDA Approved for Orphan Indication	"Cerberus Princeton, LLC"
"Phosphatidylinositol 3-Kinase ""PI3K"" Inhibitor"		11/2/2010	Treatment of chronic lymphocytic leukemia (CLL)	Designated	Not FDA Approved for Orphan Indication	Semafore Pharmaceuticals
chloropyramine		10/22/2010	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"CurFAKtor Pharmaceuticals, LLC"
Lucinactant		10/21/2010	Treatment of cystic fibrosis.	Designated	Not FDA Approved for Orphan Indication	Lee’s Pharmaceutical (HK) Limited
pegylated carboxyhemoglobin		10/21/2010	Treatment of acute painful sickling crises in patients with sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"Sangart, Inc."
bevacizumab		10/21/2010	Treatment of hereditary hemorrhagic telangiectasia	Designated	Not FDA Approved for Orphan Indication	"Terence M. Davidson, MD"
ensituximab		10/21/2010	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"Neogenix Oncology, Inc."
fresolimumab		10/21/2010	Treatment of primary focal segmental glomerulosclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genzyme, a Sanofi Company"
BCL-005 (fused (hybrid) melanoma-dendritic cells)		10/21/2010	Treatment of stage IIb to IV melanoma in HLA-A2 positive patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Brucells SA
algenpantucel-L		10/21/2010	Treatment of pancreatic cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	NewLink Genetics Corporation
alpha-tocotrienol quinone		10/21/2010	Treatment of inherited mitochondrial respiratory chain diseases	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
human monoclonal anti-PA antibody		10/21/2010	For post-exposure prophylaxis and treatment of inhalation anthrax.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Emergent Product Development Gaithersburg, Inc."
"5-((4-(6-chlorothieno[2,3-d]pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile monofumurate"		10/21/2010	Treatment of pulmonary arterial hypertension	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Forest Laboratories, Inc."
N-acetylcysteine		10/21/2010	Treatment of apnea of prematurity	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Galleon Pharmaceuticals
"(S)-10-[(dimethylamino)methyl]-4-ethyl-9hydroxy-4-O-[a-(2"",4"",5"",7""-tetranitro-9""-fluorenylideneaminooxy)propionyl]- 1H-pyrano[3',4',6',7',] indolizino [1,2-B]-quinoline-3, 14-(4H, 12H)-dione, hydrochloride"		10/6/2010	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"TLC Biopharmaceuticals, Inc."
ecopipam hydrochloride		9/29/2010	Treatment of pediatric patients with Tourette's syndrome.	Designated	Not FDA Approved for Orphan Indication	"Emalex Biosciences, Inc."
somatrogon-ghla	Ngenla	9/29/2010	Treatment of growth hormone deficiency	Designated/Approved		Pfizer Ireland Pharmaceuticals
moxidectin		9/29/2010	Treatment of onchocerciasis volvulus in children and adults	Designated/Approved		Medicines Development Limited
tecovirimat		9/29/2010	Treatment of orthopoxvirus infections.	Designated	Not FDA Approved for Orphan Indication	"SIGA Technologies, Inc."
pomalidomide		9/21/2010	Treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell tranfusion dependent.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene Corporation
"2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione"		9/21/2010	Treatment of idiopathic pulmonary fibrosis.	Designated	Not FDA Approved for Orphan Indication	Calliditas Therapeutics Suisse SA
acyclovir		9/16/2010	Treatment of herpetic keratitis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	GlaxoSmithKline
everolimus		9/16/2010	Treatment of Waldenstrom macroglobulinemia (also known as lymphoplasmacytic lymphoma)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corp.
unoprostone isopropyl		9/16/2010	Treatment of retinitis pigmentosa	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"R-Tech Ueno, Ltd."
C20-D3-retinyl acetate		9/16/2010	Treatment of Stargardt's disease	Designated	Not FDA Approved for Orphan Indication	"Alkeus pharmaceuticals, Inc."
deflazacort		9/16/2010	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	University of Rochester Medical Center
adeno-associated viral vector containing modified U11 snRNA		9/15/2010	Treatment of Duchenne muscular dystrophy.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	uniQure Inc.
Peptide that inhibits mechanosensitive ion channel (MSC) activity		9/15/2010	Treatment of Duchenne Muscular Dystrophy (DMD.)	Designated	Not FDA Approved for Orphan Indication	Rose Pharmaceuticals
amphotericin B		9/15/2010	Treatment of visceral leishmaniasis.	Designated	Not FDA Approved for Orphan Indication	iCo Therapeutics Inc.
"(1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride"		9/15/2010	Treatment of infantile spasms	Designated	Not FDA Approved for Orphan Indication	"Catalyst Pharmaceuticals, Inc."
Multistem		9/15/2010	Prophylaxis of graft vs host disease	Designated	Not FDA Approved for Orphan Indication	"Athersys, Inc."
Autologous dendritic cells pulsed with recombinant human fusion protein (mucin1- glutathione S transferase) coupled to oxidized polymannose		9/13/2010	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	Prima Biomed Ltd.
Darinaparsin		9/13/2010	Treatment of peripheral T-cell lymphoma.	Designated	Not FDA Approved for Orphan Indication	Solasia Pharma K.K.
rozrolimupab		9/13/2010	Treatment of primary immune thrombocytopenia.	Designated	Not FDA Approved for Orphan Indication	Symphogen A/S
crizotinib	Xalkori	9/13/2010	"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer"	Designated/Approved		"Pfizer, Inc."
pentamidine		9/13/2010	Treatment of pancreatic cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Oncozyme Pharma, Inc."
crizotinib	Xalkori	9/13/2010	"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer"	Designated/Approved		"Pfizer, Inc."
crizotinib	Xalkori	9/13/2010	"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer"	Designated/Approved		"Pfizer, Inc."
dichlorphenamide		9/2/2010	Treatment of primary periodic paralyses	Designated/Approved		"Xeris Pharmaceuticals, Inc."
alpha melanotropin		9/2/2010	Treatment of chronic beryllium disease	Designated	Not FDA Approved for Orphan Indication	mondoBIOTECH Laboratories AG
recombinant human lecithin:cholesterol acyltransferase (rhLCAT)		9/2/2010	Treatment of familial lecithin-cholesterol acyltransferase deficiency (FLD).	Designated	Not FDA Approved for Orphan Indication	MedImmune
Epitalon		9/2/2010	Treatment of retinitis pigmentosa	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	BioDiem Ltd
mexiletine		9/2/2010	Treatment of nondystrophic myotonia	Designated	Not FDA Approved for Orphan Indication	University of Rochester Medical Center
mycobacterium vaccae		8/20/2010	Treatment of tuberculosis	Designated	Not FDA Approved for Orphan Indication	Immodulon Therapeutics Ltd
reveglucosidase alfa		8/20/2010	Treatment of Pompe disease.	Designated	Not FDA Approved for Orphan Indication	"BioMarin Pharmaceutical, Inc."
raloxifene hydrochloride		8/20/2010	Treatment of hereditary hemorrhagic telangiectasia	Designated	Not FDA Approved for Orphan Indication	Consejo Superior de Investigaciones Cientificas
anakinra	Kineret	8/19/2010	Treatment of cryopyrin-associated periodic syndromes	Designated/Approved		Swedish Orphan Biovitrum AB (publ)
Maytansinoid DM-1 Conjugated Humanized Monoclonal Antibody N901		8/17/2010	Treatment of small cell lung cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ImmunoGen, Inc."
Glutathione pegylated liposomal doxorubicin hydrochloride		8/16/2010	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	to-BBB technologies BV
14-amino acid peptide derived from wound growth factor		8/16/2010	Treatment of delayed graft function in renal transplant recipients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	NephRx Corporation
ActRIIB-IgG1)		8/16/2010	Treatment of Duchenne muscular dystrophy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Acceleron Pharma, Inc."
ublituximab		8/6/2010	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"TG Therapeutics, Inc."
mycobacterium vaccae		8/6/2010	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Immodulon Therapeutics Ltd.
recombinant human platelet derived growth factor-BB		8/6/2010	Treatment of osteochondritis dissecans	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Biomimetic Therapeutics, Inc."
Double-stranded DNA plasmid carrying the gene for the diphtheria toxin A (DT-A) chain		8/6/2010	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"BioCancell Therapeutics USA, Inc."
14-amino acid peptide derived from wound growth factor		8/5/2010	Prevention of delayed graft function in renal transplant recipients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	NephRx Corporation
octreotide		8/5/2010	Treatment of neuroendocrine tumors	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
momelotinib	Ojjaara	8/5/2010	Treatment of myelofibrosis	Designated/Approved		GlaxoSmithKline
nifurtimox	LAMPIT	8/5/2010	Treatment of Chagas disease (American Typanosomiasis)caused by T. cruzi	Designated/Approved		"Bayer HealthCare Pharmaceuticals, Inc."
humanized monoclonal antibody against human integrin alphaVbeta6		8/5/2010	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"Biogen Idec, Inc."
gevokizumab		7/27/2010	Treatment of Behcet's disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	XOMA (US) LLC
perifosine		7/9/2010	Treatment of neuroblastoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Aeterna Zentaris GmbH
sebelipase alfa	Kanuma	7/1/2010	Treatment of lysosomal acid lipase deficiency	Designated/Approved		Alexion Pharmaceuticals
1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine		6/24/2010	Treatment of acute myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	Cyclacel Limited
1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine		6/24/2010	Treatment of myelodysplastic syndrome	Designated	Not FDA Approved for Orphan Indication	Cyclacel Limited
octreotide (oral)	MYCAPSSA (formerly Octreolin)	6/17/2010	For the oral treatment of acromegaly	Designated/Approved		"Chiesi USA, Inc."
glycopyrrolate 2%		6/17/2010	Treatment of Frey's syndrome	Designated	Not FDA Approved for Orphan Indication	"Wellesley Therapeutics, Inc."
dasiprotimut-T		6/17/2010	Treatment of mantle cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Biovest International, Inc."
treprostinil inhalation solution	Tyvaso	6/17/2010	Treatment of pulmonary arterial hypertension	Designated/Approved		United Therapeutics Corporation
treprostinil inhalation powder	Tyvaso DPI	6/17/2010	Treatment of pulmonary arterial hypertension	Designated/Approved		United Therapeutics Corporation
angiotensin 1-7		6/17/2010	"To accelerate engraftment of hematopoietic cells (treatment of neutropenia, thrombocytopenia, lymphoma, and aneima)in hematopoietic stem cell transplants."	Designated	Not FDA Approved for Orphan Indication	"Tarix Pharmaceuticals, Ltd."
recombinant human vascular endothelial growth factor		6/7/2010	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	NeuroNova AB
bosentan		6/7/2010	Reduction of the number (treatment) of new digital ulcers in patients with systemic sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Actelion Ltd.
"dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2,TRP-2, gp100 and interleukin-13 receptor alpha"		6/7/2010	Treatment of glioblastoma or brain stem glioma	Designated	Not FDA Approved for Orphan Indication	ImmunoCellular Therapeutics Ltd.
human plasminogen		6/7/2010	Treatment of ligneous conjunctivitis	Designated	Not FDA Approved for Orphan Indication	"Kedrion, S.p.A."
"anti-TCR murine monoclonal antibody (MAb, type IgM)"		6/7/2010	Treatment of patients 16 years of age and younger with immune-mediated T1DM and preserved pancreatic beta cell function	Designated	Not FDA Approved for Orphan Indication	"Tolera Therapeutics, Inc."
anti-thymocyte globulin [rabbit]		5/25/2010	Prophylaxis of acute organ rejection in patients receiving renal transplants	Designated	Not FDA Approved for Orphan Indication	Genzyme Corporation
refanalin		5/25/2010	To improve renal function and prevent delayed graft function following renal transplantation	Designated	Not FDA Approved for Orphan Indication	Angion Biomedica Corporation
Bone marrow-derived mononuclear cells		5/17/2010	Treatment of thromboangiitis obliterans (Buerger's disease)	Designated	Not FDA Approved for Orphan Indication	t2cure GmbH
telatinib		5/17/2010	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	ACT Biotech Inc.
N-(6-2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide		5/17/2010	Treatment of Friedreich's ataxia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Repligen Corporation
pitolisant	WAKIX®	5/17/2010	Treatment of narcolepsy	Designated/Approved		"Harmony Biosciences, LLC"
pitolisant	Wakix	5/17/2010	Treatment of narcolepsy	Designated/Approved		"Harmony Biosciences, LLC"
budesonide	Tarpeyo	5/17/2010	To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.	Designated/Approved		Calliditas Therapeutics AB
budesonide	Tarpeyo	5/17/2010	To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.	Designated/Approved		Calliditas Therapeutics AB
lentiviral vector containing the human MY07A gene		5/17/2010	Treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.	Designated	Not FDA Approved for Orphan Indication	Sanofi US Services Inc.
Hydroxy-Propyl-Beta-Cyclodextrin		5/17/2010	"Treatment of Niemann Pick Disease, Type C"	Designated	Not FDA Approved for Orphan Indication	"Cyclo Therapeutics, Inc."
Pitolisant	WAKIX	5/17/2010	Treatment of narcolepsy	Designated/Approved		"Harmony Biosciences, LLC"
pralatrexate		5/3/2010	Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder	Designated	Not FDA Approved for Orphan Indication	Acrotech Biopharma LLC
selexipag	Uptravi	4/30/2010	Treatment of pulmonary arterial hypertension	Designated/Approved		Actelion Pharmaceuticals Ltd
niraparib	Zejula	4/30/2010	Treatment of ovarian cancer	Designated/Approved		"GlaxoSmithKline, LLC."
Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)		4/30/2010	Treatment of Wiskott Aldrich syndrome	Designated	Not FDA Approved for Orphan Indication	Fondazione Telethon ETS
tasimelteon	Hetlioz LQ	4/30/2010	Treatment of sleep disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion	Designated/Approved		"Vanda Pharmaceuticals, Inc."
Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines		4/30/2010	Treatment of chronic myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Aduro BioTech, Inc."
midostaurin	Rydapt	4/30/2010	Treatment of mastocytosis	Designated/Approved		Novartis Pharmaceuticals Corporation
niraparib	Zejula	4/30/2010	Treatment of ovarian cancer	Designated/Approved		"GlaxoSmithKline, LLC."
cinacalcet	Sensipar	4/30/2010	"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery"	Designated/Approved		"Amgen, Inc."
cinacalcet	Sensipar	4/30/2010	"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery"	Designated/Approved		"Amgen, Inc."
denileukin diftitox		4/30/2010	Treatment of peripheral T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Eisai, Inc."
"superoxide dismutase, gliadin"		4/30/2010	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Verius Limited
levetiracetam		4/30/2010	Treatment of neonatal seizures	Designated	Not FDA Approved for Orphan Indication	University of California
Liposomal Glutathione		4/30/2010	Support of glutathione deficiency in individuals with inborn errors of metabolism of glutathione (IEMG)	Designated	Not FDA Approved for Orphan Indication	"Your Energy Systems, LLC"
Glyeraldehyde-3-phosphate dehydrogenase		4/30/2010	Treatment of pediatric multiple sclerosis	Designated	Not FDA Approved for Orphan Indication	"BPT Pharmaceuticals, Inc."
Cintredekin Besudotox		4/30/2010	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"Insys Development Company, Inc."
auranofin		4/30/2010	Treatment of amebiasis	Designated	Not FDA Approved for Orphan Indication	Ctr for Discovery & Innovation in Parasitic Diseas
lentiviral vector containing the human ABCA4 gene		4/30/2010	Treatment of Stargardt disease	Designated	Not FDA Approved for Orphan Indication	Sanofi US Services Inc.
Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)		4/30/2010	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	Ortho Biotech
"3,4 diaminopyridine and choline bitartrate"		4/30/2010	Treatment of Lambert-Eaton myasthenic syndrome	Designated	Not FDA Approved for Orphan Indication	MS Therapeutics Limited
selexipag	Uptravi	4/30/2010	Treatment of pulmonary arterial hypertension	Designated/Approved		Actelion Pharmaceuticals Ltd
niraparib	Zejula	4/30/2010	Treatment of ovarian cancer	Designated/Approved		"GlaxoSmithKline, LLC."
ex-vivo cultered adult human mesenchymal stem cells		4/30/2010	Treatment of Type 1 diabetes patients with residual beta cell function	Designated	Not FDA Approved for Orphan Indication	"Mesoblast, Inc."
tasimelteon	Hetlioz	4/30/2010	Treatment of sleep disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion	Designated/Approved		"Vanda Pharmaceuticals, Inc."
AEZS-108 (LHRH-agonist linked to doxorubicin)		4/30/2010	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Aeterna Zentaris
fingolimod		4/30/2010	Treatment of chronic inflammatory demyelinating polyneuropathy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceutical Corporation
imatinib		4/7/2010	Treatment of pulmonary arterial hypertension	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis
Fenretinide		4/7/2010	Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients	Designated	Not FDA Approved for Orphan Indication	McGill University
L-ornithine phenylacetate		4/7/2010	Treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disase	Designated	Not FDA Approved for Orphan Indication	"Ocera Therapeutics LLC, a Mallinckrodt Pharmaceuticals Company"
N-Acetylmannosamine (ManNAc)		4/5/2010	Treatment of GNE Myopathy (Hereditary Inclusion Body Myopathy Type 2)	Designated	Not FDA Approved for Orphan Indication	"Leadiant Biosciences, Inc."
Emapalumab-lzsg	GAMIFANT™	3/26/2010	Treatment of hemophagocytic lymphohistiocytosis	Designated/Approved		Swedish Orphan Biovitrum AB
Water-miscible vitamin A palmitate		3/26/2010	Prevention of bronchopulmonary dysplasia.	Designated	Not FDA Approved for Orphan Indication	"Fox Pharma, Inc."
secukinumab		3/26/2010	Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceutical Corporation
reversal agent linked to chloroquine-like moiety		3/26/2010	Treatment of malaria	Designated	Not FDA Approved for Orphan Indication	DesignMedix
GNE plasmid(H001)		3/26/2010	Treatment of hereditary inclusion body myopathy type 2	Designated	Not FDA Approved for Orphan Indication	HIBM Research Group
ruxolitinib	Jakafi	3/26/2010	Treatment of polycythemia vera	Designated/Approved		Incyte Corporation
"anti-T-lymphocyte immune globulin, rabbit"		3/26/2010	Prevention of graft versus host disease (GVHD)	Designated	Not FDA Approved for Orphan Indication	Neovii Biotech GmbH
taurine		3/22/2010	Treatment of cystathionine beta-synthase deficient homocystinuria	Designated	Not FDA Approved for Orphan Indication	"Johan L. Van Hove, MD, PhD"
ruxolitinib phosphate		3/22/2010	Treatment of essential thrombocythemia	Designated	Not FDA Approved for Orphan Indication	Incyte Corporation
Recombinant Human soluble Fc-gamma Receptor IIb		3/22/2010	Treatment of idiopathic thrombocytopenic purpura	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Baxalta US Inc., now part of Shire Plc"
chenodiol		3/22/2010	Treatment of cerebrotendinous xanthomatosis	Designated	Not FDA Approved for Orphan Indication	"Mirum Pharmaceuticals, Inc."
Recombinant human glutamic acid decarboxylase 65KDa isoform		3/22/2010	Treatment of Type I diabetes with residual beta cell function	Designated	Not FDA Approved for Orphan Indication	Diamyd Therapeutics AB
tirasemtiv		3/2/2010	Treatment of amyotrophic lateral sclerosis (ALS)	Designated	Not FDA Approved for Orphan Indication	Cytokinetics Inc.
maytansinoid DM1-conjugated humanized monoclonal antibody N901		3/2/2010	Treatment of Merkel cell carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ImmunoGen, Inc."
immune globulin (human)		3/2/2010	Treatment of Guillain-Barre syndrome	Designated	Not FDA Approved for Orphan Indication	"Octapharma USA, Inc."
"3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid"		3/2/2010	Treatment of cystic fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Vertex Pharmaceuticals Inc.
Replication-incompetent GM-CSF-expressing gene-modified allogeneic acute myeloid leukemia cancer cell lines		3/2/2010	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Aduro BioTech, Inc."
Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines		3/1/2010	Treatment of pancreatic cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Aduro BioTech, Inc."
allogeneic hematopoietic stem cell		2/2/2010	"Prevention (reduction) of transplant related mortality (TRM, which is caused by graft versus host disease and/or infections) following mismatched (haploidentical) allogeneic hematopoietic stem cell transplantation."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Kiadis Pharma Netherlands B.V.
patupilone		2/2/2010	Treatment of primary pertitoneal cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
ciprofloxacin DPI		2/2/2010	Management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bayer HealthCare Pharmaceuticals, Inc."
MA09-hRPE cells		2/2/2010	Treatment of Stargardt's macular dystrophy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Astellas Pharma Global Development Inc.
patupilone		2/2/2010	Treatment of primary fallopian tube cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
allogeneic ex vivo expanded unbilical cord blood cells		2/1/2010	For use as hematopoietic support in patients with myelodysplastic syndromes	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Gamida Cell - Teva Joint Venture
mPEG-r-crisantaspase		2/1/2010	Treatment of acute lymphoblastic leukemia.	Designated	Not FDA Approved for Orphan Indication	"Jazz Pharmaceuticals, Inc."
allogeneic ex vivo expanded umbilical cord blood cells		2/1/2010	For use as hematopoietic support in patients with chronic myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Gamida Cell - Teva Joint Venture
pimasertib		1/29/2010	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"EMD Serono, Inc."
Inhibitor of Tissue Factor Pathway Inhibitor (TFPI)		1/29/2010	Treatment of hemophilia A and hemophilia B.	Designated	Not FDA Approved for Orphan Indication	"Baxter Healthcare Corporation, Baxter BioScience"
angiotensin 1-7		1/29/2010	Treatment of sarcoma.	Designated	Not FDA Approved for Orphan Indication	"W. Jeffrey Petty, MD"
alpha1 proteinase inhibitor (human)		1/29/2010	Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.	Designated	Not FDA Approved for Orphan Indication	"Grifols Therapeutics, Inc."
2-(2-phenylvinyl)-4-[-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt		1/29/2010	Treatment of acute myeloid leukemia.	Designated	Not FDA Approved for Orphan Indication	"EntreMed, Inc."
17 amino acid peptide		1/29/2010	Prevention of ischemia reperfusion injury in the lung during lung tranplantation	Designated	Not FDA Approved for Orphan Indication	Apeptico Forschung und Entwicklung GmbH (APEPTICO)
2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate		1/19/2010	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals LP
tasimelteon	HETLIOZ	1/19/2010	Non-24-hour sleepwake disorder in blind individuals without light perception	Designated/Approved		"Vanda Pharmaceuticals, Inc."
"(1S, 2S, 3R, 4R)-3-(5-Fluoro-2-(3-methyl-4-(4-methylpiperazin-1-yl)-phenylamino)-pyrimidin-4-ylamino)bicycle[2.2.1]hept-5-ene-2-carboxamide benzoate"		1/19/2010	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"EMD Serono, Inc."
naltrexone		1/19/2010	Treatment of Crohn's disease in pediatric patients	Designated	Not FDA Approved for Orphan Indication	"Statera BioPharma, Inc."
poloxamer-188 NF		1/19/2010	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	"Phrixus Pharmaceuticals, Inc."
sodium phenylbutyrate		1/19/2010	Treatment of urea cycle disorder.	Designated	Not FDA Approved for Orphan Indication	Navinta LLC
"cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2,'4'-trioxaspiro[4.5] decane mesylate"		1/19/2010	"Treatment of malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae"	Designated	Not FDA Approved for Orphan Indication	Medicines for Malaria Venture (MMV)
amitriptyline and ketamine		1/19/2010	Treatment of postherpetic neuralgia	Designated	Not FDA Approved for Orphan Indication	"Immune Pharmaceuicals, Inc."
mesalamine		1/19/2010	Treatment of pediatric ulcerative colitis	Designated	Not FDA Approved for Orphan Indication	AbbVie Inc.
L-asparaginase encapsulated in red blood cells		1/6/2010	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	Erytech Pharma
human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa		1/6/2010	Treatment of pneumonia caused by serotype O1 positive Pseudomonas aeruginosa	Designated	Not FDA Approved for Orphan Indication	Kenta Biotech Limited
ambrisentan		12/23/2009	Treatment of idiopathic pulmonary fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
Teprasiran		12/23/2009	Prophylaxis of delayed graft function in renal transplant patients	Designated	Not FDA Approved for Orphan Indication	"Quark Pharmaceuticals, Inc."
brilliant blue G		12/16/2009	For use in ophthalmic surgery to aid in the removal of the inner limiting membrane of the eye.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Fluoron GmbH
burosumab-twza	Crysvita	12/14/2009	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	Designated/Approved		"Kyowa Kirin, Inc."
burosumab-twza	Crysvita	12/14/2009	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	Designated/Approved		"Kyowa Kirin, Inc."
afamelanotide		12/11/2009	Treatment of solar urticaria	Designated	Not FDA Approved for Orphan Indication	"Clinuvel, Inc."
monoclonal antibody 11-1F4		12/11/2009	For use as a therapeutic agent for patients AL amyloidosis.	Designated	Not FDA Approved for Orphan Indication	"Caelum Biosciences, Inc."
octreotide acetate subcutaneous implant		12/7/2009	Treatment of acromegaly	Designated	Not FDA Approved for Orphan Indication	"Endo Pharmaceuticals Solutions, Inc."
6-mercaptopurine oral liquid		12/7/2009	Treatment of acute lymphoblastic leukemia in the pediatric population	Designated	Not FDA Approved for Orphan Indication	Orbona Pharma Ltd
selisistat		12/7/2009	Treatment of Huntington's disease	Designated	Not FDA Approved for Orphan Indication	AOP Orphan Pharmaceuticals AG
monoclonal antibody 11-1F4		12/7/2009	For use as a radioimmaging agent in amyloidosis	Designated	Not FDA Approved for Orphan Indication	"Caelum Biosciences, Inc."
davunetide		12/7/2009	Treatment of progressive supranuclear palsy.	Designated	Not FDA Approved for Orphan Indication	"Allon Therapeutics, Inc."
"5'-O-(trans-9""-octadecenoyl)-1-beta-D-2'deoxy-2',2'-difluorocytidine"		12/7/2009	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Clovis Oncology, Inc."
complement factor H		12/7/2009	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	LFB Biotechnologies S.A.
pegsitacase		12/3/2009	Treatment of Lesch-Nyhan syndrome.	Designated	Not FDA Approved for Orphan Indication	Swedish Orphan Biovitrum AB
inebilizumab		12/3/2009	Treatment of scleroderma	Designated	Not FDA Approved for Orphan Indication	Viela Bio
late stage human motor neutron progenitors		11/25/2009	Treatment of spinal muscular atrophy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Caladrius Biosciences
nevirapine		11/25/2009	Prevention of HIV infection in pediatric patients under the age of 16 years	Designated	Not FDA Approved for Orphan Indication	Auritec Pharmaceuticals
ponatinib	Iclusig	11/20/2009	Treatment of chronic myeloid leukemia	Designated/Approved		ARIAD Pharmaceuticals Inc.
veliparib		11/20/2009	Treatment of hepatocellular carcinoma in combination with DNA-damaging agents	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
ponatinib	Iclusig	11/20/2009	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)	Designated/Approved		"Takeda Pharmaceuticals U.S.A., Inc."
bevacizumab		11/20/2009	In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
ponatinib	Iclusig	11/20/2009	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)	Designated/Approved		"Takeda Pharmaceuticals U.S.A., Inc."
1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea		11/12/2009	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Astex Therapeutics Ltd
amifampridine	Firdapse	11/12/2009	Treatment of Lambert-Eaton Myasthenic Syndrome	Designated/Approved		"Catalyst Pharmaceuticals, Inc."
amifampridine	Firdapse	11/12/2009	Treatment of Lambert-Eaton Myasthenic Syndrome	Designated/Approved		"Catalyst Pharmaceuticals, Inc."
fosdenopterin	Nulibry	11/5/2009	Treatment of molybdenum cofactor deficiency type A (MoCD)	Designated/Approved		"Origin Biosciences, Inc."
Exon 44 specific phosphorothioate oligonucleotide		11/5/2009	Treatment of Duchenne Muscular Dystrophy in patients who have a mutation correctable by skipping of exon 44of the dystrophin gene.	Designated	Not FDA Approved for Orphan Indication	"BioMarin Pharmaceutical, Inc."
Hypothiocyanite and lactoferrin		11/5/2009	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	Alaxia Biotechnologies Sante
Varbulin		11/5/2009	Treatment of glioblastoma multiforme.	Designated	Not FDA Approved for Orphan Indication	"Myrexis, Inc."
salmeterol xinafoate/fluticasone propionate		10/29/2009	Treatment of symptomatic exophthalmos associated with thyroid related eye disease	Designated	Not FDA Approved for Orphan Indication	"Lithera, Inc."
caprine hyperimmune serum against HIV lysate		10/28/2009	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Aimsco Ltd.
sodium stibogluconate		10/28/2009	Treatment of cutaneous leishmaniasis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Surgeon General of the US Army
dasiprotimut-T		10/28/2009	Treatment of follicular lymphoma	Designated	Not FDA Approved for Orphan Indication	"Biovest International, Inc."
diannexin		10/28/2009	Prevention of ischemia-reperfusion injury in solid organ transplants	Designated	Not FDA Approved for Orphan Indication	"Astellas Pharma Global Development, Inc."
vosaroxin		10/28/2009	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Sunesis Pharmaceuticals, Inc."
golnerminogene pradenovec		10/28/2009	Treatment of pancreatic cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"GenVec, Inc."
pazopanib	Votrient	10/20/2009	Treatment of soft tissue sarcomas	Designated/Approved		Novartis Pharmaceuticals Corp
midazolam	NAYZILAM	10/20/2009	"Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)"	Designated/Approved		"UCB, Inc."
low molecular weight dextran sulfate		10/20/2009	Prevention of graft rejection during pancreatic islet transplantation	Designated	Not FDA Approved for Orphan Indication	TikoMed AB
"S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinly-GNNDESNISFKEK"		10/20/2009	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	MBiotec GmBH
Recombinant fusion protein-extracellular portion of CD95 fused to the Fc part of human IgG1		10/13/2009	Treatment of glioblastoma multiforme	Designated	Not FDA Approved for Orphan Indication	Apogenix GmbH
bevacizumab		10/13/2009	Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
"4-benzyl-2-(a-naphtyl)-1,2,4-thiadiazolidine-3,5-dione"		10/13/2009	Treatment of progressive supranuclear palsy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"NOSCIRA, S.A."
trastuzumab	Herceptin	10/13/2009	"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction"	Designated/Approved		"Genentech, Inc."
human tumor necrosis factor coupled to the C terminus of CNGRCG peptide		10/1/2009	Treatment of liver cancer	Designated	Not FDA Approved for Orphan Indication	Molecular Medicine S.p.A. (Molmed)
Paclitaxel protein-bound particles for injection suspension		10/1/2009	Treatment of stage IIb to IV melanoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene Corporation
panobinostat		9/18/2009	Treatment of Hodgkin's lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser		9/18/2009	Prevention of delayed graft function following renal transplant	Designated	Not FDA Approved for Orphan Indication	"Araim Pharmaceuticals, Inc."
netazepide		9/10/2009	Treatment of gastric carcinoids	Designated	Not FDA Approved for Orphan Indication	Trio Medicines Ltd.
mesalamine and N-acetycysteine		9/10/2009	Treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years)	Designated	Not FDA Approved for Orphan Indication	"Altheus Therapeutics, Inc."
Nucleic acid aptamer binding to tumor cell nucleolin		9/10/2009	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Antisoma, Inc."
cethromycin		9/9/2009	Prophylactic treatment of plague due to Yersinia pestis	Designated	Not FDA Approved for Orphan Indication	"Advanced Life Sciences, Inc."
cethromycin		9/9/2009	Prophylactic treatment of tularemia due to Francisella tularensis.	Designated	Not FDA Approved for Orphan Indication	"Advanced Life Sciences, Inc."
lestaurtinib		9/3/2009	Treatment of Philadelphia-negative classic myeloproliferative disorders	Designated	Not FDA Approved for Orphan Indication	"Teva Branded Pharmaceutical Products R&D, Inc."
idursulfase IT		9/3/2009	For treatment of neurocognitive symptoms associated with Hunter Syndrome	Designated	Not FDA Approved for Orphan Indication	"Takeda Pharmaceuticals U.S.A., Inc."
Rebastinib		9/3/2009	Treatment of Philadelphia chromosome positive chronic myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Deciphera Pharmaceuticals, LLC"
gylceryl tri (4-pheynlybutyrate)		9/3/2009	For intermittent or chronic treatment of patients with cirrhosis and any grade hepatic encephalopathy.	Designated	Not FDA Approved for Orphan Indication	Horizon Therapeutics
progesterone		9/3/2009	For early intervention in the treatment of moderate to severe closed-head traumatic brain injury	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"BHR Pharma, LLC"
peptide-conjugated phosporodiamidate morpholino oligomer (PPMO)		9/3/2009	"Treatment of Duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 5"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sarepta Therapeutics, Inc."
anthrax immune globulin		9/3/2009	Treatment of inhalation anthrax disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Emergent Biosolutions, Inc."
rigosertib		9/3/2009	Treatment of myelodysplastic syndromes	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Onconova Therapeutics, Inc."
tasisulam sodium		9/3/2009	Treatment of melanoma stages IIB through IV	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Eli Lilly and Company
perifosine		9/3/2009	Treatment of multiple myeloma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Aeterna Zentaris GmbH
sodium nitrite		9/3/2009	Prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation	Designated	Not FDA Approved for Orphan Indication	Hope Pharmaceuticals
"8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naph-thyrin-3(2H)-one mono-hydrochloride"		9/3/2009	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	Merck Sharp & Dohme LLC
veliparib		9/3/2009	Treatment of epithelial ovarian cancer in combination with DNA-damaging agents	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
Taliglucerase alfa	ELELYSO for injection	9/3/2009	Treatment of Gaucher's disease	Designated/Approved		"Pfizer, Inc."
paclitaxel protein-bound particles	Abraxane	9/3/2009	Treatment of pancreatic cancer.	Designated/Approved		"Abraxis BioScience, LLC"
uridine triacetate		9/3/2009	Treatment of mitchondrial disease	Designated	Not FDA Approved for Orphan Indication	"Pharma Cinq, LLC"
macitentan	Opsumit	9/3/2009	Treatment of pulmonary arterial hypertension	Designated/Approved		Actelion Pharmaceuticals Ltd
Belinostat	Beleodaq	9/3/2009	Treatment of peripheral T-cell lymphoma (PTCL).	Designated/Approved		Acrotech Biopharma LLC
autologus CD34+ cells transfected with retroviral vector containing adenosine deaminase gene		8/26/2009	Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency.	Designated	Not FDA Approved for Orphan Indication	Fondazione Telethon ETS
liposomal amikacin		8/25/2009	Treatment of bronchiectasis in patients with Pseudomonas aeruginosa or other susceptible microbial pathogens	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Insmed, Inc."
pasireotide		8/25/2009	Treatment of acromegaly	Designated/Approved		Novartis Pharmaceuticals Corporation
doxorubicin		8/25/2009	Treatment of hepatocellular carcinoma.	Designated	Not FDA Approved for Orphan Indication	"Delcath Systems, Inc."
Exon 51 specific phosphorothioate oligonucleotide		8/25/2009	Treatment of Duchenne Muscular Dystrophy.	Designated	Not FDA Approved for Orphan Indication	"BioMarin Pharmaceutical, Inc."
recombinant adeno-associated virus encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP)		8/25/2009	Treatment of Huntington's disease.	Designated	Not FDA Approved for Orphan Indication	"Neurologix, Inc."
"5-[1-(2,6-Dichlorobenzyl)-piperidin-4-yl]methoxyquinazoline-2,4-diamine"		8/25/2009	Treatment of spinal muscular atrophy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	CureSMA
mibefradil		8/25/2009	Treatment of glioblastoma multiforme.	Designated	Not FDA Approved for Orphan Indication	"Cavion, LLC"
methotrexate		8/20/2009	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	Orbona Pharma Ltd
Recombinant antibody construct against human CD30 and CD16A		8/20/2009	Treatment of Hodgkin lymphoma	Designated	Not FDA Approved for Orphan Indication	Affimed GmbH
DNA plasmid expressing diphtheria toxin triggered by the presence of oncofetal gen H19		8/20/2009	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"BioCancell Therapeutics USA, Inc."
expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS		8/20/2009	Treatment of Dystrophic Epidermolysis Bullosa.	Designated	Not FDA Approved for Orphan Indication	Intercytex Ltd.
Anti-EphA1 monoclonal antibody conjugated to mcMMAF		7/27/2009	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"MedImmune, LLC"
"beclomethasone 17,21-dipropionate"		7/24/2009	Treatment of gastrointestinal symptoms with chronic graft versed host disease in patients undergoing allogenic hematopoietic cell transplantation	Designated	Not FDA Approved for Orphan Indication	"Soligenix, Inc."
pasireotide	Signifor	7/24/2009	Treatment of Cushing's disease	Designated/Approved		Novartis Pharmaceuticals Corporation
pasireotide	Signifor	7/24/2009	Treatment of Cushing's disease	Designated/Approved		Novartis Pharmaceuticals Corporation
ecopipam hydrochloride		7/21/2009	Symptomatic treatment of self injurious behaviors in patients with Lesch-Nyhan disease.	Designated	Not FDA Approved for Orphan Indication	"Emalex Biosciences, Inc."
trabedersen		7/21/2009	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	Oncotelic Inc.
masitinib		7/21/2009	Treatment of patients with pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	AB Science
anti-nogo-A monoclonal antibody		7/7/2009	Treatment of amyotrophic lateral sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	GlaxoSmithKline
midostaurin	Rydapt	7/7/2009	Treatment of acute myeloid leukemia	Designated/Approved		Novartis Pharmaceuticals Corporation
Gastrin 17C Diphtheria Toxoid Immunogen		7/7/2009	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Astrimmune Ltd.
tetrabenazine		7/1/2009	"Treatment of Tourette's Syndrome in school-age children, ages 5-16"	Designated	Not FDA Approved for Orphan Indication	Valeant International (Barbados) SRL
catumaxomab		7/1/2009	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	"Neoviibiotech North America, Inc."
velaglucerase-alfa	VPRIV	6/8/2009	Treatment of Gaucher disease	Designated/Approved		"Takeda Development Center Americas, Inc."
pertuzumab		6/8/2009	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
everolimus	Afinitor	6/8/2009	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	Designated/Approved		Novartis Pharmaceuticals Corp.
everolimus	Afinitor	6/8/2009	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	Designated/Approved		Novartis Pharmaceuticals Corp.
everolimus	Afinitor	6/8/2009	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	Designated/Approved		Novartis Pharmaceuticals Corp.
pentagastrin		5/29/2009	To aid in the diagnosis of medullary thyroid carcinoma	Designated	Not FDA Approved for Orphan Indication	AOP Orphan IP AG
lapatinib ditosylate hydrochloride		5/29/2009	Treatment of ErbB2 positive esophageal cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corp.
lapatinib		5/29/2009	Treatment of ErbB2 positive gastric cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corp.
astuprotimut-R		5/29/2009	Treatment of MAGE-A3 positive stages IIb to IV malignant melanoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"GlaxoSmithKline Biologicals, S.A."
astuprotimut-R		5/29/2009	Treatment of MAGE-A3 positive non-small cell lung cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"GlaxoSmithKline Biologicals, S.A."
ranagengliotucel-L		5/29/2009	Treatment of astrocytic tumors	Designated	Not FDA Approved for Orphan Indication	NovaRx Corporation
"Sterile Bicarbonate Infusate, Hemofiltration, Hemodiafiltration, and Hemopdialysis Solution"		5/29/2009	For use as a replacement solution in adults and children during Continous Renal Replacement Therapy	Designated	Not FDA Approved for Orphan Indication	"Nikkiso America, Inc."
capsaicin	Qutenza	5/22/2009	Management of neuropathic pain in patients with postherpetic neuralgia	Designated/Approved		"Averitas Pharma, Inc."
melphalan hydrochloride		5/22/2009	Treatment of neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	"Delcath Systems, Inc."
idebenone		5/22/2009	"Treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (MELAS)"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Santhera Pharmaceuticals (Switzerland) Ltd.
Fedratinib	INREBIC	5/18/2009	Treatment of secondary and primary myelofibrosis	Designated/Approved		"Impact Biomedicines, Inc. a wholly-owned subsidiary of Celgene Corporation"
tenecteplase		5/15/2009	Restore function to hemodialysis catheters	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
aztreonam		5/15/2009	Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
elosulfase alfa	Vimizim	5/15/2009	Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome)	Designated/Approved		BioMarin Pharmaceutical Inc.
picibanil		5/15/2009	Treatment of patients with lymphatic malformations	Designated	Not FDA Approved for Orphan Indication	"Royds Pharmaceuticals, Inc."
S-nitrosoglutathione		5/12/2009	Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function	Designated	Not FDA Approved for Orphan Indication	"N30 PHARMAceuticals, LLC"
dimebon		5/12/2009	Treatment of Huntington's Disease.	Designated	Not FDA Approved for Orphan Indication	"Medivation, Inc."
ascorbic acid		5/11/2009	Treatment of Charcot-Marie-Tooth disease type 1A.	Designated	Not FDA Approved for Orphan Indication	Murigenetics SAS
liposomal cyclosporine		5/11/2009	Treatment of bronchiolitis obliterans	Designated	Not FDA Approved for Orphan Indication	Zambon S.p.A.
Recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65		5/11/2009	Treatment of Leber's congential amaurosis	Designated	Not FDA Approved for Orphan Indication	AmpliPhi Biosciences Corporation
tobramycin liposomal		5/11/2009	Treatment of pulmonary infection due to Burkholderia cepacia complex pathogens in cystic fibrosis patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Axentis Pharma AG
paclitaxel		5/1/2009	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"SynCore Biotechnology Co., Ltd."
uridine triacetate		5/1/2009	An antidote in the treatment of 5-fluorouracil or capecitabine poisoning	Designated/Approved		BTG International Inc.
eculizumab	Soliris	4/29/2009	Treatment of atypical hemolytic uremic syndrome	Designated/Approved		"Alexion Pharmaceuticals, Inc."
Antihemophilic factor (recombinant) formulated with sucrose reconstituted with liposome diluent		4/29/2009	Treatment of hemophilia A	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bayer HealthCare LLC
lenalidomide	Revlimid	4/27/2009	Treatment of mantle cell lymphoma	Designated/Approved		Celgene Corporation
Antisense oligonucleotide directed against connexin43		4/27/2009	Treatment of persistent corneal epithelial defects	Designated	Not FDA Approved for Orphan Indication	Glaukos Corporation
purified bovine type collagen		4/27/2009	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	Magnolia Therapeutics LLC
glycerol phenylbutyrate	RAVICTI	4/27/2009	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	Designated/Approved		"Horizon Pharma USA, INc."
glycerol phenylbutyrate	RAVICTI	4/27/2009	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	Designated/Approved		"Horizon Pharma USA, INc."
"4,6,8-trihydroxy-10-(3,7,11-trimethyldodeca-2,6,10-trienyl)-5,10-dihydrodibenzo b,e][1,4]diazepin-11-one"		4/27/2009	Treatment of malignant glioma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Thallion Pharmaceuticals, Inc."
D-mannitol and L-proline		4/20/2009	Treatment of Cockayne syndrome	Designated	Not FDA Approved for Orphan Indication	DNage B.V.
Caplacizumab	CABLIVI	4/14/2009	Treatment of thrombotic thrombocytopenic purpura	Designated/Approved		"Ablynx, a wholly owned subsidiary of Sanofi Group"
macitentan		4/14/2009	Treatment of idiopathic pulmonary fibrosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Actelion Pharmaceuticals Ltd
tobramycin liposomal for inhalation		4/14/2009	Treatment of chronic pulmonary infection due to P. aeruginosa in cystic fibrosis patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Axentis Pharma AG
oncophage		4/14/2009	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"Agenus, Inc."
"sodium 4-{ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-d] [2] benzazepin-2-yl]-2-methoxybenzoate"		4/3/2009	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Millennium Pharmaceuticals, Inc."
"paclitaxel, micellar"		4/3/2009	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Elevar Therapeutics, Inc."
Allogeneic human aortic endothelial cells cultured in a porcine gelatin matrix		4/3/2009	Prevention of arteriovenous fistula or arteriovenous graft failure in patients with end satge renal disease receiving hemodialysis or preparing for hemodialysis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Shire
vonapanitase		4/3/2009	Prevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving hemodialysis or preparing for hemodialysis	Designated	Not FDA Approved for Orphan Indication	"Proteon Therapeutics, Inc."
chimeric murine/human IgG1 monoclonal antibody to human interleukin-3 receptor alpha chain		4/3/2009	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	CSl Limited
Anti-T cell receptor murine monoclonal antibody		4/3/2009	Prophylaxis of acute rejection of solid organ transplantation	Designated	Not FDA Approved for Orphan Indication	"Tolera Therapeutics, Inc."
plasmin (human)		3/30/2009	Treatment of acute peripheral arterial occlusion	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Grifols Therapeutics, Inc."
D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-Nh2 (disulfide bridge: 2-6) acetate		3/19/2009	"Treatment of melanoma, stages IIb through IV"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Thallion Pharmaceuticals, Inc."
2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidine L(+) tartrate salt		3/18/2009	Treatment of ovarian carcinoma	Designated	Not FDA Approved for Orphan Indication	"EntreMed, Inc."
miltefosine		3/18/2009	Topical treatment of cutaneous lymphoma encompassing cutaneous manifestations of T-cell lymphoma and B-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	ExperGen Drug Development GmbH
quizartinib	Vanflyta	3/18/2009	Treatment of acute myeloid leukemia	Designated/Approved		"Daiichi Sankyo, Inc."
tenofovir	Viread	3/17/2009	Treatment of pediatric HIV infection.	Designated/Approved		"Gilead Sciences, Inc."
"Technetium Tc99m sulfur colloid injection, lyophilized"	Technetium Tc99m Sulfur Colloi	3/17/2009	For localization of sentinel lymph nodes in patients with melanoma	Designated/Approved		"Pharmalucence, Inc."
lyso-thermosensitive lipsomal doxorubicin		3/17/2009	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Imunon
ofatumumab	ARZERRA	3/10/2009	Treatment of chronic lymphocytic leukemia	Designated/Approved		Novartis Pharmaceuticals Corporation
ofatumumab	ARZERRA	3/10/2009	Treatment of chronic lymphocytic leukemia	Designated/Approved		Novartis Pharmaceuticals Corporation
ofatumumab	ARZERRA	3/10/2009	Treatment of chronic lymphocytic leukemia	Designated/Approved		Novartis Pharmaceuticals Corporation
ofatumumab	ARZERRA	3/10/2009	Treatment of chronic lymphocytic leukemia	Designated/Approved		Novartis Pharmaceuticals Corporation
enzastaurin		3/4/2009	Treatment of diffuse large B-cell lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Denovo Biopharma LLC
beclomethasone		3/4/2009	Treatment of pediatriac patients with ulcerative colitis	Designated	Not FDA Approved for Orphan Indication	"Aptalis Pharma US, Inc."
bosutinib	Bosulif	2/24/2009	Treatment of chronic myelogenous leukemia	Designated/Approved		PF PRISM C.V.
2-iminobiotin		2/24/2009	Treatment of perinatal asphyxia.	Designated	Not FDA Approved for Orphan Indication	Neurophyxia B.V.
bosutinib	Bosulif	2/24/2009	Treatment of chronic myelogenous leukemia	Designated/Approved		PF PRISM C.V.
bosutinib	Bosulif	2/24/2009	Treatment of chronic myelogenous leukemia	Designated/Approved		PF PRISM C.V.
alpha1-proteinase inhibitor (human)		2/20/2009	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	CSL Behring LLC
peptide-based vaccine targeting telomerase reverse transcriptase		2/20/2009	Treatment of telomerase reverse transcriptase (TERT) positive non-small cell lung cancer in HLA-A*0201 positive patients	Designated	Not FDA Approved for Orphan Indication	VAXON-Biotech
cyclosporine		2/17/2009	Treatment of graft-versus-host disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Sigmoid Pharma Limited
talampanel		2/17/2009	Treatment of glioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"TEVA Neuroscience, Inc."
cyclosporine		2/17/2009	Prophylaxis of graft-versus-host disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Sigmoid Pharma Limited
"cholest-4-en-3-one, oxime"		2/17/2009	Treatment of spinal muscular atrophy.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
civamide		2/17/2009	Treatment of postherpetic neuralgia.	Designated	Not FDA Approved for Orphan Indication	"Winston Laboratories, Inc."
"(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-"		2/17/2009	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Designated	Not FDA Approved for Orphan Indication	"GlycoMimetics, Inc."
recombinant human minibody against complement component C5		2/4/2009	Treatment of primary membranoproliferative glomerulonephritis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	ADIENNE S.A.
recombinant human minibody against complement component C5 fused with RGD-motif		2/4/2009	Prevention of ischemia/reperfusion injury associated with solid organ transplantation.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	ADIENNE S.A.
gene encoding chimeric CD40 ligand		2/4/2009	Treatment of chronic lymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	"Memgen, LLC"
"(S)-4,5-dihydro-2[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiaxolecarboxylic acid"		2/4/2009	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Shire Development LLC
HPV-16 cancer therapeutic trojan peptide vaccine		1/12/2009	Treatment of HPV-16 expressing head and neck squamous cell carcinoma.	Designated	Not FDA Approved for Orphan Indication	"Gliknik, Inc."
lutetium Lu 177 dotatate	Lutathera	1/12/2009	Treatment of gastro-entero-pancreatic neuroendocrine tumors	Designated/Approved		Advanced Accelerator Applications
omacetaine mepesuccinate		1/12/2009	Treatment of myelodysplastic syndromes	Designated	Not FDA Approved for Orphan Indication	IVAX International GmbH
lutetium Lu 177 dotatate		1/12/2009	Treatment of gastro-entero-pancreatic neuroendocrine tumors	Designated/Approved		Advanced Accelerator Applications
autologous olfactory neural progenitors		12/31/2008	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"RhinoCyte, Inc."
paclitaxel aqueous gel		12/23/2008	Treatment of brain cancer.	Designated	Not FDA Approved for Orphan Indication	BTG International Inc.
2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt		12/22/2008	Treatment of multiple myeloma.	Designated	Not FDA Approved for Orphan Indication	"EntreMed, Inc."
tesetaxel		12/22/2008	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	Genta Inc.
recombinant human proinsulin (Including rhPI-Methionine)		12/10/2008	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	"ProRetina Therapeutics, S.L."
Tosedostat		12/10/2008	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	CTI BioPharma Corporation
quinine sulfate		12/2/2008	Treatment of malaria excluding Plasmodium faliparum	Designated	Not FDA Approved for Orphan Indication	"Zydus Pharmaceuticals, Inc."
dexamethasone phosphate		12/2/2008	Treatment of corneal graft rejection.	Designated	Not FDA Approved for Orphan Indication	"EyeGate Pharmaceuticals, Inc."
anti-CD30 Fc engineered humanized monoclonal antibody		12/2/2008	Treatment of Hodgkin lymphoma	Designated	Not FDA Approved for Orphan Indication	"Xencor, Inc."
chlorotoxin		12/2/2008	"Treatment of stage IIb, IIc, III & IV melanoma"	Designated	Not FDA Approved for Orphan Indication	Eisai Inc.
fosfomycin/tobramycin		11/28/2008	Treatment of pulmonary infections associated with cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"CURx Pharmaceuticals, Inc."
R-4-amino-3-(4-chlorophenyl)butanoic acid		11/28/2008	Treatment of the behavorial abnormalities associated with fragile X syndrome	Designated	Not FDA Approved for Orphan Indication	"Clinical Research Associates, LLC"
MAGE-A3 cancer therapeutic Trojan peptide vaccine		11/24/2008	Treatment of MAGE-A3 expressing head and neck squamous cell carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gliknik, Inc."
melphalan	EVOMELA	11/24/2008	High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation	Designated/Approved		Acrotech Biopharma LLC
pentosan polysulfate sodium		11/21/2008	Treatment of sickle cell disease.	Designated	Not FDA Approved for Orphan Indication	"TRF Pharma, Inc."
tesetaxel		11/21/2008	"Treatment of stages IIB, IIC, III, and stage IV melanoma"	Designated	Not FDA Approved for Orphan Indication	"Genta, Inc."
"antineoplaston A10, antineoplaston AS2-1"		11/21/2008	Treatment of gliomas	Designated	Not FDA Approved for Orphan Indication	"Burzynski Research Institute, Inc."
GNE Lipoplex		11/13/2008	Treatment of hereditary inclusion body myopathy-2	Designated	Not FDA Approved for Orphan Indication	"Gradalis, Inc."
miglustat		11/12/2008	"Treatment of the neurological manifestations of Niemann-Pick disease,type C."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Actelion Pharmaceuticals Ltd
melphalan	Hepzato	11/12/2008	Treatment of patients with ocular (uveal) melanoma.	Designated/Approved		"Delcath Systems, Inc."
liposomal gadodiamide		11/12/2008	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	"MedGenesis Therapeutix, Inc."
melphalan hydrochloride		11/12/2008	Treatment of patients with cutaneous melanoma.	Designated	Not FDA Approved for Orphan Indication	"Delcath Systems, Inc."
Itraconazole suspension		10/30/2008	Topical treatment of fungal otitis externa (otomycosis)	Designated	Not FDA Approved for Orphan Indication	"Fairfield Clinical Trials, LLC"
liposomal topotecan hydrochloride		10/30/2008	Treatment of gliomas	Designated	Not FDA Approved for Orphan Indication	"MedGenesis Therapeutix, Inc."
stiripentol	Diacomit	10/30/2008	Treatment of Dravet syndrome	Designated/Approved		Biocodex
"4, 5 dibromorhodamine methyl ester"		10/30/2008	Treatment of diffuse large B-cell lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Kiadis Pharma Canada, Inc."
"4, 5 dibromorhodamine methyl ester"		10/30/2008	Treatment of follicular lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Kiadis Pharma Netherlands B.V.
stiripentol	Diacomit	10/30/2008	Treatment of Dravet syndrome	Designated/Approved		Biocodex
"Coagulation factor IX (recombinant), Fc fusion protein"	ALPROLIX	10/30/2008	Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)	Designated/Approved		"Bioverativ Therapeutics, Inc."
brentuximab vedotin	Adcetris	10/23/2008	"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod"	Designated/Approved		Seagen Inc.
brentuximab vedotin	Adcetris	10/23/2008	"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod"	Designated/Approved		Seagen Inc.
Thawed donor matched banked umbilical cord blood enriched by cell sorting to produce a subpopulation expressing high levels of intracellular aldehyde dehydrogenase		10/23/2008	To improve patient outcomes by decreasing time to platlet and neutrophil engraftment in patients with inherited metabolic diseases (IMD) undergoing umbilical cord blood transplantation.	Designated	Not FDA Approved for Orphan Indication	"Aldagen, Inc."
recombinant human histone H1.3; recombinant human N-bis-met-histone H1.3		10/20/2008	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Xenetic Biosciences Plc
pralatrexate		10/20/2008	Treatment of follicular lymphoma	Designated	Not FDA Approved for Orphan Indication	Acrotech Biopharma LLC
anti human Nogo-A human monoclonal antibody		10/20/2008	Treatment of acute spinal cord injury	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
pralatrexate		10/20/2008	Treatment of diffuse large B-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	Acrotech Biopharma LLC
mibefradil		10/16/2008	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"Cavion, LLC"
monoclonal antibody 3F8		10/16/2008	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	United Therapeutics Corporation
cyclosporine A		9/30/2008	Prevention of corneal graft rejection	Designated	Not FDA Approved for Orphan Indication	Santen SAS
epratuzumab		9/30/2008	Treatment of acute lymphoblastic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
Adeno-associated viral vector serotype 5 containing human ABCA4 gene		9/30/2008	Treatment of Stargardt's disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Fondazione Telethon
bosentan		9/30/2008	Treatment of idiopathic pulmonary fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Actelion Pharmaceuticals Ltd
difluprednate	Durezol	9/30/2008	Treatment of endogenous and traumatic anterior uveitis and panuveitis.	Designated/Approved		Alcon Pharmaceuticals. Ltd.
canakinumab	ILARIS	9/30/2008	Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.	Designated/Approved		Novartis Pharmaceuticals Corporation
phosphorothioate antisense olignucleotide against EWS-Fli-1		9/22/2008	Treatment of Ewing's sarcoma	Designated	Not FDA Approved for Orphan Indication	The Cure Our Children Foundation
Full Phosphorothioate Antisense Oligonucleotide against EWS-Fli-1 nanoparticles		9/22/2008	Treatment of Ewing's sarcoma	Designated	Not FDA Approved for Orphan Indication	The Cure Our Children Foundation
metronidazole		9/17/2008	Treatment of pouchitis	Designated	Not FDA Approved for Orphan Indication	Avivia Project BV
[131I]-N-(2-(diethylamino) ethyl-4-(4 flurobenzamido)-5-(iodo)-2-methoxybenzamide		9/17/2008	"Treatment of metastatic melanoma, stages IIB, IIC, III and IV"	Designated	Not FDA Approved for Orphan Indication	"Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)"
eliglustat	CERDELGA	9/17/2008	Treatment of Type I Gaucher disease	Designated/Approved		Genzyme Corporation
"Human Allogeneic HLA-matched, Umbilical Cord Blood Hematopoietic Progenitor Cells Ex Vivo Expanded on Allogeneic Mesenchymal Precursor Cells"		9/12/2008	Treatment of insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with conventional chemotherapy.	Designated	Not FDA Approved for Orphan Indication	"Mesoblast, Inc."
AQ-13 (4-aminoquinoline analog)		9/12/2008	Treatment of malaria	Designated	Not FDA Approved for Orphan Indication	"Immtech Pharmaceuticals, Inc."
Asfotase alfa	Strensiq	9/12/2008	Treatment of hypophosphatasia	Designated/Approved		"Alexion Pharmaceuticals, Inc."
"anti-T-lymphocyte immune globulin, rabbit"		9/12/2008	Prophylaxis of acute allograft rejection in adult recipients in solid organ transplantation	Designated	Not FDA Approved for Orphan Indication	Neovii Biotech GmbH
lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase		9/10/2008	Treatment of mucopolysaccharidosis Type IVA (Morquio Syndrome)	Designated	Not FDA Approved for Orphan Indication	Vivendy Therapeutics LTD
Daunorubicin liposomal		9/5/2008	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Diatos USA, LLC"
ruxolitinib phosphate	Jakafi	9/5/2008	Treatment of myelofibrosis	Designated/Approved		Incyte Corporation
insecticidal toxin derived from Bacillus thuringiensis		9/5/2008	Treatment of soil transmitted helminth infection strongyloidiasis	Designated	Not FDA Approved for Orphan Indication	"University of California, San Diego"
nitric oxide		9/5/2008	Use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises)	Designated	Not FDA Approved for Orphan Indication	Mallinckrodt Pharmaceuticals Ireland Ltd.
propranolol	HEMANGEOL	9/5/2008	Treatment of proliferating infantile hemangiomas requiring systemic therapy	Designated/Approved		Pierre Fabre Dermatologie
veltuzumab		8/28/2008	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
granulocyte macrophage colony stimuling factor		8/27/2008	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	Savara Inc.
"2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl)methylsulfinyl] -1H-benzoimidazole"		8/27/2008	Treatment of hepatocellular carcinoma.	Designated	Not FDA Approved for Orphan Indication	"BioQuant, Inc."
Cytarabine:daunorubicin liposome injection; daunorubicin and cytarabine (liposome); daunorubicin and cytarabine liposome for injection	VYXEOS ; Vyxeos ; Vyxeos	8/22/2008	Treatment of acute myeloid leukemia	Designated/Approved		"Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)"
Seneca Valley virus		8/22/2008	Treatment of neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	"Seneca Therapeutics, Inc."
Cytarabine:daunorubicin liposome injection; daunorubicin and cytarabine (liposome); daunorubicin and cytarabine liposome for injection	VYXEOS ; Vyxeos ; Vyxeos	8/22/2008	Treatment of acute myeloid leukemia	Designated/Approved		"Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)"
glycafilin		8/22/2008	Prevention of delayed graft function after solid organ transplantation	Designated	Not FDA Approved for Orphan Indication	ProtAffin Biotechnologies AG
Arenegyr		8/22/2008	Treatment of malignant pleural mesothelioma	Designated	Not FDA Approved for Orphan Indication	MolMed S.p.A.
cysteamine		8/6/2008	Treatment of neuronal ceroid lipofuscinoses (Batten disease)	Designated	Not FDA Approved for Orphan Indication	"Raptor Pharmaceuticals, Inc."
Bardoxolone		8/6/2008	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Reata Pharmaceuticals, Inc."
deferiprone		7/31/2008	Treatment of Friedreich's ataxia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Chiesi USA, Inc."
Intravenous immune globulin (human) 10%		7/31/2008	Treatment of stiff-person syndrome	Designated	Not FDA Approved for Orphan Indication	"Octapharma USA, Inc."
"4-[1]benzofuro[3,2-d]pyrimidin-4-yl-N-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbothioamide"		7/30/2008	"Treatment, in combination with radiotherapy and temozolomide chemotherapy, of patients with glioblastoma multiforme."	Designated	Not FDA Approved for Orphan Indication	"SuperGen, Inc."
human anti-cellular adhesion molecule-1 monoclonal antibody		7/29/2008	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	BioInvent International AB
anthrax immune globulin (human)		7/29/2008	Treatment of inhalational anthrax	Designated/Approved		Cangene Corp. - Emergent Biosolutions
Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs		7/29/2008	"Prevention of thrombotic thrombocytopenic purpura including its congential, acquired idiopathic and secondary forms."	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
"ADAMTS13, recombinant-krhn"	Adzynma	7/29/2008	"Treatment of thrombotic thrombocytopenic purpura including its congenital, acquired idiopathic, and secondary forms"	Designated/Approved		"Takeda Development Center Americas, Inc."
3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethylnyl)-pyridin-2-yl]-benzonitrile dihydrochloride		7/28/2008	Treatment of behavioral abnormalities associated with fragile X syndrome.	Designated	Not FDA Approved for Orphan Indication	Seaside Therapeutics
sotalol (IV)	So-Aqueous	7/25/2008	"For ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible."	Designated/Approved		AltaThera Pharmaceuticals LLC
metyrosine		7/25/2008	Treatment of velocardiofacial syndrome associated psychosis.	Designated	Not FDA Approved for Orphan Indication	"Cerberus Princeton, LLC"
"sodium 2, 2 dimethylbutyrate"		7/25/2008	Treatment of sickle cell disease.	Designated	Not FDA Approved for Orphan Indication	"HemaQuest Pharmaceuticals, Inc."
crizanlizumab	ADAKVEO	7/22/2008	Treatment of sickle cell disease	Designated/Approved		Novartis Pharmaceuticals Corporation
afamelanotide	SCENESSE®	7/17/2008	Treatment of erythropoietic porphyrias	Designated/Approved		Clinuvel Inc.
polyphenon E		7/17/2008	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Mitsui Norin Co., Ltd"
sodium nitrite		7/8/2008	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	"Airess Pharmaceuticals, Inc."
Mx-dnG1		6/24/2008	Treatment of soft tissue sarcoma	Designated	Not FDA Approved for Orphan Indication	Epeius Biotechnologies Corporation
carbon monoxide		6/24/2008	For use in the reduction of the incidence and severity of delayed graft function in patients undergoing solid organ transplanation.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	INO Therapeutics
cicletanine hydrochloride		6/24/2008	Treatment for pulmonary arterial hypertension.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gilead Sciences, Inc."
retaspimycin hydrochloride		6/24/2008	Treatment of melanoma stages IIb through IV.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals LP
Mx-dnG1		6/24/2008	Treatment of osteosarcoma.	Designated	Not FDA Approved for Orphan Indication	Epeius Biotechnologies Corporation
milatuzumab		6/24/2008	Treatment of chronic lymphocytic leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
vascular endothelial growth factor 165b		6/24/2008	Treatment of advanced melanoma stages IIb through IV.	Designated	Not FDA Approved for Orphan Indication	"PhiloGene, Inc."
cardiotrophin-1		6/24/2008	To protect the liver from ischemia-reperfusion injury inherent to the procedure of transplantation.	Designated	Not FDA Approved for Orphan Indication	"Digna Biotech, S.L."
vincristine sulfate liposomes		6/24/2008	Treatment of metastatic uveal melanoma.	Designated	Not FDA Approved for Orphan Indication	Acrotech Biopharma LLC
Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2		6/24/2008	Treatment of Leber congenital amaurosis due to RPE65 mutations.	Designated	Not FDA Approved for Orphan Indication	"Spark Therapeutics, Inc."
alicaforsen		6/24/2008	Treatment of pouchitis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bensen Therapeutics Limited
omigapil		6/24/2008	Treatment of congenital muscular dystrophy.	Designated	Not FDA Approved for Orphan Indication	Santhera Pharmaceuticals (Switzerland) Limited
liposomal cyclosporine for inhalation		6/24/2008	Prevention of bronchiolitis obliterans.	Designated	Not FDA Approved for Orphan Indication	Zambon S.p.A.
humanized monocloncal antibody against human integrin alphaVbeta6		6/18/2008	Treatment of fibrosis-associated chronic allograft nephropathy in kidney transplant patients.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Stromedix, Inc."
4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]-methyl] tetrahydro-N-hydroxy-2H-pyran-4-carboxamide		6/18/2008	Prophylaxis of organ rejection in patients receiving allogeneic liver transplants	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Conatus Pharmaceuticals, Inc."
bupivacaine		6/18/2008	Relief of persistent pain associated with postherpetic neuralgia	Designated	Not FDA Approved for Orphan Indication	DURECT Corporation
hydrocortisone modified release tabs		6/18/2008	Treatment of adrenal insufficiency	Designated	Not FDA Approved for Orphan Indication	"Shire ViroPharma, Inc."
recombinant human type VII collagen		6/18/2008	Treatment of hereditary dystrophic epidermolysis bullosa (DEB)	Designated	Not FDA Approved for Orphan Indication	"David T. Woodley, MD and Mei Chen, MD"
Azacitidine	ONUREG	6/18/2008	Treatment of acute myeloid leukemia	Designated/Approved		Bristol-Myers Squibb
2 dimethylbutyrate		6/18/2008	Treatment of beta thalassemia	Designated	Not FDA Approved for Orphan Indication	"HemaQuest Pharmaceuticals, Inc."
elacytarabine		6/18/2008	Treatment of acute myeloid leukemia (AML)	Designated	Not FDA Approved for Orphan Indication	Clavis Pharma ASA
cenersen		6/18/2008	Treatment of stage IIB through IV melanoma	Designated	Not FDA Approved for Orphan Indication	"Eleos, Inc."
sulfamidase		5/22/2008	For treatment of Sanfilippo Syndrome (MPS IIIA)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Shire Human Genetic Therapies, Inc."
blinatumomab		5/16/2008	Treatment for hairy cell leukemia.	Designated	Not FDA Approved for Orphan Indication	"Amgen, Inc."
blinatumomab		5/16/2008	Treatment of prolymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	"Amgen, Inc."
Blinatumomab		5/16/2008	Treatment of chronic lymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	"Amgen, Inc."
blinatumomab	Blincyto	5/16/2008	Treatment of acute lymphocytic leukemia	Designated/Approved		"Amgen, Inc."
blinatumomab	Blincyto	5/16/2008	Treatment of acute lymphocytic leukemia	Designated/Approved		"Amgen, Inc."
blinatumomab	Blincyto	5/16/2008	Treatment of acute lymphocytic leukemia	Designated/Approved		"Amgen, Inc."
blinatumomab	Blincyto	5/16/2008	Treatment of acute lymphocytic leukemia	Designated/Approved		"Amgen, Inc."
blinatumomab	Blincyto	5/16/2008	Treatment of acute lymphocytic leukemia	Designated/Approved		"Amgen, Inc."
cysteamine		5/9/2008	Treatment of Huntington's disease	Designated	Not FDA Approved for Orphan Indication	"Horizon Therapeutics USA, Inc."
veliparib		5/9/2008	Treatment of glioblastoma multiforme when used in combination with DNA-damaging agents	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
dimethyl sulfoxide		5/9/2008	For use in combination with antimicrobial drugs for the treatment of drug resistant tuberculosis	Designated	Not FDA Approved for Orphan Indication	"Abela Pharmaceuticals, Inc."
"(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride"		5/5/2008	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
Palifosfamide		5/5/2008	Treatment of soft tissue sarcomas	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ZIOPHARM Oncology, Inc."
ammonium tetrathiomolybdate		5/5/2008	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	"Pipex Pharmaceuticals, Inc."
nabumetone		5/5/2008	Treatment of pediatric juvenile rheumatoid arthritis	Designated	Not FDA Approved for Orphan Indication	Cook Pharma
Valproate		5/5/2008	Treatment of fragile X syndrome	Designated	Not FDA Approved for Orphan Indication	"Neuropharm Ltd,"
eltrombopag	Promacta	5/5/2008	Treatment of idiopathic thrombocytopenia purpura	Designated/Approved		Novartis Pharmaceuticals Corp.
terguride		5/2/2008	Treatment of pulmonary arterial hypertension	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	ErgoNex Pharma GmbH
recombinant human arylsulphatase A		4/11/2008	Treatment of metachromatic leukodystrophy (MLD).	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Shire Human Genetic Therapies
cyclosporine A		4/9/2008	Treatment of herpes simplex virus stromal keratitis	Designated	Not FDA Approved for Orphan Indication	Santen SAS
Anti-von Willebrand Aptamer		4/9/2008	Treatment of thrombotic thrombocytopenic purpura	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Archemix Corporation
obeticholic acid	OCALIVA	4/9/2008	Treatment of primary biliary cirrhosis	Designated/Approved		"Intercept Pharmaceuticals, Inc."
6-alpha-ethylchenodeoxycholic acid		4/9/2008	Treatment of primary sclerosing cholangitis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Intercept Pharmaceuticals, Inc."
sodium nitrite and sodium thiosulfate	Nithiodote	4/9/2008	Treatment of known or suspected cyanide poisoning	Designated/Approved		Hope Pharmaceuticals
peginterferon alfa-2b	Sylatron	4/9/2008	Treatment of malignant melanoma stages IIb through IV.	Designated/Approved		"Merck, Sharpe & Dohme Corp."
"autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5"		4/3/2008	Treatment of chronic graft versus host disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Kiadis Pharma Netherlands B.V.
Alpha1-antitrypsin(human)		4/3/2008	Treatment of bronchiectasis	Designated	Not FDA Approved for Orphan Indication	Kamada Ltd.
bifidobacterium infantis 35624		3/24/2008	Treatment of pediatric ulcerative colitis	Designated	Not FDA Approved for Orphan Indication	Alimentary Health Limited
Human autologous bone-forming cell derived from bone marrow stem cells		3/24/2008	Treatment of osteonecrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bone Therapeutics S.A.
talampanel		3/24/2008	Treatment of amyotrophic lateral sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	TEVA Neuroscience
hepatitis B immune globulin (human)	HepaGam B	3/24/2008	Prevention of hepatitis B recurrence following orthotopic liver transplant	Designated/Approved		Cangene Corporation
"human fibrinogen concentrate, pasteurized"	RiaSTAP	3/13/2008	Treatment of fibrinogen deficient patients.	Designated/Approved		"CSL Behring, LLC"
pacritinib	Vonjo	3/13/2008	"Treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF"	Designated/Approved		CTI BioPharma Corporation
"5-[(E)-2-(4-hydroxyphenyl)-ethenyl] benzene-1,3 diol"		3/13/2008	Treatment of MELAS syndrome	Designated	Not FDA Approved for Orphan Indication	"Sirtris Pharmaceuticals, Inc."
amrubicin		3/10/2008	Treatment of small cell lung cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene Corporation
ataluren		3/10/2008	Treatment of spinal muscular atrophy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
milatuzumab		3/10/2008	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
mesalamine; 5-aminosalicylic acid	Lialda	2/27/2008	Treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).	Designated/Approved		"Takeda Development Center Americas, Inc."
cenersen		2/27/2008	Treatment of chronic lymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	"Eleos, Inc."
N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 Monoclonal Antibody		2/27/2008	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Biotest AG
Levofloxacin		2/27/2008	Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients	Designated	Not FDA Approved for Orphan Indication	"Horizon Therapeutics USA, Inc."
arylsulfatase A (rhASA)		2/27/2008	Treatment of metachromatic leukodystrophy	Designated	Not FDA Approved for Orphan Indication	"Takeda Development Center Americas, Inc."
Manganese superoxide dismutase mimetic		2/27/2008	Prevention of radiation- or chemotherapy-induced oral mucositis in cancer patients	Designated	Not FDA Approved for Orphan Indication	"Galera Therapeutics, LLC"
fish oil triglycerides	Omegaven	2/27/2008	Treatment of parenteral nutrition-associated liver disease	Designated/Approved		"Fresenius Kabi USA, LLC"
belatacept	Nulojix	2/20/2008	Prophylaxis of organ rejection in renal allograft recipients	Designated/Approved		Bristol-Myers Squibb Company
doxorubicin with pluronics F-127 and L-61		2/20/2008	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	"Supratek Pharma, Inc."
everolimus	Afinitor	2/14/2008	Treatment of neuroendocrine tumors	Designated/Approved		Novartis Pharmaceuticals Corp.
Cys-His-Ala-Val-Cys		2/14/2008	"For use in conjunction with melphalen for the treatment of malignant melanoma, AJCC stages IIB, IIC, III and IV"	Designated	Not FDA Approved for Orphan Indication	"Adherex Technologies, Inc."
everolimus	Afinitor	2/14/2008	Treatment of neuroendocrine tumors	Designated/Approved		Novartis Pharmaceuticals Corp.
Type 1 native bovine skin collagen		2/1/2008	Treatment of diffuse systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	"arGentis Pharmaceuticals, LLC"
paclitaxel aqueous gel		2/1/2008	Treatment of esophageal cancer	Designated	Not FDA Approved for Orphan Indication	"BTG International, Inc."
"prothrombin complex concentrate, human-lans"	Balfaxar	2/1/2008	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Designated/Approved		"Octapharma USA, Inc."
N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide		2/1/2008	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Mirati Therapeutics, Inc."
Triheptanoin		2/1/2008	Treatment of glycogen storage disorder II (Pompe disease)	Designated	Not FDA Approved for Orphan Indication	Baylor Research Institute
triciribine		2/1/2008	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"VioQuest Pharmaceuticals, Inc."
Autologous olfactory neural progenitors		2/1/2008	"Treatment of spinal cord injury patients with ASIA Impairment grades A, B, or C"	Designated	Not FDA Approved for Orphan Indication	"RhinoCyte, Inc."
"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol"		2/1/2008	Treatment of Stage IIB through Stage IV malignant melanoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Marshall Edwards, Inc."
pramipexole		1/31/2008	Treatment of Tourette's syndrome in pediatric patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Boehringer-Ingelheim Pharmaceuticals, Inc."
paromomycin sulfate/gentamicin sulfate		1/18/2008	Treatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World)	Designated	Not FDA Approved for Orphan Indication	Appili Therapeutics Inc.
carfilzomib	Kyprolis	1/18/2008	Treatment of multiple myeloma	Designated/Approved		"Onyx Therapeutics, Inc."
carfilzomib	Kyprolis	1/18/2008	Treatment of multiple myeloma	Designated/Approved		"Onyx Therapeutics, Inc."
carfilzomib	Kyprolis	1/18/2008	Treatment of multiple myeloma	Designated/Approved		"Onyx Therapeutics, Inc."
carfilzomib	Kyprolis	1/18/2008	Treatment of multiple myeloma	Designated/Approved		"Onyx Therapeutics, Inc."
IDUA-HIRMAb fusion protein		1/10/2008	Treatment of mucopolysaccharidosis Type 1 (MPS)	Designated	Not FDA Approved for Orphan Indication	"ArmaGen Technologies, Inc."
"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol"		1/10/2008	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Marshall Edwards, Inc."
"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol"		1/10/2008	Treatment of cholangiocarcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Marshall Edwards, Inc."
mitomycin-C	Mitosol	1/8/2008	Treatment of refractory glaucoma as an adjunct to surgery	Designated/Approved		"Mobius Therapeutics, LLC"
Tiotropium bromide		1/8/2008	To improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
recombinant human rod-derived cone viability factor		1/7/2008	Treatment of retinitis pigmentosa	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Fovea Pharmaceuticals
reslizumab		12/19/2007	Treatment of children with eosinophilic esophagitis	Designated	Not FDA Approved for Orphan Indication	"Teva Respiratory, LLC"
Bcl-2 Family Protein Inhibitor		12/19/2007	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	AbbVie Inc.
Alefacept		12/19/2007	For use as prophylaxis of rejection in patients receiving allogenic solid organ transplants.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Astellas Pharma Global Development, Inc."
"(R)-4-(3-morpholin-4-yl-l-phenylsulfanylmenthyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-enylmethyl]-piperazin-l-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride"		12/19/2007	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
coccidioidin SD Skin Test Antigen		12/19/2007	For the diagnosis of Coccidioidomycosis	Designated/Approved		"Allermed Labortories, Inc."
Clonazepam Intranasal Spray		12/19/2007	Treatment of recurrent acute repetitive seizures	Designated	Not FDA Approved for Orphan Indication	"Jazz Pharmaceuticals, Inc."
spherical carbon adsorbent		12/19/2007	Treatment of chronic pouchitis	Designated	Not FDA Approved for Orphan Indication	"Ocera Therapeutics, Inc."
2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimadazole-4-carboxamide		12/18/2007	Treatment of malignant melanoma stages IIb through IV.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
"beclomethasone 17,21-diproprionate"		12/18/2007	Treatment of pediatric patients with Crohn disease.	Designated	Not FDA Approved for Orphan Indication	"Soligenix, Inc."
Elesclomol		12/18/2007	Treatment of metastatic melanoma in combination with paclitaxel	Designated	Not FDA Approved for Orphan Indication	Synta Pharmaceuticals Corporation
Chlorotoxin		12/18/2007	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Eisai Inc.
Hemoximer (pyridoxalated hemoglobin polyoxyethylene)		12/18/2007	Treatment of cardiogenic shock	Designated	Not FDA Approved for Orphan Indication	"Apex Bioscience, Inc."
canakinumab	Ilaris	12/18/2007	Treatment of cryopyrin-associated periodic syndromes	Designated/Approved		Novartis Pharmaceuticals Corporation
Fludarabine phosphate oral tablets		12/18/2007	Treatment of B-cell chronic lymphocytic leukemia	Designated/Approved		"Sanofi-Aventis U.S., Inc."
clobazam	Onfi	12/18/2007	Treatment of Lennox-Gastaut Syndrome	Designated/Approved		"Lundbeck, Inc."
recombinant human antithrombin	ATryn	12/7/2007	"Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures"	Designated/Approved		"GTC Biotherapeutics, Inc."
mecasermin		12/3/2007	Treatment of myotonic dystrophy	Designated	Not FDA Approved for Orphan Indication	"Insmed, Inc."
rindopepimut		11/19/2007	Treatment of EGFRvIII-expressing glioblastoma multiforme	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Celldex Therapeutics, Inc."
varespladib sodium		11/19/2007	Prevention of acute chest syndrome in at-risk patients with sickle cell disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Anthera Pharmaceuticals, Inc."
moxetumomab pasudotox-tdfk	LUMOXITI	11/15/2007	Treatment of hairy cell leukemia	Designated/Approved		AstraZeneca Pharmaceuticals LP
Brivudin		11/15/2007	Adjunct treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"SciClone Pharmaceuticals, Inc."
moxetumomab pasudotox		11/15/2007	Treatment of CD22-positive chronic lymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals LP
glatiramer acetate		11/14/2007	Treatment of amyotrophic lateral sclerosis (ALS).	Designated	Not FDA Approved for Orphan Indication	"Teva Neurosciences, Inc."
phosphorothioate oligonucleotide		11/9/2007	Treatment of amyotrophic lateral sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Ionis Pharmaceuticals, Inc."
carlumab		11/8/2007	Treatment of idiopathic pulmonary fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Biotech, Inc."
Metronidazole 10% ointment		11/8/2007	Topical treatment of active perianal Crohn's disease	Designated	Not FDA Approved for Orphan Indication	SLA Pharma (UK) Ltd
human coagulation factor XI		11/8/2007	Treatment of severe congential Factor XI deficiency.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Laboratoire francais du Fractionnement et des Biot
Betahistine dihydrochloride		11/8/2007	Treatment of obesity associated with Prader Willi syndrome	Designated	Not FDA Approved for Orphan Indication	Altamira Therapeutics Inc.
Coagulation factor X (human)	Coagadex	11/8/2007	Treatment of hereditary factor X deficiency	Designated/Approved		Bio Products Laboratory Limited
Coagulation factor X (human)	COAGADEX	11/8/2007	Treatment of hereditary factor X deficiency	Designated/Approved		Bio Products Laboratory Limited
Coagulation factor X (human)	COAGADEX	11/8/2007	Treatment of hereditary factor X deficiency	Designated/Approved		Bio Products Laboratory Limited
romiplostim		10/31/2007	Treatment of thrombocytopenia associated with myelodysplasia syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Amgen Inc.
ursodiol		10/23/2007	Treatment of cystic fibrosis liver disease	Designated	Not FDA Approved for Orphan Indication	"Asklepion Pharmaceuticals, LLC"
"4,5 dibromorhodamine methyl ester"		10/23/2007	For immune reconstitution and prevention of graft versus host disease following allogeneic hematopoietic stem cell transplantation.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Kiadis Pharma Netherlands B.V.
N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea		10/23/2007	Treatment of acute myelogenous leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
eteplirsen	Exondys 51	10/23/2007	Treatment of Duchenne Muscular Dystrophy.	Designated/Approved		"Sarepta Therapeutics, Inc."
lomitapide	Juxtapid	10/23/2007	Treatment of homozygous familial hypercholesterolemia	Designated/Approved		Chiesi Farmaceutici S.p.A.
N-adamantanyl-N'-Geranyl-ethylenediamine		10/16/2007	Treatment of tuberculosis.	Designated	Not FDA Approved for Orphan Indication	"Sequella, Inc."
Interferon gamma		10/11/2007	Treatment of idiopathic pulmonary fibrosis	Designated	Not FDA Approved for Orphan Indication	mondoBIOTECH Laboratories AG
dexpramipexole		10/11/2007	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Knopp Biosciences LLC
Tamibarotene		10/11/2007	Treatment of acute promyelocytic leukemia (APL).	Designated	Not FDA Approved for Orphan Indication	CytRx Corporation
Microvesiculated modified glycosylated tissue factor		10/11/2007	"Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in patients with von Willebrand disease."	Designated	Not FDA Approved for Orphan Indication	Thrombotargets Corp.
recombinant human fibrinogen		10/4/2007	Treatment of bleeding in patients deficient in fibrinogen	Designated	Not FDA Approved for Orphan Indication	Pharming Technologies B.V.
Panobinostat		9/26/2007	Treatment of cutaneous T-cell lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
colchicine	Colcrys	9/25/2007	Treatment of familial Mediterranean fever	Designated/Approved		"AR Holding Company, Inc."
Colchicine		9/25/2007	Treatment of Behcet's Syndrome	Designated	Not FDA Approved for Orphan Indication	"AR Scientific, Inc."
retaspimycin		8/31/2007	Treatment for gastrointestinal stromal tumor	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Infinity Pharmaceuticals, Inc."
parathyroid hormone	Natpara	8/31/2007	Treatment of hypoparathyroidism	Designated/Approved		"Takeda Pharmaceuticals USA, Inc."
artemether/lumefantrine	Coartem	8/31/2007	For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.	Designated/Approved		Novartis Pharmaceuticals
ascorbic acid	Ascor	8/31/2007	Treatment of scurvy	Designated/Approved		McGuff Pharmaceuticals Inc.
Pafuramidine maleate		8/31/2007	Treatment of human African trypanosomiasis (sleeping sickness)	Designated	Not FDA Approved for Orphan Indication	"Immtech Pharmaceuticals, Inc."
"4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone"		8/22/2007	Treatment of hepatocellular carcinoma.	Designated	Not FDA Approved for Orphan Indication	"Ligand Pharmaceuticals, Inc."
Bendamustine hydrochloride	Treanda	8/17/2007	Treatment of chronic lymphocytic leukemia	Designated/Approved		"Cephalon, Inc."
Betulinic acid		8/9/2007	Topical treatment of metastatic melanoma	Designated	Not FDA Approved for Orphan Indication	"Advanced Life Sciences, Inc. (ALS)"
Talactoferrin alfa		8/8/2007	Treatment of stage III/IV non-small cell lung cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Agennix, Inc."
N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide		8/8/2007	Treatment of Hodgkin's lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Mirati Therapeutics, Inc."
Sodium ascorbate and menadione sodium bisulfite		7/31/2007	Treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer)	Designated	Not FDA Approved for Orphan Indication	IC-MedTech Corporation
Recombinant P-selectin glycoprotein ligand-immunoglobulin Ig		7/26/2007	Prevention of ischemia reperfusion injury in all solid organ transplants	Designated	Not FDA Approved for Orphan Indication	"Y's Therapeutics, Inc."
Intravenous immune globulin		7/26/2007	Treatment of Stage IIB to IV malignant melanoma	Designated	Not FDA Approved for Orphan Indication	GammaCan Ltd.
"(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole"		7/12/2007	Treatment of pulmonary tuberculosis.	Designated	Not FDA Approved for Orphan Indication	"Otsuka Pharmaceutical Company, Ltd"
Cordycepin		7/5/2007	Treatment of TdT-positive acute lymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	"OncoVista, Inc."
mifepristone	Korlym	7/5/2007	Treatment of the clinical manifestations of endogenous Cushing's syndrone	Designated/Approved		"Corcept Therapeutics, Inc."
Pretomanid	Pretomanid	7/5/2007	Treatment of tuberculosis	Designated/Approved		Global Alliance for TB Drug Development
iobenguane I 131		7/5/2007	Treatment of neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	"Jubilant DraxImage, Inc."
duvoglustat hydrochloride		6/18/2007	Treatment of Pompe disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Amicus Therapeutics, Inc"
"5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one"		6/18/2007	Prevention of acute radiation syndrome	Designated	Not FDA Approved for Orphan Indication	Humanetics Corporation
mibefradil		6/15/2007	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Cavion, LLC"
5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin		6/15/2007	Treatment of osteosarcoma (bone cancer)	Designated	Not FDA Approved for Orphan Indication	"Dr. Reddy's Laboratories, Inc."
cetuximab		6/15/2007	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	ImClone Systems Incorporated
Autologous cultured endothelial cells on a donor human corneal disk		6/1/2007	"Treatment of Fuch's dystrophy, pseudophakic bullous keratopathy, and bullous keratopathy"	Designated	Not FDA Approved for Orphan Indication	"Cellular Bioengineering, Inc."
axitinib		5/31/2007	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
Plevitrexed		5/29/2007	Treatment of gastric (stomach cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	BTG International Ltd
N-[4-(3-amino1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl)urea		5/23/2007	Treatment of hepatocellular carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
valine-valine-ganciclovir		5/21/2007	Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV1 and HSV2.	Designated	Not FDA Approved for Orphan Indication	"Verenta Pharmaceuticals, Inc."
adeno-associated viral vector expressing human retinoschisin-1 gene		5/21/2007	Treatment of X-linked juvenile retinoschisis (XLRS).	Designated	Not FDA Approved for Orphan Indication	"TeamedOn International, Inc."
Adeno-associated vector expressing the human lipoprotein lipase protein		5/21/2007	Treatment of lipoprotein lipase deficiency	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	uniQure B.V.
Pafuramidine maleate		5/14/2007	Treatment of malaria	Designated	Not FDA Approved for Orphan Indication	"Immtech Pharmaceuticsl, Inc."
Plevitrexed		5/14/2007	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	BTG International Ltd
macimorelin acetate	Macrelin	5/14/2007	Diagnosis of growth hormone deficiency	Designated/Approved		Aeterna Zentaris GmbH
N-Methyl-2-[3-[((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]benzamide		5/4/2007	"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
leukocyte interleukin		5/4/2007	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	Designated	Not FDA Approved for Orphan Indication	CEL-SCI Corporation
cyclosporine	Verkazia	5/4/2007	Treatment of vernal keratoconjunctivitis	Designated/Approved		"Harrow Eye, LLC"
Attenuated autologous cancer cells and granulocyte macrophage colony stimulating factor in combination with activated autologous blood derived T-cells		4/27/2007	Treatment of primary central nervous system malignancies	Designated	Not FDA Approved for Orphan Indication	"TVAX Biomedical, LLC"
von Willebrand Factor/Coagulation Factor VIII Complex (Human)	Wilate	4/18/2007	Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated	Designated/Approved		"Octapharma USA, Inc."
sodium nitrite		4/18/2007	Treatment of cyanide poisoning	Designated	Not FDA Approved for Orphan Indication	Hope Pharmaceuticals
von Willebrand Factor/Coagulation Factor VIII Complex (Human)	Wilate	4/18/2007	Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated	Designated/Approved		"Octapharma USA, Inc."
Alvocidib		4/13/2007	Teatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sumitomo Dainippon Pharma Oncology, Inc."
sodium nitrite		4/2/2007	Treatment of vaso-occlusive crisis associated with sickle cell disease	Designated	Not FDA Approved for Orphan Indication	Hope Pharmaceuticals
Thiotepa	Tepadina	4/2/2007	Conditioning treatment prior to hematopoietic stem cell transplantation	Designated/Approved		ADIENNE S.A.
Sodium nitrite/sodium thiosulfate		3/23/2007	Treatment of cyanide poisoning	Designated	Not FDA Approved for Orphan Indication	"Keystone Pharmaceuticals, Inc."
ganciclovir	Zirgan	3/22/2007	Treatment of acute herpetic keratitis (dendritic and geographic ulcers)	Designated/Approved		"Sirion Therapeutics, Inc."
Sodium phenylbutyrate		3/20/2007	Treatment of spinal muscular atrophy	Designated	Not FDA Approved for Orphan Indication	"Tikvah Therapeutics, Inc."
rapamycin		3/20/2007	Treatment of tuberous sclerosis complex	Designated	Not FDA Approved for Orphan Indication	"OncoImmune, Inc."
Cisplatin in liposomal formulation		3/20/2007	Treatment of osteosarcoma	Designated	Not FDA Approved for Orphan Indication	Eleison Pharmaceuticals LLC
Adeno-associated viral vector expressing human acid alpha glucosidase gene		3/20/2007	Treatment of Pompe disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Audentes Therapeutics, Inc."
nilotinib		3/20/2007	Treatment of gastrointestinal stromal tumors.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaeuticals Corporation
lintuzumab		3/20/2007	Treatment of myelodysplastic syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Seattle Genetics, Inc."
aminolevulinic acid hydrochloride		3/20/2007	Treatment of esophageal dysplasia	Designated	Not FDA Approved for Orphan Indication	"DUSA Pharmaceuticals, Inc."
cethromycin		2/28/2007	Prophylactic treatment of patients exposed to inhalation anthrax.	Designated	Not FDA Approved for Orphan Indication	"Advanced LIfe Sciences, Inc."
idebenone		2/16/2007	Treatment of Duchenne muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	Chiesi Farmaceutici S.p.A.
chenodeoxycholic acid		2/12/2007	Treatment of cerebrotendinous xanthomatosis	Designated	Not FDA Approved for Orphan Indication	"Leadiant Biosciences, Inc."
fenretinide		2/1/2007	Treatment of Ewing's sarcoma family of tumors.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Cancer Research UK
maribavir		2/1/2007	Prevention of cytomegalovirus viremia and disease in the populations at risk.	Designated	Not FDA Approved for Orphan Indication	"Takeda Phrmaceuticals USA, Inc."
Recombinant human platelet derived growth factor BB		2/1/2007	Treatment of osteonecrosis of the jaws	Designated	Not FDA Approved for Orphan Indication	"Luitpold Pharmaceuticals, Inc."
Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGplPTH1-34		2/1/2007	Treatment of solitary (unicameral) bone cysts	Designated	Not FDA Approved for Orphan Indication	Kuros Biosurgery AG
brentuximab vedotin	Adcetris	1/30/2007	Treatment of Hodgkin's lymphoma	Designated/Approved		Seagen Inc.
brentuximab vedotin	Adcetris	1/30/2007	Treatment of Hodgkin's lymphoma	Designated/Approved		Seagen Inc.
cytarabine liposome		1/30/2007	Treatment of gliomas	Designated	Not FDA Approved for Orphan Indication	"Bruce Frankel, MD"
brentuximab vedotin	Adcetris	1/30/2007	Treatment of Hodgkin's lymphoma	Designated/Approved		Seagen Inc.
brentuximab vedotin	Adcetris	1/30/2007	Treatment of Hodgkin's lymphoma	Designated/Approved		Seagen Inc.
lintuzumab		1/30/2007	Treatment of acute myeloid leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Seattle Genetics, Inc."
ixmyelocel-T		1/25/2007	Treatment of dilated cardiomyopathy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Vericel Corporation
ranprinase		1/25/2007	Treatment of malignant mesothelioma	Designated	Not FDA Approved for Orphan Indication	Alfacell Corporation
Microvesiculated modified glycosylated tissue factor		1/25/2007	"Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients"	Designated	Not FDA Approved for Orphan Indication	Thrombotargets Corp.
Sodium phenylbutyrate		1/25/2007	Treatment of spinal muscular atrophy	Designated	Not FDA Approved for Orphan Indication	"OrphaMed, Inc."
hydroxyprogesterone caproate	Makena	1/25/2007	Prevention of preterm birth in singleton pregnancies	Designated/Approved		"AMAG Pharma USA, Inc."
hydroxyprogesterone caproate	Makena	1/25/2007	Prevention of preterm birth in singleton pregnancies	Designated/Approved		"AMAG Pharma USA, Inc."
recombinant ovine interferon tau		1/25/2007	Treatment of pediatric multiple sclerosis	Designated	Not FDA Approved for Orphan Indication	PEPGEN Corporation
droxidopa	NORTHERA	1/17/2007	"Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy."	Designated/Approved		Lundbeck LLC
lenalidomide		1/17/2007	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Celgene Corporation
sodium nitrite		1/17/2007	Prevention of vasospasm associated with subarachnoid hemorrhage	Designated	Not FDA Approved for Orphan Indication	Hope Pharmaceuticals
dihydroartemisinin and piperaquine		1/8/2007	"Treatment of uncomplicated malaria caused by ""Plasmodium falciparum,"" Plasmodium vivax,"" Plasmodium malariae,"" or ""Plasmodium ovale."""	Designated	Not FDA Approved for Orphan Indication	Alfasigma S.p.A
vinCRIStine sulfate LIPOSOME injection	Marqibo	1/8/2007	Treatment of acute lymphoblastic leukemia	Designated/Approved		Acrotech Biopharma LLC
mepivacaine		1/8/2007	Treatment of postherpetic neuralgia	Designated	Not FDA Approved for Orphan Indication	"Relmada Therapeutics, Inc."
potassium sodium aluminosilicate		1/8/2007	For treatment of poisoning by or exposure to cesium.	Designated	Not FDA Approved for Orphan Indication	Westhaven Therapeutics Corporation
defibrotide		1/8/2007	For the prevention of hepatic veno-occlusive disease.	Designated	Not FDA Approved for Orphan Indication	"Jazz Pharmaceuticals, Inc."
Cyclosporine A implant		1/8/2007	For the prevention of acute rejection in cornea transplant patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Lux Biosciences, Inc."
"N-[3-(4',5'-bipyrimidin-2-ylamino)-4-methylphenyl]-4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide"		12/27/2006	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	CytRx Corporation
tecovirimat	TPOXX	12/27/2006	Treatment of smallpox	Designated/Approved		"SIGA Technologies, Inc."
Liposomal ciprofloxacin for inhalation		12/27/2006	Management of bronchiectasis	Designated	Not FDA Approved for Orphan Indication	Savara Inc.
tecovirimat	TPOXX	12/27/2006	Treatment of smallpox	Designated/Approved		"SIGA Technologies, Inc."
Epstein Barr Virus specific cytotoxic T lymphocytes		12/27/2006	Prevention and treatment of EBV-post transplant lymphoproliferative disease after hematopoietic stem cell transplant or solid organ transplant.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Center for Cell and Gene Therapy
Liposomal doxorubicin hydrochloride		12/27/2006	Treatment of soft tissue sarcomas	Designated	Not FDA Approved for Orphan Indication	GP-Pharm SA
Rose Bengal Disodium		12/21/2006	Treatment of metastatic melanoma	Designated	Not FDA Approved for Orphan Indication	"Provectus BioPharmaceuticals, Inc."
Human cytomegalovirus immunoglobulin		12/20/2006	Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women	Designated	Not FDA Approved for Orphan Indication	Biotest Pharmaceuticals Corporation's (BPC)
ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Designated/Approved		"Vertex Pharmaceuticals, Inc."
ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Designated/Approved		"Vertex Pharmaceuticals, Inc."
ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Designated/Approved		"Vertex Pharmaceuticals, Inc."
ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Designated/Approved		"Vertex Pharmaceuticals, Inc."
ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Designated/Approved		"Vertex Pharmaceuticals, Inc."
ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Designated/Approved		"Vertex Pharmaceuticals, Inc."
ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Designated/Approved		"Vertex Pharmaceuticals, Inc."
ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Designated/Approved		"Vertex Pharmaceuticals, Inc."
ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Designated/Approved		"Vertex Pharmaceuticals, Inc."
"Cyclo {{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobytyrl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}"		12/20/2006	"Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis"	Designated	Not FDA Approved for Orphan Indication	"Lux Biosciences, Inc."
Amonafide L-malate		12/20/2006	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Xanthus Pharmaceuticals, Inc."
budesonide	Eohilia	12/20/2006	Treatment of patients with eosinophilic esophagitis	Designated/Approved		"Takeda Pharmaceuticals U.S.A., Inc."
ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Designated/Approved		"Vertex Pharmaceuticals, Inc."
ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Designated/Approved		"Vertex Pharmaceuticals, Inc."
Sodium thiosulfate and sodium nitrite		12/18/2006	Treatment of cyanide poisoning	Designated	Not FDA Approved for Orphan Indication	"Akorn, Inc."
tecovirimat		12/18/2006	post exposure prophylaxis against smallpox	Designated	Not FDA Approved for Orphan Indication	"SIGA Technologies, Inc."
"Amyl nitrite, sodium nitrite, sodium thiosulfate"		12/18/2006	Treatment of cyanide poisoning	Designated	Not FDA Approved for Orphan Indication	"Akorn, Inc."
salirasib		12/18/2006	Treatment of pancreatic cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Kadmon Corporation, LLC"
risedronate sodium		12/18/2006	Treatment of patients with osteogenesis imperfecta	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Warner Chilcott Pharmaceuticals
tadalafil	Adcirca	12/18/2006	Treatment of pulmonary arterial hypertension	Designated/Approved		Eli Lilly and Company
Iobenguane I 123	AdreView	12/1/2006	For the diagnosis of pheochromocytomas	Designated/Approved		"GE Healthcare, Inc."
Obatoclax mesylate		12/1/2006	Treatment of myelofibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gemin X Pharmaceuticals US, Inc."
Iobenguane I 123	Adreview	12/1/2006	For the diagnosis of neuroblastomas	Designated/Approved		"GE Healthcare, Inc."
Fenobam hydrochloride		11/20/2006	Treatment of fragile X syndrome	Designated	Not FDA Approved for Orphan Indication	"Neuropharm, Ltd."
pafuramidine maleate		11/17/2006	Treatment of pneumocystis jiroveci pneumonia	Designated	Not FDA Approved for Orphan Indication	"Immtech Pharmaceuticals, Inc."
Varicella Zoster Immune Globulin (Human)	VARIZIG	11/7/2006	"Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella"	Designated/Approved		"Cangene bioPharma, Inc."
Obatoclax mesylate		11/6/2006	Treatment of myelodysplastic syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Gemin X, Inc."
idebenone		10/31/2006	Treatment of Leber's hereditary optic neuropathy.	Designated	Not FDA Approved for Orphan Indication	Chiesi Farmaceutici S.p.A.
Chimeric monoclonal antibody to mesothelin		10/31/2006	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Morphotek, Inc."
estradiol Gel		10/31/2006	Estrogen replacement therapy in females with Turner syndrome	Designated	Not FDA Approved for Orphan Indication	"Ascend Therapeutics US, LLC"
cysteamine enteric coated	PROCYSBI	10/24/2006	Treatment of cystinosis	Designated/Approved		"Horizon Therapeutics USA, Inc."
cysteamine enteric coated	PROCYSBI	10/24/2006	Treatment of cystinosis	Designated/Approved		"Horizon Therapeutics USA, Inc."
carlumab		10/24/2006	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Centocor, Inc."
cysteamine enteric coated	PROCYSBI	10/24/2006	Treatment of cystinosis	Designated/Approved		"Horizon Therapeutics USA, Inc."
cysteamine enteric coated	PROCYSBI	10/24/2006	Treatment of cystinosis	Designated/Approved		"Horizon Therapeutics USA, Inc."
R-(-)-gossypol		10/24/2006	Treatment of chronic lymphocytic leukemia.	Designated	Not FDA Approved for Orphan Indication	"Ascenta Therapeutics, Inc."
adalimumab	HUMIRA	10/19/2006	Treatment of pediatric Crohn's disease	Designated/Approved		"AbbVie, Inc."
mepivacaine		10/18/2006	Treatment of painful HIV-associated neuropathy	Designated	Not FDA Approved for Orphan Indication	"Relmada Therapeutics, Inc."
"5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(phenylmethyl)-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)- (9CI)"		10/11/2006	Treatment of malignant gliomas	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Reata Pharmaceuticals, Inc."
4-(2-fluorophenyl)-6-methyl-2-(1-piperzinyl)		10/11/2006	Treatment of Chronic Functional Vomiting to include functional vomiting and cyclic vomiting syndrome.	Designated	Not FDA Approved for Orphan Indication	"Dynogen Pharmaceuticals, Inc."
miltefosine	IMPAVIDO	10/10/2006	Treatment of leishmaniasis.	Designated/Approved		Knight Therapeutics (USA)
Coagulation Factor VIIa (Recombinant)		10/3/2006	Treatment of bleeding in patients experiencing intracranial hemorrhage.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Novo Nordisk, Inc."
Dovitinib		10/3/2006	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
Sorafenib		9/29/2006	Treatment of stage IIB through stage IV melanoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bayer Pharmaceuticals Corp.
capsaicin		9/29/2006	Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis	Designated	Not FDA Approved for Orphan Indication	Centrexion Corporation
talactoferrin alfa		9/29/2006	Treatment of renal cell carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Agennix, Inc."
teplizumab		9/29/2006	Treatment of recent-onset Type I diabetes	Designated	Not FDA Approved for Orphan Indication	"Provention Bio, Inc."
Eflornithine		9/29/2006	Treatment of anaplastic glioma	Designated	Not FDA Approved for Orphan Indication	"Orbus Therapeutics, Inc."
Rabbit anti-human thymocyte globulin (rATG)		9/26/2006	Induction treatment to prevent rejection and to minimize maintenance immunosupression in pediatric liver transplant recipients	Designated	Not FDA Approved for Orphan Indication	Children's Hospital of Pittsburgh
Cytomegalovirus DNA Vaccine w/Copolymer/Benzalkonium Chloride		9/23/2006	"For use in prevention of clinically significant CMV viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid organ transplant populations"	Designated	Not FDA Approved for Orphan Indication	Vical Inc.
tremelimumab		9/18/2006	Treatment of stage IIb to stage IV metastatic melanoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	MedImmune
"2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate"		9/18/2006	Treatment of carcinoid tumors	Designated	Not FDA Approved for Orphan Indication	"Callisto Pharmaceuticals, Inc."
Yttrium (90Y) antiferritin polyclonal antibodies		9/18/2006	Treatment of Hodgkin's disease.	Designated	Not FDA Approved for Orphan Indication	"Alissa Pharma, LLC"
glufosfamide		9/18/2006	For treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	Eleison Pharmaceuticals LLC
Heparin-binding epidermal growth factor-like growth factor		9/18/2006	"Prevention and treatment of necrotizing enterocolitis (NEC) in preterm infants with birth weight less than 1,500 grams"	Designated	Not FDA Approved for Orphan Indication	"Trillium Therapeutics, Inc."
Synthetic human secretin		9/18/2006	For use in conjunction with diagnostic procedures (excluding ERCP) for pancreatic disorders to increase pancreatic fluid secretion	Designated	Not FDA Approved for Orphan Indication	"Innovate Biopharmaceuticals, Inc."
rSP-C surfactant		9/18/2006	"For use in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygen impairment"	Designated	Not FDA Approved for Orphan Indication	Altana Pharma
Human monoclonal antibody directed against serotype 011 Pseudomonas aeruginosa		9/18/2006	Treatment of hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosa	Designated	Not FDA Approved for Orphan Indication	Kenta Biotech Limited
Melanoma autologous dendritic cell vaccine		9/6/2006	Treatment of stage IIIb through IV metastatic melanoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Caladrius Biosciences
Somatropin	Norditropin	8/9/2006	Treatment of short stature in patients with Noonan syndrome	Designated/Approved		Novo Nordisk Inc.
Bacillus Calmette-Guerin vaccine		8/9/2006	Treatment of stage IIb through IV metastatic melanoma	Designated	Not FDA Approved for Orphan Indication	OncoVac Corporation
Clindamycin hydrochloride		8/9/2006	Treatment of sarcoidosis	Designated	Not FDA Approved for Orphan Indication	Autoimmunity Research Foundation
Procarbazine HCl		8/8/2006	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Leadiant Biosciences, Inc."
decitabine		8/4/2006	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Otsuka Pharmaceutical Development &
Trypan blue	MembraneBlue	8/2/2006	Selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures	Designated/Approved		Dutch Ophthalmic Research Center International BV
Recombinant human granulocyte colony stimulating factor		7/24/2006	Prevention of implantation failure and unexplained recurrent miscarriage	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Nora Therapeutics, Inc."
immune globulin infusion (human)	Gammagard Liquid	7/20/2006	Treatment of multifocal motor neuropathy	Designated/Approved		"Baxalta US, Inc."
Tegafur/gimeracil/oteracil		7/20/2006	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	"Taiho Oncology, Inc."
4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide monohydrochloride		7/20/2006	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Johnson & Johnson Pharmaceutical Research & Dev,"
Human telomerase reverse transcriptase peptide vaccine		7/20/2006	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	GemVax A/S
pralatrexate	Folotyn	7/20/2006	Treatment of T-cell lymphoma	Designated/Approved		Acrotech Biopharma LLC
Choline chloride		7/20/2006	Prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition	Designated	Not FDA Approved for Orphan Indication	"Protara Therapeutics, Inc."
Heparin sodium		6/29/2006	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	Ockham Biotech Limited
2-methoxyestradiol		6/16/2006	Treatment of multiforme glioblastoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"EntreMed, Inc."
Sodium stibogluconate		6/16/2006	Treatment of cutaneous leishmaniasis	Designated	Not FDA Approved for Orphan Indication	"VioQuest Pharmaceuticals, Inc."
"Sodium thiosulfate, sodium nitrite, amyl nitrite"		6/16/2006	Treatment of cyanide poisoning	Designated	Not FDA Approved for Orphan Indication	"Keystone Pharmaceuticals, Inc."
Indium-111 pentetreotide		6/16/2006	Treatment of neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	RadioIsotope Therapy of America (RITA) Foundation
farletuzumab		6/16/2006	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	Eisai Inc.
vibriolysin		6/16/2006	"Debridement of severe, deep dermal burns in hospitalized patients"	Designated	Not FDA Approved for Orphan Indication	BioMarin Pharmaceutical Inc.
TD-K6a.513a.12		6/15/2006	Treatment of pachyonychia congenita	Designated	Not FDA Approved for Orphan Indication	"TransDerm, Inc."
"Polyvalent, shed-antigen melanoma vaccine"		6/9/2006	Treatment of stage IIb to stage IV melanoma	Designated	Not FDA Approved for Orphan Indication	Polynoma LLC
Recombinant human C1 inhibitor		6/9/2006	Prevention and/or treatment of delayed graft function after solid organ transplantation	Designated	Not FDA Approved for Orphan Indication	Pharming Group N.V.
Catumaxomab		6/9/2006	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Neoviibiotech North America, Inc."
obiltoxaximab	Anthim	6/9/2006	Treatment of exposure to B. anthracis spores	Designated/Approved		"Elusys Therapeutics, Inc."
glycopyrrolate	Cuvposa	6/9/2006	Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients	Designated/Approved		"Shionogi, Inc."
Recombinant human C1 inhibitor		6/9/2006	Treatment of capillary leakage syndrome	Designated	Not FDA Approved for Orphan Indication	Pharming Group N.V.
siltuximab	SYLVANT	5/26/2006	Treatment of Castleman's disease	Designated/Approved		Recordati Rare Diseases Inc.
5-hydroxymethyl-2-furfuraldehyde		5/26/2006	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"Baxalta US, Inc."
bevacizumab	Avastin	5/26/2006	Treatment of malignant glioma	Designated/Approved		"Genentech, Inc."
Mycophenolate mofetil		5/26/2006	Treatment of pemphigus vulgaris	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Hoffman-La Roche, Inc."
5-iodo-2-pyrimidinone-2'-deoxyribose		5/26/2006	Treatment of malginant glioma	Designated	Not FDA Approved for Orphan Indication	"Hana Biosciences, Inc."
Triheptanoin		5/26/2006	Treatment of fatty acid disorders	Designated	Not FDA Approved for Orphan Indication	Baylor Research Institute
Apomorphine hydrochloride		5/23/2006	For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)	Designated	Not FDA Approved for Orphan Indication	"NeuroHealing Pharmaceuticals, Inc."
mipomersen	KYNAMRO	5/23/2006	Treatment of homozygous familial hypercholesterolemia	Designated/Approved		"Kastle Therapeutics, LLC"
Liposomal cisplatin		5/23/2006	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	Eleison Pharmaceuticals LLC
Lucinactant		5/23/2006	Prevention of bronchopulmonary dysplasia in premature infants	Designated	Not FDA Approved for Orphan Indication	Lee’s Pharmaceutical (HK) Limited
tafamidis		5/23/2006	Treatment of familial amyloid polyneuropathy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
Talotrexin		5/8/2006	Treatment of acute lymphoblastic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Hana Biosciences, Inc."
midazolam		5/8/2006	Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam	Designated	Not FDA Approved for Orphan Indication	"UCB, Inc"
Combretastatin A4 phosphate		5/8/2006	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Mateon Therapeutics, Inc."
cenersen		5/8/2006	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Eleos, Inc."
nilotinib	Tasigna	4/27/2006	Treatment of chronic myelogenous leukemia	Designated/Approved		Novartis Pharmaceuticals Corporation
peptide 144 TGF beta-1 inhibitor		4/27/2006	Treatment of systemic sclerosis	Designated	Not FDA Approved for Orphan Indication	"Digna Biotech, S.L."
Bio-engineered oral mucosal tissue		4/27/2006	For use as a graft for restoring a cornea-like epithelial phenotype to substitute for the normal corneal epithelium that is lost in patients due to total limbal stem cell deficiency	Designated	Not FDA Approved for Orphan Indication	"TissueTech, Inc."
nilotinib	Tasigna	4/27/2006	Treatment of chronic myelogenous leukemia	Designated/Approved		Novartis Pharmaceuticals Corporation
nilotinib	Tasigna	4/27/2006	Treatment of chronic myelogenous leukemia	Designated/Approved		Novartis Pharmaceuticals Corporation
Recombinant coagulation factor VIIa		4/26/2006	Treatment of diffuse alveolar hemorrhage	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Savara Inc.
4-aminosalicylic acid		4/26/2006	Treatment of acute flares in pediatric patients with ileo-cecal Crohn's disease	Designated	Not FDA Approved for Orphan Indication	"Jacobus Pharmaceutical Co., Inc."
Peptide 144 TGF beta-1-inhibitor		4/26/2006	Treatment of localized scleroderma	Designated	Not FDA Approved for Orphan Indication	"Digna Biotech, S.L."
Sorafenib	Nexavar	4/20/2006	Treatment of hepatocellular carcinoma	Designated/Approved		Bayer Pharmaceuticals Corporation
liposomal ciprofloxacin for inhalation		4/19/2006	Management of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	Savara Inc.
Oxalobacter formigenes		3/29/2006	Treatment of primary hyperoxaluria	Designated	Not FDA Approved for Orphan Indication	OxThera Inc.
Ethanol gel		3/29/2006	Treatment of congenital venous malformations	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Orfagen
Recombinant P-Selectin glycoprotein ligand		3/29/2006	Prevention of delayed graft function in renal transplant patients	Designated	Not FDA Approved for Orphan Indication	"Y's Therapeutics, Inc."
Human immune globulin		3/29/2006	Treatment of post-polio syndrome	Designated	Not FDA Approved for Orphan Indication	"Instituto Grifols, S.A."
artesunate		3/28/2006	Immediate treatment of malaria	Designated/Approved		Amivas Inc.
Ceftriaxone sodium		3/28/2006	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Mass General Hospital
Minocycline hydrochloride		3/28/2006	Treatment of sarcoidosis	Designated	Not FDA Approved for Orphan Indication	Autoimmunity Research Foundation
Alpha-tocopherol quinone		3/28/2006	Treatment of inherited mitochondrial respiratory chain diseases	Designated	Not FDA Approved for Orphan Indication	Penwest Pharmaceuticals Company
(UDU-stereoisomer of c-UJUun UNU-terminal UkUnhibitor)		3/28/2006	Treatment of acute sensorineural hearing loss	Designated	Not FDA Approved for Orphan Indication	Altamira Therapeutics Inc.
"N-[4-(4-amino-2-ethyl-lH-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide"		3/24/2006	Treatment of cutaneous T-cell lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
lestaurtinib		3/24/2006	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Teva Branded Pharmaceutical Products R&D, Inc."
Ethanol gel		3/13/2006	Treatment of congenital lymphatic malformations	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Orfagen
Clotrimazole		3/13/2006	Treatment of Huntington's disease	Designated	Not FDA Approved for Orphan Indication	"EnVivo Pharmaceuticals, Inc."
Human umbilical tissue-derived cells		3/13/2006	Treatment of retinitis pigmentosa	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system		3/13/2006	Treatment of osteonecrosis.	Designated	Not FDA Approved for Orphan Indication	"Aastrom Biosciences, Inc."
Thymalfasin		3/13/2006	Treatment of stage IIb through Stage IV malignant melanoma	Designated	Not FDA Approved for Orphan Indication	"SciClone Pharmaceuticals, Inc."
omacetaxine mepesuccinate	Synribo	3/10/2006	Treatment of chronic myelogenous leukemia	Designated/Approved		IVAX International GmbH
liposomal amikacin		3/9/2006	Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Insmed, Inc."
Recombinant fully human monoclonal antibody to anthrax protective antigen		2/16/2006	Treatment of anthrax infection	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Altimmune, Inc."
clazosentan		2/16/2006	Treatment of cerebral vasospasm following subarachnoid hemorrhage	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Idorsia Pharmaceuticals US Inc.
Nikkomycin Z		2/14/2006	Treatment of coccidioidomycosis	Designated	Not FDA Approved for Orphan Indication	Valley Fever Center for Excellence (1-111 INF)
rituximab	Rituxan	2/14/2006	"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)"	Designated/Approved		"Genentech, Inc."
rituximab	Rituxan	2/14/2006	"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)"	Designated/Approved		"Genentech, Inc."
bevacizumab	Avastin	2/9/2006	Therapeutic treatment of patients with ovarian cancer	Designated/Approved		"Genentech, Inc."
bevacizumab	Avastin	2/9/2006	Therapeutic treatment of patients with ovarian cancer	Designated/Approved		"Genentech, Inc."
bevacizumab	Avastin	2/9/2006	Therapeutic treatment of patients with ovarian cancer	Designated/Approved		"Genentech, Inc."
blinatumomab		2/6/2006	"Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement"	Designated	Not FDA Approved for Orphan Indication	"Amgen, Inc."
otelixizumab		2/6/2006	Treatment of new-onset type I diabetes mellitus	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	GlaxoSmithKline
N-acetyl-glucosamine thiazoline		2/6/2006	Treatment of adult Tay-Sachs disease	Designated	Not FDA Approved for Orphan Indication	ExSAR Corporation
Solasonine and solamargine		2/6/2006	"Treaatment of high risk stage II, stage III and stage IV melanoma"	Designated	Not FDA Approved for Orphan Indication	Solbec Pharmaceuticals Limited
"6,8-bis-benzylsulfanyl-octanoic acid"		2/6/2006	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Cornerstone Pharmaceuticals, Inc."
velmanase alfa-tycv	Lamzede	2/2/2006	Treatment of alpha-mannosidosis	Designated/Approved		"Chiesi USA, Inc."
Recombinant anti-CD-40 monoclonal antibody		1/25/2006	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceutical Corporation
aripiprazole	Abilify	1/25/2006	Treatment of Tourette's syndrome	Designated/Approved		Otsuka Pharmaceutical Development
Recombinant human microplasmin		1/23/2006	Treatment of peripheral arterial occlusion	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	ThromboGenics Ltd
Iobenguane I 131	Azedra Ultratrace	1/18/2006	Treatment of neuroendocrine tumors	Designated/Approved		"Progenics Pharmaceuticals, Inc."
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal		1/18/2006	Treatment of Duchenne and Becker muscular dystrophy	Designated	Not FDA Approved for Orphan Indication	CepTor Corporation
Lentiviral vector encoded with a human beta-globin gene plasmid		1/11/2006	Treatment of beta-thalassemia major and beta-thalassemia intermedia	Designated	Not FDA Approved for Orphan Indication	"San Rocco Therapeutics, LLC"
Fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1		1/11/2006	Treatment of X-linked hypohidrotic ectodermal dysplasia	Designated	Not FDA Approved for Orphan Indication	Espoir XLHED Sarl
Human immunoglobin anti-CD30 monoclonal antibody		1/10/2006	Treatment of CD30+ T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb
isofagomine tartrate		1/10/2006	Treatment of Gaucher disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Amicus Therapeutics, Inc."
Inalimarev and falimarev		1/10/2006	Treatment of adenocarcinoma of the pancreas	Designated	Not FDA Approved for Orphan Indication	Therion Biologics Corporation
imatinib mesylate	Gleevec	12/19/2005	Treatment of dermatofibrosarcoma protuberans	Designated/Approved		Novartis Pharmaceuticals Corporation
Mycophenolate mofetil		12/19/2005	Treatment of myasthenia gravis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Hoffman-LaRoche, Inc."
Somatropin	Humatrope	12/15/2005	Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency	Designated/Approved		Eli Lilly and Company
Zosuquidar trihydrochloride		12/15/2005	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Kanisa Pharmaceuticals, Inc."
Amphotericin B inhalation powder		12/15/2005	"Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
eniluracil		12/15/2005	Treatment of hepatocellular carcinoma.	Designated	Not FDA Approved for Orphan Indication	"Adherex Technologies, Inc."
Coxsackievirus A21		12/15/2005	"Treatment of stage II (T4), stage III, and stage IV melanoma"	Designated	Not FDA Approved for Orphan Indication	"Viralytics Limited, a wholly owned subsidiary of Merck Sharp & Dohme, LLC"
Urea for intravitreal injection		12/14/2005	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	"Vitreo Retinal Techologies, Inc"
ex vivo cultured adult human mesenchymal stem cells		12/14/2005	Treatment of acute graft versus host disease	Designated	Not FDA Approved for Orphan Indication	"Mesoblast, Inc."
4-Aminopyridine		12/14/2005	Treatment chronic functional motor and sensory deficits from Guillain-Barre syndrome	Designated	Not FDA Approved for Orphan Indication	"Acorda Therapeutics, Inc."
solvent/detergent treated non-blood-group specific human coagulation active plasma		12/12/2005	Treatment of thrombotic thrombocytopenic purpura	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Octapharma USA, Inc."
4-(3-Methanesulfonyl-phenyl)-1-propylpiperidine HCl		12/12/2005	Treatment of Huntington's disease.	Designated	Not FDA Approved for Orphan Indication	Prilenia Therapeutics
"4-cholest-en-3-one, oxime"		12/1/2005	Treatment of amyotrophic lateral sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Trophos SA
dasatinib	Sprycel	11/28/2005	Treatment of chronic myelogenous leukemia	Designated/Approved		Bristol-Myers Squibb Company
dasatinib	Sprycel	11/28/2005	Treatment of chronic myelogenous leukemia	Designated/Approved		Bristol-Myers Squibb Company
Histrelin	Supprelin LA	11/18/2005	Treatment of central precocious puberty	Designated/Approved		"Endo Pharmaceuticals Solutions, Inc."
Dasatinib	Sprycel	11/18/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Designated/Approved		Bristol-Myers Squibb Company
Exon 46 specific phosphorothioate oligonucleotide		11/18/2005	Treatment of Duchenne muscular dystrophy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Prosensa Therapuetics BV
Dasatinib	Sprycel	11/18/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Designated/Approved		Bristol-Myers Squibb Company
recombinant deriative of C3 transferase		11/18/2005	Treatment of acute spinal cord injury	Designated	Not FDA Approved for Orphan Indication	"Vertex Pharmaceuticals, Inc."
Heparin		11/3/2005	Treatment of cystic fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Vectura Group, Inc."
Solasonine and solamargine		11/2/2005	Treatment of renal cell carcinoma	Designated	Not FDA Approved for Orphan Indication	Solbec Pharmaceuticals Limited
bivalirudin		11/2/2005	For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome	Designated	Not FDA Approved for Orphan Indication	The Medicines Company
Picoplatin		11/2/2005	Treatment of small cell lung cancer	Designated	Not FDA Approved for Orphan Indication	Poniard Pharmaceuticals
Lucinactant		10/21/2005	Treatment of bronchopulmonary dysplasia in premature infants.	Designated	Not FDA Approved for Orphan Indication	Lee’s Pharmaceutical (HK) Limited
vandetanib	CAPRELSA(r)	10/21/2005	"Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma"	Designated/Approved		Genzyme Corporation
iobenguane sulfate I-123		10/21/2005	"For the detection, localization, and staging of pheochromocytomas."	Designated	Not FDA Approved for Orphan Indication	"Brogan Pharmaceuticals, Inc."
Iobenguane Sulfate I-123		10/17/2005	"For scintigraphic detection, localization and staging of neuroblastoma."	Designated	Not FDA Approved for Orphan Indication	"Brogan Pharmaceuticals, LLC"
N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole) mesylate		10/17/2005	Treatment of multiple myeloma.	Designated	Not FDA Approved for Orphan Indication	AB Science
siltuximab		10/11/2005	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
Creatine		10/11/2005	Treatment of Huntington's disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Marathon Pharmaceuticals, LLC"
imatinib	Gleevec	10/11/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Designated/Approved		Novartis Pharmaceuticals Corporation
imatinib	Gleevec	10/11/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Designated/Approved		Novartis Pharmaceuticals Corporation
Doxorubicin HCl with pluronic L-61 and pluronic F-127		10/7/2005	Treatment of esophageal carcinoma	Designated	Not FDA Approved for Orphan Indication	Supratek Pharma Inc.
dacetuzumab		10/6/2005	Treatment of chronic lymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	"Seattle Genetics, Inc."
Fenretinide		10/5/2005	Treatment of neuroblastoma	Designated	Not FDA Approved for Orphan Indication	USC-CHLA Institute for Pediatric Clinical Research
Buthionine sulfoxamine		10/5/2005	For use in children as a modulator of chemotherapy for the treatment of pediatric patients with neuroblastoma	Designated	Not FDA Approved for Orphan Indication	USC-CHLA Institute for Pediatric Clinical Research
brivaracetam		10/5/2005	Treatment of symptomatic myoclonus	Designated	Not FDA Approved for Orphan Indication	"UCB Pharma, Inc."
Buthionine sulfoxamine		10/5/2005	Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors	Designated	Not FDA Approved for Orphan Indication	USC-CHLA Institute for Pediatric Clinical Research
Imatinib mesylate	Gleevec	10/5/2005	Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements	Designated/Approved		Novartis Pharmaceuticals Corporation
Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131		10/4/2005	Treatment of primary malignant brain tumors	Designated	Not FDA Approved for Orphan Indication	"Bradmer Pharmaceuticals, Inc."
"chimeric monoclonal antibodies, c-alphaStx2"		10/4/2005	For treatment of shiga-toxin producing bacterial infection	Designated	Not FDA Approved for Orphan Indication	Taro Pharmaceuticals Inc.
Patupilone		10/4/2005	Treatment of ovarian cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceutical Corporation
Recombinant Human Interleukin-21 (rIL-21)		10/4/2005	"Treatment of stage II (T4), III or IV malignant melanoma."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Zymo Genetics, Inc"
Enzastaurin		9/19/2005	Treatment of glioblastoma multiforme	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Denovo Biopharma LLC
masitinib		9/14/2005	Treatment of mastocytosis	Designated	Not FDA Approved for Orphan Indication	AB Science
Imatinib mesylate	Gleevec	9/9/2005	Treatment of systemic mastocytosis without the D816V c-kit mutation	Designated/Approved		Novartis Pharmaceuticals Corporation
Imatinib mesylate	Gleevec	8/25/2005	Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia	Designated/Approved		Novartis Pharmaceuticals Corporation
Recombinant Epstein-Barr virus gp350 glycoprotein vaccine		8/18/2005	Prevention of post-transplantation lymphoproliferative disorders in pediatric recipients of solid-organ transplantation	Designated	Not FDA Approved for Orphan Indication	Henogen S.A.
Balsalazide disodium	Colazal	8/12/2005	Treatment of pediatric patients with ulcerative colitis	Designated/Approved		"Salix Pharmaceuticals, Inc."
imexon		8/12/2005	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	AmpliMed Corporation
Recombinant anti-CD40 monoclonal antibody		8/12/2005	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceutical Corporation
ridaforolimus		8/12/2005	Treatment of soft tissue sarcoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Merck Sharp & Dohme Corp.
Alfentanil		8/9/2005	Treatment of painful HIV-associated neuropathy	Designated	Not FDA Approved for Orphan Indication	"Cinergen, LLC"
Rapamycin (mTOR) inhibitor		8/9/2005	Treatment of bone sarcoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Merck Sharp & Dohme Corp.
bicarbonate infusate	Normocarb HF	8/9/2005	Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration	Designated/Approved		"Dialysis Solutions, Inc."
Capsaicin		8/3/2005	Treatment of postherpetic neuralgia.	Designated	Not FDA Approved for Orphan Indication	"TheraQuest Biosciences, LLC"
Edotreotide		7/28/2005	Treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors	Designated	Not FDA Approved for Orphan Indication	"Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)"
Nucleic acid aptamer binding to tumor cell nucleon		7/28/2005	Treatment of renal cell carcinoma	Designated	Not FDA Approved for Orphan Indication	Antisoma Inc.
Autologous or allogeneic limbal epithelial stem cells expanded ex vivo on human amniotic membrane		7/14/2005	Treatment of ocular surface diseases that are characterized by total limbal stem cell deficiency	Designated	Not FDA Approved for Orphan Indication	"TissueTech, Inc."
raloxifene	Evista	7/14/2005	Reduction of the risk of breast cancer in postmenopausal women	Designated/Approved		Eli Lilly and Company
Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase		7/14/2005	"Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease"	Designated	Not FDA Approved for Orphan Indication	"Lysosomal Acid Lipase, LLC"
Alfentanil		7/8/2005	Management of postherpetic neuralgia	Designated	Not FDA Approved for Orphan Indication	"Cinergen, LLC"
SDF-1 (108) Lysine Dlmer		7/7/2005	Treatment of osteogenic sarcoma	Designated	Not FDA Approved for Orphan Indication	Chemokine Therapeutics Corporation
Contulakin-G		7/7/2005	Intrathecal treatment of neuropathic pain associated with spinal cord injury	Designated	Not FDA Approved for Orphan Indication	"Cognetix, Inc."
human leukocyte-derived cytokine mixture		7/7/2005	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	Designated	Not FDA Approved for Orphan Indication	"IRX Therapeutics, Inc."
"Valproic acid, sodium"		6/24/2005	Treatment of familial adenomatous polyposis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Topotarget A/S
Recombinant truncated SPINT2 protease inhibitor		6/24/2005	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Aerovance, Inc."
Liposomal annamycin		6/17/2005	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Callisto Pharmaceuticals, Inc."
Liposomal annamycin		6/17/2005	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	"Callisto Pharmaceuticals, Inc."
Adenoviral vector expressing Herpes simplex virus thymidine kinase gene		6/17/2005	Treatment of malignant brain tumors	Designated	Not FDA Approved for Orphan Indication	"Candel Therapeutics, Inc."
Clotrimazole		6/14/2005	Topical treatment of children and adults with pouchitis	Designated	Not FDA Approved for Orphan Indication	"AesRx, LLC"
Geneticin		6/6/2005	Treatment of amoebiasis.	Designated	Not FDA Approved for Orphan Indication	"ProcesScience, Inc. (PSI)"
Polyethylene glycol-modified uricase		6/6/2005	Treatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated	Designated	Not FDA Approved for Orphan Indication	Swedish Orphan Biovitrum AB
Tacrolimus	Prograf	6/6/2005	Prophylaxis of organ rejection in patients receiving heart transplants.	Designated/Approved		"Astellas Pharma US, Inc."
Iboctadekin		6/3/2005	Treatment of renal cell carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	GlaxoSmithKline LLC
Sodium phenylacetate/sodium benzoate 10%/10% Injection		6/3/2005	Treatment of grade III and IV hepatic encephalopathy	Designated	Not FDA Approved for Orphan Indication	"Ucyclyd Pharma, Inc."
Cytomegalovirus DNA vaccine with plasmids expressing pp65 and gB genes		6/3/2005	"Prevention of clinically significant cytomegalovirus (CMV) viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid transplant populations"	Designated	Not FDA Approved for Orphan Indication	"Astellas Pharma Global Development, Inc."
cilengitide		5/27/2005	Treatment of malignant glioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"EMD Serono, Inc."
digitoxin		5/27/2005	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	Silver Pharmaceuticals
Titanium dioxide and bisoctrizole		5/25/2005	"For the secondary prevention (prevention of lesional induction) of disorders with UV-A and visible light-induced photosensitivity, specifically Actinic prurigo, Hydroa vacciniforme, Solar urticara (SU), Chronic Actinic Dermatitis (CAD), the cutaneous prop"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Orfagen
Glyceryl tri (4-phenylbutyrate)		5/24/2005	Treatment of spinal muscular atrophy	Designated	Not FDA Approved for Orphan Indication	"Ucyclyd Pharma, Inc"
Human anti-integrin receptor av monoclonal antibody		5/5/2005	Treatment of patients with angiosarcoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
Recombinant human alpha 1-antitrypsin		4/28/2005	Prevention of bronchopulmonary dysplasia	Designated	Not FDA Approved for Orphan Indication	"Arriva Pharmaceuticals, Inc."
L-threonyl-L-prolyl-L-prolyl-L-threonine		4/26/2005	Treatment of neuropathic pain associated with spinal cord injury	Designated	Not FDA Approved for Orphan Indication	"Nyxis Neurotherapies, Inc."
Tramadol hydrochloride		4/26/2005	Management of postherpetic neuralgia	Designated	Not FDA Approved for Orphan Indication	"TheraQuest Biosciences, LLC"
masitinib		4/20/2005	Treatment of malignant gastrointestinal stromal tumors	Designated	Not FDA Approved for Orphan Indication	AB Science
Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA		4/15/2005	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	"Lorus Therapeutics, Inc."
hydroxyurea		4/15/2005	Treatment of pediatric patients with sickle cell anemia.	Designated	Not FDA Approved for Orphan Indication	"UPM Pharmaceuticals, Inc."
Anatibant		4/15/2005	Treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome	Designated	Not FDA Approved for Orphan Indication	"Xytis, Inc."
2-methoxyestradiol		4/11/2005	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	"PR Pharmaceuticals, Inc."
Tilarginine acetate		4/11/2005	Treatment of cardiogenic shock	Designated	Not FDA Approved for Orphan Indication	"Arginox Pharmceuticals, Inc."
myo-inositol		4/7/2005	Prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity	Designated	Not FDA Approved for Orphan Indication	Abbott Nutrition
Interleukin-1 Trap		4/4/2005	Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease	Designated	Not FDA Approved for Orphan Indication	"Regeneron Pharmaceuticals, Inc."
DNA plasmid vector expressing human IL-12 gene		4/4/2005	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	"Imunon, Inc."
Troxacitabine		4/4/2005	Treatment of acute myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Structural GenomiX, Inc. (SGX)"
2-methoxyestradiol		4/4/2005	Treatment of ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"EntreMed, Inc."
"Human alpha 2,6 sialyltransferase adenoviral gene therapy"		4/4/2005	"Treatment of patients with invasive (malignant) brain and central nervous system tumors lacking alpha 2,6 sialyltransferase."	Designated	Not FDA Approved for Orphan Indication	Falk Center for Molecular Therapeutics
Plasmid DNA vector expressing cystic fibrosis transmembrane gene		3/29/2005	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Copernicus Therapeutics, Inc."
Melanoma peptide vaccine		3/29/2005	"Treatment of HLA-A2+ patients with stage IIB, IIC, III, and IV malignant melanoma"	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Research Inst
trabectedin		3/29/2005	Treatment of patients with ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
arimoclomol		3/29/2005	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	KemPharm Denmark A/S
aminosidine		3/29/2005	Treatment of visceral leishmaniasis	Designated	Not FDA Approved for Orphan Indication	The Institute for One World Health
humanized anti-human CD16 monoclonal antibody		3/21/2005	Treatment of adult idiopathic thrombocytopenic purpura	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genzyme Corporation
adalimumab	Humira	3/21/2005	Treatment of juvenile rheumatoid arthritis	Designated/Approved		AbbVie Inc.
adalimumab	Humira	3/21/2005	Treatment of juvenile rheumatoid arthritis	Designated/Approved		AbbVie Inc.
doxorubicin nanoparticles		3/14/2005	Treatment of hepatocellular carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Onxeo SA
Arsenic trioxide		3/4/2005	Treatment of malignant glioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Teva Branded Pharmaceutical Products R&D, Inc."
Sodium aluminosilicate		3/4/2005	Treatment of chronic hepatic encephalopathy	Designated	Not FDA Approved for Orphan Indication	Westhaven Therapeutics Corporation
Stem and progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood		3/4/2005	For use as hematopoietic support in patients with relapsed or refractory hematologic malignancies who are receiving high-dose therapy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Gamida Cell Ltd - Teva Joint Venture
c-myb antisense oligodeoxynucleotide		2/22/2005	Treatment of chronic myelogenous leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genta, Inc."
aviptadil		2/22/2005	Treatment of pulmonary arterial hypertension	Designated	Not FDA Approved for Orphan Indication	Mondobiotech Laboratories AG
Recombinant human anti-GDF-8 (growth and differentiation factor-8) antibody		2/16/2005	Treatment of Duchenne and Becker muscular dystrophies	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Wyeth Pharmaceuticals, Inc."
Nitric oxide		2/16/2005	Diagnosis of sarcoidosis	Designated	Not FDA Approved for Orphan Indication	SensorMedics Corporation
MANNITOL	Bronchitol®	2/11/2005	For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis	Designated/Approved		"Chiesi Farmaceutici S.p.A (Chiesi USA, Inc.)"
rAAV2-CB-hRPE65		2/11/2005	Treatment of type II Leber's Congenital Amaurosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Applied Genetic Technologies Corp.
Mifepristone		2/7/2005	Treatment of Cushing's syndrome secondary to ectopic ACTH secretion	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	HRA Pharma
deferoxamine starch conjugate		1/28/2005	Treatment of acute iron poisoning	Designated	Not FDA Approved for Orphan Indication	"Biomedical Frontiers, Inc."
"Allogeneic T-cells cultured with anti-CD3 and IL-2; transduced with retroviral vector (SFCMM-3), expressing herpes simplex 1 virus-thymidine kinase (HSV-TK) and truncated low affinity nerve growth factor receptor; selected with anti-low affinity nerve gro"		1/28/2005	Immunotherapy for acceleration of T-cell reconstitution in patients undergoing allogeneic hematopoietic stem cell transplantation	Designated	Not FDA Approved for Orphan Indication	MolMed S.p.A.
recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin		1/28/2005	Treatment of Ep-CAM-positive squamous cell carcinoma of the head and neck	Designated	Not FDA Approved for Orphan Indication	"Sesen Bio, Inc. (Sesen Bio)"
Tramadol hydrochloride		1/28/2005	Treatment of painful HIV-associated neuropathy	Designated	Not FDA Approved for Orphan Indication	"TheraQuest Biosciences, LLC"
"N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide, phosphate (1:2)"		1/13/2005	Treatment of gastrointestinal stromal tumors	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Amgen, Inc."
bedaquiline	SIRTURO	1/10/2005	Treatment of active tuberculosis	Designated/Approved		"Janssen Research & Development, LLC"
bedaquiline	SIRTURO	1/10/2005	Treatment of active tuberculosis	Designated/Approved		"Janssen Research & Development, LLC"
(2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hepten-6-ynamide		1/10/2005	"Prevention of acute rejection following kidney, heart, and liver transplantation"	Designated	Not FDA Approved for Orphan Indication	"Astellas Pharma US, Inc."
ataluren		1/10/2005	Treatment of Muscular Dystrophy resulting from premature stop mutations in the dystrohin gene	Designated	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
bedaquiline	SIRTURO	1/10/2005	Treatment of active tuberculosis	Designated/Approved		"Janssen Research & Development, LLC"
misoprostol		1/10/2005	Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.	Designated	Not FDA Approved for Orphan Indication	"Gynuity Health Projects, LLC"
doxorubicin HCL liposome injection	Doxil	12/29/2004	Treatment of multiple myeloma	Designated/Approved		Johnson & Johnson Pharmaceutical Research & Dev.
paclitaxel		12/22/2004	Treatment of non-superficial urothelial cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sonus Pharmaceuticals, Inc."
Alpha1-Proteinase Inhibitor (Human)		12/22/2004	Inhalation therapy for the treatment of congential deficiency of alpha1-proteinase inhibitor.	Designated	Not FDA Approved for Orphan Indication	Kamada Ltd.
"Floxuridine, FUDR"		12/22/2004	Intraperitoneal treatment of gastric cancer.	Designated	Not FDA Approved for Orphan Indication	"Franco Muggia, M.D."
Rilonacept	Arcalyst	12/20/2004	Treatment of CIAS1-Associated Periodic Syndromes	Designated/Approved		"Regeneron Pharmaceuticals, Inc."
Temsirolimus	Torisel	12/16/2004	Treatment of renal cell carcinoma	Designated/Approved		"Wyeth Pharmaceuticals, Inc."
20-mer complementary to Akt mRNA		12/10/2004	Treatment of stomach cancer	Designated	Not FDA Approved for Orphan Indication	Rexahn Corporation
"(9-[N-(3-morpholinopropyl)-sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid"		12/8/2004	Prevention of post-operative complications of aortic anuerysm surgical repair	Designated	Not FDA Approved for Orphan Indication	Inotek Pharmaceuticals Corporation
20-mer oligonucleotide complementary to Akt mRNA		12/8/2004	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Rexahn Corporation
20-mer oligonucleotide complementary to Akt mRNA		12/8/2004	Treatment of glioblastoma	Designated	Not FDA Approved for Orphan Indication	Rexahn Corporation
human anti-integrin receptor avb3/avb5 monoclonal antibody		12/1/2004	"Treatment of patients with high-risk stage II, stage III, and stage IV malignant melanoma"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
20-mer oligonucleotide complementary to Akt mRNA		12/1/2004	Treatment of renal cell carcinoma	Designated	Not FDA Approved for Orphan Indication	Rexahn Corporation
20-mer oligonucleotide complementary to Akt mRNA		12/1/2004	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	Rexahn Corporation
Porfimer sodium		11/18/2004	Treatment of cholangiocarcinoma	Designated	Not FDA Approved for Orphan Indication	"Concordia Laboratories, Inc., Sarl"
Potassium Iodide Oral Solution	ThyroShield	11/17/2004	For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine	Designated/Approved		"Fleming & Company, Pharmaceuticals"
Nimotuzumab		11/17/2004	Treatment of glioma	Designated	Not FDA Approved for Orphan Indication	InnoKeys PTE Ltd.
Sitaxsentan Sodium		11/2/2004	For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.	Designated	Not FDA Approved for Orphan Indication	Pfizer Global Research and Development
Human monoclonal antibody against platelet-derived growth factor D		11/2/2004	To slow the progression of IgA nephropathy and delay kidney failure in patients affected by the disease.	Designated	Not FDA Approved for Orphan Indication	CuraGen Corporation
golimumab		11/2/2004	Treatment of chronic sarcoidosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Centocor, Inc."
terlipressin	Terlivaz	10/29/2004	Treatment of Hepatorenal Syndrome	Designated/Approved		Mallinckrodt Pharmaceuticals Ireland Ltd
Cyclosporin A		10/29/2004	Treatment of amyotrophic lateral sclerosis and its variants	Designated	Not FDA Approved for Orphan Indication	"Maas Biolab,LLC"
Desmoglein 3 synthetic peptide (PI-0824)		10/26/2004	Treatment of pemphigus vulgaris	Designated	Not FDA Approved for Orphan Indication	"Peptimmune, Inc."
laromustine		10/21/2004	Treatment of acute myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	"Vion Pharmaceuticals, Inc."
bevacizumab		10/20/2004	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Genentech, Inc."
Temozolomide		10/18/2004	Treatment of newly diagnosed high grade glioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Merck & Company
Sorafenib	Nexavar	10/8/2004	Treatment of renal cell carcinoma.	Designated/Approved		Bayer Pharmaceutical Corporation
rufinamide	Banzel	10/8/2004	Treatment of Lennox-Gastaut Syndrome.	Designated/Approved		"Eisai, Inc."
obatoclax mesylate		10/8/2004	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Teva Branded Pharmaceutical Products R&D, Inc."
romidepsin	Istodax	9/30/2004	Treatment of non-Hodgkin T-cell lymphomas	Designated/Approved		Celgene Corporation
romidepsin	Istodax	9/30/2004	Treatment of non-Hodgkin T-cell lymphomas	Designated/Approved		Celgene Corporation
trabectedin	Yondelis	9/30/2004	Treatment of soft tissue sarcoma	Designated/Approved		"Janssen Research & Development, LLC"
N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide		9/30/2004	Treatment of neuroblastoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
plitidepsin		9/30/2004	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"PharmaMar USA, Inc."
Nitric oxide		9/27/2004	To reduce the risk of chronic lung disease in premature neonates	Designated	Not FDA Approved for Orphan Indication	Mallinckrodt Pharmaceuticals Ireland Ltd.
thalidomide		9/27/2004	Treatment of myelodysplastic syndrome	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
Human anti-CD30 monoclonal antibody		9/27/2004	Treatment of Hodgkin's disease	Designated	Not FDA Approved for Orphan Indication	"Bristol-Myers Squibb, Inc."
Immune Globulin Subcutaneous (Human)		9/22/2004	Treatment of patients with primary immune deficiency (PID) that are intolerant to immune globulin intravenous (IGIV) due to severe adverse events or poor venous access	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	CSL Behring
Coagulation factor VIIa (recombinant)	NovoSeven	9/10/2004	Prevention of bleeding episodes in patients with congenital Factor VII deficiency	Designated/Approved		"Novo Nordisk, Inc."
Coagulation factor VIIa (recombinant)	NovoSeven	9/10/2004	Treatment of bleeding episodes in patients with congenital factor VII deficiency	Designated/Approved		"Novo Nordisk, Inc."
L-tyrosine-L-serine-L-leucine		9/10/2004	Treatment of hepatocellular carcinoma.	Designated	Not FDA Approved for Orphan Indication	CMS Peptides Patent Holding Company Limited
Tanespimycin		9/9/2004	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb
Buffered Ursodeoxycholic Acid		9/3/2004	Treatment of pruritus in patients with Alagille Syndrome	Designated	Not FDA Approved for Orphan Indication	"Digestive Care, Inc."
17-allylamino-17-demethoxygeldanamycin (17-AGG)		9/3/2004	Treatment of chronic myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Company
Nine amino acid polypeptide derived from proteinase 3		9/3/2004	Treatment of myelodysplastic syndromes requiring therapy	Designated	Not FDA Approved for Orphan Indication	The Vaccine Company
A10 & AS2-1 Antineoplaston		9/3/2004	Treatment for patients with brain stem glioma	Designated	Not FDA Approved for Orphan Indication	"Burzynski Research Institute, Inc."
Autologous incubated macrophage		9/3/2004	Therapy to improve the motor and sensory neurological outcome in acute cases of spinal cord injury	Designated	Not FDA Approved for Orphan Indication	"Proneuron Biotechnologies, Inc."
heat killed Mycobacterium w immunomodulator		9/3/2004	Active tuberculosis	Designated	Not FDA Approved for Orphan Indication	"Cadila Pharmaceuticals Limited, Inc."
Nine amino acid polypeptide derived from proteinase 3		9/3/2004	Treatment of chronic myelogenous leukemia.	Designated	Not FDA Approved for Orphan Indication	The Vaccine Company
Nine amino acid polypeptide derived from proteinase 3		9/3/2004	Treatment of acute myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	The Vaccine Company
Alpha1-Proteinase Inhibitor (Human)		9/1/2004	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	Kamada Ltd.
ataluren		9/1/2004	For use in the treatment of cystic fibrosis resulting fron a nonsense (premature stopcodon) mutation in the cystic bibrosis transmembrane conductance regulatory gene	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"PTC Therapeutics, Inc."
Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor		9/1/2004	Treatment of retinitis pigmentosa	Designated	Not FDA Approved for Orphan Indication	"Neurotech USA, Inc."
Implitapide		8/19/2004	Treatment of patients with Fredrickson type I or V hyperlipoproteinemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Medical Research Laboratories International
Nucleic acid aptamer binding to tumor cell nucleolin		8/17/2004	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Antisoma Research Ltd.
Iloprost inhalation solution	Ventavis	8/17/2004	Treatment of pulmonary arterial hypertension	Designated/Approved		"CoTherix, Inc."
meclorethamine	Valchlor	8/17/2004	Treatment of mycosis fungoides	Designated/Approved		Helsinn Birex Pharmaceuticals Ltd.
human anti-CD4 monoclonal antibody		8/13/2004	Treatment of mycosis fungoides	Designated	Not FDA Approved for Orphan Indication	"Emergent Product Development Seattle, LLC"
"N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide"		8/13/2004	Treatment of stages IIB-IV melanoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
"(6R,S)5,10-methylene-tetrahydrofolic acid"		8/13/2004	For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Adventrx Pharmaceuticals, Inc."
"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride"		8/13/2004	Treatment of acute lymphoblastic leukemia	Designated	Not FDA Approved for Orphan Indication	Mundipharma Research Limited
dacetuzumab		8/13/2004	Treatment of multiple myeloma.	Designated	Not FDA Approved for Orphan Indication	"Seattle Genetics, Inc."
Implitapide		8/13/2004	Treatment of homozygous familial hypercholesterolemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Medical Research Laboratories International
dexanabinol		8/11/2004	For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury	Designated	Not FDA Approved for Orphan Indication	Pharmos Corporation
"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride"		8/10/2004	"Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia"	Designated	Not FDA Approved for Orphan Indication	Mundipharma Research Ltd.
nelarabine	Arranon	8/10/2004	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma	Designated/Approved		Novartis Pharmaceuticals Corp.
efaproxiral		7/28/2004	Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer	Designated	Not FDA Approved for Orphan Indication	"Allos Therapeutics, Inc."
Immune Globulin (Human)	Gamunex-C	7/27/2004	Treatment of chronic inflammatory demyelinating polyneuropathy	Designated/Approved		"Grifols Therapeutics, Inc."
Multi-ligand somatostatin analog		7/27/2004	"Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
Coagulation factor VIIa (recombinant)	NovoSeven	7/21/2004	Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Designated/Approved		"Novo Nordisk, Inc."
Coagulation Factor VIIa (Recombinant)	NovoSeven	7/16/2004	Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Designated/Approved		"Novo Nordisk, Inc."
Doripenem		7/16/2004	Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.	Designated	Not FDA Approved for Orphan Indication	"Shionogi, Inc."
Immortalized human liver cells found in the extracorporeal liver assist device		7/16/2004	Treatment of fulminant hepatic failure (acute liver failure)	Designated	Not FDA Approved for Orphan Indication	"Vital Therapies, Inc."
posaconazole		7/16/2004	Treatment of zygomycosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Merck Sharp & Dohme LLC
C1 esterase inhibitor (human)	Cinryze	7/16/2004	Treatment of angioedema	Designated/Approved		"Takeda Development Center Americas, Inc."
ambrisentan	Letairis	7/16/2004	Treatment of pulmonary arterial hypertension	Designated/Approved		Gilead Colorado
C1 esterase inhibitor (human)	Cinryze	7/16/2004	Treatment of angioedema	Designated/Approved		"Takeda Development Center Americas, Inc."
"human anti-transforming growth factor-B1,2,3"		7/9/2004	Treatment of idiopathic pulmonary fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genzyme Corporation
Melatonin		7/9/2004	Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception	Designated	Not FDA Approved for Orphan Indication	"Neurim Pharmaceuticals, Ltd."
Tipifarnib		7/6/2004	Treatment of acute myeloid leukemia	Designated	Not FDA Approved for Orphan Indication	Johnson & Johnson Pharmaceutical Research & Dev.
Vaccinia Immune Globulin (Human) Intravenous		6/18/2004	Treatment of severe complications from the smallpox vaccine	Designated/Approved		DynPort Vaccine Company LLC
liarozole		6/18/2004	Treatment of congenital ichthyosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Stiefel Laboratories, Inc."
Plitidepsin		6/18/2004	Treatment of acute lymphoblastic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"PharmaMar USA, Inc"
sarsasapogenin		6/18/2004	Treatment of amyotrophic lateral sclerosis (ALS)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Phytopharm plc
Coagulation factor VIIa (recombinant)	NovoSeven	6/18/2004	"Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors"	Designated/Approved		"Novo Nordisk, Inc."
coagulation factor VIIa (recombinant)	NovoSeven RT	6/18/2004	Treatment of bleeding episodes in Glanzmann's thrombasthenia	Designated/Approved		Novo Nordisk Inc.
Vaccinia Immune Globulin (Human) Intravenous	CNJ-016	6/18/2004	Treatment of complications of vaccinia vaccination	Designated/Approved		Cangene Corporation
Coagulation factor VIIa (recombinant)		6/18/2004	Prevention of bleeding episodes in Glanzmann's thrombasthenia	Designated	Not FDA Approved for Orphan Indication	"Novo Nordisk, Inc."
ipilimumab	Yervoy	6/3/2004	"Treatment of high risk Stage II, Stage III, and Stage IV melanoma"	Designated/Approved		Bristol-Myers Squibb Company
ipilimumab	Yervoy	6/3/2004	"Treatment of high risk Stage II, Stage III, and Stage IV melanoma"	Designated/Approved		Bristol-Myers Squibb Company
ipilimumab	Yervoy	6/3/2004	"Treatment of high risk Stage II, Stage III, and Stage IV melanoma"	Designated/Approved		Bristol-Myers Squibb Company
ipilimumab	Yervoy	6/3/2004	"Treatment of high risk Stage II, Stage III, and Stage IV melanoma"	Designated/Approved		Bristol-Myers Squibb Company
quinine Sulfate		6/3/2004	Treatment of malaria	Designated/Approved		"AR Holding Company, Inc."
Thymosin beta 4		5/28/2004	Treatment of epidermolysis bullosa	Designated	Not FDA Approved for Orphan Indication	"HLB Therapeutics Co., Ltd"
mepolizumab	NUCALA®	5/28/2004	Treatment of hypereosinophilic syndrome	Designated/Approved		GlaxoSmithKline LLC
Diethylnorspermine (DENSPM)		5/25/2004	Treatment for hepatocellular carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genzyme Corporation
icatibant		5/5/2004	Treatment of burn patients hospitalized with burn-induced edema	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Shire Human Genetic Therapies
Immune Globulin Intravenous (human)		5/4/2004	Treatment for Guillain Barre Syndrome	Designated	Not FDA Approved for Orphan Indication	ZLB Bioplasma AG
Diethylenetriaminepentaacetic acid (DTPA)		4/28/2004	"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination."	Designated/Approved		Hameln Pharmaceuticals gmbh
mannopentaose phosphate sulfate		4/27/2004	"Treatment of high-risk Stage II, Stage III, and Stage IV melanoma"	Designated	Not FDA Approved for Orphan Indication	Medigen Biotechnology Corp.
temocillin sodium		4/21/2004	Treatment of pulmonary infections caused by Burkholderia cepacia	Designated	Not FDA Approved for Orphan Indication	Belpharma S.A.
Fluoxetine		4/14/2004	Treatment of body dysmorphic disorder in children and adolescents	Designated	Not FDA Approved for Orphan Indication	"Hollander, Eric MD"
Deferitrin		4/14/2004	Treatment of iron overload	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genzyme Corporation
etaracizumab		4/14/2004	"For the treatment of of stage IIb, stage IIc, stage III and stage IV melanoma"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"MedImmune, LLC"
diethylenetriaminepentaacetate (DPTA)		4/14/2004	"For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination."	Designated	Not FDA Approved for Orphan Indication	CIS-US
ubiquinol		4/12/2004	Treatment of Huntington's Disease	Designated	Not FDA Approved for Orphan Indication	"Gel-Tec, Division of Tishcon Corp."
pentetate trisodium		4/12/2004	"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium."	Designated	Not FDA Approved for Orphan Indication	Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG
"Ubiquinol, coenzyme Q10, ubiquinone"		4/12/2004	Treatment of pediatric congestive heart failure	Designated	Not FDA Approved for Orphan Indication	"Gel-Tec, Division of Tishcon Corporation"
Hydralazine		4/9/2004	Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy	Designated	Not FDA Approved for Orphan Indication	Bioniche Pharma USA LLC
Vapreotide		4/6/2004	Treatment of symptomatic carcinoid tumors	Designated	Not FDA Approved for Orphan Indication	"H3 Pharma, Inc."
idebenone		3/25/2004	Treatment of Friedreich's ataxia	Designated	Not FDA Approved for Orphan Indication	Chiesi Farmaceutici S.p.A.
dexrazoxane	Totect(r)	3/25/2004	Treatment of anthracycline extravasation during chemotherapy	Designated/Approved		"Clinigen, Inc."
Alpha-1-acid glycoprotein		3/17/2004	Treatment of tricyclic antidepressant poisoning	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bio Products Laboratory
sodium thiosulfate	Pedmark	3/17/2004	Prevention of platinum-induced ototoxicity in pediatric patients	Designated/Approved		"Fennec Pharmaceuticals, Inc."
vorinostat		3/17/2004	Treatment of mesothelioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Merck & Co., Inc."
Immune Globulin (Human) containing high titers of West Nile virus antibodies		3/17/2004	Treatment of the West Nile virus infection	Designated	Not FDA Approved for Orphan Indication	"OMRIX Biopharmaceuticals, Ltd."
vorinostat	Zolinza	3/16/2004	Treatment of T-cell non-Hodgkin's lymphoma	Designated/Approved		"Merck & Co., Inc."
rofecoxib		3/16/2004	Treatment of juvenile rheumatoid arthritis	Designated	Not FDA Approved for Orphan Indication	"MERCK & Co., Inc."
"antihemophilic factor (recombinant), porcine sequence"	OBIZUR	3/16/2004	Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII	Designated/Approved		"Takeda Development Center Americas, Inc."
"rh-microplasmin, ocriplasmin"		3/16/2004	Adjunct to surgery in cases of pediatric vitrectomy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	ThromboGenics Inc.
Somatropin		3/16/2004	Treatment of patients with HIV-associated adipose redistribution syndrome	Designated	Not FDA Approved for Orphan Indication	"EMD Serono, Inc."
multi-vitamin infusion without vitamin K	M.V.I.-12	3/8/2004	Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy	Designated/Approved		Mayne Pharma (USA) Inc.
pirfenidone	ESBRIET	3/5/2004	Treatment of idiopathic pulmonary fibrosis	Designated/Approved		Genentech
Alpha-1-acid glycoprotein		3/5/2004	Treatment of cocaine overdose	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bio Products Laboratory
DEAE-rebeccamycin		3/1/2004	Treatment of bile duct tumors	Designated	Not FDA Approved for Orphan Indication	Helsinn Healthcare SA
Trisodium zinc Diethylenetriaminepentaacetate		2/27/2004	"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination."	Designated	Not FDA Approved for Orphan Indication	CustomCare Pharmacy
migalastat hydrochloride	GALAFOLD	2/25/2004	Treatment of Fabry Disease	Designated/Approved		"Amicus Therapeutics, Inc."
Chimeric monoclonal antibody to CD30 (anti-CD30 antibody)		2/18/2004	Treatment of CD30 positive T-cell lymphomas	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Seattle Genetics, Inc."
rituximab	Rituxan	1/29/2004	Treatment of chronic lymphocytic leukemia	Designated/Approved		"Genentech, Inc."
oral unfractionated heparin		1/29/2004	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"TRF Technologies, Inc."
Staphylococcus aureus Immune Globulin (Human)		1/29/2004	Prophylaxis against Staphylococcus aureus infections in low birth weight neonates	Designated	Not FDA Approved for Orphan Indication	Biotest Pharmaceuticals Corporation
lenalidomide	Revlimid	1/29/2004	Treatment of myelodysplastic syndromes	Designated/Approved		Celgene Corporation
sapropterin	Kuvan	1/29/2004	Treatment of hyperphenylalaninemia	Designated/Approved		"BioMarin Pharmaceutical, Inc."
Chenodeoxycholic acid		1/29/2004	Treatment of cerebrotendinous xanthomatosis	Designated	Not FDA Approved for Orphan Indication	Dr. Falk Pharma GmbH
recombinant human fibroblast growth factor-20		1/29/2004	Treatment of radiation induced oral mucositis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	CuraGen Corporation
crotalidae immune F(ab')2 (equine)	Anavip	1/29/2004	Treatment of envenomation by Crotaline snakes	Designated/Approved		"Rare Disease Therapeutics, Inc."
crotalidae immune F(ab')2 (equine)	Anavip	1/29/2004	Treatment of envenomation by Crotaline snakes	Designated/Approved		"Rare Disease Therapeutics, Inc."
"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride"		1/29/2004	Treatment of T-cell non-Hodgkin's lymphoma	Designated	Not FDA Approved for Orphan Indication	Mundipharma Research Limited
90Y-hPAMA4		1/29/2004	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
rhIGF-I/rhIGFBP-3		12/9/2003	"Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)"	Designated	Not FDA Approved for Orphan Indication	"Insmed, Inc."
recombinant human neutrophil inhibitor (hNE)		12/9/2003	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	Dyax Corporation
N-acetyl-sarcosyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl_L-prolylethylaminde acetate		12/9/2003	Treatment of soft tissue sarcoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AbbVie, Inc."
liposomal p-ethoxy growth receptor bound protein-2 antisense product		12/5/2003	Treatment of chronic myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	"Bio-Path, Inc."
Tranilast		12/2/2003	For the treatment of maligant glioma	Designated	Not FDA Approved for Orphan Indication	"Angiogen Pharmaceuticals, Pty. Ltd."
"2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate"		12/2/2003	Treatment of mulitple myeloma and associated bone resorption	Designated	Not FDA Approved for Orphan Indication	"Callisto Pharmaceuticals, Inc."
baclofen		12/2/2003	Treatment of dystonia	Designated	Not FDA Approved for Orphan Indication	Medtronic Neurological
Cyclosporine		11/25/2003	Prophylaxis of organ rejection in patients receiving allogeneic lung transplant	Designated	Not FDA Approved for Orphan Indication	"APT Pharmaceuticals, Inc."
Cyclosporine		11/25/2003	Treatment of acute rejection in patients requiring allogenic lung transplants	Designated	Not FDA Approved for Orphan Indication	"APT Pharmaceuticals, Inc."
icatibant	Firazyr	11/25/2003	Treatment of angioedema	Designated/Approved		"Takeda Development Center Americas, Inc."
abagovomab		11/25/2003	Treatment of epithelial ovarian cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Menarini Ricerche S.p.A.
Hydroxocobalamin	Cyanokit	11/25/2003	Treatment of acute cyanide poisoning	Designated/Approved		"SERB, S.A."
anti-interferon-gamma Fab from goats		11/18/2003	For the treatment of immunologic corneal allograft rejection	Designated	Not FDA Approved for Orphan Indication	"Advanced Biotherapy, Inc."
human gammaglobulin		11/14/2003	Treatment of idiopathic inflammatory myopathies	Designated	Not FDA Approved for Orphan Indication	"Latona Life Sciences, Inc."
monarsen		11/14/2003	Treatment of myasthenia gravis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bioline Rx, Ltd."
SC-1 monoclonal antibody		11/12/2003	Treatment of patients with CD55 (sc-1) positive gastric tumors	Designated	Not FDA Approved for Orphan Indication	Patrys Ltd.
Infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Designated/Approved		"Centocor, Inc."
infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	Designated/Approved		"Janssen Biotech, Inc."
raxibacumab	ABthraxTM	11/12/2003	Treatment of anthrax	Designated/Approved		"Human Genome Sciences, Inc."
coagulation factor XIII A-subunit (recombinant)	TRETTEN	11/6/2003	Prophylaxis of bleeding associated with congential factor XIII deficiency	Designated/Approved		"Novo Nordisk, Inc."
bevacizumab	Avastin	11/6/2003	Treatment of renal cell carcinoma	Designated/Approved		"Genentech, Inc."
"[5,10,15,20-tetrakis(1,3-diethylimidazolium-2-yl)porphyrinato] manganese(III)pentachloride"		11/4/2003	Treatment of Amyotrophic Lateral Sclerosis	Designated	Not FDA Approved for Orphan Indication	"Aeolus Pharmaceuticals, Inc."
tin ethyl etiopurpurin		11/4/2003	Prevention of access graft disease in hemodialysis patients	Designated	Not FDA Approved for Orphan Indication	Miravant Medical Technologies
vapreotide		11/4/2003	Treatment of acromegaly	Designated	Not FDA Approved for Orphan Indication	"H3 Pharma, Inc."
Imexon		11/1/2003	Treatment of pancreatic adenocarcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AmpliMed Corporation
Atomoxetine hydrochloride		8/26/2003	Treatment of Tourette's Syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Eli Lilly & Company
anacaulase-bcdb	NexoBrid	8/20/2003	"Debridement of acute, deep dermal burns in hospitalized patients"	Designated/Approved		"MediWound, Ltd."
"5,5',5""-[Phosphinothioylidyne-tris(imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride"		8/20/2003	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Now Pharm AG
talactoferrin alfa		8/20/2003	For the prevention of graft-versus-host disease	Designated	Not FDA Approved for Orphan Indication	"Agennix, Inc."
Tinidazole	Tindamax	8/20/2003	Treatment of amebiasis	Designated/Approved		"Presutti Laboratories, Inc."
talactoferrin alfa		8/20/2003	For the treatment of graft versus host disease	Designated	Not FDA Approved for Orphan Indication	"Agennix, Inc."
eculizumab	Soliris	8/20/2003	Treatment of paroxysmal nocturnal hemoglobinuria	Designated/Approved		"Alexion Pharmaceuticals, Inc."
"(3S)-3-[(2S)-2-({N-[2-tert-butyl)phenyl]carbamoyl}carbonylamino) propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanoci acid"		8/19/2003	Treatment of patients undergoing solid organ transplantation.	Designated	Not FDA Approved for Orphan Indication	Pfizer Global Research and Development
glucarpidase	Voraxaze	8/19/2003	Treatment of patients at risk of methotrexate toxicity	Designated/Approved		BTG International Inc.
Dehydroepiandrosterone (DHEA)		8/19/2003	Replacement therapy in individuals with adrenal insufficiency	Designated	Not FDA Approved for Orphan Indication	"Paladin Labs, Inc."
allogeneic processed thymus tissue-agdc	Rethymic	8/15/2003	Treatment of congenital athymia	Designated/Approved		Enzyvant Therapeutics GmbH
Mx-dnG1 or Rexin-G retroviral vector		8/15/2003	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	Epeius Biotechnologies Corporation
niprisan		8/15/2003	Treatment of sickle cell disease	Designated	Not FDA Approved for Orphan Indication	"Xechem International, Inc."
"2-0-Butyryl-1-0-octyl-myo-inositol 3,4,5,6-tetrakisphosphate"		8/15/2003	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Inologic, Inc."
Combretastatin A4 Phosphate		7/23/2003	"Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer"	Designated	Not FDA Approved for Orphan Indication	"Mateon Therapeutics, Inc."
conjugated bile acids		7/18/2003	Treatment of steatorrhea in patients with short bowel syndrome	Designated	Not FDA Approved for Orphan Indication	"Jarrow Formulas, Inc."
Chimeric monoclonal antibody to CD30 (anti-CD30 antibody)		7/18/2003	Treatment of Hodgkin's disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Seattle Genetics, Inc"
Erlotinib Hydrochloride		7/18/2003	Treatment of malignant gliomas	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc"
cholic acid	Cholbam	7/18/2003	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	Designated/Approved		"Mirum Pharmaceuticals, Inc."
"Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab 19, exbivirumab"		7/15/2003	For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Cubist Pharmaceuticals
siplizumab		7/15/2003	Treatment of T-cell lymphomas	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"MedImmune, LLC"
plerixafor	Mozobil (r)	7/10/2003	For use to improve the yield of progentor cells in the apheresis product for subsequest stem cell transplantation following myelosuppressive or myeloablative chemotherapy	Designated/Approved		Genzyme Corporation
sodium dichloroacetate		7/3/2003	Use as an antidote in the management of systemic monochloroacetic acid poisoning	Designated	Not FDA Approved for Orphan Indication	EBD Group
(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide		7/3/2003	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	Designated	Not FDA Approved for Orphan Indication	"Phase 2 Discovery, Inc."
"ferric hexacyanoferrate (II) ""Prussian Blue"""		6/26/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Designated	Not FDA Approved for Orphan Indication	Degussa AG
diferuloylmethane		6/13/2003	Treatment of cystic fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Allertein Therapeutics, LLC"
diphenylcyclopenone		6/13/2003	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])	Designated	Not FDA Approved for Orphan Indication	"Lloyd E. King, Jr."
arsenic trioxide		6/13/2003	Treatment of liver cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Teva Branded Pharmaceutical Products R&D, Inc."
vorinostat		6/12/2003	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Merck Research Laboratories
myristoylated recombinant SCR1-3 of human complement reseptor type I		5/21/2003	Prevention of delayed graft function in solid organ transplant	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Orexo AB
"Factor XIII [A2] homodimer, recombinant DNA origin"		5/21/2003	Treatment of congenital FXIII deficiency	Designated	Not FDA Approved for Orphan Indication	"Novo Nordisk Pharmaceuticals, INc."
Protaxel		5/21/2003	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"Biophysica, Inc."
Infliximab		5/21/2003	Treatment of chronic sarcoidosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Centocor, Inc."
Anti-CEA Sheep-human chimeric monoclonal antibody labeled w/iodine-131 (KAb201)		5/21/2003	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Avaant Pharmaceuticals India Ltd.
repository corticotropin or adrenocorticotropic hormone	H.P. Acthar Gel	5/21/2003	Treatment of infantile spasms	Designated/Approved		"Questcor Pharmaceuticals, Inc."
defibrotide	Defitelio	5/21/2003	For the treatment of hepatic veno-occlusive disease	Designated/Approved		"Jazz Pharmaceuticals, Inc."
Arsenic trioxide		5/13/2003	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Teva Branded Pharmaceutical Products R&D, Inc."
resiniferatoxin		5/13/2003	Treatment of intractable pain at end-stage disease	Designated	Not FDA Approved for Orphan Indication	"Sorrento Theraeputics, Inc."
cinacalcet	Sensipar	5/12/2003	Treatment of hypercalcemia in patients with parathyroid carcinoma	Designated/Approved		"Amgen, Inc."
infliximab		5/6/2003	Treatment of giant cell arteritis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Centocor, Inc."
Recombinant T-cell receptor ligand		5/2/2003	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55	Designated	Not FDA Approved for Orphan Indication	"Artielle ImmunoTherapeutics, Inc."
capsaicin		5/2/2003	Treatment of painful HIV-associated neuropathy	Designated	Not FDA Approved for Orphan Indication	"Averitas Pharma, Inc."
iron(III)-hexacyanoferrate(II)	Radiogardase	5/1/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Designated/Approved		"Heyl Chemisch-Pharmzeutische Fabrik GMBH & Co, KG"
DHA-paclitaxel		5/1/2003	Treatment of adenocarcinoma of the stomach or lower esophagus	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Luitpold Pharmaceuticals, Inc."
Tretinoin		4/11/2003	Treatment of T-cell non-Hodgkin's lymphoma	Designated	Not FDA Approved for Orphan Indication	"Antigenics, Inc."
"4,5-dibromorhodamine 123"		4/10/2003	Treatment of chronic myelogenous leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Kiadis Pharma Canada, Inc."
ribavirin	REBETOL	4/4/2003	Treatment of chronic hepatitis C in pediatric patients	Designated/Approved		Schering Corporation
Sodium pyruvate		3/31/2003	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Cellular Sciences, Inc"
"(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid"		3/31/2003	Prevention of serious adverse events associated with vascular leak syndrome caused by Interleukin-2 therapy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Intarcia Therapeutics, Inc."
alendronate		3/31/2003	Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Merck, Sharpe & Dohme Corp."
romiplostim	Nplate	3/27/2003	Treatment of immune thrombocytopenic purpura	Designated/Approved		"Amgen, Inc."
romiplostim	Nplate	3/27/2003	Treatment of immune thrombocytopenic purpura	Designated/Approved		"Amgen, Inc."
romiplostim	Nplate	3/27/2003	Treatment of immune thrombocytopenic purpura	Designated/Approved		"Amgen, Inc."
dextran 1		3/21/2003	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	BCY LifeSciences Inc.
antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA]		3/12/2003	Treatment for renal cell carcinoma	Designated	Not FDA Approved for Orphan Indication	"Lorus Therapeutics, Inc"
MaxAdFVIII		3/3/2003	Treatment of Hemophilia A	Designated	Not FDA Approved for Orphan Indication	GenStar Therapeutics Corporation
polyinosinic-polycytidilic acid		3/3/2003	"Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses"	Designated	Not FDA Approved for Orphan Indication	Oncovir
"anti-CD23 IgG1, kappa monoclonal antibody"		2/12/2003	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Biogen IDEC, Inc."
ecallantide	Kalbitor	2/4/2003	Treatment of angioedema	Designated/Approved		"Takeda Pharmaceuticals USA, Inc."
ecallantide	Kalbitor	2/4/2003	Treatment of angioedema	Designated/Approved		"Takeda Pharmaceuticals USA, Inc."
Tezacitabine		1/27/2003	Treatment of adenocarcinoma of the esophagus and stomach	Designated	Not FDA Approved for Orphan Indication	"Sanofi-Aventis US, Inc."
recombinant adeno-associated virus alpha 1-antitrypsin vector		1/27/2003	Treatment of alpha1-antitrypsin deficiency	Designated	Not FDA Approved for Orphan Indication	University of Massachusetts Medical School
motexafin gadolinium		1/27/2003	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Designated	Not FDA Approved for Orphan Indication	"Pharmacyclics, LLC"
Replication defective recombinant adenovirus serotype 5 vector carrying the p53 gene in its E1 deleted region		1/27/2003	Treatment of head and neck cancer	Designated	Not FDA Approved for Orphan Indication	"Introgen Therapeutics, Inc."
reparixin		1/27/2003	Prevention of delayed graft function in solid organ transplant	Designated	Not FDA Approved for Orphan Indication	Dompe S.p.A.
alteplase		1/27/2003	Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage	Designated	Not FDA Approved for Orphan Indication	"Daniel F. Hanley, MD"
a-Galactosidase A		1/21/2003	Treatment of Fabry's disease	Designated	Not FDA Approved for Orphan Indication	"iBio, Inc."
Mafosfamide		1/21/2003	Treatment of neoplastic meningitis	Designated	Not FDA Approved for Orphan Indication	Baxter Healthcare Corporation
Human Anti-tumor Necrosis factor alpha monoclonal antibody		1/16/2003	"Treatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Centocor, Inc."
bifidobacterium longum infantis 35624		1/16/2003	Treatment of pediatric Crohn's disease	Designated	Not FDA Approved for Orphan Indication	Alimentary Health Limited
pomalidomide	Pomalyst	1/15/2003	Treatment of multiple myeloma	Designated/Approved		Celgene Corporation
bortezomib	Velcade	1/15/2003	Treatment of multiple myeloma	Designated/Approved		"Millennium Pharmaceuticals, Inc."
bortezomib	Velcade	1/15/2003	Treatment of multiple myeloma	Designated/Approved		"Millennium Pharmaceuticals, Inc."
bortezomib	Velcade	1/15/2003	Treatment of multiple myeloma	Designated/Approved		"Millennium Pharmaceuticals, Inc."
"2',3',5'-tri-o-acetyluridine"		1/13/2003	Treatment of mitochondrial disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Repligen Corporation
civamide		12/9/2002	Treatment of postherpetic neuralgia of the trigeminal nerve	Designated	Not FDA Approved for Orphan Indication	"Winston Laboratories, Inc."
R-etodolac		12/9/2002	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Cephalon, Inc."
"(4S)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1-H-pyrano[3?,4?:6,7]-indolizino-[1,2-b]-quinoline-11-carbaldehyde O-(tert-butyl)-(E)-oxime"		11/29/2002	Treatment malignant glioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sigma-Tau Research, Inc."
Autologous dendritic cells pulsed with autologous antigens from primay malignant brain tumor cells		11/29/2002	Treatment of primary brain malignant cancer	Designated	Not FDA Approved for Orphan Indication	"Northwest Biotherapeutics, Inc."
busulfan		11/25/2002	Preparative therapy for pediatric patients undergoing bone marrow transplantation	Designated	Not FDA Approved for Orphan Indication	"SuperGen, Inc."
meloxicam	Mobic	11/22/2002	Treatment of juvenile rheumatoid arthritis	Designated/Approved		"Boehringer Ingelheim Pharmaceuticals, Inc."
allantoin		11/21/2002	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Scioderm, Inc."
Deferasirox	Exjade; Jadenu Sprinkles	11/21/2002	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Designated/Approved		Novartis Pharmaceuticals Corp.
Deferasirox	Exjade; Jadenu Sprinkles	11/21/2002	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Designated/Approved		Novartis Pharmaceuticals Corp.
heat killed mycobacterium w immunomodulator		11/21/2002	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	Designated	Not FDA Approved for Orphan Indication	"CPL, Inc."
polyinosinic-polycytidilic acid (Poly-ICLC)		11/19/2002	Treatment for orthopox virus infections	Designated	Not FDA Approved for Orphan Indication	Oncovir
natural human lymphoblastoid interferon-alpha		11/18/2002	Treatment of polycythemia vera	Designated	Not FDA Approved for Orphan Indication	"Amarillo Biosciences, Inc."
cobiprostone		11/14/2002	Treatment of cystic fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sucampo Pharma Americas, LLC."
Hepatitis C virus immune globulin (human)		11/14/2002	Prophylaxis of hepatitis C infection in liver transplant recipients.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ADMA Biologics, Inc."
D-peptide of the sequence AKRHHGYKRKFH - NH2		10/23/2002	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Demegen, Inc."
tirapazamine		10/23/2002	Treatment of head and neck cancer	Designated	Not FDA Approved for Orphan Indication	"Sanofi-Aventis US, Inc."
infliximab		10/23/2002	Treatment of juvenile rheumatoid arthritis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Centocor, Inc."
inolimomab		10/23/2002	Treatment of graft versus host disease	Designated	Not FDA Approved for Orphan Indication	ElsaLys Biotech SAS
capsaicin		10/23/2002	Treatment of erythromelalgia	Designated	Not FDA Approved for Orphan Indication	"Averitas Pharma, Inc."
antiangiogenic components extracted from marine cartilage		10/16/2002	Treatment of renal cell carcinoma	Designated	Not FDA Approved for Orphan Indication	"AEterna Zentaris, Inc."
DHA-paclitaxel		10/10/2002	Treatment of metastatic malignant melanoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Luitpold Pharmaceuticals, Inc."
human gammaglobulin		9/16/2002	"Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients."	Designated	Not FDA Approved for Orphan Indication	"Latona Life Sciences, Inc."
recombinant human monoclonal antibody to hsp90		9/16/2002	Treatment of invasive candidiasis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corp.
interferon gamma-1b		9/12/2002	Treatment of idiopathic pulmonary fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"InterMune, Inc."
N-acetylcysteine		9/9/2002	Treatment of acute liver failure	Designated	Not FDA Approved for Orphan Indication	"Cumberland Pharmaceuticals, Inc."
decitabine		9/9/2002	Treatment of sickle cell anemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Otsuka Pharmaceutical Development &
lintuzumab		9/9/2002	Treatment of acute myelogenous leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Protein Design Labs, Inc."
recombinant human porphobilinogen deaminase		9/9/2002	Treatment of acute intermittent porphyria attacks	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Chiesi USA, Inc."
polyinosinic-polycytidilic acid		8/2/2002	As an adjuvant to smallpox vaccination	Designated	Not FDA Approved for Orphan Indication	Oncovir
G17DT Immunogen		7/18/2002	Treatment of gastric cancer	Designated	Not FDA Approved for Orphan Indication	"Cancer Advances, Inc."
rubitecan		7/17/2002	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	Designated	Not FDA Approved for Orphan Indication	"SuperGen, Inc."
autologous tumor-derived gp96 heat shock protein-peptide complex		7/11/2002	Treatment of metastatic melanoma	Designated	Not FDA Approved for Orphan Indication	"Agenus, Inc."
"recombinant human porphobilinogen deaminase, erythropoetic form"		7/11/2002	Treatment of acute intermittent porphyria preventing attacks	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Chiesi USA, Inc."
G17DT Immunogen		7/10/2002	Treatment of adenocarcinoma of the pancreas	Designated	Not FDA Approved for Orphan Indication	"Cancer Advances, Inc."
Cells produced using the AastromReplicelle System and SC-I Therapy Kit		7/10/2002	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Designated	Not FDA Approved for Orphan Indication	Aastrom Biosciences Incorporated
trabedersen		6/5/2002	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Oncotelic Inc.
mecasermin rinfabate	Iplex	5/17/2002	Treatment of growth hormone insensitivity syndrome (GHIS)	Designated/Approved		"Insmed, Inc."
octavalent Psuedomonas aeruginosa O-polysaccaharide-toxin A conjugate		5/16/2002	Prevention of Psuedomonas aeruginosa infections in patients with cystic fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Berna Biotech Ltd.
"N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea"		5/13/2002	Treatment of sickle cell disease	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	NeuroSearch A/S
autologous tumor-derived gp96 heat shock protein-peptide complex		5/10/2002	Treatment of renal cell carcinoma	Designated	Not FDA Approved for Orphan Indication	"Agenus, Inc."
genetically engineered herpes simplex virus (G207)		4/29/2002	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Aettis, Inc."
retroviral gamma-c cDNA containing vector		4/29/2002	Treatment of X linked severe combined immune deficiency disease	Designated	Not FDA Approved for Orphan Indication	"AVAX technologies, Inc."
autologous antigen presenting cells pulsed with autologous tumor Ig idiotype		4/18/2002	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Dendreon Corporation
tinidazole	Tindamax	4/18/2002	Treatment of giardiasis	Designated/Approved		"Presutti Laboratories, Inc."
hyaluronic acid		3/19/2002	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	Designated	Not FDA Approved for Orphan Indication	CoTherix
toralizumab		3/14/2002	Treatment of immune thrombocytopenic purpura	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Biogen IDEC Inc.
S(-)-3-[3-amino-phthalimido]-glutaramide		3/14/2002	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	EntreMed Incorporated
clofarabine		3/14/2002	Treatment of acute myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	"Genzyme Corp (Ilex Products, Inc.)"
aztreonam	Cayston	3/12/2002	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Designated/Approved		"Gilead Sciences, Inc."
rituximab		3/12/2002	Treatment of immune thrombocytopenic purpura	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
Albuterol		3/12/2002	Prevention of paralysis due to spinal cord injury	Designated	Not FDA Approved for Orphan Indication	"MotoGen, Inc."
recombinant human endostatin protein		2/21/2002	Treatment of metastatic melanoma	Designated	Not FDA Approved for Orphan Indication	"EntreMed, Inc."
nitazoxanide	Alinia	2/14/2002	Treatment of intestinal giardiasis	Designated/Approved		"Romark Laboratories, L.C."
I(131)-TM-601 (chlorotoxin)		2/14/2002	Treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	Eisai Inc.
phenylephrine		2/14/2002	Treatment of ileal pouch anal anastomosis related fecal incontinence	Designated	Not FDA Approved for Orphan Indication	S.L.A. Pharma
creatine		2/12/2002	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	"Avicena Group, Inc."
Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin		2/11/2002	Treatment of malignant mesothelioma	Designated	Not FDA Approved for Orphan Indication	National Institutes of Health
Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)		2/11/2002	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Designated	Not FDA Approved for Orphan Indication	"Excorp Medical, Inc."
Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin		2/11/2002	Treatment of epithelial ovarian cancer	Designated	Not FDA Approved for Orphan Indication	National Institutes of Health
homoharringtonine		2/8/2002	Treatment for chronic myelogenous leukemia	Designated	Not FDA Approved for Orphan Indication	"American BioScience, Inc."
clofarabine	Clolar	2/7/2002	Treatment of acute lymphoblastic leukemia	Designated/Approved		Genzyme Corporation
"lipase, amylase, and protease"		1/23/2002	Treatment of pancreatic insufficiency	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Altus Biologics Inc.
"lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)"		1/15/2002	Prevention of disease relapse in patients with chronic pouchitis	Designated	Not FDA Approved for Orphan Indication	"VSL Pharmaceuticals, Inc."
"carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-,ethyl ester"		1/15/2002	Management of cystic fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc"
"lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)"		1/15/2002	Treatment of active chronic pouchitis	Designated	Not FDA Approved for Orphan Indication	"VSL Pharmaceuticals, Inc."
human anti-transforming growth factor beta 1 monoclonal antibody		1/11/2002	Treatment of systemic sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genzyme Corporation
deferiprone	Ferriprox	12/12/2001	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	Designated/Approved		"Chiesi USA, Inc."
deferiprone	Ferriprox	12/12/2001	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	Designated/Approved		"Chiesi USA, Inc."
deferiprone	Ferriprox	12/12/2001	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	Designated/Approved		"Chiesi USA, Inc."
deferiprone	Ferriprox	12/12/2001	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	Designated/Approved		"Chiesi USA, Inc."
bryostatin-1		12/3/2001	For use in combination with paclitaxel in the treatment of esophageal cancer	Designated	Not FDA Approved for Orphan Indication	"GPC Biotech, Inc."
azacitidine	Vidaza	12/3/2001	Treatament of myelodysplastic syndromes	Designated/Approved		Celgene Corporation
conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)		12/3/2001	Treatment of malignant tumors of the central nervous system	Designated	Not FDA Approved for Orphan Indication	Xenova Biomedix Limited
idursulfase	Elaprase	11/28/2001	Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome)	Designated/Approved		"Takeda Pharmaceuticals U.S.A., Inc."
"Hu1D10, humanized monoclonal antibody"		11/28/2001	For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma	Designated	Not FDA Approved for Orphan Indication	"PDL BioPharma, Inc."
tri-antennary glycotripeptide derivative of 5-fluorodeoxyuridine monophosphate		11/23/2001	Treatment for hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	Cell Works Inc.
recombinant human alpha 1-antitrypsin (rAAT)		11/20/2001	Treatment of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	AiroMedica LLC
2-chloroethyl-3-sarcosinamide-1-nitrosourea		11/15/2001	Treatment for malignant glioma	Designated	Not FDA Approved for Orphan Indication	Pangene Corporation
cintredekin besudotox		11/2/2001	Treatment of malignant glioma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Insys Development Company, Inc."
digitoxin		11/2/2001	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	SimRx Advisors LLC
arsenic		11/2/2001	"Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Teva Branded Pharmaceutical Products R&D, Inc."
imatinib mesylate	Gleevec	11/1/2001	Treatment of gastrointestinal stromal tumors	Designated/Approved		Novartis Pharmaceuticals Corp.
T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells		11/1/2001	Treatment of chronic granulomatous disease	Designated	Not FDA Approved for Orphan Indication	Nexell Therapeutics Inc.
imatinib mesylate	Gleevec	11/1/2001	Treatment of gastrointestinal stromal tumors	Designated/Approved		Novartis Pharmaceuticals Corp.
nitazoxanide		10/23/2001	Treatment for intestinal amebiasis	Designated	Not FDA Approved for Orphan Indication	"Romark Laboratories, L.C."
acetylcysteine	Acetadote	10/19/2001	For the intravenous treatment of moderate to severe acetaminophen overdose	Designated/Approved		"Cumberland Pharmaceuticals, Inc."
nitisinone		10/19/2001	Treatment of alkaptonuria	Designated	Not FDA Approved for Orphan Indication	Swedish Orphan Biovitrum AB (publ)
porfimer	Photofrin	10/19/2001	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy	Designated/Approved		Axcan Scandipharm Inc.
arsenic trioxide		10/18/2001	Treatment of chronic myeloid leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Teva Branded Pharmaceutical Products R&D, Inc."
nolatrexed		10/18/2001	Treatment of hepatocellular carcinoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	EXIMIAS Pharmaceutical Corporation
digitoxin		10/18/2001	Treatment of soft tissue sarcomas	Designated	Not FDA Approved for Orphan Indication	SimRx Advisors LLC
(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide		10/3/2001	Treatment of circadian rhythm sleep disorders in blind people with no light perception	Designated	Not FDA Approved for Orphan Indication	"Phase 2 Discovery, Inc."
DHA-paclitaxel		9/25/2001	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Luitpold Pharmaceuticals, Inc."
oglufanide disodium		9/24/2001	Treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	Implicit Bioscience Pty Ltd
lenalidomide	Revlimid	9/20/2001	Treatment of multiple myeloma	Designated/Approved		Celgene Corporation
lenalidomide	Revlimid	9/20/2001	Treatment of multiple myeloma	Designated/Approved		Celgene Corporation
lenalidomide	Revlimid	9/20/2001	Treatment of multiple myeloma	Designated/Approved		Celgene Corporation
humanized monoclonal antibody against Shiga-like toxin II		9/12/2001	To prevent the development of or to decrease the incidence and severity of hemolytic uremic syndrome and associated sequelae of Shiga-like toxin-producing E. coli.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Teijin America, Inc."
"beclomethasone 17,21-dipropionate"		8/28/2001	Prevention of gastrointestinal graft-versus-host disease	Designated	Not FDA Approved for Orphan Indication	"Soligenix, Inc."
oblimersen		8/28/2001	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	"Genta, Inc."
oblimersen		8/28/2001	Treatment of chronic lymphocytic leukemia	Designated	Not FDA Approved for Orphan Indication	"Genta, Inc."
recombinant human alpha-1 antitrypsin (rAAT)		8/28/2001	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	Designated	Not FDA Approved for Orphan Indication	AiroMedica LLC
oblimersen		8/28/2001	Treatment of acute myelocytic leukemia	Designated	Not FDA Approved for Orphan Indication	"Genta, Inc."
pemetrexed disodium	Alimta	8/28/2001	Treatment of malignant pleural mesothelioma	Designated/Approved		Eli Lilly and Company
metreleptin		8/22/2001	Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy	Designated	Not FDA Approved for Orphan Indication	Chiesi Farmaceutici S.p.A.
metreleptin	MYALEPT	8/22/2001	Treatment of metabolic disorders secondary to lipodystrophy	Designated/Approved		Chiesi Farmaceutici S.p.A.
Recombinant human endostatin protein		8/13/2001	Treatment of neuroendocrine tumors	Designated	Not FDA Approved for Orphan Indication	"EntreMed, Inc."
"Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide"		8/13/2001	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	Designated	Not FDA Approved for Orphan Indication	Fallien Cosmeceuticals Ltd.
2-chloroethyl-3-sarcosinamide-1-nitrosourea		8/3/2001	Treatment for malignant gliomas	Designated	Not FDA Approved for Orphan Indication	"Lawrence Panasci, MD"
Angiotensin 1-7		8/3/2001	Treatment of myelodysplastic syndrome	Designated	Not FDA Approved for Orphan Indication	"Tarix Pharmaceuticals, Ltd"
Imexon		8/3/2001	Treatment of metastatic malignant melanoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AmpliMed Corporation
Thyrotropin alfa	Thyrogen	8/3/2001	"Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid"	Designated/Approved		Genzyme Corporation
L-glutamine	Endari	8/1/2001	Treatment of sickle cell disease	Designated/Approved		"Emmaus Medical, Inc."
Intraoral fluoride releasing system		7/31/2001	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Designated	Not FDA Approved for Orphan Indication	"Digestive Care, Inc."
sitimagene ceradenovec		7/31/2001	Use with gancyclovir in the treatment of malignant glioma	Designated	Not FDA Approved for Orphan Indication	"Gliotherapy, Ltd."
2-methoxyestradiol		7/10/2001	Treatment of multiple myeloma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"EntreMed, Inc."
Reviparin sodium		6/18/2001	Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients	Designated	Not FDA Approved for Orphan Indication	Abbott
Latrodectus immune F(ab)2		6/18/2001	Treatment of black widow spider envenomations	Designated	Not FDA Approved for Orphan Indication	"Instituto Bioclon, S.A. de C.V."
Reviparin sodium		6/18/2001	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Designated	Not FDA Approved for Orphan Indication	Abbott
Adeno-associated viral vector containing the gene for human coagulation factor IX		6/13/2001	Intrahepatic treatment of patients with moderate to severe hemophilia	Designated	Not FDA Approved for Orphan Indication	"Avigen, Inc."
Adeno-associated viral vector containing the gene for human coagulation factor IX		6/13/2001	Intramuscular treatment of patients with moderate to severe hemophilia	Designated	Not FDA Approved for Orphan Indication	"Avigen, Inc."
Staphylococcal immunoglobulin (human)		6/13/2001	Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Inhibitex, Inc."
mifamuritide		6/5/2001	Treatment of osteosarcoma	Designated	Not FDA Approved for Orphan Indication	"Millennium Pharmaceuticals, Inc."
Glatiramer acetate for injection		6/5/2001	Treatment of primary-progressive multiple sclerosis	Designated	Not FDA Approved for Orphan Indication	Teva Pharmaceuticals USA
human gammaglobulin		5/25/2001	Treatment for juvenile rheumatoid arthritis	Designated	Not FDA Approved for Orphan Indication	"Latona Life Sciences, Inc."
9-nitro-20-(S)-camptothecin		5/15/2001	Treatment of pediatric HIV infection/AIDS	Designated	Not FDA Approved for Orphan Indication	"NovoMed Pharmaceuticals, Inc."
squalamine lactate		5/11/2001	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Designated	Not FDA Approved for Orphan Indication	Genaera Corporation
Perflubron		4/26/2001	Treatment of acute respiratory distress disease (ARDS) in adults	Designated	Not FDA Approved for Orphan Indication	PFC Development/New Alliance Pharmaceutical
Interferon-alfa-1b		4/17/2001	Treatment of multiple myeloma	Designated	Not FDA Approved for Orphan Indication	Ernest C.Borden
Recombinant human highly phosphorylated alpha-L-iduronidase (rhHP-IDUA)		4/11/2001	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Designated	Not FDA Approved for Orphan Indication	"Novazyme Pharmaceuticals, Inc."
Girentuximab		3/22/2001	Treatment of renal cell carcinoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Heidelberg Pharma AG
Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7		3/19/2001	Treatment of recurrent respiratory papillomatosis (RRP)	Designated	Not FDA Approved for Orphan Indication	"StressGen Biotechnologies, Inc. is now Nventa"
Vasoactive intestinal peptide		3/9/2001	Treatment of Acute Respiratory Distress Syndrome.	Designated	Not FDA Approved for Orphan Indication	mondoBIOTECH
"p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt"		3/7/2001	For the treatment of cystic fibrosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Inspire Pharmaceuticals, Inc."
Coenzyme Q10		3/5/2001	Treatment of Huntington's disease	Designated	Not FDA Approved for Orphan Indication	"Integrative Therapeutics, Inc."
eculizumab		3/5/2001	Treatment of idiopathic membranous glomerular nephropathy	Designated	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc."
Busulfan		3/5/2001	Intrathecal therapy for neoplastic meningitis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"SuperGen, Inc."
docosahexanoic acid-paclitaxel		3/5/2001	Treatment of hormone-refractory prostate cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Luitpold Pharmaceuticals, Inc."
Medroxyprogesterone acetate		2/22/2001	Treatment of immune thrombocytopenic purpura.	Designated	Not FDA Approved for Orphan Indication	"ZaBeCor Pharmaceutical Company, LLC"
Recombinant Human Alpha-Fetoprotein (rhAFP)		2/22/2001	Treatment of myasthenia gravis	Designated	Not FDA Approved for Orphan Indication	"Alpha Cancer Technologies, Inc."
pegloticase	Krystexxa	2/21/2001	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective	Designated/Approved		Horizon Therapeutics Ireland DAC
pegloticase	Krystexxa	2/21/2001	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Designated/Approved		Horizon Therapeutics Ireland DAC
B Lymphocyte Stimulator		2/21/2001	Treatment of common variable immunodeficiency (CVID)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Human Genome Sciences, Inc."
Nitroprusside		2/21/2001	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Designated	Not FDA Approved for Orphan Indication	"Thomas, MD, Jeffrey Evan"
Pyruvate		2/21/2001	Treatment of interstitial lung disease.	Designated	Not FDA Approved for Orphan Indication	"Cellular Sciences, Inc"
Alendronate disodium		2/13/2001	Treatment of the bone manifestations of Gaucher disease	Designated	Not FDA Approved for Orphan Indication	"Richard J. Wenstrup, M.D."
Virulizin		2/1/2001	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"ZOR Pharmaceuticals, LLC"
Imatinib	Gleevec	1/31/2001	Treatment of chronic myelogenous leukemia	Designated/Approved		Novartis Pharmaceuticals Corporation
Novel Acting Thrombolytic (NAT)		1/26/2001	Treatment of peripheral arterial occlusion (PAO)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Nuvelo, Inc. Inc."
Synthetic Human Parathyroid Hormone 1-34		1/26/2001	Treatment of hypoparathyroidism	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Rare Disease Therapeutics, Inc."
MTC-DOX for Injection		1/3/2001	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	FeRx Incorporated
N-acetylcysteinate Lysine		12/27/2000	For the management of cystic fibrosis	Designated	Not FDA Approved for Orphan Indication	"Galephar Pharmaceutical Research, Inc."
Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide)		12/27/2000	Chronic myelogenous leukemia (CML)	Designated	Not FDA Approved for Orphan Indication	Valeant Pharmaceuticals North America
somatropin [rDNA]	Genotropin	12/27/2000	Treatment of growth failure in children who were born small for gestational age.	Designated/Approved		Pharmacia and Upjohn Company
N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maystansine-Conjugated Humanized C242 Monoclonal Antibody		12/7/2000	For pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	SmithKline Beecham Pharmaceuticals
Cyclosporine in combination with omega-3 polyunsaturated fatty acids		12/6/2000	Prevention of solid organ graft rejection.	Designated	Not FDA Approved for Orphan Indication	RTP Pharma Corporation
Gavilimomab		11/20/2000	Acute graft-versus-host disease (aGVHD)	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Amgen
Technetium Tc99m rh-Annexin V		11/3/2000	"Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants."	Designated	Not FDA Approved for Orphan Indication	Theseus Imaging Corporation
taberminogene vadenovec		10/24/2000	Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.	Designated	Not FDA Approved for Orphan Indication	"Finvector Vision Therapies, Ltd."
Recombinant urate oxidase		10/11/2000	Prophylaxis of chemotherapy-induced hyperuricemia.	Designated	Not FDA Approved for Orphan Indication	Sanofi-Synthelabo Research
rasburicase	Elitek	10/11/2000	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	Designated/Approved		Sanofi-Synthelabo Research
bosentan	Tracleer	10/6/2000	Treatment of pulmonary arterial hypertension	Designated/Approved		Actelion Pharmaceuticals Ltd
bosentan	Tracleer	10/6/2000	Treatment of pulmonary arterial hypertension	Designated/Approved		Actelion Pharmaceuticals Ltd
Hydroxocobalamin		9/22/2000	Treatment of acute cyanide poisoning	Designated	Not FDA Approved for Orphan Indication	"Rare Disease Therapeutics, Inc."
DNP-Modified autologous tumor vaccine		9/21/2000	Adjuvant therapy for the treatment of ovarian cancer	Designated	Not FDA Approved for Orphan Indication	"AVAX Technologies, Inc."
Eculizumab		9/21/2000	Treatment of dermatomyositis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Alexion Pharmaceuticals, Inc."
Recombinant human highly phosphorylated acid alpha-glucosidase		9/20/2000	"For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)"	Designated	Not FDA Approved for Orphan Indication	"Novazyme Pharmaceuticals, Inc."
"3,5,3'-triiodothyroacetate"		9/20/2000	"Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland."	Designated	Not FDA Approved for Orphan Indication	"Elliot Danforth, Jr., M.D."
Lanreotide	Somatuline Depot	9/11/2000	Treatment for acromegly	Designated/Approved		"IPSEN, Inc."
Cisplatin/epinephrine		9/7/2000	Treatment of metastatic malignant melanoma.	Designated	Not FDA Approved for Orphan Indication	"Matrix Pharmaceutical, Inc."
anti-thymocyte Globulin (rabbit)		9/6/2000	Treatment of myelodysplastic syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genzyme Corporation
calfactant		9/5/2000	Treatment of acute respiratory distress syndrome (ARDS)	Designated	Not FDA Approved for Orphan Indication	"ONY, Inc."
Zoledronate	"Zometa, Zabel"	8/18/2000	Treatment of tumor induced hypercalcemia.	Designated/Approved		Novartis Pharmaceuticals Corp.
Trimetrexate		8/10/2000	Treatment of metastatic osteogenic sarcoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Medimmune Oncology, Inc."
Natural human lymphoblastoid interferon-alpha		8/10/2000	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Designated	Not FDA Approved for Orphan Indication	"Amarillo Biosciences, Inc."
"Chimeric, humanized monoclonal antibody to staphylococcus"		8/3/2000	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Designated	Not FDA Approved for Orphan Indication	"Biosynexus, Inc."
Hypericin		8/3/2000	Treatment of glioblastoma multiforme.	Designated	Not FDA Approved for Orphan Indication	"Soligenix, Inc."
olipudase alfa-rpcp	Xenpozyme	8/3/2000	Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease)	Designated/Approved		Genzyme Corporation
Fluocinolone	Retisert	7/31/2000	Treatment uveitis involving the posterior segment of the eye.	Designated/Approved		"Bausch & Lomb Pharmaceuticals, Inc."
oblimersen		7/31/2000	"Treatment of advanced malignant melanoma (Stages II,III, IV)."	Designated	Not FDA Approved for Orphan Indication	"Genta, Inc."
Abetimus		7/28/2000	Treatment of lupus nephritis.	Designated	Not FDA Approved for Orphan Indication	La Jolla Pharmaceutical Co.
Chimeric (human-murine) G250 IgG monoclonal antibody		7/24/2000	Treatment of renal cell carcinoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Wilex Biotechnology GmbH
arsenic trioxide		7/17/2000	Treatment of myelodysplastic syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Teva Branded Pharmaceutical Products R&D, Inc."
cetuximab	Erbitux	7/3/2000	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor	Designated/Approved		ImClone Systems Incorporated
Carmustine		7/3/2000	Treatment of intracranial malignancies.	Designated	Not FDA Approved for Orphan Indication	"Direct Therapeutics, Inc."
teduglutide [rDNA origin]; teduglutide [rDNA origin]	GATTEX; GATTEX	6/29/2000	Treatment of short bowel syndrome.	Designated/Approved		"Takeda Pharmaceuticals U.S.A., Inc."
Fluorouracil		6/29/2000	Treatment of glioblastoma multiforme.	Designated	Not FDA Approved for Orphan Indication	Ethypharm SA
teduglutide [rDNA origin]; teduglutide [rDNA origin]	GATTEX; GATTEX	6/29/2000	Treatment of short bowel syndrome.	Designated/Approved		"Takeda Pharmaceuticals U.S.A., Inc."
Liposomal nystatin		6/13/2000	Treatment of invasive fungal infections.	Designated	Not FDA Approved for Orphan Indication	The University of Texas
vigabatrin	Sabril	6/12/2000	Treatment of infantile spasms.	Designated/Approved		H. Lundbeck A/S
Centruroides immune F(ab)2	Anascorp	6/12/2000	Treatment of scorpion envenomations requiring medical attention.	Designated/Approved		"Rare Disease Therapeutics, Inc."
Omega-3 (n-3) polyunsaturated fatty acids		5/4/2000	Treatment of IgA nephropathy.	Designated	Not FDA Approved for Orphan Indication	"Pronova Biocare, AS"
Tetraiodothyroacetic acid		5/1/2000	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Designated	Not FDA Approved for Orphan Indication	"Danforth, Jr., MD, Elliot"
Arsenic trioxide		4/28/2000	Treatment of multiple myeloma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"TEVA Branded Pharmaceutical Products R & D, Inc."
"DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2"		4/28/2000	Treatment of renal cell carcinoma.	Designated	Not FDA Approved for Orphan Indication	Vical Incorporated
Meropenem		4/27/2000	"Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AstraZeneca Pharmaceuticals
IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)		4/6/2000	Treatment of astrocytic glioma.	Designated	Not FDA Approved for Orphan Indication	"Medicenna Therapeutics, Inc."
Recombinant human antithrombin III		4/6/2000	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	Designated	Not FDA Approved for Orphan Indication	AT III LLC
Ethyl eicosapentaenoate		4/6/2000	Treatment of Huntington's disease.	Designated	Not FDA Approved for Orphan Indication	Laxdale Ltd.
rSP-C lung surfactant		4/3/2000	Treatment of adult respiratory distress syndrome.	Designated	Not FDA Approved for Orphan Indication	Byk Gulden Pharmaceuticals
Cisplatin/epinephrine		4/3/2000	Treatment of squamous cell carcinoma of the head and neck.	Designated	Not FDA Approved for Orphan Indication	"Matrix Pharmaceutical, Inc."
"3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one"		3/23/2000	Treatment of von Hippel-Lindau disease.	Designated	Not FDA Approved for Orphan Indication	"Sugen, Inc."
Synthetic human secretin		3/7/2000	"For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion"	Designated	Not FDA Approved for Orphan Indication	"ChiRhoClin, Inc."
Synthetic porcine secretin	Secreflo	3/7/2000	"For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion"	Designated/Approved		"ChiRhoClin, Inc."
vapreotide		3/6/2000	Prevention of early postoperative complications following pancreatic resection.	Designated	Not FDA Approved for Orphan Indication	Debiopharm S.A.
Soluble complement receptor type 1		3/6/2000	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Designated	Not FDA Approved for Orphan Indication	"Avant Immunotherapeutics, Inc."
Thymalfasin		3/6/2000	Treatment of hepatocellular carcinoma.	Designated	Not FDA Approved for Orphan Indication	"SciClone Pharmaceuticals, Inc."
Remacemide		3/6/2000	Treatment of Huntington's disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	AstraZeneca LP
Bis(4-fluorophenyl)phenylacetamide		3/2/2000	Treatment of sickle cell disease.	Designated	Not FDA Approved for Orphan Indication	ICAgen Inc.
Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab')2 bispecific monoclonal antibody		2/22/2000	Treatment of small-cell lung cancer.	Designated	Not FDA Approved for Orphan Indication	"IBC Pharmaceuticals, L.L.C."
etarfolatide		2/16/2000	For the identification of ovarian carcinomas	Designated	Not FDA Approved for Orphan Indication	"Endocyte, Inc."
Angiotensin 1-7		2/16/2000	Treatment of neutropenia associated with autologous bone marrow transplantation.	Designated	Not FDA Approved for Orphan Indication	Tarix Pharmaceuticals Ltd
Recombinant human insulin-like growth factor-I		2/16/2000	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	Designated	Not FDA Approved for Orphan Indication	GroPep Pty Ltd.
Halofuginone		2/7/2000	Treatment of systemic sclerosis.	Designated	Not FDA Approved for Orphan Indication	Collgard Biopharmaceuticals Ltd.
Brimonidine		2/7/2000	Treatment of anterior ischemic optic neuropathy.	Designated	Not FDA Approved for Orphan Indication	AbbVie
hypericin		2/7/2000	Treatment of cutaneous T-cell lymphoma	Designated	Not FDA Approved for Orphan Indication	"Soligenix, Inc."
Histamine		2/1/2000	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	Designated	Not FDA Approved for Orphan Indication	EpiCept Corporation
Phenylbutyrate		1/19/2000	Treatment of acute promyelocytic leukemia.	Designated	Not FDA Approved for Orphan Indication	"Elan Drug Delivery, Inc."
"1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine hydrogen methanesulfonate"		1/18/2000	Treatment of hormone refractory prostate carcinoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Cell Therapeutics, Inc."
levodopa and carbidopa	Duopa	1/18/2000	Treatment of late stage Parkinson's disease	Designated/Approved		"AbbVie, Inc."
Natural human lymphoblastoid interferon-alpha		1/18/2000	Treatment of Behcet's disease	Designated	Not FDA Approved for Orphan Indication	"Amarillo Biosciences, Inc."
vapreotide		1/10/2000	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Designated	Not FDA Approved for Orphan Indication	"Debiovision, Inc."
vapreotide		1/10/2000	Treatment of gastrointestinal and pancreatic fistulas.	Designated	Not FDA Approved for Orphan Indication	Debiopharm S.A.
Recombinant human keratinocyte growth factor		12/20/1999	Reducing the incidence and severity of radiation-induced xerostomia.	Designated	Not FDA Approved for Orphan Indication	Swedish Orphan Biovitrum AB (publ) (SOBI)
Adenovirus-based vector Factor VIII complementary DNA to somatic cells		12/15/1999	Treatment of hemophilia A.	Designated	Not FDA Approved for Orphan Indication	GenStar Therapeutics Corporation
Histamine		12/15/1999	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	Designated	Not FDA Approved for Orphan Indication	EpiCept Corporation
trastuzumab		12/14/1999	Treatment of patients with pancreatic cancer that overexpress p185HER2.	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
Ubiquinone		12/14/1999	Treatment of mitochondrial cytopathies.	Designated	Not FDA Approved for Orphan Indication	"Gel-Tec, Division of Tishcon Corp."
Alpha1-proteinase inhibitor (human)		11/24/1999	For slowing the progression of emphysema in alpha1-antitrypsin deficient patients.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	CSL Behring L.L.C.
Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP)		11/24/1999	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bellicum Pharmaceuticals, Inc."
Gemtuzumab ozogamicin	Mylotarg	11/24/1999	Treatment of acute myeloid leukemia	Designated/Approved		"Wyeth Pharmaceuticals, Inc., a Pfizer Company"
Pentostatin		11/24/1999	Treatment of peripheral T-cell lymphomas.	Designated	Not FDA Approved for Orphan Indication	"SuperGen, Inc."
Gemtuzumab ozogamicin	Mylotarg	11/24/1999	Treatment of acute myeloid leukemia	Designated/Approved		"Wyeth Pharmaceuticals, Inc., a Pfizer Company"
Gemtuzumab ozogamicin	Mylotarg	11/24/1999	Treatment of acute myeloid leukemia	Designated/Approved		"Wyeth Pharmaceuticals, Inc., a Pfizer Company"
Silver sulfadiazine and cerium nitrate		11/17/1999	Treatment of patients with severe dermal burns	Designated	Not FDA Approved for Orphan Indication	Alliance Pharmaceuticals Ltd
pVGI.1(VEGF2)		11/9/1999	Treatment of thromboangiitis obliterans.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Corautus Genetics, Inc."
Temoporfin		10/28/1999	"Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy."	Designated	Not FDA Approved for Orphan Indication	Biolitec Pharma Ireland Ltd.
Somatropin (rDNA origin)	Nutropin Depot	10/28/1999	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Designated/Approved		"Genentech, Inc."
Teriparatide		10/28/1999	Treatment of idiopathic osteoporosis.	Designated	Not FDA Approved for Orphan Indication	"Biomeasure, Inc."
Botulinum toxin type A	Dysport	10/20/1999	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Designated/Approved		"Ipsen Biopharmaceuticals, Inc."
L-glutamyl-L-tryptophan		10/20/1999	Treatment of AIDS-related Kaposi's sarcoma.	Designated	Not FDA Approved for Orphan Indication	Implicit Bioscience Pty Ltd
Amifostine		10/4/1999	Treatment of myelodysplastic syndromes.	Designated	Not FDA Approved for Orphan Indication	"Clinigen, Inc."
HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex		9/30/1999	"Treatment of invasive and metastatic melanoma (Stages II, III, and IV)."	Designated	Not FDA Approved for Orphan Indication	Vical Incorporated
Peginterferon alfa-2a		9/30/1999	Treatment of chronic myelogenous leukemia.	Designated	Not FDA Approved for Orphan Indication	Hoffman-La Roche Inc.
Polyethylene glycol-modified uricase		9/14/1999	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	Designated	Not FDA Approved for Orphan Indication	Swedish Orphan Biovitrum AB
Azathioprine		9/14/1999	Treatment of oral manifestations of graft-versus-host disease.	Designated	Not FDA Approved for Orphan Indication	"Oral Solutions, Inc."
Epirubicin	Ellence	9/14/1999	Treatment of breast cancer.	Designated/Approved		Pharmacia & Upjohn Company
nelarabine		9/2/1999	Treatment of chronic lymphocytic leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corp.
"Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II)"		9/1/1999	Treatment of malignant mesothelioma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Antigenics Incorporated
Mitoxantrone	Novantrone	8/13/1999	Treatment of secondary-progressive multiple sclerosis.	Designated/Approved		"Serono, Inc."
Mitoxantrone	Novantrone	8/13/1999	Treatment of progressive-relapsing multiple sclerosis.	Designated/Approved		"Serono, Inc."
guanfacine		8/5/1999	Treatment of fragile X syndrome.	Designated	Not FDA Approved for Orphan Indication	"Watson Laboratories, Inc."
Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembroyonic antigen IgG antibody		8/3/1999	Treatment of ovarian carcinoma.	Designated	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
irofulven		7/27/1999	Treatment of renal cell carcinoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Eisai, Inc."
Artesunate		7/19/1999	Treatment of malaria.	Designated	Not FDA Approved for Orphan Indication	World Health Organization
Somatropin [rDNA]	Genotropin	7/6/1999	Treatment of short stature in patients with Prader-Willi syndrome.	Designated/Approved		Pharmacia & Upjohn
irofulven		7/6/1999	Treatment of ovarian cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Eisai, Inc."
Lactic acid		6/29/1999	"Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients."	Designated	Not FDA Approved for Orphan Indication	"Frontier Pharmaceutical, Inc."
Tobramycin		6/18/1999	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	Designated	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corp.
Synthetic porcine secretin		6/18/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	Designated	Not FDA Approved for Orphan Indication	"ChiRhoClin, Inc."
Synthetic porcine secretin	Secreflo	6/18/1999	For use in the evaluation of exocrine pancreas function.	Designated/Approved		"ChiRhoClin, Inc."
Synthetic porcine secretin	Secreflo	6/18/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	Designated/Approved		"ChiRhoClin, Inc."
Bexarotene	Targretin	6/18/1999	Treatment of cutaneous T-cell lymphoma.	Designated/Approved		"Eisai, Inc."
Synthetic human secretin	Chirostim	6/16/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	Designated/Approved		"ChiRhoClin, Inc."
Synthetic human secretin		6/16/1999	For use in the evaluation of exocrine pancreas function.	Designated	Not FDA Approved for Orphan Indication	"ChiRhoClin, Inc."
Synthetic human secretin		6/16/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	Designated	Not FDA Approved for Orphan Indication	"ChiRhoClin, Inc."
Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3		6/15/1999	Treatment of major burns that require hospitalization.	Designated	Not FDA Approved for Orphan Indication	"Insmed, Inc."
Sodium dichloroacetate		6/14/1999	Treatment of severe head injury.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Questcor Pharmaceuticals, Inc."
Lisofylline		6/10/1999	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Designated	Not FDA Approved for Orphan Indication	"Cell Therapeutics, Inc."
111Indium pentetreotide		6/10/1999	Treatment of somatostatin receptor positive neuroendocrine tumors.	Designated	Not FDA Approved for Orphan Indication	Louisiana State University Medical Center Foundation
Marijuana		5/25/1999	Treatment of HIV-associated wasting syndrome.	Designated	Not FDA Approved for Orphan Indication	"Multidisciplinary Association for Psychedelic Studies, Inc."
Transgenic human alpha 1 antitrypsin		5/19/1999	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	Designated	Not FDA Approved for Orphan Indication	PPL Therapeutics (Scotland) Limited
"Japanese encephalitis vaccine (live, attenuated)"		5/19/1999	Prevention of Japanese encephalitis.	Designated	Not FDA Approved for Orphan Indication	"Glovax Co., Ltd."
Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine		5/7/1999	Prevention of transient aplastic crisis in patients with sickle cell anemia.	Designated	Not FDA Approved for Orphan Indication	"MedImmune, Inc."
Fluoxetine		4/30/1999	Treatment of autism.	Designated	Not FDA Approved for Orphan Indication	"Neuropharm, Ltd."
Beraprost		4/29/1999	"Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV)."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"LungRx, Inc."
CT-2584 mesylate		4/16/1999	Treatment of malignant mesothelioma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Cell Therapeutics, Inc."
CT-2584 Mesylate		4/16/1999	Treatment of adult soft tissue sarcoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Cell Therapeutics, Inc."
Recombinant human nerve growth factor		4/16/1999	Treatment of HIV-associated sensory neuropathy.	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
Rifalazil		4/13/1999	Treatment of pulmonary tuberculosis.	Designated	Not FDA Approved for Orphan Indication	PathoGenesis Corporation
Recombinant replication deficient adenovirus vector carrying human p53 gene		4/12/1999	Treatment of primary ovarian cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Pegylated arginine deiminase		4/12/1999	Treatment of invasive malignant melanoma.	Designated	Not FDA Approved for Orphan Indication	"Polaris Pharmaceuticals, Inc."
Etanercept		4/6/1999	Treatment of Wegener's granulomatosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Immunex Corporation
eprodisate		4/6/1999	Treatment of secondary amyloidosis	Designated	Not FDA Approved for Orphan Indication	"C. T. Development America, Inc."
Thalidomide		4/6/1999	Treatment of Crohn's disease.	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
6-hydroxymethylacylfulvene		4/6/1999	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Eisai, Inc."
pegylated arginine deiminase		3/26/1999	Treatment of hepatocellular carcinoma	Designated	Not FDA Approved for Orphan Indication	"Polaris Pharmaceuticals, Inc."
Recombinant humanized MAb 5c8		3/22/1999	Prevention of rejection of solid organ transplants.	Designated	Not FDA Approved for Orphan Indication	"Biogen, Inc."
"Murine MAb to polymorphic epithelial mucin, human milk fat globule 1"		3/22/1999	Adjuvant treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	Antisoma plc
epoprostenol	Flolan	3/22/1999	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	Designated/Approved		GlaxoSmithKline
Recombinant humanized MAb 5c8		3/22/1999	Prevention of rejection of pancreatic islet cell transplants.	Designated	Not FDA Approved for Orphan Indication	"Biogen, Inc."
decitabine		3/8/1999	Treatment of chronic myelogenous leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Otsuka Pharmaceutical Development &
decitabine	Dacogen	3/8/1999	Treatment of myelodysplastic syndromes.	Designated/Approved		Otsuka Pharmaceutical Development
Recombinant human C1-esterase inhibitor		2/23/1999	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Designated	Not FDA Approved for Orphan Indication	Pharming Group N.V.
Autologous DNP-conjugated tumor vaccine		2/23/1999	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Designated	Not FDA Approved for Orphan Indication	"Avax Technologies, Inc."
C1-esterase inhibitor (recombinant)	RUCONEST	2/23/1999	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Designated/Approved		Pharming Group N.V.
"N-acetylgalactosamine-4-sulfatase, recombinant human"	Naglazyme	2/17/1999	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	Designated/Approved		"BioMarin Pharmaceutical, Inc."
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)		2/12/1999	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Designated	Not FDA Approved for Orphan Indication	"Peregrine Pharmaceuticals, Inc."
Chelating agent delivering Holmium-166		2/10/1999	Treatment of multiple myeloma.	Designated	Not FDA Approved for Orphan Indication	NeoRx Corporation
Bleomycin		2/9/1999	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"Genetronics, Inc."
Humanized MAb (IDEC-131) to CD40L		2/9/1999	Treatment of systemic lupus erythematosus.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Biogen IdecInc.
L-5-hydroxytryptophan		1/20/1999	Treatment of tetrahydrobiopterin deficiency.	Designated	Not FDA Approved for Orphan Indication	"Watson Laboratories, Inc."
Interferon beta-1a (recombinant human)		1/7/1999	Treatment of pulmonary fibrosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Biogen Idec, Inc."
Polyethylene glycol-modified uricase		12/21/1998	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	Designated	Not FDA Approved for Orphan Indication	Swedish Orphan Biovitrum AB
deferoxamine starch conjugate		12/21/1998	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	Designated	Not FDA Approved for Orphan Indication	"Biomedical Frontiers, Inc."
"Papain, trypsin, and chymotrypsin"		12/21/1998	Treatment of multiple myeloma.	Designated	Not FDA Approved for Orphan Indication	"Marlyn Nutraceuticals, Inc."
"Follitropin alfa, recombinant"	Gonal-F	12/21/1998	For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure	Designated/Approved		"EMD Serono, Inc."
Xenogeneic hepatocytes		11/27/1998	Treatment of severe liver failure.	Designated	Not FDA Approved for Orphan Indication	"Circe Biomedical, Inc."
Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma		11/27/1998	Treatment of B-cell non-Hodgkin's lymphoma.	Designated	Not FDA Approved for Orphan Indication	"Peregrine Pharmaceuticals, Inc."
Aldesleukin		11/24/1998	For the treatment non-Hodgkin's lymphoma.	Designated	Not FDA Approved for Orphan Indication	"Iovance Biotherapeutics, Inc."
MN14 monoclonal antibody to carcinoembryonic antigen		11/24/1998	Treatment of pancreatic cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
Amifostine		11/24/1998	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	Designated	Not FDA Approved for Orphan Indication	"Clinigen, Inc."
Humanized anti-CD2 monoclonal antibody		11/13/1998	Treatment of graft-versus-host disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"MedImmune, Inc."
Oxypurinol		11/9/1998	Treatment of hyperuricemia in patients intolerant to allopurinol.	Designated	Not FDA Approved for Orphan Indication	Cardiome Pharma Corp.
Doxorubicin liposome	Doxil	11/4/1998	Treatment of ovarian cancer.	Designated/Approved		Alza Corporation
etanercept	Enbrel	10/27/1998	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Designated/Approved		Immunex Corporation
"P1, P4-Di(uridine 5'-tetraphosphate), tetrasodium salt"		10/27/1998	Treatment of cystic fibrosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Inspire Pharmaceuticals, Inc."
Methoxsalen		10/14/1998	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Designated	Not FDA Approved for Orphan Indication	Mallinckrodt Hospital Products IP Limited
Recombinant humanized MAb 5c8		10/14/1998	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Designated	Not FDA Approved for Orphan Indication	"Biogen, Inc."
Thalidomide	thalomid	10/14/1998	Treatment of multiple myeloma	Designated/Approved		Celgene Corporation
interferon Beta-1a		10/14/1998	Treatment of juvenile rheumatoid arthritis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Biogen, Inc."
Temozolomide		10/14/1998	Treatment of advanced metastatic melanoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Merck & Company
Mecamylamine		10/14/1998	Treatment of Tourette's syndrome.	Designated	Not FDA Approved for Orphan Indication	"Targacept, Inc."
temozolomide	Temodar	10/5/1998	Treatment of recurrent malignant glioma.	Designated/Approved		Schering-Plough Research Institute
temozolomide	Temodar	10/5/1998	Treatment of recurrent malignant glioma.	Designated/Approved		Schering-Plough Research Institute
MN14 monoclonal antibody to carcinoembryonic antigen		9/18/1998	Treatment of small cell lung cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
Humanized anti-human CD2 MAb		9/17/1998	"For the induction of donor-specific immunologic unresponsiveness resulting in prophylaxis of organ rejection without the need for chronic immunosuppressive therapy, in patients receiving allogeneic renal transplants."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Biotransplant, Inc."
"3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one"		9/11/1998	Treatment of Kaposi's sarcoma.	Designated	Not FDA Approved for Orphan Indication	"Sugen, Inc."
dexamethasone intravitreal implant	Ozurdex	9/11/1998	"Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis"	Designated/Approved		Allergan
Octreotide	Sandostatin LAR	8/24/1998	Treatment of acromegaly.	Designated/Approved		Novartis Pharmaceuticals Corporation
Octreotide	Sandostatin LAR	8/24/1998	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Designated/Approved		Novartis Pharmaceuticals Corporation
Octreotide	Sandostatin LAR	8/24/1998	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Designated/Approved		Novartis Pharmaceuticals Corporation
Botulinum toxin type A		8/12/1998	Treatment of spasmodic torticollis (cervical dystonia).	Designated	Not FDA Approved for Orphan Indication	Ipsen Biopharm Limited
Aldesleukin		7/31/1998	Treatment of acute myelogenous leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Chiron Corporation
Thalidomide		7/29/1998	Treatment of Kaposi's sarcoma.	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
Recombinant human Clara Cell 10kDa protein		7/13/1998	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Designated	Not FDA Approved for Orphan Indication	"Trove Therapeutics, Inc."
Peginterferon alfa-2a		7/13/1998	Treatment of renal cell carcinoma.	Designated	Not FDA Approved for Orphan Indication	Hoffman-La Roche Inc.
epratuzumab		7/13/1998	Treatment of non-Hodgkin's lymphoma	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
Recombinant bactericidal/permeability-increasing protein		6/22/1998	Treatment of severe meningococcal disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Xoma (US) LLC
Alpha-galactosidase A		6/22/1998	Long-term enzyme replacement therapy for the treatment of Fabry disease	Designated	Not FDA Approved for Orphan Indication	"Shire Human Genetic Therapies, Inc."
Prostaglandin E1 enol ester (AS-013)		6/12/1998	Treatment of Fontaine Stage IV chronic critical limb ischemia.	Designated	Not FDA Approved for Orphan Indication	"LTT Baio-Pharma Co., Ltd"
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl		6/10/1998	Treatment of Ewing's sarcoma.	Designated	Not FDA Approved for Orphan Indication	Endorex Corp.
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl		6/10/1998	Treatment of osteosarcoma.	Designated	Not FDA Approved for Orphan Indication	Endorex Corp.
miglustat	Zavesca	5/29/1998	Treatment of Gaucher disease.	Designated/Approved		IC-MedTech Corporation
"Fructose-1,6-diphosphate"		5/29/1998	Treatment of painful vaso-occlusive episodes associated with sickle cell disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Questcor Pharmaceuticals, Inc."
Benzydamine hydrochloride		5/18/1998	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Designated	Not FDA Approved for Orphan Indication	"Angelini Pharmaceuticals, Inc."
"Ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate"		5/13/1998	Treatment of Crohn's disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Tap Holdings Inc.
Amifostine	Ethyol	5/12/1998	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	Designated/Approved		"Medimmune Oncology, Inc."
Tetrabenazine		5/12/1998	Treatment of moderate/severe tardive dyskinesia.	Designated	Not FDA Approved for Orphan Indication	"Prestwick Pharmaceuticals, Inc."
"1,5-(Butylimino)-1,5 dideoxy,D-glucitol"		5/12/1998	Treatment of Fabry's disease.	Designated	Not FDA Approved for Orphan Indication	Oxford GlycoSciences
S-adenosylmethionine		4/30/1998	Treatment of AIDS-myelopathy.	Designated	Not FDA Approved for Orphan Indication	"Genopia USA, Inc."
Liposomal cyclosporin A		4/30/1998	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation	Designated	Not FDA Approved for Orphan Indication	"Vernon Knight, M.D."
Sodium phenylbutyrate		4/24/1998	"For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma."	Designated	Not FDA Approved for Orphan Indication	"Elan Drug Delivery, Inc."
Tiapride		4/21/1998	Treatment of Tourette's syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sanofi-Synthelabo, Inc."
"Corticotropin-releasing factor, human"		4/6/1998	Treatment of peritumoral brain edema.	Designated	Not FDA Approved for Orphan Indication	"Neurobiological Technologies, Inc."
Dimethylsulfoxide		4/6/1998	Treatment of palmar-plantar erythrodysethesia syndrome.	Designated	Not FDA Approved for Orphan Indication	"Cancer Technologies, Inc."
Tacrolimus		4/6/1998	Prophylaxis of graft-versus-host-disease.	Designated	Not FDA Approved for Orphan Indication	"Fujisawa USA, Inc."
beclomethasone dipropionate		3/27/1998	For oral administration in the treatment of intestinal graft-versus-host disease.	Designated	Not FDA Approved for Orphan Indication	"Soligenix, Inc."
Pentostatin		3/27/1998	Treatment of cutaneous T-cell lymphoma.	Designated	Not FDA Approved for Orphan Indication	"SuperGen, Inc."
Alitretinoin	Panretin	3/24/1998	Treatment of AIDS-related Kaposi's sarcoma.	Designated/Approved		Concordia Pharmaceuticals Inc.
Phenylacetate		3/6/1998	"For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma."	Designated	Not FDA Approved for Orphan Indication	"Elan Drug Delivery, Inc."
recombinant human alpha-1 antitrypsin		3/6/1998	Treatment of cystic fibrosis.	Designated	Not FDA Approved for Orphan Indication	PPL Therapeutics (Scotland) Limited
Arsenic trioxide	Trisenox	3/3/1998	Treatment of acute promyelocytic leukemia.	Designated/Approved		"Teva Branded Pharmaceutical Products R&D, Inc."
Arsenic trioxide	Trisenox	3/3/1998	Treatment of acute promyelocytic leukemia.	Designated/Approved		"Teva Branded Pharmaceutical Products R&D, Inc."
Thalidomide		2/27/1998	Treatment of primary brain malignancies.	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
Recombinant humanized monoclonal antibody 5c8		2/18/1998	Treatment of systemic lupus erythematosus.	Designated	Not FDA Approved for Orphan Indication	"Biogen, Inc."
rifaximin	Xifaxan	2/10/1998	Treatment of hepatic encephalopathy	Designated/Approved		"Salix Pharmaceuticals, Inc."
Bindarit		2/3/1998	Treatment of lupus nephritis.	Designated	Not FDA Approved for Orphan Indication	"Angelini Pharmaceuticals, Inc."
Recombinant humanized monclonal antibody 5c8		2/3/1998	Treatment of immune thrombocytopenic purpura.	Designated	Not FDA Approved for Orphan Indication	"Biogen, Inc."
carglumic acid	Carbaglu	1/20/1998	Treatment of N-acetylglutamate synthetase deficiency.	Designated/Approved		Orphan Europe SARL
Thymalfasin		1/8/1998	Treatment of DiGeorge anomaly with immune defects.	Designated	Not FDA Approved for Orphan Indication	"SciClone Pharmaceuticals, Inc."
L-baclofen		1/6/1998	Treatment of trigeminal neuralgia	Designated	Not FDA Approved for Orphan Indication	Osmotica Pharmaceutical Corp.
Sodium dichloroacetate		12/31/1997	Treatment of congenital lactic acidosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Questcor Pharmaceuticals, Inc."
Basiliximab	Simulect	12/12/1997	Prophylaxis of solid organ rejection.	Designated/Approved		Novartis Pharmaceuticals Corporation
Genetically engineered human recombinant IgG4 monoclonal antibody directed against human TNF alpha		12/11/1997	Treatment of Crohn's disease.	Designated	Not FDA Approved for Orphan Indication	Celltech Chiroscience Limited
Tetrabenazine	Xenazine	12/11/1997	Treatment of Huntington's disease	Designated/Approved		"Prestwick Pharmaceuticals, Inc"
Duramycin		12/11/1997	Treatment of cystic fibrosis.	Designated	Not FDA Approved for Orphan Indication	"Lantibio, Inc."
Sterile talc	Steritalc	12/8/1997	Treatment of pneumothorax	Designated/Approved		Novatech SA
Sterile talc	Steritalc	12/8/1997	Treatment of malignant pleural effusion	Designated/Approved		Novatech SA
Urofollitropin		12/5/1997	"For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"EMD Serono, Inc."
Chondrocyte-alginate gel suspension		12/1/1997	For use in correcting vesicoureteral reflux in the pediatric population.	Designated	Not FDA Approved for Orphan Indication	"Curis, Inc."
Pergolide		11/20/1997	Treatment of Tourette's syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sallee, Floyd R. M.D., Ph.D."
Calcium gluconate		11/20/1997	For use as a wash for hydrofluoric acid spills on human skin.	Designated	Not FDA Approved for Orphan Indication	Calgonate Corp.
Pegylated recombinant human megakaryocyte growth and development factor		10/20/1997	For reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Amgen, Inc."
alemtuzumab	Campath	10/20/1997	Treatment of chronic lymphocytic leukemia.	Designated/Approved		Genzyme Corporation
Apomorphine		10/20/1997	For use as rescue treatment for early morning motor dysfunction in late-stage Parkinson's disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Scherer DDS
Recombinant human interleukin-12		10/20/1997	Treatment of renal cell carcinoma.	Designated	Not FDA Approved for Orphan Indication	"Genetics Institute, Inc."
Recombinant human thrombopoietin		9/29/1997	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
laronidase	Aldurazyme	9/24/1997	Treatment of patients with mucopolysaccharidosis-I.	Designated/Approved		"BioMarin Pharmaceutical, Inc."
Testosterone		9/22/1997	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	Designated	Not FDA Approved for Orphan Indication	Watson Laboratories
Purified extract of Pseudomonas aeruginosa		9/22/1997	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	Designated	Not FDA Approved for Orphan Indication	"Able Laboratories, Inc."
Cysteamine hydrochloride	Cystaran	8/19/1997	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Designated/Approved		"Leadiant Biosciences, Inc."
Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	8/19/1997	Treatment of glycogen storage disease type II.	Designated/Approved		Genzyme Corporation
Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	8/19/1997	Treatment of glycogen storage disease type II.	Designated/Approved		Genzyme Corporation
Alpha-melanocyte stimulating hormone		8/19/1997	Prevention and treatment of intrinsic acute renal failure due to ischemia.	Designated	Not FDA Approved for Orphan Indication	"National Institute of Diabetes, and Digestive and Kidney Diseases"
Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	8/19/1997	Treatment of glycogen storage disease type II.	Designated/Approved		Genzyme Corporation
Short chain fatty acid enema		8/19/1997	Treatment of chronic radiation proctitis.	Designated	Not FDA Approved for Orphan Indication	"Richard I. Breuer, M.D."
Poloxamer 188		8/5/1997	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	Designated	Not FDA Approved for Orphan Indication	CytRx Corporation
"Pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-D-glucopyranosyl unit, and one alpha-L-fucopyranosyl unit"		7/18/1997	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Designated	Not FDA Approved for Orphan Indication	Cytel Corporation
Allogeneic human retinal pigment epithelial cells on gelatin microcarriers		7/18/1997	Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bayer Healthcare Pharmaceuticals, Inc."
Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution	Extraneal (with 7.5% Icodextrin) Peritoneal Dialysis Solutio	7/18/1997	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Designated/Approved		Baxter Healthcare Corporation
Busulfan		7/7/1997	Treatment of primary brain malignancies.	Designated	Not FDA Approved for Orphan Indication	"SuperGen, Inc."
Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue		6/24/1997	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Designated	Not FDA Approved for Orphan Indication	"Titan Pharmaceuticals, Inc."
Pegvisomant	Somavert	6/24/1997	Treatment of acromegaly.	Designated/Approved		Sensus Corporation
Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture		6/13/1997	Treatment of pancreatic cancer	Designated	Not FDA Approved for Orphan Indication	"Applied Immunotherapeutics, LLC"
treprostinil	Remodulin;Orenitram	6/4/1997	Treatment of pulmonary arterial hypertension.	Designated/Approved		United Therapeutics Corp.
treprostinil	Remodulin;Orenitram	6/4/1997	Treatment of pulmonary arterial hypertension.	Designated/Approved		United Therapeutics Corp.
treprostinil	Remodulin;Orenitram	6/4/1997	Treatment of pulmonary arterial hypertension.	Designated/Approved		United Therapeutics Corp.
Fampridine		6/2/1997	"Treatment of chronic, incomplete spinal cord injury."	Designated	Not FDA Approved for Orphan Indication	"Acorda Therapeutics, Inc."
"Retroviral vector, R-GC and GC gene 1750"		5/6/1997	Treatment of Gaucher disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genzyme Corporation
Suramin		5/6/1997	Treatment of hormone-refractory prostate cancer.	Designated	Not FDA Approved for Orphan Indication	Warner-Lambert Company
Oxandrolone		4/22/1997	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Designated	Not FDA Approved for Orphan Indication	"Savient Pharmaceuticals, Inc."
Paclitaxel		4/15/1997	Treatment of AIDS-related Kaposi's sarcoma.	Designated	Not FDA Approved for Orphan Indication	"Baker Norton Pharmaceuticals, Inc."
Dimethylsulfoxide		4/15/1997	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Designated	Not FDA Approved for Orphan Indication	"Cancer Technologies, Inc."
Levocarnitine		4/7/1997	Treatment of zidovudine-induced mitochondrial myopathy.	Designated	Not FDA Approved for Orphan Indication	"Leadiant Biosciences, Inc."
MART-1 adenoviral gene therapy for malignant melanoma		3/28/1997	Treatment of metastatic melanoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genzyme Corporation
Paclitaxel	Taxol	3/25/1997	Treatment of AIDS-related Kaposi's sarcoma.	Designated/Approved		Bristol-Myers Squibb Pharmaceutical Research Institute
Gp100 adenoviral gene therapy		3/25/1997	Treatment of metastatic melanoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genzyme Corporation
Beta alethine		3/24/1997	Treatment of multiple myeloma.	Designated	Not FDA Approved for Orphan Indication	"Dovetail Technologies, Inc."
"8 Cyclopentyl 1,3-dipropylxanthine"		3/24/1997	Treatment of cystic fibrosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"SciClone Pharmaceuticals, Inc."
Beta alethine		3/24/1997	Treatment of metastatic melanoma.	Designated	Not FDA Approved for Orphan Indication	"Dovetail Technologies, Inc."
Poly-ICLC		3/17/1997	Treatment of primary brain tumors.	Designated	Not FDA Approved for Orphan Indication	Oncovir
Porfiromycin		3/13/1997	Treatment of cervical cancer.	Designated	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
chlorobutanol/propylene glycol/hydrochloric acid		2/18/1997	Treatment of patulous eustachian tube	Designated	Not FDA Approved for Orphan Indication	Ear Foundation
Lepirudin	Refluden	2/13/1997	Treatment of heparin-associated thrombocytopenia type II.	Designated/Approved		Hoechst Marion Roussel
Dehydroepiandrosterone sulfate sodium		1/29/1997	Treatment of serious burns requiring hospitalization.	Designated	Not FDA Approved for Orphan Indication	"Pharmadigm, Inc."
Enadoline hydrochloride		1/28/1997	Treatment of severe head injury.	Designated	Not FDA Approved for Orphan Indication	Warner-Lambert Company
Dehydroepiandrosterone sulfate sodium		1/28/1997	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Designated	Not FDA Approved for Orphan Indication	"Pharmadigm, Inc."
9-cis-retinoic acid		1/2/1997	Prevention of retinal detachment due to proliferative vitreoretinopathy.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Allergan, Inc."
Oprelvekin	Neumega	12/17/1996	Prevention of severe chemotherapy-induced thrombocytopenia.	Designated/Approved		"Genetics Institute, Inc."
Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation.		12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Designated	Not FDA Approved for Orphan Indication	Diacrin/Genzyme LLC
Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation		12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Designated	Not FDA Approved for Orphan Indication	Diacrin/Genzyme LLC
Nitazoxanide	Alinia	12/12/1996	Treatment of cryptosporidiosis.	Designated/Approved		"Romark Laboratories, L.C."
Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.		12/10/1996	Treatment of Huntington's disease.	Designated	Not FDA Approved for Orphan Indication	Diacrin/Genzyme LLC
Liposomal amphotericin B	AmBisome	12/10/1996	Treatment of cryptococcal meningitis.	Designated/Approved		"Fujisawa USA, Inc."
Liposomal amphotericin B		12/10/1996	Treatment of histoplasmosis.	Designated	Not FDA Approved for Orphan Indication	"Fujisawa USA, Inc."
Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation		12/10/1996	Treatment of Huntington's disease.	Designated	Not FDA Approved for Orphan Indication	Diacrin/Genzyme LLC
N-acetyl-procainamide		12/10/1996	Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.	Designated	Not FDA Approved for Orphan Indication	NAPA of the Bahamas
Liposomal amphotericin B	AmBisome	12/6/1996	Treatment of visceral leishmaniasis.	Designated/Approved		"Fujisawa USA, Inc."
Monoclonal antibody-B43.13		11/25/1996	Treatment of epithelial ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	CanariaBio Inc.
Somatropin for injection	Nutropin	11/18/1996	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Designated/Approved		"Genentech, Inc."
Imexon		11/8/1996	Treatment of multiple myeloma.	Designated	Not FDA Approved for Orphan Indication	AmpliMed Corporation
Filgrastim	Neupogen	11/7/1996	"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia."	Designated/Approved		"Amgen, Inc."
Ibuprofen lysine	NeoProfen	10/29/1996	Treatment of patent ductus arteriosus	Designated/Approved		"Lundbeck, Inc."
Ibuprofen i.v. solution		10/29/1996	Prevention of patent ductus arteriosus.	Designated	Not FDA Approved for Orphan Indication	"Farmacon-IL, LLC"
Leflunomide		10/18/1996	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	Designated	Not FDA Approved for Orphan Indication	"Williams, MD, James W."
Riluzole		10/15/1996	Treatment of Huntington's disease.	Designated	Not FDA Approved for Orphan Indication	"Rhone-Poulenc Rorer Pharmaceuticals, Inc."
Interferon gamma-1b	Actimmune	9/30/1996	"Delaying time to disease progression in patients with severe, malignant osteopetrosis."	Designated/Approved		Horizon Therapeutic Ireland DAC
Amphotericin B lipid complex		9/23/1996	Treatment of invasive sporotrichosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"The Liposome Company, Inc."
9-nitro-20-(S)-camptothecin		9/16/1996	Treatment of pancreatic cancer.	Designated	Not FDA Approved for Orphan Indication	"SuperGen, Inc."
"Human acid precursor alpha-glucosidase, recombinant"		9/10/1996	Treatment of glycogen storage disease type II.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pharming/Genzyme LLC
Prostaglandin E1 in lipid emulsion		9/10/1996	Treatment of ischemic ulceration of the lower limbs due to peripheral arterial disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Alpha Therapeutic Corporation
Aldesleukin	Proleukin	9/10/1996	Treatment of metastatic melanoma.	Designated/Approved		Chiron Corporation
2'-deoxycytidine		9/9/1996	As a host-protective agent in the treatment of acute myelogenous leukemia.	Designated	Not FDA Approved for Orphan Indication	"Grant, Steven M.D."
C1 esterase inhibitor (human)		8/21/1996	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Designated	Not FDA Approved for Orphan Indication	Alpha Therapeutic Corporation
Methionine/L-methionine		8/21/1996	Treatment of AIDS myelopathy.	Designated	Not FDA Approved for Orphan Indication	"Genopia USA, Inc."
denileukin diftitox	Ontak	8/21/1996	Treatment of patients with cutaneous T-cell lymphoma	Designated/Approved		"Eisai, Inc."
Amphotericin B lipid complex		8/21/1996	Treatment of invasive protothecosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"The Liposome Company, Inc."
Mitoxantrone	Novantrone	8/21/1996	Treatment of hormone refractory prostate cancer.	Designated/Approved		Serono
L-2-oxothiazolidine-4-carboxylic acid		7/30/1996	Treatment of amyotrophic lateral sclerosis.	Designated	Not FDA Approved for Orphan Indication	"Transcend Therapeutics, Inc."
Lucinactant		7/30/1996	Treatment of meconium aspiration syndrome in newborn infants	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Windtree Therapeutics, Inc."
Amphotericin B lipid complex		6/27/1996	Treatment of invasive candidiasis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"The Liposome Company, Inc."
Gusperimus		6/27/1996	Treatment of acute renal graft rejection episodes.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Pharmaceutical Research Institute
Uridine 5'-triphosphate		6/26/1996	To facilitate the removal of lung secretions in the treatment of patients with primary ciliary dyskinesia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Inspire Pharmaceuticals, Inc."
Methylnaltrexone		6/17/1996	Treatment of chronic opioid-induced constipation unresponsive to conventional therapy.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Progenics Pharmaceuticals, Inc."
Selective inhibitor of polymorphonuclear leukocyte (PMN) elastase		6/4/1996	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	Designated	Not FDA Approved for Orphan Indication	DuPont Pharmaceuticals Company
collagenase clostridium histolyticum	Xiaflex	5/23/1996	Treatment of advanced (involutional or residual stage) Dupuytren's disease	Designated/Approved		"Auxilium Pharmaceuticals, Inc."
Arcitumomab		5/10/1996	"Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
Etiocholanedione		5/7/1996	Treatment of Prader-Willi syndrome.	Designated	Not FDA Approved for Orphan Indication	"SuperGen, Inc."
Amphotericin B lipid complex		5/6/1996	Treatment of invasive zygomycosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"The Liposome Company, Inc."
Amphotericin B lipid complex		5/6/1996	Treatment of invasive coccidioidomycosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"The Liposome Company, Inc."
Liposomal prostaglandin E1 injection		4/25/1996	Treatment of acute respiratory distress syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Liposome Company, Inc."
Idoxuridine		4/8/1996	Treatment of nonparenchymatous sarcomas.	Designated	Not FDA Approved for Orphan Indication	"NeoPharm, Inc."
Lipid/DNA human cystic fibrosis gene		4/8/1996	Treatment of cystic fibrosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genzyme Corporation
Somatropin (r-DNA) for injection		3/26/1996	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	Designated	Not FDA Approved for Orphan Indication	"EMD Serono, Inc."
Rifapentine		3/12/1996	Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.	Designated	Not FDA Approved for Orphan Indication	"Hoechst Marion Roussel, Inc."
N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide		3/12/1996	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	"Sugen, Inc."
collagenase clostridium histolyticum	XIAFLEX	3/12/1996	Treatment of Peyronie's disease.	Designated/Approved		"Auxilium Pharmaceuticals, Inc."
Thalidomide		3/11/1996	Treatment of HIV-associated wasting syndrome.	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
Interferon beta-1a		3/11/1996	Treatment of patients with secondary progressive multiple sclerosis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"EMD Serono, Inc."
Antihemophilic factor (recombinant)	"ReFacto, Xyntha"	2/8/1996	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Designated/Approved		"Wyeth Pharmaceuticals, Inc."
Testosterone		2/5/1996	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Unimed Pharmaceuticals, Inc."
Dihydrotestosterone		2/5/1996	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Designated	Not FDA Approved for Orphan Indication	"Besins Internaitonal, US Inc."
Albendazole	Albenza	1/18/1996	"Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocys"	Designated/Approved		"Impax Laboratories, LLC"
Albendazole	Albenza	1/17/1996	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	Designated/Approved		"Impax Laboratories, LLC"
Antihemophilic factor (human)	Alphanate	1/5/1996	Treatment of von Willebrand's disease	Designated/Approved		Grifols Biologicals Inc.
"Valine, isoleucine and leucine"		1/5/1996	Treatment of hyperphenylalaninemia	Designated	Not FDA Approved for Orphan Indication	Leas Research Products
Mecasermin	Increlex	12/12/1995	Treatment of growth hormone insensitivity syndrome.	Designated/Approved		"Ipsen Biopharmaceuticals, Inc."
Uridine 5'-triphosphate		12/4/1995	Treatment of cystic fibrosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Inspire Pharmaceuticals, Inc."
Interferon gamma-1b		12/4/1995	Treatment of renal cell carcinoma.	Designated	Not FDA Approved for Orphan Indication	Horizon Therapeutic Ireland DAC
Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration		11/22/1995	Prevention of organ graft rejection.	Designated	Not FDA Approved for Orphan Indication	Research Triangle Pharmaceuticals
Recombinant methionyl human stem cell factor		11/22/1995	Treatment of primary bone marrow failure.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Amgen, Inc."
infliximab	Remicade	11/14/1995	Treatment of Crohn's disease	Designated/Approved		"Centocor, Inc."
Sorivudine		11/9/1995	Treatment of herpes zoster (shingles) in immunocompromised patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb
Etiocholanedione		11/3/1995	Treatment of aplastic anemia.	Designated	Not FDA Approved for Orphan Indication	"SuperGen, Inc."
Recombinant human relaxin		11/3/1995	Treatment of progressive systemic sclerosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Connetics Corporation
Lidocaine patch 5%	Lidoderm Patch	10/24/1995	"For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia."	Designated/Approved		"Teikoku Pharma USA, Inc."
Lucinactant		10/18/1995	Treatment of respiratory distress syndrome in premature infants.	Designated	Not FDA Approved for Orphan Indication	Lee’s Pharmaceutical (HK) Limited
Recombinant human insulin-like growth factor-I		10/13/1995	Treatment of post-poliomyelitis syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Teva Branded Pharmaceutical Product R&D, Inc."
Mycobacterium avium sensitin RS-10		10/11/1995	For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals.	Designated	Not FDA Approved for Orphan Indication	Statens Seruminstitut
Elcatonin		9/25/1995	Intrathecal treatment of intractable pain.	Designated	Not FDA Approved for Orphan Indication	"Innapharma, Inc."
Porfiromycin		9/19/1995	Treatment of head and neck cancer.	Designated	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
Broxuridine		9/18/1995	Radiation sensitizer in the treatment of primary brain tumors.	Designated	Not FDA Approved for Orphan Indication	"NeoPharm, Inc."
Sterile talc powder	Sclerosol Intrapleural Aerosol	9/18/1995	Treatment of malignant pleural effusion.	Designated/Approved		"Sciarra Laboratories, Inc."
"RGG0853, E1A lipid complex"		9/15/1995	Treatment of ovarian cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Targeted Genetics Corporation
Fibrinogen (human)		8/23/1995	For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.	Designated	Not FDA Approved for Orphan Indication	Alpha Therapeutic Corporation
Lamotrigine	Lamictal	8/23/1995	Treatment of Lennox-Gastaut syndrome.	Designated/Approved		Glaxo Wellcome Research and Development
Thalidomide	Thalomid	7/26/1995	Treatment of erythema nodosum leprosum.	Designated/Approved		Celgene Corporation
Alglucerase injection		7/21/1995	Replacement therapy in patients with Type II and III Gaucher's disease.	Designated	Not FDA Approved for Orphan Indication	Genzyme Corporation
Apomorphine		7/17/1995	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Designated	Not FDA Approved for Orphan Indication	"Pentech Pharmaceuticals, Inc."
Synsorb Pk		7/17/1995	Treatment of verocytotoxogenic E. coli infections.	Designated	Not FDA Approved for Orphan Indication	Synsorb Biotech Inc.
Filgrastim	Neupogen	7/17/1995	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	Designated/Approved		"Amgen, Inc."
Lucinactant		7/17/1995	Treatment of acute respiratory distress syndrome in adults.	Designated	Not FDA Approved for Orphan Indication	Lee’s Pharmaceutical (HK) Limited
Mitolactol		7/12/1995	As adjuvant therapy in the treatment of primary brain tumors.	Designated	Not FDA Approved for Orphan Indication	"Targent, Inc."
Nitric oxide		7/10/1995	Treatment of acute respiratory distress syndrome in adults.	Designated	Not FDA Approved for Orphan Indication	Mallinckrodt Hopspital Products
Ancestim		7/5/1995	For use in combination with filgrastim to decrease the number of phereses required to collect peripheral blood progenitor cells capable of providing rapid multi-lineage hematopoietic reconstitution following myelosuppressive or myeloablative therapy.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Amgen, Inc."
Encapsulated porcine islet preparation		7/5/1995	Treatment of type I diabetic patients who are already on immunosuppression.	Designated	Not FDA Approved for Orphan Indication	VivoRx
gabapentin		7/5/1995	Treatment of amyotrophic lateral sclerosis	Designated	Not FDA Approved for Orphan Indication	Warner-Lambert Company
Trisodium citrate concentration		6/15/1995	For use in leukapheresis procedures.	Designated	Not FDA Approved for Orphan Indication	"Hemotec Medical Products, Inc."
Rifapentine	Priftin	6/9/1995	Treatment of pulmonary tuberculosis.	Designated/Approved		Hoechst Marion Roussel
Rifapentine		6/9/1995	Treatment of Mycobacterium avium complex in patients with AIDS.	Designated	Not FDA Approved for Orphan Indication	"Hoechst Marion Roussel , Inc."
Recombinant human insulin-like growth factor 1		6/7/1995	Treatment of antibody-mediated growth hormone resistance in patients with isolated growth hormone deficiency Ia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pharmacia & Upjohn
Ganciclovir intravitreal implant	Vitrasert Implant	6/7/1995	Treatment of cytomegalovirus retinitis.	Designated/Approved		"Bausch & Lomb Surgical, Chiron Vision Products"
Recombinant human insulin-like growth factor 1		6/7/1995	Treatment of growth hormone receptor deficiency.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pharmacia & Upjohn
N-[4-(trifluoromethyl)phenyl] 5 methylisoxazole-4-carboxamide		5/25/1995	Treatment of malignant glioma.	Designated	Not FDA Approved for Orphan Indication	"Sugen, Inc."
Nitisinone; Nitisinone	Orfadin; Orfadin	5/16/1995	Treatment of tyrosinemia type 1.	Designated/Approved		Swedish Orphan Biovitrum AB (publ)
Nitisinone; Nitisinone	Orfadin; Orfadin	5/16/1995	Treatment of tyrosinemia type 1.	Designated/Approved		Swedish Orphan Biovitrum AB (publ)
Thalidomide		5/15/1995	"Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients."	Designated	Not FDA Approved for Orphan Indication	Andrulis Research Corporation
Thalidomide		5/1/1995	"Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients."	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
Clotrimazole		4/24/1995	Treatment of sickle cell disease.	Designated	Not FDA Approved for Orphan Indication	"Brugnara, Carlo M.D."
Cystic fibrosis Tr gene therapy (recombinant adenovirus)		3/9/1995	Treatment of cystic fibrosis.	Designated	Not FDA Approved for Orphan Indication	"GenVec, Inc."
Tyloxapol		3/8/1995	Treatment of cystic fibrosis.	Designated	Not FDA Approved for Orphan Indication	"Kennedy & Hoidal, M.D.'s"
Hepatitis B immune globulin intravenous (human)		3/8/1995	Prophylaxis against hepatitis B virus reinfection in liver transplant patients.	Designated	Not FDA Approved for Orphan Indication	Biotest Pharmaceuticals Corporation
Facilitated DNA Plasmid Vaccine		3/8/1995	Treatment of cutaneous T cell lymphoma.	Designated	Not FDA Approved for Orphan Indication	Wyeth-Lederle Vaccines and Pediatrics
pegvaliase-pqpz	PALYNZIQ	3/8/1995	Treatment of hyperphenylalaninemia	Designated/Approved		BioMarin Pharmaceutical Inc.
Glutamine	NutreStore	3/6/1995	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Designated/Approved		"Emmaus Medical, Inc."
Sargramostim	Leukine	3/6/1995	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Designated/Approved		Immunex Corporation
Somatropin (r-DNA)	Zorbtive	3/6/1995	For use alone or in combination with glutamine in the treatment of short bowel syndrome.	Designated/Approved		"EMD Serono, Inc."
Recombinant human gelsolin		3/6/1995	Treatment of acute and chronic respiratory symptoms of bronchiectasis.	Designated	Not FDA Approved for Orphan Indication	"BioAgeis, Therapeutics, Inc."
Adeno-associated viral-based vector cystic fibrosis gene therapy		2/15/1995	Treatment of cystic fibrosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Targeted Genetics Corporation
Glyceryl trioleate and glyceryl trierucate		2/14/1995	Treatment of adrenoleukodystrophy.	Designated	Not FDA Approved for Orphan Indication	"Moser, Hugo W. M.D."
Purified type II collagen		2/9/1995	Treatment of juvenile rheumatoid arthritis.	Designated	Not FDA Approved for Orphan Indication	"AutoImmune, Inc."
Chondroitinase		2/9/1995	Treatment of patients undergoing vitrectomy.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Bausch & Lomb Pharmaceuticals, Inc."
Aminocaproic acid		1/6/1995	For the topical treatment of traumatic hyphema of the eye.	Designated	Not FDA Approved for Orphan Indication	Eastern Virginia Medical School
Human immunodeficiency virus immune globulin		1/4/1995	Treatment of HIV-infected pediatric patients.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	NABI
Orgotein for injection		12/22/1994	"Treatment of familial amyotrophic lateral sclerosis associated with a mutation of the gene (on chromosome 21q) for copper, zinc superoxide dismutase."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Oxis International, Inc."
progesterone		12/22/1994	Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.	Designated	Not FDA Approved for Orphan Indication	"Watson Laboratories, Inc."
Somatostatin		12/22/1994	Treatment of bleeding esophageal varices.	Designated	Not FDA Approved for Orphan Indication	Eumedica Pharmaceuticals A.G. (Schweiz)
Coumarin		12/22/1994	Treatment of renal cell carcinoma.	Designated	Not FDA Approved for Orphan Indication	Drossapharm LTD
Recombinant methionyl brain-derived neurotrophic factor		11/28/1994	Treatment of amyotrophic lateral sclerosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Amgen, Inc."
Dimethyl sulfoxide		11/22/1994	"Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available."	Designated	Not FDA Approved for Orphan Indication	"Abela Pharmaceuticals, Inc."
Soluble recombinant human complement receptor type 1		11/21/1994	Prevention or reduction of adult respiratory distress syndrome.	Designated	Not FDA Approved for Orphan Indication	"T Cell Sciences, Inc."
Sodium dichloroacetate		11/10/1994	Treatment of lactic acidosis in patients with severe malaria.	Designated	Not FDA Approved for Orphan Indication	"Stacpoole, Peter W. M.D., Ph.D."
sodium oxybate	Xyrem	11/7/1994	Treatment of narcolepsy.	Designated/Approved		Jazz Pharmaceuticals Ireland Limited
"calcium, magnesium, potassium, and sodium oxybates"	Xywav	11/7/1994	Treatment of narcolepsy.	Designated/Approved		Jazz Pharmaceuticals Ireland Limited
Dapsone		11/7/1994	Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.	Designated	Not FDA Approved for Orphan Indication	"Jacobus Pharmaceutical Company, Inc."
sodium oxybate	Xyrem	11/7/1994	Treatment of narcolepsy.	Designated/Approved		Jazz Pharmaceuticals Ireland Limited
sodium oxybate	Xyrem	11/7/1994	Treatment of narcolepsy.	Designated/Approved		Jazz Pharmaceuticals Ireland Limited
buprenorphine in combination with naloxone	Suboxone	10/27/1994	Treatment of opiate addiction in opiate users	Designated/Approved		"Indivior, Inc."
Tobramycin for inhalation	TOBI	10/13/1994	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Designated/Approved		Mylan Specialty LP
Melanoma cell vaccine		10/13/1994	Treatment of invasive melanoma.	Designated	Not FDA Approved for Orphan Indication	CancerVax Corporation
Recombinant human luteinizing hormone	Luveris	10/7/1994	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	Designated/Approved		"EMD Serono, Inc."
Coagulation Factor IX (recombinant)	BeneFix	10/3/1994	Treatment of hemophilia B	Designated/Approved		"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc."
Coagulation Factor IX (recombinant)	BeneFix	10/3/1994	Treatment of hemophilia B	Designated/Approved		"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc."
Coagulation Factor IX (recombinant)	BeneFix	10/3/1994	Treatment of hemophilia B	Designated/Approved		"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc."
Baclofen		9/26/1994	Treatment of spasticity associated with cerebral palsy.	Designated	Not FDA Approved for Orphan Indication	"Medtronic, Inc."
Monoclonal Ab(murine) anti-idiotype melanoma-associated antigen		9/19/1994	Treatment of invasive cutaneous melanoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	IDEC Pharmaceuticals Corporation
Neurotrophin-1		9/13/1994	Treatment of motor neuron disease/amyotrophic lateral sclerosis.	Designated	Not FDA Approved for Orphan Indication	"Ericsson, Arthur Dale, M.D."
Aminosidine		9/9/1994	Treatment of visceral leishmaniasis (kala-azar).	Designated	Not FDA Approved for Orphan Indication	"Kanyok, Thomas P. Pharm.D."
Ricin (blocked) conjugated murine monoclonal antibody (CD6)		9/6/1994	"Treatment of cutaneous T-cell lymphomas, acute T-cell leukemia-lymphoma, and related mature T-cell malignancies."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ImmunoGen, Inc."
ibritumomab tiuxetan	Zevalin	9/6/1994	Treatment of B-cell non-Hodgkin's lymphoma.	Designated/Approved		Acrotech Biopharma LLC
Somatropin	Genotropin	9/6/1994	Treatment of adults with growth hormone deficiency.	Designated/Approved		Pharmacia & Upjohn
Buffered intrathecal electrolyte/dextrose injection	Elliotts B Solution	8/24/1994	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment meningeal leukemia and lymphocytic lymphoma	Designated/Approved		"Lukare Medical, LLC"
Recombinant vaccinia (human papillomavirus)		8/24/1994	Treatment of cervical cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Xenova Research Limited
Clonazepam		8/4/1994	Treatment of hyperekplexia (startle disease).	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Hoffmann-La Roche, Inc."
Busulfan	Busulfex	7/28/1994	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Designated/Approved		"Otsuka Pharmaceutical Company, Ltd"
Gammalinolenic acid		7/27/1994	Treatment of juvenile rheumatoid arthritis.	Designated	Not FDA Approved for Orphan Indication	"Zurier, Robert B. M.D."
Dehydroepiandrosterone		7/13/1994	Treatment of systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	GlaxoSmithKline
Autolymphocyte therapy		7/12/1994	Treatment of renal cell carcinoma.	Designated	Not FDA Approved for Orphan Indication	Cytogen Corporation
Liposome encapsulated recombinant interleukin-2		6/20/1994	Treatment of cancers of the kidney and renal pelvis	Designated	Not FDA Approved for Orphan Indication	"Oncothyreon Canada, Inc."
Buprenorphine hydrochloride		6/15/1994	Treatment of opiate addiction in opiate users.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Indivior, Inc."
Buprenorphine hydrochloride		6/15/1994	Treatment of opiate addiction in opiate users.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Indivior, Inc."
L-2-oxothiazolidine-4-carboxylic acid		6/14/1994	Treatment of adult respiratory distress syndrome.	Designated	Not FDA Approved for Orphan Indication	"Transcend Therapeutics, Inc."
rituximab	Rituxan	6/13/1994	Treatment of non-Hodgkin's B-cell lymphoma	Designated/Approved		"Genentech, Inc."
rituximab	Rituxan	6/13/1994	Treatment of non-Hodgkin's B-cell lymphoma	Designated/Approved		"Genentech, Inc."
Isobutyramide		5/25/1994	Treatment of sickle cell disease and beta thalassemia.	Designated	Not FDA Approved for Orphan Indication	Alpha Therapeutic Corporation
Arginine butyrate		5/25/1994	Treatment of sickle cell disease and beta thalassemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Vertex Pharmaceuticals Inc.
Ganaxolone		5/25/1994	Treatment of infantile spasms.	Designated	Not FDA Approved for Orphan Indication	"Marinus Pharmaceuticals, Inc."
Valrubicin	Valstar	5/23/1994	Treatment of carcinoma in situ of the urinary bladder.	Designated/Approved		"Anthra Pharmaceuticals, Inc."
Betaine	Cystadane	5/16/1994	Treatment of homocystinuria.	Designated/Approved		Orphan Europe SARL
Treosulfan		5/16/1994	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	Medac GmbH
L-cysteine		5/16/1994	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	Designated	Not FDA Approved for Orphan Indication	Brigham and Women's Hospital
Tositumomab and iodine I 131 tositumomab	Bexxar	5/16/1994	Treatment of non-Hodgkin's B-cell lymphoma.	Designated/Approved		GlaxoSmithKline LLC
methoxsalen		5/12/1994	For the prevention of acute rejection of cardiac allografts	Designated	Not FDA Approved for Orphan Indication	Mallinckrodt Hospital Products IP Limited
Busulfan		4/21/1994	For use as preparative therapy for malignancies treated with bone marrow transplantation.	Designated	Not FDA Approved for Orphan Indication	"Sparta Pharmaceuticals, Inc."
Cladribine		4/19/1994	Treatment of the chronic progressive form of multiple sclerosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Johnson & Johnson Pharmaceutical R & D, LLC"
Mitoguazone		3/18/1994	"Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma."	Designated	Not FDA Approved for Orphan Indication	"ILEX Oncology, Inc."
Oxandrolone		3/18/1994	Treatment of moderate/severe acute alcoholic hepatitis in the presence of moderate protein calorie malnutrition.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bio-Technology General Corp.
Immunotherapeutic vaccine consisting of (PAM)2-Lys-Ser-Ser-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val		3/16/1994	Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.	Designated	Not FDA Approved for Orphan Indication	Cytel Corporation
Amiodarone HCl	Cordarone	3/16/1994	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Designated/Approved		Wyeth-Ayerst Laboratories
Sulfadiazine		3/14/1994	For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS	Designated/Approved		"Eon Labs Manufacturing, Inc."
Heme arginate		3/1/1994	Treatment of myelodysplastic syndromes.	Designated	Not FDA Approved for Orphan Indication	Orphan Europe SARL
"Bovine immunoglobulin concentrate, Cryptosporidium parvum"		3/1/1994	Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.	Designated	Not FDA Approved for Orphan Indication	"GalaGen, Inc."
Exisulind		2/14/1994	For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.	Designated	Not FDA Approved for Orphan Indication	"OSI Pharmaceuticals, Inc."
Reduced L-glutathione		2/14/1994	Treatment of AIDS-associated cachexia.	Designated	Not FDA Approved for Orphan Indication	Telluride Pharmaceutical Corporation
Choline chloride		2/10/1994	"Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition."	Designated	Not FDA Approved for Orphan Indication	"Protara Therapeutics, Inc."
Ammonium tetrathiomolybdate		1/31/1994	Treatment of Wilson's disease.	Designated	Not FDA Approved for Orphan Indication	"Pipex Pharmaceuticals, Inc."
Tizanidine HCl		1/31/1994	Treatment of spasticity associated with multiple sclerosis and spinal cord injury.	Designated	Not FDA Approved for Orphan Indication	"Athena Neurosciences, Inc."
"Antivenin, crotalidae polyvalent immune Fab (ovine)"	CroFab	1/12/1994	Treatment of envenomations inflicted by North American crotalid snakes.	Designated/Approved		"Protherics, Inc."
Recombinant human gelsolin		1/12/1994	Treatment of the respiratory symptoms of cystic fibrosis.	Designated	Not FDA Approved for Orphan Indication	"BioAegis Therapeutics, Inc."
Neutrophil-endothelial interaction inhibitor		12/22/1993	Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.	Designated	Not FDA Approved for Orphan Indication	Cytel Corporation
"5a8, monoclonal antibody to CD4"		12/20/1993	For use in post-exposure prophylaxis for occupational exposure to human immunodeficiency virus.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Biogen, Inc."
Beractant		12/20/1993	"Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis."	Designated	Not FDA Approved for Orphan Indication	Ross Laboratories
Hemin and zinc mesoporphyrin		12/20/1993	Treatment of acute porphyric syndromes.	Designated	Not FDA Approved for Orphan Indication	"Bonkovsky, Herbert L. M.D."
Epoetin alfa		12/20/1993	Treatment of myelodysplastic syndrome.	Designated	Not FDA Approved for Orphan Indication	"Johnson & Johnson Pharmaceutical Research & Dev.,"
Sacrosidase	Sucraid	12/10/1993	Treatment of congenital sucrase-isomaltase deficiency	Designated/Approved		"QOL Medical, LLC"
Poly I: poly C12U		12/9/1993	"Treatment of invasive metastatic melanoma (stage IIb, III, IV)."	Designated	Not FDA Approved for Orphan Indication	AIM ImmunoTech Inc.
Poly I: poly C12U		12/9/1993	Treatment of chronic fatigue syndrome	Designated	Not FDA Approved for Orphan Indication	AIM ImmunoTech Inc.
Levocarnitine		11/22/1993	Treatment of pediatric cardiomyopathy.	Designated	Not FDA Approved for Orphan Indication	"Leadiant Biosciences, Inc."
Immune globulin intravenous (human)		11/22/1993	Treatment of patients with acute myocarditis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Immuno Clinical Research Corp.
benzoate/phenylacetate	Ammonul	11/22/1993	Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Designated/Approved		Medicis Pharmaceutical Corp.
sodium phenylbutyrate	Buphenyl	11/22/1993	"Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency."	Designated/Approved		Medicis Pharmaceutical Corp.
Aprotinin	Trasylol	11/17/1993	"For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c"	Designated/Approved		Bayer Corporation
Aminosidine		11/15/1993	Treatment of Mycobacterium avium complex.	Designated	Not FDA Approved for Orphan Indication	"Kanyok, Thomas P. Pharm.D."
Melatonin		11/15/1993	Treatment of circadian rhythm sleep disorders in blind people with no light perception.	Designated	Not FDA Approved for Orphan Indication	"Sack, Robert, M.D."
Recombinant retroviral vector - glucocerebrosidase		11/15/1993	"For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease."	Designated	Not FDA Approved for Orphan Indication	"Genetic Therapy, Inc."
Rho (D) immune globulin intravenous (human)	WinRho SD	11/9/1993	Treatment of immune thrombocytopenic purpura.	Designated/Approved		"Rh Pharmaceuticals, Inc."
Alprostadil		10/20/1993	"Treatment of severe peripheral arterial occlusive disease (critical limb ischemia) in patients where other procedures, grafts or angioplasty, are not indicated."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Schwarz Pharma, Inc."
Peldesine		10/5/1993	Treatment of cutaneous T-cell lymphoma.	Designated	Not FDA Approved for Orphan Indication	"BioCryst Pharmaceuticals, Inc."
Bispecific antibody 520c9x22		10/5/1993	For in vivo serotherapy of patients with ovarian cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Medarex, Inc."
Bovine whey protein concentrate		9/30/1993	Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.	Designated	Not FDA Approved for Orphan Indication	"Biomune Systems, Inc."
"Interleukin-3, human, recombinant"		9/30/1993	For sequential administration with sargramostim to accelerate neutrophil and platelet recovery in patients undergoing autologous bone marrow transplantation for the treatment of Hodgkin's disease or non-Hodgkin's lymphoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Sandoz Pharmaceuticals Corp.
2-0-desulfated heparin		9/17/1993	Treatment of cystic fibrosis.	Designated	Not FDA Approved for Orphan Indication	"Kennedy & Hoidal, M.D.'s"
Bleomycin sulfate	Blenoxane	9/17/1993	Treatment of malignant pleural effusion.	Designated/Approved		Bristol-Myers Squibb Pharmaceutical Research Institute
Protirelin		8/24/1993	Prevention of infant respiratory distress syndrome associated with prematurity.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"UCB Pharma, Inc."
methotrexate		8/23/1993	Treatment of juvenile rheumatoid arthritis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Wyeth-Ayerst Laboratories
Mitomycin-C		8/20/1993	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	Designated	Not FDA Approved for Orphan Indication	IOP Inc.
Amiodarone		8/17/1993	Treatment of incessant ventricular tachycardia.	Designated	Not FDA Approved for Orphan Indication	"Academic Pharmaceuticals, Inc."
Toremifene		8/17/1993	Treatment of desmoid tumors.	Designated	Not FDA Approved for Orphan Indication	Orion Corporation
"Pulmonary surfactant replacement, porcine"	Curosurf	8/2/1993	For the treatment and prevention of respiratory distress syndrome in premature infants.	Designated/Approved		"Chiesi USA, Inc."
Secalciferol		7/26/1993	Treatment of familial hypophosphatemic rickets.	Designated	Not FDA Approved for Orphan Indication	Teva Pharmaceuticals USA
Primaquine phosphate		7/23/1993	For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.	Designated	Not FDA Approved for Orphan Indication	"Sanofi Winthrop, Inc."
Sucralfate		7/15/1993	Treatment of oral mucositis and stomatitis following radiation therapy for head and neck cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Fuisz Technologies, Ltd."
Roquinimex		7/1/1993	To prolong time to relapse in leukemia patients who have undergone autologous bone marrow transplantation.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pharmacia & Upjohn
Vasoactive intestinal polypeptide		6/23/1993	Treatment of acute esophageal food impaction.	Designated	Not FDA Approved for Orphan Indication	Research Triangle Pharmaceuticals
Nitric oxide	INOmax	6/22/1993	Treatment of persistent pulmonary hypertension in the newborn.	Designated/Approved		Mallinckrodt Hospital Products
8-methoxsalen		6/22/1993	For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.	Designated	Not FDA Approved for Orphan Indication	Mallinckrodt Hospital Products IP Limited
Disodium clodronate		6/16/1993	Treatment of hypercalcemia of malignancy.	Designated	Not FDA Approved for Orphan Indication	"Discovery Experimental & Development, Inc."
Anti-thymocyte serum		6/2/1993	"Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation."	Designated	Not FDA Approved for Orphan Indication	Applied Medical Research
Cytarabine liposomal	DepoCyt	6/2/1993	Treatment of neoplastic meningitis.	Designated/Approved		"Pacira Pharmaceuticals, Inc."
Aminosidine		5/14/1993	Treatment of tuberculosis.	Designated	Not FDA Approved for Orphan Indication	"Kanyok, Thomas P. Pharm.D."
Daunorubicin citrate liposome injection	DaunoXome	5/14/1993	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	Designated/Approved		"NeXstar Pharmaceuticals, Inc."
RII retinamide		5/6/1993	Treatment of myelodysplastic syndromes.	Designated	Not FDA Approved for Orphan Indication	"Sparta Pharmaceuticals, Inc."
Monolaurin		4/29/1993	Treatment of congenital primary ichthyosis.	Designated	Not FDA Approved for Orphan Indication	Glaxo Wellcome Inc.
"Factor XIII, recombinant"		4/22/1993	Treatment of congenital factor XIII deficiency.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Zymogenetics, Inc."
Protein C concentrate		4/22/1993	For use in the prevention and treatment of purpura fulminans in meningococcemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Immuno Clinical Research Corp.
Apomorphine HCl	Apokyn	4/22/1993	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Designated/Approved		"MDD US Operations, LLC, a subsidiary of Supernus Pharmaceuticals, Inc."
Cladribine		4/19/1993	Treatment of non-Hodgkin's lymphoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
Aminosalicylate sodium		4/6/1993	Treatment of Crohn's disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Syncom Pharmaceuticals, Inc."
Riluzole	Rilutek	3/16/1993	Treatment of amyotrophic lateral sclerosis.	Designated/Approved		"Rhone-Poulenc Rorer Pharmaceuticals, Inc."
Atovaquone		3/16/1993	Treatment and suppression of Toxoplasma gondii encephalitis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"GlaxoSmithKline, Inc."
Atovaquone		3/16/1993	Primary prophylaxis of HIV-infected persons at high risk for developing Toxoplasma gondii encephalitis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"GlaxoSmithKline, Inc."
Modafinil	Provigil	3/15/1993	Treatment of excessive daytime sleepiness in narcolepsy.	Designated/Approved		"Cephalon, Inc."
Daclizumab	Zenapax	3/5/1993	Prevention of acute renal allograft rejection.	Designated/Approved		"Hoffmann-La Roche, Inc."
Humanized anti-tac		3/5/1993	Prevention of acute graft-vs-host disease following bone marrow transplantation.	Designated	Not FDA Approved for Orphan Indication	"Hoffmann-La Roche, Inc."
"Immune globulin intravenous, human"	Gamimune N	2/18/1993	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	Designated/Approved		Bayer Corporation
Somatropin		2/12/1993	Treatment of cachexia associated with AIDS.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bio-Technology General Corp.
Tretinoin		1/14/1993	Treatment of acute and chronic leukemia.	Designated	Not FDA Approved for Orphan Indication	"Antigenics, Inc."
Interferon beta (recombinant human)		1/13/1993	Treatment of primary brain tumors.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Biogen Idec, Inc."
Thalidomide		1/12/1993	Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.	Designated	Not FDA Approved for Orphan Indication	Celgene Corporation
"Colfosceril palmitate, cetyl alcohol, tyloxapol"		1/11/1993	Treatment of adult respiratory distress syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	GlaxoSmithKline
Cystic fibrosis transmembrane conductance regulator gene		1/8/1993	Treatment of cystic fibrosis.	Designated	Not FDA Approved for Orphan Indication	"Genetic Therapy, Inc."
Monoclonal antibody for immunization against lupus nephritis		1/7/1993	Treatment of lupus nephritis.	Designated	Not FDA Approved for Orphan Indication	"VivoRx Autoimmune, Inc."
Tumor necrosis factor-binding protein 1		1/6/1993	Treatment of symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm3.	Designated	Not FDA Approved for Orphan Indication	"EMD Serono, Inc."
Tumor necrosis factor-binding protein II		1/6/1993	Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	Designated	Not FDA Approved for Orphan Indication	"EMD Serono, Inc."
Isobutyramide		12/18/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.	Designated	Not FDA Approved for Orphan Indication	"Perrine, Susan P., M.D."
Transforming growth factor-beta 2		12/18/1992	Treatment of full thickness macular holes.	Designated	Not FDA Approved for Orphan Indication	"Celtrix Pharmaceuticals, Inc."
Immune globulin intravenous (human)		12/16/1992	Treatment of juvenile rheumatoid arthritis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Immuno Clinical Research Corp.
PEG-glucocerebrosidase		12/9/1992	For use as chronic enzyme replacement therapy in patients with Gaucher's disease who are deficient in glucocerebrosidase.	Designated	Not FDA Approved for Orphan Indication	"National Institute of Mental Health, NIH"
Idarubicin		12/2/1992	Treatment of chronic myelogenous leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pharmacia & Upjohn
Interferon beta-1a (recombinant)		12/2/1992	Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"EMD Serono, Inc."
Idarubicin		12/1/1992	Treatment of myelodysplastic syndromes.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pharmacia & Upjohn
Topiramate	Topamax	11/25/1992	Treatment of Lennox-Gastaut syndrome.	Designated/Approved		"Johnson & Johnson Pharmaceutical R & D, LLC"
Herpes simplex virus gene		10/16/1992	Treatment of primary and metastatic brain tumors.	Designated	Not FDA Approved for Orphan Indication	"Genetic Therapy, Inc."
C1 esterase inhibitor subcutaneous (human)	Haegarda	10/16/1992	Prevention and/or treatment of acute attacks of hereditary angioedema.	Designated/Approved		CSL Behring LLC
C1 esterase inhibitor subcutaneous (human)	Haegarda	10/16/1992	Prevention and/or treatment of acute attacks of hereditary angioedema.	Designated/Approved		CSL Behring LLC
"Interleukin-1 receptor antagonist, human recombinant"		10/16/1992	Prevention and treatment of graft versus host disease in transplant recipients.	Designated	Not FDA Approved for Orphan Indication	Swedish Orphan Biovitrum AB (publ) (SOBI)
C1 esterase inhibitor (human)	Berinert	10/16/1992	Prevention and/or treatment of acute attacks of hereditary angioedema.	Designated/Approved		CSL Behring LLC
Allopurinol sodium	Aloprim for Injection	10/16/1992	"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy."	Designated/Approved		"Catalytica Pharmaceuticals, Inc"
"Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized"	Humate-P	10/16/1992	Treatment of patients with von Willebrand's disease	Designated/Approved		CSL Behring
Immune globulin intravenous (human)		10/13/1992	Treatment of polymyositis/dermatomyositis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Immuno Clinical Research Corp.
AI-RSA		10/8/1992	Treatment of autoimmune uveitis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AutoImmune, Inc."
Oxaliplatin		10/6/1992	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	Debiopharm S.A.
Butyrylcholinesterase		9/30/1992	Treatment of post-surgical apnea.	Designated	Not FDA Approved for Orphan Indication	Shire Laboratories Inc.
Botulinum toxin type A		9/15/1992	Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.	Designated	Not FDA Approved for Orphan Indication	"Botulinum Toxin Research Associates, Inc."
Anaritide acetate		8/27/1992	Treatment of patients with acute renal failure.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Scios, Inc."
fialuridine		7/24/1992	Adjunctive treatment of chronic active hepatitis B.	Designated	Not FDA Approved for Orphan Indication	"Oclassen Pharmaceuticals, Inc."
L-threonine		7/24/1992	Treatment of spasticity associated with familial spastic paraparesis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Interneuron Pharmaceuticals, Inc."
Interferon beta-1a (recombinant human)		7/24/1992	"Treatment of acute non-A, non-B hepatitis."	Designated	Not FDA Approved for Orphan Indication	"Biogen, Inc."
sodium phenylbutyrate		7/2/1992	"Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy."	Designated	Not FDA Approved for Orphan Indication	Medicis Pharmaceutical Corp.
Cystic fibrosis gene therapy		6/30/1992	Treatment of cystic fibrosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genzyme Corporation
Secretory leukocyte protease inhibitor		6/30/1992	Treatment of bronchopulmonary dysplasia.	Designated	Not FDA Approved for Orphan Indication	"Synergen, Inc."
Protein C concentrate	Ceprotin	6/23/1992	"For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans."	Designated/Approved		"Baxalta US, Inc."
Protein C concentrate		6/19/1992	For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.	Designated	Not FDA Approved for Orphan Indication	Immuno Clinical Research Corp.
Minocycline HCl		6/19/1992	Treatment of chronic malignant pleural effusion.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Lederle Laboratories Division
Dianeal peritoneal dialysis solution with 1.1% amino acids		6/11/1992	For use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.	Designated	Not FDA Approved for Orphan Indication	Baxter Healthcare Corporation
"Imported fire ant venom, allergenic extract"		5/12/1992	"For skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of IgE-mediated anaphylactic reactions."	Designated	Not FDA Approved for Orphan Indication	"ALK Laboratories, Inc."
"5,6-dihydro-5-azacytidine"		5/11/1992	Treatment of malignant mesothelioma.	Designated	Not FDA Approved for Orphan Indication	"ILEX Oncology, Inc."
"Ciliary neurotrophic factor, recombinant human"		5/8/1992	"Treatment of motor neuron disease (including amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis)."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Syntex-Synergen Neuroscience
Sodium Monomercaptoundecahydro-closo-dodecaborate		4/15/1992	For use in boron neutron capture therapy (BNCT) in the treatment of glioblastoma multiforme.	Designated	Not FDA Approved for Orphan Indication	Neutron Technology Corp.& Neutron R&D Partner
Alitretinoin		4/10/1992	Treatment of acute promyelocytic leukemia	Designated	Not FDA Approved for Orphan Indication	"Ligand Pharmaceuticals, Inc."
Anaritide acetate		4/10/1992	Improvement of early renal allograft function following renal transplantation.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Scios, Inc."
Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell		4/7/1992	"Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia."	Designated	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
Arginine butyrate		4/7/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia.	Designated	Not FDA Approved for Orphan Indication	"Perrine, Susan P., M.D."
"Ciliary neurotrophic factor, recombinant human"		4/2/1992	Treatment of spinal muscular atrophies.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Syntex-Synergen Neuroscience
Polymeric oxygen		3/25/1992	Treatment of sickle cell anemia.	Designated	Not FDA Approved for Orphan Indication	Capmed USA
Human immunodeficiency virus immune globulin		3/25/1992	Treatment of HIV-infected pregnant women and infants of HIV-infected mothers.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	NABI
Butyrylcholinesterase		3/25/1992	For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.	Designated	Not FDA Approved for Orphan Indication	Shire Laboratories Inc.
HIV neutralizing antibodies		3/24/1992	Treatment of acquired immunodeficiency syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Hemacare Corporation
Melphalan		3/3/1992	For use in hyperthermic regional limb perfusion to treat metastatic melanoma of the extremity.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Glaxo Wellcome Research and Development
Pilocarpine HCl	Salagen	2/28/1992	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	Designated/Approved		"MGI Pharma, Inc."
Diazepam viscous solution for rectal administration	Diastat	2/25/1992	"For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity."	Designated/Approved		Valeant Pharmaceuticals
Melphalan	Alkeran For Injection	2/24/1992	Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.	Designated/Approved		Glaxo Wellcome Inc.
Thyrotropin alpha	Thyrogen	2/24/1992	As an adjunct in the diagnosis of thyroid cancer.	Designated/Approved		Genzyme Corporation
Loxoribine		2/24/1992	Treatment of common variable immunodeficiency.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	R. W. Johnson Pharmaceutical Research Institute
Aminosalicylic acid	Paser Granules	2/19/1992	Treatment of tuberculosis infections	Designated/Approved		Jacobus Pharmaceutical Company
Papaverine topical gel		2/6/1992	Treatment of sexual dysfunction in spinal cord injury patients.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pharmedic Company
Ciliary neurotrophic factor		1/30/1992	Treatment of amyotrophic lateral sclerosis.	Designated	Not FDA Approved for Orphan Indication	Regeneron Pharmaceuticals Inc
L-baclofen		1/30/1992	Treatment of intractable spasticity in children with cerebral palsy.	Designated	Not FDA Approved for Orphan Indication	Osmotica Pharmaceutical Corp.
"Ananain, comosain"		1/21/1992	For the enzymatic debridement of severe burns.	Designated	Not FDA Approved for Orphan Indication	Genzyme Corporation
Botulinum toxin type B	Myobloc	1/16/1992	Treatment of cervical dystonia.	Designated/Approved		"Soltice Neurosciences, LLC"
Cystic fibrosis transmembrane conductance regulator		1/14/1992	For cystic fibrosis transmembrane conductance regulator protein replacement therapy in cystic fibrosis patients.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Genzyme Corporation
Dapsone USP		1/8/1992	For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.	Designated	Not FDA Approved for Orphan Indication	Jacobus Pharmaceutical Company
Cryptosporidium hyperimmune bovine colostrum IgG concentrate		12/30/1991	Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.	Designated	Not FDA Approved for Orphan Indication	ImmuCell Corporation
Dapsone USP		12/24/1991	Prophylaxis for Pneumocystis carinii pneumonia.	Designated	Not FDA Approved for Orphan Indication	Jacobus Pharmaceutical Company
Dexrazoxane	Zinecard	12/17/1991	For the prevention of cardiomyopathy associated with doxorubicin administration.	Designated/Approved		Pharmacia & Upjohn
L-baclofen		12/17/1991	Treatment of spasticity associated with spinal cord injury or multiple sclerosis.	Designated	Not FDA Approved for Orphan Indication	Osmotica Pharmaceutical Corp.
Interferon beta-1a	Avonex	12/16/1991	Treatment of multiple sclerosis.	Designated/Approved		"Biogen, Inc."
baclofen	OZOBAX	12/16/1991	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	Designated/Approved		"Metacel Pharmaceuticals, LLC"
botulinum toxin type A	Botox	12/6/1991	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients	Designated/Approved		"Allergan, Inc."
Matrix metalloproteinase inhibitor		12/5/1991	Treatment of corneal ulcers.	Designated	Not FDA Approved for Orphan Indication	"Glycomed, Inc"
Amphotericin B lipid complex	Abelcet	12/5/1991	Treatment of invasive fungal infections.	Designated/Approved		"Liposome Company, Inc."
Botulinum toxin type A		12/5/1991	Treatment of essential blepharospasm.	Designated	Not FDA Approved for Orphan Indication	"Ipsen Biopharmaceuticals, Inc."
Sermorelin acetate		12/5/1991	Treatment of AIDS-associated catabolism/weight loss.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"EMD Serono, Inc."
Liposome encapsulated recombinant interleukin-2		11/25/1991	Treatment of brain and CNS tumors.	Designated	Not FDA Approved for Orphan Indication	"Oncothyreon Canada, Inc."
Somatropin for injection	Serostim	11/15/1991	Treatment of AIDS-associated catabolism/weight loss.	Designated/Approved		"EMD Serono, Inc."
Monoclonal antibody to cytomegalovirus (human)		11/15/1991	Treatment of cytomegalovirus retinitis in patients with AIDS.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Protein Design Labs, Inc."
Imiglucerase	Cerezyme	11/5/1991	"Replacement therapy in patients with types I, II, and III Gaucher's disease."	Designated/Approved		Genzyme Corporation
Pramiracetam Sulfate		11/4/1991	For the management of cognitive dysfunction and enhancement of antidepressant activity associated with electroconvulsive therapy.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Cambridge Neuroscience, Inc."
Halofantrine	Halfan	11/4/1991	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	Designated/Approved		SmithKline Beecham Pharmaceuticals
Botulinum toxin type F		10/24/1991	Treatment of spasmodic torticollis (cervical dystonia).	Designated	Not FDA Approved for Orphan Indication	Ipsen Limited
"Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid"		10/24/1991	Prophylactic treatment of sickle cell disease.	Designated	Not FDA Approved for Orphan Indication	"Omex International, Inc."
Metronidazole		10/24/1991	Treatment of perioral dermatitis.	Designated	Not FDA Approved for Orphan Indication	"Galderma Laboratories, Inc."
Lodoxamide tromethamine	Alomide Ophthalmic Solution	10/16/1991	Treatment of vernal keratoconjunctivitis.	Designated/Approved		"Alcon Laboratories, Inc."
Dynamine		10/16/1991	Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).	Designated	Not FDA Approved for Orphan Indication	Mayo Foundation
"Interleukin-1 receptor antagonist, human recombinant"		9/23/1991	Treatment of juvenile rheumatoid arthritis.	Designated	Not FDA Approved for Orphan Indication	Swedish Orphan Biovitrum AB (publ) (SOBI)
Toremifene	Fareston	9/19/1991	Hormonal therapy of metastatic carcinoma of the breast.	Designated/Approved		Orion Corporation
Exemestane	Aromasin	9/19/1991	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Designated/Approved		Pharmacia & Upjohn
Monoclonal antibody to cytomegalovirus (human)		9/13/1991	Prophylaxis of cytomegalovirus disease in patients undergoing solid organ transplantation.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Protein Design Labs, Inc."
Oxandrolone		9/6/1991	Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.	Designated	Not FDA Approved for Orphan Indication	Bio-Technology General Corp.
Filgrastim		9/3/1991	"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir"	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Amgen, Inc."
Atovaquone	Mepron	8/14/1991	"Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3."	Designated/Approved		Glaxo Wellcome Research and Development
Tiratricol		8/13/1991	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Designated	Not FDA Approved for Orphan Indication	Laphal Laboratoires
mecasermin		8/5/1991	Treatment of amyotrophic lateral sclerosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Teva Branded Pharmaceutical Products R&D, Inc."
cyclosporine 2% ophthalmic ointment		8/1/1991	Treatment of patients at high risk of graft rejection following penetrating keratoplasty	Designated	Not FDA Approved for Orphan Indication	"Allergan, Inc."
cyclosporine 2% ophthalmic ointment		8/1/1991	"For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer"	Designated	Not FDA Approved for Orphan Indication	"Allergan, Inc."
Levoleucovorin	Fusilev	8/1/1991	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Designated/Approved		Acrotech Biopharma LLC
Testosterone propionate ointment 2%		7/31/1991	Treatment of vulvar dystrophies.	Designated	Not FDA Approved for Orphan Indication	"Star Pharmaceuticals, Inc."
Epoetin alfa	Epogen	7/1/1991	Treatment of anemia associated with HIV infection or HIV treatment.	Designated/Approved		"Amgen, Inc."
Monoclonal antibody -81		6/27/1991	Adjunctive treatment of acute myelogenous leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Medarex, Inc."
Myelin		6/27/1991	Treatment of multiple sclerosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"AutoImmune, Inc."
Ursodiol	URSO 250	6/20/1991	Treatment of patients with primary biliary cirrhosis	Designated/Approved		"Aptalis Pharma US, Inc."
"Interleukin-1 alpha, human recombinant"		6/17/1991	For the promotion of early engraftment in bone marrow transplantation.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Immunex Corporation
Monoclonal antibody to hepatitis B virus (human)		6/17/1991	Prophylaxis of hepatitis B reinfection in patients undergoing liver transplantation secondary to end-stage chronic hepatitis B infection.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Protein Design Labs, Inc."
"Interleukin-1 alpha, human recombinant"		6/17/1991	For hematopoietic potentiation in aplastic anemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Immunex Corporation
Alpha-galactosidase A		6/17/1991	Treatment of alpha-galactosidase A deficiency (Fabry's disease).	Designated	Not FDA Approved for Orphan Indication	"David Calhoun, Ph.D."
Nifedipine		6/13/1991	Treatment of interstitial cystitis.	Designated	Not FDA Approved for Orphan Indication	"Fleischmann, Jonathan M.D."
Chimeric M-T412 (human-murine) IgG monoclonal anti-CD4		6/5/1991	Treatment of multiple sclerosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Centocor, Inc."
Fosphenytoin	Cerebyx	6/4/1991	For the acute treatment of patients with status epilepticus of the grand mal type.	Designated/Approved		Warner-Lambert Company
Calcium gluconate gel		5/21/1991	For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Designated	Not FDA Approved for Orphan Indication	Calgonate Corporation
Interleukin-3 human (recombinant)		5/20/1991	Promotion of erythropoiesis in Diamond-Blackfan anemia (congenital pure red cell aplasia).	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Immunex Corporation
Poly I: poly C12U		5/20/1991	Treatment of renal cell carcinoma.	Designated	Not FDA Approved for Orphan Indication	AIM ImmunoTech Inc.
Interferon beta (recombinant)		5/9/1991	For the intralesional and/or systemic treatment of AIDS-related Kaposi's sarcoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Biogen, Inc."
thymalfasin		5/3/1991	Treatment of chronic active hepatitis B	Designated	Not FDA Approved for Orphan Indication	"SciClone Pharmaceuticals, Inc."
Histrelin		5/3/1991	"Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria."	Designated	Not FDA Approved for Orphan Indication	"Anderson, Karl E., M.D."
Etidronate disodium		5/2/1991	Prevention of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"MGI Pharma, Inc."
Etidronate disodium		5/2/1991	Treatment of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"MGI Pharma, Inc."
Ofloxacin	Ocuflox Ophthalmic Solution	4/18/1991	Treatment of bacterial corneal ulcers.	Designated/Approved		"Allergan, Inc."
Interferon beta (recombinant)		4/18/1991	For the systemic treatment of cutaneous T-cell lymphoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Biogen, Inc."
Recombinant human superoxide dismutase		4/18/1991	Prevention of bronchopulmonary dysplasia in premature neonates weighing less than 1500 grams.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Savient Pharmaceuticals, Inc."
ribavirin		4/12/1991	Treatment of hemorrhagic fever with renal syndrome	Designated	Not FDA Approved for Orphan Indication	Valeant Pharmaceuticals International
Interferon beta-1a (recombinant)		4/3/1991	For the systemic treatment of cutaneous malignant melanoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Biogen, Inc."
Recombinant secretory leucocyte protease inhibitor		3/29/1991	Treatment of cystic fibrosis.	Designated	Not FDA Approved for Orphan Indication	"Amgen, Inc."
Recombinant secretory leucocyte protease inhibitor		3/29/1991	Treatment of congenital alpha-1 antitrypsin deficiency.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Amgen Inc.
Ketoconazole		3/27/1991	For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pharmedic Company
Succimer		3/22/1991	Treatment of mercury intoxication.	Designated	Not FDA Approved for Orphan Indication	"Sanofi Winthrop, Inc."
Poloxamer 331		3/21/1991	Initial therapy of toxoplasmosis in patients with AIDS.	Designated	Not FDA Approved for Orphan Indication	CytRx Corporation
Dextran and deferoxamine		3/8/1991	Treatment of acute iron poisoning.	Designated	Not FDA Approved for Orphan Indication	"Biomedical Frontiers, Inc."
Sucralfate suspension		3/4/1991	Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.	Designated	Not FDA Approved for Orphan Indication	"Darby Pharmaceuticals, Inc."
Ursodiol		2/19/1991	Management of the clinical signs and symptoms associated with primary biliary cirrhosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
Interferon beta (recombinant)		2/12/1991	For the systemic treatment of metastatic renal cell carcinoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Biogen, Inc."
Idarubicin HCl for injection		2/12/1991	Treatment of acute lymphoblastic leukemia in pediatric patients.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
Antivenom (crotalidae) purified (avian)		2/12/1991	Treatment of envenomation by poisonous snakes belonging to the Crotalidae family.	Designated	Not FDA Approved for Orphan Indication	"Ophidian Pharmaceuticals, Inc."
Gentamicin impregnated PMMA beads on surgical wire		1/31/1991	"Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin."	Designated	Not FDA Approved for Orphan Indication	"Lipha Pharmaceuticals, Inc."
Pentostatin		1/29/1991	Treatment of patients with chronic lymphocytic leukemia.	Designated	Not FDA Approved for Orphan Indication	"SuperGen, Inc."
Cytomegalovirus immune globulin intravenous (human)		1/28/1991	For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.	Designated	Not FDA Approved for Orphan Indication	Bayer Corporation
Ricin (blocked) conjugated murine MCA (n901)		1/25/1991	Treatment of small cell lung cancer	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ImmunoGen, Inc."
Cysteamine	Cystagon	1/25/1991	Treatment of nephropathic cystinosis.	Designated/Approved		"Mylan Laboratories, Inc."
Ricin (blocked) conjugated murine mca (anti-b4)		1/24/1991	For the ex-vivo purging of leukemic cells from the bone marrow of non-T cell acute lymphocytic leukemia patients who are in complete remission.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ImmunoGen, Inc."
Desmopressin acetate		1/22/1991	Treatment of mild hemophilia A and von Willebrand's disease.	Designated/Approved		"Ferring Pharmaceuticals, Inc."
Dornase alfa	Pulmozyme	1/16/1991	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Designated/Approved		"Genentech, Inc."
Testosterone sublingual		1/16/1991	Treatment of constitutional delay of growth and puberty in boys.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bio-Technology General Corp.
Dronabinol	Marinol	1/15/1991	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Designated/Approved		"Unimed Pharmaceuticals, Inc."
Mucoid exopolysaccharide Pseudomonas hyperimmune globulin		1/9/1991	Treatment of pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"North American Biologicals, Inc."
cladribine		12/31/1990	Treatment of chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
levoleucovorin	Fusilev	12/18/1990	For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum	Designated/Approved		Acrotech Biopharma LLC
amifampridine		12/18/1990	Treatment of Lambert-Eaton myasthenic syndrome.	Designated	Not FDA Approved for Orphan Indication	"Catalyst Pharmaceuticals, Inc."
Bovine colostrum		11/19/1990	Treatment of AIDS-related diarrhea.	Designated	Not FDA Approved for Orphan Indication	"Hastings, Donald DVM"
Microbubble contrast agent		11/16/1990	Intraoperative aid in the identification and localization of intracranial tumors.	Designated	Not FDA Approved for Orphan Indication	"Cav-Con, Inc."
Cladribine	Leustatin Injection	11/15/1990	Treatment of hairy cell leukemia.	Designated/Approved		R. W. Johnson Pharmaceutical Research Institute
Mucoid exopolysaccharide Pseudomonas hyperimmune globulin		11/7/1990	Prevention of pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"North American Biologicals, Inc."
Filgrastim	Neupogen	11/7/1990	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).	Designated/Approved		"Amgen, Inc."
Succimer		11/5/1990	Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.	Designated	Not FDA Approved for Orphan Indication	"Sanofi Winthrop, Inc."
Calcitonin salmon nasal spray		10/29/1990	Treatment of symptomatic Paget's disease (osteitis deformans).	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Sandoz Pharmaceuticals Corp.
Tretinoin	Vesanoid	10/24/1990	Treatment of acute promyelocytic leukemia.	Designated/Approved		"Hoffmann-La Roche, Inc."
Gossypol		10/22/1990	Treatment of cancer of the adrenal cortex.	Designated	Not FDA Approved for Orphan Indication	"Reidenberg, Marcus M. M.D."
Taxol isolated from Taxus brevifolia		10/15/1990	Treatment of ovarian cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb
Methotrexate with laurocapram		10/15/1990	Topical treatment of mycosis fungoides.	Designated	Not FDA Approved for Orphan Indication	"Echo Therapeutics, Ltd."
"Dextran sulfate (inhaled, aerosolized)"		10/5/1990	For use as an adjunct to the treatment of cystic fibrosis.	Designated	Not FDA Approved for Orphan Indication	"Kennedy & Hoidal, M.D.'s"
Oxandrolone		10/5/1990	Treatment of constitutional delay of growth and puberty.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bio-Technology General Corp.
Hydroxyurea	Droxia	10/1/1990	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Designated/Approved		Bristol-Myers Squibb Pharmaceutical Research Institute
Filgrastim	Neupogen	10/1/1990	Treatment of neutropenia associated with bone marrow transplants.	Designated/Approved		"Amgen, Inc."
Respiratory Syncytial Virus Immune Globulin (human)		9/27/1990	Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.	Designated	Not FDA Approved for Orphan Indication	"MedImmune, Inc."
Respiratory syncytial virus immune globulin (Human)	Respigam	9/27/1990	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	Designated/Approved		MedImmune & Massachussetts Public Health Biologics Labs.
Pilocarpine	Salagen	9/24/1990	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	Designated/Approved		"MGI Pharma, Inc."
Leupeptin		9/18/1990	For use as an adjunct to microsurgical peripheral nerve repair.	Designated	Not FDA Approved for Orphan Indication	"Neuromuscular Adjuncts, Inc."
Lactobin		9/12/1990	Treatment of AIDS-associated diarrhea unresponsive to initial antidiarrheal therapy.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Roxane Laboratories, Inc."
Anti-CD45 monoclonal antibodies		9/10/1990	Prevention of acute graft rejection of human organ transplants.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Baxter Healthcare Corporation
Calcium gluconate gel 2.5%		9/10/1990	Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Designated	Not FDA Approved for Orphan Indication	"Paddock Laboratories, Inc."
Sulfapyridine		9/10/1990	Treatment of dermatitis herpetiformis.	Designated	Not FDA Approved for Orphan Indication	Jacobus Pharmaceutical Company
Atovaquone	Mepron	9/10/1990	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Designated/Approved		Glaxo Wellcome Inc.
C1-inhibitor		8/30/1990	"Prevention of acute attacks of angioedema, including short-term prophylaxis for patients requiring dental or other surgical procedures."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Baxter Healthcare Corp.
Filgrastim		8/30/1990	Treatment of myelodysplastic syndrome	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Amgen, Inc."
C1-inhibitor		8/30/1990	Treatment of acute attacks of angioedema.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Baxter Healthcare Corp.
Recombinant human CD4 immunoglobulin G		8/30/1990	Treatment of AIDS resulting from infection with HIV-1.	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
Triptorelin pamoate		8/10/1990	For use in the palliative treatment of advanced ovarian carcinoma of epithelial origin.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Debio R.A. Inc.
Liothyronine sodium injection	Triostat	7/30/1990	Treatment of myxedema coma/precoma.	Designated/Approved		SmithKline Beecham Pharmaceuticals
Alpha-galactosidase A		7/20/1990	Treatment of Fabry's disease.	Designated	Not FDA Approved for Orphan Indication	"Desnick, Robert J. M.D."
Cladribine		7/20/1990	Treatment of acute myeloid leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
Pr-320 (molecusol-carbamazepine)		7/20/1990	"For the emergency rescue treatment of status epilepticus, grand mal type."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pharmos
Amiloride HCl solution for inhalation		7/18/1990	Treatment of cystic fibrosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Glaxo Wellcome Research and Development
Mafenide acetate solution	Sulfamylon solution	7/18/1990	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Designated/Approved		"Mylan Laboratories, Inc."
L-baclofen		7/13/1990	Treatment of trigeminal neuralgia.	Designated	Not FDA Approved for Orphan Indication	"Fromm, Gerhard M.D."
Morphine sulfate concentrate (preservative free)	Infumorph	7/12/1990	For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	Designated/Approved		"Elkins-Sinn, Inc."
Gentamicin liposome injection		7/10/1990	Treatment of disseminated Mycobacterium avium-intracellulare infection.	Designated	Not FDA Approved for Orphan Indication	"Liposome Company, Inc."
Pr-122 (redox-phenytoin)		7/5/1990	"For the emergency rescue treatment of status epilepticus, grand mal type."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pharmos
Coagulation Factor IX (human)	AlphaNine	7/5/1990	"For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis."	Designated/Approved		Alpha Therapeutic Corporation
Oxandrolone		7/5/1990	Treatment of short stature associated with Turner's syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bio-Technology General Corp.
Sodium dichloroacetate		6/11/1990	Treatment of congenital lactic acidosis	Designated	Not FDA Approved for Orphan Indication	Saol Therapeutics Inc.
Sodium dichloroacetate		6/11/1990	Treatment of homozygous familial hypercholesterolemia.	Designated	Not FDA Approved for Orphan Indication	"Stacpoole, Peter W. M.D., Ph.D."
Calcium carbonate		6/6/1990	Treatment of hyperphosphatemia in patients with end stage renal disease.	Designated	Not FDA Approved for Orphan Indication	"R & D Laboratories, Inc."
Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.	Designated/Approved		"Medimmune Oncology, Inc."
Amifostine		5/30/1990	For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.	Designated	Not FDA Approved for Orphan Indication	"Clinigen, Inc."
Amifostine		5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.	Designated	Not FDA Approved for Orphan Indication	"Clinigen, Inc."
PR-225 (redox-acyclovir)		5/29/1990	Treatment of herpes simplex encephalitis in individuals afflicted with AIDS.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pharmos
Short chain fatty acid solution		5/29/1990	Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.	Designated	Not FDA Approved for Orphan Indication	Richard I. Breuer
His-D-Trp-Ala-Trp-D-Phe-Lys NH2		5/23/1990	For the long term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	SmithKline Beecham Pharmaceuticals
PR-239 (redox penicillin G)		5/23/1990	Treatment of AIDS associated neurosyphilis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pharmos
Interferon alfa-2a (recombinant)		5/14/1990	For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.	Designated	Not FDA Approved for Orphan Indication	"Hoffmann-La Roche, Inc."
Iloprost solution for infusion		5/14/1990	Treatment of heparin-associated thrombocytopenia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Berlex Laboratories, Inc."
Interferon alfa-2a (recombinant)		5/11/1990	For the treatment of metastatic malignant melanoma in combination with Teceleukin.	Designated	Not FDA Approved for Orphan Indication	"Hoffmann-La Roche, Inc."
Interleukin-2		5/11/1990	In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.	Designated	Not FDA Approved for Orphan Indication	"Hoffmann-La Roche, Inc."
Somatropin	Humatrope	5/8/1990	Treatment of short stature associated with Turner syndrome.	Designated/Approved		Eli Lilly and Company
Group B streptococcus immune globulin		5/8/1990	Treatment of neonates for disseminated group B streptococcal infection.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"North American Biologicals, Inc."
Granulocyte macrophage-colony stimulating factor		5/4/1990	Treatment of chronic lymphocytic leukemia to increase granulocyte count.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Interferon alfa-2b (recombinant)		5/4/1990	Treatment of chronic delta hepatitis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
sargramostim	Leukine	5/3/1990	"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment."	Designated/Approved		Immunex Corporation
Granulocyte macrophage-colony stimulating factor		5/3/1990	Treatment of neutropenia due to hairy cell leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Anti-cytomegalovirus monoclonal antibodies		5/3/1990	1. Treatment of human cytomegalovirus infection in patients diagnosed with AIDS 2. Prevention of human cytomegalovirus infection in patients diagnosed with AIDS	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Biomedical Research Institute
Interleukin-2		5/3/1990	In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.	Designated	Not FDA Approved for Orphan Indication	"Hoffmann-La Roche, Inc."
Interferon alfa-2a (recombinant)		5/2/1990	For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.	Designated	Not FDA Approved for Orphan Indication	"Hoffmann-La Roche, Inc."
Anti-cytomegalovirus monoclonal antibodies		5/2/1990	1. Treatment of human cytomegalovirus infection in bone marrow and organ transplant patients 2. Prevention of human cytomegalovirus infection in bone marrow and organ transplant patients	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Biomedical Research Institute
chelmab-y or chelamusab-Y		4/24/1990	Treatment of ovarian cancer.	Designated	Not FDA Approved for Orphan Indication	Cytogen Corporation
Fluorouracil		4/18/1990	"For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma."	Designated	Not FDA Approved for Orphan Indication	"Hoffmann-La Roche, Inc."
N-acetylprocainamide		3/23/1990	To lower the defibrillation energy requirement sufficiently to allow automatic implantable cardioverter defibrillator therapy in those patients who could otherwise not use the device.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Medco Research, Inc."
Monoclonal antibodies PM-81 and AML-2-23		3/12/1990	For the exogenous depletion of CD14 and CD15 positive acute myeloid leukemic bone marrow cells from patients undergoing bone marrow transplantation.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Medarex, Inc."
Sucralfate suspension		3/12/1990	Treatment of oral complications of chemotherapy in bone marrow transplant patients.	Designated	Not FDA Approved for Orphan Indication	"Darby Pharmaceuticals, Inc."
Thalidomide		3/5/1990	Prevention of graft versus host disease.	Designated	Not FDA Approved for Orphan Indication	Andrulis Research Corporation
Thalidomide		3/5/1990	Treatment of graft versus host disease.	Designated	Not FDA Approved for Orphan Indication	Andrulis Research Corporation
Dextran 70		3/5/1990	Treatment of recurrent corneal erosion unresponsive to conventional therapy.	Designated	Not FDA Approved for Orphan Indication	"Holles Laboratories, Inc."
Disodium clodronate tetrahydrate		3/5/1990	Treatment of increased bone resorption due to malignancy.	Designated	Not FDA Approved for Orphan Indication	"Anthra Pharmaceuticals, Inc."
Disaccharide tripeptide glycerol dipalmitoyl		3/1/1990	Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.	Designated	Not FDA Approved for Orphan Indication	"ImmunoTherapeutics, Inc."
Glyceol		2/22/1990	To decrease intracranial hypertension and/or alleviate cerebral edema in patients who may benefit from osmotherapy.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Chugai Pharmaceutical Co., Ltd."
Poloxamer 188		2/22/1990	Treatment of severe burns requiring hospitalization.	Designated	Not FDA Approved for Orphan Indication	CytRx Corporation
Sermorelin acetate		2/13/1990	Adjunct to gonadotropin therapy in the induction of ovulation in women with anovulatory or oligo-ovulatory infertility who fail to ovulate in response to adequate treatment with clomiphene citrate alone and gonadotropin therapy alone.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"EMD Serono, Inc."
Interleukin-2		2/6/1990	Treatment of metastatic malignant melanoma.	Designated	Not FDA Approved for Orphan Indication	"Hoffmann-La Roche, Inc."
Indium In-111 altumomab pentetate		2/6/1990	Detection of suspected and previously unidentified tumor foci of recurrent colorectal carcinoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Hybritech, Inc."
Interleukin-2		2/5/1990	Treatment of metastatic renal cell carcinoma.	Designated	Not FDA Approved for Orphan Indication	"Hoffmann-La Roche, Inc."
Dynamine		2/5/1990	Treatment of Lambert Eaton myasthenic syndrome.	Designated	Not FDA Approved for Orphan Indication	Mayo Foundation
PEG-interleukin-2		2/1/1990	Treatment of primary immunodeficiencies associated with T-cell defects.	Designated	Not FDA Approved for Orphan Indication	Chiron Corporation
Ricin (blocked) conjugated murine MCA (anti-my9)		2/1/1990	For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ImmunoGen, Inc."
Melanoma vaccine		12/20/1989	Treatment of stage III - IV melanoma.	Designated	Not FDA Approved for Orphan Indication	"Ribi ImmunoChem Research, Inc."
Rifabutin	Mycobutin	12/18/1989	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.	Designated/Approved		"Adria Laboratories, Inc."
Rifabutin		12/18/1989	Treatment of disseminated Mycobacterium avium complex disease.	Designated	Not FDA Approved for Orphan Indication	Pfizer Inc.
4-aminosalicylic acid		12/13/1989	Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.	Designated	Not FDA Approved for Orphan Indication	"Beeken, Warren M.D."
Carbovir		12/13/1989	Treatment of persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Glaxo Wellcome Inc.
polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma.	Designated/Approved		"Guilford Pharmaceuticals, Inc."
polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma.	Designated/Approved		"Guilford Pharmaceuticals, Inc."
Granulocyte macrophage-colony stimulating factor		12/12/1989	Treatment of neutropenia associated with bone marrow transplants.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Multi-vitamin infusion (neonatal formula)		12/12/1989	For establishment and maintenance of total parenteral nutrition in very low birth weight infants.	Designated	Not FDA Approved for Orphan Indication	"Astra Pharmaceuticals, L.P."
Perfosfamide		12/4/1989	"For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Scios Nova, Inc."
Bethanidine sulfate		11/24/1989	Prevention of recurrence of primary ventricular fibrillation.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Medco Research, Inc."
Corticorelin ovine triflutate	Acthrel	11/24/1989	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Designated/Approved		"Ferring Laboratories, Inc."
Human immunodeficiency virus immune globulin		11/21/1989	Treatment of AIDS.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	NABI
CD4 human truncated 369 AA polypeptide		11/21/1989	Treatment of acquired immunodeficiency syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	SmithKline Beecham
Human T-lymphotropic virus type III Gp160 antigens		11/20/1989	Treatment of AIDS.	Designated	Not FDA Approved for Orphan Indication	"MicroGeneSys, Inc."
Recombinant soluble human CD4		11/20/1989	Treatment of acquired immunodeficiency syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Biogen, Inc."
"3'-azido-2',3'dideoxyuridine"		11/20/1989	Treatment of acquired immunodeficiency syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Berlex Laboratories, Inc."
Porfimer sodium		11/15/1989	For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.	Designated	Not FDA Approved for Orphan Indication	"QLT Phototherapeutics, Inc."
levocarnitine		11/15/1989	1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in valproic acid toxicity	Designated	Not FDA Approved for Orphan Indication	"Leadiant Biosciences, Inc."
Interferon alfa-2a (recombinant)		10/27/1989	For use in combination with fluorouracil for the treatment of esophageal carcinoma.	Designated	Not FDA Approved for Orphan Indication	"Hoffmann-La Roche, Inc."
Fluorouracil		10/27/1989	"For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma."	Designated	Not FDA Approved for Orphan Indication	"Hoffmann-La Roche, Inc."
enisoprost		10/20/1989	1. For use with cyclosporine in organ transplant recipients to reduce acute transplant rejection 2. For use in organ transplant patients to diminish the nephrotoxicity induced by cyclosporine.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	G.D. Searle & Company
Pegaspargase	Oncaspar; Asparlas	10/20/1989	Treatment of acute lymphocytic leukemia.	Designated/Approved		Servier Pharmaceuticals LLC
"Colfosceril palmitate, cetyl alcohol, tyloxapol"	Exosurf Neonatal for Intratracheal Suspension	10/20/1989	"1. Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less 2. Treatment of established hyaline membrane disease at all gestational ages"	Designated/Approved		Glaxo Wellcome Inc.
Pegaspargase	Oncaspar; Asparlas	10/20/1989	Treatment of acute lymphocytic leukemia.	Designated/Approved		Servier Pharmaceuticals LLC
Ancrod		10/20/1989	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Designated	Not FDA Approved for Orphan Indication	Knoll Pharmaceutical Company
Antihemophilic factor (recombinant)	Kogenate	9/25/1989	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Designated/Approved		Bayer Corporation
Molgramostim		9/25/1989	Treatment of aplastic anemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Satumomab pendetide	Oncoscint CR/OV	9/25/1989	Detection of ovarian carcinoma.	Designated/Approved		Cytogen Corporation
Troleandomycin		9/21/1989	Treatment of severe steroid-requiring asthma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Szefler, Stanley M. M.D."
Iloprost solution for infusion		9/21/1989	Treatment of Raynaud's phenomenon secondary to systemic sclerosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Berlex Laboratories, Inc."
Iodine I 131 murine monoclonal antibody IgG2a to B cell		9/18/1989	Treatment of B-cell leukemia and B-cell lymphoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
"Citric acid, glucono-delta-lactone and magnesium carbonate"	Renacidin Irrigation	8/28/1989	Treatment of renal and bladder calculi of the apatite or struvite variety.	Designated/Approved		"United-Guardian, Inc."
somatorelin		8/8/1989	Diagnostic measure of the capacity of the pituitary gland to release growth hormone.	Designated	Not FDA Approved for Orphan Indication	"Ferring Laboratories, Inc."
Human IgM monoclonal antibody (C-58) To CMV		8/7/1989	Treatment of cytomegalovirus infections in allogenic bone marrow transplant patients.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Centocor, Inc."
Human IgM monoclonal antibody (C-58) To CMV		8/7/1989	Prophylaxis of cytomegalovirus infections in bone marrow transplant patients.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Centocor, Inc."
Indium In 111 murine monoclonal antibody FAB to myosin		8/7/1989	To aid in the diagnosis of myocarditis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Centocor, Inc."
Technetium Tc99m murine monoclonal antibody to hCG		8/7/1989	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
Granulocyte macrophage-colony stimulating factor		8/7/1989	Treatment of myelodysplastic syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Growth hormone releasing factor		8/7/1989	For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Designated	Not FDA Approved for Orphan Indication	Valeant Pharmaceuticals North America
Somatropin for injection	Nutropin	8/4/1989	Treatment of growth retardation associated with chronic renal failure.	Designated/Approved		"Genentech, Inc."
Ricin (blocked) conjugated murine MCA (anti-my9)		8/3/1989	"Treatment of myeloid leukemia, including AML, and blast crisis of CML."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ImmunoGen, Inc."
L-cycloserine		8/1/1989	Treatment of Gaucher's disease.	Designated	Not FDA Approved for Orphan Indication	"Lev, Meir M.D."
Technetium Tc99m murine monoclonal antibody to human alpha-fetoprotein		8/1/1989	Detection of hepatocellular carcinoma and hepatoblastoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
Adenosine		8/1/1989	For use in conjunction with BCNU in the treatment of brain tumors.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Medco Research, Inc."
Technetium Tc99m murine monoclonal antibody to human AFP		8/1/1989	Detection of alpha-fetoprotein producing germ cell tumors.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
Lysine acetylsalicylate injectable		8/1/1989	Treatment of pain and fever secondary to sickle cell disease crisis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	G.D. Searle & Company
Ethiofos		8/1/1989	Use as a chemoprotective agent for cisplatin and cyclophosphamide in the treatment of ovarian cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	U.S. Bioscience
Coagulation factor IX	Mononine	6/27/1989	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	Designated/Approved		Armour Pharmaceutical Company
"T4 endonuclease V, liposome encapsulated"		6/27/1989	To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.	Designated	Not FDA Approved for Orphan Indication	AGI Dermatics
poloxamer 188 (purified)		6/27/1989	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	Designated	Not FDA Approved for Orphan Indication	Mast Therapeutics Inc.
Calcium acetate		6/27/1989	Treatment of hyperphosphatemia in end stage renal disease.	Designated	Not FDA Approved for Orphan Indication	Pharmedic Company
Interferon alfa-2a	Roferon A	6/6/1989	Treatment of chronic myelogenous leukemia.	Designated/Approved		"Hoffmann-La Roche, Inc."
Porfimer sodium	Photofrin	6/6/1989	For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.	Designated/Approved		"QLT Phototherapeutics, Inc."
Granulocyte macrophage-colony stimulating factor		6/6/1989	Treatment of severe thermal injuries in patients with greater than 40% full or partial thickness burns.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Bromhexine		5/15/1989	Treatment of mild to moderate keratoconjunctivitis sicca in patients with Sjogren's syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Boehringer Ingelheim Pharmaceuticals, Inc."
Somatropin (rDNA)		5/3/1989	For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.	Designated	Not FDA Approved for Orphan Indication	"EMD Serono, Inc."
Fludarabine phosphate		4/18/1989	Treatment and management of patients with non-Hodgkins lymphoma.	Designated	Not FDA Approved for Orphan Indication	"Berlex Laboratories, Inc."
Fludarabine phosphate	Fludara	4/18/1989	"Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL."	Designated/Approved		"Berlex Laboratories, Inc."
Somatropin for injection	Nutropin	3/23/1989	Treatment of short stature associated with Turner's syndrome.	Designated/Approved		"Genentech, Inc."
Botulinum toxin type A		3/23/1989	Treatment of essential blepharospasm.	Designated	Not FDA Approved for Orphan Indication	"Porton International, Inc."
Recombinant soluble human CD4 (rCD4)		3/23/1989	Treatment of AIDS in patients infected with HIV virus.	Designated	Not FDA Approved for Orphan Indication	"Genentech, Inc."
Antiepilepsirine		3/23/1989	Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.	Designated	Not FDA Approved for Orphan Indication	Children's Hospital
Aldesleukin		3/22/1989	Treatment of primary immunodeficiency disease associated with T-cell defects.	Designated	Not FDA Approved for Orphan Indication	"Iovance Biotherapeutics, Inc."
Cascara sagrada fluid extract		3/21/1989	Treatment of oral drug overdosage to speed lower bowel evacuation.	Designated	Not FDA Approved for Orphan Indication	Intramed Corporation
Epoetin alpha		3/7/1989	Treatment of HIV associated anemia related to HIV infection or HIV treatment.	Designated	Not FDA Approved for Orphan Indication	R. W. Johnson Pharmaceutical Research Institute
L-threonine		2/6/1989	Treatment of amyotrophic lateral sclerosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Tyson And Associates
Fluorouracil		2/6/1989	For use in combination with leucovorin for therapy of metastatic adenocarcinoma of the colon and rectum.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Lederle Laboratories
Botulism immune globulin	BabyBIG	1/31/1989	Treatment of infant botulism.	Designated/Approved		California Department of Health Services
Imciromab pentetate		1/25/1989	Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Centocor, Inc."
Clonidine	Duraclon	1/24/1989	"For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates."	Designated/Approved		"Roxane Laboratories, Inc."
Felbamate	Felbatol	1/24/1989	Treatment of Lennox-Gastaut syndrome.	Designated/Approved		Wallace Laboratories
Molgramostim		1/24/1989	"Treatment of AIDS patients with neutropenia due to the disease, AZTor ganciclovir."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Mitolactol		1/23/1989	Treatment of invasive carcinoma of the uterine cervix	Designated	Not FDA Approved for Orphan Indication	"Targent, Inc.."
Aerosolized pooled immune globulin		1/3/1989	Treatment of respiratory syncytial virus lower respiratory tract disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Pediatric Pharmaceuticals, Inc."
Branched chain amino acids		12/23/1988	Treatment of amyotrophic lateral sclerosis.	Designated	Not FDA Approved for Orphan Indication	Mount Sinai Medical Center
Cetiedil citrate injection		12/22/1988	Treatment of sickle cell disease crisis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Baker Cummins Pharmaceuticals, Inc."
Calcium acetate	Phos-Lo	12/22/1988	Treatment of hyperphosphatemia in end stage renal failure.	Designated/Approved		Fresenius Medical Care North America
fomepizole	Antizole	12/22/1988	Treatment of methanol or ethylene glycol poisoning.	Designated/Approved		"Par Pharmaceuticals, Inc"
fomepizole	Antizole	12/22/1988	Treatment of methanol or ethylene glycol poisoning.	Designated/Approved		"Par Pharmaceuticals, Inc"
Gallium nitrate injection	Ganite	12/5/1988	Treatment of hypercalcemia of malignancy.	Designated/Approved/Designation Withdrawn or Revoked		Solopak Pharmaceutical Co.
Fibronectin (plasma derived)		12/5/1988	Treatment of non-healing corneal ulcers or epithelial defects which are unresponsive to conventional therapy and for which any infectious cause of the defect has been eliminated.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Chiron Vision
Pulmonary surfactant replacement		12/5/1988	Prevention and treatment of infant respiratory distress syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Scios Nova, Inc."
Ricin (blocked) conjugated murine MCA (anti-B4)		11/17/1988	Treatment of B-cell leukemia and B-cell lymphoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"ImmunoGen, Inc."
Gangliosides as sodium salts		11/17/1988	Treatment of retinitis pigmentosa.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Fidia Pharmaceutical Corp.
Interferon alfa-2b (recombinant)		11/17/1988	Treatment of acute hepatitis B.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Interferon beta-1b	Betaseron	11/17/1988	Treatment of multiple sclerosis.	Designated/Approved		Chiron Corp. & Berlex Laboratories
"Interferon beta, recombinant human"		11/15/1988	Treatment of acquired immunodeficiency syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Berlex Laboratories, Inc."
Thalidomide		11/15/1988	Treatment and maintenance of reactional lepromatous leprosy.	Designated	Not FDA Approved for Orphan Indication	"Pediatric Pharmaceuticals, Inc."
Cyclosporine ophthalmic		11/9/1988	Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.	Designated	Not FDA Approved for Orphan Indication	University Of Georgia
Iodine I 123 murine monoclonal antibody to hCG		11/7/1988	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Designated	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
Iodine I 131 murine monoclonal antibody to hCG		11/7/1988	Treatment of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
Clindamycin		10/28/1988	Prevention of Pneumocystis carinii pneumonia in AIDS patients.	Designated	Not FDA Approved for Orphan Indication	Pfizer Inc.
Clindamycin		10/28/1988	Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.	Designated	Not FDA Approved for Orphan Indication	Pharmacia & Upjohn
Iodine I 131 murine monoclonal antibody to alpha-fetoprotein		9/30/1988	1. Treatment of hepatocellular carcinoma and hepatoblastoma 2. Treatment of alpha-fetoprotein producing germ cell tumors	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
Iodine I 123 murine monoclonal antibody to alpha-fetoprotein		9/30/1988	1. Detection of hepatocellular carcinoma and hepatoblastoma 2. Detection of alpha-fetoprotein producing germ cell tumors	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Immunomedics, Inc."
Interferon gamma 1-b	Actimmune	9/30/1988	Treatment of chronic granulomatous disease.	Designated/Approved		Horizon Therapeutic Ireland DAC
Sotalol HCl	Betapace	9/23/1988	1. Treatment of life-threatening ventricular tachyarrhythmias 2. Prevention of life treatening ventricular tachyarrhythmias	Designated/Approved		"Berlex Laboratories, Inc."
Bethanidine sulfate		9/20/1988	Treatment of primary ventricular fibrillation.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Medco Research, Inc."
Inosine pranobex		9/20/1988	Treatment of subacute sclerosing panencephalitis.	Designated	Not FDA Approved for Orphan Indication	Newport Pharmaceuticals
Caffeine	Cafcit	9/20/1988	Treatment of apnea of prematurity.	Designated/Approved		"O.P.R. Development, L.P."
thalidomide		9/19/1988	1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving bone marrow transplantation	Designated	Not FDA Approved for Orphan Indication	"Pediatric Pharmaceuticals, Inc."
Sermorelin acetate	Geref	9/14/1988	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Designated/Approved		"EMD Serono, Inc."
Aldesleukin	Proleukin	9/14/1988	Treatment of metastatic renal cell carcinoma.	Designated/Approved		Chiron Corporation
Phosphocysteamine		9/12/1988	Treatment of cystinosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Medea Research Laboratories
Serratia marcescens extract (polyribosomes)		9/7/1988	Treatment of primary brain malignancies.	Designated	Not FDA Approved for Orphan Indication	"Cell Technology, Inc."
Levocarnitine	Carnitor	9/6/1988	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Designated/Approved		"Leadiant Biosciences, Inc."
Fibronectin (human plasma derived)		9/5/1988	Treatment of non-healing corneal ulcers or epithelial defects which have been unresponsive to conventional therapy and the underlying cause has been eliminated.	Designated	Not FDA Approved for Orphan Indication	"Melville Biologics, Inc."
Interferon alfa-2b (recombinant)		8/17/1988	Treatment of laryngeal (respiratory) papillomatosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Leucovorin	Leucovorin calcium	8/17/1988	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Designated/Approved		Immunex Corporation
Interferon alfa-2b (recombinant)		8/10/1988	Treatment of carcinoma in situ of the urinary bladder.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Histrelin acetate	Supprelin Injection	8/10/1988	Treatment of central precocious puberty.	Designated/Approved		Roberts Pharmaceutical Corp.
Dipalmitoylphosphatidylcholine /phosphatidylglycerol		7/28/1988	Prevention and treatment of neonatal respiratory distress syndrome.	Designated	Not FDA Approved for Orphan Indication	"Forum Products, Inc."
Leuprolide acetate	Lupron Depot-Ped	7/25/1988	Treatment of central precocious puberty	Designated/Approved		AbbVie Endocrine Inc.
Leuprolide acetate	Lupron Injection	7/25/1988	Treatment of central precocious puberty	Designated/Approved		AbbVie Endocrine Inc.
Idarubicin HCl for injection	Idamycin	7/25/1988	"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia."	Designated/Approved		"Adria Laboratories, Inc."
Epoetin alpha		7/21/1988	Treatment of anemia of prematurity in preterm infants.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Janssen Research & Development, LLC"
Nafarelin acetate	Synarel Nasal Solution	7/20/1988	Treatment of central precocious puberty.	Designated/Approved		"Syntex (USA), Inc."
Polyribonucleotide; Polyribo-inosinic/-cyclidylic/-uridylic acid		7/19/1988	Treatment of AIDS	Designated	Not FDA Approved for Orphan Indication	AIM ImmunoTech Inc.
Zalcitabine	Hivid	6/28/1988	Treatment of AIDS.	Designated/Approved		"Hoffmann-La Roche, Inc."
Leucovorin calcium		6/23/1988	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Glaxo Wellcome Research and Development
Dideoxyinosine		6/22/1988	Treatment of acquired immunodeficiency syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb
"Ethinyl Estradiol, USP"		6/22/1988	Treatment of Turner's syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bio-Technology General Corp.
Aconiazide		6/20/1988	Treatment of tuberculosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Lincoln Diagnostics
Somatostatin		6/20/1988	"Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas."	Designated	Not FDA Approved for Orphan Indication	"Ferring Laboratories, Inc."
Piritrexim isethionate		6/13/1988	"Treatment of infections caused by Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium-intracellulare."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Burroughs Wellcome Company
Coagulation factor VIIa (recombinant)	NovoSeven	6/6/1988	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Designated/Approved		"Novo Nordisk, Inc."
Superoxide dismutase (recombinant human)		5/17/1988	Prevention of reperfusion injury to donor organ tissue.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bio-Technology General Corp.
Interferon alfa-2b (recombinant)		5/13/1988	Treatment of primary malignant brain tumors.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Praziquantel		4/18/1988	Treatment of neurocysticercosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"EM Pharmaceuticals, Inc."
Interferon alfa-2b (recombinant)		4/18/1988	Treatment of invasive carcinoma of the cervix.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Interferon alfa-2a (recombinant)		4/18/1988	Treatment of renal cell carcinoma.	Designated	Not FDA Approved for Orphan Indication	"Hoffmann-La Roche, Inc."
Tocophersolan oral solution (vitamin E-tpgs)		4/15/1988	Treatment of vitamin E deficiency resulting from malabsorption due to prolonged cholestatic hepatobiliary disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Sterling Winthrop
Trisaccharides A and B		4/15/1988	Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.	Designated	Not FDA Approved for Orphan Indication	"Chembiomed, Ltd."
Megestrol acetate	Megace	4/13/1988	"Treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of AIDS."	Designated/Approved		Bristol-Myers Squibb Pharmaceutical Research Institute
mefloquine HCL	Lariam	4/13/1988	"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs"	Designated/Approved		"Hoffmann-La Roche, Inc."
mefloquine HCL	Lariam	4/13/1988	"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs"	Designated/Approved		"Hoffmann-La Roche, Inc."
Monoclonal antibody 17-1a		4/4/1988	Treatment of pancreatic cancer.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Centocor, Inc."
Propamidine isethionate 0.1% ophthalmic solution		3/10/1988	Treatment of acanthamoeba keratitis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Bausch & Lomb
Heme arginate		3/10/1988	Treatment of symptomatic stage of acute porphyria.	Designated	Not FDA Approved for Orphan Indication	Orphan Europe SARL
Levocabastine HCl ophthalmic suspension 0.05%		2/29/1988	Treatment of vernal keratoconjunctivitis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Iolab Pharmaceuticals
Anagrelide	Agrylin	1/27/1988	Treatment of essential thrombocythemia.	Designated/Approved		"Takeda Development Center Americas, Inc."
agalsidase beta	Fabrazyme	1/19/1988	Treatment of Fabry's disease.	Designated/Approved		Genzyme Corporation
agalsidase beta	Fabrazyme	1/19/1988	Treatment of Fabry's disease.	Designated/Approved		Genzyme Corporation
Trimetrexate glucuronate		1/13/1988	Treatment of patients with advanced non-small cell carcinoma of the lung.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Medimmune Oncology, Inc."
Pentamidine isethionate	Nebupent	1/12/1988	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Designated/Approved		"Fujisawa USA, Inc."
Mesna		12/16/1987	Inhibition of the urotoxic effects induced by oxazaphosphorine compounds such as cyclophosphamide.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Asta Medica , Inc."
Interferon alfa-2a (recombinant)	Roferon-A	12/14/1987	Treatment of AIDS related Kaposi's sarcoma.	Designated/Approved		"Hoffmann-La Roche, Inc."
Dantrolene sodium		12/14/1987	Treatment of the neuroleptic malignant syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Norwich Eaton Pharmaceuticals
Gamma hydroxybutyrate		12/3/1987	"Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior."	Designated	Not FDA Approved for Orphan Indication	"Biocraft Laboratories, Inc."
Urofollitropin	Metrodin	11/25/1987	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	Designated/Approved		"EMD Serono, Inc."
Metronidazole (topical)		11/24/1987	"Treatment of grade III and IV, anaerobically infected, decubitus ulcers."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Searle
Dextran sulfate sodium		11/19/1987	Treatment of aquired immunodeficiency syndrome.	Designated	Not FDA Approved for Orphan Indication	"Ueno Fine Chemicals Industry, Ltd."
"Erythropoietin (human, recombinant)"		11/19/1987	Treatment of anemia associated with end stage renal disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Organon Teknika Corporation
Thymoxamine HCl		11/16/1987	Reversal of phenylephrine-induced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of angle-closure glaucoma following mydriasis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Iolab Pharmaceuticals
baclofen	Lioresal Intrathecal	11/10/1987	"Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy)."	Designated/Approved		"Medtronic, Inc."
glatiramer acetate	Copaxone	11/9/1987	Treatment of multiple sclerosis	Designated/Approved		Teva Pharmaceuticals USA
Allopurinol sodium		11/9/1987	Ex-vivo preservation of cadaveric kidneys for transplantation	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Burroughs Wellcome Company
"Ammonium trichloro [dioxoethylene-O,O') tellurium (IV)"		11/9/1987	Treatment of acquired immunodeficiency syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"NPDC-AS101, Inc."
Deslorelin		11/5/1987	Treatment of central precocious puberty.	Designated	Not FDA Approved for Orphan Indication	Roberts Pharmaceutical Corp.
Iodine I 131 Lym-1 Monoclonal Antibody		11/2/1987	Treatment of B-cell lymphoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Lederle Laboratories Division
substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits		10/23/1987	Treatment of sickle cell disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Burroughs Wellcome Company
Epoetin beta		10/22/1987	Treatment of anemia associated with end stage renal disease.	Designated	Not FDA Approved for Orphan Indication	"Chugai-USA, Inc."
Metronidazole (topical)	Metrogel	10/22/1987	Treatment of acne rosacea.	Designated/Approved		"Galderma Laboratories, Inc."
Interferon alfa-nl		10/16/1987	Treatment of human papillomavirus in patients with severe resistant/recurrent respiratory (laryngeal) papillomatosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Glaxo Wellcome Inc.
Epidermal growth factor (human)		10/5/1987	For acceleration of corneal epithelial regeneration and the healing of stromal tissue in the condition of non-healing corneal defects.	Designated	Not FDA Approved for Orphan Indication	Chiron Vision
Pentamidine isethionate (inhalation)		10/5/1987	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease	Designated	Not FDA Approved for Orphan Indication	Fisons Corporation
Piracetam		10/2/1987	Treatment of myoclonus.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"UCB Pharma, Inc."
"Benzylpenicillin, benzylpenicilloic, benzylpenilloic acid"		9/28/1987	Assessing the risk of administrating penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.	Designated	Not FDA Approved for Orphan Indication	AllerQuest LLC
pentostatin for injection	Nipent	9/10/1987	Treatment of hairy cell leukemia	Designated/Approved		"SuperGen, Inc."
Somatropin		9/1/1987	"Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novo Nordisk Pharmaceuticals
CD5-T lymphocyte immunotoxin		8/27/1987	Treatment of graft versus host disease and/or rejection in patients who have received bone marrow transplants.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Xoma Corporation
Epoetin alpha		8/27/1987	Treatment of anemia associated with end stage renal disease.	Designated	Not FDA Approved for Orphan Indication	R. W. Johnson Pharmaceutical Research Institute
Erythropoietin (recombinant human)		8/19/1987	Treatment of anemia associated with end stage renal disease.	Designated	Not FDA Approved for Orphan Indication	McDonnell Douglas Corp
Acetylcysteine		8/13/1987	Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Company
ST1-RTA immunotoxin (SR 44163)		8/12/1987	1. Prevention of acute graft versus host disease in allogenic bone marrow transplantation 2. Treatment of patients with B-chronic lymphocytic leukemia	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Sanofi Winthrop, Inc."
Cytomegalovirus immune globulin (human)	CytoGam	8/3/1987	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	Designated/Approved		CSL Behring LLC
5-aza-2'-deoxycytidine		8/3/1987	Treatment of acute leukemia.	Designated	Not FDA Approved for Orphan Indication	"SuperGen, Inc."
Trisaccharides A and B		8/3/1987	"Treatment of moderate to very severe clinical forms of transfusion reactions arising from ABO incompatible transfusions of blood, blood products, and blood derivatives."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Chembiomed, Ltd."
Interferon alfa-2b (recombinant)		8/3/1987	Treatment of ovarian carcinoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Mefloquine HCl		7/22/1987	Treatment and prevention of chloroquine-resistant Falciparummalaria	Designated	Not FDA Approved for Orphan Indication	Mepha AG
2'-3'-dideoxyadenosine		7/21/1987	Treatment of aquired immunodeficiency syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"National Cancer Institute, Dct"
Mitoxantrone HCl	Novantrone	7/13/1987	"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia."	Designated/Approved		Lederle Laboratories
somapacitan-beco	Sogroya	7/10/1987	1. Treatment of growth failure in children due to inadequate growth hormone secretion 2. Treatment of short stature associated with Turner's syndrome	Designated/Approved		Novo Nordisk Pharmaceuticals
Somatropin (rDNA origin) injection	Norditropin	7/10/1987	1. Treatment of growth failure in children due to inadequate growth hormone secretion 2. Treatment of short stature associated with Turner's syndrome	Designated/Approved		Novo Nordisk Pharmaceuticals
Interferon alfa-2b (recombinant)	Intron A	6/24/1987	Treatment of AIDS-related Kaposi's sarcoma.	Designated/Approved		Schering Corporation
Interferon alfa-2b (recombinant)		6/22/1987	Treatment of chronic myelogenous leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Interferon alfa-2b (recombinant)		6/22/1987	Treatment of metastatic renal cell carcinoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Schering Corporation
Technetium Tc99m anti-melanoma murine monoclonal antibody		6/2/1987	"For use in detecting, by imaging, metastases of malignant melanoma."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	NeoRx Corporation
dalfampridine	Ampyra	6/2/1987	Relief of symptoms of multiple sclerosis	Designated/Approved		Acorda Therapeutics
Gonadorelin acetate	Lutrepulse	4/22/1987	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Designated/Approved		"Ferring Laboratories, Inc."
Trisaccharides A and B		4/20/1987	"For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas."	Designated	Not FDA Approved for Orphan Indication	"Chembiomed, Ltd."
Trisaccharides A and B		4/12/1987	Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.	Designated	Not FDA Approved for Orphan Indication	"Chembiomed, Ltd."
Surfactant (human) (amniotic fluid derived)		3/25/1987	Prevention and treatment of neonatal respiratory distress syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Merritt, T. Allen M.D."
Somatropin	Nutropin	3/6/1987	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Designated/Approved		"Genentech, Inc."
Anti-tap-72 immunotoxin		3/6/1987	Treatment of metastatic colorectal adenocarcinoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Xoma Corporation
Somatropin (rDNA origin)	Saizen	3/6/1987	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Designated/Approved		"EMD Serono, Inc."
"24,25 dihydroxycholecalciferol"		2/27/1987	Treatment of uremic osteodystrophy.	Designated	Not FDA Approved for Orphan Indication	Lemmon Company
Ifosfamide	Ifex	1/20/1987	Treatment of testicular cancer.	Designated/Approved		Bristol-Myers Squibb Pharmaceutical Research Institute
Calcitonin-human for injection	Cibacalcin	1/20/1987	Treatment of symptomatic Paget's disease (osteitis deformans).	Designated/Approved		Novartis Pharmaceutical Corporation
Teriparatide	Parathar	1/9/1987	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Designated/Approved		"Rhone-Poulenc Rorer Pharmaceuticals, Inc."
Zalcitabine		12/9/1986	Treatment of AIDS.	Designated	Not FDA Approved for Orphan Indication	"National Cancer Institute, DCT"
Leucovorin	Leucovorin calcium	12/8/1986	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Designated/Approved		Immunex Corporation
Mazindol		12/8/1986	Treatment of Duchenne muscular dystrophy.	Designated	Not FDA Approved for Orphan Indication	"Collipp, Platon J. M.D."
Levocarnitine		11/24/1986	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Leadiant Biosciences, Inc."
Nebacumab		10/1/1986	Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Centocor, Inc."
Interferon alfa-nl		8/25/1986	Treatment of AIDS related Kaposi's sarcoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Burroughs Wellcome Company
Botulinum toxin type A	Botox	8/20/1986	Treatment of cervical dystonia.	Designated/Approved		"Allergan, Inc."
Chlorhexidine gluconate mouthrinse		8/18/1986	For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.	Designated	Not FDA Approved for Orphan Indication	Procter & Gamble Company
Erwinia L-asparaginase	Erwinase	7/30/1986	Treatment of acute lymphocytic leukemia.	Designated/Approved/Designation Withdrawn or Revoked		"Jazz Pharmaceuticals, Inc."
Anagrelide		7/14/1986	Treatment of thrombocytosis in chronic myelogenous leukemia.	Designated	Not FDA Approved for Orphan Indication	Roberts Pharmaceutical Corp.
Disodium silibinin dihemisuccinate		7/10/1986	Treatment of hepatic intoxication by Amanita phalloides (mushroom poisoning).	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pharmaquest Corporation
Somatropin for injection	Humatrope	6/12/1986	For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.	Designated/Approved		Eli Lilly and Company
Sodium tetradecyl sulfate		6/10/1986	Treatment of bleeding esophageal varices.	Designated	Not FDA Approved for Orphan Indication	"Elkins-Sinn, Inc."
Dimethyl sulfoxide		6/6/1986	Treatment of cutaneous manifestations of scleroderma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Research Industries Corp.
Trimetrexate glucuronate	Neutrexin	5/15/1986	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Designated/Approved		"Medimmune Oncology, Inc."
Monoclonal antibodies (murine or human) to B-cell lymphoma		5/6/1986	Treatment of B-cell lymphoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	IDEC Pharmaceuticals Corporation
Cysteamine		5/1/1986	Treatment of nephropathic cystinosis.	Designated	Not FDA Approved for Orphan Indication	"Thoene, Jess G., M.D."
Eflornithine HCl	Ornidyl	4/23/1986	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	Designated/Approved		Hoechst Marion Roussel
Eflornithine HCl		4/18/1986	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Marion Merrell Dow, Inc."
Epoetin alfa	Epogen	4/10/1986	Treatment of anemia associated with end stage renal disease.	Designated/Approved		"Amgen, Inc."
Diethyldithiocarbamate		4/3/1986	Treatment of AIDS.	Designated	Not FDA Approved for Orphan Indication	Connaught Laboratories
Etidronate disodium	Didronel	3/21/1986	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	Designated/Approved		"MGI Pharma, Inc."
Terlipressin		3/6/1986	Treatment of bleeding esophageal varices.	Designated	Not FDA Approved for Orphan Indication	Ferring Pharmaceuticals Inc.
Potassium citrate and citric acid		2/14/1986	For the dissolution and control of uric acid and cysteine calculi in the urinary tract.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Willen Drug Company
Beractant	Survanta intratracheal suspension	2/5/1986	Treatment of neonatal respiratory distress syndrome	Designated/Approved		Ross Laboratories
Beractant	Survanta intratracheal suspension	2/5/1986	Treatment of neonatal respiratory distress syndrome	Designated/Approved		Ross Laboratories
Anti pan T lymphocyte monoclonal antibody		1/29/1986	1. For ex-vivo treatment to eliminate mature T cells from potential bone marrow grafts 2. For in-vivo treatment of bone marrow recipients to prevent graft rejection and graft versus host disease.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Xoma Corporation
Benzoate and phenylacetate	Ucephan	1/21/1986	"For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency."	Designated/Approved		ImmunexImmunex
Tiopronin	Thiola	1/17/1986	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Designated/Approved		Mission Pharmacal Company
Tiopronin	Thiola	1/17/1986	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Designated/Approved		Mission Pharmacal Company
Tiopronin	Thiola	1/17/1986	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Designated/Approved		Mission Pharmacal Company
Guanethidine monosulfate		1/6/1986	Treatment of moderate to severe reflex sympathetic dystrophy and causalgia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Novartis Pharmaceuticals Corporation
flunarizine		1/6/1986	Treatment of alternating hemiplegia.	Designated	Not FDA Approved for Orphan Indication	Janssen Research Foundation
Antithrombin III human		1/2/1986	Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.	Designated	Not FDA Approved for Orphan Indication	American National Red Cross
Somatrem for injection	Protropin	12/9/1985	"1. Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion (prevalence 15,000) 2. Treatment of short stature associated with Turner's syndrome (prevalence 8000)."	Designated/Approved		"Genentech, Inc."
Rifampin	Rifadin I.V.	12/9/1985	For antituberculosis treatment where use of the oral form of the drug is not feasible.	Designated/Approved		Hoechst Marion Roussel
Colchicine		12/9/1985	For arresting the progression of neurologic disability caused by chronic progressive multiple sclerosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pharmacontrol Corporation
Allopurinol riboside		12/4/1985	1. Treatment of Chagas' disease 2. Treatment of cutaneous and visceral leishmaniasis	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Burroughs Wellcome Company
tranexamic acid	Cyklokapron	12/3/1985	"For use in patients with congenital coagulopathies undergoing surgical procedures, e.g. dental extractions"	Designated/Approved/Designation Withdrawn or Revoked		Pharmacia Inc.
Mesna	Mesnex	11/14/1985	For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.	Designated/Approved		Degussa Corporation
Zinc acetate	Galzin	11/6/1985	Treatment of Wilson's disease.	Designated/Approved		Lemmon Company
Monoclonal antiendotoxin antibody XMMEn-0e5		11/4/1985	Treatment of patients with gram-negative sepsis which has progressed to shock.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Pfizer, Inc."
Ganciclovir sodium	Cytovene	10/31/1985	Treatment of cytomegalovirus retinitis in immunocompromised patients with AIDS.	Designated/Approved/Designation Withdrawn or Revoked		"Syntex (USA), Inc."
Methotrexate sodium	Methotrexate	10/21/1985	Treatment of osteogenic sarcoma.	Designated/Approved		Lederle Laboratories
Hydroxycobalamin/sodium thiosulfate		10/4/1985	Treatment of severe acute cyanide poisoning.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Hall, Alan H., M.D."
Epoprostenol	Flolan	9/25/1985	Treatment of primary pulmonary hypertension.	Designated/Approved		Glaxo Wellcome Inc.
"Rifampin, isoniazid, pyrazinamide"	Rifater	9/12/1985	For the short-course treatment of tuberculosis.	Designated/Approved		Hoechst Marion Roussel
Pentastarch	Pentaspan	8/28/1985	As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.	Designated/Approved		DuPont Pharmaceuticals
Pentosan polysulfate sodium	Elmiron	8/7/1985	Treatment of interstitial cystitis.	Designated/Approved		Alza Corporation
ifosfamide		8/7/1985	Treatment of soft tissue and bone sarcomas	Designated	Not FDA Approved for Orphan Indication	Bristol-Myers Squibb Company
Trimetrexate glucuronate		7/25/1985	Treatment of pancreatic adenocarcinoma.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Medimmune Oncology, Inc."
Cromolyn sodium 4% ophthalmic solution	Opticrom 4% ophthalmic solution	7/24/1985	Treatment of vernal keratoconjunctivitis.	Designated/Approved		Fisons Corporation
ammonium 21-tungsto-9-antimoniate		7/17/1985	Treatment of acquired immunodeficiency syndrome.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Rhone-Poulenc Rorer Pharm.
zidovudine	Retrovir	7/17/1985	Treatment of AIDS	Designated/Approved		Glaxo Wellcome Inc.
Defibrotide		7/5/1985	Treatment of thrombotic thrombocytopenic purpura.	Designated	Not FDA Approved for Orphan Indication	Crinos International
Antithrombin III (human) concentrate IV		7/2/1985	For prophylaxis and treatment of thromboembolic episodes in patients with genetic AT-III deficiency.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	CSL Behring
Midodrine HCl	Amatine	6/21/1985	Treatment of patients with symptomatic orthostatic hypotension.	Designated/Approved		"Takeda Development Center Americas, Inc."
Prednimustine		6/17/1985	Treatment of malignant non-Hodgkin's lymphomas.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Pharmacia Inc.
Anagrelide		6/11/1985	Treatment of polycythemia vera.	Designated	Not FDA Approved for Orphan Indication	Roberts Pharmaceutical Corp.
Gancyclovir		6/7/1985	Treatment of severe human cytomegalovirus infections in specific immunosuppressed patient populations.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Burroughs Wellcome Company
calfactant	Infasurf	6/7/1985	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	Designated/Approved		ONY Biotech Inc.
Tretinoin		4/15/1985	Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.	Designated	Not FDA Approved for Orphan Indication	"Hannan Ophthalmic Marketing Services, Inc"
Oxymorphone		3/19/1985	For relief of severe intractable pain in narcotic-tolerant patients.	Designated	Not FDA Approved for Orphan Indication	DuPont Merck Pharmaceutical Company
Digoxin immune fab(ovine)		3/11/1985	"Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia."	Designated	Not FDA Approved for Orphan Indication	Boehringer Mannheim Corp.
Naltrexone HCl	Trexan	3/11/1985	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.	Designated/Approved		DuPont Pharmaceuticals
Alglucerase injection	Ceredase	3/11/1985	For replacement therapy in patients with Gaucher's disease type I.	Designated/Approved		Genzyme Corporation
Superoxide dismutase (human)		3/6/1985	"For protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary periods of ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative procedure."	Designated	Not FDA Approved for Orphan Indication	Pharmacia-Chiron Partnership
Epidermal growth factor (human)		3/6/1985	For promotion of cutaneous wound healing in extreme burn treatment protocols.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Ethicon, Inc."
Antipyrine Test		2/21/1985	For use as an index of hepatic drug-metabolizing capacity.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Upsher-Smith Laboratories, Inc"
Antithrombin III (human)	ATnativ	2/8/1985	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Designated/Approved		Pharmacia & Upjohn AB
Erwinia L-asparaginase		1/25/1985	For use as an alternative to E. coli asparaginase in those situations where repeat courses of asparaginase therapy for acute lymphoblastic leukemia are required or where allergic reactions force the discontinuance of the E. coli preparation.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Lyphomed, Inc."
Levomethadyl acetate hydrochloride	Orlaam	1/24/1985	Treatment of heroin addicts suitable for maintenance on opiate agonists.	Designated/Approved		Biodevelopment Corporation
Gamma-hydroxybutyric acid		1/22/1985	"Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations, and automatic behavior."	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Sigma Chemical Company
factor XIII concentrate (human)	Corifact	1/16/1985	Treatment of congenital factor XIII deficiency	Designated/Approved		CSL Behring LLC
factor XIII concentrate (human)	Corifact	1/16/1985	Treatment of congenital factor XIII deficiency	Designated/Approved		CSL Behring LLC
physostigmine salicylatephysostigmine salicylate		1/16/1985	Treatment of Friedreich's and other inherited ataxias.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Forest Pharmaceuticals.3-.3-.30 6
Flumecinol		1/15/1985	Treatment of hyperbilirubinemia in newborn infants unresponsive to phototherapy.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Farmacon, Inc."
Protirelin injection		1/10/1985	Treatment of amyotrophic lateral sclerosis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Abbott Laboratories
Trientine HCl	Syprine	12/24/1984	"Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine."	Designated/Approved		Merck Sharp & Dohme Research
Sodium monomercaptoundecahydro-closo-dodecaborate		12/18/1984	For use in conjunction with a thermal or epithermal neutron beam in boron nuclear capture therapy of glioblastoma multiforme.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Theragenics Corporation
Alpha1-proteinase inhibitor (human)	Prolastin	12/7/1984	For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.	Designated/Approved		Bayer Corporation
Amsacrine		12/7/1984	Treatment of acute adult leukemia.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Warner-Lambert Company
Antithrombin III (human)	Thrombate III	11/26/1984	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Designated/Approved		Bayer Corporation
Antimelanoma Antibody XMMME-001-DTPA 111 Indium		11/14/1984	Diagnostic use in imaging systemic and nodal melanoma metastasis.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Xoma Corporation
Antimelanoma Antibody XMMME-001-RTA		11/14/1984	Treatment of stage III melanoma not amenable to surgical resection.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Xoma Corporation
Iobenguane Sulfate I 131		11/14/1984	For use as a diagnostic adjunct in patients with pheochromocytoma.	Designated/Approved/Designation Withdrawn or Revoked		University of Michigan
Selegiline HCl	Eldepryl	11/7/1984	"As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism."	Designated/Approved		"Somerset Pharmaceuticals, Inc."
Digoxin immune FAB (Ovine)	Digibind	11/1/1984	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	Designated/Approved		Glaxo Wellcome Inc.
Potassium citrate	Urocit-K	11/1/1984	1. Prevention of calcium renal stones in patients with hypocitraturia 2. For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	Designated/Approved		University of Texas Health Science Center at Dallas
Urogastrone		11/1/1984	For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.	Designated	Not FDA Approved for Orphan Indication	Chiron Vision
Potassium citrate	Urocit-K	11/1/1984	Prevention of uric acid nephrolithiasis.	Designated/Approved		University of Texas Health Science Center at Dallas
L-5 Hydroxytrytophan		11/1/1984	Treatment of postanoxic intention myoclonus.	Designated	Not FDA Approved for Orphan Indication	"Watson Laboratories, Inc."
Teniposide	Vumon for injection	11/1/1984	Treatment of refractory childhood acute lymphocytic leukemia.	Designated/Approved		Bristol-Myers Squibb Pharmaceutical Research Institute
Pentamidine isethionate		10/29/1984	Treatment of Pneumocystis carinii pneumonia.	Designated	Not FDA Approved for Orphan Indication	Aventis Behring L.L.C.
Epoprostenol		10/29/1984	Replacement of heparin in patients requiring hemodialysis and who are at increased risk of hemorrhage.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Upjohn Company
Cyproterone acetate		10/26/1984	Treatment of severe hirsutism.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Berlex Laboratories, Inc."
Quinacrine hydrochloride		10/17/1984	For prevention of recurrence of pneumothorax in patients at high risk of recurrence.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	"Lyphomed, Inc."
Spiramycin		10/17/1984	For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Rhone-Poulenc Rorer Pharmaceuticals
chenodiol	Chenix	9/21/1984	"For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age"	Designated/Approved		Solvay
Iodine 131 6B-iodomethyl-19-norcholesterol		8/1/1984	For use in adrenal cortical imaging.	Designated	Not FDA Approved for Orphan Indication	"David E. Kuhl, M.D."
Levocarnitine	Carnitor	7/26/1984	Treatment of primary and secondary carnitine deficiency of genetic origin.	Designated/Approved		"Leadiant Biosciences, Inc."
Clofazimine	Lamprene	6/11/1984	"Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum."	Designated/Approved		Novartis Pharmaceutical Corporation
viloxazine HCL		6/11/1984	Treatment of cataplexy and narcolepsy	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Stuart Pharmaceuticals
Monooctanoin	Moctanin	5/30/1984	For dissolution of cholesterol gallstones retained in the common bile duct.	Designated/Approved		"Ethitek Pharmaceuticals, Inc."
Pegademase bovine	Adagen	5/29/1984	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Designated/Approved		"Sigma-tau Pharmaceuticals, Inc."
Succimer	Chemet capsules	5/9/1984	Treatment of lead poisoning in children.	Designated/Approved		Bock Pharmacal Company
Epoprostenol		3/29/1984	Replacement of heparin in patients requiring hemodialysis and who are at risk of hemmorrage	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Glaxo Wellcome Inc.
Botulinum toxin type A	Botox	3/22/1984	Treatment of strabismus and blepharospasms	Designated/Approved		"Allergan, Inc."
Botulinum toxin type A	Botox	3/22/1984	Treatment of strabismus and blepharospasms	Designated/Approved		"Allergan, Inc."
Ethanolamine oleate	Ethamolin	3/22/1984	"Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding."	Designated/Approved		QOL Medical
Hemin	Panhematin	3/16/1984	"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria."	Designated/Approved		Abbott Laboratories
Bacitracin		3/13/1984	Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.	Designated	Not FDA Approved for Orphan Indication	"A. L. Laboratories, Inc."
Cromolyn sodium	Gastrocrom	3/8/1984	Treatment of mastocytosis.	Designated/Approved		Fisons Corporation
Pentamidine isethionate	Pentam 300	2/28/1984	Treatment of Pneumocystis carinii pneumonia.	Designated/Approved		"Fujisawa USA, Inc."
Levocarnitine	Carnitor	2/28/1984	Treatment of genetic carnitine deficiency.	Designated/Approved		"Leadiant Biosciences, Inc."
Altretamine	Hexalen	2/9/1984	Treatment of advanced adenocarcinoma of the ovary.	Designated/Approved		"Medimmune Oncology, Inc."
Alpha-1-antitrypsin (recombinant DNA Origin)		1/1/1984	As supplementation therapy for alpha-1-antitrypsin deficiency in the ZZ phenotype population.	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Chiron Corporation
Diaziquone		11/10/1983	Treatment of primary brain malignancies (grade III and IV astrocytomas).	Designated/Designation Withdrawn or Revoked	Not FDA Approved for Orphan Indication	Warner-Lambert Company
Note: Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.						
Note: Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.						
